PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Aronson, JK				Aronson, JK			"Where name and image meet" - the argument for "adrenaline"	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SIMULATED CRITICAL INCIDENTS; CONFUSION; DRUGS	A European Commission directive requiring member states to use recommended international non-proprietary names for all drugs is soon to be implemented For most drug names there will be little or no change For around two dozen drugs the changes are more important: these will be dual labelled during the five year changeover period It is intended that adrenaline (British approved name) will be changed to epinephrine (recommended international non-propietary name) The strong arguments for persuading the European Union to resist this particular change are based on usage, history, etymology,and, most importantly, risk of clinical errors.	Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Aronson, JK (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England.	jeffrey.aronson@clinpharm.ox.ac.uk						Abel JJ., 1898, P AM PHYS SOC, V3, P3; ADRENALIN, 1908, PRACTITIONER     MAR, P422; ALEXANDER SPH, 1999, TRENDS PHARMACOL SCI, P4; ARONSON JK, 1995, DRUG SAFETY, V12, P155, DOI 10.2165/00002018-199512030-00001; *CHIEF MED OFF, 1999, CMOS UPD 21; COUSINS DH, 1998, PHARM PRACT      MAY, P209; COUSINS DH, 1993, HOSP PHARM PRACT JUL, P376; DAVENPORT H W, 1982, Physiologist, V25, P76; Davies DM, 1998, LANCET, V352, P2025, DOI 10.1016/S0140-6736(05)61378-5; Frankel S., 1897, J CHEM SOC ABSTR, V72, P63; GABA DM, 1989, ANESTH ANALG, V68, P444; George CF, 1996, BRIT MED J, V312, P1315, DOI 10.1136/bmj.312.7042.1315; HYRD J, 1880, ONOMATOLOGIA ANATOMI; James RH, 1998, ANAESTHESIA, V53, P511, DOI 10.1046/j.1365-2044.1998.04771.x; JAMES RR, 1994, H WELLCOME, P292; *JOINT FORM COMM, 1999, BRIT NAT FORM; KOPPKUBBEL S, 1996, PRACTICE MED CHEM, P863; *MED COMM, 1998, BRIT APPR NAM 1997 S, V4; *MED CONTR AG, 1997, MAIL, V103, P2; *MED CONTR AG, 1998, MAIL, V108, P2; *MED CONTR AG, 1995, MAIL, V91, P5; Navarro FA, 1996, BRIT MED J, V313, P688; *NPA BOARD, 1998, PHARM J, V260, P188; Oliver G., 1894, J PHYSL LONDON, V16, pi; PEACOCK JB, 1985, ANN EMERG MED, V14, P407, DOI 10.1016/S0196-0644(85)80282-1; Schafer EA, 1908, BMJ-BRIT MED J, V1908, P1277, DOI 10.1136/bmj.1.2474.1277; SCHWID HA, 1992, ANESTHESIOLOGY, V76, P495, DOI 10.1097/00000542-199204000-00002; *STAT OFF, 1999, BRIT PHARM; SULLIVAN MJJ, 1986, LANCET, V2, P618; Takamine J, 1901, J PHYSIOL-LONDON, V27, pXXIX; TANSEY EM, 1995, MED HIST, V39, P459, DOI 10.1017/S0025727300060373; von Furth O, 1900, Z PHYSL CHEM, V29, P105	32	23	24	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	2000	320	7233					506	509		10.1136/bmj.320.7233.506	http://dx.doi.org/10.1136/bmj.320.7233.506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678871	Green Published			2022-12-28	WOS:000085562200034
J	Martinez, JS; Zhang, GP; Holt, PD; Jung, HT; Carrano, CJ; Haygood, MG; Butler, A				Martinez, JS; Zhang, GP; Holt, PD; Jung, HT; Carrano, CJ; Haygood, MG; Butler, A			Self-assembling amphiphilic siderophores from marine bacteria	SCIENCE			English	Article							EQUATORIAL PACIFIC-OCEAN; MYCOBACTERIUM-TUBERCULOSIS; AMINO-ACIDS; IRON; ORGANIZATION; ACQUISITION; EXOCHELINS; ECOSYSTEMS; WATERS	Most aerobic bacteria secrete siderophores to facilitate iron acquisition. Two families of siderophores were isolated from strains belonging to two different genera of marine bacteria. The aquachelins, from Halomonas aquamarina strain DS40M3, and the marinobactins, from Marinobacter sp. strains DS40M6 and DS40M8, each contain a unique peptidic head group that coordinates iron(III) and an appendage of one of a series of fatty acid moieties. These siderophores have low critical micelle concentrations (CMCs). In the absence of iron, the marinobactins are present as micelles at concentrations exceeding their CMC; upon addition of iron(III), the micelles undergo a spontaneous phase change to form vesicles. These observations suggest that unique iron acquisition mechanisms may have evolved in marine bacteria.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA; SW Texas State Univ, Dept Chem, San Marcos, TX 78666 USA; Univ Calif San Diego, Scripps Inst Oceanog, Div Marine Biol Res, La Jolla, CA 92093 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Texas State University System; Texas State University San Marcos; University of California System; University of California San Diego; Scripps Institution of Oceanography	Butler, A (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.		Butler, Alison/D-5094-2015; Jung, Hee-Tae/C-1574-2011	Butler, Alison/0000-0002-3525-7864; 	NIGMS NIH HHS [GM38130] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038130, R29GM038130, R55GM038130] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azam F, 1998, SCIENCE, V280, P694, DOI 10.1126/science.280.5364.694; BELLARE JR, 1988, J ELECTRON MICR TECH, V10, P87, DOI 10.1002/jemt.1060100111; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; BRULAND KW, 1991, LIMNOL OCEANOGR, V36, P1555, DOI 10.4319/lo.1991.36.8.1555; Butler A, 1998, SCIENCE, V281, P207, DOI 10.1126/science.281.5374.207; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; DEMANGE P, 1988, J CHROMATOGR, V438, P291, DOI 10.1016/S0021-9673(00)90260-7; Fendler JH, 1994, COLLOIDAL DOMAIN PHY, DOI [10.1002/adma.19960080318, DOI 10.1002/ADMA.19960080318]; GOBIN J, 1995, P NATL ACAD SCI USA, V92, P5189, DOI 10.1073/pnas.92.11.5189; Gobin J, 1996, J EXP MED, V183, P1527, DOI 10.1084/jem.183.4.1527; GOYNE ER, 1974, LIMNOL OCEANOGR, V19, P840; Granger J, 1999, LIMNOL OCEANOGR, V44, P541, DOI 10.4319/lo.1999.44.3.0541; HAYGOOD MG, 1993, LIMNOL OCEANOGR, V38, P1091, DOI 10.4319/lo.1993.38.5.1091; Hutchins DA, 1999, NATURE, V400, P858, DOI 10.1038/23680; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; JALAL MAF, 1989, J AM CHEM SOC, V111, P292, DOI 10.1021/ja00183a044; Lee KC, 1999, LANGMUIR, V15, P5500, DOI 10.1021/la9900775; Maidak BL, 1999, NUCLEIC ACIDS RES, V27, P171, DOI 10.1093/nar/27.1.171; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; MARTIN JH, 1991, LIMNOL OCEANOGR, V36, P1793, DOI 10.4319/lo.1991.36.8.1793; OKUJO N, 1994, BIOMETALS, V7, P109; Pakulski JD, 1996, NATURE, V383, P133, DOI 10.1038/383133b0; REID RT, 1993, NATURE, V366, P455, DOI 10.1038/366455a0; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SAAGER PM, 1989, GEOCHIM COSMOCHIM AC, V53, P2259, DOI 10.1016/0016-7037(89)90348-7; Stackebrandt E, 1990, NUCL ACID TECHNIQUES, P115; SWOFFORD DL, 1999, PAUP PHYLOGENETIC AN; Tortell PD, 1999, FEMS MICROBIOL ECOL, V29, P1; Tortell PD, 1996, NATURE, V383, P330, DOI 10.1038/383330a0; TRICK CG, 1989, CURR MICROBIOL, V18, P375, DOI 10.1007/BF01571131; Wilhelm SW, 1996, LIMNOL OCEANOGR, V41, P89, DOI 10.4319/lo.1996.41.1.0089; WILHELM SW, 1994, LIMNOL OCEANOGR, V39, P1974; Wu JF, 1996, GEOCHIM COSMOCHIM AC, V60, P2729, DOI 10.1016/0016-7037(96)00135-4	34	249	260	4	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1245	1247		10.1126/science.287.5456.1245	http://dx.doi.org/10.1126/science.287.5456.1245			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678827				2022-12-28	WOS:000085444700044
J	Schuurman, PR; Bosch, DA; Bossuyt, PMM; Bonsel, GJ; van Someren, EJW; de Bie, RMA; Merkus, MP; Speelman, JD				Schuurman, PR; Bosch, DA; Bossuyt, PMM; Bonsel, GJ; van Someren, EJW; de Bie, RMA; Merkus, MP; Speelman, JD			A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-BRAIN-STIMULATION; CHRONIC ELECTRICAL-STIMULATION; ADVANCED PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; MOVEMENT-DISORDERS; STEREOTAXIC THALAMOTOMY; SUBTHALAMIC NUCLEUS; CEREBELLAR TREMOR; ACTIVITIES INDEX; STROKE PATIENTS	Background: Deep-brain stimulation through an electrode implanted in the thalamus was developed as an alternative to thalamotomy for the treatment of drug-resistant tremor. Stimulation is thought to be as effective as thalamotomy but to have fewer complications. We examined the effects of these two procedures on the functional abilities of patients with drug-resistant tremor due to Parkinson's disease, essential tremor, or multiple sclerosis. Methods: Sixty-eight patients (45 with Parkinson's disease, 13 with essential tremor, and 10 with multiple sclerosis) were randomly assigned to undergo thalamotomy or thalamic stimulation. The primary outcome measure was the change in functional abilities six months after surgery, as measured by the Frenchay Activities Index. Scores for this index can range from 0 to 60, with higher scores indicating better function. Secondary outcome measures were the severity of tremor, the number of adverse effects, and patients' assessment of the outcome. Results: Functional status improved more in the thalamic-stimulation group than in the thalamotomy group, as indicated by increases in the score for the Frenchay Activities Index (from 31.4 to 36.3 and from 32.0 to 32.5, respectively; difference between groups, 4.4 points; 95 percent confidence interval, 2.0 to 6.9). After adjustment for base-line characteristics, multivariate analysis also showed that the thalamic-stimulation group had greater improvement (difference between groups, 5.1 points; 95 percent confidence interval, 2.3 to 7.9). Tremor was suppressed completely or almost completely in 27 of 34 patients in the thalamotomy group and in 30 of 33 patients in the thalamic-stimulation group. One patient in the thalamic-stimulation group died perioperatively after an intracerebral hemorrhage. With the exception of this incident, thalamic stimulation was associated with significantly fewer adverse effects than thalamotomy. Functional status was reported as improved by 8 patients in the thalamotomy group, as compared with 18 patients in the thalamic-stimulation group (P=0.01). Conclusions: Thalamic stimulation and thalamotomy are equally effective for the suppression of drug-resistant tremor, but thalamic stimulation has fewer adverse effects and results in a greater improvement in function. (N Engl J Med 2000;342:461-8.) (C) 2000, Massachusetts Medical Society.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Netherlands Inst Brain Res, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Speelman, JD (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.d.speelman@amc.uva.nl	Bossuyt, Patrick M/AAR-1183-2021; Bossuyt, Patrick M./B-4557-2016; Schuurman, Rick/ABE-9100-2021; Van Someren, Eus/AAA-6789-2020	Bossuyt, Patrick M/0000-0003-4427-0128; Bossuyt, Patrick M./0000-0003-4427-0128; de Bie, Rob/0000-0001-5267-0784				ALESCH F, 1995, ACTA NEUROCHIR, V136, P75, DOI 10.1007/BF01411439; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; BENABID AL, 1993, ACTA NEUROCHIR, P39; Blankensteijn JD, 1998, BRIT J SURG, V85, P1624; BLOND S, 1992, J NEUROSURG, V77, P62, DOI 10.3171/jns.1992.77.1.0062; BOSCH DA, 1986, STEREOTACTIC TECHNIQ; Critchley GR, 1998, BRIT J NEUROSURG, V12, P559, DOI 10.1080/02688699844439; Fahn S., 1987, RECENT DEV PARKINSON, P153; Fahn S, 1988, PARKINSONS DIS MOVEM, P225; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOX MW, 1991, J NEUROSURG, V75, P723, DOI 10.3171/jns.1991.75.5.0723; Geny C, 1996, MOVEMENT DISORD, V11, P489, DOI 10.1002/mds.870110503; GOLDMAN MS, 1992, J NEUROSURG, V76, P924, DOI 10.3171/jns.1992.76.6.0924; Haddow LJ, 1997, NEUROSURG QUART, V7, P23; Hariz GM, 1998, MOVEMENT DISORD, V13, P78, DOI 10.1002/mds.870130117; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Hooper J, 1998, LANCET, V352, P1984, DOI 10.1016/S0140-6736(05)61329-3; Hubble JP, 1996, NEUROLOGY, V46, P1150, DOI 10.1212/WNL.46.4.1150; JANKOVIC J, 1995, NEUROSURGERY, V37, P680, DOI 10.1227/00006123-199510000-00011; KELLY PJ, 1980, J NEUROSURG, V53, P332, DOI 10.3171/jns.1980.53.3.0332; Koller W, 1997, ANN NEUROL, V42, P292, DOI 10.1002/ana.410420304; Krack P, 1999, BRAIN, V122, P1133, DOI 10.1093/brain/122.6.1133; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LENZ FA, 1995, MOVEMENT DISORD, V10, P318, DOI 10.1002/mds.870100315; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; Limousin P, 1999, J NEUROL NEUROSUR PS, V66, P289, DOI 10.1136/jnnp.66.3.289; MATSUMOTO K, 1977, APPL NEUROPHYSIOL, V39, P257; NAGASEKI Y, 1986, J NEUROSURG, V65, P296, DOI 10.3171/jns.1986.65.3.0296; Ondo W, 1998, NEUROLOGY, V51, P1063, DOI 10.1212/WNL.51.4.1063; POLLAK P, 1993, ADV NEUROL, V60, P408; Rodriguez MC, 1998, MOVEMENT DISORD, V13, P111; Ryan RM, 1997, ANN ROY COLL SURG, V79, P423; SAMRA K, 1970, J NEUROL NEUROSUR PS, V33, P7, DOI 10.1136/jnnp.33.1.7; SCHALTENBRAND G, 1982, STEREOTAXY HUMAN BRA; Schaltenbrand G., 1977, ATLAS STEREOTAXY HUM; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; SELBY G, 1967, J NEUROL SCI, V5, P343, DOI 10.1016/0022-510X(67)90140-2; Shahzadi S, 1995, STEREOT FUNCT NEUROS, V65, P11, DOI 10.1159/000098890; SIEGFRIED J, 1994, STEREOT FUNCT NEUROS, V62, P71, DOI 10.1159/000098599; SPEELMAN JD, 1984, J NEUROL NEUROSUR PS, V47, P596, DOI 10.1136/jnnp.47.6.596; SPEELMAN JD, 1991, THESIS U AMSTERDAM; Tasker RR, 1996, ADV NEUROL, V69, P563; Tasker RR, 1997, ADV STER F, V12, P49; WESTER K, 1990, J NEUROL NEUROSUR PS, V53, P427, DOI 10.1136/jnnp.53.5.427; Whittle IR, 1998, LANCET, V351, P109, DOI 10.1016/S0140-6736(98)24002-5	48	701	725	0	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2000	342	7					461	468		10.1056/NEJM200002173420703	http://dx.doi.org/10.1056/NEJM200002173420703			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284FA	10675426	Green Published			2022-12-28	WOS:000085319100003
J	Vijan, S; Hofer, TP; Hayward, RA				Vijan, S; Hofer, TP; Hayward, RA			Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-HISPANIC WHITES; MEXICAN-AMERICANS; COMPLICATIONS; NIDDM; MORTALITY; CARE; OPHTHALMOSCOPY; PHOTOGRAPHY; POPULATION; MODEL	Context Annual eye screening for patients with diabetes mellitus is frequently proposed as a measure of quality of care. However, the benefit of annual vs less frequent screening intervals has not been well evaluated, especially for low-risk patients. Objective To examine the marginal cost-effectiveness of various screening intervals for eye disease in patients with type 2 diabetes, stratified by age and level of glycemic control. Design Markov cost-effectiveness model. Setting and Participants Hypothetical patients based on the US population of diabetic patients older than 40 years from the Third National Health and Nutrition Examination Survey. Main Outcome Measures Patient time spent blind, quality-adjusted life-years (QALYs), and costs of annual vs less frequent screening compared by age and level of hemoglobin A(1c). Results Retinal screening in patients with type 2 diabetes is an effective intervention; however, the risk reduction varies dramatically by age and level of glycemic control. On average, a high-risk patient who is aged 45 years and has a hemoglobin A(1c) level of 11% gains 21 days of sight when screened annually as opposed to every third year, while a low-risk patient who is aged 65 years and has a hemoglobin A(1c) level of 7% gains an average of 3 days of sight. The marginal cost-effectiveness of screening annually vs every other year also varies; patients in the high-risk group cost an additional $40 530 per QALY gained, while those in the low-risk group cost an additional $211 570 per QALY gained. In the US population, retinal screening annually vs every other year for patients with type 2 diabetes costs $107 510 per QALY gained, while screening every other year vs every third year costs $49 760 per QALY gained. Conclusions Annual retinal screening for all patients with type 2 diabetes without previously detected retinopathy may not be warranted on the basis of cost-effectiveness, and tailoring recommendations to individual circumstances may be preferable. Organizations evaluating quality of care should consider costs and benefits carefully before setting universal standards.	Vet Affairs Hlth Serv Res & Dev, Qual Enhancement Res Initiat, Ann Arbor, MI 48113 USA; Univ Michigan, Michigan Diabet Res & Training Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Vijan, S (corresponding author), Vet Affairs Hlth Serv Res & Dev, Qual Enhancement Res Initiat, POB 130170, Ann Arbor, MI 48113 USA.	svijan@umich.edu	Hofer, Timothy Philip/AAC-9238-2022	Hofer, Timothy/0000-0003-0434-8787	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60 DK20572] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; [Anonymous], 1991, OPHTHALMOLOGY, V98, P741; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], 1991, Ophthalmology, V98, P786; [Anonymous], 1995, DIAB AM; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062; DASBACH EJ, 1991, MED CARE, V29, P20, DOI 10.1097/00005650-199101000-00003; DASBACH EJ, 1992, MED DECIS MAKING, V12, P4; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Eastman RC, 1997, DIABETES CARE, V20, P725, DOI 10.2337/diacare.20.5.725; FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761; FREDERICK FL, 1993, JAMA-J AM MED ASSOC, V269, P1290; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; HAFFNER SM, 1988, DIABETES, V37, P878, DOI 10.2337/diabetes.37.7.878; HAMMAN RF, 1989, DIABETES, V38, P1231, DOI 10.2337/diabetes.38.10.1231; Harris EL, 1999, DIABETES CARE, V22, P779, DOI 10.2337/diacare.22.5.779; HARRIS EL, 1993, DIABETES CARE, V16, P748, DOI 10.2337/diacare.16.5.748; Harris MI, 1998, DIABETES CARE, V21, P1230, DOI 10.2337/diacare.21.8.1230; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017; JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909; JONES D, 1988, BRIT MED J, V296, P1029, DOI 10.1136/bmj.296.6628.1029; KINYOUN J, 1989, OPHTHALMOLOGY, V96, P746; KLEIN R, 1986, AM J EPIDEMIOL, V124, P104, DOI 10.1093/oxfordjournals.aje.a114353; KLEIN R, 1987, DIABETES CARE, V10, P633, DOI 10.2337/diacare.10.5.633; KLEIN R, 1989, ARCH INTERN MED, V149, P266, DOI 10.1001/archinte.149.2.266; KLEIN R, 1985, OPHTHALMOLOGY, V92, P485; KROLEWSKI AS, 1977, DIABETOLOGIA, V13, P345, DOI 10.1007/BF01223277; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; MANNING WG, 1996, COST EFFECTIVENESS H; MARTIN TL, 1995, DIABETES CARE, V18, P1124, DOI 10.2337/diacare.18.8.1124; MAYFIELD JA, 1994, DIABETES CARE, V17, P918, DOI 10.2337/diacare.17.8.918; Medhi J, 1994, STOCHASTIC PROCESSES; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; MOSS SE, 1985, OPHTHALMOLOGY, V92, P62; MUGGEO M, 1995, DIABETOLOGIA, V38, P318, DOI 10.1007/s001250050288; MULLAHY J, 1995, STAT ISSUES COST EFF, P149; *NAT COMM QUAL ASS, 1997, HLTH EMPL DAT INF SE, P2; NATHAN DM, 1991, DIABETES CARE, V14, P26, DOI 10.2337/diacare.14.1.26; Nathan DM, 1996, ANN INTERN MED, V124, P86, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00002; PANZRAM G, 1981, DIABETOLOGIA, V20, P587; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGER DE, 1992, ANN INTERN MED, V116, P660, DOI 10.7326/0003-4819-116-8-660; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; SUSSMAN EJ, 1982, JAMA-J AM MED ASSOC, V247, P3231, DOI 10.1001/jama.247.23.3231; Tudor SM, 1998, DIABETES CARE, V21, P53, DOI 10.2337/diacare.21.1.53; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vijan S, 1997, ANN INTERN MED, V127, P788, DOI 10.7326/0003-4819-127-9-199711010-00003; WYLIEROSETT J, 1995, J DIABETES COMPLICAT, V9, P49, DOI 10.1016/1056-8727(94)00005-9; 1996, FED REG, V61; 1994, VITAL HLTH STAT 1, V32, P1	57	180	185	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2000	283	7					889	896		10.1001/jama.283.7.889	http://dx.doi.org/10.1001/jama.283.7.889			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	281WT	10685713				2022-12-28	WOS:000085185000027
J	Hutter, H; Vogel, BE; Plenefisch, JD; Norris, CR; Proenca, RB; Spieth, J; Guo, CB; Mastwal, S; Zhu, XP; Scheel, J; Hedgecock, EM				Hutter, H; Vogel, BE; Plenefisch, JD; Norris, CR; Proenca, RB; Spieth, J; Guo, CB; Mastwal, S; Zhu, XP; Scheel, J; Hedgecock, EM			Cell biology: Conservation and novelty in the evolution of cell adhesion and extracellular matrix genes	SCIENCE			English	Review							CAENORHABDITIS-ELEGANS CUTICLE; REVERSE-TRANSCRIPTASE; C-ELEGANS; IMMUNOGLOBULIN SUPERFAMILY; CONCERTED EVOLUTION; MUSCULAR-DYSTROPHY; COLLAGEN GENE; RICH REPEATS; PROTEIN; DROSOPHILA	New proteins and modules have been invented throughout evolution. Gene "birth dates" in Caenorhabditis elegans range from the origins of cellular life through adaptation to a soil habitat. Possibly half are "metazoan" genes, having arisen sometime between the yeast-metazoan and nematode-chordate separations. These include basement membrane and cel adhesion molecules implicated in tissue organization. by contrast epithelial surfaces facing the environment have specialized components invented within the nematode lineage. Moreover, interstitial matrices were likely elaborated within the vertebrate lineage. A strategy for concerted evolution of new gene families, as well as conservation of adaptive genes, may underlie the differences between heterochromatin and euchromatin.	Max Planck Inst Med Res, D-69120 Heidelberg, Germany; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Univ Toledo, Dept Biol, Toledo, OH 43606 USA; Washington Univ, Genome Sequencing Ctr, St Louis, MO 63108 USA; Max Planck Inst Dev Biol, D-72076 Tubingen, Germany	Max Planck Society; Johns Hopkins University; University System of Ohio; University of Toledo; Washington University (WUSTL); Max Planck Society	Hutter, H (corresponding author), Max Planck Inst Med Res, Jahnstr 29, D-69120 Heidelberg, Germany.	hutter@mpimf-heidelberg.mpg.de						ALBERTSON DG, 1997, MONOGRAPH, V33, P47; Almeida A, 1998, ONCOGENE, V16, P2997, DOI 10.1038/sj.onc.1201828; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Blaxter M, 1998, SCIENCE, V282, P2041, DOI 10.1126/science.282.5396.2041; Brosius J, 1995, VIRUS GENES, V11, P163, DOI 10.1007/BF01728656; Brummendorf T, 1996, CURR OPIN NEUROBIOL, V6, P584, DOI 10.1016/S0959-4388(96)80089-4; Buechner M, 1999, DEV BIOL, V214, P227, DOI 10.1006/dbio.1999.9398; Burgeson RE, 1997, CURR OPIN CELL BIOL, V9, P651, DOI 10.1016/S0955-0674(97)80118-4; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Clarke ND, 1998, SCIENCE, V282, P2018, DOI 10.1126/science.282.5396.2018; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; DOVER G, 1994, CURR BIOL, V4, P1165, DOI 10.1016/S0960-9822(00)00265-7; Du HP, 1996, NEURON, V16, P183, DOI 10.1016/S0896-6273(00)80035-5; Eichler EE, 1999, HUM MOL GENET, V8, P151, DOI 10.1093/hmg/8.2.151; FLAVELL AJ, 1995, COMP BIOCHEM PHYS B, V110, P3, DOI 10.1016/0305-0491(94)00122-B; Fryxell KJ, 1996, TRENDS GENET, V12, P364, DOI 10.1016/S0168-9525(96)80020-5; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Gilleard JS, 1997, GENE, V193, P181, DOI 10.1016/S0378-1119(97)00112-1; Hadjantonakis AK, 1997, GENOMICS, V45, P97, DOI 10.1006/geno.1997.4892; Henikoff S, 1998, BIOESSAYS, V20, P532, DOI 10.1002/(SICI)1521-1878(199807)20:7<532::AID-BIES3>3.3.CO;2-0; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUTTER H, UNPUB; JACKSON FR, 1993, COMP BIOCHEM PHYS A, V104, P749, DOI 10.1016/0300-9629(93)90150-3; JOHNSTONE IL, 1994, BIOESSAYS, V16, P171, DOI 10.1002/bies.950160307; Johnstone IL, 1996, EMBO J, V15, P3633, DOI 10.1002/j.1460-2075.1996.tb00732.x; JONES SJM, 1995, MOL GEN GENET, V248, P719, DOI 10.1007/BF02191712; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; Kohara Y, 1996, Tanpakushitsu Kakusan Koso, V41, P715; KRAMER JM, 1997, MONOGRAPH, V33, P471; KUWABARA PE, 1994, NUCLEIC ACIDS RES, V22, P4414, DOI 10.1093/nar/22.21.4414; LASSANDRO F, 1994, MOL BIOCHEM PARASIT, V65, P147, DOI 10.1016/0166-6851(94)90123-6; LE MH, 1995, GENETICS, V141, P283; Liao DQ, 1997, EMBO J, V16, P588, DOI 10.1093/emboj/16.3.588; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Maness PF, 1996, PERSPECT DEV NEUROBI, V4, P169; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nei M, 1997, P NATL ACAD SCI USA, V94, P7799, DOI 10.1073/pnas.94.15.7799; NOUVEL P, 1994, GENETICA, V93, P191, DOI 10.1007/BF01435251; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; Peixoto CA, 1997, J PARASITOL, V83, P368, DOI 10.2307/3284396; PIMPINELLI S, 1995, P NATL ACAD SCI USA, V92, P3804, DOI 10.1073/pnas.92.9.3804; Robertson HM, 1998, GENOME RES, V8, P449, DOI 10.1101/gr.8.5.449; Rose D, 1997, DEVELOPMENT, V124, P1561; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SALA C, 1995, J NEUROSCI, V15, P520; Semple C, 1999, J MOL EVOL, V48, P555, DOI 10.1007/PL00006498; Shishido E, 1998, SCIENCE, V280, P2118, DOI 10.1126/science.280.5372.2118; Sicot FX, 1997, EUR J BIOCHEM, V246, P50, DOI 10.1111/j.1432-1033.1997.00050.x; SMITH GP, 1976, SCIENCE, V191, P528, DOI 10.1126/science.1251186; Sonnhammer ELL, 1997, GENOMICS, V46, P200, DOI 10.1006/geno.1997.4989; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; Suzuki Y, 1996, J BIOL CHEM, V271, P22522, DOI 10.1074/jbc.271.37.22522; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; VOGEL B, UNPUB; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; 1996, CURR OPIN GENET DEV, V6, P193	69	206	218	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2000	287	5455					989	994		10.1126/science.287.5455.989	http://dx.doi.org/10.1126/science.287.5455.989			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669422				2022-12-28	WOS:000085245400036
J	Sasaki, T; Irie-Sasaki, J; Jones, RG; Oliveira-dos-Santos, AJ; Stanford, WL; Bolon, B; Wakeham, A; Itie, A; Bouchard, D; Kozieradzki, I; Joza, N; Mak, TW; Ohashi, PS; Suzuki, A; Penninger, JM				Sasaki, T; Irie-Sasaki, J; Jones, RG; Oliveira-dos-Santos, AJ; Stanford, WL; Bolon, B; Wakeham, A; Itie, A; Bouchard, D; Kozieradzki, I; Joza, N; Mak, TW; Ohashi, PS; Suzuki, A; Penninger, JM			Function of PI3K gamma in thymocyte development, T cell activation, and neutrophil migration	SCIENCE			English	Article							3-KINASE; KINASE; PHOSPHORYLATION; INHIBITION; WORTMANNIN; PEPTIDE; SYSTEM; PI3K	Phosphoinositide 3-kinases (PI3Ks) regulate fundamental cellular responses such as proliferation, apoptosis, cell motility, and adhesion. Viable gene-targeted mice Lacking the p110 catalytic subunit of PI3K gamma were generated. We show that PI3K gamma controls thymocyte survival and activation of mature T cells but has no role in the development or function of B cells. PI3K gamma-deficient neutrophils exhibited severe defects in migration and respiratory burst in response to heterotrimeric CTP-binding protein (G protein)-coupled receptor (GPCR) agonists and chemotactic agents. PI3K gamma Links GPCR stimulation to the formation of phosphatidylinositol 3,4,5-triphosphate and the activation of protein kinase B, ribosomal protein S6 kinase, and extracellular signal-regulated kinases 1 and 2. Thus, PI3K gamma regulates thymocyte development, T cell activation, neutrophil migration, and the oxidative burst.	Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Genet, Toronto, ON M5G 2C1, Canada; Univ Toronto, Mt Sinai Hosp, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Mt Sinai Hosp, Dept Immunol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Amgen, Dept Pathol, Thousand Oaks, CA 91320 USA	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Amgen	Penninger, JM (corresponding author), Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Jones, Russell/AAC-2861-2022; Penninger, Josef M/I-6860-2013; Suzuki, Akira/GYD-6697-2022; Jones, Russell Graham/ABD-5261-2021	Penninger, Josef M/0000-0002-8194-3777; Suzuki, Akira/0000-0002-5950-8808; Jones, Russell Graham/0000-0003-2250-4675; Stanford, William/0000-0002-5813-8016; Ohashi, Pamela S./0000-0003-2915-9317; Sasaki, Takehiko/0000-0003-1837-3748				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; COURNOYER D, 1993, ANNU REV IMMUNOL, V11, P297; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Mariathasan S, 1999, SEMIN IMMUNOL, V11, P263, DOI 10.1006/smim.1999.0182; OKADA T, 1994, J BIOL CHEM, V269, P3563; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; Sasaki T, 1996, BIOCHEM J, V315, P1035, DOI 10.1042/bj3151035; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648	23	891	988	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1040	1046		10.1126/science.287.5455.1040	http://dx.doi.org/10.1126/science.287.5455.1040			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669416				2022-12-28	WOS:000085245400048
J	Song, WQ; Raden, D; Mandon, EC; Gilmore, R				Song, WQ; Raden, D; Mandon, EC; Gilmore, R			Role of Sec61 alpha in the regulated transfer of the ribosome-nascent chain complex from the signal recognition particle to the translocation channel	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN TRANSLOCATION; GTP HYDROLYSIS; BETA-SUBUNIT; ER MEMBRANE; SEQUENCE RECOGNITION; SECRETORY PROTEIN; ALPHA-SUBUNIT; RECEPTOR; BINDING	Targeting of ribosome-nascent chain complexes to the translocon in the endoplasmic reticulum is mediated by the concerted action of the signal recognition particle (SRP) and the SRP receptor (SR). Ribosome-stripped microsomes were digested with proteases to sever cytoplasmic domains of SR alpha, SR beta, TRAM, and the Sec61 complex. We characterized protein translocation intermediates that accumulate when Sec61 alpha or SRP is inactivated by proteolysis. In the absence of a functional Sec61 complex, dissociation of SRP54 from the signal sequence is blocked. Experiments using SR proteoliposomes confirmed the assembly of a membrane-bound posttargeting intermediate. These results strongly suggest that the Sec61 complex regulates the GTP hydrolysis cycle of the SRP-SR complex at the stage of signal sequence dissociation from SRP54.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Gilmore, R (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01655 USA.	reid.gilmore@umassmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035687] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35687] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacher G, 1999, J CELL BIOL, V146, P723, DOI 10.1083/jcb.146.4.723; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1993, J CELL BIOL, V123, P799, DOI 10.1083/jcb.123.4.799; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; Knight BC, 1998, BIOCHEM J, V331, P161, DOI 10.1042/bj3310161; LAUFFER L, 1985, NATURE, V318, P334, DOI 10.1038/318334a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; Ogg SC, 1998, J CELL BIOL, V142, P341, DOI 10.1083/jcb.142.2.341; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Raden D, 1998, MOL BIOL CELL, V9, P117, DOI 10.1091/mbc.9.1.117; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Wilkinson BM, 1997, EMBO J, V16, P4549, DOI 10.1093/emboj/16.15.4549; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650	38	113	115	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					333	343		10.1016/S0092-8674(00)80669-8	http://dx.doi.org/10.1016/S0092-8674(00)80669-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676815	Bronze			2022-12-28	WOS:000085204400007
J	Verhage, M; Maia, AS; Plomp, JJ; Brussaard, AB; Heeroma, JH; Vermeer, H; Toonen, RF; Hammer, RE; van den Berg, TK; Missler, M; Geuze, HJ; Sudhof, TC				Verhage, M; Maia, AS; Plomp, JJ; Brussaard, AB; Heeroma, JH; Vermeer, H; Toonen, RF; Hammer, RE; van den Berg, TK; Missler, M; Geuze, HJ; Sudhof, TC			Synaptic assembly of the brain in the absence of neurotransmitter secretion	SCIENCE			English	Article							ACETYLCHOLINE-RELEASE; HIPPOCAMPAL-NEURONS; TRANSMITTER RELEASE; VESICLE EXOCYTOSIS; EMBRYONIC NEURON; AXON GUIDANCE; SYNAPSIN-I; RAT-BRAIN; PROTEIN; SYNTAXIN	Brain function requires precisely orchestrated connectivity between neurons. Establishment of these connections is believed to require signals secreted from outgrowing axons, followed by synapse formation between selected neurons. Deletion of a single protein, Munc18-1, in mice Leads to a complete Loss of neurotransmitter secretion from synaptic vesicles throughout development. However, this does not prevent normal brain assembly, including formation of Layered structures, fiber pathways, and morphologically defined synapses. After assembly is completed, neurons undergo apoptosis, leading to widespread neurodegeneration. Thus, synaptic connectivity does not depend on neurotransmitter secretion, but its maintenance does. Neurotransmitter secretion probably functions to validate already established synaptic connections.	Univ Utrecht, Med Ctr, Rudolf Magnus Inst, Utrecht, Netherlands; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Physiol, Leiden, Netherlands; Vrije Univ Amsterdam, Inst Neurosci, Dept Neurophysiol, Amsterdam, Netherlands; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Vrije Univ Amsterdam, Dept Cell Biol & Immunol, Amsterdam, Netherlands; Univ Utrecht, Dept Cell Biol, Utrecht, Netherlands	Utrecht University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Vrije Universiteit Amsterdam; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vrije Universiteit Amsterdam; Utrecht University	Verhage, M (corresponding author), Univ Utrecht, Med Ctr, Rudolf Magnus Inst, Utrecht, Netherlands.		Heeroma, Joost/AFI-8727-2022; Heeroma, Joost/AAF-4310-2022; van den Berg, Timo K/AAC-2479-2022; Heeroma, Joost/C-1749-2008	verhage, matthijs/0000-0002-6085-7503; Hammer, Robert E./0000-0001-5487-7551; Missler, Markus/0000-0001-8008-984X				[Anonymous], 1990, SYNAPTIC ORG BRAIN; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Brussaard AB, 1997, NEURON, V19, P1103, DOI 10.1016/S0896-6273(00)80401-8; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Calakos N, 1996, PHYSIOL REV, V76, P1; CATSICAS S, 1994, TRENDS NEUROSCI, V17, P368, DOI 10.1016/0166-2236(94)90045-0; Coco S, 1998, J NEUROCHEM, V71, P1987; Daly C, 1997, J NEUROSCI, V17, P2365; de Vries J., UNPUB; Fernandez-Chacon R, 1999, ANNU REV PHYSIOL, V61, P753, DOI 10.1146/annurev.physiol.61.1.753; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; Hallonet M, 1998, DEVELOPMENT, V125, P2599; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HUME DA, 1983, J EXP MED, V157, P1704, DOI 10.1084/jem.157.5.1704; Igarashi M, 1997, J NEUROSCI, V17, P1460; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KONIG N, 1975, ANAT EMBRYOL, V148, P73, DOI 10.1007/BF00315564; MAIA AS, UNPUB; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; Milner LD, 1999, J NEUROSCI, V19, P3007; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OsenSand A, 1996, J COMP NEUROL, V367, P222, DOI 10.1002/(SICI)1096-9861(19960401)367:2<222::AID-CNE5>3.0.CO;2-7; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PLOMP JJ, 1994, J PHYSIOL-LONDON, V478, P125, DOI 10.1113/jphysiol.1994.sp020236; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUN YA, 1987, P NATL ACAD SCI USA, V84, P2540, DOI 10.1073/pnas.84.8.2540; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Williamson LC, 1998, J NEUROSCI RES, V52, P569, DOI 10.1002/(SICI)1097-4547(19980601)52:5<569::AID-JNR9>3.0.CO;2-A; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069	42	947	976	0	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					864	869		10.1126/science.287.5454.864	http://dx.doi.org/10.1126/science.287.5454.864			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657302				2022-12-28	WOS:000085136400049
J	Baptiste, KE; Naylor, JM; Bailey, J; Barber, EM; Post, K; Thornhill, J				Baptiste, KE; Naylor, JM; Bailey, J; Barber, EM; Post, K; Thornhill, J			Physiology - A function for guttural pouches in the horse	NATURE			English	Article							BLOOD-FLOW; EXERCISE; HEAT		Univ Saskatchewan, Dept Vet Internal Med, Saskatoon, SK S7N 5B4, Canada; Univ Saskatchewan, Dept Vet Anaesthesia Radiol & Surg, Saskatoon, SK S7N 5B4, Canada; Univ Saskatchewan, Dept Agr Engn, Saskatoon, SK S7N 5B4, Canada; Univ Saskatchewan, Dept Physiol, Saskatoon, SK S7N 5B4, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Baptiste, KE (corresponding author), Danish Vet Lab, Bulowsvej 27, Copenhagen, Denmark.	keb@svs.dk						BAKER MA, 1982, ANNU REV PHYSIOL, V44, P85, DOI 10.1146/annurev.ph.44.030182.000505; BRANDT JF, 1863, B ACAD IMPERIAL SCI, V5, P508; Day M, 1999, NEW SCI, V161, P7; Ghoshal N, 1981, VENOUS DRAINAGE DOME; HINCHCLIFFE R, 1969, J ZOOL, V157, P277; HODGSON DR, 1993, J APPL PHYSIOL, V74, P1161, DOI 10.1152/jappl.1993.74.3.1161; McConaghy F F, 1996, Equine Vet J Suppl, P42; McConaghy FF, 1995, J APPL PHYSIOL, V79, P1849, DOI 10.1152/jappl.1995.79.6.1849; ORR JA, 1983, AM J PHYSIOL, V244, pH142, DOI 10.1152/ajpheart.1983.244.1.H142; PARKS CM, 1983, AM J VET RES, V44, P1861	10	36	37	0	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					382	383		10.1038/35000284	http://dx.doi.org/10.1038/35000284			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667779				2022-12-28	WOS:000085121100035
J	Paltiel, Y; Zeldov, E; Myasoedov, YN; Shtrikman, H; Bhattacharya, S; Higgins, MJ; Xiao, ZL; Andrei, EY; Gammel, PL; Bishop, DJ				Paltiel, Y; Zeldov, E; Myasoedov, YN; Shtrikman, H; Bhattacharya, S; Higgins, MJ; Xiao, ZL; Andrei, EY; Gammel, PL; Bishop, DJ			Dynamic instabilities and memory effects in vortex matter	NATURE			English	Article							FLUX-LINE-LATTICE; HIGH-TEMPERATURE SUPERCONDUCTORS; TRANSPORT-PROPERTIES; PHASE-TRANSITIONS; BI2SR2CACU2O8; CRYSTALS; SURFACE; MOTION; FLOW; PEAK	The magnetic flux line lattice in type II superconductors serves as a useful system in which to study condensed matter flow, as its dynamic properties are tunable. Recent studies have shown a number of puzzling phenomena associated with vortex motion, including: low-frequency noise(1-5) and slow voltage oscillations(3,6); a history-dependent dynamic response(7-12), and memory of the direction, amplitude duration and frequency of the previously applied current(13,14); high vortex mobility for alternating current, but no apparent vortex motion for direct currents(13,15,16); and strong suppression of an a.c. response by small d.c. bias(13). Taken together, these phenomena are incompatible with current understanding of vortex dynamics. Here we report a generic mechanism that accounts for these observations. Our model, which is derived from investigations of the current distribution across single crystals of NbSe2, is based on a competition between the injection of a disordered vortex phase at the sample edges, and the dynamic annealing of this metastable disorder by the transport current. For an alternating current, only narrow regions near the edges are in the disordered phase, while for d.c. bias, most of the sample is in the disordered phase-preventing vortex motion because of more efficient pinning. The resulting spatial dependence of the disordered vortex system serves as an active memory of the previous history.	Weizmann Inst Sci, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel; Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA; NEC Res Inst, Princeton, NJ 08540 USA; Tata Inst Fundamental Res, Mumbai 400005, India; Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08855 USA	Weizmann Institute of Science; Alcatel-Lucent; Lucent Technologies; AT&T; NEC Corporation; Tata Institute of Fundamental Research (TIFR); Rutgers State University New Brunswick	Paltiel, Y (corresponding author), Weizmann Inst Sci, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel.	hpalt@wis.weizmann.ac.il	Paltiel, Yossi/AAJ-3917-2020; Zeldov, Eli/K-1546-2012	Zeldov, Eli/0000-0002-8200-4974; Paltiel, Yossi/0000-0002-8739-9952				Andrei EY, 1999, J PHYS IV, V9, P5, DOI 10.1051/jp4:19991002; Banerjee SS, 1999, APPL PHYS LETT, V74, P126, DOI 10.1063/1.123139; Banerjee SS, 1998, PHYS REV B, V58, P995, DOI 10.1103/PhysRevB.58.995; BEAN CP, 1964, PHYS REV LETT, V12, P14, DOI 10.1103/PhysRevLett.12.14; BHATTACHARYA S, 1995, PHYS REV B, V52, P64, DOI 10.1103/PhysRevB.52.64; Burlachkov L, 1996, PHYS REV B, V54, P6750, DOI 10.1103/PhysRevB.54.6750; DANNA G, 1995, PHYS REV LETT, V75, P3521, DOI 10.1103/PhysRevLett.75.3521; Ertas D, 1996, PHYSICA C, V272, P79, DOI 10.1016/S0921-4534(96)00563-1; Fuchs DT, 1998, NATURE, V391, P373, DOI 10.1038/34879; Fuchs DT, 1998, PHYS REV LETT, V80, P4971, DOI 10.1103/PhysRevLett.80.4971; Gammel PL, 1998, PHYS REV LETT, V80, P833, DOI 10.1103/PhysRevLett.80.833; GIAMARCHI T, 1994, PHYS REV LETT, V72, P1530, DOI 10.1103/PhysRevLett.72.1530; Gordeev SN, 1997, NATURE, V385, P324, DOI 10.1038/385324a0; Henderson W, 1998, PHYS REV LETT, V81, P2352, DOI 10.1103/PhysRevLett.81.2352; Henderson W, 1996, PHYS REV LETT, V77, P2077, DOI 10.1103/PhysRevLett.77.2077; Khaykovich B, 1996, PHYS REV LETT, V76, P2555, DOI 10.1103/PhysRevLett.76.2555; Kokkaliaris S, 1999, PHYS REV LETT, V82, P5116, DOI 10.1103/PhysRevLett.82.5116; Kwok WK, 1997, PHYSICA C, V293, P111, DOI 10.1016/S0921-4534(97)01525-6; MARLEY AC, 1995, PHYS REV LETT, V74, P3029, DOI 10.1103/PhysRevLett.74.3029; Merithew RD, 1996, PHYS REV LETT, V77, P3197, DOI 10.1103/PhysRevLett.77.3197; METLUSHKO V, 1999, CONDMAT9804121; Paltiel Y, 1998, PHYS REV B, V58, P14763, DOI 10.1103/PhysRevB.58.R14763; Pardo F, 1997, PHYS REV LETT, V78, P4633, DOI 10.1103/PhysRevLett.78.4633; Tsuboi T, 1998, PHYS REV LETT, V80, P4550, DOI 10.1103/PhysRevLett.80.4550; Vinokur V, 1998, PHYSICA C, V295, P209, DOI 10.1016/S0921-4534(97)01795-4; WORDENWEBER R, 1986, PHYS REV B, V33, P3172, DOI 10.1103/PhysRevB.33.3172; Xiao ZL, 1999, PHYS REV LETT, V83, P1664, DOI 10.1103/PhysRevLett.83.1664; YARON U, 1995, NATURE, V376, P753, DOI 10.1038/376753a0	28	238	241	3	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					398	401		10.1038/35000145	http://dx.doi.org/10.1038/35000145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667785	Green Submitted			2022-12-28	WOS:000085121100041
J	Feltham, JL; Gierasch, LM				Feltham, JL; Gierasch, LM			GroEL-substrate interactions: Molding the fold, or folding the mold?	CELL			English	Review							POLYPEPTIDE BINDING; IN-VIVO; PROTEIN; MODEL		Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Feltham, JL (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA.		Gierasch, Lila M/D-1494-2009					Brazil BT, 1997, J BIOL CHEM, V272, P5105, DOI 10.1074/jbc.272.8.5105; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Capaldi AP, 1998, CURR OPIN STRUC BIOL, V8, P86, DOI 10.1016/S0959-440X(98)80014-6; Chen LL, 1999, CELL, V99, P757, DOI 10.1016/S0092-8674(00)81673-6; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Coyle JE, 1999, NAT STRUCT BIOL, V6, P683; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Kobayashi N, 1999, J MOL BIOL, V292, P181, DOI 10.1006/jmbi.1999.3042; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Preuss M, 1999, BIOCHEMISTRY-US, V38, P10272, DOI 10.1021/bi990342l; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Tanaka N, 1999, J MOL BIOL, V292, P173, DOI 10.1006/jmbi.1999.3041; Wang ZL, 1999, BIOCHEMISTRY-US, V38, P12537, DOI 10.1021/bi991070p; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	20	30	31	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2000	100	2					193	196		10.1016/S0092-8674(00)81557-3	http://dx.doi.org/10.1016/S0092-8674(00)81557-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660042	Bronze			2022-12-28	WOS:000084932200003
J	Barth, JH				Barth, JH			Should men still go bald gracefully?	LANCET			English	Editorial Material							ANDROGENETIC ALOPECIA; RECEPTOR; WOMEN		Gen Infirm, Dept Clin Biochem & Immunol, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary	Barth, JH (corresponding author), Gen Infirm, Dept Clin Biochem & Immunol, Leeds LS1 3EX, W Yorkshire, England.		Barth, Julian H/F-6028-2010					GRINO PB, 1990, ENDOCRINOLOGY, V126, P1165, DOI 10.1210/endo-126-2-1165; Hamilton JB, 1942, AM J ANAT, V71, P451, DOI 10.1002/aja.1000710306; Kaufman KD, 1998, J AM ACAD DERMATOL, V39, P578, DOI 10.1016/S0190-9622(98)70007-6; Orme S, 1999, BRIT J DERMATOL, V141, P521; Price VH, 1999, J AM ACAD DERMATOL, V41, P717, DOI 10.1016/S0190-9622(99)70006-X; Reynolds AJ, 1999, NATURE, V402, P33, DOI 10.1038/46938; Roberts JL, 1999, J AM ACAD DERMATOL, V41, P555, DOI 10.1016/S0190-9622(99)70296-3; RUSHTON DH, 1992, CLIN ENDOCRINOL, V36, P421; RUSHTON DH, 1991, CLIN EXP DERMATOL, V16, P188, DOI 10.1111/j.1365-2230.1991.tb00343.x; Sawaya ME, 1997, J INVEST DERMATOL, V109, P296, DOI 10.1111/1523-1747.ep12335779	10	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2000	355	9199					161	162		10.1016/S0140-6736(99)00412-2	http://dx.doi.org/10.1016/S0140-6736(99)00412-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675111				2022-12-28	WOS:000084879700005
J	Jenni, OG				Jenni, OG			On the other of the tracks	LANCET			English	Editorial Material									Univ Zurich, Childrens Hosp, CH-8032 Zurich, Switzerland	University Children's Hospital Zurich; University of Zurich	Jenni, OG (corresponding author), Univ Zurich, Childrens Hosp, CH-8032 Zurich, Switzerland.		Jenni, Oskar/AAG-4391-2019	Jenni, Oskar/0000-0002-4561-6277					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					139	140		10.1016/S0140-6736(99)11156-5	http://dx.doi.org/10.1016/S0140-6736(99)11156-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675183				2022-12-28	WOS:000085557200040
J	Showalter, E				Showalter, E			Commentary: An inconclusive study	BRITISH MEDICAL JOURNAL			English	Editorial Material									Princeton Univ, Dept English, Princeton, NJ 08544 USA	Princeton University	Showalter, E (corresponding author), Princeton Univ, Dept English, Princeton, NJ 08544 USA.							1996, SCI NEWS UPDATE 1030	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1604	1605						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10660324				2022-12-28	WOS:000084562600010
J	Shannon, JR; Flattem, NL; Jordan, J; Jacob, G; Black, BK; Biaggioni, I; Blakely, RD; Robertson, D				Shannon, JR; Flattem, NL; Jordan, J; Jacob, G; Black, BK; Biaggioni, I; Blakely, RD; Robertson, D			Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VALVE PROLAPSE SYNDROME; NORADRENALINE TRANSPORTER; HEART; GENE; FAILURE; CLONING; PLASMA; HUMANS	Background: Orthostatic intolerance is a syndrome characterized by lightheadedness, fatigue, altered mentation, and syncope and associated with postural tachycardia and plasma norepinephrine concentrations that are disproportionately high in relation to sympathetic outflow. We tested the hypothesis that impaired functioning of the norepinephrine transporter contributes to the pathophysiologic mechanism of orthostatic intolerance. Methods: In a patient with orthostatic intolerance and her relatives, we measured postural blood pressure, heart rate, plasma catecholamines, and systemic norepinephrine spillover and clearance, and we sequenced the norepinephrine-transporter gene and evaluated its function. Results: The patient had a high mean plasma norepinephrine concentration while standing, as compared with the mean (+/-SD) concentration in normal subjects (923 vs. 439+/-129 pg per milliliter [5.46 vs. 2.59+/-0.76 nmol per liter]), reduced systemic norepinephrine clearance (1.56 vs. 2.42+/-0.71 liters per minute), impairment in the increase in the plasma norepinephrine concentration after the administration of tyramine (12 vs. 56+/-63 pg per milliliter [0.07 vs. 0.33+/-0.37 pmol per liter]), and a disproportionate increase in the concentration of plasma norepinephrine relative to that of dihydroxyphenylglycol. Analysis of the norepinephrine-transporter gene revealed that the proband was heterozygous for a mutation in exon 9 (encoding a change from guanine to cytosine at position 237) that resulted in more than a 98 percent loss of function as compared with that of the wild-type gene. Impairment of synaptic norepinephrine clearance may result in a syndrome characterized by excessive sympathetic activation in response to physiologic stimuli. The mutant allele in the proband's family segregated with the postural heart rate and abnormal plasma catecholamine homeostasis. Conclusions: Genetic or acquired deficits in norepinephrine inactivation may underlie hyperadrenergic states that lead to orthostatic intolerance. (N Engl J Med 2000;342:541-9.) (C)2000, Massachusetts Medical Society.	Vanderbilt Univ, Autonom Dysfunct Ctr, Nashville, TN USA; Vanderbilt Univ, Ctr Mol Neurosci, Dept Med, Nashville, TN USA; Vanderbilt Univ, Ctr Mol Neurosci, Dept Neurol, Nashville, TN USA; Vanderbilt Univ, Ctr Mol Neurosci, Dept Pharmacol, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Robertson, D (corresponding author), Gen Clin Res Ctr, AA3228 MCN, Nashville, TN 37232 USA.	david.robertson@mcmail.vanderbilt.edu			NCRR NIH HHS [RR00095] Funding Source: Medline; NHLBI NIH HHS [P01 HL56693] Funding Source: Medline; NIMH NIH HHS [MH58921] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058921] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADLERGRASCHINSK.E, 1975, BRIT J PHARMACOL, V53, P43, DOI 10.1111/j.1476-5381.1975.tb07328.x; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733; BLAKELY RD, 1994, J EXP BIOL, V196, P263; BOUDOULAS H, 1980, CIRCULATION, V61, P1200, DOI 10.1161/01.CIR.61.6.1200; BRUSS M, 1993, HUM GENET, V91, P278; DAVIS D, 1987, CIRC RES, V61, P87; DEMANET JC, 1976, CARDIOLOGY, V61, P213, DOI 10.1159/000169812; ESLER M, 1990, PHYSIOL REV, V70, P963, DOI 10.1152/physrev.1990.70.4.963; ESLER MD, 1991, AM J PHYSIOL, V260, pR817, DOI 10.1152/ajpregu.1991.260.4.R817; FOUAD FM, 1986, ANN INTERN MED, V104, P298, DOI 10.7326/0003-4819-104-3-298; Fraser F, 1918, BRIT MED J, V1918, P27, DOI 10.1136/bmj.2.3002.27; Furlan R, 1998, CIRCULATION, V98, P2154, DOI 10.1161/01.CIR.98.20.2154; GOLDBERG MR, 1982, CLIN EXP HYPERTENS, V4, P595, DOI 10.3109/10641968209061601; GOLDSTEIN DS, 1988, J CLIN INVEST, V81, P213, DOI 10.1172/JCI113298; GOLDSTEIN DS, 1988, CIRCULATION, V78, P41, DOI 10.1161/01.CIR.78.1.41; Jacob G, 1997, CIRCULATION, V96, P575; Jacob G, 1999, CIRCULATION, V99, P1706, DOI 10.1161/01.CIR.99.13.1706; LOW PA, 1995, NEUROLOGY, V45, pS19; Mosqueda-Garcia R, 1995, DISORDERS AUTONOMIC, P25; Novak V, 1996, J AUTONOM NERV SYST, V61, P313, DOI 10.1016/S0165-1838(96)00101-4; Novak V, 1998, STROKE, V29, P1876, DOI 10.1161/01.STR.29.9.1876; NOVI AM, 1968, ANAT REC, V160, P123, DOI 10.1002/ar.1091600111; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Porzgen P, 1996, BIOCHEM BIOPH RES CO, V227, P642, DOI 10.1006/bbrc.1996.1559; PORZGEN P, 1995, BIOCHEM BIOPH RES CO, V215, P1145, DOI 10.1006/bbrc.1995.2582; RILEY M, 1991, CLIN SCI, V80, P633, DOI 10.1042/cs0800633; ROSEN SG, 1982, AM J MED, V72, P847, DOI 10.1016/0002-9343(82)90559-9; SCHONDORF R, 1993, NEUROLOGY, V43, P132, DOI 10.1212/WNL.43.1_Part_1.132; Schondorf R, 1999, AM J MED SCI, V317, P117, DOI 10.1097/00000441-199902000-00006; Shannon JR, 1998, CIRCULATION, V98, P336; Shannon JR, 1998, HYPERTENSION, V32, P101, DOI 10.1161/01.HYP.32.1.101; SHOUP RE, 1977, CLIN CHEM, V23, P1268; Stober G, 1996, AM J MED GENET, V67, P523, DOI 10.1002/(SICI)1096-8628(19961122)67:6<523::AID-AJMG3>3.0.CO;2-I; STREETEN DHP, 1987, ORTHOSTATIC DISORDER, P111; TUNG CS, 1983, J PHARMACOL EXP THER, V227, P484; WOOLEY CF, 1976, CIRCULATION, V53, P749, DOI 10.1161/01.CIR.53.5.749	36	402	418	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					541	549		10.1056/NEJM200002243420803	http://dx.doi.org/10.1056/NEJM200002243420803			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684912				2022-12-28	WOS:000085422400003
J	Henson, R; Shallice, T; Dolan, R				Henson, R; Shallice, T; Dolan, R			Neuroimaging evidence for dissociable forms of repetition priming	SCIENCE			English	Article							RECOGNITION MEMORY; WORD IDENTIFICATION; TEMPORAL CORTEX; IMPLICIT MEMORY; MECHANISMS; FACES; FMRI	Repetition priming has been characterized neurophysiologically as a decreased response following stimulus repetition. The present study used event-related functional magnetic resonance imaging to investigate whether this repetition-related response is sensitive to stimulus familiarity. A right fusiform region exhibited an attenuated response to the repetition of familiar stimuli, both faces and symbols, but exhibited an enhanced response to the repetition of unfamiliar stimuli. Moreover, both repetition effects were modulated by lag between successive presentations. Further experiments replicated the interactions between repetition, familiarity, and lag and demonstrated the persistence of these effects over multiple repetitions. Priming-related responses are therefore not unitary but depend on the presence or absence of preexisting stimulus representations.	UCL, Wellcome Dept Cognit Neurol, Inst Neurol, London WC1E 6BT, England; UCL, Inst Cognit Neurosci, London WC1E 6BT, England; UCL, Dept Psychol, London WC1E 6BT, England; Scuola Int Super Studi Avanzati, I-34014 Trieste, Italy; Royal Free & Univ Coll, Sch Med, London NW3 2PF, England	University of London; University College London; University of London; University College London; University of London; University College London; International School for Advanced Studies (SISSA); University of London; University College London; UCL Medical School	Henson, R (corresponding author), UCL, Wellcome Dept Cognit Neurol, Inst Neurol, London WC1E 6BT, England.	r.henson@ucl.ac.uk	Henson, Richard/H-8822-2019	Henson, Richard/0000-0002-0712-2639; Dolan, Ray/0000-0001-9356-761X				BENTIN S, 1988, J EXP PSYCHOL GEN, V117, P148, DOI 10.1037/0096-3445.117.2.148; Blaxton TA, 1996, CAN J EXP PSYCHOL, V50, P42, DOI 10.1037/1196-1961.50.1.42; Brown MW, 1998, PROG NEUROBIOL, V55, P149, DOI 10.1016/S0301-0082(98)00002-1; BROWN MW, 1987, BRAIN RES, V409, P158, DOI 10.1016/0006-8993(87)90753-0; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; Buckner RL, 1998, NEURON, V20, P285, DOI 10.1016/S0896-6273(00)80456-0; CAVE CB, 1992, J EXP PSYCHOL LEARN, V18, P509, DOI 10.1037/0278-7393.18.3.509; Cocosco C. A., 1997, NEUROIMAGE, V5, P425; Dale AM, 1997, HUM BRAIN MAPP, V5, P329, DOI 10.1002/(SICI)1097-0193(1997)5:5<329::AID-HBM1>3.0.CO;2-5; Desimone R, 1996, P NATL ACAD SCI USA, V93, P13494, DOI 10.1073/pnas.93.24.13494; Dolan RJ, 1997, NATURE, V389, P596, DOI 10.1038/39309; ELLIS AW, 1989, BRAIN, V112, P1469, DOI 10.1093/brain/112.6.1469; Gauthier I, 1999, NAT NEUROSCI, V2, P568, DOI 10.1038/9224; George N, 1999, NAT NEUROSCI, V2, P574, DOI 10.1038/9230; Josephs O, 1999, PHILOS T R SOC B, V354, P1215, DOI 10.1098/rstb.1999.0475; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Lewis MB, 1999, Q J EXP PSYCHOL-A, V52, P927, DOI 10.1080/027249899390873; MILLER EK, 1994, SCIENCE, V263, P520, DOI 10.1126/science.8290960; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MORTON J, 1969, PSYCHOL REV, V76, P165, DOI 10.1037/h0027366; NAGY ME, 1989, PSYCHOPHYSIOLOGY, V26, P431, DOI 10.1111/j.1469-8986.1989.tb01946.x; Reber PJ, 1998, LEARN MEMORY, V5, P420; ROLLS ET, 1989, EXP BRAIN RES, V76, P153; SALASOO A, 1985, J EXP PSYCHOL GEN, V114, P50, DOI 10.1037/0096-3445.114.1.50; SCHACTER DL, 1990, ANN NY ACAD SCI, V608, P543, DOI 10.1111/j.1749-6632.1990.tb48909.x; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCHACTER DL, 1995, NATURE, V376, P587, DOI 10.1038/376587a0; Tempini MLG, 1998, BRAIN, V121, P2103, DOI 10.1093/brain/121.11.2103; TENPENNY PL, 1995, PSYCHON B REV, V2, P339, DOI 10.3758/BF03210972; Wiggs CL, 1998, CURR OPIN NEUROBIOL, V8, P227, DOI 10.1016/S0959-4388(98)80144-X	31	504	510	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2000	287	5456					1269	1272		10.1126/science.287.5456.1269	http://dx.doi.org/10.1126/science.287.5456.1269			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	286KG	10678834	Green Published			2022-12-28	WOS:000085444700051
J	Santer, BD; Wigley, TML; Gaffen, DJ; Bengtsson, L; Doutriaux, C; Boyle, JS; Esch, M; Hnilo, JJ; Jones, PD; Meehl, GA; Roeckner, E; Taylor, KE; Wehner, MF				Santer, BD; Wigley, TML; Gaffen, DJ; Bengtsson, L; Doutriaux, C; Boyle, JS; Esch, M; Hnilo, JJ; Jones, PD; Meehl, GA; Roeckner, E; Taylor, KE; Wehner, MF			Interpreting differential temperature trends at the surface and in the lower troposphere	SCIENCE			English	Article							AIR-TEMPERATURE; CLIMATE-CHANGE; TIME-SERIES; SATELLITE; REANALYSIS; RECORDS; AEROSOL	Estimated global-scale temperature trends at Earth's surface (as recorded by thermometers) and in the Lower troposphere (as monitored by satellites) diverge by up to 0.14 degrees C per decade over the period 1979 to 1998. Accounting for differences in the spatial coverage of satellite and surface measurements reduces this differential, but still Leaves a statistically significant residual of roughly 0.1 degrees C per decade. Natural internal climate variability alone, as simulated in three state-of-the-art coupled atmosphere-ocean models, cannot completely explain this residual trend difference. A model forced by a combination of anthropogenic factors and volcanic aerosols yields surface-troposphere temperature trend differences closest to those observed.	Univ Calif Lawrence Livermore Natl Lab, Program Climate Model Diag & Intercomparison, Livermore, CA 94550 USA; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; NOAA, Air Resources Lab, Silver Spring, MD 20910 USA; Max Planck Inst Meteorol, D-20146 Hamburg, Germany; Univ E Anglia, Climat Res Unit, Norwich NR4 7TJ, Norfolk, England	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; National Center Atmospheric Research (NCAR) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; Max Planck Society; University of East Anglia	Santer, BD (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Program Climate Model Diag & Intercomparison, Livermore, CA 94550 USA.		Wigley, Tom M.L./B-4705-2008; Santer, Ben/ABA-1099-2021; Taylor, Karl E/F-7290-2011; Santer, Benjamin D/F-9781-2011; Jones, Philip Douglas/C-8718-2009; Wehner, Michael/F-7841-2015	Taylor, Karl E/0000-0002-6491-2135; Jones, Philip Douglas/0000-0001-5032-5493; Wehner, Michael/0000-0001-5991-0082				Andronova NG, 1999, J GEOPHYS RES-ATMOS, V104, P16807, DOI 10.1029/1999JD900165; Angell JK, 1999, GEOPHYS RES LETT, V26, P2761, DOI 10.1029/1999GL900375; Bengtsson L, 1999, J GEOPHYS RES-ATMOS, V104, P3865, DOI 10.1029/1998JD200046; Berntsen TK, 1997, J GEOPHYS RES-ATMOS, V102, P28101, DOI 10.1029/97JD02226; Boville BA, 1998, J CLIMATE, V11, P1327, DOI 10.1175/1520-0442(1998)011<1327:ACOTAC>2.0.CO;2; Boville BA, 1998, J CLIMATE, V11, P1115, DOI 10.1175/1520-0442(1998)011<1115:TNCSMV>2.0.CO;2; Christy JR, 1998, J CLIMATE, V11, P2016, DOI 10.1175/1520-0442-11.8.2016; CHRISTY JR, 1994, NATURE, V367, P325, DOI 10.1038/367325a0; CHRISTY JR, IN PRESS J ATMOS OCE; GAFFEN DJ, 1994, J GEOPHYS RES-ATMOS, V99, P3667, DOI 10.1029/93JD03179; Gaffen DJ, 2000, SCIENCE, V287, P1242, DOI 10.1126/science.287.5456.1242; Gibson J.K., 1997, EUR CENT MED RANG WE; Hansen J, 1997, J GEOPHYS RES-ATMOS, V102, P6831, DOI 10.1029/96JD03436; HANSEN J, 1995, CLIMATIC CHANGE, V30, P103, DOI 10.1007/BF01093228; Hansen J, 1997, J GEOPHYS RES-ATMOS, V102, P25679, DOI 10.1029/97JD01495; HASSELMANN K, 1993, J CLIMATE, V6, P1957, DOI 10.1175/1520-0442(1993)006<1957:OFFTDO>2.0.CO;2; Hurrell JW, 1999, B AM METEOROL SOC, V80, P2661, DOI 10.1175/1520-0477(1999)080<2661:GSSTAM>2.0.CO;2; Hurrell JW, 1997, NATURE, V386, P164, DOI 10.1038/386164a0; Hurrell JW, 1996, J CLIMATE, V9, P2222, DOI 10.1175/1520-0442(1996)009<2222:SVSEOA>2.0.CO;2; Jones PD, 1989, J CLIMATE, V2, P285, DOI 10.1175/1520-0442(1989)002<0285:TEOUWO>2.0.CO;2; Jones PD, 1997, J CLIMATE, V10, P2548, DOI 10.1175/1520-0442(1997)010<2548:ESEILS>2.0.CO;2; JONES PD, 1994, GEOPHYS RES LETT, V21, P1149, DOI 10.1029/94GL01042; Jones PD, 1997, J GEOPHYS RES-ATMOS, V102, P30135, DOI 10.1029/97JD02432; JONES PD, 1990, NATURE, V347, P169, DOI 10.1038/347169a0; JONES PD, 1994, J CLIMATE, V7, P1794, DOI 10.1175/1520-0442(1994)007<1794:HSATVA>2.0.CO;2; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Leggett J., 1992, CLIMATE CHANGE 1992, P69; MICHAELS PJ, 1999, WORLD CLIM REP, V4, P1; Mitchell JM, 1966, 79 WORLD MET ORG; *NAT RES COUNC BOA, 2000, REC OBS GLOB TEMP CH; NICHOLLS N, 1995, CLIMATE CHANGE; NICHOLLS N, 1996, SCI CLIMATE CHANGE, P133; PARKER DE, 1995, INT J CLIMATOL, V15, P473, DOI 10.1002/joc.3370150502; Parker DE, 1997, GEOPHYS RES LETT, V24, P1499, DOI 10.1029/97GL01186; PARKER DE, 1994, J GEOPHYS RES-ATMOS, V99, P14373, DOI 10.1029/94JD00548; PENNER JE, 1992, SCIENCE, V256, P1432, DOI 10.1126/science.256.5062.1432; Roeckner E, 1999, J CLIMATE, V12, P3004, DOI 10.1175/1520-0442(1999)012<3004:TCCSWA>2.0.CO;2; Santer BD, 1999, J GEOPHYS RES-ATMOS, V104, P6305, DOI 10.1029/1998JD200096; SANTER BD, 1996, NATURE, V384, P523; SANTER BD, IN PRESS J GEOPHYS R; SPENCER RW, 1990, SCIENCE, V247, P1558, DOI 10.1126/science.247.4950.1558; TEGEN I, 1995, J GEOPHYS RES-ATMOS, V100, P18707, DOI 10.1029/95JD02051; Tett SFB, 1999, NATURE, V399, P569, DOI 10.1038/21164; Tett SFB, 1996, SCIENCE, V274, P1170, DOI 10.1126/science.274.5290.1170; WASHINGTON WM, UNPUB; Wentz FJ, 1998, NATURE, V394, P661, DOI 10.1038/29267; Wigley TML, 1998, CLIM DYNAM, V14, P781, DOI 10.1007/s003820050254; [No title captured]	49	79	84	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1227	1232		10.1126/science.287.5456.1227	http://dx.doi.org/10.1126/science.287.5456.1227			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678823				2022-12-28	WOS:000085444700040
J	Ashkar, S; Weber, GF; Panoutsakopoulou, V; Sanchirico, ME; Jansson, M; Zawaideh, S; Rittling, SR; Denhardt, DT; Glimcher, MJ; Cantor, H				Ashkar, S; Weber, GF; Panoutsakopoulou, V; Sanchirico, ME; Jansson, M; Zawaideh, S; Rittling, SR; Denhardt, DT; Glimcher, MJ; Cantor, H			Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity	SCIENCE			English	Article							HERPES STROMAL KERATITIS; DENDRITIC CELLS; IN-VITRO; SECRETED PHOSPHOPROTEIN; BACTERIAL-INFECTION; GRANULOMA-FORMATION; GENETIC-RESISTANCE; AUTOIMMUNE-DISEASE; ESCHERICHIA-COLI; UP-REGULATION	Cell-mediated (type-1) immunity is necessary for immune protection against most intracellular pathogens and, when excessive, can mediate organ-specific autoimmune destruction. Mice deficient in Eta-1 (also called osteopontin) gene expression have severely impaired type-1 immunity to viral infection [herpes simplex virus-type 1 (KOS strain)] and bacterial infection (Listeria monocytogenes) and do not develop sarcoid-type granulomas. Interleukin-12 (IL-12) and interferon-gamma production is diminished, and IL-10 production is increased. A phosphorylation-dependent interaction between the amino-terminal portion of Eta-1 and its integrin receptor stimulated IL-12 expression, whereas a phosphorylation-independent interaction with CD44 inhibited IL-10 expression. These findings identify Eta-1 as a key cytokine that sets the stage for efficient type-1 immune responses through differential regulation of macrophage IL-12 and IL-10 cytokine expression.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp,Dept Orthoped Surg, Lab Skeletal Disorders & Rehabil, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Rutgers State Univ, Fac Arts & Sci, Div Life Sci, Piscataway, NJ 08854 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Rutgers State University New Brunswick	Cantor, H (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.	Harvey_Cantor@DFCl.harvard.edu	Eckhardt, Erik/G-1567-2010	Panoutsakopoulou, Vily/0000-0002-1569-1508	NATIONAL CANCER INSTITUTE [R29CA076176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012184, R01AI012184, P01AI037833] Funding Source: NIH RePORTER; NCI NIH HHS [CA76176] Funding Source: Medline; NIAID NIH HHS [AI37833, AI12184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V194, P274, DOI 10.1006/bbrc.1993.1815; ASHKAR S, 1995, ANN NY ACAD SCI, V760, P296, DOI 10.1111/j.1749-6632.1995.tb44639.x; ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V191, P126, DOI 10.1006/bbrc.1993.1193; AVERY AC, 1995, NATURE, V376, P431, DOI 10.1038/376431a0; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CONSTANT SL, 1999, ANNU REV IMMUNOL, V15, P297; Cousens LP, 1999, J EXP MED, V189, P1315, DOI 10.1084/jem.189.8.1315; Daheshia M, 1997, J IMMUNOL, V159, P1945; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; JERRELLS TR, 1981, INFECT IMMUN, V31, P1014, DOI 10.1128/IAI.31.3.1014-1022.1981; Kelly JL, 1997, SURGERY, V122, P146, DOI 10.1016/S0039-6060(97)90003-9; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; KUBOTA T, 1989, BIOCHEM BIOPH RES CO, V162, P1453, DOI 10.1016/0006-291X(89)90837-1; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Lyons A, 1997, ANN SURG, V226, P450, DOI 10.1097/00000658-199710000-00006; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Medzhitov R, 1998, SEMIN IMMUNOL, V10, P351, DOI 10.1006/smim.1998.0136; Murphy KM, 1998, CURR OPIN IMMUNOL, V10, P226, DOI 10.1016/S0952-7915(98)80253-7; Nau GJ, 1997, P NATL ACAD SCI USA, V94, P6414, DOI 10.1073/pnas.94.12.6414; NEMIR M, 1989, J BIOL CHEM, V264, P18202; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; O'Regan AW, 1999, J IMMUNOL, V162, P1024; Oxenius A, 1999, J IMMUNOL, V162, P965; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PATARCA R, 1993, CRIT REV IMMUNOL, V13, P225; Ria F, 1998, EUR J IMMUNOL, V28, P2003, DOI 10.1002/(SICI)1521-4141(199806)28:06<2003::AID-IMMU2003>3.0.CO;2-S; Rittling SR, 1999, EXP NEPHROL, V7, P103; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; Salih E, 1997, J BIOL CHEM, V272, P13966, DOI 10.1074/jbc.272.21.13966; SCHEICHER C, 1995, EUR J IMMUNOL, V25, P1566, DOI 10.1002/eji.1830250615; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; SCHULTZ JF, 1995, J BIOL CHEM, V270, P11522, DOI 10.1074/jbc.270.19.11522; Segal BM, 1998, J EXP MED, V187, P537, DOI 10.1084/jem.187.4.537; Sharma MD, 1998, J IMMUNOL, V161, P5357; SINGH RP, 1990, J EXP MED, V171, P1931, DOI 10.1084/jem.171.6.1931; SORENSEN ES, 1994, BIOCHEM BIOPH RES CO, V198, P200, DOI 10.1006/bbrc.1994.1028; Stordeur P, 1998, Int Rev Immunol, V16, P501, DOI 10.3109/08830189809043006; STORDEUR P, 1995, MOL IMMUNOL, V32, P233, DOI 10.1016/0161-5890(94)00158-W; Streilein JW, 1997, IMMUNOL TODAY, V18, P443, DOI 10.1016/S0167-5699(97)01114-6; TRIPP CS, 1994, J IMMUNOL, V152, P1883; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; TRIPP CS, 1995, J IMMUNOL, V155, P3427; Unanue ER, 1997, IMMUNOL REV, V158, P11, DOI 10.1111/j.1600-065X.1997.tb00988.x; VANDENBOGERT C, 1986, VIRCHOWS ARCH B, V51, P39; Weber GF, 1997, P ASSOC AM PHYSICIAN, V109, P1; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Yin ZH, 1997, ARTHRITIS RHEUM, V40, P1788, DOI 10.1002/art.1780401010; Yu XQ, 1998, P ASSOC AM PHYSICIAN, V110, P50; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	52	921	984	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2000	287	5454					860	864		10.1126/science.287.5454.860	http://dx.doi.org/10.1126/science.287.5454.860			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657301				2022-12-28	WOS:000085136400048
J	Lewis, HA; Musunuru, K; Jensen, KB; Edo, C; Chen, H; Darnell, RB; Burley, SK				Lewis, HA; Musunuru, K; Jensen, KB; Edo, C; Chen, H; Darnell, RB; Burley, SK			Sequence-specific RNA binding by a Nova KH domain: Implications for paraneoplastic disease and the fragile X syndrome	CELL			English	Article							CRYSTAL-STRUCTURE; ANTI-RI; MESSENGER-RNA; FMR-1 GENE; CGG REPEAT; PROTEIN; RECOGNITION; SYSTEM; MOTIF; CRYSTALLOGRAPHY	The structure of a Nova protein K homology (KH) domain recognizing single-stranded RNA has been determined at 2.4 Angstrom resolution. Mammalian Nova antigens (1 and 2) constitute an important family of regulators of RNA metabolism in neurons, first identified using sera from cancer patients with the autoimmune disorder paraneoplastic opsoclonus-myoclonus ataxia (POMA). The structure of the third KH domain (KH3) of Nova-2 bound to a stem loop RNA resembles a molecular vise, with 5'-Ura-Cyt-Ade-Cyt-3' pinioned between an invariant Gly-X-X-Gly motif and the variable loop. Tetranucleotide recognition is supported by an aliphatic alpha helix/beta sheet RNA-binding platform, which mimics 5'-Ura-Gua-3' by making Watson-Crick-like hydrogen bonds with 5'-Cyt-Ade-3'. Sequence conservation suggests that fragile X mental retardation results from perturbation of RNA binding by the FMR1 protein.	Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Mol Neurooncol Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Burley, SK (corresponding author), Rockefeller Univ, Labs Mol Biophys, 1230 York Ave, New York, NY 10021 USA.	burley@rockvax.rockefeller.edu	Darnell, Robert B/B-9022-2008; Jensen, Kirk/B-4756-2008; Jensen, Kirk/AAL-5883-2020	Darnell, Robert B/0000-0002-5134-8088; Jensen, Kirk/0000-0002-2084-1734; Jensen, Kirk/0000-0002-2084-1734; Burley, Stephen K./0000-0002-2487-9713	NIGMS NIH HHS [GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert ML, 1998, NAT MED, V4, P1321, DOI 10.1038/3315; Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; Baber JL, 1999, J MOL BIOL, V289, P949, DOI 10.1006/jmbi.1999.2818; Baehrecke EH, 1997, DEVELOPMENT, V124, P1323; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buckanovich RJ, 1996, J NEUROSCI, V16, P1114; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; Darnell RB, 1999, NEW ENGL J MED, V340, P1831, DOI 10.1056/NEJM199906103402311; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; DARNELL RB, 1993, LANCET, V341, P21, DOI 10.1016/0140-6736(93)92485-C; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; Garcia-Mena J, 1999, MOL MICROBIOL, V33, P235, DOI 10.1046/j.1365-2958.1999.01451.x; GEDEON AK, 1992, NAT GENET, V1, P341, DOI 10.1038/ng0892-341; GRAUS F, 1993, NEUROSCI LETT, V150, P212, DOI 10.1016/0304-3940(93)90538-V; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hodel AE, 1998, MOL CELL, V1, P443, DOI 10.1016/S1097-2765(00)80044-1; HORMIGO A, 1994, ANN NEUROL, V36, P896, DOI 10.1002/ana.410360615; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; JENSEN KB, 2000, IN PRESS P NATL ACAD; JENSEN KB, 2000, IN PRESS NEURON; JONES DR, 1995, PHYSIOL ZOOL, V68, P9, DOI 10.1086/physzool.68.4.30166356; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis HA, 1999, STRUCTURE, V7, P191, DOI 10.1016/S0969-2126(99)80025-2; LUGENBEEL KA, 1995, NAT GENET, V10, P483, DOI 10.1038/ng0895-483; LUQUE FA, 1991, ANN NEUROL, V29, P241, DOI 10.1002/ana.410290303; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; Musco G, 1997, NAT STRUCT BIOL, V4, P712, DOI 10.1038/nsb0997-712; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NUSSBAUM RL, 1995, METABOLIC BASIS INHE, P795; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Okano HJ, 1999, GENE DEV, V13, P2087, DOI 10.1101/gad.13.16.2087; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; SAKNARANARAYANA.R, 1999, CELL, V97, P371; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Yang YYL, 1998, P NATL ACAD SCI USA, V95, P13254, DOI 10.1073/pnas.95.22.13254	59	267	272	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					323	332		10.1016/S0092-8674(00)80668-6	http://dx.doi.org/10.1016/S0092-8674(00)80668-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676814	Bronze			2022-12-28	WOS:000085204400006
J	Srinivasan, MV; Zhang, SW; Altwein, M; Tautz, J				Srinivasan, MV; Zhang, SW; Altwein, M; Tautz, J			Honeybee navigation: Nature and calibration of the "odometer"	SCIENCE			English	Article							DISTANCE; BEES	There are two theories about how honeybees estimate the distance to food sources. One theory proposes that distance flown is estimated in terms of energy consumption. The other suggests that the cue is visual, and is derived from the extent to which the image of the world has moved on the eye during the trip. Here the two theories are tested by observing dances of bees that have flown through a short, narrow tunnel to collect a food reward. The results show that the honeybee's "odometer" is visually driven. They also provide a calibration of the dance and the odometer in visual terms.	Australian Natl Univ, Res Sch Biol Sci, Ctr Visual Sci, Canberra, ACT 2601, Australia; Univ Wurzburg, Biozentrum, D-97074 Wurzburg, Germany	Australian National University; University of Wurzburg	Srinivasan, MV (corresponding author), Australian Natl Univ, Res Sch Biol Sci, Ctr Visual Sci, Canberra, ACT 2601, Australia.		Zhang, Shaowu/C-9139-2009; Srinivasan, Mandyam V/G-5571-2010	Zhang, Shaowu/0000-0002-3551-5587; 				BISETZKY AR, 1957, Z VERGL PHYSIOL, V40, P264, DOI 10.1007/BF00340571; BOCH R, 1957, Z VERGL PHYSIOL, V40, P289, DOI 10.1007/BF00340572; ESCH HE, 1995, NATURWISSENSCHAFTEN, V82, P38, DOI 10.1007/BF01167870; Esch HE, 1996, J EXP BIOL, V199, P155; HERAN H, 1956, Z VERGL PHYSIOL, V38, P168, DOI 10.1007/BF00338625; KIRCHNER WH, 1994, ANIM BEHAV, V48, P1437, DOI 10.1006/anbe.1994.1379; SRINIVASAN MV, 1991, VISUAL NEUROSCI, V6, P519, DOI 10.1017/S095252380000136X; Srinivasan MV, 1996, J EXP BIOL, V199, P237; Srinivasan MV, 1997, J EXP BIOL, V200, P2513; Tautz J, 1996, NATURE, V382, P32, DOI 10.1038/382032a0; von Frisch K, 1969, DANCE LANGUAGE ORIEN	11	262	268	3	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					851	853		10.1126/science.287.5454.851	http://dx.doi.org/10.1126/science.287.5454.851			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657298				2022-12-28	WOS:000085136400045
J	Pan, JW; Bouwmeester, D; Daniell, M; Weinfurter, H; Zeilinger, A				Pan, JW; Bouwmeester, D; Daniell, M; Weinfurter, H; Zeilinger, A			Experimental test of quantum nonlocality in three-photon Greenberger-Horne-Zeilinger entanglement	NATURE			English	Article							ENTANGLING PHOTONS; BELLS-INEQUALITY; CONVERSION; THEOREM; PAIRS; VIOLATION; LOCALITY; STATES	Bell's theorem(1) states that certain statistical correlations predicted by quantum physics for measurements on two-particle systems cannot be understood within a realistic picture based on local properties of each individual particle-even if the two particles are separated by large distances. Einstein, Podolsky and Rosen first recognized(2) the fundamental significance of these quantum correlations (termed 'entanglement' by Schrodinger(3)) and the two-particle quantum predictions have found ever-increasing experimental support(4). A more striking conflict between quantum mechanical and local realistic predictions (for perfect correlations) has been discovered(5,6); but experimental verification has been difficult, as it requires entanglement between at least three particles. Here we report experimental confirmation of this conflict, using our recently developed method: to observe three-photon entanglement, or 'Greenberger-Horne-Zeilinger' (GHZ) states. The results of three specific experiments, involving-measurements of polarization correlations between three photons, lead to predictions for a fourth experiment; quantum physical predictions are mutually contradictory with expectations based on local realism. We find the results of the fourth experiment to be in agreement with the quantum prediction and in striking conflict with local realism.	Univ Vienna, Inst Expt Phys, A-1090 Vienna, Austria; Univ Oxford, Clarendon Lab, Oxford OX1 3PU, England; Univ Munich, Sekt Phys, D-80799 Munich, Germany	University of Vienna; University of Oxford; University of Munich	Zeilinger, A (corresponding author), Univ Vienna, Inst Expt Phys, Boltzmanngasse 5, A-1090 Vienna, Austria.		Weinfurter, Harald/F-8225-2015; Zeilinger, Anton/A-1170-2011; Pan, Jian-Wei/A-2332-2010	Weinfurter, Harald/0000-0001-6882-3909; Pan, Jian-Wei/0000-0002-6100-5142				Aspect A, 1999, NATURE, V398, P189, DOI 10.1038/18296; Bell JS., 1964, PHYS, V1, P195, DOI [10.1103/PhysicsPhysiqueFizika.1.195, 10.1103/Physics-PhysiqueFizika.1.195, DOI 10.1103/PHYSICSPHYSIQUEFIZIKA.1.195]; Bose S, 1998, PHYS REV A, V57, P822, DOI 10.1103/PhysRevA.57.822; Bouwmeester D, 1997, NATURE, V390, P575, DOI 10.1038/37539; Bouwmeester D, 1999, PHYS REV LETT, V82, P1345, DOI 10.1103/PhysRevLett.82.1345; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; CLAUSER JF, 1978, REP PROG PHYS, V41, P1881, DOI 10.1088/0034-4885/41/12/002; Cleve R, 1997, PHYS REV A, V56, P1201, DOI 10.1103/PhysRevA.56.1201; DECARO L, 1994, PHYS REV A, V50, pR2803, DOI 10.1103/PhysRevA.50.R2803; Einstein A, 1935, PHYS REV, V47, P0777, DOI 10.1103/PhysRev.47.777; Greenberger DM, 1989, BELLS THEOREM QUANTU, P73; HAROCHE S, 1995, ANN NY ACAD SCI, V755, P73, DOI 10.1111/j.1749-6632.1995.tb38957.x; KWIAT PG, 1994, PHYS REV A, V49, P3209, DOI 10.1103/PhysRevA.49.3209; KWIAT PG, 1995, PHYS REV LETT, V75, P4337, DOI 10.1103/PhysRevLett.75.4337; Laflamme R, 1998, PHILOS T R SOC A, V356, P1941, DOI 10.1098/rsta.1998.0257; MERMIN ND, 1990, PHYS REV LETT, V65, P1838, DOI 10.1103/PhysRevLett.65.1838; MERMIN ND, 1990, PHYS TODAY, V43, P9; OU ZY, 1988, PHYS REV LETT, V61, P50, DOI 10.1103/PhysRevLett.61.50; Pan JW, 1998, PHYS REV LETT, V80, P3891, DOI 10.1103/PhysRevLett.80.3891; PEARLE PM, 1970, PHYS REV D, V2, P1418, DOI 10.1103/PhysRevD.2.1418; Popescu S, 1997, PHYS REV A, V56, pR4353, DOI 10.1103/PhysRevA.56.R4353; ROY SM, 1991, PHYS REV LETT, V67, P2761, DOI 10.1103/PhysRevLett.67.2761; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P844, DOI 10.1007/BF01491987; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P807, DOI 10.1007/BF01491891; Schroedinger E., 1935, NATURWISSENSCHAFTEN, V23, P823, DOI [DOI 10.1007/BF01491914, 10.1007/BF01491914]; SHIH YH, 1988, PHYS REV LETT, V61, P2921, DOI 10.1103/PhysRevLett.61.2921; Weihs G, 1998, PHYS REV LETT, V81, P5039, DOI 10.1103/PhysRevLett.81.5039; Zeilinger A, 1997, PHYS REV LETT, V78, P3031, DOI 10.1103/PhysRevLett.78.3031; ZUKOWSKI M, 1995, ANN NY ACAD SCI, V755, P91, DOI 10.1111/j.1749-6632.1995.tb38959.x; Zukowski M, 1997, PHYS REV A, V56, pR1682, DOI 10.1103/PhysRevA.56.R1682; ZUKOWSKI M, 2000, PHYS REV A, V61	32	684	713	5	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					515	519		10.1038/35000514	http://dx.doi.org/10.1038/35000514			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676953				2022-12-28	WOS:000085227300041
J	Lindblad, B				Lindblad, B			Antithrombotic drug therapy after infrainguinal vascular surgery	LANCET			English	Editorial Material									Univ Lund, Malmo Univ Hosp, Dept Renal & Vasc Dis, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Lindblad, B (corresponding author), Univ Lund, Malmo Univ Hosp, Dept Renal & Vasc Dis, S-20502 Malmo, Sweden.							[Anonymous], 1994, BMJ, V308, P159; FRANKS PJ, 1992, EUR J VASCULAR SURG, V6, P185, DOI 10.1016/S0950-821X(05)80238-5; ONeill RT, 1997, CONTROL CLIN TRIALS, V18, P550, DOI 10.1016/S0197-2456(97)00075-5; Tangelder MJD, 1999, J VASC SURG, V30, P701, DOI 10.1016/S0741-5214(99)70109-6	4	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					334	334		10.1016/S0140-6736(99)90415-4	http://dx.doi.org/10.1016/S0140-6736(99)90415-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665549				2022-12-28	WOS:000085122100005
J	Schon, JH; Kloc, C; Bucher, E; Batiogg, B				Schon, JH; Kloc, C; Bucher, E; Batiogg, B			RETRACTED: Efficient organic photovoltaic diodes based on doped pentacene (Retracted article. See vol 422 pg 93 2003)	NATURE			English	Article; Retracted Publication							SOLAR-CELLS; THIN-FILM; TRANSISTORS; HETEROJUNCTIONS; SEMICONDUCTORS; VAPOR	Recent work on solar cells based on interpenetrating polymer networks(1-3) and solid-state dye-sensitized devices' shows that efficient solar-energy conversion is possible using organic materials. Further, it has been demonstrated that the performance of photovoltaic devices based on small molecules can be effectively enhanced by doping the organic material with electron-accepting molecules'. But as inorganic solar cells show much higher efficiencies, well above 15 per cent, the practical utility of organic-based cells will require their fabrication by lower-rest techniques, ideally on flexible substrates. Here we demonstrate efficiency enhancement by molecular doping in Schottky-type photovoltaic diodes based on pentacene-an organic semiconductor that has received much attention as a promising material for organic thin-film transistors(6-8), but relatively little attention for use in photovoltaic devices(9,10). The incorporation of the dopant improves the internal quantum efficiency by more than five orders of magnitude and yields an external energy conversion efficiency as high as 2.4 per cent for a standard solar spectrum. Thin-film devices based on doped pentacene therefore appear promising for the production of efficient 'plastic' solar cells.	Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA; Univ Konstanz, Fac Phys, D-78457 Constance, Germany	Alcatel-Lucent; Lucent Technologies; AT&T; University of Konstanz	Schon, JH (corresponding author), Lucent Technol, Bell Labs, 600 Mt Ave, Murray Hill, NJ 07974 USA.	hendrik@lucent.com	Kloc, Christian/A-2255-2011					Bach U, 1998, NATURE, V395, P583, DOI 10.1038/26936; CHAMBERLAIN GA, 1981, NATURE, V289, P45, DOI 10.1038/289045a0; CHAMBERLAIN GA, 1982, J APPL PHYS, V53, P6262, DOI 10.1063/1.331544; Dimitrakopoulos CD, 1999, SCIENCE, V283, P822, DOI 10.1126/science.283.5403.822; Granstrom M, 1998, NATURE, V395, P257, DOI 10.1038/26183; HALLS JJM, 1995, NATURE, V376, P498, DOI 10.1038/376498a0; HOVEL HJ, 1975, SEMICONDUCT SEMIMET, V11, P71; Karl N., 1985, LANDOLTBORNSTEIN, V17i, P106; Laudise RA, 1998, J CRYST GROWTH, V187, P449, DOI 10.1016/S0022-0248(98)00034-7; Lin YY, 1997, IEEE T ELECTRON DEV, V44, P1325, DOI 10.1109/16.605476; MINAKATA T, 1991, J APPL PHYS, V69, P7354, DOI 10.1063/1.347594; MINITAKA T, 1992, J APPL PHYS, V72, P5220; Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205; Schon JH, 1998, PHYS REV B, V58, P12952, DOI 10.1103/PhysRevB.58.12952; Signerski R, 1998, SYNTHETIC MET, V94, P135, DOI 10.1016/S0379-6779(97)04160-X; TANG CW, 1986, APPL PHYS LETT, V48, P183, DOI 10.1063/1.96937; Videlot C, 1998, J CHIM PHYS PCB, V95, P1335, DOI 10.1051/jcp:1998277; Videlot C, 1999, SYNTHETIC MET, V102, P885, DOI 10.1016/S0379-6779(98)00377-4; WOHRLE D, 1995, J MATER CHEM, V5, P1819, DOI 10.1039/jm9950501819; WOHRLE D, 1991, ADV MATER, V3, P129, DOI 10.1002/adma.19910030303; YU G, 1995, SCIENCE, V270, P1789, DOI 10.1126/science.270.5243.1789	21	169	180	2	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					408	410		10.1038/35000172	http://dx.doi.org/10.1038/35000172			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667788				2022-12-28	WOS:000085121100044
J	Kikkawa, M; Okada, Y; Hirokawa, N				Kikkawa, M; Okada, Y; Hirokawa, N			15 angstrom resolution model of the monomeric kinesin motor, KIF1A	CELL			English	Article							X-RAY STRUCTURE; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE; MICROTUBULE POLARITY; ELECTRON-MICROGRAPHS; DIMERIC KINESIN; IMAGE-ANALYSIS; BETA-TUBULIN; PROTEIN; TRANSPORT	A two-headed structure has been widely believed to be essential for the kinesin molecular motor to move processively on the track, microtubules. However, we have recently demonstrated that a monomeric motor domain construct of KIF1A (C351), a kinesin superfamily protein, moves processively, taking about 700 steps before being detached from microtubules. To elucidate the mechanism of its single-headed processivity, we examined the C351-MT interaction by mutant analysis and high-resolution cryo-EM. Mutant analysis indicated the importance of a highly positively charged loop, the "K loop," for such processivity A15 Angstrom resolution structure unambiguously docked with the available atomic models revealed "K loop" as an extra microtubule-binding domain specific to KIF1A, and bound to the C terminus of tubulin. The site-specific crosslinking further confirmed this model.	Univ Tokyo, Grad Sch Med, Dept Cell Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Okada, Yasushi/N-5067-2015; Kikkawa, Masahide/A-6692-2010	Okada, Yasushi/0000-0003-2601-3689; Kikkawa, Masahide/0000-0001-7656-8194				Arnal I, 1998, STRUCTURE, V6, P33, DOI 10.1016/S0969-2126(98)00005-7; AUDEBERT S, 1994, J CELL SCI, V107, P2313; Beroukhim R, 1997, ULTRAMICROSCOPY, V70, P57, DOI 10.1016/S0304-3991(97)00070-3; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; Chretien D, 1996, STRUCTURE, V4, P1031, DOI 10.1016/S0969-2126(96)00110-4; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; Hirose K, 1999, MOL BIOL CELL, V10, P2063, DOI 10.1091/mbc.10.6.2063; Hoenger A, 1998, J CELL BIOL, V141, P419, DOI 10.1083/jcb.141.2.419; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIKKAWA M, 1994, J CELL BIOL, V127, P1965, DOI 10.1083/jcb.127.6.1965; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; Kozielski F, 1998, CURR BIOL, V8, P191, DOI 10.1016/S0960-9822(98)70083-1; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Sosa H, 1997, J STRUCT BIOL, V118, P149, DOI 10.1006/jsbi.1997.3851; Sosa H, 1998, CELL MOTIL CYTOSKEL, V40, P38; TOYOSHIMA C, 1988, NATURE, V336, P247, DOI 10.1038/336247a0; VONHEEL M, 1987, ULTRAMICROSCOPY, V21, P95; Wriggers W, 1999, J STRUCT BIOL, V125, P185, DOI 10.1006/jsbi.1998.4080; Wriggers W, 1998, BIOPHYS J, V75, P646, DOI 10.1016/S0006-3495(98)77555-1; Yasunaga T, 1996, J STRUCT BIOL, V116, P155, DOI 10.1006/jsbi.1996.0025; Yonekawa Y, 1998, J CELL BIOL, V141, P431, DOI 10.1083/jcb.141.2.431	38	142	153	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					241	252		10.1016/S0092-8674(00)81562-7	http://dx.doi.org/10.1016/S0092-8674(00)81562-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660047	Bronze			2022-12-28	WOS:000084932200008
J	Morris, J				Morris, J			Commentary: Report of statistical referee	BRITISH MEDICAL JOURNAL			English	Editorial Material									Withington Hosp, S Manchester Univ Hosp NHS Trust, Dept Med Stat, Manchester M20 2LR, Lancs, England	Wythenshawe Hospital NHS Foundation Trust	Morris, J (corresponding author), Withington Hosp, S Manchester Univ Hosp NHS Trust, Dept Med Stat, Manchester M20 2LR, Lancs, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1617	1617						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10660325				2022-12-28	WOS:000084562600019
J	An, WF; Bowlby, MR; Betty, M; Cao, J; Ling, HP; Mendoza, G; Hinson, JW; Mattsson, KI; Strassle, BW; Trimmer, JS; Rhodes, KJ				An, WF; Bowlby, MR; Betty, M; Cao, J; Ling, HP; Mendoza, G; Hinson, JW; Mattsson, KI; Strassle, BW; Trimmer, JS; Rhodes, KJ			Modulation of A-type potassium channels by a family of calcium sensors	NATURE			English	Article							K+ CHANNEL; SUBTHRESHOLD POTENTIALS; PYRAMIDAL NEURONS; BINDING PROTEIN; MAMMALIAN BRAIN; ASSOCIATION; DENDRITES; SUBUNITS; SYSTEM	In the brain and heart, rapidly inactivating (A-type) voltage-gated potassium (Kv) currents operate at subthreshold membrane potentials to control the excitability of neurons and cardiac myocytes(1,2). Although pore-forming alpha-subunits of the Kv4, or Shal-related, channel family form A-type currents in heterologous cells(3), these differ significantly from native A-type currents. Here we describe three Kv channel-interacting proteins (KChIPs) that bind to the cytoplasmic amino termini of Kv4 alpha-subunits. We find that expression of KChIP and Kv4 together reconstitutes several features of native A-type currents by modulating the density, inactivation kinetics and rate of recovery from inactivation of Kv4 channels in heterologous cells. All three KChIPs co-localize and co-immunoprecipitate with brain Kv4 alpha-subunits, and are thus integral components of native Kv4 channel complexes. The KChIPs have four EF-hand-like domains and bind calcium ions. As the activity and density of neuronal A-type currents tightly control responses to excitatory synaptic inputs, these KChIPs may regulate A-type currents, and hence neuronal excitability, in response to changes in intracellular calcium.	Wyeth Ayerst Res, Div Neurosci, Princeton, NJ 08543 USA; Millennium Pharmaceut, Cambridge, MA 02139 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Pfizer; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Rhodes, KJ (corresponding author), Wyeth Ayerst Res, Div Neurosci, Princeton, NJ 08543 USA.							BAIROCH A, 1990, FEBS LETT, V269, P454, DOI 10.1016/0014-5793(90)81214-9; BOWLBY MR, 1995, J NEUROPHYSIOL, V73, P2221, DOI 10.1152/jn.1995.73.6.2221; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; CHABALA LD, 1993, J GEN PHYSIOL, V102, P713, DOI 10.1085/jgp.102.4.713; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Hoffman DA, 1998, J NEUROSCI, V18, P3521; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; Linse Sara, 1995, V30, P89; NEF P, 1996, GUIDEBOOK CALCIUM BI, P94; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; RUDY B, 1988, NEURON, V1, P649, DOI 10.1016/0896-6273(88)90164-X; SERODIO P, 1994, J NEUROPHYSIOL, V72, P1516, DOI 10.1152/jn.1994.72.4.1516; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Song WJ, 1998, J NEUROSCI, V18, P3124; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	22	783	811	1	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					553	556		10.1038/35000592	http://dx.doi.org/10.1038/35000592			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676964				2022-12-28	WOS:000085227300052
J	Stark, CP; Stieglitz, M				Stark, CP; Stieglitz, M			Hydrology - The sting in a fractal tail	NATURE			English	Editorial Material									Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	Columbia University	Stark, CP (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.			Stark, Colin/0000-0002-0150-9664				BARNABY F, 1986, AMBIO, V15, P332; Kirchner JW, 2000, NATURE, V403, P524, DOI 10.1038/35000537; Schnoor J., 1996, ENV MODELING FATE TR	3	12	13	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					493	+		10.1038/35000689	http://dx.doi.org/10.1038/35000689			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676945				2022-12-28	WOS:000085227300030
J	GrandPre, T; Nakamura, F; Vartanian, T; Strittmatter, SM				GrandPre, T; Nakamura, F; Vartanian, T; Strittmatter, SM			Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein	NATURE			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; FAMILY ENCODING RETICULONS; GROWTH CONE COLLAPSE; NEURITE GROWTH; GENOMIC ORGANIZATION; GENE; EXPRESSION	Adult mammalian axon regeneration is generally successful in the peripheral nervous system (PNS) but is dismally poor in the central nervous system (CNS), However, many classes of CNS axons can extend for long distances in peripheral nerve grafts(1). A comparison of myelin from the CNS and the PNS has revealed that CNS white matter is selectively inhibitory for axonal outgrowth(2). Several components of CNS white matter, NI35, NI250(Nogo) and MAG, that have inhibitory activity for axon extension have been described(3-7) The IN-1 antibody, which recognizes NI35 and NI250(Nogo), allows moderate degrees of axonal regeneration and functional recovery after spinal cord injury(8,9). Here we identify Nogo as a member of the Reticulon family, Reticulon 4-A. Nogo is expressed by oligodendrocytes but not by Schwann cells, and associates primarily with the endoplasmic reticulum. A 66-residue lumenal/extracellular domain inhibits axonal extension and collapses dorsal root ganglion growth cones. In contrast to Nogo, Reticulon 1 and 3 ape not expressed by oligodendrocytes, and the 66-residue lumenal/extracellular domains from Reticulon 1, 2 and 3 do not inhibit axonal regeneration. These data provide a molecular basis to assess the contribution of Nogo to the failure of axonal regeneration in the adult CNS.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA USA	Yale University; Yale University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, 333 Cedar St, New Haven, CT 06510 USA.	stephen.strittmatter@yale.edu	Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				Bandtlow CE, 1997, EUR J NEUROSCI, V9, P2743, DOI 10.1111/j.1460-9568.1997.tb01703.x; BENFEY M, 1982, NATURE, V296, P150, DOI 10.1038/296150a0; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Jin Z, 1997, J NEUROSCI, V17, P6256; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Moreira EF, 1999, GENOMICS, V58, P73, DOI 10.1006/geno.1999.5807; MORRIS NJ, 1991, BIOCHIM BIOPHYS ACTA, V1450, P68; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Roebroek AJM, 1998, GENOMICS, V51, P98, DOI 10.1006/geno.1997.5175; Roebroek AJM, 1996, GENOMICS, V32, P191, DOI 10.1006/geno.1996.0105; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Senden NHM, 1996, EUR J CELL BIOL, V69, P197; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; Vartanian T, 1999, P NATL ACAD SCI USA, V96, P731, DOI 10.1073/pnas.96.2.731; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 2000, CONT NEUROS, P131	25	931	1052	2	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					439	444		10.1038/35000226	http://dx.doi.org/10.1038/35000226			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667797				2022-12-28	WOS:000085121100053
J	Komiyama, S; Astafiev, O; Antonov, V; Kutsuwa, T; Hirai, H				Komiyama, S; Astafiev, O; Antonov, V; Kutsuwa, T; Hirai, H			A single-photon detector in the far-infrared range	NATURE			English	Article							QUANTUM; WAVELENGTHS	The far-infrared region (wavelengths in the range 10 mu m-1 mm) is one of the richest areas of spectroscopic research(1), encompassing the rotational spectra of molecules and vibrational spectra of solids, liquids and gases. But studies in this spectral region are hampered by the absence of sensitive detectors(2-5)-despite recent efforts to improve superconducting bolometers(6), attainable sensitivities are currently far below the level of single-photon detection. This is in marked contrast to the visible and near-infrared regions (wavelengths shorter than about 1.5 mu m), in which single-photon counting is possible using photomultiplier tubes. Here we report the detection of single far-infrared photons in the wavelength range 175-210 mu m (6.0-7.1 meV), using a single-electron transistor consisting of a semiconductor quantum dot in high magnetic field. We detect, with a time resolution of a millisecond, an incident flux of 0.1 photons per second on an effective detector area of 0.1 mm(2)-a sensitivity that exceeds previously reported values by a factor of more than 10(4). The sensitivity is a consequence of the unconventional detection mechanism, in which one absorbed photon leads to a current of 10(6)-10(12) electrons through the quantum dot By contrast, mechanisms of conventional detectors(2-6) or photon assisted tunnelling(7) in single-electron transistors produce only a few electrons per incident photon.	Univ Tokyo, Dept Basic Sci, Meguro Ku, Tokyo 153, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Komiyama, S (corresponding author), Univ Tokyo, Dept Basic Sci, Meguro Ku, Komaba 3-8-1, Tokyo 153, Japan.	csusumu@ASone.c.u.-tokyo.ac.jp	Astafiev, Oleg/L-9771-2013; Antonov, Vladimir/P-2372-2015	Antonov, Vladimir/0000-0002-0415-5267; Komiyama, Susumu/0000-0001-5887-127X				AVERIN DV, 1986, J LOW TEMP PHYS, V62, P345, DOI 10.1007/BF00683469; Bollweg K, 1996, PHYS REV LETT, V76, P2774, DOI 10.1103/PhysRevLett.76.2774; Fujiwara M, 1997, JPN J APPL PHYS 1, V36, P4262, DOI 10.1143/JJAP.36.4262; GORNIK E, 1976, INFRARED PHYS, V16, P285, DOI 10.1016/0020-0891(76)90048-8; Kawamura J, 1997, APPL PHYS LETT, V70, P1619, DOI 10.1063/1.118634; Kawano Y, 1999, PHYS REV B, V59, P12537, DOI 10.1103/PhysRevB.59.12537; Kouwenhoven LP, 1997, NATO ADV SCI I E-APP, V345, P105; RICHARDS PL, 1994, J APPL PHYS, V76, P1, DOI 10.1063/1.357128; Schoelkopf RJ, 1999, IEEE T APPL SUPERCON, V9, P2935, DOI 10.1109/77.783645; Schoelkopf RJ, 1998, SCIENCE, V280, P1238, DOI 10.1126/science.280.5367.1238; Stopa M, 1996, PHYS REV LETT, V76, P2145, DOI 10.1103/PhysRevLett.76.2145; TUCKER JR, 1985, REV MOD PHYS, V57, P1055, DOI 10.1103/RevModPhys.57.1055; vanderVaart NC, 1997, PHYS REV B, V55, P9746, DOI 10.1103/PhysRevB.55.9746; VANDISBOECK EF, 1996, P EUR SPACE AGENCY S, V388, P3	14	315	324	3	159	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					405	407		10.1038/35000166	http://dx.doi.org/10.1038/35000166			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667787				2022-12-28	WOS:000085121100043
J	Walt, DR				Walt, DR			Molecular biology - Bead-based fiber-optic arrays	SCIENCE			English	Article							DNA MICROARRAYS; GENE-EXPRESSION; POINT MUTATIONS; BIOSENSOR; SENSOR; POLYNUCLEOTIDES; GENOSENSOR		Tufts Univ, Dept Chem, Medford, MA 02155 USA	Tufts University	Walt, DR (corresponding author), Tufts Univ, Dept Chem, 62 Talbot Ave, Medford, MA 02155 USA.	david.walt@tufts.edu						Abel AP, 1996, ANAL CHEM, V68, P2905, DOI 10.1021/ac960071+; Bier FF, 1997, SENSOR ACTUAT B-CHEM, V38, P78, DOI 10.1016/S0925-4005(97)80174-8; Blanchard AP, 1996, BIOSENS BIOELECTRON, V11, P687, DOI 10.1016/0956-5663(96)83302-1; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Case-Green SC, 1998, CURR OPIN CHEM BIOL, V2, P404, DOI 10.1016/S1367-5931(98)80016-1; CHEE M, UNPUB; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; Ferguson JA, 1996, NAT BIOTECHNOL, V14, P1681, DOI 10.1038/nbt1296-1681; Fodor SPA, 1997, SCIENCE, V277, P393, DOI 10.1126/science.277.5324.393; Fulton RJ, 1997, CLIN CHEM, V43, P1749; Gerry NP, 1999, J MOL BIOL, V292, P251, DOI 10.1006/jmbi.1999.3063; Healey BG, 1997, ANAL BIOCHEM, V251, P270, DOI 10.1006/abio.1997.2254; Kleinjung F, 1997, ANAL CHIM ACTA, V350, P51, DOI 10.1016/S0003-2670(97)00192-X; Liu XJ, 1999, ANAL CHEM, V71, P5054, DOI 10.1021/ac990561c; Lyon LA, 1998, ANAL CHEM, V70, P5177, DOI 10.1021/ac9809940; McAllister L, 1997, AM J HUM GENET, V61, pA239; Michael KL, 1998, ANAL CHEM, V70, P1242, DOI 10.1021/ac971343r; Pantano P, 1996, CHEM MATER, V8, P2832, DOI 10.1021/cm9603314; PIUNNO PAE, 1995, ANAL CHEM, V67, P2635, DOI 10.1021/ac00111a022; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Steemers FJ, 2000, NAT BIOTECHNOL, V18, P91, DOI 10.1038/72006; Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i; Uddin AH, 1997, NUCLEIC ACIDS RES, V25, P4139, DOI 10.1093/nar/25.20.4139; Walt DR, 1998, ACCOUNTS CHEM RES, V31, P267, DOI 10.1021/ar970069k; Zhang GJ, 1999, ANAL LETT, V32, P2725, DOI 10.1080/00032719908543001	26	220	284	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2000	287	5452					451	452		10.1126/science.287.5452.451	http://dx.doi.org/10.1126/science.287.5452.451			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10671175				2022-12-28	WOS:000084929900035
J	Yarus, M				Yarus, M			Protein synthesis - Unraveling the riddle of ProCys tRNA synthetase	SCIENCE			English	Editorial Material							TRANSFER-RNA-SYNTHETASE; COMPLETE GENOME SEQUENCE		Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Yarus, M (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.		Yarus, Michael/Q-9813-2019					Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cerini C, 1997, EUR J BIOCHEM, V244, P176, DOI 10.1111/j.1432-1033.1997.00176.x; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P13, DOI 10.1021/bi00672a003; Hamann CS, 1999, J BACTERIOL, V181, P5880, DOI 10.1128/JB.181.18.5880-5884.1999; Rath VL, 1998, STRUCT FOLD DES, V6, P439, DOI 10.1016/S0969-2126(98)00046-X; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Stathopoulos C, 2000, SCIENCE, V287, P479, DOI 10.1126/science.287.5452.479	9	7	8	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					440	441		10.1126/science.287.5452.440	http://dx.doi.org/10.1126/science.287.5452.440			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10671174				2022-12-28	WOS:000084929900032
J	Elowitz, MB; Leibler, S				Elowitz, MB; Leibler, S			A synthetic oscillatory network of transcriptional regulators	NATURE			English	Article							GREEN FLUORESCENT PROTEIN; ESCHERICHIA-COLI; TAGGING SYSTEM; DEGRADATION; ELEMENTS	Networks of interacting biomolecules carry out many essential functions in living cells(1), but the 'design principles' underlying the functioning of such intracellular networks remain poorly understood, despite intensive efforts including quantitative analysis of relatively simple systems(2). Here we present a complementary approach to this problem: the design and construction of a synthetic network to implement a particular function. We used three transcriptional repressor systems that are not part of any natural biological clock(3-5) to build an oscillating network, termed the repressilator, in Escherichia coli. The network periodically induces the synthesis of green fluorescent protein as a readout of its state in individual cells. The resulting oscillations, with typical periods of hours, are slower than the cell-division cycle, so the state of the oscillator has to be transmitted from generation to generation. This artificial clock displays noisy behaviour, possibly because of stochastic fluctuations of its components. Such 'rational network design' may lead both to the engineering of new cellular behaviours and to an improved understanding of naturally occurring networks.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University; Princeton University	Elowitz, MB (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Andersen JB, 1998, APPL ENVIRON MICROB, V64, P2240; Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Elowitz MB., 1999, THESIS PRINCETON U P; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Glascock CB, 1998, GENE, V223, P221, DOI 10.1016/S0378-1119(98)00240-6; Goldbeter A., 1996, BIOCH OSCILLATIONS C; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; Koshland DE, 1998, SCIENCE, V280, P852, DOI 10.1126/science.280.5365.852; KUSHNER SR, 1996, ESCHERICHIA COLI SAL; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; Thomas R., 1990, BIOL FEEDBACK; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Winfree AT, 1990, GEOMETRY BIOL TIME	20	3026	3205	35	715	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					335	338		10.1038/35002125	http://dx.doi.org/10.1038/35002125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659856				2022-12-28	WOS:000084899700059
J	Houghton, RA; Skole, DL; Nobre, CA; Hackler, JL; Lawrence, KT; Chomentowski, WH				Houghton, RA; Skole, DL; Nobre, CA; Hackler, JL; Lawrence, KT; Chomentowski, WH			Annual fluxes or carbon from deforestation and regrowth in the Brazilian Amazon	NATURE			English	Article							PASTURE SOILS; LAND-USE; FOREST; BIOMASS; BUDGET	The distribution of sources and sinks of carbon among the world's ecosystems is uncertain. Some analyses show northern midlatitude lands to be a large sink, whereas the tropics are a net source(1); other analyses show the tropics to be nearly neutral. whereas northern mid-latitudes are a small sink(2,3). Here we show that the annual flux of carbon from deforestation and abandonment of agricultural lands in the Brazilian Amazon was a source of about 0.2 g C yr(-1) over the period 1989-1998 (1 Pg is 10(15) g). This estimate is based on annual rates of deforestation and spatially detailed estimates of deforestation, regrowing forests and biomass. Logging may add another 5-10% to this estimate(4), and fires may double the magnitude of the source in years following a drought(4), The annual source of carbon from land-use change and fire approximately offsets the sink calculated for natural ecosystems in the region(5,6). Thus this large area of tropical forest is nearly balanced with respect to carbon, but has an interannual variability of +/- 0.2 PgC yr(-1).	Woods Hole Res Ctr, Woods Hole, MA 02543 USA; Michigan State Univ, Dept Geog, E Lansing, MI 48824 USA; Inst Nacl Pesquisas Espaciais, BR-12201970 Sao Jose Dos Campos, SP, Brazil	Woods Hole Research Center; Michigan State University; Instituto Nacional de Pesquisas Espaciais (INPE)	Houghton, RA (corresponding author), Woods Hole Res Ctr, POB 296, Woods Hole, MA 02543 USA.			skole, david/0000-0002-8575-3540				Alves DS, 1996, INT J REMOTE SENS, V17, P835, DOI 10.1080/01431169608949049; *BRAZ MIN MIN EN D, 1973, LEV REC NAT, V1; BROWN S, 1992, INTERCIENCIA, V17, P8; BROWN S, 1990, J TROP ECOL, V6, P1, DOI 10.1017/S0266467400003989; BROWN S, 1989, FOREST SCI, V35, P881; Cairns MA, 1997, OECOLOGIA, V111, P1, DOI 10.1007/s004420050201; Carrera-Rotllan J, 1998, MECH AGEING DEV, V103, P13, DOI 10.1016/S0047-6374(98)00007-4; CIAIS P, 1995, J GEOPHYS RES-ATMOS, V100, P5051, DOI 10.1029/94JD02847; Cochrane MA, 1999, SCIENCE, V284, P1832, DOI 10.1126/science.284.5421.1832; DAVIDSON EA, 1995, NATURE, V376, P472, DOI 10.1038/376472a0; Delaney M, 1998, BIOTROPICA, V30, P2, DOI 10.1111/j.1744-7429.1998.tb00364.x; Fearnside P., 1986, HUMAN CARRYING CAPAC; Fearnside Philip M., 1998, Forest Ecology and Management, V108, P147, DOI 10.1016/S0378-1127(98)00222-9; Fearnside PM, 1997, CLIMATIC CHANGE, V35, P321, DOI 10.1023/A:1005336724350; FEARNSIDE PM, 1992, INTERCIENCIA, V17, P19; FEARNSIDE PM, 1993, J GEOPHYS RES-ATMOS, V98, P16733, DOI 10.1029/93JD01140; FISHER MJ, 1994, NATURE, V371, P236, DOI 10.1038/371236a0; HALL CAS, 1991, CAN J FOREST RES, V21, P118, DOI 10.1139/x91-016; HOUGHTON R A, 1987, Tellus Series B Chemical and Physical Meteorology, V39, P122; Houghton RA, 1999, TELLUS B, V51, P298, DOI 10.1034/j.1600-0889.1999.00013.x; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; MORAN EF, 1994, BIOSCIENCE, V44, P329, DOI 10.2307/1312383; Neill C, 1996, OECOLOGIA, V107, P113, DOI 10.1007/BF00582241; NEPSTAD DC, 1991, AMBIO, V20, P248; Nepstad DC, 1999, NATURE, V398, P505, DOI 10.1038/19066; Prentice IC, 1998, NATURE, V396, P619, DOI 10.1038/25224; Rayner PJ, 1999, TELLUS B, V51, P213, DOI 10.1034/j.1600-0889.1999.t01-1-00008.x; SCHROEDER PE, 1995, FOREST ECOL MANAG, V75, P87, DOI 10.1016/0378-1127(95)03533-G; SKOLE DL, 1994, BIOSCIENCE, V44, P314, DOI 10.2307/1312381; Tian HQ, 1998, NATURE, V396, P664, DOI 10.1038/25328	30	502	610	6	173	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					301	304		10.1038/35002062	http://dx.doi.org/10.1038/35002062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659847				2022-12-28	WOS:000084899700050
J	Pestova, TV; Lomakin, IB; Lee, JH; Choi, SK; Dever, TE; Hellen, CUT				Pestova, TV; Lomakin, IB; Lee, JH; Choi, SK; Dever, TE; Hellen, CUT			The joining of ribosomal subunits in eukaryotes requires eIF5B	NATURE			English	Article							TRANSLATION INITIATION; PROTEIN-SYNTHESIS; RABBIT RETICULOCYTES; FACTOR-5; PURIFICATION; COMPLEX; BINDING; CODON	Initiation of eukaryotic protein synthesis begins with the ribosome separated into its 40S and 60S subunits(1). The 40S subunit first binds eukaryotic initiation factor (eIF) 3 and an eIF2-GTP-initiator transfer RNA ternary complex. The resulting complex requires eIF1, eIF1A, eIF4A, eIF4B and eIF4F to bind to a messenger RNA and to scan to the initiation codon(2). eIF5 stimulates hydrolysis of eIF2-bound GTP and eIF2 is released from the 48S complex formed at the initiation codon before it is joined by a 60S subunit to form an active 80S ribosome(3-8). Here we show that hydrolysis of eIF2-bound GTP induced by eIF5 in 48S complexes is necessary but not sufficient for the subunits to join. A second factor termed eIF5B (relative molecular mass 175,000) is essential for this process. It is a homologue of the prokaryotic initiation factor IF2 (refs 6, 7) and, like it(8-12), mediates joining of subunits and has a ribosome-dependent GTPase activity that is essential for its function.	SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Brooklyn, NY 11203 USA; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Lomonosov Moscow State University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Pestova, TV (corresponding author), SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, 450 Clarkson Ave, Brooklyn, NY 11203 USA.		Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678; Lomakin, Ivan/0000-0001-6528-5068	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010, ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004, Z01HD001010] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENNE R, 1978, J BIOL CHEM, V253, P3070; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; Choi SK, 1998, SCIENCE, V280, P1757, DOI 10.1126/science.280.5370.1757; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; GODEFROYCOLBURN T, 1975, J MOL BIOL, V94, P461, DOI 10.1016/0022-2836(75)90215-6; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; KOLAKOFSKY D, 1968, P NATL ACAD SCI USA, V61, P1066, DOI 10.1073/pnas.61.3.1066; Lee JH, 1999, P NATL ACAD SCI USA, V96, P4342, DOI 10.1073/pnas.96.8.4342; LOCKWOOD AH, 1972, P NATL ACAD SCI USA, V69, P3602, DOI 10.1073/pnas.69.12.3602; Luchin S, 1999, J BIOL CHEM, V274, P6074, DOI 10.1074/jbc.274.10.6074; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; SACERDOT C, 1984, P NATL ACAD SCI-BIOL, V81, P7787, DOI 10.1073/pnas.81.24.7787; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8	17	295	299	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					332	335		10.1038/35002118	http://dx.doi.org/10.1038/35002118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659855				2022-12-28	WOS:000084899700058
J	Bais, JE; Bartelsman, JFWM; Bonjer, HJ; Cuesta, MA; Go, PMNYH; Klinkenberg-Knol, EC; van Lanschot, JJB; Nadorp, JHSM; Smout, AJPM; van der Graaf, Y; Gooszen, HG				Bais, JE; Bartelsman, JFWM; Bonjer, HJ; Cuesta, MA; Go, PMNYH; Klinkenberg-Knol, EC; van Lanschot, JJB; Nadorp, JHSM; Smout, AJPM; van der Graaf, Y; Gooszen, HG		Netherlands Antireflux Surg Study	Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial	LANCET			English	Article							GASTROESOPHAGEAL REFLUX; ANTIREFLUX SURGERY; CONSECUTIVE PATIENTS; FOLLOW-UP	Background For the surgical treatment of gastrooesophageal reflux disease (GORD), laparoscopic Nissen fundoplication has largely replaced the open procedure. Retrospective and prospective non-randomized studies have shown similar results after laparoscopic Nissen fundoplication compared with the open procedure. Methods in a multicentre randomised trial candidates for surgical treatment of GORD were randomly assigned to either laparoscopic or open 360 degrees Nissen fundoplication. Primary endpoints were dysphagia, recurrent GORD, and intrathoracic hernia. Secondary endpoints were effectiveness and quality of life. This planned interim analysis focuses on endpoints and complications and in-hospital costs. Findings At the time of interim analysis 11 patients in the laparoscopic group and one in the conventional group had reached a primary endpoint (p=0.01; relative risk=8.8, 95% CI 1.2-66.3). This difference was caused mainly by whether or not patients hd dysphagia (seven patients in the laparoscopic group and none in the conventional group p=0.016). Interpretation Although laparoscopic Nissen fundoplication was as effective as the open procedure in controlling reflux, the significantly higher risk of reaching a primary endpoint in the laparoscopic group led us to stop the study.	Univ Utrecht, Med Ctr, Dept Surg, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Gastroenterol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Clin Epidemiol, NL-3508 GA Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands; Free Univ Amsterdam, Acad Hosp, Dept Surg, Amsterdam, Netherlands; Free Univ Amsterdam, Acad Hosp, Dept Gastroenterol, Amsterdam, Netherlands; Antonius Hosp, Dept Surg, Nieuwegein, Netherlands; Antonius Hosp, Dept Gastroenterol, Nieuwegein, Netherlands; Erasmus Hosp, Dept Surg, Rotterdam, Netherlands	Utrecht University; Utrecht University; Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC	Gooszen, HG (corresponding author), Univ Utrecht, Med Ctr, Dept Surg, POB 85500, NL-3508 GA Utrecht, Netherlands.		Gooszen, H.G./H-8036-2014					Anvari M, 1998, ANN SURG, V227, P25, DOI 10.1097/00000658-199801000-00004; BITTNER HB, 1994, AM J SURG, V167, P193, DOI 10.1016/0002-9610(94)90073-6; CADIERE GB, 1994, BRIT J SURG, V81, P400, DOI 10.1002/bjs.1800810327; COLLARD JM, 1994, ANN SURG, V220, P146, DOI 10.1097/00000658-199408000-00005; Dallemagne B, 1991, Surg Laparosc Endosc, V1, P138; DEMEESTER TR, 1992, WORLD J SURG, V16, P335, DOI 10.1007/BF02071542; DEMEESTER TR, 1986, ANN SURG, V204, P9, DOI 10.1097/00000658-198607000-00002; Eshraghi N, 1998, AM J SURG, V175, P371, DOI 10.1016/S0002-9610(98)00049-X; Gotley DC, 1996, GUT, V38, P487, DOI 10.1136/gut.38.4.487; HINDER RA, 1994, ANN SURG, V220, P472, DOI 10.1097/00000658-199410000-00006; HINDER RA, 1997, AM J MED S, V103, P144; HORBACH JMLM, 1994, GUT, V35, P1529, DOI 10.1136/gut.35.11.1529; Hunter JG, 1996, ANN SURG, V224, P51, DOI 10.1097/00000658-199607000-00008; JAMIESON GG, 1994, ANN SURG, V220, P137, DOI 10.1097/00000658-199408000-00004; Laine S, 1997, SURG ENDOSC-ULTRAS, V11, P441, DOI 10.1007/s004649900386; Lundell L, 1996, BRIT J SURG, V83, P830, DOI 10.1002/bjs.1800830633; LUOSTARINEN M, 1993, ANN SURG, V217, P329, DOI 10.1097/00000658-199304000-00004; ORRINGER MB, 1972, J THORAC CARDIOV SUR, V63, P25, DOI 10.1016/S0022-5223(19)41954-5; Peters JH, 1998, ANN SURG, V228, P40, DOI 10.1097/00000658-199807000-00007; RATTNER DW, 1995, ARCH SURG-CHICAGO, V130, P289; Ritter DW, 1997, AM J SURG, V174, P715, DOI 10.1016/S0002-9610(97)00191-8; SAVARY M, 1978, HDB ATLAS ENDOSCOPY, P135; van der Peet DL, 1998, SURG ENDOSC-ULTRAS, V12, P1159, DOI 10.1007/s004649900806; WATSON A, 1995, BRIT J SURG, V82, P651, DOI 10.1002/bjs.1800820527; Watson DI, 1997, ANN SURG, V226, P642, DOI 10.1097/00000658-199711000-00009; Watson DI, 1996, ANN SURG, V224, P198, DOI 10.1097/00000658-199608000-00013; WEERTS JM, 1993, SURG LAPAROSC ENDOSC, V3, P359	27	203	205	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					170	174		10.1016/S0140-6736(99)03097-4	http://dx.doi.org/10.1016/S0140-6736(99)03097-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675115				2022-12-28	WOS:000084879700009
J	Hubler, GK				Hubler, GK			Fluff balls of fire	NATURE			English	Editorial Material									USN, Res Lab, Washington, DC 20375 USA	United States Department of Defense; United States Navy; Naval Research Laboratory	Hubler, GK (corresponding author), USN, Res Lab, Code 6370, Washington, DC 20375 USA.	hubler@ccs.nrl.navy.mil						Abrahamson J, 2000, NATURE, V403, P519, DOI 10.1038/35000525; ARAGO F, 1855, METEOROLOGICAL ESSAY; Turner DJ, 1998, PHYS REP, V293, P2, DOI 10.1016/S0370-1573(97)00043-4	3	3	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2000	403	6769					487	488		10.1038/35000674	http://dx.doi.org/10.1038/35000674			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676940				2022-12-28	WOS:000085227300025
J	Whitcup, SM				Whitcup, SM			Cytomegalovirus retinitis in the era of highly active antiretroviral therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNE-DEFICIENCY SYNDROME; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MAINTENANCE THERAPY; COMBINATION THERAPY; CONTROLLED TRIAL; CMV RETINITIS; CD4+ COUNTS; AIDS; GANCICLOVIR; INFECTION	A number of striking changes have occurred recently in the presentation and course of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are receiving highly active antiretroviral therapy (HAART), Before the use of HAART, CMV retinitis was the most common intraocular infection in patients with AIDS, occurring in up to 40% of patients, typically when CD4(+) cell counts have decreased to less than 0.10 x 10(9)/L, By studying CMV retinitis, clinicians can investigate whether the rejuvenated immune system that results from HAART can effectively control opportunistic infections in patients with AIDS. in some patients, retinitis has not progressed when specific anti-CMV therapy was discontinued, but a number of patients have developed substantial intraocular inflammation, which has resulted in decreased visual acuity, Anterior uveitis, cataract, vitritis, cystoid macular edema, epiretinal membrane, and disc edema may occur in patients with CMV retinitis who have experienced HAART-associated elevation in CD4(+) cell counts. Since immune recovery uveitis does not occur in eyes without CMV retinitis, the ocular inflammation appears to be related to the CMV infection. Anti-CMV maintenance therapy likely can be safely discontinued in some patients with CMV retinitis if CD4(+) cell counts are stable or increasing and have been higher than 0.10 x 10(9)/L for at least 3 months. Immune recovery in patients receiving HAART has been effective in controlling opportunistic infections, but it may also result in intraocular inflammation, which can have adverse effects on the eye.	NEI, Clin Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Whitcup, SM (corresponding author), NEI, Clin Branch, NIH, Bldg 10,Room 10S221,10 Ctr Dr, Bethesda, MD 20892 USA.	whitcup_scott@allergan.com						[Anonymous], 1999, MMWR Recomm Rep, V48, P1; Carpenter C, 1998, ANN INTERN MED, V128, P1057, DOI 10.7326/0003-4819-128-12_Part_2-199806151-00002; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; FREEMAN WR, 1984, AM J OPHTHALMOL, V97, P133, DOI 10.1016/S0002-9394(14)76082-9; Henderson HWA, 1999, BRIT J OPHTHALMOL, V83, P540, DOI 10.1136/bjo.83.5.540; HOLLAND GN, 1992, ARCH OPHTHALMOL-CHIC, V110, P1435, DOI 10.1001/archopht.1992.01080220097029; JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401; Jabs DA, 1997, AM J OPHTHALMOL, V124, P227, DOI 10.1016/S0002-9394(14)70789-5; Jabs DA, 1998, AM J OPHTHALMOL, V126, P817, DOI 10.1016/S0002-9394(98)00285-2; JACOBSON MA, 1988, Q J MED, V67, P473; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; Karavellas MP, 1999, J INFECT DIS, V179, P697, DOI 10.1086/314639; Karavellas MP, 1998, ARCH OPHTHALMOL-CHIC, V116, P169; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; KUPPERMANN BD, 1993, AM J OPHTHALMOL, V115, P575, DOI 10.1016/S0002-9394(14)71453-9; Lalezari JP, 1997, ANN INTERN MED, V126, P257, DOI 10.7326/0003-4819-126-4-199702150-00001; Lederman MM, 1998, J INFECT DIS, V178, P70, DOI 10.1086/515591; Lewis RA, 1997, ANN INTERN MED, V126, P264, DOI 10.7326/0003-4819-126-4-199702150-00002; Macdonald JC, 1998, J INFECT DIS, V177, P1182, DOI 10.1086/515281; Magone MT, 1997, AM J OPHTHALMOL, V124, P190, DOI 10.1016/S0002-9394(14)70783-4; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; PEPOSE JS, 1989, CURR TOP AIDS, V2, P191; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Race EM, 1998, LANCET, V351, P252, DOI 10.1016/S0140-6736(97)04352-3; Reed JB, 1997, AM J OPHTHALMOL, V124, P199, DOI 10.1016/S0002-9394(14)70784-6; SCHUMAN JS, 1983, T OPHTHAL SOC UK, V103, P177; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; Vrabec TR, 1998, OPHTHALMOLOGY, V105, P1259, DOI 10.1016/S0161-6420(98)97031-2; WEINBERG DV, 1996, RETINA, V16, P1443; Whitcup SM, 1998, BRIT J OPHTHALMOL, V82, P845; Whitcup SM, 1999, JAMA-J AM MED ASSOC, V282, P1633, DOI 10.1001/jama.282.17.1633; Whitcup SM, 1997, JAMA-J AM MED ASSOC, V277, P1519, DOI 10.1001/jama.277.19.1519; Whitcup SM, 1999, INVEST OPHTH VIS SCI, V40, pS189; Woods ML, 1998, AIDS, V12, P1491, DOI 10.1097/00002030-199812000-00011; Zegans ME, 1998, AM J OPHTHALMOL, V125, P292, DOI 10.1016/S0002-9394(99)80134-2; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x	40	55	58	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					653	657		10.1001/jama.283.5.653	http://dx.doi.org/10.1001/jama.283.5.653			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665706				2022-12-28	WOS:000084956500032
J	Padilla, A; Gibson, I				Padilla, A; Gibson, I			Science moves to centre stage	NATURE			English	Editorial Material									Parliamentary Off Sci & Technol, London SW1P 3JA, England; House Commons, London SW1A 0AA, England		Padilla, A (corresponding author), Parliamentary Off Sci & Technol, 7 Millbank, London SW1P 3JA, England.							*ESRC, 1999, 5 ESRC; GIBSON I, 1999, SAFER ATTITUDE RISK; GIBSON L, 1999, NATL SCI STRATEGY; *POST, 1996, SAF NUMB RISK ASS EN	4	6	7	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					357	359		10.1038/35000299	http://dx.doi.org/10.1038/35000299			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667767				2022-12-28	WOS:000085121100018
J	Espinal, RA; Perez, EN; Baez, J; Henriquez, L; Fernandez, K; Lopez, M; Olivo, P; Reingold, AL				Espinal, RA; Perez, EN; Baez, J; Henriquez, L; Fernandez, K; Lopez, M; Olivo, P; Reingold, AL			Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: a prospective study	LANCET			English	Article							PULMONARY TUBERCULOSIS; IMMUNODEFICIENCY; HIV	Background Previous studies concerning the relative infectiousness of HIV-1-positive individuals with pulmonary tuberculosis have produced conflicting results, Thus, we assessed the effect of HIV-1 on the infectiousness of Mycobacterium tuberculosis in a prospective study. Methods We organised in Santo Domingo, Dominican Republic, a cohort study of household contacts of HIV-1-positive and HIV-1-negative individuals with newly diagnosed pulmonary tuberculosis. Household contacts were assessed at their houses at baseline and followed up for 14 months for evidence of M tuberculosis infection and tuberculosis with a multi-step tuberculin skin test, anergy skin test, physical examinations, chest radiographs, and sputum smears. Findings Tuberculin induration of 5 mm or greater was seen in 153 (61%) of 252 household contacts of HIV-1-positive index cases and in 418 (76%) of 551 household contacts of HIV-1-negative index cases (odds ratio 0.49 [95% CI 0.35-0.67], p=0.00001). In multivariate logistic-regression analysis after allowance for between-household variation in tuberculin response, HIV-1 infection of the index case remained inversely associated with the tuberculin response of the household contacts (0.52 [0.29-0.93], p=0.02). When the analysis was restricted to household contacts aged between 2 years and 15 years the adjusted association remained significant (0.37 [0.14-0.98], p=0.04). Among household contacts who had a negative tuberculin skin test at baseline, conversion to tuberculin skin test positivity was less frequent among household contacts of HIV-1-posilive index cases (cut-off greater than or equal to 5 mm: 32/131 [24%] vs 71/204 [35%], p=0.05; cut-off greater than or equal to 10 mm: 23/153 [15%] vs 55/245 [22%0], p=0.07). Interpretation These data suggest that HIV-1-positive individuals with tuberculosis are less likely than HIV-1-negative individuals with tuberculosis to transmit M tuberculosis to their close contacts. No changes in the current policy regarding tuberculosis contact tracing are needed in the presence of HIV-1.	Natl Ctr Res Maternal & Child Hlth, Santo Domingo, Dominican Rep; Antituberculosis Dispensary, Santo Domingo, Dominican Rep; Padre Billini Hosp, Santo Domingo, Dominican Rep; Francisco Moscoso Puello Hosp, Santo Domingo, Dominican Rep; Univ Calif Berkeley, Sch Publ Hlth, Div Publ Hlth Biol & Epidemiol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Espinal, RA (corresponding author), WHO Communicable Dis Surveillance & Response, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	espinalm@who.ch		Perez-Then, Eddy/0000-0001-7724-0668	FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW00003] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		*AM THOR SOC, 1981, AM REV RESPIR DIS, V124, P356; CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; Cayla J, 1993, 9 INT C AIDS BERL GE; ELLIOTT AM, 1993, AIDS, V7, P981, DOI 10.1097/00002030-199307000-00012; Espinal M, 1994, Bol Oficina Sanit Panam, V116, P452; Espinal MA, 1996, J ACQ IMMUN DEF SYND, V13, P155, DOI 10.1097/00042560-199610010-00006; GAUTHEN GM, 1996, AM J EPIDEMIOL, V144, P69; GUWATUDDE D, 1998, 12 INT C AIDS GEN SW, P138; HUEBNER RE, 1994, CLIN INFECT DIS, V19, P26, DOI 10.1093/clinids/19.1.26; KALENDE P, 1988, MED TROP, V48, P19; KLAUSNER JD, 1993, J INFECT DIS, V168, P106, DOI 10.1093/infdis/168.1.106; LOUDON RG, 1969, AM REV RESPIR DIS, V99, P109; MANFRIN V, 1993, 9 INT C AIDS BERL GE; NARAIN R, 1966, B WORLD HEALTH ORGAN, V34, P639; NUNN P, 1994, TUBERCLE LUNG DIS, V75, P25, DOI 10.1016/0962-8479(94)90098-1; ROUILLON A, 1976, TUBERCLE, V57, P275, DOI 10.1016/S0041-3879(76)80006-2; SHAW JB, 1954, AM REV TUBERC PULM, V69, P724; STANDAERT B, 1989, AIDS RES HUM RETROV, V5, P247, DOI 10.1089/aid.1989.5.247; Toman K, 1979, TUBERCULOSIS CASE FI, P65; *WHO, 1992, WKLY EPIDEMIOL REC, V67, P145; *WHO, 1991, WHO WORK GROUP M GEN	21	73	74	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2000	355	9200					275	280		10.1016/S0140-6736(99)04402-5	http://dx.doi.org/10.1016/S0140-6736(99)04402-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675075				2022-12-28	WOS:000085045600011
J	Smith, GN; Kingdom, JC; Penning, DH; Matthews, SG				Smith, GN; Kingdom, JC; Penning, DH; Matthews, SG			Antenatal corticosteroids: is more better?	LANCET			English	Editorial Material							BRAIN; GROWTH; GLUCOCORTICOIDS; DEXAMETHASONE; BETAMETHASONE; SINGLE		Queens Univ, Dept Obstet & Gynaecol, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Anat, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Cell Biol, Kingston, ON K7L 2V7, Canada; Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Duke Univ, Dept Anaesthesia, Durham, NC 27706 USA	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; University of Toronto; University of Toronto; Duke University	Smith, GN (corresponding author), Queens Univ, Dept Obstet & Gynaecol, Kingston, ON K7L 2V7, Canada.		Kingdom, John/A-3247-2013; Smith, Graeme Neil/ABB-6863-2021; Matthews, Stephen/R-5147-2019; Matthews, Stephen G/N-7555-2018; Kingdom, John/AAF-2145-2020	Smith, Graeme Neil/0000-0002-3128-4523; Matthews, Stephen/0000-0002-9654-9940; Matthews, Stephen G/0000-0002-9654-9940; Penning, Donald/0000-0001-7010-2430				Banks BA, 1999, AM J OBSTET GYNECOL, V181, P709, DOI 10.1016/S0002-9378(99)70517-X; Baud O, 1999, NEW ENGL J MED, V341, P1190, DOI 10.1056/NEJM199910143411604; Brocklehurst P, 1999, BRIT J OBSTET GYNAEC, V106, P977, DOI 10.1111/j.1471-0528.1999.tb08440.x; CROWLEY P, 1999, COCHRANE LIB; Dean F, 1999, BRAIN RES, V846, P253, DOI 10.1016/S0006-8993(99)02064-8; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; French NP, 1999, AM J OBSTET GYNECOL, V180, P114, DOI 10.1016/S0002-9378(99)70160-2; Huang WL, 1999, OBSTET GYNECOL, V94, P213, DOI 10.1016/S0029-7844(99)00265-3; Ikegami M, 1997, AM J RESP CRIT CARE, V156, P178, DOI 10.1164/ajrccm.156.1.9612036; Jobe AH, 1998, AM J OBSTET GYNECOL, V178, P880, DOI 10.1016/S0002-9378(98)70518-6; Levitt NS, 1996, NEUROENDOCRINOLOGY, V64, P412, DOI 10.1159/000127146; LIGGINS GC, 1969, J ENDOCRINOL, V45, P515, DOI 10.1677/joe.0.0450515; MACARTHUR BA, 1982, PEDIATRICS, V70, P99; Matthews SG, 1998, DEV BRAIN RES, V107, P123, DOI 10.1016/S0165-3806(98)00008-X; Pratt L, 1999, AM J OBSTET GYNECOL, V180, P995, DOI 10.1016/S0002-9378(99)70672-1; Quinlivan JA, 1999, PRENAT NEONAT MED, V4, P47; Stewart JD, 1998, AM J OBSTET GYNECOL, V179, P1241, DOI 10.1016/S0002-9378(98)70140-1; UNO H, 1990, DEV BRAIN RES, V53, P157, DOI 10.1016/0165-3806(90)90002-G; UNO H, 1994, HORM BEHAV, V28, P336, DOI 10.1006/hbeh.1994.1030	19	38	39	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					251	252		10.1016/S0140-6736(99)00448-1	http://dx.doi.org/10.1016/S0140-6736(99)00448-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675070				2022-12-28	WOS:000085045600006
J	Sharkey, TD				Sharkey, TD			Plant biology - Some like it hot	SCIENCE			English	Editorial Material							MEMBRANE-LIPIDS; UNSATURATION; PHOTOSYNTHESIS; ARABIDOPSIS; TEMPERATURE; MUTANT		Univ Wisconsin, Dept Bot, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Sharkey, TD (corresponding author), Univ Wisconsin, Dept Bot, 430 Lincoln Dr, Madison, WI 53706 USA.		Sharkey, Thomas D/B-4032-2009; Sharkey, Thomas/ABF-1317-2020	Sharkey, Thomas D/0000-0002-4423-3223; Sharkey, Thomas/0000-0002-4423-3223				Bukhov NG, 1999, PHOTOSYNTH RES, V59, P81, DOI 10.1023/A:1006149317411; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; GOUNARIS K, 1984, BIOCHIM BIOPHYS ACTA, V766, P198, DOI 10.1016/0005-2728(84)90232-9; KUNST L, 1989, PLANT PHYSIOL, V91, P401, DOI 10.1104/pp.91.1.401; Law RD, 1999, PLANT PHYSIOL, V120, P173, DOI 10.1104/pp.120.1.173; MCCOURT P, 1987, PLANT PHYSIOL, V84, P353, DOI 10.1104/pp.84.2.353; MOON BY, 1995, P NATL ACAD SCI USA, V92, P6219, DOI 10.1073/pnas.92.14.6219; Murakami Y, 2000, SCIENCE, V287, P476, DOI 10.1126/science.287.5452.476; NASH D, 1985, BIOCHIM BIOPHYS ACTA, V807, P127, DOI 10.1016/0005-2728(85)90115-X; Pastenes C, 1996, PLANT PHYSIOL, V112, P1253, DOI 10.1104/pp.112.3.1253; THOMAS PG, 1986, BIOCHIM BIOPHYS ACTA, V849, P131, DOI 10.1016/0005-2728(86)90104-0; Williams WP, 1998, LIPIDS PHOTOSYNTHESI, P103	12	31	34	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					435	+		10.1126/science.287.5452.435	http://dx.doi.org/10.1126/science.287.5452.435			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10671172				2022-12-28	WOS:000084929900029
J	Kobayashi, N; Fujiwara, T; Westerman, KA; Inoue, Y; Sakaguchi, M; Noguchi, H; Miyazaki, M; Cai, J; Tanaka, N; Fox, IJ; Leboulch, P				Kobayashi, N; Fujiwara, T; Westerman, KA; Inoue, Y; Sakaguchi, M; Noguchi, H; Miyazaki, M; Cai, J; Tanaka, N; Fox, IJ; Leboulch, P			Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes	SCIENCE			English	Article							MAMMALIAN-CELLS; TRANSPLANTATION; ACTIVATION	Because of a critical shortage in suitable organs, many patients with terminal liver disease die each year before liver transplantation can be performed. Transplantation of isolated hepatocytes has been proposed for the temporary metabolic support of patients awaiting liver transplantation or spontaneous reversion of their liver disease. A major limitation of this form of therapy is the present inability to isolate an adequate number of transplantable hepatocytes. A highly differentiated cell line, NKNT-3, was generated by retroviral transfer in normal primary adult human hepatocytes of an immortalizing gene that can be subsequently and completely excised by Cre/Lox site-specific recombination. When transplanted into the spleen of rats under transient immunosuppression, reversibly immortalized NKNT-3 cells provided life-saving metabolic support during acute liver failure induced by 90% hepatectomy.	Okayama Univ, Dept Surg 1, Okayama 7008558, Japan; Okayama Univ, Dept Cell Biol, Okayama 7008558, Japan; MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Genetix Pharmaceut, Cambridge, MA 02139 USA; Univ Nebraska, Dept Surg, Omaha, NE 68198 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA	Okayama University; Okayama University; Massachusetts Institute of Technology (MIT); University of Nebraska System; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Kobayashi, N (corresponding author), Okayama Univ, Dept Surg 1, 2-5-1 Shikata Cho, Okayama 7008558, Japan.		Sakaguchi, Masakiyo/B-2280-2011; Inoue, Yusuke/O-6207-2018	Inoue, Yusuke/0000-0002-9710-7482; Noguchi, Hirofumi/0000-0002-0880-6805	NHLBI NIH HHS [HL55435] Funding Source: Medline; NIDDK NIH HHS [DK48794] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048794] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arkadopoulos N, 1998, HEPATOLOGY, V28, P1365, DOI 10.1002/hep.510280527; Chowdhury JR, 1998, PEDIATRICS, V102, P647, DOI 10.1542/peds.102.3.647; DEMETRIOU AA, 1986, SCIENCE, V233, P1190, DOI 10.1126/science.2426782; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; Gartner HV, 1996, NEW ENGL J MED, V335, P1494, DOI 10.1056/NEJM199611143352004; GEBHARDT R, 1989, HISTOCHEMISTRY, V92, P337, DOI 10.1007/BF00500550; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Nakamura J, 1997, TRANSPLANTATION, V63, P1541, DOI 10.1097/00007890-199706150-00001; Paradis K, 1999, SCIENCE, V285, P1236, DOI 10.1126/science.285.5431.1236; Pawliuk R, 1999, NAT MED, V5, P768, DOI 10.1038/10488; Schumacher IK, 1996, HEPATOLOGY, V24, P337; Strom SC, 1997, TRANSPLANTATION, V63, P559, DOI 10.1097/00007890-199702270-00014; Strom SC, 1999, SEMIN LIVER DIS, V19, P39, DOI 10.1055/s-2007-1007096; Westerman KA, 1996, P NATL ACAD SCI USA, V93, P8971, DOI 10.1073/pnas.93.17.8971	15	245	302	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1258	1262		10.1126/science.287.5456.1258	http://dx.doi.org/10.1126/science.287.5456.1258			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678831				2022-12-28	WOS:000085444700048
J	Grant, G; Goodenough, T; Harvey, I; Hine, C				Grant, G; Goodenough, T; Harvey, I; Hine, C			A randomised controlled trial and economic evaluation of a referrals facilitator between primary care and the voluntary sector	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; PSYCHOSOCIAL PROBLEMS; QUESTIONNAIRE	Objectives To compare outcome and resource utilisation among patients referred to the Amalthea Project, a liaison organisation that facilitates contact between voluntary organisations and patients in primary care, with patients receiving routine general practitioner care. Design Randomised controlled trial with follow up at one and four months. Setting 26 general practices in Avon. Participants 161 patients identified by their general practitioner as having psychosocial problems. Main outcome measures Primary outcomes were psychological wellbeing (assessed with the hospital anxiety and depression scale) and social support (assessed using the Duke-UNC functional social support questionnaire). Secondary outcomes were quality of life measures (the Dartmouth COOP/WONCA functional health assessment charts and the delighted-terrible faces scale), cost of contacts with the primary healthcare team and Amalthea Project, cost of prescribing in primary care, and cost of referrals to other agencies, over four months. Results The Amalthea group showed significantly greater improvements in anxiety (average difference between groups after adjustment for baseline -1.9, 95% confidence interval -3.0 to -0.7), other emotional feelings (average adjusted difference -0.5, -0.8 to -0.2), ability to carry out everyday activities (-0.5, -0.8 to -0.2), feelings about general health (-0.4, -0.7 to -0.1), and quality of life (-0.5, -0.9 to -0.1). No difference was detected in depression or perceived social support. The mean cost was significantly greater in the Amalthea arm than the general practitioner care arm (pound 153 v pound 133, P = 0.025). Conclusion Referral to the Amalthea Project and subsequent contact with the voluntary sector results in clinically important benefits compared with usual general practitioner care in managing psychosocial problems, but at a higher cost.	Univ Bristol, Div Primary Hlth Care, Bristol BS8 2PR, Avon, England; Avon Hlth Author, Bristol BS2 8EE, Avon, England; Univ E Anglia, Sch Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England	University of Bristol; University of East Anglia	Grant, G (corresponding author), Univ Bristol, Div Primary Hlth Care, Bristol BS8 2PR, Avon, England.							ANDREWS FM, 1974, SOC INDIC RES, V1, P1, DOI 10.1007/BF00286419; [Anonymous], 1997, UNIT COSTS HLTH SOCI; BAKER D, 1996, LIAISON VOLUNTARY 2; BLACK ME, 1988, BRIT MED J, V296, P1485, DOI 10.1136/bmj.296.6635.1485; BLACK N, 1988, BRIT MED J, V296, P82, DOI 10.1136/bmj.296.6615.82; BROADHEAD WE, 1988, MED CARE, V26, P709, DOI 10.1097/00005650-198807000-00006; Fairhurst K, 1996, J Health Serv Res Policy, V1, P77; FLETCHER J, 1995, BRIT J GEN PRACT, V45, P467; Gordon D., 1995, PEOPLE PLACES 2 SOCI; GRAHAM N, 1995, BRIT J GEN PRACT, V45, P272; Gulbrandsen P, 1997, BRIT MED J, V314, P1014, DOI 10.1136/bmj.314.7086.1014; Harvey I, 1998, BRIT J GEN PRACT, V48, P1043; Nelson EC, 1987, J CHRON DIS, V40, P55; PAYNE M, 1987, BR J GEN PRACT, V37, P339; *SECR STAT HLTH, 1999, SAV LIV OUR HEALTH N; SHARP DJ, 1989, J ROY COLL GEN PRACT, V39, P356; SIBBALD B, 1993, BMJ-BRIT MED J, V306, P29, DOI 10.1136/bmj.306.6869.29; TOGNONI G, 1991, BRIT MED J, V303, P969, DOI 10.1136/bmj.303.6808.969; VERHAAK PFM, 1990, INT J PSYCHIAT MED, V20, P151, DOI 10.2190/WHGG-2KQG-65GN-57YJ; WHITEHOUSE CR, 1987, J ROY COLL GEN PRACT, V37, P112; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	21	79	79	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					419	+		10.1136/bmj.320.7232.419	http://dx.doi.org/10.1136/bmj.320.7232.419			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	285EU	10669447	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000085377400024
J	Regan, FAM; Hewitt, P; Barbara, JAJ; Contreras, M				Regan, FAM; Hewitt, P; Barbara, JAJ; Contreras, M		TTI Study Grp	Prospective investigation of transfusion transmitted infection in recipients of over 20 000 units of blood	BRITISH MEDICAL JOURNAL			English	Article							HEPATITIS-C VIRUS; TRANSMISSION; DONORS; RISK; SURGEON; HIV	Objectives To follow up recipients of 20 000 units of blood to identify any transmissions of infections through blood transfusion. Design Follow up study of recipients of transfusion. Setting 22 hospitals in north London. Participant Adult patients who had recently been transfused. Main outcome measures Patients had further blood samples taken at 9 months that were tested for markers of hepatitis B and C and HIV and human T cell leukaemia/lymphoma virus type I or II (HTLV) infections. Recent infections were distinguished from pre-existing infections by comparison with blood samples taken before transfusion. Results 9220 patients were recruited, and 5579 recipients of 21 923 units of blood were followed up. No transfusion transmitted infections were identified. The incidence of transfusion transmitted infections was 0 in 21 043 units (95% confidence interval for risk 0 to 1 in 5706 recipients) for hepatitis B; 0 in 21 800 units (0 to 1 in 5911 recipients) for hepatitis C; 0 in 21 923 units (0 to 1 in 5944 recipients) for HIV; and 0 in 21 902 units (0 to 1 in 5939 recipients) for human T cell leukaemia/lymphoma virus. Three patients acquired hepatitis B during or after hospital admission but not through transfusion; 176 (3%) had pre-existing hepatitis B infection. Sixteen (0.29%) patients had hepatitis C, and five (0.09%) had human T cell leukaemia/lymphoma virus. Conclusions The current risk of transfusion transmitted infections in the United Kingdom is very small, though hospital acquired infections may arise from sources other than transfusion. A considerable proportion of patients have pre-existing infections.	Natl Blood Serv, N London Ctr, London NW9 5BG, England		Hewitt, P (corresponding author), Natl Blood Serv, N London Ctr, London & S East Zone, London NW9 5BG, England.							ALLAIN JP, 1995, TRANSFUSION MED, V5, P259, DOI 10.1111/j.1365-3148.1995.tb00211.x; ALLANDER T, 1995, LANCET, V345, P603, DOI 10.1016/S0140-6736(95)90518-9; ALTER HJ, 1992, HEPATOLOGY, V15, P350, DOI 10.1002/hep.1840150228; BELL DM, 1993, J PUBLIC HEALTH DENT, V53, P170, DOI 10.1111/j.1752-7325.1993.tb02697.x; BLAJCHMAN MA, 1995, LANCET, V345, P21, DOI 10.1016/S0140-6736(95)91153-7; BRENNAN M, 1993, BRIT MED J, V307, P1235, DOI 10.1136/bmj.307.6914.1235; COHEN ND, 1989, NEW ENGL J MED, V320, P1172, DOI 10.1056/NEJM198905043201803; CONTRERAS M, 1991, LANCET, V337, P753, DOI 10.1016/0140-6736(91)91370-A; CONTRERAS M, 1993, CURRENT MED LIT RSM, V4, P67; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; FLANAGAN P, 1995, VOX SANG, V68, P220, DOI 10.1111/j.1423-0410.1995.tb02576.x; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; KOJIMA M, 1991, VOX SANG, V60, P34, DOI 10.1111/j.1423-0410.1991.tb00868.x; Korelitz JJ, 1996, TRANSFUSION, V36, P203, DOI 10.1046/j.1537-2995.1996.36396182135.x; MOSELY JW, 1995, TRANSFUSION, V35, P5; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; WILLIAMSON LM, 1998, SHOT ANN REPORT 1996; 1995, NIH CONSENSUS STATEM, V13, P1	19	63	72	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					403	406		10.1136/bmj.320.7232.403	http://dx.doi.org/10.1136/bmj.320.7232.403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669443	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000085377400020
J	Gibbs, CR; Jackson, G; Lip, GYH				Gibbs, CR; Jackson, G; Lip, GYH			ABC of heart failure - Non-drug management	BRITISH MEDICAL JOURNAL			English	Review									Guys & St Thomas Hosp, Dept Cardiol, London SE1 9RT, England; City Hosp, Dept Med, Birmingham, W Midlands, England; City Hosp, Dept Cardiol, Birmingham, W Midlands, England; Selly Oak Hosp, Dept Cardiol, Birmingham B29 6JD, W Midlands, England	Guy's & St Thomas' NHS Foundation Trust; University of Birmingham; University of Birmingham	Gibbs, CR (corresponding author), Guys & St Thomas Hosp, Dept Cardiol, London SE1 9RT, England.							DEMAKIS JG, 1974, ANN INTERN MED, V80, P293, DOI 10.7326/0003-4819-80-3-293; KOSTIS JB, 1994, CHEST, V106, P996, DOI 10.1378/chest.106.4.996; MCKELVIE RS, 1995, J AM COLL CARDIOL, V25, P789, DOI 10.1016/0735-1097(94)00428-S; Remme WJ, 1997, EUR HEART J, V18, P736	4	25	25	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					366	369		10.1136/bmj.320.7231.366	http://dx.doi.org/10.1136/bmj.320.7231.366			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657338	Green Published			2022-12-28	WOS:000085211400036
J	Stott, S				Stott, S			Recent advances - Recent advances in intensive care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RESPIRATORY-DISTRESS-SYNDROME; INHALED NITRIC-OXIDE; PERCUTANEOUS DILATATIONAL TRACHEOSTOMY; PULMONARY-ARTERY CATHETER; CRITICALLY ILL PATIENTS; DILATIONAL TRACHEOSTOMY; VENTILATION STRATEGY; PARENTERAL-NUTRITION; BEDSIDE PROCEDURE; SYNDROME ARDS		Grampian Univ Hosp Trust, Aberdeen AB25 2ZN, Scotland	University of Aberdeen	Stott, S (corresponding author), Grampian Univ Hosp Trust, Aberdeen AB25 2ZN, Scotland.	s.a.stott@abdn.ac.uk						Abel SJC, 1998, THORAX, V53, P292, DOI 10.1136/thx.53.4.292; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Atkinson S, 1998, CRIT CARE MED, V26, P1164, DOI 10.1097/00003246-199807000-00013; BEALE RJ, IN PRESS CRIT CARE M; BENNETT D, 1991, INTENS CARE MED, V17, pR1, DOI 10.1007/BF01704735; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Blok WL, 1996, J NUTR, V126, P1515, DOI 10.1093/jn/126.6.1515; BRITTENDEN J, 1994, SURGERY, V115, P205; Cariou A, 1998, CRIT CARE MED, V26, P2066, DOI 10.1097/00003246-199812000-00043; CIAGLIA P, 1985, CHEST, V87, P715, DOI 10.1378/chest.87.6.715; Cobean R, 1996, ARCH SURG-CHICAGO, V131, P265; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Cuthbertson BH, 1997, INTENS CARE MED, V23, P1212, DOI 10.1007/s001340050488; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; Dellinger RP, 1998, CRIT CARE MED, V26, P15, DOI 10.1097/00003246-199801000-00011; Flaatten H, 1998, ACTA ANAESTH SCAND, V42, P329, DOI 10.1111/j.1399-6576.1998.tb04925.x; Gadek JE, 1999, CRIT CARE MED, V27, P1409, DOI 10.1097/00003246-199908000-00001; GATTINONI L, 1991, ANESTHESIOLOGY, V74, P15, DOI 10.1097/00000542-199101000-00004; Germann P, 1998, ANESTHESIOLOGY, V89, P1401, DOI 10.1097/00000542-199812000-00017; Griffiths RD, 1997, NUTRITION, V13, P295; HEFFNER JE, 1986, CHEST, V14, P742; Hill BB, 1996, J TRAUMA, V41, P238, DOI 10.1097/00005373-199608000-00007; Jolliet P, 1998, CRIT CARE MED, V26, P1977, DOI 10.1097/00003246-199812000-00023; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lundin S, 1999, INTENS CARE MED, V25, P911, DOI 10.1007/s001340050982; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; ORIORDAIN MG, 1994, ANN SURG, V220, P212, DOI 10.1097/00000658-199408000-00014; Papazian L, 1998, AM J RESP CRIT CARE, V157, P580, DOI 10.1164/ajrccm.157.2.9705046; PIEHL MA, 1976, CRIT CARE MED, V4, P13, DOI 10.1097/00003246-197601000-00003; PINSKY MR, 1994, INTENS CARE MED, V20, P1, DOI 10.1007/BF02425045; Poelaert J, 1999, ANAESTHESIA, V54, P128, DOI 10.1046/j.1365-2044.1999.00666.x; Sandham JD, 1998, CRIT CARE MED, V26, P1288, DOI 10.1097/00003246-199807000-00037; SCHACHNER A, 1989, CRIT CARE MED, V17, P1052, DOI 10.1097/00003246-198910000-00017; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; WINKLER WB, 1994, INTENS CARE MED, V20, P476, DOI 10.1007/BF01711898; Zwissler B, 1996, AM J RESP CRIT CARE, V154, P1671, DOI 10.1164/ajrccm.154.6.8970353	37	5	6	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2000	320	7231					358	361		10.1136/bmj.320.7231.358	http://dx.doi.org/10.1136/bmj.320.7231.358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657335	Green Published			2022-12-28	WOS:000085211400029
J	Benton, MJ; Wills, MA; Hitchin, R				Benton, MJ; Wills, MA; Hitchin, R			Quality of the fossil record through time	NATURE			English	Article							TAXONOMIC DIVERSITY; MOLECULAR EVIDENCE; MASS EXTINCTIONS; METAZOAN PHYLA	Does the fossil record present a true picture of the history of life(1-3), or should it be viewed with caution(4-6)? Raup(5) argued that plots of the diversification of life(2) were an illustration of bias: the older the rocks, the less we know. The debate was partially resolved by the observation(7) that different data sets gave similar patterns of rising diversity through time. Here we show that new assessment methods, in which the order of fossils in the rocks (stratigraphy) is compared with the order inherent in evolutionary trees (phylogeny), provide a more convincing analytical tool: stratigraphy and phylogeny offer independent data on history. Assessments of congruence between stratigraphy and phylogeny for a sample of 1,000 published phylogenies show no evidence of diminution of quality backwards in time. Ancient rocks clearly preserve less information, on average, than more recent rocks. However, if scaled to the stratigraphic level of the stage and the taxonomic level of the family, the past 540 million years of the fossil record provide uniformly good documentation of the life of the past.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Univ Oxford, Museum Hist Nat, Oxford OX1 3PW, England	University of Bristol; University of Oxford	Benton, MJ (corresponding author), Univ Bristol, Dept Earth Sci, Wills Mem Bldg, Bristol BS8 1RJ, Avon, England.		Benton, Michael J/A-5639-2008; Wills, Matthew Albion/AAE-1790-2019	Benton, Michael J/0000-0002-4323-1824; Wills, Matthew/0000-0002-7344-7749				Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; Benton Michael J., 1996, Historical Biology, V12, P111; BENTON MJ, 1994, GEOLOGY, V22, P111, DOI 10.1130/0091-7613(1994)022<0111:TTQOTF>2.3.CO;2; Benton MJ, 1999, SYST BIOL, V48, P581, DOI 10.1080/106351599260157; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; BENTON MJ, 1993, FOSSIL RECORD, V2; Cooper A, 1997, SCIENCE, V275, P1109, DOI 10.1126/science.275.5303.1109; Foote M, 1999, SCIENCE, V283, P1310, DOI 10.1126/science.283.5406.1310; Foote M, 1999, NATURE, V398, P415, DOI 10.1038/18872; FOREY PL, 1992, CLADISTICS PRACTICAL; HARLAND WB, 1993, GEOLOGIC TIME SCALE; HENNIG W, 1999, PHYLOGENETIC SYSTEMA; Hillis DM., 1996, MOL SYSTEMATICS, V2nd; HUELSENBECK JP, 1994, PALEOBIOLOGY, V20, P470, DOI 10.1017/S009483730001294X; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Norell Mark A., 1992, P89; PATTERSON C, 1981, ANNU REV ECOL SYST, V12, P195, DOI 10.1146/annurev.es.12.110181.001211; Paul CRC, 1998, ADEQUACY OF THE FOSSIL RECORD, P1; RAUP DM, 1972, SCIENCE, V177, P1065, DOI 10.1126/science.177.4054.1065; RAUP DM, 1984, P NATL ACAD SCI-BIOL, V81, P801, DOI 10.1073/pnas.81.3.801; RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501; SEPKOSKI JJ, 1981, NATURE, V293, P435, DOI 10.1038/293435a0; SEPKOSKI JJ, 1984, PALEOBIOLOGY, V10, P246, DOI 10.1017/S0094837300008186; Siddall ME, 1996, SYST BIOL, V45, P111, DOI 10.2307/2413516; Simpson G.G., 1944, TEMPO MODE EVOLUTION, DOI DOI 10.1073/pnas.1821292116; SMITH AB, 1994, SYSTEMATICS FOSSIL R; Valentine J. W., 1969, Palaeontology, V12, P684; Wagner PJ, 1998, ADEQUACY OF THE FOSSIL RECORD, P165; Wills MA, 1999, SYST BIOL, V48, P559, DOI 10.1080/106351599260148; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568	30	153	162	1	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					534	537		10.1038/35000558	http://dx.doi.org/10.1038/35000558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676959				2022-12-28	WOS:000085227300047
J	Chadwick, D				Chadwick, D			Seizures and epilepsy after traumatic brain injury	LANCET			English	Editorial Material							POPULATION				Chadwick, D (corresponding author), Univ Liverpool, Walton Ctr Neurol & Neurosurg, Liverpool L9 7LJ, Merseyside, England.							Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; GODDARD GV, 1969, EXP NEUROL, V25, P294; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; Jennett B., 1975, EPILEPSY NONMISSILE, V2nd; King MA, 1998, LANCET, V352, P1007, DOI 10.1016/S0140-6736(98)03543-0; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593	10	23	24	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					334	336		10.1016/S0140-6736(99)00452-3	http://dx.doi.org/10.1016/S0140-6736(99)00452-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665550				2022-12-28	WOS:000085122100006
J	Griffiths, TL; Burr, ML; Campbell, IA; Lewis-Jenkins, V; Mullins, J; Shiels, K; Turner-Lawlor, PJ; Payne, N; Newcombe, RG; Lonescu, AA; Thomas, J; Tunbridge, J				Griffiths, TL; Burr, ML; Campbell, IA; Lewis-Jenkins, V; Mullins, J; Shiels, K; Turner-Lawlor, PJ; Payne, N; Newcombe, RG; Lonescu, AA; Thomas, J; Tunbridge, J			Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial	LANCET			English	Article							QUALITY-OF-LIFE; LONG-TERM BENEFITS; EXERCISE TOLERANCE; RESPIRATORY REHABILITATION; DISEASE; COPD; PROGRAM; HOME; QUESTIONNAIRE; IMPROVES	Background Pulmonary rehabilitation seems to be an effective intervention in patients with chronic obstructive pulmonary disease. We undertook a randomised controlled trial to assess the effect of outpatient pulmonary rehabilitation on use of health care and patients' wellbeing over 1 year. Methods 200 patients with disabling chronic lung disease (the majority with chronic obstructive pulmonary disease) were randomly assigned a 6-week multidisciplinary rehabilitation programme (18 visits) or standard medical management. Use of health services was assessed from hospital and general-practice records. Analysis was by intention to treat. Findings There was no difference between the rehabilitation (n=99) and control (n=101) groups in the number of patients admitted to hospital (40 vs 41) but the number of days these patients spent in hospital differed significantly (mean 10.4 [SD 9.7] vs 21.0 [20.7], p=0.022). The rehabilitation group had more primary-care consultations at the general-practitioner's premises than did the control group (8.6 [6.8] vs 7.3 [8.3], p=0.033) but fewer primary-care home visits (1.5 [2.8] vs 2.8 [4.6], p=0.037). Compared with control, the rehabilitation group also showed greater improvements in walking ability and in general and disease-specific health status. Interpretation For patients chronically disabled by obstructive pulmonary disease, an intensive, multidisciplinary, outpatient programme of rehabilitation is an effective intervention, in the short term and the long term, that decreases use of health services.	Cardiff Univ, Dept Med, Sect Resp Med, Llandough Hosp, Penarth CF64 2XX, S Glam, Wales; Cardiff Univ, Dept Publ Hlth Med, Cardiff CF4 4XN, S Glam, Wales; Cardiff Univ, Dept Med Comp & Stat, Cardiff CF4 4XN, S Glam, Wales; Univ Wales Hosp, Penarth, S Glam, Wales; Llandough Hosp NHS Trust, Penarth, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University	Griffiths, TL (corresponding author), Cardiff Univ, Dept Med, Sect Resp Med, Llandough Hosp, Penarth CF64 2XX, S Glam, Wales.	griffithsti@cf.ac.uk	Newcombe, Robert G/B-4897-2009					American Thoracic Society, 1999, AM J RESP CRIT CARE, V159, P1666; Bendstrup KE, 1997, EUR RESPIR J, V10, P2801, DOI 10.1183/09031936.97.10122801; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Cambach W, 1997, EUR RESPIR J, V10, P104, DOI 10.1183/09031936.97.10010104; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Cotes JE, 1975, LUNG FUNCTION; Foglio K, 1999, EUR RESPIR J, V13, P125, DOI 10.1183/09031936.99.13112599; GOLDSTEIN RS, 1994, LANCET, V344, P1394, DOI 10.1016/S0140-6736(94)90568-1; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; Harper R, 1997, THORAX, V52, P879, DOI 10.1136/thx.52.10.879; HUDSON LD, 1976, CHEST, V70, P606, DOI 10.1378/chest.70.5.606; JOHNSON HR, 1980, RESP THER, V3, P15; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Ketelaars CAJ, 1997, CHEST, V112, P363, DOI 10.1378/chest.112.2.363; Lacasse Y, 1996, LANCET, V348, P1115, DOI 10.1016/S0140-6736(96)04201-8; MAHLER DA, 1995, CHEST, V107, P1585, DOI 10.1378/chest.107.6.1585; Pearson MG, 1997, THORAX, V52, pS1; PETTY TL, 1969, ANN INTERN MED, V70, P1109, DOI 10.7326/0003-4819-70-6-1109; Ries AL, 1997, CHEST, V112, P1363, DOI 10.1378/chest.112.5.1363; RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; SINGH SJ, 1992, THORAX, V47, P1019, DOI 10.1136/thx.47.12.1019; Singh SJ, 1998, RESP MED, V92, P1146, DOI 10.1016/S0954-6111(98)90410-3; Strijbos JH, 1996, CHEST, V109, P366, DOI 10.1378/chest.109.2.366; VALE F, 1993, CHEST, V103, P42, DOI 10.1378/chest.103.1.42; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 1994, PHYSICAL MENTAL HLTH; Wedzicha JA, 1998, EUR RESPIR J, V12, P363, DOI 10.1183/09031936.98.12020363; White RJ, 1997, J ROY COLL PHYS LOND, V31, P541; WIJKSTRA PJ, 1994, EUR RESPIR J, V7, P269, DOI 10.1183/09031936.94.07020269; WIJKSTRA PJ, 1995, THORAX, V50, P824, DOI 10.1136/thx.50.8.824; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	32	608	626	0	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	2000	355	9201					362	368		10.1016/S0140-6736(99)07042-7	http://dx.doi.org/10.1016/S0140-6736(99)07042-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665556				2022-12-28	WOS:000085122100012
J	Delfs, JM; Zhu, Y; Druhan, JP; Aston-Jones, G				Delfs, JM; Zhu, Y; Druhan, JP; Aston-Jones, G			Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion	NATURE			English	Article							NUCLEUS-ACCUMBENS; OPIOID WITHDRAWAL; CLONIDINE; RATS; LESIONS; MEDULLA; LOCUS; RETROGRADE; MORPHINE; NALOXONE	Cessation of drug use in chronic opiate abusers produces a severe withdrawal syndrome that is highly aversive, and avoidance of withdrawal or associated stimuli is a major factor contributing to opiate abuse(1,2). Increased noradrenaline in the brain has long been implicated in opiate withdrawal(3), but it has not been clear which noradrenergic systems are invoked. Here we show that microinjection of beta-noradrenergic-receptor antagonists, or of an alpha 2-receptor agonist, into the bed nucleus of the stria terminalis (BNST) in rats markedly attenuates opiate-withdrawal-induced conditioned place aversion, Immunohistochemical studies revealed that numerous BNST-projecting cells in the A1 and A2 noradrenergic cell groups of the caudal medulla were activated during withdrawal Lesion of these ascending medullary projections also greatly reduced opiate-withdrawal-induced place aversion. whereas lesion of locus coeruleus noradrenergic projections had no effect on opiate-withdrawal behaviour. We conclude that noradrenergic inputs to the BNST from the caudal medulla are critically involved in the aversiveness of opiate withdrawal.	Univ Penn, Sch Med, Dept Psychiat, VA Med Ctr 151, Philadelphia, PA 19104 USA	University of Pennsylvania	Aston-Jones, G (corresponding author), Univ Penn, Sch Med, Dept Psychiat, VA Med Ctr 151, Univ & Woodland Ave, Philadelphia, PA 19104 USA.							Akaoka H., 1992, Society for Neuroscience Abstracts, V18, P374; Alheid George F., 1995, P495; ASTONJONES G, 1993, NEUROBIOLOGY OPIATES, P175; Bechara A, 1998, PHARMACOL BIOCHEM BE, V59, P1, DOI 10.1016/S0091-3057(97)00047-6; Blessing W, 1997, LOWER BRAINSTEM BODI; BRITTON KT, 1984, LIFE SCI, V34, P133, DOI 10.1016/0024-3205(84)90583-6; Brownstein MJ, 1984, HDB CHEM NEUROANAT 1, P23; Caille S, 1999, J PHARMACOL EXP THER, V290, P881; Chen S, 1996, NEUROSCIENCE, V71, P443, DOI 10.1016/0306-4522(95)00437-8; CHIENG B, 1995, NEUROSCI LETT, V186, P37, DOI 10.1016/0304-3940(95)11276-3; Christie MJ, 1997, TRENDS PHARMACOL SCI, V18, P134, DOI 10.1016/S0165-6147(97)01045-6; DROLET G, 1992, J NEUROSCI, V12, P3162, DOI 10.1523/JNEUROSCI.12-08-03162.1992; EVERITT BJ, 1983, NEUROSCIENCE, V10, P397, DOI 10.1016/0306-4522(83)90142-2; FRITSCHY JM, 1990, J CHEM NEUROANAT, V3, P309; GOLD MS, 1978, LANCET, V2, P599; GROSZ HJ, 1972, LANCET, V2, P564; HARRIS GC, 1994, NATURE, V371, P155, DOI 10.1038/371155a0; HARRIS GC, 1993, NEUROPSYCHOPHARMACOL, V9, P303, DOI 10.1038/npp.1993.66; HIGGINS GA, 1994, PHARMACOL BIOCHEM BE, V48, P1, DOI 10.1016/0091-3057(94)90489-8; Maldonado R, 1997, NEUROSCI BIOBEHAV R, V21, P91, DOI 10.1016/0149-7634(95)00061-5; McKittrick C. R., 1999, Society for Neuroscience Abstracts, V25, P948; Nader K, 1996, BEHAV NEUROSCI, V110, P389, DOI 10.1037/0735-7044.110.2.389; O'Brien C P, 1988, NIDA Res Monogr, V84, P44; POTHOS E, 1991, BRAIN RES, V566, P348, DOI 10.1016/0006-8993(91)91724-F; ROEHRICH H, 1987, AM J PSYCHIAT, V144, P1099; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; STINUS L, 1990, NEUROSCIENCE, V37, P767, DOI 10.1016/0306-4522(90)90106-E; STORNETTA RL, 1993, BRAIN RES, V624, P19, DOI 10.1016/0006-8993(93)90055-R; TEJANIBUTT SM, 1992, J PHARMACOL EXP THER, V260, P427; TERENZI MG, 1995, BRAIN RES, V672, P289, DOI 10.1016/0006-8993(94)01453-O	30	360	365	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					430	434		10.1038/35000212	http://dx.doi.org/10.1038/35000212			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667795				2022-12-28	WOS:000085121100051
J	Verschuren, D; Laird, KR; Cumming, BF				Verschuren, D; Laird, KR; Cumming, BF			Rainfall and drought in equatorial east Africa during the past 1,100 years	NATURE			English	Article							LAKE-LEVEL; CLIMATE; KENYA	Knowledge of natural long-term rainfall variability is essential for water-resource and land-use management in sub-humid regions of the world. In tropical Africa, data relevant to determining this variability are scarce because of the lack of long instrumental climate records and the limited potential of standard high-resolution proxy records such as tree rings and ice cores(1-3). Here we present a decade-scale reconstruction of rainfall and drought in equatorial east Africa over the past 1,100 years, based on lake-level and salinity fluctuations of Lake Naivasha (Kenya) inferred from three different palaeolimnological proxies: sediment stratigraphy and the species compositions of fossil diatom and midge assemblages. Our data indicate that, over the past millennium, equatorial east Africa has alternated between contrasting climate conditions, with significantly drier climate than today during the 'Medieval Warm Period' (similar to AD 1000-1270) and a relatively wet climate during the 'Little ice Age' (similar to AD 1270-1850) which was interrupted by three prolonged dry episodes. We also find strong chronological links between the reconstructed history of natural long-term rainfall variation and the pre-colonial cultural history of east Africa(4), highlighting the importance of a detailed knowledge of natural long-term rainfall fluctuations for sustainable socio-economic development.	Univ Minnesota, Limnol Res Ctr, Minneapolis, MN 55455 USA; State Univ Ghent, Dept Biol, B-9000 Ghent, Belgium; Queens Univ, Dept Biol, Paleoecol Environm Assessment & Res Lab, Kingston, ON K7L 3N6, Canada	University of Minnesota System; University of Minnesota Twin Cities; Ghent University; Queens University - Canada	Verschuren, D (corresponding author), Univ Minnesota, Limnol Res Ctr, Minneapolis, MN 55455 USA.							Cohen AS, 1997, GEOL SOC AM BULL, V109, P444, DOI 10.1130/0016-7606(1997)109<0444:LLAPHO>2.3.CO;2; Connah G., 1987, AFRICAN CIVILIZATION; Fritz Sherilyn C., 1999, P41; GASSE F, 1995, PALAEOGEOGR PALAEOCL, V117, P31, DOI 10.1016/0031-0182(94)00122-O; HALFMAN JD, 1994, PALAEOGEOGR PALAEOCL, V111, P83, DOI 10.1016/0031-0182(94)90349-2; HARPER D, 1992, HYDROBIOLOGIA, V232, P65, DOI 10.1007/BF00014613; KILHAM P, 1986, LIMNOL OCEANOGR, V31, P1169, DOI 10.4319/lo.1986.31.6.1169; KILHAM P, 1990, LIMNOL OCEANOGR, V35, P80, DOI 10.4319/lo.1990.35.1.0080; KNOX JC, 1993, NATURE, V361, P430, DOI 10.1038/361430a0; KUTZBACH JE, 1985, NATURE, V317, P130, DOI 10.1038/317130a0; LEAN J, 1995, GEOPHYS RES LETT, V22, P3195, DOI 10.1029/95GL03093; Line J. M., 1994, Journal of Paleolimnology, V10, P147, DOI 10.1007/BF00682511; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; Nicholson S., 1995, PHYS GEOGRAPHY AFRIC, P60; Nicholson S.E., 1996, LIMNOLOGY CLIMATOLOG, V1st ed., P25, DOI [DOI 10.1201/9780203748978-2, 10.1201/9780203748978-2]; Nicholson S.E., 1998, ENV CHANGE RESPONSE, P7, DOI DOI 10.1007/978-94-017-1437-2; OJIAMBO BS, 1996, LIMNOLOGY CLIMATOLOG, P267; OWEN RB, 1989, PALAEOECOL AFR, V20, P109; RIND D, 1993, QUATERNARY SCI REV, V12, P357, DOI 10.1016/S0277-3791(05)80002-2; ROBERTS N, 1993, NATURE, V366, P146, DOI 10.1038/366146a0; STREETPERROTT FA, 1990, NATURE, V343, P607, DOI 10.1038/343607a0; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; Verschuren D, 1999, QUATERNARY SCI REV, V18, P821, DOI 10.1016/S0277-3791(98)00065-1; VERSCHUREN D, IN PRESS ECOLOGY; VERSCHUREN D, IN PRESS J PALEOLIMN; VERSCHUREN D, 1997, ARCH HYDROBIOL S, V107, P467; Webster J.B, 1980, TRANSAFR J HIST, V9, P70; Webster J. M., 1979, CEGB Technical Disclosure Bulletin, P1; Woodhouse CA, 1998, B AM METEOROL SOC, V79, P2693, DOI 10.1175/1520-0477(1998)079<2693:YODVIT>2.0.CO;2; [No title captured]; [No title captured]	31	515	543	2	234	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					410	414		10.1038/35000179	http://dx.doi.org/10.1038/35000179			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667789				2022-12-28	WOS:000085121100045
J	Glezen, WP; Greenberg, SB; Atmar, RL; Piedra, PA; Couch, RB				Glezen, WP; Greenberg, SB; Atmar, RL; Piedra, PA; Couch, RB			Impact of respiratory virus infections on persons with chronic underlying conditions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYNCYTIAL VIRUS; AIR-POLLUTION; DISEASE HOSPITALIZATIONS; INFLUENZA EPIDEMICS; VIRAL-INFECTIONS; ASTHMA; CHILDREN; ADULTS; ILLNESS; VACCINE	Context While hospitalization rates have declined overall, hospitalizations for acute lower respiratory tract infections have increased steadily since 1980. Development of new approaches for prevention of acute respiratory tract conditions requires studies of the etiologies of infections and quantification of the risk of hospitalization for vulnerable patients. Objective To determine the frequency of specific virus infections associated with acute respiratory tract conditions leading to hospitalization of chronically ill patients. Design Analysis of viral etiology of patients hospitalized with acute respiratory tract conditions between July 1991 and June 1995. Setting Four large clinics and related hospitals serving diverse populations representative of Harris County, Texas. Patients A total of 1029 patients who were hospitalized for pneumonia, tracheobronchitis, bronchiolitis, croup, exacerbations of asthma or chronic obstructive pulmonary disease, and/or congestive heart failure. Main Outcome Measure Virus infection, defined by culture, antigen detection, and significant rise in serum antibodies, by underlying condition; hospitalization rates by low- vs middle-income status. Results Ninety-three percent of patients older than 5 years had a chronic underlying condition; a chronic pulmonary condition was most common. Patients with chronic pulmonary disease from low-income populations were hospitalized at a rate of 398.6 per 10 000, almost 8 times higher than the rate for patients from middle-income groups (52.2 per 10 000; P<.001). Of the 403 patients (44.4% of adults and 32.3% of children) who submitted convalescent serum specimens for antibody testing, respiratory tract virus infections were detected in 181 (44.9%). influenza, parainfluenza, and respiratory syncytial virus (RSV) infections accounted for 75% of all virus infections. Conclusions Our study suggests that respiratory virus infections commonly trigger serious acute respiratory conditions that result in hospitalization of patients with chronic underlying conditions, highlighting the need for development of effective vaccines for these viruses, especially for parainfluenza and RSV.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Glezen, WP (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.	wglezen@bcm.tmc.edu	Atmar, Robert/AFQ-5392-2022	Atmar, Robert/0000-0001-9989-6772	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015103] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15103] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON M, 1994, J ASTHMA, V31, P367, DOI 10.3109/02770909409061316; AGIUS G, 1990, J MED VIROL, V30, P117, DOI 10.1002/jmv.1890300208; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; BAXTER BD, 1977, J CLIN MICROBIOL, V6, P19; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42, DOI 10.1164/ajrccm/145.1.42; BUSSE WW, 1993, ASTHMA, P345; Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137; ENGLUND JA, 1988, ANN INTERN MED, V109, P203, DOI 10.7326/0003-4819-109-3-203; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; Fleiss J. L., 1981, STAT METHODS RATES P, V2; FRANK AL, 1979, J CLIN MICROBIOL, V10, P32, DOI 10.1128/JCM.10.1.32-36.1979; FRANK AL, 1980, J CLIN MICROBIOL, V12, P426, DOI 10.1128/JCM.12.3.426-432.1980; GARDNER G, 1984, J EPIDEMIOL COMMUN H, V38, P42, DOI 10.1136/jech.38.1.42; GILL EP, 1994, J CLIN MICROBIOL, V32, P2372, DOI 10.1128/JCM.32.10.2372-2376.1994; GLEZEN WP, 1987, J INFECT DIS, V155, P1119, DOI 10.1093/infdis/155.6.1119; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GLEZEN WP, 1977, PEDIATR RES, V11, P239; GLEZEN WP, 1984, CLIN CHEST MED, V5, P635; HALFON N, 1993, PEDIATRICS, V91, P56; Han LL, 1999, J INFECT DIS, V179, P25, DOI 10.1086/314567; Kim PE, 1996, CLIN INFECT DIS, V22, P100, DOI 10.1093/clinids/22.1.100; LAMY ME, 1973, CHEST, V63, P336, DOI 10.1378/chest.63.3.336; Marx A, 1999, CLIN INFECT DIS, V29, P134, DOI 10.1086/520142; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124; Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Pamuk E., 1998, SOCIOECONOMIC STATUS; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; PHILIT F, 1992, REV MAL RESPIR, V9, P191; PIEDRA PA, 1993, VACCINE, V11, P1415, DOI 10.1016/0264-410X(93)90170-3; PIEDRA PA, 1995, VACCINE, V13, P1095, DOI 10.1016/0264-410X(95)00034-X; Piedra PA, 1996, PEDIATR INFECT DIS J, V15, P23, DOI 10.1097/00006454-199601000-00006; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123, DOI 10.1164/ajrccm/145.5.1123; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; Simonsen L, 1998, ARCH INTERN MED, V158, P1923, DOI 10.1001/archinte.158.17.1923; SMITH CB, 1980, J INFECT DIS, V141, P271, DOI 10.1093/infdis/141.3.271; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; WOOD PR, 1993, PEDIATRICS, V91, P62	42	386	402	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					499	505		10.1001/jama.283.4.499	http://dx.doi.org/10.1001/jama.283.4.499			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659876	Bronze			2022-12-28	WOS:000084879800029
J	Schairer, C; Lubin, J; Troisi, R; Sturgeon, S; Brinton, L; Hoover, R				Schairer, C; Lubin, J; Troisi, R; Sturgeon, S; Brinton, L; Hoover, R			Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROLIFERATION; WOMEN	Context Whether menopausal hormone replacement therapy using a combined estrogen-progestin regimen increases risk of breast cancer beyond that associated with estrogen alone is unknown. Objective To determine whether increases in risk associated with the estrogen-progestin regimen are greater than those associated with estrogen alone. Design Cohort study of follow-up data for 1980-1995 from the Breast Cancer Detection Demonstration Project, a nationwide breast cancer screening program. Setting Twenty-nine screening centers throughout the United States. Participants A total of 46 355 postmenopausal women (mean age at start of followup, 58 years). Main Outcome Measure Incident breast cancers by recency, duration, and type of hormone use. Results During follow-up, 2082 cases of breast cancer were identified. Increases in risk with estrogen only and estrogen-progestin only were restricted to use within the previous 4 years (relative risk [RR], 1.2 [95% confidence interval {CI}, 1.0-1.4] and 1.4 [95% CI, 1.1-1.8], respectively); the relative risk increased by 0.01 (95% CI, 0.002-0.03) with each year of estrogen-only use and by 0.08 (95% CI, 0.02-0.16) with each year of estrogen-progestin-only use among recent users, after adjustment for mammographic screening, age at menopause, body mass index (BMI), education, and age. The P value associated with the test of homogeneity of these estimates was .02. Among women with a BMI of 24.4 kg/m(2) or less, increases in RR with each year of estrogen-only use and estrogen-progestin-only use among recent users were 0.03 (95% CI, 0.01-0.06) and 0.12 (95% CI, 0.02-0.25), respectively. These associations were evident for the majority of invasive tumors with ductal histology and regardless of extent of invasive disease. Risk in heavier women did not increase with use of estrogen only or estrogen-progestin only. Conclusion Our data suggest that the estrogen-progestin regimen increases breast cancer risk beyond that associated with estrogen alone.	NCI, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA; Social & Sci Syst Inc, Bethesda, MD USA; Univ Massachusetts, Dept Biostat & Epidemiol, Amherst, MA 01003 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Social & Scientific Systems; University of Massachusetts System; University of Massachusetts Amherst	Schairer, C (corresponding author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS Room 7080,MSC 7234, Rockville, MD 20852 USA.		Brinton, Louise A/G-7486-2015	Brinton, Louise A/0000-0003-3853-8562	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP010113] Funding Source: NIH RePORTER	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Breslow NE, 1987, STAT METHODS CANC RE; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Gapstur SM, 1999, JAMA-J AM MED ASSOC, V281, P2091, DOI 10.1001/jama.281.22.2091; Greendale GA, 1997, AM J EPIDEMIOL, V146, P763; Hargreaves DF, 1998, BRIT J CANCER, V78, P945, DOI 10.1038/bjc.1998.606; LAIDLAW IJ, 1995, ENDOCRINOLOGY, V136, P164, DOI 10.1210/en.136.1.164; Persson I, 1999, CANCER CAUSE CONTROL, V10, P253, DOI 10.1023/A:1008909128110; Pike MC, 1998, AM J EPIDEMIOL, V147, P718; Poutanen M, 1995, J STEROID BIOCHEM, V55, P525, DOI 10.1016/0960-0760(95)00201-4; PRESTON DL, 1996, EPICURE SOFTWARE REL; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; Schairer C, 1999, J NATL CANCER I, V91, P264, DOI 10.1093/jnci/91.3.264	15	786	821	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					485	491		10.1001/jama.283.4.485	http://dx.doi.org/10.1001/jama.283.4.485			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659874	Bronze			2022-12-28	WOS:000084879800027
J	Gerstein, HC; Yusuf, S; Mann, JFE; Hoogwerf, B; Zinman, B; Held, C; Fisher, M; Wolffenbuttel, B; Bosch, J; Richardson, L; Pogue, J; Halle, JP; Yusuf, S; Sleight, P; Dagenais, G; Montague, T; Bosch, J; Pogue, J; Taylor, W; Sardo, L; Arnold, M; Baigrie, R; Davies, R; Gerstein, H; Jha, P; Johnstone, D; Joyner, C; Kuritzky, R; Lonn, E; Mitchell, B; Morris, A; Sussex, B; Teo, K; Tsuyuki, R; Zinman, B; Probstfield, J; Young, J; Diaz, R; Paolasso, E; Avezum, A; Piegas, L; Mann, J; Wolffenbuttel, B; Ostergren, J; Meaney, E; Aprile, M; Bedard, D; Cossett, J; Ewart, G; Harris, L; Kellen, J; LaForge, D; Magi, A; Skanes, J; Squires, P; Stevens, K; Bosch, J; Cherian, F; Holadyk-Gris, I; Kalkbrenner, P; Lonn, E; Mazur, F; McQueen, M; Micks, M; Monti, S; Pogue, J; Sardo, L; Thompson, K; Westfall, L; Yusuf, S; Richardson, L; Raw, N; Genisans, M; Diaz, R; Paolasso, E; Avezum, A; Piegas, L; Gerstein, H; Zinman, B; Dagenais, G; Arnold, M; Auger, P; Avezum, A; Bata, I; Bernstein, V; Bourassa, M; Diaz, R; Fisher, B; Gerstein, H; Grover, J; Gun, C; Gupta, M; Held, C; Hoeschen, R; Kouz, S; Lonn, E; Mann, J; Mathew, J; Meaney, E; Meldrum, D; Pilon, C; Ramos, R; Roccaforte, R; Starra, R; Trivi, M; Davies, R; Johnstone, D; Lonn, E; Probstfield, J; McQueen, M; Sackett, D; Collins, R; Davis, E; Furberg, C; Hennekens, C; Pitt, B; Turner, R; Braver, J; Cuneo, C; Diaz, M; Dizeo, C; Guzman, L; Lipshitz, S; Llanos, S; Lopez, J; Lorenzatti, A; Machado, R; Mackey, C; Mancini, M; Marino, M; Martinez, F; Matrone, A; Nordaby, R; Orlandini, A; Romero, G; Ruiz, M; Rusculleda, M; Saavedra, S; San Damaso, J; Serra, J; Tuero, E; Zapata, G; Zavala, A; Grisold, M; Klein, W; Brosch, E; Baumans, P; Brusselmans, H; Bodson, A; Boland, J; Cano, J; Chaudron, JM; Degaute, JP; Duprez, D; Heyndrickx, G; Krzentowski, G; Mockel, J; Wautrecht, J; Alexandre, E; Amodeo, C; Armaganijan, D; Ayub, J; Bertolami, M; Bodanese, L; Borges, J; Caramelli, B; Carvalho, A; Coelho, O; Dioguardi, G; Faludi, A; Brage, JF; Fichino, M; Franken, R; Ghorayeb, N; de Souza, MG; Greque, G; Guedes, A; Kadri, T; Kawamura, T; Labrunie, A; Malheiros, F; Marafon, L; Nakamura, M; Nonohay, N; Ogawa, C; Pavanello, R; Puech-Leao, P; Ramires, F; Ramires, L; Sampaio, M; Saraiva, L; Savioli, F; Seixas, A; Shibata, M; Souza, A; Tanajura, L; Ueti, O; Vitola, D; Armstrong, F; Armstrong, W; Baptie, B; Basinger, M; Bell, N; Beresford, P; Black, W; Brass, N; Browne, M; Browne, K; Brownoff, R; Chaytors, G; Cottier, W; Donnelly, R; Dzavik, V; Edwards, A; Felker, P; Giannoccaro, P; Goeres, M; Greenwood, P; Grose, M; Grossman, L; Gulamhusein, S; Hui, W; Hutchison, F; Irving, A; Kasian, L; Kasza, L; Korner, L; Kvill, L; Lakhani, Z; Lam, S; Lesoway, R; Ma, P; Martinez, V; Meldrum, D; Mitchell, B; Mitchell, D; Montague, T; Musseau, A; Muzyka, T; Neffgen, C; Neffgen, J; Nichol, R; O'Beirne, M; Paradis, J; Paterson, D; Plesko, A; Prosser, A; Radomsky, N; Roth, D; Ryan, E; Senaratne, M; Simon, M; Stenerson, P; Stone, J; Talibi, T; Wedel, R; Wyse, D; Altwasser, F; Ashton, T; Askew, J; Bernstein, V; Bishop, W; Bloomberg, G; Boone, J; Breakwell, L; Buller, L; Calvert, K; Carere, G; Dahl, M; Dawson, K; Dodek, A; Dufton, J; Geddis, R; Ghosh, S; Heath, J; Hilton, D; Imrie, J; Jay, D; Kiess, M; Klinke, P; Kornder, J; Lee, P; Leong, W; Lewis, J; Lounsbury, N; MacDonald, L; MacDonald, K; MacNeil, A; MacRitchie, D; McGee, L; Mitchell, L; Mulcahy, K; O'Donoghue, S; Pearce, A; Perreault, L; Polasek, P; Rabkin, S; Reilly, M; Richardson, P; Scoffield, E; Sweeney, R; Terwiel, M; Thompson, C; Wagner, K; Webb, J; Wedding, K; Woo, K; Wright, M; Zutz, A; Briol, L; Hoeschen, R; Mehta, P; Mohammed, I; Ong, A; Ong, G; Bessoudo, R; O'Brien, L; McLellan, L; Milton, J; Elgar, F; Joyce, C; O'Keefe, D; Parsons, M; Ravalia, M; Sherman, G; Smith, R; Worrall, G; Atkinson, A; Barnhill, S; Bata, I; Crossman, L; Folkins, D; Hatheway, R; Johnson, B; MacFarlane, M; Machel, T; Morash, J; Sheridan, W; Shirley, M; Anderson, I; Arnold, M; Baigrie, R; Baird, M; Baitz, T; Barnie, A; Basta, M; Blakely, J; Bozek, B; Bradley, W; Brown, K; Burnham, G; Cameron, W; Cann, M; Carroll, S; Carter, R; Chan, N; Chan, Y; Charles, J; Cheung, M; Cina, C; Cleghorn, L; Curnew, G; Currado, P; Davies, R; DeGagne, S; DeYoung, P; Dhaliwal, R; Dowell, H; Drobac, M; Dubbin, J; Duffield, K; Edmonds, M; Fallen, E; Feldman, D; Fell, D; Ferguson, C; Finkelstein, L; Fong, G; Fowlis, R; Fraser, M; Frenette, L; Fulop, J; Glanz, A; Goode, E; Gupta, M; Hanna, A; Harris, K; Hess, A; Hierlihy, P; Houlden, R; Hramiak, I; Hrycyshyn, B; Iwanochko, R; Janzen, I; Kannampuzha, P; Keely, E; Kennedy, R; Kenshole, A; Kent, E; Khan, S; Kostuk, W; Kowaleski, M; Krupa, M; Kumar, G; Kuruvilla, G; Kwok, K; Lai, C; Langer, A; Laor, J; Lau, D; LaVallee, T; Lent, B; Liu, P; Lochnan, H; Lovell, M; Lowe, D; Mabb, T; Maclean, S; Man, K; Marois, L; Massel, D; Matthews, E; McManus, R; McPhee, E; McQueen, M; McSherry, J; Millar, D; Miller, F; Miners, L; Misterski, J; Moe, G; Mulaisho, C; Munoz, C; Nawaz, S; Noseworthy, C; O'Keefe, H; Oosterveld, L; Panju, A; Paquette, H; Parkovnick, M; Paterson, R; Pflugfelder, P; Powers, S; Rebane, T; Redda, A; Reeves, E; Ricci, J; Sasson, Z; Sayles, M; Scott, M; Sibbick, M; Singh, N; Southern, R; Spence, D; Sternberg, L; Stewart, J; Styling, S; Sulllivan, B; Sullivan, H; Sullivan, M; Swan, J; Taichman, J; Tan, K; Tanser, P; Tartaglia, C; Taylor, K; Thomson, D; Turek, M; Vakani, T; vanWalraven, A; Varey, M; Vexler, R; Walters, J; Weeks, A; Weingert, M; Wetmore, S; Whitsitt, P; Willing, J; Wilson, C; Wilson, J; Wisenberg, G; Wolfe, M; Wolter, B; Yao, L; Costain, G; Hickey, E; MacMillan, E; Aris-Jilwan, N; Auger, P; Banville, P; Beaudoin, J; Belanger, A; Belanger, N; Belleville, L; Bilodeau, N; Bogaty, P; Boulianne, M; Bourassa, M; Brophy, J; Brouillette, M; Buithieu, J; Calve, C; Campeau, J; Carmichael, P; Carrier, S; Chiasson, J; Coutu, B; Coutu, D; Croteau, S; D'Amours, G; Dagenais, N; Delage, F; Deschamps, J; Dion, D; Douville, Y; Dumont, F; Dupuis, R; Frechette, L; Gauthier, S; Gervais, P; Giguere, G; Giroux, R; Gossard, D; Gosselin, G; Goulet, G; Grondin, F; Halle, J; Henri, L; Houde, G; Joyal, M; Kandalaft, N; Karabatsos, A; Kiwan, G; Kouz, S; Labbe, R; Langlais, M; Lauzon, C; LeBlanc, M; Lenis, J; Leroux, S; Loisel, R; MacLellan, K; Morissette, A; Noel, H; Ouimet, F; Pedneault, L; Piche, J; Pilon, C; Plourde, P; Poirier, C; Poisson, D; Primeau, L; Pruneau, G; Remillard, C; Roberge, B; Robert, M; Rodrique, M; Roy, C; Roy, L; Ruel, M; Samson, M; Saulnier, D; Savard, D; Serpa, A; Sestier, F; Smilovitch, M; Starra, R; St-Hilaire, R; Theroux, P; Toupin-Halle, A; Tremblay, J; Truchen, H; Turcotte, J; Vachon, S; Vienneau, R; Wilson, P; Habib, M; Habib, N; Ahmed, S; Hart, M; Walker, J; Walker, M; Thomasse, G; Meunier, L; Sayeed, Z; Juhl, H; Kolendorf, K; Hamalainen, T; Gin, H; Rigellau, V; Bohm, M; Erdmann, E; Forst, P; Gordalla, A; Hampel, R; Hartmann, C; Hasslacher, G; Henrichs, H; Hensen, J; Hopf, R; Kromer, E; Martin, T; Maus, J; Mayer, B; Miedlich, S; Moeller, A; Nast, H; Oehmen-Britsch, R; Paschke, R; Prehn, B; Riegger, G; Riel, R; Rosak, C; Schroeder, C; Schulze-Schleppinghoff, B; Schunkert, H; Schweda, R; Stablein, A; Stein, U; Truchon, H; Unger, H; Wetzel, H; Crean, P; White, U; Aina, F; Balzan, C; Barbaresi, F; Brancaleoni, R; Brunazzi, M; Brunelli, C; Cambiano, A; Caponnetto, S; Casaccia, M; Centofante, P; Cernigliaro, C; Goi, AC; Cicciarello, C; Cotogni, A; DeJoannon, U; Dellavesa, P; di Gerogio, L; Di Luzio, S; Fava, A; Frigeni, G; Gatto, E; Giani, P; Giorgi-Pierfranceschi, D; Imparato, C; Landoni, M; Magnani, B; Manicardi, E; Mantovani, B; Marini, M; Martini, U; Mazzantini, S; Merni, M; Miglierina, E; Marini, M; Molinari, G; Nanni, D; Paciaroni, E; Pareschi, P; Pasqualini, M; Perazzoli, F; Polese, A; Poletti, F; Portioli, I; Provasoli, S; Repetto, S; Rigatelli, G; Roccaforte, R; Romano, E; Rossi, E; Rugolotto, M; Rusticali, F; Saccomanno, G; Simoni, C; Stucci, N; Terranova, P; Tortul, C; Velussi, M; Vincenzi, M; Vincenzi, P; Zavaroni, D; Cardona-Munoz, E; Elizondo, L; Fausto, M; Galindo, R; Gloria-Breceda, F; Hernandez-Garcia, H; Ibarra-Flores, M; Illescas-Diaz, J; Lopez-Alvarado, A; Meaney, E; Olvera-Ruiz, R; Rivera-Capello, J; Romero-Soltero, M; Samaniego-Mendez, V; Vidrio-Velazquez, M; Kruseman, A; Mulder, H; Sels, J; van Doorn, L; Vogel, N; Hjerkinn, E; Reikvam, A; Albert, X; Alvarez, A; Cardona, M; Cosio, FG; Gilabert, R; Karoni, A; Lopez-Bescos, L; Masia, R; Saenz, L; Sanz, G; Ahnberg, K; Andersson, D; Andersson, O; Astrom, L; Bergsten, L; Bjorkman, H; Borgman, C; Cervin, P; Dalhgren, C; Ekholm, L; Ericsson, UB; Eriksson, C; Fagher, B; Gertow, O; Gillberg, P; Hagg, A; Hallberg, A; Hansson, B; Hansson, P; Held, C; Heinonen, M; Henning, R; Jacobsson, L; Jagren, C; Jonasson, T; Kahan, T; Katzman, P; Kristensson, B; Krogager, K; Leijd, B; Lennerhagen, P; Ljungdahl, L; Menyes, H; Ohman, P; Olsson, PO; Rosenqvist, U; Ryden, L; Sartor, G; Sjostedt, P; Smith, L; Stahl, L; Svensson, A; Svensson, K; Taghavi, A; Thulin, T; Torebo, E; Weber, P; Wysocki, M; Anesini, A; Boman, P; Cozzi, R; Gerber, P; Honegger, R; Kick, A; Kiowski, W; Lehmann, R; Lull, B; Moccetti, T; Pasotti, E; Rojas, J; Rossi, A; Rossi, M; Safwan, E; Schindler, R; Sessa, F; Spinas, G; Allan, B; Cumming, L; Fisher, B; Heller, S; Kennedy, J; Kesson, C; Lochiel, R; Manns, J; McGroarty, E; Raeburn, K; Small, M; Struthers, S; Wilkinson, I; Brown, E; Holt, J; Perry, G; Singh, B; Szlachcic, Y; Vlachou, M; Yee, F; Clegg, L; Horwitz, L; St John, M; Anderson, J; Rashkow, A; Schwartz, K; Abercrombie, L; Cintron, G; Garrett, D; McHale, J; Miller, A; Sullebarger, J; Tripp, G; Zoble, R; Orander, P; Sridharan, M; Sridharan, V; Berger, S; Davidson, M; Geohas, J; Islam, N; Rajanahally, R; Seikel, K; Susmano, A; Wentworth, M; Advani, S; Rough, R; Wickemeyer, W; Young, N; Goldstein, M; Dinneen, S; Farkouh, M; Helgemoe, P; Miller, T; Parkulo, M; Pierpont, G; Weigenant, J; Rich, M; Schmidt, P; Abrams, J; Robbins, D; Bonora, M; Cohen, G; Constantinou, M; Dimova, A; Fitzpatrick, P; Gage, L; Graham, S; Kohn, R; Lader, E; Powers, J; Reiter, P; Witt, N; Buchsbaum, R; Donese, B; Gupta, S; Hoogwerf, B; Suhan, P; Suryaprasad, A; Williams, D; Danisa, K; Lowery, M; Lyon, K; Rae, C; Gandara, B; Gramberg, M; Grover, J; Amidi, M; Bell, M; DiTommaso, M; Day, J; Durand, J; Farmer, J; Torre, G; Vooletich, M; Gorham, J; Gowing, B; Kingry, C; Lehmann, K; Letterer, R; Lorch, G; Lwai, S; Mack, R; Nemanich, J; Primm, R; Utley, R; Vaughn, L; Bergentoft, A; Borgman, C; Brosch, E; Engbers, A; Flores, M; Forst, P; Frisenda, L; Gerle, S; Huber, D; La Tour, F; Lehtonen, R; Luca, C; Keays, JS; Masterson, N; Moore, R; Morales-Virgen, J; Penson; Persson, C; Pina, C; Plouffe, D; Reglier, JC; Riley, J; Rolstad, T; Ronsted, P; Spinewine, P; Styner, L; van den Boom, N; Yuki-Miyakoshi, S				Gerstein, HC; Yusuf, S; Mann, JFE; Hoogwerf, B; Zinman, B; Held, C; Fisher, M; Wolffenbuttel, B; Bosch, J; Richardson, L; Pogue, J; Halle, JP; Yusuf, S; Sleight, P; Dagenais, G; Montague, T; Bosch, J; Pogue, J; Taylor, W; Sardo, L; Arnold, M; Baigrie, R; Davies, R; Gerstein, H; Jha, P; Johnstone, D; Joyner, C; Kuritzky, R; Lonn, E; Mitchell, B; Morris, A; Sussex, B; Teo, K; Tsuyuki, R; Zinman, B; Probstfield, J; Young, J; Diaz, R; Paolasso, E; Avezum, A; Piegas, L; Mann, J; Wolffenbuttel, B; Ostergren, J; Meaney, E; Aprile, M; Bedard, D; Cossett, J; Ewart, G; Harris, L; Kellen, J; LaForge, D; Magi, A; Skanes, J; Squires, P; Stevens, K; Bosch, J; Cherian, F; Holadyk-Gris, I; Kalkbrenner, P; Lonn, E; Mazur, F; McQueen, M; Micks, M; Monti, S; Pogue, J; Sardo, L; Thompson, K; Westfall, L; Yusuf, S; Richardson, L; Raw, N; Genisans, M; Diaz, R; Paolasso, E; Avezum, A; Piegas, L; Gerstein, H; Zinman, B; Dagenais, G; Arnold, M; Auger, P; Avezum, A; Bata, I; Bernstein, V; Bourassa, M; Diaz, R; Fisher, B; Gerstein, H; Grover, J; Gun, C; Gupta, M; Held, C; Hoeschen, R; Kouz, S; Lonn, E; Mann, J; Mathew, J; Meaney, E; Meldrum, D; Pilon, C; Ramos, R; Roccaforte, R; Starra, R; Trivi, M; Davies, R; Johnstone, D; Lonn, E; Probstfield, J; McQueen, M; Sackett, D; Collins, R; Davis, E; Furberg, C; Hennekens, C; Pitt, B; Turner, R; Braver, J; Cuneo, C; Diaz, M; Dizeo, C; Guzman, L; Lipshitz, S; Llanos, S; Lopez, J; Lorenzatti, A; Machado, R; Mackey, C; Mancini, M; Marino, M; Martinez, F; Matrone, A; Nordaby, R; Orlandini, A; Romero, G; Ruiz, M; Rusculleda, M; Saavedra, S; San Damaso, J; Serra, J; Tuero, E; Zapata, G; Zavala, A; Grisold, M; Klein, W; Brosch, E; Baumans, P; Brusselmans, H; Bodson, A; Boland, J; Cano, J; Chaudron, JM; Degaute, JP; Duprez, D; Heyndrickx, G; Krzentowski, G; Mockel, J; Wautrecht, J; Alexandre, E; Amodeo, C; Armaganijan, D; Ayub, J; Bertolami, M; Bodanese, L; Borges, J; Caramelli, B; Carvalho, A; Coelho, O; Dioguardi, G; Faludi, A; Brage, JF; Fichino, M; Franken, R; Ghorayeb, N; de Souza, MG; Greque, G; Guedes, A; Kadri, T; Kawamura, T; Labrunie, A; Malheiros, F; Marafon, L; Nakamura, M; Nonohay, N; Ogawa, C; Pavanello, R; Puech-Leao, P; Ramires, F; Ramires, L; Sampaio, M; Saraiva, L; Savioli, F; Seixas, A; Shibata, M; Souza, A; Tanajura, L; Ueti, O; Vitola, D; Armstrong, F; Armstrong, W; Baptie, B; Basinger, M; Bell, N; Beresford, P; Black, W; Brass, N; Browne, M; Browne, K; Brownoff, R; Chaytors, G; Cottier, W; Donnelly, R; Dzavik, V; Edwards, A; Felker, P; Giannoccaro, P; Goeres, M; Greenwood, P; Grose, M; Grossman, L; Gulamhusein, S; Hui, W; Hutchison, F; Irving, A; Kasian, L; Kasza, L; Korner, L; Kvill, L; Lakhani, Z; Lam, S; Lesoway, R; Ma, P; Martinez, V; Meldrum, D; Mitchell, B; Mitchell, D; Montague, T; Musseau, A; Muzyka, T; Neffgen, C; Neffgen, J; Nichol, R; O'Beirne, M; Paradis, J; Paterson, D; Plesko, A; Prosser, A; Radomsky, N; Roth, D; Ryan, E; Senaratne, M; Simon, M; Stenerson, P; Stone, J; Talibi, T; Wedel, R; Wyse, D; Altwasser, F; Ashton, T; Askew, J; Bernstein, V; Bishop, W; Bloomberg, G; Boone, J; Breakwell, L; Buller, L; Calvert, K; Carere, G; Dahl, M; Dawson, K; Dodek, A; Dufton, J; Geddis, R; Ghosh, S; Heath, J; Hilton, D; Imrie, J; Jay, D; Kiess, M; Klinke, P; Kornder, J; Lee, P; Leong, W; Lewis, J; Lounsbury, N; MacDonald, L; MacDonald, K; MacNeil, A; MacRitchie, D; McGee, L; Mitchell, L; Mulcahy, K; O'Donoghue, S; Pearce, A; Perreault, L; Polasek, P; Rabkin, S; Reilly, M; Richardson, P; Scoffield, E; Sweeney, R; Terwiel, M; Thompson, C; Wagner, K; Webb, J; Wedding, K; Woo, K; Wright, M; Zutz, A; Briol, L; Hoeschen, R; Mehta, P; Mohammed, I; Ong, A; Ong, G; Bessoudo, R; O'Brien, L; McLellan, L; Milton, J; Elgar, F; Joyce, C; O'Keefe, D; Parsons, M; Ravalia, M; Sherman, G; Smith, R; Worrall, G; Atkinson, A; Barnhill, S; Bata, I; Crossman, L; Folkins, D; Hatheway, R; Johnson, B; MacFarlane, M; Machel, T; Morash, J; Sheridan, W; Shirley, M; Anderson, I; Arnold, M; Baigrie, R; Baird, M; Baitz, T; Barnie, A; Basta, M; Blakely, J; Bozek, B; Bradley, W; Brown, K; Burnham, G; Cameron, W; Cann, M; Carroll, S; Carter, R; Chan, N; Chan, Y; Charles, J; Cheung, M; Cina, C; Cleghorn, L; Curnew, G; Currado, P; Davies, R; DeGagne, S; DeYoung, P; Dhaliwal, R; Dowell, H; Drobac, M; Dubbin, J; Duffield, K; Edmonds, M; Fallen, E; Feldman, D; Fell, D; Ferguson, C; Finkelstein, L; Fong, G; Fowlis, R; Fraser, M; Frenette, L; Fulop, J; Glanz, A; Goode, E; Gupta, M; Hanna, A; Harris, K; Hess, A; Hierlihy, P; Houlden, R; Hramiak, I; Hrycyshyn, B; Iwanochko, R; Janzen, I; Kannampuzha, P; Keely, E; Kennedy, R; Kenshole, A; Kent, E; Khan, S; Kostuk, W; Kowaleski, M; Krupa, M; Kumar, G; Kuruvilla, G; Kwok, K; Lai, C; Langer, A; Laor, J; Lau, D; LaVallee, T; Lent, B; Liu, P; Lochnan, H; Lovell, M; Lowe, D; Mabb, T; Maclean, S; Man, K; Marois, L; Massel, D; Matthews, E; McManus, R; McPhee, E; McQueen, M; McSherry, J; Millar, D; Miller, F; Miners, L; Misterski, J; Moe, G; Mulaisho, C; Munoz, C; Nawaz, S; Noseworthy, C; O'Keefe, H; Oosterveld, L; Panju, A; Paquette, H; Parkovnick, M; Paterson, R; Pflugfelder, P; Powers, S; Rebane, T; Redda, A; Reeves, E; Ricci, J; Sasson, Z; Sayles, M; Scott, M; Sibbick, M; Singh, N; Southern, R; Spence, D; Sternberg, L; Stewart, J; Styling, S; Sulllivan, B; Sullivan, H; Sullivan, M; Swan, J; Taichman, J; Tan, K; Tanser, P; Tartaglia, C; Taylor, K; Thomson, D; Turek, M; Vakani, T; vanWalraven, A; Varey, M; Vexler, R; Walters, J; Weeks, A; Weingert, M; Wetmore, S; Whitsitt, P; Willing, J; Wilson, C; Wilson, J; Wisenberg, G; Wolfe, M; Wolter, B; Yao, L; Costain, G; Hickey, E; MacMillan, E; Aris-Jilwan, N; Auger, P; Banville, P; Beaudoin, J; Belanger, A; Belanger, N; Belleville, L; Bilodeau, N; Bogaty, P; Boulianne, M; Bourassa, M; Brophy, J; Brouillette, M; Buithieu, J; Calve, C; Campeau, J; Carmichael, P; Carrier, S; Chiasson, J; Coutu, B; Coutu, D; Croteau, S; D'Amours, G; Dagenais, N; Delage, F; Deschamps, J; Dion, D; Douville, Y; Dumont, F; Dupuis, R; Frechette, L; Gauthier, S; Gervais, P; Giguere, G; Giroux, R; Gossard, D; Gosselin, G; Goulet, G; Grondin, F; Halle, J; Henri, L; Houde, G; Joyal, M; Kandalaft, N; Karabatsos, A; Kiwan, G; Kouz, S; Labbe, R; Langlais, M; Lauzon, C; LeBlanc, M; Lenis, J; Leroux, S; Loisel, R; MacLellan, K; Morissette, A; Noel, H; Ouimet, F; Pedneault, L; Piche, J; Pilon, C; Plourde, P; Poirier, C; Poisson, D; Primeau, L; Pruneau, G; Remillard, C; Roberge, B; Robert, M; Rodrique, M; Roy, C; Roy, L; Ruel, M; Samson, M; Saulnier, D; Savard, D; Serpa, A; Sestier, F; Smilovitch, M; Starra, R; St-Hilaire, R; Theroux, P; Toupin-Halle, A; Tremblay, J; Truchen, H; Turcotte, J; Vachon, S; Vienneau, R; Wilson, P; Habib, M; Habib, N; Ahmed, S; Hart, M; Walker, J; Walker, M; Thomasse, G; Meunier, L; Sayeed, Z; Juhl, H; Kolendorf, K; Hamalainen, T; Gin, H; Rigellau, V; Bohm, M; Erdmann, E; Forst, P; Gordalla, A; Hampel, R; Hartmann, C; Hasslacher, G; Henrichs, H; Hensen, J; Hopf, R; Kromer, E; Martin, T; Maus, J; Mayer, B; Miedlich, S; Moeller, A; Nast, H; Oehmen-Britsch, R; Paschke, R; Prehn, B; Riegger, G; Riel, R; Rosak, C; Schroeder, C; Schulze-Schleppinghoff, B; Schunkert, H; Schweda, R; Stablein, A; Stein, U; Truchon, H; Unger, H; Wetzel, H; Crean, P; White, U; Aina, F; Balzan, C; Barbaresi, F; Brancaleoni, R; Brunazzi, M; Brunelli, C; Cambiano, A; Caponnetto, S; Casaccia, M; Centofante, P; Cernigliaro, C; Goi, AC; Cicciarello, C; Cotogni, A; DeJoannon, U; Dellavesa, P; di Gerogio, L; Di Luzio, S; Fava, A; Frigeni, G; Gatto, E; Giani, P; Giorgi-Pierfranceschi, D; Imparato, C; Landoni, M; Magnani, B; Manicardi, E; Mantovani, B; Marini, M; Martini, U; Mazzantini, S; Merni, M; Miglierina, E; Marini, M; Molinari, G; Nanni, D; Paciaroni, E; Pareschi, P; Pasqualini, M; Perazzoli, F; Polese, A; Poletti, F; Portioli, I; Provasoli, S; Repetto, S; Rigatelli, G; Roccaforte, R; Romano, E; Rossi, E; Rugolotto, M; Rusticali, F; Saccomanno, G; Simoni, C; Stucci, N; Terranova, P; Tortul, C; Velussi, M; Vincenzi, M; Vincenzi, P; Zavaroni, D; Cardona-Munoz, E; Elizondo, L; Fausto, M; Galindo, R; Gloria-Breceda, F; Hernandez-Garcia, H; Ibarra-Flores, M; Illescas-Diaz, J; Lopez-Alvarado, A; Meaney, E; Olvera-Ruiz, R; Rivera-Capello, J; Romero-Soltero, M; Samaniego-Mendez, V; Vidrio-Velazquez, M; Kruseman, A; Mulder, H; Sels, J; van Doorn, L; Vogel, N; Hjerkinn, E; Reikvam, A; Albert, X; Alvarez, A; Cardona, M; Cosio, FG; Gilabert, R; Karoni, A; Lopez-Bescos, L; Masia, R; Saenz, L; Sanz, G; Ahnberg, K; Andersson, D; Andersson, O; Astrom, L; Bergsten, L; Bjorkman, H; Borgman, C; Cervin, P; Dalhgren, C; Ekholm, L; Ericsson, UB; Eriksson, C; Fagher, B; Gertow, O; Gillberg, P; Hagg, A; Hallberg, A; Hansson, B; Hansson, P; Held, C; Heinonen, M; Henning, R; Jacobsson, L; Jagren, C; Jonasson, T; Kahan, T; Katzman, P; Kristensson, B; Krogager, K; Leijd, B; Lennerhagen, P; Ljungdahl, L; Menyes, H; Ohman, P; Olsson, PO; Rosenqvist, U; Ryden, L; Sartor, G; Sjostedt, P; Smith, L; Stahl, L; Svensson, A; Svensson, K; Taghavi, A; Thulin, T; Torebo, E; Weber, P; Wysocki, M; Anesini, A; Boman, P; Cozzi, R; Gerber, P; Honegger, R; Kick, A; Kiowski, W; Lehmann, R; Lull, B; Moccetti, T; Pasotti, E; Rojas, J; Rossi, A; Rossi, M; Safwan, E; Schindler, R; Sessa, F; Spinas, G; Allan, B; Cumming, L; Fisher, B; Heller, S; Kennedy, J; Kesson, C; Lochiel, R; Manns, J; McGroarty, E; Raeburn, K; Small, M; Struthers, S; Wilkinson, I; Brown, E; Holt, J; Perry, G; Singh, B; Szlachcic, Y; Vlachou, M; Yee, F; Clegg, L; Horwitz, L; St John, M; Anderson, J; Rashkow, A; Schwartz, K; Abercrombie, L; Cintron, G; Garrett, D; McHale, J; Miller, A; Sullebarger, J; Tripp, G; Zoble, R; Orander, P; Sridharan, M; Sridharan, V; Berger, S; Davidson, M; Geohas, J; Islam, N; Rajanahally, R; Seikel, K; Susmano, A; Wentworth, M; Advani, S; Rough, R; Wickemeyer, W; Young, N; Goldstein, M; Dinneen, S; Farkouh, M; Helgemoe, P; Miller, T; Parkulo, M; Pierpont, G; Weigenant, J; Rich, M; Schmidt, P; Abrams, J; Robbins, D; Bonora, M; Cohen, G; Constantinou, M; Dimova, A; Fitzpatrick, P; Gage, L; Graham, S; Kohn, R; Lader, E; Powers, J; Reiter, P; Witt, N; Buchsbaum, R; Donese, B; Gupta, S; Hoogwerf, B; Suhan, P; Suryaprasad, A; Williams, D; Danisa, K; Lowery, M; Lyon, K; Rae, C; Gandara, B; Gramberg, M; Grover, J; Amidi, M; Bell, M; DiTommaso, M; Day, J; Durand, J; Farmer, J; Torre, G; Vooletich, M; Gorham, J; Gowing, B; Kingry, C; Lehmann, K; Letterer, R; Lorch, G; Lwai, S; Mack, R; Nemanich, J; Primm, R; Utley, R; Vaughn, L; Bergentoft, A; Borgman, C; Brosch, E; Engbers, A; Flores, M; Forst, P; Frisenda, L; Gerle, S; Huber, D; La Tour, F; Lehtonen, R; Luca, C; Keays, JS; Masterson, N; Moore, R; Morales-Virgen, J; Penson; Persson, C; Pina, C; Plouffe, D; Reglier, JC; Riley, J; Rolstad, T; Ronsted, P; Spinewine, P; Styner, L; van den Boom, N; Yuki-Miyakoshi, S		Heart Outcomes Prevention Evaluati	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy	LANCET			English	Article							CONVERTING ENZYME-INHIBITION; CORONARY HEART-DISEASE; ACE-INHIBITOR; RISK FACTOR; FOLLOW-UP; MORTALITY; HYPERTENSION; NIDDM; PREDICTOR; STROKE	Background Diabetes mellitus is a strong risk factor for cardiovascular and renal disease. We investigated whether the angiotensin-converting-enzyme (ACE) inhibitor ramipril can lower these risks in patients with diabetes. Methods 3577 people with diabetes included in the Heart Outcomes Prevention Evaluation study, aged 55 years or older, who had a previous cardiovascular event or at least one other cardiovascular risk factor, no clinical proteinuria, heart failure, or low ejection fraction, and who were not taking ACE inhibitors, were randomly assigned ramipril (10 mg/day) or placebo, and Vitamin E or placebo, according to a two-by-two factorial design. The combined primary outcome was myocardial infarction, stroke, or cardiovascular death. Overt nephropathy was a main outcome in a substudy. Findings The study was stopped 6 months early (after 4.5 years) by the independent data safety and monitoring board because of a consistent benefit of ramipril compared with placebo. Ramipril lowered the risk of the combined primary outcome by 25% (95% CI 12-36, p=0.0004), myocardial infarction by 22% (6-36), stroke by 33% (10-50), cardiovascular death by 37% (21-51), total mortality by 24% (8-37), revascularisation by 17% (2-30), and overt nephropathy by 24% (3-40, p=0.027). After adjustment for the changes in systolic (2.4 mm Hg) and diastolic (1.0 mm Hg) brood pressures, ramipril stilt lowered the risk of the combined primary outcome by 25% (12-36, p=0.0004). Interpretation Ramipril was beneficial for cardiovascular events and overt nephropathy in people with diabetes. The cardiovascular benefit was greater than that attributable to the decrease in blood pressure. This treatment represents a vasculoprotective and renoprotective effect for people with diabetes.	HGH McMaster Clin, Canadian Cardiovasc Collaborat Project Off, Hamilton, ON L8L 2X2, Canada		Gerstein, HC (corresponding author), HGH McMaster Clin, Canadian Cardiovasc Collaborat Project Off, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	HOPE@ccc.master.ca	Ghorayeb, Nabil/G-4333-2015; Fréchette, Luc G./AAF-2042-2020; Wolffenbuttel, Bruce/A-8419-2011; Galindo, Ruben/AAT-1406-2020; Avezum, Alvaro AA/K-6137-2016; brophy, james/H-6673-2019; Lehmann, Roger/B-9120-2015; Rosenqvist, Urban/Q-1986-2016; Tsuyuki, Ross T/E-2462-2016; Mann, Johannes/AAI-8803-2020; Avezum, Alvaro/AAP-7687-2020; Elgar, Frank/ABE-7450-2020; Caramelli, Bruno/B-9916-2008; Elgar, Frank/GSN-3521-2022; Böhm, Michael/C-3638-2011; Nabil Ghorayeb, Instituto Dante Pazzanese de Cardiologia/AAA-7193-2019; Gerstein, Hertzel C/B-1235-2013; McManus, Ruth/G-3938-2011; Leao, Pedro P/B-5495-2016; CONSTANTINOU, MARIA/GXV-1684-2022; Arnold, Malcolm/G-2869-2011; Fréchette, Luc G/D-1920-2014; Ramires, Felix JA/D-5996-2012; Gerstein, Hertzel/ABB-8781-2020; Bosch, Jacqueline/AAP-6910-2021; Zinman, Bernard/E-7266-2013	Ghorayeb, Nabil/0000-0002-7056-7593; Fréchette, Luc G./0000-0001-7138-0811; Wolffenbuttel, Bruce/0000-0001-9262-6921; Galindo, Ruben/0000-0001-9407-9183; Avezum, Alvaro AA/0000-0002-3073-6890; brophy, james/0000-0001-8049-6875; Lehmann, Roger/0000-0002-3681-4431; Tsuyuki, Ross T/0000-0002-3724-598X; Caramelli, Bruno/0000-0001-6718-8456; Nabil Ghorayeb, Instituto Dante Pazzanese de Cardiologia/0000-0002-7056-7593; Gerstein, Hertzel C/0000-0001-8072-2836; Fréchette, Luc G/0000-0001-7138-0811; Ramires, Felix JA/0000-0003-2437-2485; Gerstein, Hertzel/0000-0001-8072-2836; Bosch, Jacqueline/0000-0001-6292-4207; 				BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; DAMSGAARD EM, 1992, KIDNEY INT, V41, P731; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; *ETDRS INV, 1992, JAMA-J AM MED ASSOC, V266, P1292; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; Gerstein HC, 1996, DIABETES CARE, V19, P1225, DOI 10.2337/diacare.19.11.1225; GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862; Gu K, 1999, JAMA-J AM MED ASSOC, V281, P1291, DOI 10.1001/jama.281.14.1291; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; *HEART OUTC PREV E, 2000, IN PRESS N ENGL J ME; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; Laakso M, 1999, DIABETES, V48, P937, DOI 10.2337/diabetes.48.5.937; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; Mindlen F, 1996, CAN J CARDIOL, V12, P127; MORRISH NJ, 1991, DIABETOLOGIA, V34, P584, DOI 10.1007/BF00400278; NEIL A, 1993, DIABETES CARE, V16, P996, DOI 10.2337/diacare.16.7.996; Olsen S, 1996, DIABETOLOGIA, V39, P1638, DOI 10.1007/s001250050628; PARVING HH, 1992, KIDNEY INT, V41, P758, DOI 10.1038/ki.1992.118; Ravid M, 1996, ARCH INTERN MED, V156, P286, DOI 10.1001/archinte.156.3.286; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; Ritz E, 1999, NEW ENGL J MED, V341, P1127, DOI 10.1056/NEJM199910073411506; Shindler DM, 1996, AM J CARDIOL, V77, P1017, DOI 10.1016/S0002-9149(97)89163-1; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Wingard DL., 1995, DIABETES AM, P429; Yusuf S, 1998, EUR HEART J, V19, pJ36; Zuanetti G, 1997, CIRCULATION, V96, P4239	34	2063	2124	4	144	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2000	355	9200					253	259						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675071				2022-12-28	WOS:000085045600007
J	Haslberger, AG				Haslberger, AG			Genetic technologies - Monitoring and labeling for genetically modified products	SCIENCE			English	Article									Fed Chancellory, Sci Sect Biotechnol, A-1030 Vienna, Austria		Haslberger, AG (corresponding author), Fed Chancellory, Sci Sect Biotechnol, Radetzkystr 2, A-1030 Vienna, Austria.	hasi1@via.at	Haslberger, Alexander G/B-9120-2013	Haslberger, Alexander/0000-0001-9699-537X				Butler D, 1999, NATURE, V398, P651, DOI [10.1038/19348, 10.1038/19381]; *EUR COMM SCI COMM, 1999, OP SCP BT RES MON; Ewen SWB, 1999, LANCET, V354, P684, DOI 10.1016/S0140-6736(05)77668-6; *HOUS COMM ENV AUD, 1999, GMOS ENV COORD GOV P; KILMAN S, WALL STREET J; Lehrman S, 1999, NATURE, V401, P107, DOI 10.1038/43536; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; Miller HI, 1999, SCIENCE, V284, P1471, DOI 10.1126/science.284.5419.1471; Mitchell P, 1999, LANCET, V353, P1769, DOI 10.1016/S0140-6736(99)90090-9; MITSCH FJ, 1999, DTSCH BANC A BR 0712; Reichhardt T, 1999, NATURE, V400, P298, DOI 10.1038/22371; Roush RT, 1997, NAT BIOTECHNOL, V15, P816, DOI 10.1038/nbt0997-816; *UK HOUS COMM SCI, 1999, SCI ADV SYST GEN MOD; 1999, AGRAFOOD BIOTEC 1110, P15; 1999, AGRAFOOD BIOTEC 0914, P11	15	26	28	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2000	287	5452					431	432		10.1126/science.287.5452.431	http://dx.doi.org/10.1126/science.287.5452.431			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10671171				2022-12-28	WOS:000084929900026
J	Schleich, WP				Schleich, WP			Quantum physics - Engineering decoherence	NATURE			English	Editorial Material							STATES		Univ Ulm, Abt Quantenphys, D-89069 Ulm, Germany	Ulm University	Schleich, WP (corresponding author), Univ Ulm, Abt Quantenphys, D-89069 Ulm, Germany.							Bonifacio R, 1999, NUOVO CIMENTO B, V114, P473; BRUNE M, 1996, PHYS REV LETT, V77, P4728; Dirac P. A. M., 1958, PRINCIPLES QUANTUM M; Giulini D., 1996, DECOHERENCE APPEARAN; Meekhof DM, 1996, PHYS REV LETT, V76, P1796, DOI 10.1103/PhysRevLett.76.1796; Monroe C, 1996, SCIENCE, V272, P1131, DOI 10.1126/science.272.5265.1131; Poyatos JF, 1996, PHYS REV LETT, V77, P4728, DOI 10.1103/PhysRevLett.77.4728; SCHLEICH W, 1987, NATURE, V326, P574, DOI 10.1038/326574a0	10	19	19	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					256	257		10.1038/35002223	http://dx.doi.org/10.1038/35002223			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659831				2022-12-28	WOS:000084899700031
J	de Swiet, M				de Swiet, M			Maternal blood pressure and birthweight	LANCET			English	Editorial Material									Queen Charlottes Hosp, Dept Med, London W6 0XG, England		de Swiet, M (corresponding author), Queen Charlottes Hosp, Dept Med, London W6 0XG, England.							BUTTER NR, 1972, BRIT MED J, V11, P127; BUTTERS L, 1990, BMJ-BRIT MED J, V301, P587, DOI 10.1136/bmj.301.6752.587; LONG PA, 1980, BRIT J OBSTET GYNAEC, V87, P13, DOI 10.1111/j.1471-0528.1980.tb04419.x; Steer P, 1997, BRIT MED J, V315, P1542, DOI 10.1136/bmj.315.7121.1542	4	19	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					81	82		10.1016/S0140-6736(99)00288-3	http://dx.doi.org/10.1016/S0140-6736(99)00288-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675159				2022-12-28	WOS:000085557200003
J	Gibbs, CR; Davies, MK; Lip, GYH				Gibbs, CR; Davies, MK; Lip, GYH			ABC of heart failure - Management: digoxin and other inotropes, beta blockers, and antiarrhythmic and antithrombotic treatment	BRITISH MEDICAL JOURNAL			English	Review							AMIODARONE		Univ Birmingham, Dept Med, Birmingham, W Midlands, England; City Hosp, Dept Cardiol, Birmingham, W Midlands, England; Selly Oak Hosp, Dept Cardiol, Birmingham B29 6JD, W Midlands, England	University of Birmingham; University of Birmingham	Gibbs, CR (corresponding author), Univ Birmingham, Dept Med, Birmingham, W Midlands, England.							DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; Hjalmarson A, 1999, LANCET, V353, P2001; Lip GYH, 1996, POSTGRAD MED J, V72, P731, DOI 10.1136/pgmj.72.854.731; MacMahon S, 1997, LANCET, V349, P375; Massie BM, 1996, CIRCULATION, V93, P2128, DOI 10.1161/01.CIR.93.12.2128; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Perry G, 1997, NEW ENGL J MED, V336, P525	7	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					495	498		10.1136/bmj.320.7233.495	http://dx.doi.org/10.1136/bmj.320.7233.495			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678868	Green Published			2022-12-28	WOS:000085562200030
J	Chambers, JC; Obeid, OA; Refsum, H; Ueland, P; Hackett, D; Hooper, J; Turner, RM; Thompson, SG; Kooner, JS				Chambers, JC; Obeid, OA; Refsum, H; Ueland, P; Hackett, D; Hooper, J; Turner, RM; Thompson, SG; Kooner, JS			Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men	LANCET			English	Article							VASCULAR-DISEASE; PREVALENCE; MORTALITY	Background Reasons for the increase in mortality due to coronary heart disease (CHD) in UK Indian Asians are not well understood. In this study, we tested the hypotheses that elevated plasma homocysteine concentrations are a risk factor for CHD in Indian Asians, and explain part of their increased CHD risk, compared with Europeans. Methods We undertook two parallel case-control studies, one in Europeans and one in Indian Asians. We recruited 551 male cases (294 European, 257 Indian Asian) and 1025 healthy male controls (507 European, 518 Indian Asian). Fasting and post-methionine load homocysteine, vitamin B-12 and folate concentrations, and conventional CHD risk factors were measured, Findings Fasting homocysteine concentrations were 8% higher (95% CI 3-14) in cases compared with controls, in both ethnic groups. The odds ratio of CHD for a 5 mu mol/L increment in fasting plasma homocysteine was 1.3 (1.1-1.6) in Europeans and 1.2 (1.0-1.4) in Indian Asians. The association between fasting plasma homocysteine and CHD was independent of conventional CHD risk factors in both ethnic groups. Post-load homocysteine concentrations were not significantly different in cases compared with controls. Among the controls, fasting homocysteine concentrations were 6% (2-10) higher in Indian Asians than in Europeans. From the results we estimate that elevated homocysteine may contribute to twice as many CHD deaths in Indian Asians, compared with Europeans. The differences in homocysteine concentrations between the two ethnic groups were explained by lower vitamin B-12 and folate levels in Asians. Interpretation Plasma homocysteine is a novel and independent risk factor for CHD in Indian Asians, and may contribute to their increased CHD risk, Raised homocysteine concentrations in Indian Asians may be related to their reduced vitamin B-12 and folate levels, implying that the increased CHD risk in this group may be reduced by dietary vitamin supplementation.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Natl Heart & Lung Inst, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Med Stat & Evaluat, London W12 0NN, England; Ealing Gen Hosp, Dept Cardiol, Uxbridge, Middx, England; St Bartholomews & Royal London Sch Med & Dent, Dept Human Nutr, London, England; Hemel Hempstead Gen Hosp, Hemel Hempstead, England; Royal Brompton Hosp, Dept Clin Biochem, London SW3 6LY, England; Univ Bergen, Dept Pharmacol, N-5020 Bergen, Norway	Imperial College London; Imperial College London; University of London; Queen Mary University London; Royal Brompton Hospital; University of Bergen	Kooner, JS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Natl Heart & Lung Inst, Du Cane Rd, London W12 0NN, England.	j.kooner@ic.ac.uk	Obeid, Omar/AAK-1669-2020; Refsum, Helga/A-4073-2010; Obeid, Omar/AAS-4457-2021; Ueland, Per M/C-7340-2013	Ueland, Per Magne/0000-0002-1903-0571				ABRAHAM R, 1987, HUM NUTR-APPL NUTR, V41A, P164; Altman D.G., 1997, PRACTICAL STAT MED R; ARMITAGE P, 1987, STATISTICAL METHODS, P91; Balarajan R, 1996, HLTH TRENDS, V28, P45; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; Clarke R, 1998, CLIN CHEM, V44, P102; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; Danesh J, 1998, J Cardiovasc Risk, V5, P229, DOI 10.1097/00043798-199808000-00004; DAWSON DW, 1994, BRIT J BIOMED SCI, V51, P221; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9; Kooner JS, 1997, HEART, V78, P530, DOI 10.1136/hrt.78.6.530; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MATTHEWS JH, 1984, CLIN LAB HAEMATOL, V6, P1; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877	23	207	216	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2000	355	9203					523	527		10.1016/S0140-6736(99)93019-2	http://dx.doi.org/10.1016/S0140-6736(99)93019-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10683001				2022-12-28	WOS:000085487400009
J	Wynar, R; Freeland, RS; Han, DJ; Ryu, C; Heinzen, DJ				Wynar, R; Freeland, RS; Han, DJ; Ryu, C; Heinzen, DJ			Molecules in a Bose-Einstein condensate	SCIENCE			English	Article							FESHBACH RESONANCES; COLLISIONS; SCATTERING; ATOMS; PHOTOASSOCIATION; DECAY; RB-85	State-selected rubidium-87 molecules were created at rest in a dilute Bose-Einstein condensate of rubidium-87 atoms with coherent free-bound stimulated Raman transitions. The transition rate exhibited a resonance Line shape with an extremely narrow width as small as 1.5 kilohertz. The precise shape and position of the resonance are sensitive to the mean-field interactions between the molecules and the atomic condensate. As a result, we were able to measure the molecule-condensate interactions. This method allows molecular binding energies to be determined with unprecedented accuracy and is of interest as a mechanism for the generation of a molecular Bose-Einstein condensate.	Univ Texas, Dept Phys, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Heinzen, DJ (corresponding author), Univ Texas, Dept Phys, Austin, TX 78712 USA.							ABRAHAM ERI, 1995, PHYS REV LETT, V74, P1315, DOI 10.1103/PhysRevLett.74.1315; ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Balakrishnan N, 1998, PHYS REV LETT, V80, P3224, DOI 10.1103/PhysRevLett.80.3224; Balakrishnan N, 1997, CHEM PHYS LETT, V280, P5, DOI 10.1016/S0009-2614(97)01052-X; Bohn JL, 1999, PHYS REV A, V60, P414, DOI 10.1103/PhysRevA.60.414; BRADLEY CC, 1995, PHYS REV LETT, V75, P1687, DOI 10.1103/PhysRevLett.75.1687; Burt EA, 1997, PHYS REV LETT, V79, P337, DOI 10.1103/PhysRevLett.79.337; Courteille P, 1998, PHYS REV LETT, V81, P69, DOI 10.1103/PhysRevLett.81.69; Dalfovo F, 1999, REV MOD PHYS, V71, P463, DOI 10.1103/RevModPhys.71.463; Drummond PD, 1998, PHYS REV LETT, V81, P3055, DOI 10.1103/PhysRevLett.81.3055; Fioretti A, 1998, PHYS REV LETT, V80, P4402, DOI 10.1103/PhysRevLett.80.4402; Forrey RC, 1998, PHYS REV A, V58, pR2645, DOI 10.1103/PhysRevA.58.R2645; Forrey RC, 1999, PHYS REV LETT, V82, P2657, DOI 10.1103/PhysRevLett.82.2657; Fried DG, 1998, PHYS REV LETT, V81, P3811, DOI 10.1103/PhysRevLett.81.3811; GARDNER JR, 1995, PHYS REV LETT, V74, P3764, DOI 10.1103/PhysRevLett.74.3764; Han DJ, 1998, PHYS REV A, V57, pR4114, DOI 10.1103/PhysRevA.57.R4114; HEINZEN DJ, UNPUB; INGUSCIO M, 1999, BOSEEINSTEIN CONDENS; Inouye S, 1998, NATURE, V392, P151, DOI 10.1038/32354; Javanainen J, 1999, PHYS REV A, V59, pR3186, DOI 10.1103/PhysRevA.59.R3186; Julienne PS, 1998, PHYS REV A, V58, pR797, DOI 10.1103/PhysRevA.58.R797; Julienne PS, 1997, PHYS REV LETT, V78, P1880, DOI 10.1103/PhysRevLett.78.1880; Nikolov AN, 1999, PHYS REV LETT, V82, P703, DOI 10.1103/PhysRevLett.82.703; Roberts JL, 1998, PHYS REV LETT, V81, P5109, DOI 10.1103/PhysRevLett.81.5109; Takekoshi T, 1999, PHYS REV A, V59, pR5, DOI 10.1103/PhysRevA.59.R5; Timmermans E, 1999, PHYS REV LETT, V83, P2691, DOI 10.1103/PhysRevLett.83.2691; Tsai CC, 1997, PHYS REV LETT, V79, P1245, DOI 10.1103/PhysRevLett.79.1245; van Abeelen FA, 1999, PHYS REV LETT, V83, P1550, DOI 10.1103/PhysRevLett.83.1550; Vogels JM, 1997, PHYS REV A, V56, pR1067, DOI 10.1103/PhysRevA.56.R1067; Vuletic V, 1999, PHYS REV LETT, V82, P1406, DOI 10.1103/PhysRevLett.82.1406; Yurovsky VA, 1999, PHYS REV A, V60, pR765, DOI 10.1103/PhysRevA.60.R765	31	504	509	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1016	1019		10.1126/science.287.5455.1016	http://dx.doi.org/10.1126/science.287.5455.1016			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669408				2022-12-28	WOS:000085245400040
J	Tuite, MF				Tuite, MF			Yeast prions and their prion-forming domain	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; PROTEIN; PSI(+); GENE		Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of Kent	Tuite, MF (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.		Tuite, Mick/ABC-7909-2020	Tuite, Mick/0000-0002-5214-540X				Bailleul PA, 1999, GENETICS, V153, P81; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 2000, IN PRESS MOL MICROBI; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; DOEL SM, 1994, GENETICS, V137, P659; KUSHNIROV VV, 2000, IN PRESS EMBO J; LI L, 2000, IN PRESS SCIENCE; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Maddelein ML, 1999, MOL CELL BIOL, V19, P4516; PRUSINER SB, 1999, PRION BIOL DIS; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; TERAVANESYAN MD, 1994, GENETICS, V137, P671; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Weissmann C, 1999, COLD SPRING HARBOR M, V38, P273; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1999, COLD SPRING HARBOR M, V38, P229	19	60	62	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					289	292		10.1016/S0092-8674(00)80663-7	http://dx.doi.org/10.1016/S0092-8674(00)80663-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676809	Bronze			2022-12-28	WOS:000085204400001
J	Bergquist, DC; Williams, FM; Fisher, CR				Bergquist, DC; Williams, FM; Fisher, CR			Longevity record for deep-sea invertebrate - The growth rate of a marine tubeworm is tailored to different environments.	NATURE			English	Article							COMMUNITIES; ECOLOGY; VENTS		Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Bergquist, DC (corresponding author), Penn State Univ, Dept Biol, University Pk, PA 16802 USA.		Fisher, Charles/H-7912-2012					ANDERSON RK, 1983, SCIENCE, V222, P619, DOI 10.1126/science.222.4624.619; FISHER CR, 1997, PSZNI MAR ECOL, V18, P83; GRASSLE JF, 1986, ADV MAR BIOL, V23, P301; HECKER B, 1985, BIOL SOC WASH B, V6, P465; KENNICUTT MC, 1988, DEEP-SEA RES, V35, P1639, DOI 10.1016/0198-0149(88)90107-0; LUTZ RA, 1994, NATURE, V371, P663, DOI 10.1038/371663a0; PAULL CK, 1984, SCIENCE, V226, P965, DOI 10.1126/science.226.4677.965; Sarrazin J, 1997, MAR ECOL PROG SER, V153, P5, DOI 10.3354/meps153005; TUNNICLIFFE V, 1991, OCEANOGR MAR BIOL, V29, P319; Urcuyo IA, 1998, CAH BIOL MAR, V39, P267	10	80	85	2	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					499	500		10.1038/35000647	http://dx.doi.org/10.1038/35000647			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676948				2022-12-28	WOS:000085227300034
J	Macilwain, C				Macilwain, C			Livermore plans radical rescue for 'mismanaged' laser facility	NATURE			English	News Item																			0	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					469	470						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676927				2022-12-28	WOS:000085227300003
J	Seitz, F				Seitz, F			Decline of the generalist - The vigour of every discipline depends on people of broad vision.	NATURE			English	Editorial Material									Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Seitz, F (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.								0	4	4	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					483	483		10.1038/35000668	http://dx.doi.org/10.1038/35000668			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676938	Bronze			2022-12-28	WOS:000085227300023
J	Rowland, M				Rowland, M			Transmission of Helicobacter pylori: is it all child's play?	LANCET			English	Editorial Material							INFECTION; ACQUISITION; AGE		Georgetown Univ, Med Ctr, Dept Lab Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; WESTAT, Rockville, MD USA	Georgetown University; Georgetown University; Georgetown University; University of British Columbia; Westat	Rowland, M (corresponding author), Georgetown Univ, Med Ctr, Dept Lab Med, Washington, DC 20007 USA.							CLYNE M, 1995, INFECT IMMUN, V63, P1669, DOI 10.1128/IAI.63.5.1669-1673.1995; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; FOX JG, 1993, GASTROENTEROLOGY, V104, P86, DOI 10.1016/0016-5085(93)90839-5; Goodman KJ, 1996, AM J EPIDEMIOL, V144, P290, DOI 10.1093/oxfordjournals.aje.a008924; Granstrom M, 1997, J CLIN MICROBIOL, V35, P468; Grubel P, 1997, J CLIN MICROBIOL, V35, P1300; Leung WK, 1999, AM J GASTROENTEROL, V94, P2881, DOI 10.1111/j.1572-0241.1999.01431.x; Lindkvist P, 1996, SCAND J INFECT DIS, V28, P181, DOI 10.3109/00365549609049072; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; Rowland M, 1999, GASTROENTEROLOGY, V117, P336, DOI 10.1053/gast.1999.0029900336	10	26	28	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					332	333		10.1016/S0140-6736(99)00427-4	http://dx.doi.org/10.1016/S0140-6736(99)00427-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665548				2022-12-28	WOS:000085122100004
J	Topol, CE; Califf, RM; Simes, RJ; Van de Werf, F; Diaz, R; Paolasso, E; Aylward, PE; Keech, A; Klein, W; Piegas, L; Tomov, I; Armstrong, PW; Widimsky, P; Grande, P; Halinen, M; Vahanian, A; Neuhaus, K; Dimas, AP; Preda, I; Kristinsson, A; Tzivoni, D; Ardissino, D; White, HD; Madsen, S; Sugrue, D; Sadowski, Z; Seabra-Gomes, R; Apetrei, E; Dalby, A; Betriu, A; Pfisterer, M; Verheugt, F; Fox, K; Bates, ER; Gibler, WB; Granger, CB; Harrington, RA; Hochman, JS; Holmes, DR; Kleiman, NS; Lee, KL; Moliterno, DJ; Newby, LK; Ohman, EM; Califf, R; Newby, K; Zillman, L; Lee, K; Lemons, P; McCourt, B; Campbell, C; Tardiff, B; Snapp, J; Bassett, K; Hodgson, P; Hannan, K; Kandzari, L; Hawkins, S; Hinman-Smith, E; McDougal, M; Raffetto, K; Thompson, D; Wehrle, T; Ange, C; Brown, R; Grissom, G; Heuckel, M; McCall, J; Pennachi, W; Spychala, M; Veasey, S; Pullium, M; Journey, T; Quintero, K; Mark, D; Davidson-Ray, L; Diner, L; Nelson, C; Sowers, C; Webb, G; Young, M; Bhapkar, M; Pacchiana, C; Sparapani, R; Tuttle, R; Weaver, D; Borzak, S; Douthat, L; Topol, E; Moliterno, D; Konczos, L; Baishnab, R; Baishnab, R; Bakos, A; Blashford, L; Bratsch, J; Brown, K; Cadorini, E; Carlson, J; Clemmons, P; DelValle, M; Drabik, M; Fu, G; Gates, K; Gibson, Y; Heil, L; Hill, N; Klancar, R; McHale, B; Montague, E; Pasca, N; Pergi, L; Randall, R; Rosso, R; Sankovich, K; Smith, D; Wisniewski, L; Witkowski, M; Zovkic, V; Alexander, K; Bhatt, D; Brener, S; Campbell, L; Cho, L; Cole, C; Deedy, M; Foody, J; Gassler, J; Ghaffari, S; Haas, G; Kapadia, S; Lauer, M; Lauer, MS; Lincoff, M; Lutton, S; Marso, S; Mukherjee, D; Patel, V; Penn, M; Robbins, M; Roe, M; Sila, C; Thamilarasan, M; Wagner, G; Armstrong, P; Bestilny, S; Van de Werf, F; Budts, W; Graux, S; Luyten, A; Simes, J; Keech, A; Kava, M; Bower, T; Chan, S; Crampton, L; Monro, C; Nayak, M; Parente, G; Riley, V; Wilton, D; Aylward, P; Dolan, S; Thomas, C; White, H; Scott, M; Frye, R; Alpert, J; Bertrand, M; Ryan, T; Fisher, L; Asarch, L; Smith, M; Lim, L; Bokslag, M; Chiu, P; Chung, J; Collins, S; Dougherty, C; Guimaraes, D; Hakim, Z; Mathieson, J; Montgomery, L; Novotny, B; Steiner, B; Wittke, B				Topol, CE; Califf, RM; Simes, RJ; Van de Werf, F; Diaz, R; Paolasso, E; Aylward, PE; Keech, A; Klein, W; Piegas, L; Tomov, I; Armstrong, PW; Widimsky, P; Grande, P; Halinen, M; Vahanian, A; Neuhaus, K; Dimas, AP; Preda, I; Kristinsson, A; Tzivoni, D; Ardissino, D; White, HD; Madsen, S; Sugrue, D; Sadowski, Z; Seabra-Gomes, R; Apetrei, E; Dalby, A; Betriu, A; Pfisterer, M; Verheugt, F; Fox, K; Bates, ER; Gibler, WB; Granger, CB; Harrington, RA; Hochman, JS; Holmes, DR; Kleiman, NS; Lee, KL; Moliterno, DJ; Newby, LK; Ohman, EM; Califf, R; Newby, K; Zillman, L; Lee, K; Lemons, P; McCourt, B; Campbell, C; Tardiff, B; Snapp, J; Bassett, K; Hodgson, P; Hannan, K; Kandzari, L; Hawkins, S; Hinman-Smith, E; McDougal, M; Raffetto, K; Thompson, D; Wehrle, T; Ange, C; Brown, R; Grissom, G; Heuckel, M; McCall, J; Pennachi, W; Spychala, M; Veasey, S; Pullium, M; Journey, T; Quintero, K; Mark, D; Davidson-Ray, L; Diner, L; Nelson, C; Sowers, C; Webb, G; Young, M; Bhapkar, M; Pacchiana, C; Sparapani, R; Tuttle, R; Weaver, D; Borzak, S; Douthat, L; Topol, E; Moliterno, D; Konczos, L; Baishnab, R; Baishnab, R; Bakos, A; Blashford, L; Bratsch, J; Brown, K; Cadorini, E; Carlson, J; Clemmons, P; DelValle, M; Drabik, M; Fu, G; Gates, K; Gibson, Y; Heil, L; Hill, N; Klancar, R; McHale, B; Montague, E; Pasca, N; Pergi, L; Randall, R; Rosso, R; Sankovich, K; Smith, D; Wisniewski, L; Witkowski, M; Zovkic, V; Alexander, K; Bhatt, D; Brener, S; Campbell, L; Cho, L; Cole, C; Deedy, M; Foody, J; Gassler, J; Ghaffari, S; Haas, G; Kapadia, S; Lauer, M; Lauer, MS; Lincoff, M; Lutton, S; Marso, S; Mukherjee, D; Patel, V; Penn, M; Robbins, M; Roe, M; Sila, C; Thamilarasan, M; Wagner, G; Armstrong, P; Bestilny, S; Van de Werf, F; Budts, W; Graux, S; Luyten, A; Simes, J; Keech, A; Kava, M; Bower, T; Chan, S; Crampton, L; Monro, C; Nayak, M; Parente, G; Riley, V; Wilton, D; Aylward, P; Dolan, S; Thomas, C; White, H; Scott, M; Frye, R; Alpert, J; Bertrand, M; Ryan, T; Fisher, L; Asarch, L; Smith, M; Lim, L; Bokslag, M; Chiu, P; Chung, J; Collins, S; Dougherty, C; Guimaraes, D; Hakim, Z; Mathieson, J; Montgomery, L; Novotny, B; Steiner, B; Wittke, B		SYMPHONY Investigators	Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial	LANCET			English	Article							PLATELET; INHIBITORS; BLOCKADE; DISEASE	Background Aspirin lowers risks of death and myocardial infarction in patients with acute coronary syndromes. Intravenous glycoprotein IIIb/IIIa receptor antagonists further reduce the rates of ischaemic events in these patients, but the efficacy of long-term oral glycoprotein IIb/IIIa receptor blockade has not been established. We tested whether the oral glycoprotein IIb/IIIa receptor antagonist sibrafiban would prevent more cardiovascular events than aspirin, when given within 7 days of, and sustained for 90 days after, an acute coronary syndrome event. Methods 9233 patients who had stabilised after an acute coronary syndrome event were randomly assigned aspirin (80 mg orally twice daily) or low-dose or high-dose sibrafiban. Sibrafiban doses (3.0 mg, 4.5 mg, or 6.0 mg) were based on a model accounting for weight and serum creatinine and designed to achieve at least 25% steady-state inhibition of platelet aggregation (low dose) or at least 50% inhibition (high dose). The primary endpoint was the composite of death, non-fatal infarction or reinfarction, or severe recurrent ischaemia at 90 days. Analysis was by intention to treat. Findings The 90-day rate of the primary endpoint did not differ significantly between the groups assigned aspirin (302 [9.8%]), low-dose sibrafiban (310 [10.1%]; odds ratio 1.03 [95% Cl 0/8.-1.21]), and high-dose sibrafiban (303 [10.1%]; 1.03 [0.87-1.21]). The groups did not differ significantly in the rates of the component events or secondary efficacy endpoints. Major bleeding was more common with high-dose sibrafiban (171 [5.7%]) than with aspirin (120 [3.9%]) or low-dose sibrafiban (159 [5.2%]). Interpretation Sibrafiban showed no additional benefit over aspirin for secondary prevention of major ischaemic events after an acute coronary syndrome, and was associated with more dose-related bleeding.	Duke Clin Res Inst, Durham, NC 27715 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Univ Calgary, Canadian VIGOUR Ctr, Edmonton, AB, Canada; Leuven Coordinating Ctr, Louvain, Belgium; Univ Sydney, Natl Hlth & Med Res Council Clin Trials Ctr, Sydney, NSW 2006, Australia; Flinders Coordinating Ctr, Adelaide, SA, Australia; Green lane Coordinating Ctr, Auckland, New Zealand; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Univ Arizona, Hlth Sci Ctr, Tucson, AZ 85721 USA; Univ Lille, Lille, France; Boston Univ, Med Ctr, Boston, MA 02215 USA; Univ Washington, Seattle, WA 98195 USA; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland	Duke University; Cleveland Clinic Foundation; University of Calgary; KU Leuven; University of Sydney; Mayo Clinic; University of Arizona; University of Arizona Health Sciences; Universite de Lille - ISITE; Universite de Lille; Boston University; University of Washington; University of Washington Seattle; Roche Holding	Newby, LK (corresponding author), Duke Clin Res Inst, Box 17969, Durham, NC 27715 USA.	newby001@mc.duke.edu	Budts, Werner/AAG-1643-2019; haas, gretchen/GQP-4644-2022; Ardissino, Diego/AAC-4041-2022; Simes, Robert John/P-1497-2014; Widimsky, Petr/P-8088-2016; Granger, Christopher B/D-3458-2014; Lauer, Michael S/L-9656-2013	Widimsky, Petr/0000-0001-5686-7752; Granger, Christopher B/0000-0002-0045-3291; Lauer, Michael S/0000-0002-9217-8177				Alexander J H, 1999, Am Heart J, V138, P175, DOI 10.1016/S0002-8703(99)90000-5; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Ault KA, 1999, J AM COLL CARDIOL, V33, P634, DOI 10.1016/S0735-1097(98)00635-4; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Cannon CP, 1998, CIRCULATION, V97, P340; CANNON CP, 1999, 48 SCI SESS AM COLL; Cox D, 1999, THROMB HAEMOSTASIS, P727; Ferguson JJ, 1998, J AM COLL CARDIOL, V31, p185A, DOI 10.1016/S0735-1097(97)84509-3; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Jennings LK, 1998, CIRCULATION, V98, P359; Kereiakes DJ, 1998, CIRCULATION, V98, P1268, DOI 10.1161/01.CIR.98.13.1268; Mehta JL, 1998, CLIN CARDIOL, V21, P879, DOI 10.1002/clc.4960211204; Newby LK, 1999, AM HEART J, V138, P210, DOI 10.1016/S0002-8703(99)70104-3; O'Neill WW, 1999, J INTERV CARDIOL, V12, P109, DOI 10.1111/j.1540-8183.1999.tb00219.x; ONEILL WW, 1999, 48 SCI SESS AM COLL; Peter K, 1998, BLOOD, V92, P3240, DOI 10.1182/blood.V92.9.3240.421k21_3240_3249; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; STEINER B, 1993, THROMB HAEMOSTASIS, V69, P782; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol E, 1998, CIRCULATION, V97, P2386; VANE J, 1987, DRUGS, V33, P18, DOI 10.2165/00003495-198700331-00005	22	216	217	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	2000	355	9201					337	345						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665552				2022-12-28	WOS:000085122100008
J	Wickware, P				Wickware, P			Exploring the territory in tissue engineering	NATURE			English	Article																			0	4	4	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					464	465		10.1038/35000344	http://dx.doi.org/10.1038/35000344			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667803				2022-12-28	WOS:000085121100059
J	Liu, F; Wan, Q; Pristupa, ZB; Yu, XM; Wang, YT; Niznik, HB				Liu, F; Wan, Q; Pristupa, ZB; Yu, XM; Wang, YT; Niznik, HB			Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors	NATURE			English	Article							GABA(A) RECEPTORS; BETA-SUBUNITS; PHOSPHORYLATION; SUBTYPES; CURRENTS; D1; SCHIZOPHRENIA; MODULATION; DIVERSITY; SYNAPSES	GABAA (gamma-aminobutyric-acid A) and dopamine D1 and D5 receptors represent two structurally and functionally divergent families of neurotransmitter receptors, The former comprises a class of multi-subunit ligand-gated channels mediating fast interneuronal synaptic transmission, whereas the latter belongs to the seven-transmembrane-domain single-polypeptide receptor superfamily that exerts its biological effects, including the modulation of GABA(A) receptor function, through the activation of second-messenger signalling cascades by G proteins, Here we show that GABA(A)-ligand-gated channels complex selectively with D5 receptors through the direct binding of the D5 carboxy-terminal domain with the second intracellular loop of the GABA(A) gamma 2(short) receptor subunit, This physical association enables mutually inhibitory functional interactions between these receptor systems, The data highlight a previously unknown signal transduction mechanism whereby subtype-selective G-protein-coupled receptors dynamically regulate synaptic strength independently of classically defined second-messenger systems, and provide a heuristic framework in which to view these receptor systems in the maintenance of psychomotor disease states.	Hosp Sick Children, Program Brain & Behav, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Oral Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Mol Neurobiol Sect, Toronto, ON M5T 1R8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	Wang, YT (corresponding author), Hosp Sick Children, Program Brain & Behav, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Wang, Yu Tian/A-4729-2008; Wang, Yu Tian/J-8255-2015					Barnard EA, 1998, PHARMACOL REV, V50, P291; Benes FM, 1997, J PSYCHIATR RES, V31, P257, DOI 10.1016/S0022-3956(96)00044-1; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Brunig I, 1999, P NATL ACAD SCI USA, V96, P2456, DOI 10.1073/pnas.96.5.2456; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Costa E, 1998, ANNU REV PHARMACOL, V38, P321, DOI 10.1146/annurev.pharmtox.38.1.321; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; GoldmanRakic PS, 1997, SCHIZOPHRENIA BULL, V23, P437, DOI 10.1093/schbul/23.3.437; Gorrie GH, 1997, J NEUROSCI, V17, P6587; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Huntsman MM, 1998, P NATL ACAD SCI USA, V95, P15066, DOI 10.1073/pnas.95.25.15066; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Keverne EB, 1999, BRAIN RES BULL, V48, P467, DOI 10.1016/S0361-9230(99)00025-8; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MARSHALL FH, 1999, TRENDS PHARMACOL SCI, V10, P369; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; MCDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; MONIYAMA T, 1996, J NEUROSCI, V16, P7502; Moore H, 1999, BIOL PSYCHIAT, V46, P40, DOI 10.1016/S0006-3223(99)00078-5; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; NIZNIK HB, IN PRESS HDB EXPT PH; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; NUSSER Z, 1995, EUR J NEUROSCI, V7, P60; Okubo Y, 1997, NATURE, V385, P634, DOI 10.1038/385634a0; Poisbeau P, 1999, J NEUROSCI, V19, P674; Radnikow G, 1998, J NEUROSCI, V18, P2009; Sibley DR, 1999, ANNU REV PHARMACOL, V39, P313, DOI 10.1146/annurev.pharmtox.39.1.313; Sidhu A, 1998, MOL NEUROBIOL, V16, P125, DOI 10.1007/BF02740640; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Sperk G, 1997, NEUROSCIENCE, V80, P987, DOI 10.1016/S0306-4522(97)00146-2; Sugamori KS, 1998, J NEUROCHEM, V71, P2593; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; Tretter V, 1997, J NEUROSCI, V17, P2728; UNWIN N, 1991, CELL S, V72, P653; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Wan Q, 1997, J NEUROSCI, V17, P5062; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Yan Z, 1997, NEURON, V19, P1115, DOI 10.1016/S0896-6273(00)80402-X; Yu XM, 1998, NATURE, V396, P469, DOI 10.1038/24877	49	366	380	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					274	280		10.1038/35002014	http://dx.doi.org/10.1038/35002014			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659839				2022-12-28	WOS:000084899700042
J	Port, S; Demer, L; Jennrich, R; Walter, D; Garfinkel, A				Port, S; Demer, L; Jennrich, R; Walter, D; Garfinkel, A			Systolic blood pressure and mortality	LANCET			English	Article								Background The current systolic blood-pressure threshold for hypertension treatment is 140 mm Hg for all adults. WHO and the International Society of Hypertension have proposed that normal pressure be lower than 130 mm Hg, with an optimum pressure of less than 120 mm Hg. These recommendations are based largely on the assumption that cardiovascular and overall mortality depend in a strictly increasing manner on systolic blood pressure. The Framingham study was instrumental in establishing this viewpoint. We reassessed data from that study to find out whether the relation is strictly increasing or whether there is a threshold in this relation. Methods We used logistic splines to model the relation of risk of cardiovascular and all-cause death with systolic blood pressure, using age-specific and sex-specific rates. We tested for the independence of the slope parameters from age and sex, and the reduced model with common slopes was used to produce a model different from the conventional linear logistic model. Findings Against the predictions of the linear logistic model, neither all-cause nor cardiovascular deaths depended on systolic blood pressure in a strictly increasing manner. The linear logistic model was rejected by the Framingham data. Instead, risk was independent of systolic blood pressure for all pressures lower than a threshold at the 70th percentile for a person of a given age and sex. Risk sharply increased with pressure higher than the 80th percentile. Since systolic blood pressure steadily increases with age, the threshold increases with age, but more rapidly in women than in men. Interpretation The Framingham data contradict the concept that lower pressures imply lower risk and the idea that 140 mm Hg is a useful cut-off value for hypertension for all adults. There is an age-dependent and sex-dependent threshold for hypertension. A substantial proportion of the population who would currently be thought to be at increased risk are, therefore, at no increased risk.	Univ Calif Los Angeles, Dept Math, Los Angeles, CA 90025 USA; Univ Calif Los Angeles, Dept Med Cardiol, Los Angeles, CA 90025 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90025 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90025 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Port, S (corresponding author), Univ Calif Los Angeles, Dept Math, Los Angeles, CA 90025 USA.		Demer, Linda L/I-5770-2013	Demer, Linda L/0000-0002-9618-6895	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052319] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL52319] Funding Source: Medline; PHS HHS [P01 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1980, 7 COUNTRIES MULTIVAR; Black HR, 1997, ARCH INTERN MED, V157, P2413; Borghi C, 1998, J CARDIOVASC PHARM, V32, pS24, DOI 10.1097/00005344-199800004-00005; Chalmers J, 1999, J HYPERTENS, V17, P151; *COOP RES, 1991, JAMA-J AM MED ASSOC, V275, P1557; KANNEL WB, 1971, AM J CARDIOL, V27, P335, DOI 10.1016/0002-9149(71)90428-0; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; *NAT CTR HLTH STAT, 1964, BLOOD PRESS AD AG SE; O'Brien E, 1999, LANCET, V353, P1541, DOI 10.1016/S0140-6736(99)00157-9; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; *USHEW, 1968, 74599 USHEW NIH	11	160	162	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					175	180		10.1016/S0140-6736(99)07051-8	http://dx.doi.org/10.1016/S0140-6736(99)07051-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675116				2022-12-28	WOS:000084879700010
J	Ritchie, K; Touchon, J				Ritchie, K; Touchon, J			Mild cognitive impairment: conceptual basis and current nosological status	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE; DISORDER; VALIDITY; DEMENTIA		CRLC Val Daurelle, CNS, INSERM, F-34298 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)	Ritchie, K (corresponding author), CRLC Val Daurelle, CNS, INSERM, E99-30, F-34298 Montpellier, France.	ritchie@valdorel.fnclcc.fr	Ritchie, Karen/G-3571-2013	Ritchie, Karen/0000-0002-0688-8982				American Psychiatric Association, 1994, DIAGN STAT MAN; Black SE, 1999, CAN J NEUROL SCI, V26, P4; BLACKFORD RC, 1989, DEV NEUROPSYCHOL, V5, P295, DOI 10.1080/87565648909540440; Celsis P, 1997, J NEUROL NEUROSUR PS, V62, P601, DOI 10.1136/jnnp.62.6.601; CHRISTENSEN H, 1995, PSYCHOL MED, V25, P105, DOI 10.1017/S0033291700028130; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; FLICKER C, 1991, NEUROLOGY, V41, P1006, DOI 10.1212/WNL.41.7.1006; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; Gussekloo J, 1997, BRIT MED J, V315, P1053, DOI 10.1136/bmj.315.7115.1053; Jelic V, 1996, DEMENTIA, V7, P314, DOI 10.1159/000106897; Johnson KA, 1998, NEUROLOGY, V50, P1563, DOI 10.1212/WNL.50.6.1563; JULIN P, 1997, THESIS KAROLINSKA I; KENDELL RE, 1989, PSYCHOL MED, V19, P45, DOI 10.1017/S0033291700011016; Kluger A, 1997, Int Psychogeriatr, V9 Suppl 1, P307, DOI 10.1017/S1041610297005048; KRAL VA, 1962, CAN MED ASSOC J, V86, P257; Krasuski JS, 1998, BIOL PSYCHIAT, V43, P60, DOI 10.1016/S0006-3223(97)00013-9; Levy R, 1994, Int Psychogeriatr, V6, P63, DOI 10.1017/S1041610294001626; McKelvey R, 1999, CAN J NEUROL SCI, V26, P23; Petersen R C, 1997, Int Psychogeriatr, V9 Suppl 1, P65, DOI 10.1017/S1041610297004717; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Richards M, 1999, INT J GERIATR PSYCH, V14, P534, DOI 10.1002/(SICI)1099-1166(199907)14:7<534::AID-GPS963>3.0.CO;2-B; Ritchie K, 1996, BRIT J PSYCHIAT, V168, P470, DOI 10.1192/bjp.168.4.470; Ritchie K, 1999, COMPR PSYCHIAT, V40, P1; WHO, 2012, ICD 10 CLASS MENT BE; Wolf H, 1998, J NEURAL TRANSM-SUPP, P31; Zaudig M, 1992, Int Psychogeriatr, V4 Suppl 2, P203	26	291	316	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2000	355	9199					225	228		10.1016/S0140-6736(99)06155-3	http://dx.doi.org/10.1016/S0140-6736(99)06155-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	276LR	10675135				2022-12-28	WOS:000084879700043
J	Kroman, N; Jensen, MB; Wohlfahrt, J; Mouridsen, HT; Andersen, PK; Melbye, M				Kroman, N; Jensen, MB; Wohlfahrt, J; Mouridsen, HT; Andersen, PK; Melbye, M			Factors influencing the effect of age on prognosis in breast cancer: population based study	BRITISH MEDICAL JOURNAL			English	Article							INTERNATIONAL CONSENSUS PANEL; YOUNG-WOMEN; CARCINOMA; SURVIVAL; RISK; CHEMOTHERAPY; RADIOTHERAPY; RECURRENCE; HIGHLIGHTS; CHILDBIRTH	Objective To investigate whether young age at diagnosis is a negative prognostic factor in primary breast cancer and how stage of disease at diagnosis and treatment influences such an association. Design Retrospective cohort study based on a population based database of patients with breast cancer containing detailed information on tumour characteristics, treatment regimens, and survival. Setting Denmark. Subjects 10 356 women with primary breast cancer who were less than 50 years old at diagnosis. Main outcome measures Relative risk of dying within the first 10 years after. diagnosis according to age at diagnosis after adjustment for known prognostic factors and expected mortality. Results Overall, young women with low risk disease who did not receive adjuvant treatment had a significantly increased risk of dying; risk increased with decreasing age at diagnosis (adjusted relative risk: 45-49 years (reference): 1: 40-44 years: 1.12 (95% confidence interval 0.89 to 1.40): 35-39 years: 1.40 (1.10 to 1.78); < 35 years: 2.18 (1.64 to 2.89). However, no similar trend was seen in patients who received adjuvant cytotoxic treatment. The increased risk in younger women who did not receive adjuvant treatment compared with those who did remained when women were grouped according to presence of node negative disease and by tumour size. Conclusion The negative prognostic effect of young age is almost exclusively seen in women diagnosed with low risk disease who did not receive adjuvant cytotoxic treatment. These results suggest that young women with breast cancer on the basis of age alone, should be regarded as high risk patients and be given adjuvant cytotoxic treatment.	Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; Rigshosp, Danish Breast Canc Cooperat Grp, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Dept Biostat, DK-2200 Copenhagen, Denmark	Aarhus University; Statens Serum Institut; Danish Breast Cancer Cooperative Group (DBCG); Rigshospitalet; University of Copenhagen; University of Copenhagen	Melbye, M (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.			melbye, mads/0000-0001-8264-6785				ABE O, 1992, LANCET, V339, P71; ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; AFZELIUS P, 1994, ACTA ONCOL, V33, P345, DOI 10.3109/02841869409098427; ALBAIN KS, 1994, MONOGR NATL CANC I, V16, P35; ANDERSEN KW, 1988, ACTA ONCOL, V27, P627, DOI 10.3109/02841868809091763; ANDERSON BO, 1995, ANN SURG ONCOL, V2, P407, DOI 10.1007/BF02306373; BONNIER P, 1995, INT J CANCER, V62, P138, DOI 10.1002/ijc.2910620205; BOYAGES J, 1990, RADIOTHER ONCOL, V19, P29, DOI 10.1016/0167-8140(90)90163-Q; Chung M, 1996, CANCER, V77, P97, DOI 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.3.CO;2-T; DELAROCHEFORDIERE A, 1993, LANCET, V341, P1039, DOI 10.1016/0140-6736(93)92407-K; Fisher B, 1997, JNCI-J NATL CANCER I, V89, P1673, DOI 10.1093/jnci/89.22.1673; FOURQUET A, 1989, INT J RADIAT ONCOL, V17, P719, DOI 10.1016/0360-3016(89)90057-6; FOWBLE BL, 1994, INT J RADIAT ONCOL, V30, P23, DOI 10.1016/0360-3016(94)90515-0; Goldhirsch A, 1998, J NATL CANCER I, V90, P1601, DOI 10.1093/jnci/90.21.1601; GOLDHIRSCH A, 1995, J NATL CANCER I, V87, P1441, DOI 10.1093/jnci/87.19.1441; Henderson IC, 1997, LANCET, V349, P1488, DOI 10.1016/S0140-6736(97)22021-0; HOST H, 1986, CANCER-AM CANCER SOC, V57, P2217, DOI 10.1002/1097-0142(19860601)57:11<2217::AID-CNCR2820571124>3.0.CO;2-T; Kollias J, 1997, BRIT J CANCER, V75, P1318, DOI 10.1038/bjc.1997.223; Kroman N, 1997, BRIT MED J, V315, P851, DOI 10.1136/bmj.315.7112.851; Kroman N, 1998, BRIT J CANCER, V78, P1529, DOI 10.1038/bjc.1998.718; LEES AW, 1989, BREAST CANCER RES TR, V13, P143, DOI 10.1007/BF01806526; MAX MH, 1984, AM SURGEON, V50, P23; Melbye M, 1997, NEW ENGL J MED, V336, P81, DOI 10.1056/NEJM199701093360201; *MIN INT, 1994, STAT YB 1994; NIXON AJ, 1994, J CLIN ONCOL, V12, P888, DOI 10.1200/JCO.1994.12.5.888; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Petrek J A, 1994, J Natl Cancer Inst Monogr, P113; REMVIKOS Y, 1995, BREAST CANCER RES TR, V34, P25, DOI 10.1007/BF00666488; SCHMIDT RT, 1991, AM J SURG, V162, P197, DOI 10.1016/0002-9610(91)90068-O; Storm H H, 1991, IARC Sci Publ, P220; VERONESI U, 1990, ANN SURG, V211, P250; Walker RA, 1996, BRIT J CANCER, V74, P1796, DOI 10.1038/bjc.1996.632; Winchester DP, 1996, CANCER-AM CANCER SOC, V78, P1838, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1838::AID-CNCR27>3.0.CO;2-Y	33	258	268	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					474	478		10.1136/bmj.320.7233.474	http://dx.doi.org/10.1136/bmj.320.7233.474			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678859	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000085562200021
J	Beech, PL; Nheu, T; Schultz, T; Herbert, S; Lithgow, T; Gilson, PR; McFadden, GI				Beech, PL; Nheu, T; Schultz, T; Herbert, S; Lithgow, T; Gilson, PR; McFadden, GI			Mitochondrial FtsZ in a chromophyte alga	SCIENCE			English	Article							BACTERIAL-CELL-DIVISION; ESCHERICHIA-COLI; PROTEIN FTSZ; HOMOLOG; DYNAMICS; FISSION; TUBULIN; FUSION; RING	A homolog of the bacterial cell division gene ftsZ was isolated from the alga Mallomonas splendens. The nuclear-encoded protein (MsFtsZ-mt) was closely related to FtsZs of the alpha-proteobacteria, possessed a mitochondrial targeting signal, and localized in a pattern consistent with a role in mitochondrial division. Although FtsZs are known to act in the division of chloroplasts, MsFtsZ-mt appears to be a mitochondrial FtsZ and may represent a mitochondrial division protein.	Deakin Univ, Sch Biol & Chem Sci, Ctr Cellular & Mol Biol, Melbourne, Vic 3125, Australia; Univ Melbourne, Plant Cell Biol Res Ctr, Melbourne, Vic 3010, Australia; Univ Melbourne, Sch Bot, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia	Deakin University; University of Melbourne; University of Melbourne; University of Melbourne	Beech, PL (corresponding author), Deakin Univ, Sch Biol & Chem Sci, Ctr Cellular & Mol Biol, 221 Burwood Highway, Melbourne, Vic 3125, Australia.		Beech, Peter/C-3709-2014; Lithgow, Trevor/H-5925-2017	Beech, Peter/0000-0003-1669-6623; Lithgow, Trevor/0000-0002-0102-7884; Schultz, Thomas/0000-0001-9694-9920				Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; BEECH PL, 1990, J PHYCOL, V26, P90, DOI 10.1111/j.0022-3646.1990.00090.x; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Bramhill D, 1997, ANNU REV CELL DEV BI, V13, P395, DOI 10.1146/annurev.cellbio.13.1.395; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; GAFFAL KP, 1987, ENDOCYTOBIOSIS CELL, V4, P41; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; Margolin W, 1998, TRENDS MICROBIOL, V6, P233, DOI 10.1016/S0966-842X(98)01280-3; MARGOLIN W, 1991, J BACTERIOL, V173, P5822, DOI 10.1128/jb.173.18.5822-5830.1991; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Osteryoung KW, 1998, PLANT CELL, V10, P1991, DOI 10.1105/tpc.10.12.1991; OSTERYOUNG KW, 1995, NATURE, V376, P473, DOI 10.1038/376473b0; Palmer JD, 1997, SCIENCE, V275, P790, DOI 10.1126/science.275.5301.790; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Strepp R, 1998, P NATL ACAD SCI USA, V95, P4368, DOI 10.1073/pnas.95.8.4368; Sun Q, 1998, J BACTERIOL, V180, P2050, DOI 10.1128/JB.180.8.2050-2056.1998; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493	26	137	147	0	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1276	1279		10.1126/science.287.5456.1276	http://dx.doi.org/10.1126/science.287.5456.1276			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678836				2022-12-28	WOS:000085444700053
J	Truog, RD; Burns, JP; Mitchell, C; Johnson, J; Robinson, W				Truog, RD; Burns, JP; Mitchell, C; Johnson, J; Robinson, W			Pharmacologic paralysis and withdrawal of mechanical ventilation at the end of life.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESPIRATORY-DISTRESS SYNDROME; CRITICALLY ILL PATIENTS; CLINICAL MANAGEMENT; DYING PATIENTS; STRATEGY; CARE		Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Truog, RD (corresponding author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.		Burns, Jeffrey P/AAW-8474-2021					Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; BURNS JP, IN PRESS CRIT CARE M; deLeeuw R, 1996, J PEDIATR-US, V129, P661, DOI 10.1016/S0022-3476(96)70146-4; Domino KB, 1999, ANESTHESIOLOGY, V90, P1053, DOI 10.1097/00000542-199904000-00019; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; Field MJ, 1997, APPROACHING DEATH IM; Hatherill M, 1998, BMJ-BRIT MED J, V317, P80, DOI 10.1136/bmj.317.7150.80a; Hoyt J W, 1994, New Horiz, V2, P48; HUNTER JM, 1995, NEW ENGL J MED, V332, P1691, DOI 10.1056/NEJM199506223322507; KIRKLAND L, 1994, J CLIN ETHIC, V5, P38; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LOPER KA, 1989, PAIN, V37, P315, DOI 10.1016/0304-3959(89)90196-6; MEISEL A, 1995, RIGHT DIE; RIDDICK CA, 1994, J CLIN ETHIC, V5, P41; Rushton C H, 1995, Am J Crit Care, V4, P112; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; SOTTILE FD, 1995, CHEST, V108, P887, DOI 10.1378/chest.108.3.887-a; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; TRUOG RD, 1994, J CLIN ETHIC, V5, P39; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	24	55	56	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2000	342	7					508	511		10.1056/NEJM200002173420712	http://dx.doi.org/10.1056/NEJM200002173420712			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284FA	10675435				2022-12-28	WOS:000085319100012
J	Piscitelli, SC; Burstein, AH; Chaitt, D; Alfaro, RM; Falloon, J				Piscitelli, SC; Burstein, AH; Chaitt, D; Alfaro, RM; Falloon, J			Indinavir concentrations and St John's wort	LANCET			English	Article								St John's wort reduced the area under the curve of the HIV-1 protease inhibitor indinavir by a mean of 57% (SD 19) and decreased the extrapolated 8-h indinavir trough by 81% (16) in healthy volunteers. A reduction in indinavir exposure of this magnitude could lead to the development of drug resistance and treatment failure.	NIAID, Dept Pharm, NIH, Bethesda, MD 20892 USA; NIAID, Warren G Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Piscitelli, SC (corresponding author), NIAID, Dept Pharm, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	spisc@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000866] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Clevenbergh P, 1999, AIDS REV, V1, P156; Ernst E, 1999, LANCET, V354, P2014, DOI 10.1016/S0140-6736(99)00418-3; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Li WZ, 1999, THER DRUG MONIT, V21, P360, DOI 10.1097/00007691-199906000-00021; *US PHARM, 2000, ST JOHNS WORT, P2509	5	647	665	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2000	355	9203					547	548		10.1016/S0140-6736(99)05712-8	http://dx.doi.org/10.1016/S0140-6736(99)05712-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10683007				2022-12-28	WOS:000085487400015
J	Salkeld, G; Cameron, ID; Cumming, RG; Easter, S; Seymour, J; Kurrle, SE; Quine, S				Salkeld, G; Cameron, ID; Cumming, RG; Easter, S; Seymour, J; Kurrle, SE; Quine, S			Quality of life related to fear of falling and hip fracture in older women: a time trade off study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PEOPLE; HEALTH STATES; POPULATION; UTILITIES; OUTCOMES	Objective To estimate the utility (preference for health) associated with hip facture and fear of falling among older women. Design Quality of life survey with the time trade off technique. The technique derives an estimate of preference for health stales by finding the point at which respondents show no preference between a longer but lower quality of life and a shorter time in full health. Setting A randomised trial of external hip protectors for older women at risk of hip fracture. Participants 194 women aged greater than or equal to 75 years enrolled in the randomised controlled trial or who were eligible for the trial but refused completed a quality of life inter view face to face. Outcome measures Respondents were asked to rate their own health by using the Euroqol instrument and then rate three health states (fear of falling, a "good" hip fracture, and a "bad" hip fracture) by using time trade off technique. Results On an interval scale between 0 (death) and 1 (full health), a "bad" hip fracture (which results in admission to a nursing home) was valued at 0.05; a "good" hip fracture (maintaining independent living-in the community) 0.31, and fear of falling 0.67. Of women surveyed, 80% would rather be dead (utility = 0) than experience the loss of independence and quality of life that results from a:bad hip:fracture and subsequent admission to a nursing home. The differences in mean utility weights between the trial groups and the refusers were not significant. A test-retest study on 36 women found that the results were reliable with correlation coefficients within classes ranging from 0.61 to 0.88. Conclusions Among older women who have exceeded average life expectancy, quality of life is profoundly threatened by falls and hip fractures. Older x-omen place a very high marginal value on their health. Any loss of ability to live independently in the community has a consider-able detrimental effect on-their quality of life.	Hornsby Ku Ring Gai Hosp, Sydney, NSW 2077, Australia; Univ Sydney, Dept Med, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Univ Sydney, Dept Publ Hlth & Community Med, Social & Publ Hlth Econ Res Grp, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Salkeld, G (corresponding author), Univ Sydney, Dept Publ Hlth & Community Med, Social & Publ Hlth Econ Res Grp, Sydney, NSW 2006, Australia.	glenns@pub.health.usyd.edu.au	Cumming, Robert G/R-1548-2016	Cumming, Robert G/0000-0002-0261-6103				ARMITAGE PA, 1984, STAT METODS MED RES; Brazier J., 1999, HEALTH TECHNOL ASSES, V4, P174, DOI [10.1177/135581969900400310, DOI 10.1177/135581969900400310, DOI 10.3310/hta3090]; CAMERON ID, IN PRESS AGE AGEING; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; COOPER C, 1993, AM J EPIDEMIOL, V137, P1001, DOI 10.1093/oxfordjournals.aje.a116756; Cumming RG, 1997, EPIDEMIOL REV, V19, P244, DOI 10.1093/oxfordjournals.epirev.a017956; Dolan P, 1996, J HEALTH ECON, V15, P209, DOI 10.1016/0167-6296(95)00038-0; Dolan P, 1996, HEALTH ECON, V5, P141, DOI 10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P459, DOI 10.1016/0895-4356(89)90136-4; FURLONG M, 1990, WORKING PAPER SERIES, V909; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; GLASZIOU PP, 1994, MED J AUSTRALIA, V161, P532, DOI 10.5694/j.1326-5377.1994.tb127596.x; JACOBSEN SJ, 1992, AM J PUBLIC HEALTH, V82, P1147, DOI 10.2105/AJPH.82.8.1147; Kane RL, 1998, J AM GERIATR SOC, V46, P1525, DOI 10.1111/j.1532-5415.1998.tb01537.x; Kannus P, 1997, LANCET, V350, P1174, DOI 10.1016/S0140-6736(97)26042-3; Kannus P, 1999, BMJ-BRIT MED J, V318, P205; LAUPACIS A, 1993, J BONE JOINT SURG AM, V75A, P1619, DOI 10.2106/00004623-199311000-00006; MAHONEY F I, 1965, Md State Med J, V14, P61; March L, 1996, PREVENTION TREATMENT; Melton LJ, 1996, BONE, V18, pS121, DOI 10.1016/8756-3282(95)00492-0; MOSSEY JM, 1989, AM J PUBLIC HEALTH, V79, P279, DOI 10.2105/AJPH.79.3.279; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; Richardson J, 1996, INT J TECHNOL ASSESS, V12, P151, DOI 10.1017/S026646230000948X; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TORGERSON DJ, 1995, QJM-MON J ASSOC PHYS, V88, P135; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; Tsevat J, 1998, JAMA-J AM MED ASSOC, V279, P371, DOI 10.1001/jama.279.5.371; Williams A, 1997, HEALTH ECON, V6, P117, DOI 10.1002/(SICI)1099-1050(199703)6:2<117::AID-HEC256>3.0.CO;2-B	29	336	347	0	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2000	320	7231					341	345		10.1136/bmj.320.7231.341	http://dx.doi.org/10.1136/bmj.320.7231.341			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	282HC	10657327	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000085211400022
J	Henney, JE				Henney, JE			First drug device to treat actinic keratoses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Commissioner Food & Drugs, Rockville, MD 20857 USA		Henney, JE (corresponding author), Commissioner Food & Drugs, HF 1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					596	596		10.1001/jama.283.5.596-b	http://dx.doi.org/10.1001/jama.283.5.596-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665687				2022-12-28	WOS:000084956500006
J	Tangelder, MJD; Algra, A; Lawson, JA; Eikelboom, BC; Tangelder, MJD; Algra, A; Tijssen, JGP; Briet, E; Hamming, JJ; Algra, A; Banga, JD; Eikelboom, BC; van Gijn, J; Hauer, RNW; de Jaegere, PPT; Kappelle, LJ; Lawson, JA; Rinkel, GJE; Tangelder, MJD; Weaver, EFD; van Aken, PJ; Algra, A; van Bockel, JH; Buth, J; van den Dungen, JJAM; Eikelboom, BC; Lawson, JA; Moll, FL; Rauwerda, JA; de Smit, P; Tangelder, MJD; van Urk, H; de Vries-Goldschmeding, J; Sixma, JJ; Tangelder, MJD; van Gelder, EAM; van Leeuwerden, M; van Nimwegen, MWM; van Ossanen-Holierhoek, YCW; Poerschke, MA				Tangelder, MJD; Algra, A; Lawson, JA; Eikelboom, BC; Tangelder, MJD; Algra, A; Tijssen, JGP; Briet, E; Hamming, JJ; Algra, A; Banga, JD; Eikelboom, BC; van Gijn, J; Hauer, RNW; de Jaegere, PPT; Kappelle, LJ; Lawson, JA; Rinkel, GJE; Tangelder, MJD; Weaver, EFD; van Aken, PJ; Algra, A; van Bockel, JH; Buth, J; van den Dungen, JJAM; Eikelboom, BC; Lawson, JA; Moll, FL; Rauwerda, JA; de Smit, P; Tangelder, MJD; van Urk, H; de Vries-Goldschmeding, J; Sixma, JJ; Tangelder, MJD; van Gelder, EAM; van Leeuwerden, M; van Nimwegen, MWM; van Ossanen-Holierhoek, YCW; Poerschke, MA		Dutch Bypass Oral Anticoagulants A	Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial	LANCET			English	Article							PERIPHERAL ARTERIAL-DISEASE; INTERMITTENT CLAUDICATION; GRAFTS; DIPYRIDAMOLE; MORTALITY; PATENCY; ISCHEMIA	Background Oral anticoagulants and aspirin are antithrombotic drugs that are commonly used in patients with vascular disease. We investigated whether either of these treatments prevented more effectively than the other bypass complications after infrainguinal bypass surgery. Methods We did a multicentre, randomised, open trial. 2690 patients who had undergone infrainguinal grafting were randomly assigned oral anticoagulants (target international normalised ratio 3.0-4.5, n=1339) or aspirin (80 mg daily, n=1351). We followed up patients for a mean of 21 months. The primary outcome was graft occlusion. Findings 308 graft occlusions occurred in the oral-anticoagulants group compared with 322 in the aspirin group (hazard ratio 0.95 [95% Cl 0.82-1.11]), which suggested no overall advantage for either treatment. Oral anticoagulants were beneficial in patients with vein grafts (0.69 [0.54-0.88]), whereas aspirin had better results for non-venous grafts (1.26 [1.03-1.55]). The composite outcome of vascular death, myocardial infarction, stroke, or amputation occurred 248 times in the oral-anticoagulants group and 275 times in the aspirin group (0.89 [0.75-1.06]). Patients treated with oral anticoagulants had more major bleeding episodes than those treated with aspirin (108 vs 56; 1.96 [1.42-2.71]). Interpretation Oral anticoagulation was better for prevention of infrainguinal-vein-graft occlusion and tor lowering the rate of ischaemic events. Aspirin was better for the prevention of non-venous graft occlusion, and was associated with fewer bleeding episodes.	Dept Vasc Surg, BOA Trial Off, NL-3508 GA Utrecht, Netherlands		Eikelboom, BC (corresponding author), Dept Vasc Surg, BOA Trial Off, POB 85500, NL-3508 GA Utrecht, Netherlands.	B.C.Eikelboom@chir.azu.nl	van Gijn, Jan/A-9444-2008					ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; CLYNE CAC, 1987, BRIT J SURG, V74, P246, DOI 10.1002/bjs.1800740406; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P159, DOI [10.1136/bmj.308.6922.159, DOI 10.1136/BMJ.308.6922.159]; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; DONALDSON DR, 1985, VASCULAR SURG, V19, P224, DOI 10.1177/153857448501900405; GOLDMAN MD, 1984, J VASC SURG, V8, P217; GREEN RM, 1982, SURGERY, V92, P1016; Jonsson B, 1996, EUR J VASC ENDOVASC, V11, P315, DOI 10.1016/S1078-5884(96)80078-5; KANNEL WB, 1970, CIRCULATION, V41, P875, DOI 10.1161/01.CIR.41.5.875; KOHLER TR, 1984, SURGERY, V96, P462; KRETSCHMER G, 1992, ARCH SURG-CHICAGO, V127, P1112; LAWSON JA, 1992, NED TIJDSCHR GENEES, V136, P998; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; LINDBLAD B, 1995, EUR J VASC ENDOVASC, V9, P267, DOI 10.1016/S1078-5884(05)80129-7; MCCOLLUM C, 1991, J VASC SURG, V13, P150, DOI 10.1016/0741-5214(91)90022-M; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; SMITH GD, 1990, CIRCULATION, V82, P1925, DOI 10.1161/01.CIR.82.6.1925; Tangelder MJD, 1999, J VASC SURG, V30, P701, DOI 10.1016/S0741-5214(99)70109-6; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WOLFE JHN, 1986, BRIT J SURG, V73, P321	21	279	292	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	2000	355	9201					346	351						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665553				2022-12-28	WOS:000085122100009
J	Jankowsky, E; Gross, CH; Shuman, S; Pyle, AM				Jankowsky, E; Gross, CH; Shuman, S; Pyle, AM			The DExH protein NPH-II is a processive and directional motor for unwinding RNA	NATURE			English	Article							MESSENGER-RNA; HELICASE; SPECIFICITY; MECHANISMS; ENZYME	All aspects of cellular RNA metabolism and processing involve DExH/D proteins, which are a family of enzymes that unwind or manipulate RNA in an ATP-dependent fashion(1). DExH/D proteins are also essential for the replication of many viruses, and therefore provide targets for the development of therapeutics(2). All DExH/D proteins characterized to date hydrolyse nucleoside triphosphates and, in most cases, this activity is stimulated by the addition of RNA or DNA(1). Several members of the family unwind RNA duplexes in an NTP-dependent fashion in vitro(1,3); therefore it has been proposed that DExH/D proteins couple NTP hydrolysis to RNA conformational chang-e in complex macromolecular assemblies(4). Despite the central role of DExH/D proteins, their mechanism of RNA helicase activity remains unknown. Here we show that the DExH protein NPH-II unwinds RNA duplexes in a processive, unidirectional fashion with a step size of roughly one-half helix turn. We show that there is a quantitative connection between ATP utilization and helicase processivity, thereby providing direct evidence that DExH/D proteins can function as molecular motors on RNA.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Columbia University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute	Pyle, AM (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.			Jankowsky, Eckhard/0000-0001-7677-7412				Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Gross CH, 1996, J VIROL, V70, P2615, DOI 10.1128/JVI.70.4.2615-2619.1996; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Jankowsky E, 1996, BIOCHEMISTRY-US, V35, P15313, DOI 10.1021/bi961397f; Jeltsch A, 1998, BIOCHEMISTRY-US, V37, P2160, DOI 10.1021/bi9719206; Kadare G, 1997, J VIROL, V71, P2583; Kelemen BR, 1999, BIOCHEMISTRY-US, V38, P5302, DOI 10.1021/bi990325w; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; Pyle AM, 2000, METHOD ENZYMOL, V317, P140; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SCHNAPP BJ, 1995, NATURE, V373, P655, DOI 10.1038/373655a0; Shimamoto N, 1999, J BIOL CHEM, V274, P15293, DOI 10.1074/jbc.274.22.15293; SHUMAN S, 1992, P NATL ACAD SCI USA, V89, P10935, DOI 10.1073/pnas.89.22.10935; SHUMAN S, 1993, J BIOL CHEM, V268, P11798; STALEY JP, 1998, CELL, V90, P1041; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; Xiang Q, 1998, BIOCHEMISTRY-US, V37, P3839, DOI 10.1021/bi972661n; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	22	189	195	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					447	451		10.1038/35000239	http://dx.doi.org/10.1038/35000239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667799				2022-12-28	WOS:000085121100055
J	Schier, AF; Shen, MM				Schier, AF; Shen, MM			Nodal signalling in vertebrate development	NATURE			English	Article							LEFT-RIGHT ASYMMETRY; MESODERM INDUCTION; XENOPUS EMBRYOS; MOUSE EMBRYO; SPEMANNS ORGANIZER; TRUNCATED ACTIVIN; FLOOR PLATE; ZEBRAFISH; GASTRULATION; EXPRESSION	Communication between cells during early embryogenesis establishes the basic organization of the vertebrate body plan. Recent work suggests that a signalling pathway centering on Nodal, a transforming growth factor P-related signal, is responsible for many of the events that configure the vertebrate embryo. The activity of Nodal signals is regulated extracellularly by EGF-CFC cofactors and antagonists of the Lefty and Cerberus families of proteins, allowing precise control of mesoderm and endoderm formation, the positioning of the anterior-posterior axis, neural patterning and left-right axis specification.	NYU, Sch Med, Dept Cell Biol, Skirball Inst Biomol Med,Dev Genet Program, New York, NY 10016 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, Piscataway, NJ 08854 USA	New York University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Schier, AF (corresponding author), NYU, Sch Med, Dept Cell Biol, Skirball Inst Biomol Med,Dev Genet Program, New York, NY 10016 USA.	schier@saturn.med.nyu.edu; mshen@cabm.rutgers.edu	Shen, Michael M/C-7546-2009	Shen, Michael M/0000-0002-4042-1657; Schier, Alexander Franz/0000-0001-7645-5325				Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; Bisgrove BW, 1999, DEVELOPMENT, V126, P3253; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; CHENG A, IN PRESS DEVELOPMENT; Clements D, 1999, DEVELOPMENT, V126, P4903; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; Dyson S, 1997, CURR BIOL, V7, P81, DOI 10.1016/S0960-9822(06)00030-3; Erter CE, 1998, DEV BIOL, V204, P361, DOI 10.1006/dbio.1998.9097; Esteban CR, 1999, NATURE, V401, P243, DOI 10.1038/45738; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; GRITSMAN K, IN PRESS DEVELOPMENT; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Gurdon JB, 1998, CELL, V95, P159, DOI 10.1016/S0092-8674(00)81747-X; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; Heisenberg CP, 1997, DEV BIOL, V184, P85, DOI 10.1006/dbio.1997.8511; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8; JONES CM, 1995, DEVELOPMENT, V121, P3651; Joseph EM, 1997, DEV BIOL, V184, P367, DOI 10.1006/dbio.1997.8510; Joseph EM, 1998, DEVELOPMENT, V125, P2677; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; Kimelman D, 1998, CELL, V94, P419, DOI 10.1016/S0092-8674(00)81582-2; Kofron M, 1999, DEVELOPMENT, V126, P5759; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1999, MOL CELL, V4, P287, DOI 10.1016/S1097-2765(00)80331-7; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Osada SI, 1999, DEVELOPMENT, V126, P3229; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Rebagliati MR, 1998, DEV BIOL, V199, P261, DOI 10.1006/dbio.1998.8935; Rodaway A, 1999, DEVELOPMENT, V126, P3067; Salomon DS, 1999, BIOESSAYS, V21, P61, DOI 10.1002/(SICI)1521-1878(199901)21:1&lt;61::AID-BIES8&gt;3.0.CO;2-H; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; Schauerte HE, 1998, DEVELOPMENT, V125, P2983; Schier AF, 1997, DEVELOPMENT, V124, P327; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; Shen MM, 1997, DEVELOPMENT, V124, P429; Simpson EH, 1999, DEV BIOL, V213, P202, DOI 10.1006/dbio.1999.9372; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SMITH FA, 1995, BIOTROPIA, V8, P1; Song JW, 1999, DEV BIOL, V213, P157, DOI 10.1006/dbio.1999.9370; Strahle U, 1997, Genes Funct, V1, P131; Sun BI, 1999, DEVELOPMENT, V126, P1467; Thisse B, 2000, NATURE, V403, P425, DOI 10.1038/35000200; Thisse C, 1999, DEVELOPMENT, V126, P229; Varlet I, 1997, DEVELOPMENT, V124, P1033; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Yan YT, 1999, GENE DEV, V13, P2527, DOI 10.1101/gad.13.19.2527; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yasuo H, 1999, CURR BIOL, V9, P869, DOI 10.1016/S0960-9822(99)80391-1; Yokouchi Y, 1999, CELL, V98, P573, DOI 10.1016/S0092-8674(00)80045-8; Zhang J, 1998, CELL, V94, P515, DOI 10.1016/S0092-8674(00)81592-5; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0; Zhu L, 1999, CURR BIOL, V9, P931, DOI 10.1016/S0960-9822(99)80419-9	71	410	419	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					385	389		10.1038/35000126	http://dx.doi.org/10.1038/35000126			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667782				2022-12-28	WOS:000085121100038
J	Liao, YL; McGee, DL; Cao, G; Cooper, RS				Liao, YL; McGee, DL; Cao, G; Cooper, RS			Quality of the last year of life of older adults: 1986 vs 1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FUNCTIONAL STATUS; UNITED-STATES; HEALTH-STATUS; TRENDS; DEATH; DISABILITY; EXPENDITURES; AMERICANS; MORBIDITY; CARE	Context The population is aging and life expectancy is increasing, but whether morbidity and disability late in life also increase is unknown. Objective To examine whether the use of health care services, disability and cognitive function, and overall quality of life in the year before death among older adults has changed over time. Design and Setting The 1986 and 1993 National Mortality Followback Surveys, which were probability samples of all deaths in the United States with response rates of next of kin of 90% and 88% for those aged 65 years and older. Participants Next of kin were asked to report the health status of a total of 9179 decedents who were 65 years and older in 1986 and 6735 in 1993, representing 1.5 and 1.6 million decedents aged 65 years and older. Main Outcome Measures Days of hospital or nursing home stays, number and length of disability in 5 activities of daily living, duration of impairment in 3 measures of cognitive function, and an overall sickness score among individuals aged 65 through 84 years and those aged 85 years and older. Results Women used significantly fewer hospital and nursing home services in the last year of life in 1993 vs 1986 (mean reduction, 3.3 nights for both age groups for hospital services; mean reduction 18.4 nights for nursing home for women aged 65-84 years and 42.3 nights for women greater than or equal to 85 years). Men had no changes except those aged 85 years and older had a decline in nursing home nights of 32.6. The proportion of women aged 85 years and older with restriction of at least 2 activities of daily living decreased from 62.5% in 1986 to 52.1% in 1993 (P<.01), and those with normal cognitive function increased from 50.3% to 56.2% (P<.05). Their mean overall sickness score decreased and quality-of-life improved. Among women aged 65 through 84 years, the number with normal cognitive function increased and the mean sickness score decreased, but those with at least 2 activities of daily living impairments increased and the overall quality of life declined. A similar pattern of change was found in the oldest-old men except that cognitive function worsened. Most parameters for men aged 65 through 84 years did not change significantly. Conclusions Men and women at least 85 years old in the US experienced a better overall quality of life in the last year of life in 1993 than those in 1986. Most measures for men and women aged 65 through 84 years improved or did not change.	Loyola Univ, Stritch Sch Med, Dept Prevent Med & Epidemiol, Maywood, IL 60153 USA	Loyola University Chicago	Liao, YL (corresponding author), Loyola Univ, Stritch Sch Med, Dept Prevent Med & Epidemiol, 2160 S 1st Ave, Maywood, IL 60153 USA.							COLVEZ A, 1983, INT J EPIDEMIOL, V12, P86; Crimmins EM, 1997, J GERONTOL B-PSYCHOL, V52, pS59, DOI 10.1093/geronb/52B.2.S59; Crimmins EM, 1997, POPUL DEV REV, V23, P555, DOI 10.2307/2137572; Freedman VA, 1998, AM J PUBLIC HEALTH, V88, P1457, DOI 10.2105/AJPH.88.10.1457; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; GARDNER P, 1996, 7 NAT CTR HLTH STAT; GRABBE L, 1995, J AGING HEALTH, V7, P339, DOI 10.1177/089826439500700301; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; GURALNIK JM, 1991, AM J PUBLIC HEALTH, V81, P443, DOI 10.2105/AJPH.81.4.443; KATZMAN R, 1985, HLTH OLDER SOC US CO, P129; Lakatta EG, 1985, HLTH OLDER SOC, P73; LAWRENCE RH, 1995, J AGING HEALTH, V7, P74, DOI 10.1177/089826439500700104; LENTZNER HR, 1992, AM J PUBLIC HEALTH, V82, P1093, DOI 10.2105/AJPH.82.8.1093; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Manton Kenneth G., 1992, P199; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; Moore J.C., 1988, J OFF STAT, V4, P155; *NAT CTR HLTH STAT, 1996, HLTH US 1995; *NAT CTR HLTH STAT, 1998, NAT MORT FOLL SURV 1; Olshansky S.J., 1991, J AGING HEALTH, V3, P194, DOI DOI 10.1177/089826439100300205; ROTHMAN ML, 1991, MED CARE, V29, P115, DOI 10.1097/00005650-199102000-00004; RUSSELL JN, 1997, VITAL HLTH STAT SERI; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SEEMAN I, 1992, VITAL HLTH STAT SERI, V20; Shah BV, 1996, SUDAAN USERS MANUAL; SHAPIRO E, 1983, J AM GERIATR SOC, V31, P348, DOI 10.1111/j.1532-5415.1983.tb05745.x; STRAHAN GW, 1997, VITAL HLTH STAT SERI; Suzman Richard M., 1992, P341; *US BUR CENS, 1991, 1990 CENS POP CPHL74; VERBRUGGE LM, 1984, MILBANK FUND Q, V62, P475, DOI 10.2307/3349861	31	64	64	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					512	518		10.1001/jama.283.4.512	http://dx.doi.org/10.1001/jama.283.4.512			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	276LT	10659878				2022-12-28	WOS:000084879800031
J	Aldiss, B				Aldiss, B			Cognitive ability and the light bulb	NATURE			English	Editorial Material																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					253	253		10.1038/35002217	http://dx.doi.org/10.1038/35002217			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659829	Bronze			2022-12-28	WOS:000084899700029
J	Paul, C				Paul, C			Internal and external morality of medicine: lessons from New Zealand	BRITISH MEDICAL JOURNAL			English	Article								The stories we tell about failures of good medical practice, such as about the Bristol case and the New Zealand cervical cancer study, can restrict our thinking about solutions In New Zealand, the stories told in the report of the judicial inquiry and by women's health advocacy groups were shaped by a concentration on external morality-the view from the outside, reflecting the ethos of the wider society and of bioethics Internal morality-those values, norms, and rules that are intrinsic to the practice of medicine-was ignored or even denigrated; external controls were proposed as solutions The story that best fits the facts is that it was doctors acting in accord with their traditional obligations who brought the problem to light and limited the harm to patients We conclude that external controls are blunt instruments for finding the solutions ill particular cases and require a functioning internal morality to interpret them.	Univ Otago, Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand	University of Otago	Paul, C (corresponding author), Univ Otago, Sch Med, Dept Prevent & Social Med, POB 913, Dunedin, New Zealand.							Cartwright Silvia, 1988, REPORT COMMITTEE ENQ; DELMONTHE T, 1998, BRIT MED J, V316, P1757	2	30	31	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					499	502		10.1136/bmj.320.7233.499	http://dx.doi.org/10.1136/bmj.320.7233.499			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	288KP	10678869	Green Published			2022-12-28	WOS:000085562200031
J	Mi, J; Law, C; Zhang, KL; Osmond, C; Stein, C; Barker, D				Mi, J; Law, C; Zhang, KL; Osmond, C; Stein, C; Barker, D			Effects of infant birthweight and maternal body mass index in pregnancy on components of the insulin resistance syndrome in China	ANNALS OF INTERNAL MEDICINE			English	Article						body mass index; pregnancy; birth weight; insulin resistance	DEPENDENT DIABETES-MELLITUS; BLOOD-PRESSURE; GLUCOSE-TOLERANCE; BIRTH-WEIGHT; NUTRITIONAL-STATUS; SERUM-CHOLESTEROL; HEART-DISEASE; FETAL; POPULATION; GROWTH	Background: Reduced birthweight is associated with increased risk for the insulin resistance syndrome. Part of this risk is hypothesized to originate from undernutrition in utero. The prevalence of the insulin resistance syndrome increases in countries that undergo the transition from chronic malnutrition to adequate nutrition, when postnatal nutrition improves more rapidly than prenatal nutrition. Objective: To determine whether the components of the insulin resistance syndrome are associated with reduced fetal growth and maternal undernutrition. Design: A nonconcurrent, prospective study of men and women whose mothers' heights and weights were recorded during pregnancy. Setting: Beijing, China. Participants: 627 men and women (mean age, 45 years) whose mothers' obstetric records were preserved. Measurements: Adult offspring's blood pressure, plasma glucose levels, insulin levels, and lipid concentrations during an oral glucose tolerance test. The main explanatory measurements were mothers' body mass index during pregnancy and offspring's birthweight and adult size. Results: After adjustment for sex and current body mass index, low birthweight was associated with elevated plasma glucose levels, insulin levels, triglyceride concentrations, and blood pressure. For every l-kg increase in birthweight, systolic blood pressure decreased by 2.9 mm Hg (95% CI, 0.3 to 5.4 mm Hg) and the 2-hour plasma glucose level decreased by 5.1%(CI, 0.7% to 9.3%). Low maternal body mass index in early and late pregnancy was associated with elevated levels of plasma glucose, insulin, and triglycerides in adult offspring but was not associated with elevated blood pressure. Conclusions: Risk for the insulin resistance syndrome may be partially established through low maternal body mass before pregnancy and consequent fetal undernutrition. This risk is independent of that associated with adult obesity. In developing countries such as China, improved nutrition in girls and young women may offer long-term benefits to offspring.	Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England; Peking Union Med Coll, Beijing, Peoples R China	University of Southampton; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Mi, J (corresponding author), Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.		Law, Catherine/A-1353-2009	Osmond, Clive/0000-0002-9054-4655; Law, Catherine/0000-0002-1777-9386				Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ALPHA B, 1992, EUR J CLIN CHEM CLIN, V30, P27; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; Barker DJP, 1998, MOTHERS BABIES HLTH; Clark PM, 1998, OBSTET GYNECOL, V91, P103, DOI 10.1016/S0029-7844(97)00581-4; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; Forsen T, 1997, BRIT MED J, V315, P837, DOI 10.1136/bmj.315.7112.837; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GODFREY KM, 1994, BRIT J OBSTET GYNAEC, V101, P398, DOI 10.1111/j.1471-0528.1994.tb11911.x; Gregory J., 1990, DIETARY NUTR SURVEY; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; James WPT, 1997, NUTR REV, V55, pS31, DOI 10.1111/j.1753-4887.1997.tb06097.x; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; Laor A, 1997, BRIT MED J, V315, P449, DOI 10.1136/bmj.315.7106.449; Law CM, 1996, J HYPERTENS, V14, P935; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; LEE C C, 1948, Chin Med J, V66, P153; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; NI T. G., 1949, Chinese Medical Journal, V87, P677; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; Ramachandran A, 1997, DIABETOLOGIA, V40, P232, DOI 10.1007/s001250050668; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; Taylor SJC, 1998, BRIT MED J, V317, P680, DOI 10.1136/bmj.317.7159.680; UTTLEY K. H., 1940, CHINESE MED JOUR, V58, P582; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; Whincup PH, 1997, DIABETOLOGIA, V40, P319, DOI 10.1007/s001250050681; Zimmet PZ, 1997, J DIABETES COMPLICAT, V11, P60, DOI 10.1016/S1056-8727(96)00090-6	36	210	234	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2000	132	4					253	+		10.7326/0003-4819-132-4-200002150-00002	http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285CY	10681279				2022-12-28	WOS:000085372900001
J	Lindblom, A; Liljegren, A				Lindblom, A; Liljegren, A			Tumour markers in malignancies	BMJ-BRITISH MEDICAL JOURNAL			English	Review							POLYMERASE-CHAIN-REACTION; ACUTE LYMPHOBLASTIC-LEUKEMIA; REVERSE-TRANSCRIPTASE; COLORECTAL-CANCER; PROSTATE-CANCER; GENE FUSION; SOLID TUMORS; TRANSLOCATION; MELANOMA; SARCOMA		Karolinska Hosp, Dept Clin Genet, S-17176 Stockholm, Sweden; Huddinge Univ Hosp, Dept S Stockholm Oncol, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Lindblom, A (corresponding author), Karolinska Hosp, Dept Clin Genet, S-17176 Stockholm, Sweden.	annika.lindblom@cmm.ki.se						Arden KC, 1996, GENE CHROMOSOME CANC, V16, P254, DOI 10.1002/(SICI)1098-2264(199608)16:4<254::AID-GCC5>3.0.CO;2-X; Bast RC, 1998, J CLIN ONCOL, V16, P793; BLENNERHASSETT GT, 1988, LEUKEMIA, V2, P648; Bown NP, 1997, CANCER GENET CYTOGEN, V96, P115, DOI 10.1016/S0165-4608(96)00280-4; CRIST W, 1990, BLOOD, V76, P489; Dean RC, 1998, UROL CLIN N AM, V25, P365, DOI 10.1016/S0094-0143(05)70027-6; DeiTos AP, 1997, VIRCHOWS ARCH, V431, P83; Forestier E, 1997, ACTA PAEDIATR, V86, P819; HEEREMA NA, 1994, BLOOD, V83, P2274, DOI 10.1182/blood.V83.8.2274.bloodjournal8382274; HEIM S, 1994, CANC CYTOGENETICS CH; Hisaoka M, 1998, DIAGN MOL PATHOL, V7, P96, DOI 10.1097/00019606-199804000-00006; Hunerbein M, 1998, RECENT RES CANCER, V146, P48; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Krag D, 1998, NEW ENGL J MED, V339, P941, DOI 10.1056/NEJM199810013391401; Kuban DA, 1998, SEMIN RADIAT ONCOL, V8, P72, DOI 10.1016/S1053-4296(98)80002-7; Ladenson PW, 1996, CLIN CHEM, V42, P183; Lamerz R, 1997, ANTICANCER RES, V17, P2927; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; Liefers GJ, 1998, NEW ENGL J MED, V339, P223, DOI 10.1056/NEJM199807233390403; McCarthy M, 1998, LANCET, V351, P1563, DOI 10.1016/S0140-6736(05)61131-2; Melo JV, 1996, LEUKEMIA, V10, P751; Montie JE, 1997, UROL CLIN N AM, V24, P247, DOI 10.1016/S0094-0143(05)70369-4; Olsson CA, 1996, J UROLOGY, V155, P1557, DOI 10.1016/S0022-5347(01)66125-1; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; Pelkey TJ, 1996, CLIN CHEM, V42, P1369; Raj GV, 1998, CANCER-AM CANCER SOC, V82, P1419, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1419::AID-CNCR1>3.0.CO;2-4; Ratto C, 1998, DIS COLON RECTUM, V41, P1033, DOI 10.1007/BF02237397; Ristamaki R, 1997, BLOOD, V90, P4039, DOI 10.1182/blood.V90.10.4039; Shivers SC, 1998, JAMA-J AM MED ASSOC, V280, P1410, DOI 10.1001/jama.280.16.1410; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH B, 1991, LANCET, V338, P1227, DOI 10.1016/0140-6736(91)92100-G; Speleman F, 1997, MODERN PATHOL, V10, P496; Wasik MA, 1996, ARCH DERMATOL, V132, P42, DOI 10.1001/archderm.132.1.42	35	59	62	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2000	320	7232					424	427		10.1136/bmj.320.7232.424	http://dx.doi.org/10.1136/bmj.320.7232.424			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669448	Green Published			2022-12-28	WOS:000085377400025
J	Li, Z; Jiang, HP; Xie, W; Zhang, ZC; Smrcka, AV; Wu, DQ				Li, Z; Jiang, HP; Xie, W; Zhang, ZC; Smrcka, AV; Wu, DQ			Roles of PLC-beta 2 and -beta 3 and PI3K gamma in chemoattractant-mediated signal transduction	SCIENCE			English	Article							PROTEIN-KINASE-C; NADPH OXIDASE; 3-KINASE	The roles of phosphoinositide 3-kinase (PI3K) and phospholipase C (PLC) in chemoattractant-elicited responses were studied in mice lacking these key enzymes. PI3K gamma was required for chemoattractant-induced production of phosphatidylinositol 3,4,5-trisphosphate [Ptdlns (3,4,5)P-3] and has an important role in chemoattractant-induced superoxide production and chemotaxis in mouse neutrophils and in production of T cell-independent antigen-specific antibodies composed of the immunoglobulin lambda Light chain (Tl-Ig lambda(L). The study of the mice Lacking PLC-beta 2 and -beta 3 revealed that the PLC pathways have an important role in chemoattractant-mediated production of superoxide and regulation of protein kinases, but not chemotaxis. The PLC pathways also appear to inhibit the chemotactic activity induced by certain chemoattractants and to suppress TI-Ig lambda(L) production.	Univ Rochester, Dept Pharmacol, Rochester, NY 14642 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Rochester; University of Connecticut	Wu, DQ (corresponding author), Univ Rochester, Dept Pharmacol, Rochester, NY 14642 USA.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hawkins PT, 1997, BIOCHEM SOC T, V25, P1147, DOI 10.1042/bst0251147; Jiang HP, 1997, P NATL ACAD SCI USA, V94, P7971, DOI 10.1073/pnas.94.15.7971; Jung S, 1999, CURR OPIN IMMUNOL, V11, P319, DOI 10.1016/S0952-7915(99)80051-X; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li Z.B., UNPUB; PARK JW, 1992, J BIOL CHEM, V267, P19901; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Xie W, 1999, P NATL ACAD SCI USA, V96, P10385, DOI 10.1073/pnas.96.18.10385	23	703	754	3	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1046	1049		10.1126/science.287.5455.1046	http://dx.doi.org/10.1126/science.287.5455.1046			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669417				2022-12-28	WOS:000085245400049
J	Bhasin, S; Storer, TW; Javanbakht, M; Berman, N; Yarasheski, KE; Phillips, J; Dike, M; Sinha-Hikim, I; Shen, RQ; Hays, RD; Beall, G				Bhasin, S; Storer, TW; Javanbakht, M; Berman, N; Yarasheski, KE; Phillips, J; Dike, M; Sinha-Hikim, I; Shen, RQ; Hays, RD; Beall, G			Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HYPOGONADAL MEN; MUSCLE SIZE; LEAN BODY; MASS; AIDS; ENDOCRINE; FITNESS; TRIAL; WOMEN	Context Previous studies of testosterone supplementation in HIV-infected men failed to demonstrate improvement in muscle strength. The effects of resistance exercise combined with testosterone supplementation in HIV-infected men are unknown. Objective To determine the effects of testosterone replacement with and without resistance exercise on muscle strength and body composition in HIV-infected men with low testosterone levels and weight loss. Design and Setting Placebo-controlled, double-blind, randomized clinical trial conducted from September 1995 to July 1998 at a general clinical research center. Participants Sixty-one HIV-infected men aged 18 to 50 years with serum testosterone levels of less than 12.1 nmol/L (349 ng/dL) and weight loss of 5% or more in the previous 6 months, 49 of whom completed the study. Interventions Participants were randomly assigned to 1 of 4 groups: placebo, no exercise (n = 14); testosterone enanthate (100 mg/wk intramuscularly), no exercise (n = 17); placebo and exercise (n = 15); or testosterone and exercise (n = 15). Treatment duration was 16 weeks. Main Outcome Measures Changes in muscle strength, body weight, thigh muscle volume, and lean body mass compared among the 4 treatment groups. Results Body weight increased significantly by 2.6 kg (P<.001) in men receiving testosterone alone and by 2.2 kg (P = .02) in men who exercised-alone but did not change in men receiving placebo alone (-0.5 kg; P = .55) or testosterone and exercise (0.7 kg; P = .08). Men treated with testosterone alone, exercise alone, or both experienced significant increases in maximum voluntary muscle strength in leg press (range, 22%-30%), leg curls (range, 18%-36%), bench press (range, 19%-33%), and latissimus pulls (range, 17%-33%). Gains in strength in all exercise categories were greater in men assigned to the testosterone-exercise group or to the exercise-alone group than in those assigned to the placebo-alone group. There was a greater increase in thigh muscle volume in men receiving testosterone alone (mean change, 40 cm(3); P<.001 vs zero change) or exercise alone (62 cm(3); P = .003) than in men receiving placebo alone (5 cm(3); P = .70). Average lean body mass increased by 2.3 kg (P = .004) and 2.6 kg (P<.001), respectively, in men who received testosterone alone or testosterone and exercise but did not change in men receiving placebo alone (0.9 kg; P = .21). Hemoglobin levels increased in men receiving testosterone but not in those receiving placebo. Conclusion Our data suggest that testosterone and resistance exercise promote gains in body weight, muscle mass, muscle strength, and lean body mass in HIV-infected men with weight loss and low testosterone levels. Testosterone and exercise together did not produce greater gains than either intervention alone.	Charles R Drew Univ Med & Sci, Div Endocrinol Metab & Mol Med, Los Angeles, CA 90059 USA; Univ Calif Los Angeles, Dept Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA; Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Pediat, Torrance, CA 90509 USA; Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Radiol, Torrance, CA 90509 USA; Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Med, Torrance, CA 90509 USA; El Camino Coll, Lab Exercise Sci, Torrance, CA USA; Washington Univ, Sch Med, Div Endocrinol Diabet & Metab, St Louis, MO USA	Charles R. Drew University of Medicine & Science; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Washington University (WUSTL)	Bhasin, S (corresponding author), Charles R Drew Univ Med & Sci, Div Endocrinol Metab & Mol Med, 1731 E 120th St, Los Angeles, CA 90059 USA.		Javanbakht, Marjan/Q-2183-2019; Yarasheski, Kevin/AAC-7450-2021; Hays, Ronald/D-5629-2013; Yarasheski, Kevin E/A-3025-2008	Javanbakht, Marjan/0000-0003-0088-3803; Yarasheski, Kevin/0000-0001-5436-2451; Hays, Ronald/0000-0001-6697-907X; 	NCRR NIH HHS [G12 RR003026, P20 RR011145] Funding Source: Medline; NIA NIH HHS [R01 AG014369] Funding Source: Medline; NIDDK NIH HHS [R01 DK054163, 1ROKDK 50473, R01 DK054163-04, R01 DK049296, R01 DK049393-08, R01 DK049393, R01 DK054163-05, R01 DK054163-03, R01 DK049393-05, R01 DK049393-06, R01 DK049393-07, R01 DK054163-02, 1RO1DK49296, 1RO1DK49393] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011145, G12RR003026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049296, R01DK049393, R13DK050473, R01DK054163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014369] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arver S, 1999, J ANDROL, V20, P611; BERGER JR, 1993, SOUTHERN MED J, V86, P865, DOI 10.1097/00007611-199308000-00003; Bhasin S, 1998, J CLIN ENDOCR METAB, V83, P3155, DOI 10.1210/jc.83.9.3155; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P407, DOI 10.1210/jc.82.2.407; Brodsky IG, 1996, J CLIN ENDOCR METAB, V81, P3469, DOI 10.1210/jc.81.10.3469; BUCHER G, 1996, 11 INT C AIDS JUL 7; CHLEBOWSKI RT, 1989, AM J GASTROENTEROL, V84, P1288; Coodley GO, 1997, AIDS, V11, P1347, DOI 10.1097/00002030-199711000-00008; COODLEY GO, 1994, J ACQ IMMUN DEF SYND, V7, P46; CROXSON TS, 1989, J CLIN ENDOCR METAB, V68, P317, DOI 10.1210/jcem-68-2-317; DEPAEPE ME, 1989, HUM PATHOL, V20, P572, DOI 10.1016/0046-8177(89)90246-3; Dobs AS, 1999, AM J MED, V107, P126, DOI 10.1016/S0002-9343(99)00193-X; Dobs AS, 1996, J CLIN ENDOCR METAB, V81, P4108, DOI 10.1210/jc.81.11.4108; DOBS AS, 1988, AM J MED, V84, P611, DOI 10.1016/0002-9343(88)90144-1; Gold J, 1996, AIDS, V10, P745, DOI 10.1097/00002030-199606001-00008; Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P4051, DOI 10.1210/jc.81.11.4051; Grinspoon S, 1998, ANN INTERN MED, V129, P18, DOI 10.7326/0003-4819-129-1-199807010-00005; HAYS RD, 1995, ASSESSMENT, V2, P363; Hengge UR, 1996, BRIT J NUTR, V75, P129, DOI 10.1079/BJN19960116; Katznelson L, 1996, J CLIN ENDOCR METAB, V81, P4358, DOI 10.1210/jc.81.12.4358; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; MACARTHUR RD, 1993, MED SCI SPORT EXER, V25, P684; POLES MA, 1996, INF DIS SOC AM C SEP; Rabkin JG, 1999, J CLIN PSYCHOPHARM, V19, P19, DOI 10.1097/00004714-199902000-00006; RAFFI F, 1991, AIDS, V5, P729, DOI 10.1097/00002030-199106000-00013; REBOUCHE CJ, 1987, AM J CLIN NUTR, V45, P373, DOI 10.1093/ajcn/45.2.373; Roubenoff R, 1999, AIDS, V13, P231, DOI 10.1097/00002030-199902040-00011; SALEHIAN B, 1993, 18 ANN M AM SOC ANDR; Sattler FR, 1999, J CLIN ENDOCR METAB, V84, P1268, DOI 10.1210/jc.84.4.1268; Schambelan M, 1996, ANN INTERN MED, V125, P873, DOI 10.7326/0003-4819-125-11-199612010-00002; Sellmeyer DE, 1996, ENDOCR REV, V17, P518, DOI 10.1210/er.17.5.518; Sinha-Hikim I, 1998, J CLIN ENDOCR METAB, V83, P1312, DOI 10.1210/jc.83.4.1312; Strawford A, 1999, J ACQ IMMUN DEF SYND, V20, P137, DOI 10.1097/00042560-199902010-00005; Strawford A, 1999, JAMA-J AM MED ASSOC, V281, P1282, DOI 10.1001/jama.281.14.1282; Stringer WW, 1998, MED SCI SPORT EXER, V30, P11, DOI 10.1097/00005768-199801000-00003; VONROENN JH, 1994, ANN INTERN MED, V121, P393, DOI 10.7326/0003-4819-121-6-199409150-00001; WATERS D, 1996, ANN INTERN MED, V125, P8665	39	261	267	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					763	770		10.1001/jama.283.6.763	http://dx.doi.org/10.1001/jama.283.6.763			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280XL	10683055	Green Accepted, Bronze			2022-12-28	WOS:000085129000028
J	Modell, B; Harris, R; Lane, B; Khan, M; Darlison, M; Petrou, M; Old, J; Layton, M; Varnavides, L				Modell, B; Harris, R; Lane, B; Khan, M; Darlison, M; Petrou, M; Old, J; Layton, M; Varnavides, L			Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRENATAL-DIAGNOSIS; DISORDERS	Objective National audit of informed choice in antenatal screening for thalassaemia. Design Audit from the UK Confidential Enquiry into Counselling for Genetic Disorders. Setting Thalassaemia module of the UK Confidential Enquiry into Counselling for Genetic Disorders. Subjects 138 of 156 couples who had had a pregnancy affected by a major beta thalassaemia from 1990 to 1994. Main outcome measures How and when genetic risk was identified for each couple, and whether and when prenatal diagnosis was offered. Results Risk was detected by screening before or during the first pregnancy in 49% (68/138) of couples and by diagnosis of an affected child in 28% (38/138) of couples. Prenatal diagnosis was offered in 69% (274/400) of pregnancies, ranging from 94% (122/130) fur British Cypriots to 54% (80/149) for British Pakistanis and from 90% in the south east of England to 39% in the West Midlands. Uptake of prenatal diagnosis was 80% (216/274), ranging from 98% (117/120) among British Cypriots in either the first or second trimester to 73% (35/48) among British Pakistanis in the first trimester and 39% (11/28) in the second trimester. A demonstrable service failure occurred in 28% (110/400) of pregnancies, including 110 of 126 where prenatal diagnosis was not offered and 48 of 93 that ended with an affected liveborn infant. Conclusion Although antenatal screening and counselling fur haemoglobin disorders are standard practices in the United Kingdom, they are delivered inadequately and inequitably. An explicit national policy is needed, aiming to make prenatal diagnosis in the first trimester available to all couples and including ongoing national audit.	UCL Royal Free & UCL Med Sch, Dept Primary Care & Populat Sci, Whittington Hosp, London N19 5NF, England; St Marys Hosp, Manchester M13 0JH, Lancs, England; UCL Royal Free & UCL Med Sch, Ctr Hlth Informat & Mutiprofess Educ, Whittington Hosp, London N19 5NF, England; UCL Royal Free & UCL Med Sch, Dept Obstet & Gynaecol, London WC1E 6HX, England; Kings Coll Hosp London, Sch Med, Dept Haematol Med, London SE5 9RS, England; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England	University of London; University College London; University of Manchester; University of London; University College London; University of London; University College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of Oxford	Modell, B (corresponding author), UCL Royal Free & UCL Med Sch, Dept Primary Care & Populat Sci, Whittington Hosp, London N19 5NF, England.	b.modell@ucl.ac.uk	Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANIONWU EN, 1996, RES CULTURAL DIFFERE; Bain BJ, 1998, BRIT J HAEMATOL, V101, P783, DOI 10.1046/j.1365-2141.1998.00809.x; HARRIS R, 1991, BRIT MED J, V303, P1412, DOI 10.1136/bmj.303.6815.1412; Harris R, 1999, BRIT J OBSTET GYNAEC, V106, P658, DOI 10.1111/j.1471-0528.1999.tb08364.x; Hickman M, 1999, BRIT J HAEMATOL, V104, P860, DOI 10.1046/j.1365-2141.1999.01275.x; *HLTH ED AUTH, 1998, SICKL CELL THAL ACH; Jones D, 1998, BRIT MED J, V316, P1476, DOI 10.1136/bmj.316.7143.1476; Modell B, 1997, BRIT MED J, V315, P779, DOI 10.1136/bmj.315.7111.779; MODELL B, 1993, HLTH SERVICES RES; MODELL B, 1980, BRIT MED J, V2, P737; MODELL B, 2000, IN PRESS LANCET; MODELL B, 1985, LANCET, V2, P1383; Modell M, 1998, BMJ-BRIT MED J, V317, P788, DOI 10.1136/bmj.317.7161.788; *NAT CONF ENQ COUN, 1998, HOM BET THAL GREAT B; Neuenschwander H, 1997, BRIT MED J, V315, P784; *NUFF COUNC BIOETH, GEN SCREEN ETH ISS; OLD JM, 1990, LANCET, V336, P834, DOI 10.1016/0140-6736(90)92338-I; PETROV RV, 1995, BIOSCIENCE REP, V15, P1, DOI 10.1007/BF01200210; *STAND MED ADV COM, 1994, SICKL CELL THAL OTH	19	82	87	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2000	320	7231					337	341		10.1136/bmj.320.7231.337	http://dx.doi.org/10.1136/bmj.320.7231.337			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657326	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000085211400021
J	Perez, GI; Trbovich, AM; Gosden, RG; Tilly, JL				Perez, GI; Trbovich, AM; Gosden, RG; Tilly, JL			Reproductive biology - Mitochondria and the death of oocytes	NATURE			English	Article							APOPTOSIS; OVARY		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Vincent Ctr Reprod Biol, Boston, MA 02114 USA; Univ Leeds, Leeds Gen Infirm, Ctr Reprod Growth & Dev, Leeds LS2 9NS, W Yorkshire, England	Harvard University; Harvard Medical School; Massachusetts General Hospital; Leeds General Infirmary; University of Leeds	Perez, GI (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Vincent Ctr Reprod Biol, VBK137E-GYN, Boston, MA 02114 USA.		Perez, Gloria I/GMX-1286-2022					BAKER TG, 1963, PROC R SOC SER B-BIO, V158, P417, DOI 10.1098/rspb.1963.0055; BEAUMONT HM, 1962, PROC R SOC SER B-BIO, V155, P557, DOI 10.1098/rspb.1962.0019; FADDY MJ, 1992, HUM REPROD, V7, P1342, DOI 10.1093/oxfordjournals.humrep.a137570; FORABOSCO A, 1991, ANAT RECORD, V231, P201, DOI 10.1002/ar.1092310208; Krakauer DC, 1999, NATURE, V400, P125, DOI 10.1038/22026; LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6; Morita Y, 1999, DEV BIOL, V213, P1, DOI 10.1006/dbio.1999.9344; Morita Y, 1999, MOL ENDOCRINOL, V13, P841, DOI 10.1210/me.13.6.841; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Perez GI, 1999, MOL HUM REPROD, V5, P414, DOI 10.1093/molehr/5.5.414; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; PIKO L, 1976, DEV BIOL, V49, P1, DOI 10.1016/0012-1606(76)90253-0; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; TILLY JL, 1999, MOL BIOL REPROD MED, P79	14	126	140	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					500	501		10.1038/35000651	http://dx.doi.org/10.1038/35000651			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676949				2022-12-28	WOS:000085227300035
J	Sacher, RA; Schreiber, GB; Kleinman, SH				Sacher, RA; Schreiber, GB; Kleinman, SH			Prevention of transfusion-transmitted hepatitis	LANCET			English	Editorial Material							POSTTRANSFUSION HEPATITIS; VIRUS-INFECTION; RISK		Georgetown Univ, Med Ctr, Dept Lab Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA; WESTAT, Rockville, MD USA; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Georgetown University; Georgetown University; Georgetown University; Westat; University of British Columbia	Sacher, RA (corresponding author), Georgetown Univ, Med Ctr, Dept Lab Med, Washington, DC 20007 USA.							Allain JP, 1999, BRIT J HAEMATOL, V107, P186, DOI 10.1046/j.1365-2141.1999.01665.x; ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; Busch MP, 1998, VOX SANG, V74, P147, DOI 10.1111/j.1423-0410.1998.tb05413.x; Busch MP, 1998, TRANSFUSION, V38, p72S; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; Flanagan P, 1999, TRANSFUS MED REV, V13, P164, DOI 10.1016/S0887-7963(99)80030-3; HOOFNAGLE JH, 1990, TRANSFUSION, V30, P384, DOI 10.1046/j.1537-2995.1990.30590296367.x; JAGODZINSKI L, 1994, TRANSFUSION, V34, pS37; Matsumoto A, 1999, HEPATOLOGY, V30, P283, DOI 10.1002/hep.510300118; Rawal BD, 1998, TRANSFUSION, V38, p91S; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Schuttler CG, 2000, LANCET, V355, P41, DOI 10.1016/S0140-6736(99)04719-4	13	14	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					331	332		10.1016/S0140-6736(99)00391-8	http://dx.doi.org/10.1016/S0140-6736(99)00391-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665547				2022-12-28	WOS:000085122100003
J	Chyba, CF				Chyba, CF			Energy for microbial life on Europa - A radiation-driven ecosystem on Jupiter's moon is not beyond the bounds of possibility	NATURE			English	Article							SATELLITES		SETI Inst, Mountain View, CA 94043 USA; Stanford Univ, Dept Geol & Environm Sci, Moffett Field, CA 94035 USA	Stanford University	Chyba, CF (corresponding author), SETI Inst, 2035 Landings Dr, Mountain View, CA 94043 USA.	chyba@seti.org						Brucato JR, 1997, ICARUS, V125, P135, DOI 10.1006/icar.1996.5561; Carlson RW, 1999, SCIENCE, V283, P2062, DOI 10.1126/science.283.5410.2062; Delitsky ML, 1998, J GEOPHYS RES-PLANET, V103, P31391, DOI 10.1029/1998JE900020; Delitsky ML, 1997, J GEOPHYS RES-PLANET, V102, P16385, DOI 10.1029/97JE01250; Gaidos EJ, 1999, SCIENCE, V284, P1631, DOI 10.1126/science.284.5420.1631; Greenberg R, 1999, ICARUS, V141, P263, DOI 10.1006/icar.1999.6187; Jakosky BM, 1998, J GEOPHYS RES-PLANET, V103, P19359, DOI 10.1029/98JE01892; Johnson RE, 1998, ASTROPHYS SPACE SC L, V227, P303, DOI 10.1007/978-94-011-5252-5_13; Madigan MT, 1997, BROCK BIOL MICROORGA; McCord TB, 1998, J GEOPHYS RES-PLANET, V103, P8603, DOI 10.1029/98JE00788; Pappalardo RT, 1999, J GEOPHYS RES-PLANET, V104, P24015, DOI 10.1029/1998JE000628; REYNOLDS RT, 1983, ICARUS, V56, P246, DOI 10.1016/0019-1035(83)90037-4; VARNES ES, 1999, LUNAR PLANET SCI; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; Zahnle K, 1998, ICARUS, V136, P202, DOI 10.1006/icar.1998.6015	15	151	156	0	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					381	382		10.1038/35000281	http://dx.doi.org/10.1038/35000281			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667778				2022-12-28	WOS:000085121100034
J	Druss, BG; Bradford, DW; Rosenheck, RA; Radford, MJ; Krumholz, HM				Druss, BG; Bradford, DW; Rosenheck, RA; Radford, MJ; Krumholz, HM			Mental disorders and use of cardiovascular procedures after myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC-CATHETERIZATION FACILITIES; CORONARY HEART-DISEASE; UNITED-STATES; MEDICARE PATIENTS; ELDERLY PATIENTS; RACIAL-DIFFERENCES; ANXIETY DISORDERS; OUTCOMES; ANGIOGRAPHY; CARE	Context A number of studies have found race- and sex-based differences in rates of cardiovascular procedures in the United States, Similarly, mental disorders might be expected to be associated with lower rates of such procedures on the basis of clinical, socioeconomic, patient, and provider factors, Objective To assess whether having a comorbid mental disorder is associated with a lower likelihood of cardiac catheterization and/or revascularization after acute myocardial infarction. Design Retrospective cohort study using data from medical charts and administrative files as part of the Cooperative Cardiovascular Project. Setting Acute care nongovernmental hospitals in the United States. Patients National cohort of 113 653 eligible patients 65 years or older who were hospitalized for confirmed acute myocardial infarction between February 1994 and July 1995. Main Outcome Measures Likelihood of cardiac catheterization, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass graft (CABG) surgery during the index hospitalization, comparing patients with and without mental disorders (classified as schizophrenia, major affective disorder, substance abuse/ dependence disorder, or other mental disorder). Results Compared with the remainder of the sample, patients with any comorbid mental disorder (n = 5365; 4.7%) were significantly less likely to undergo PTCA (11.8% vs 16.8%; P<.001) or CABG (8.2% vs 12.6%; P<.001), After adjusting for demographic, clinical, hospital, and regional factors, individuals with mental disorders were 41% (for schizophrenia) to 78% (for substance use) as likely to undergo cardiac catheterization as those without mental disorders (P<.001 for all). Among those undergoing catheterization, rates of PTCA or CABG for patients with mental disorders were not significantly different from rates for patients without mental disorders (for those with any mental disorder, P =.12 for PTCA and P =.06 for CABG), In multivariate models, the 30-day mortality did not differ between patients with and without mental disorders. Conclusions In this study, individuals with comorbid mental disorders were substantially less likely to undergo coronary revascularization procedures than those without mental disorders. Further research is needed to understand the degree to which patient and provider factors contribute to this difference and its implications for quality and long-term outcomes of care.	Yale Univ, Sch Med, VA NE Program Evaluat Ctr, Dept Psychiat, New Haven, CT 06520 USA; Yale Univ, Sch Med, VA NE Program Evaluat Ctr, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT USA; VA Connecticut Mental Illness Res Educ & Clin Ctr, New Haven, CT USA; Yale Univ, Dept Med, Sect Cardiovasc med, New Haven, CT 06520 USA; Qualidigm, Middletown, CT USA; Med Univ S Carolina, Ctr Hlth Care Res, Charleston, SC 29425 USA	Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Medical University of South Carolina	Druss, BG (corresponding author), 950 Campbell Ave 116A, W Haven, CT 06516 USA.		, Harlan/AAI-2875-2020	Radford, Martha/0000-0001-7503-9557	NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001556] Funding Source: NIH RePORTER; NIMH NIH HHS [K08 MH01556] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARO S, 1995, BRIT J PSYCHIAT, V166, P759, DOI 10.1192/bjp.166.6.759; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Ayanian JZ, 1997, J GEN INTERN MED, V12, P311, DOI 10.1046/j.1525-1497.1997.012005311.x; BAUGHAN DM, 1995, AM FAM PHYSICIAN, V52, P447; BEHAR S, 1995, ARCH INTERN MED, V155, P813, DOI 10.1001/archinte.155.8.813; BLUMENTHAL JA, 1982, PSYCHOSOM MED, V44, P519, DOI 10.1097/00006842-198212000-00003; Callahan CM, 1997, ANN INTERN MED, V126, P426, DOI 10.7326/0003-4819-126-6-199703150-00002; CARNEY RM, 1995, HEALTH PSYCHOL, V14, P88, DOI 10.1037/0278-6133.14.1.88; Clark RE, 1996, HEALTH SERV RES, V31, P153; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; Druss BG, 1998, AM J PSYCHIAT, V155, P1775, DOI 10.1176/ajp.155.12.1775; Druss BG, 1999, AM J PSYCHIAT, V156, P477; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; FORD ES, 1995, HEALTH SERV RES, V30, P237; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; GUTHEIL TG, 1986, AM J PSYCHIAT, V143, P1020; Henk HJ, 1996, ARCH GEN PSYCHIAT, V53, P899; Huff ED, 1997, J CLIN EPIDEMIOL, V50, P1395, DOI 10.1016/S0895-4356(97)00218-7; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; Jeste DV, 1996, SCHIZOPHRENIA BULL, V22, P413, DOI 10.1093/schbul/22.3.413; KATON W, 1990, Journal of Clinical Psychiatry, V51, P3; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Krumholz HM, 1997, NEW ENGL J MED, V336, P1522, DOI 10.1056/NEJM199705223362111; Krumholz HM, 1998, CIRCULATION, V98, P2010, DOI 10.1161/01.CIR.98.19.2010; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; O'Connor GT, 1999, JAMA-J AM MED ASSOC, V281, P627, DOI 10.1001/jama.281.7.627; Olfson M, 1999, HEALTH AFFAIR, V18, P79, DOI 10.1377/hlthaff.18.2.79; Penn DL, 1998, PSYCHIAT QUART, V69, P235, DOI 10.1023/A:1022153327316; Pilote L, 1996, NEW ENGL J MED, V335, P1198, DOI 10.1056/NEJM199610173351606; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Schwartz LM, 1999, NEW ENGL J MED, V341, P279, DOI 10.1056/NEJM199907223410411; SIMON G, 1995, AM J PSYCHIAT, V152, P352; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618; US Dept of Health and Human Services . International Classification of Diseases, 1988, INT CLASS DIS; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; Whittle J, 1997, J GEN INTERN MED, V12, P267, DOI 10.1046/j.1525-1497.1997.012005267.x; Wirshing DA, 1998, AM J PSYCHIAT, V155, P1508, DOI 10.1176/ajp.155.11.1508; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zubenko GS, 1997, AM J PSYCHIAT, V154, P1360	46	388	393	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					506	511		10.1001/jama.283.4.506	http://dx.doi.org/10.1001/jama.283.4.506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	276LT	10659877				2022-12-28	WOS:000084879800030
J	Huard, B; Karlsson, L				Huard, B; Karlsson, L			KIR expression on self-reactive CD8(+) T cells is controlled by T-cell receptor engagement	NATURE			English	Article							NATURAL-KILLER-CELLS; CLASS-I MOLECULES; INHIBITORY RECEPTORS; HLA-E; LYMPHOCYTES; CD94/NKG2A; CYTOTOXICITY	Natural killer cell tolerance is maintained by the interaction of killer inhibitory receptors (KIRs) with self-major histocompatibility complex class I gene products. A subset of T cells also expresses inhibitory receptors, but the functional significance of these receptors on T cells is unclear(1-3). Here we show that, in the absence of T-cell receptor (TCR) engagement, KIRs expressed on CD8(+) T cells are slowly downregulated by KIR ligands expressed on antigen-presenting cells. The resulting expression levels of KIR are no longer able to inhibit T-cell function. In contrast, TCR engagement sustains KIR expression, and re-induces functional levels of KIR expression after ligand-induced downregulation of KIR. Our data indicate that KIR expression on CD8(+) T cells in vivo maybe maintained through continuous encounters with antigen. As KIR-mediated inhibition of T-cell activation can be bypassed at high antigen concentrations, dynamic KIR expression may mediate T-cell tolerance to self-antigens by sparing self-reactive T cells, thus enabling them to mediate potentially useful immune functions to quantitatively or qualitatively different antigens.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Fac Pharm Chatenay Malabry, Lab Immunol Tumeurs, F-92296 Chatenay Malabry, France	Johnson & Johnson; Johnson & Johnson USA; UDICE-French Research Universities; Universite Paris Saclay	Huard, B (corresponding author), Ctr Med Univ Geneva, Dermatol Lab 5 222, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.		huard, bertrand/L-8011-2013	huard, bertrand/0000-0003-1358-6576				Borrego F, 1998, J EXP MED, V187, P813, DOI 10.1084/jem.187.5.813; Boullier S, 1998, EUR J IMMUNOL, V28, P3399, DOI 10.1002/(SICI)1521-4141(199811)28:11<3399::AID-IMMU3399>3.0.CO;2-W; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Cai ZL, 1996, P NATL ACAD SCI USA, V93, P14736, DOI 10.1073/pnas.93.25.14736; Carena I, 1997, J EXP MED, V186, P1769, DOI 10.1084/jem.186.10.1769; FALK CS, 1995, J EXP MED, V182, P1005, DOI 10.1084/jem.182.4.1005; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; Gumperz JE, 1996, J EXP MED, V183, P1817, DOI 10.1084/jem.183.4.1817; Hoglund P, 1997, IMMUNOL REV, V155, P11, DOI 10.1111/j.1600-065X.1997.tb00936.x; HUARD B, 1995, EUR J IMMUNOL, V25, P2718, DOI 10.1002/eji.1830250949; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Le Drean E, 1998, EUR J IMMUNOL, V28, P264, DOI 10.1002/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Mingari MC, 1998, IMMUNOL TODAY, V19, P153, DOI 10.1016/S0167-5699(97)01236-X; Mingari MC, 1997, INT IMMUNOL, V9, P485, DOI 10.1093/intimm/9.4.485; Mingari MC, 1996, P NATL ACAD SCI USA, V93, P12433, DOI 10.1073/pnas.93.22.12433; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; Muller U, 1997, NEUROGENETICS, V1, P1; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; Ponte M, 1999, P NATL ACAD SCI USA, V96, P5674, DOI 10.1073/pnas.96.10.5674; Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093; SHIMIZU Y, 1989, J IMMUNOL, V142, P3320; Speiser DE, 1999, EUR J IMMUNOL, V29, P1990, DOI 10.1002/(SICI)1521-4141(199906)29:06<1990::AID-IMMU1990>3.3.CO;2-0; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; vanDeurs B, 1996, EUR J CELL BIOL, V69, P343	26	120	124	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					325	328		10.1038/35002105	http://dx.doi.org/10.1038/35002105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659853				2022-12-28	WOS:000084899700056
J	Bae, S; Kurtz, RC				Bae, S; Kurtz, RC			Strategy after diagnosis of pancreatic dysplasia	LANCET			English	Editorial Material							HEREDITARY PANCREATITIS; CANCER		Mem Sloan Kettering Canc Ctr, Serv Gastroenterol & Nutr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Kurtz, RC (corresponding author), Mem Sloan Kettering Canc Ctr, Serv Gastroenterol & Nutr, 1275 York Ave, New York, NY 10021 USA.							Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Brentnall TA, 1999, ANN INTERN MED, V131, P247, DOI 10.7326/0003-4819-131-4-199908170-00003; Finch MD, 1997, DIGESTION, V58, P564, DOI 10.1159/000201502; Flanders TY, 1996, J MED GENET, V33, P889, DOI 10.1136/jmg.33.11.889; GRUBAN RH, 1993, AM J PATHOL, V143, P545; LEE JG, 1995, GASTROINTEST ENDOSC, V42, P317, DOI 10.1016/S0016-5107(95)70129-X; Lowenfels AB, 1997, J NATL CANCER I, V89, P442, DOI 10.1093/jnci/89.6.442; Lynch HT, 1996, SEMIN ONCOL, V23, P251; Markowitz A, 1999, GASTROENTEROLOGY, V116, pA458; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861	10	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	2000	355	9198					85	86		10.1016/S0140-6736(99)00354-2	http://dx.doi.org/10.1016/S0140-6736(99)00354-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675163				2022-12-28	WOS:000085557200007
J	Ganzini, L; Nelson, HD; Schmidt, TA; Kraemer, DF; Delorit, MA; Lee, MA				Ganzini, L; Nelson, HD; Schmidt, TA; Kraemer, DF; Delorit, MA; Lee, MA			Physicians' experiences with the Oregon Death with Dignity Act.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASSISTED SUICIDE; TERMINALLY ILL; EUTHANASIA; DESIRE; CARE	Background: Physician-assisted suicide was legalized in Oregon in October 1997. There are data on patients who have received prescriptions for lethal medications and died after taking the medications. There is little information, however, on physicians' experiences with requests for assistance with suicide. Methods: Between February and August 1999, we mailed a questionnaire to physicians who were eligible to prescribe lethal medications under the Oregon Death with Dignity Act. Results: Of 4053 eligible physicians, 2649 (65 percent) returned the survey. Of the respondents, 144 (5 percent) had received a total of 221 requests for prescriptions for lethal medications since October 1997. We received information on the outcome in 165 patients (complete information for 143 patients and partial for an additional 22). The mean age of the patients was 68 years; 76 percent had an estimated life expectancy of less than six months. Thirty-five percent requested a prescription from another physician. Twenty-nine patients (18 percent) received prescriptions, and 17 (10 percent) died from taking the prescribed medication. Twenty percent of the patients had symptoms of depression; none of these patients received a prescription for a lethal medication. In the case of 68 patients, including 11 who received prescriptions and 8 who died by taking the prescribed medication, the physician implemented at least one substantive palliative intervention, such as control of pain or other symptoms, referral to a hospice program, a consultation, or a trial of antidepressant medication. Forty-six percent of the patients for whom substantive interventions were made changed their minds about assisted suicide, as compared with 15 percent of those for whom no substantive interventions were made (P<0.001). Conclusions: Our data indicate that in Oregon, physicians grant about 1 in 6 requests for a prescription for a lethal medication and that 1 in 10 requests actually results in suicide. Substantive palliative interventions lead some -- but not all -- patients to change their minds about assisted suicide. (N Engl J Med 2000;342:557-63.) (C)2000, Massachusetts Medical Society.	Dept Vet Affairs, Portland, OR USA; Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Div Med Informat & Outcomes Res, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA; Providence Hlth Syst, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Ganzini, L (corresponding author), Vet Affairs Med Ctr, Div Mental Hlth, P-7-1DMH,POB 1034, Portland, OR 97207 USA.							Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BATTIN MP, 1995, ACAD MED, V70, P583; Breitbart W., 1998, OXFORD TXB PALLIATIV, P933; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; EMANUEL EJ, 1998, 1997 98 ASCO SURVEY; Faber-Langendoen K, 1998, CANCER-AM CANCER SOC, V82, P35, DOI 10.1002/(SICI)1097-0142(19980101)82:1<35::AID-CNCR4>3.3.CO;2-#; Fisher LD., 1997, BIOMETRICS, V53, P1182; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; Henriksson MM, 1995, J AFFECT DISORDERS, V36, P11, DOI 10.1016/0165-0327(95)00047-X; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; *OR HLTH DIV, 1997, OR VIT STAT ANN REP, V12; Reagan P, 1999, LANCET, V353, P1265, DOI 10.1016/S0140-6736(98)12219-5; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L	19	275	275	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					557	563		10.1056/NEJM200002243420806	http://dx.doi.org/10.1056/NEJM200002243420806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684915				2022-12-28	WOS:000085422400006
J	Christakis, NA; Lamont, EB				Christakis, NA; Lamont, EB			Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							INDEX HELP; PREFERENCES; SURVIVAL; CANCER; UNCERTAINTY; PREDICTIONS; ACCURACY; CARE	Objective To describe doctors' prognostic accuracy in terminally ill patients and to evaluate the determinants of that accuracy. Design Prospective cohort study. Setting Five outpatient hospice programmes in Chicago. Participants 343 doctors provided survival estimates for 468 terminally ill patients at the time of hospice referral. Main outcome measures Patients' estimated and actual survival. Results Median survival was 24 days. Only 20% (92/468) of predictions were accurate (within 33% of actual survival); 63% (295/468) were overoptimistic and 17% (81/468) were over-pessimistic. Overall, doctors overestimated survival by a factor of 5.3. Few patient or doctor characteristics were associated with prognostic accuracy. Male patients were 58% less likely to have over-pessimistic predictions. Non-oncology medical specialists were 326% more likely than general internists to make overpessimistic predictions. Doctors in the upper quartile of practice experience were the most accurate. As duration of doctor-patient relationship increased and time since last contact decreased, prognostic accuracy decreased. Conclusion Doctors are inaccurate in their prognoses for terminally ill patients and the error is systematically optimistic The inaccuracy is, in general, not restricted to certain kinds of doctors or patients. These phenomena may be adversely affecting the quality of care given to patients near the end of life.	Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Med Ctr, Robert Wood Johnson Clin Scholars Program, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago Medical Center	Christakis, NA (corresponding author), Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA.		Christakis, Nicholas A/C-3205-2009; Christakis, Nicholas A/B-6690-2008; Ram, Prem/K-4511-2012	Lamont, Elizabeth/0000-0001-6604-678X				ADDINGTONHALL JM, 1990, BRIT J CANCER, V62, P695, DOI 10.1038/bjc.1990.360; [Anonymous], 1999, DEATH FORETOLD PROPH; BLANCHARD CG, 1988, SOC SCI MED, V27, P1139, DOI 10.1016/0277-9536(88)90343-7; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis NA, 1997, SOC SCI MED, V44, P301, DOI 10.1016/S0277-9536(96)00100-1; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; EVANS C, 1985, LANCET, V1, P1204; FLETCHER SW, 1981, BIOMEDICAL INNOVATIO; FORSTER LE, 1988, ARCH INTERN MED, V148, P2540, DOI 10.1001/archinte.148.12.2540; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; HEVSEMOORE LH, 1987, PALLIATIVE MED, V1, P165; IWASHYNA TJ, 1998, PALLIATIVE MED, V1, P241; LYNN J, 1995, WESTERN J MED, V163, P250; Mackillop WJ, 1997, J CLIN EPIDEMIOL, V50, P21, DOI 10.1016/S0895-4356(96)00316-2; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; PARKES CM, 1972, BRIT MED J, V2, P29, DOI 10.1136/bmj.2.5804.29; PEARLMAN RA, 1988, ARCH INTERN MED, V148, P2537, DOI 10.1001/archinte.148.12.2537; POSES RM, 1991, CRIT CARE MED, V19, P1533, DOI 10.1097/00003246-199112000-00016; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Zubrod C.G., 1960, J CHRON DIS, V11, P7	21	907	914	0	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					469	472		10.1136/bmj.320.7233.469	http://dx.doi.org/10.1136/bmj.320.7233.469			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678857	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000085562200018
J	Lichtenstein, GR; Yang, YX; Nunes, FA; Lewis, JD; Tuchman, M; Tino, G; Kaiser, LR; Palevsky, HI; Kotloff, RM; Furth, EE; Bavaria, JE; Stecker, MM; Kaplan, P; Berry, GT				Lichtenstein, GR; Yang, YX; Nunes, FA; Lewis, JD; Tuchman, M; Tino, G; Kaiser, LR; Palevsky, HI; Kotloff, RM; Furth, EE; Bavaria, JE; Stecker, MM; Kaplan, P; Berry, GT			Fatal hyperammonemia after orthotopic lung transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							IDIOPATHIC HYPERAMMONEMIA; ENCEPHALOPATHY; AMMONIA	Background: A case of fatal hyperammonemia complicating orthotopic lung transplantation was previously reported. Objective: To describe the incidence, clinical features, and treatment of hyperammonemia associated with orthotopic lung transplantation. Design: Retrospective cohort analysis. Setting: Academic medical center and lung transplantation center in Philadelphia, Pennsylvania. Patients: 145 sequential adult patients who underwent orthotopic lung transplantation. Measurements: Plasma ammonium levels. Results: Six of the 145 patients who had had orthotopic lung transplantation developed hyperammonemia, all within the first 26 days after transplantation. The 30-day post-transplantation mortality rate was 67% for patients with hyperammonemia compared with 17% for those without hyperammonemia (P = 0.01). Development of major gastrointestinal complications (P = 0.03), use of total parenteral nutrition (P < 0.001), and lung transplantation for primary pulmonary hypertension (P = 0.045) were associated with hyperammonemia. Conclusions: Hyperammonemia is a potentially fatal event occurring after orthotopic lung transplantation. It is associated with high nitrogen load, concurrent medical stressors, primary pulmonary hypertension, and hepatic glutamine synthetase deficiency.	Hosp Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; Washington Childrens Hosp, Washington, DC USA	University of Pennsylvania; Pennsylvania Medicine; Children's National Health System	Lichtenstein, GR (corresponding author), Hosp Univ Penn, Sch Med, Dept Med, Div Gastroenterol, 3 Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.		Kaiser, Larry/L-7940-2019; Kotloff, Robert/R-2579-2019	Berry, Gerard/0000-0001-5299-3313; Stecker, Mark/0000-0002-9632-168X				Armitage P., 1987, STAT METHODS MED RES; Berry GT, 1999, ARCH NEUROL-CHICAGO, V56, P481, DOI 10.1001/archneur.56.4.481; Breningstall G N, 1986, Pediatr Neurol, V2, P253, DOI 10.1016/0887-8994(86)90016-0; BRESSLER R, 1969, PHARMACOL REV, V21, P105; Brusilow SW HA., 1995, METABOLIC MOL BASES, P1187; COULTER DL, 1981, J PEDIATR-US, V99, P317, DOI 10.1016/S0022-3476(81)80489-1; Davies SM, 1996, BONE MARROW TRANSPL, V17, P1119; EGGERMONT E, 1980, ACTA PAEDIATR BELG, V33, P163; GLASGOW AM, 1972, AM J DIS CHILD, V124, P827, DOI 10.1001/archpedi.1972.02110180029003; HOYUMPA AM, 1979, GASTROENTEROLOGY, V76, P184; Lichtenstein GR, 1997, GASTROENTEROLOGY, V112, P236, DOI 10.1016/S0016-5085(97)70240-3; MOURE JMB, 1970, ARCH NEUROL-CHICAGO, V23, P365, DOI 10.1001/archneur.1970.00480280079009; Rueda JF, 1998, ANN INTERN MED, V128, P956, DOI 10.7326/0003-4819-128-11-199806010-00022; SAMTOY B, 1980, PEDIATRICS, V65, P294, DOI 10.1542/peds.65.2.294; TRULOCK EP, 1993, CHEST, V103, P1566, DOI 10.1378/chest.103.5.1566; Tuchman M, 1997, ANN INTERN MED, V127, P446, DOI 10.7326/0003-4819-127-6-199709150-00005; WATSON AJ, 1985, LANCET, V2, P1271	17	65	67	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2000	132	4					283	287		10.7326/0003-4819-132-4-200002150-00006	http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285CY	10681283				2022-12-28	WOS:000085372900005
J	Banatvala, J; Kane, M; Da Villa, G; Esteban, R; Franco, E; Goudeau, A; Grob, P; Jilg, W; Rizzetto, M; Van Damme, P; Van Hattum, J; West, D; Zuckerman, J				Banatvala, J; Kane, M; Da Villa, G; Esteban, R; Franco, E; Goudeau, A; Grob, P; Jilg, W; Rizzetto, M; Van Damme, P; Van Hattum, J; West, D; Zuckerman, J		European Consensus Grp Hepatitis B	Are booster immunisations needed for lifelong hepatitis B immunity?	LANCET			English	Article							VACCINE; IMMUNOGENICITY; PERSISTENCE; IMMUNIZATION; EFFICACY; CHILDREN; ANTIGEN	Long-term protection against clinically significant breakthrough hepatitis B (HB) virus infection and chronic carriage depends on immunological memory, which allows a protective anamnestic antibody response to antigen challenge. Memory seems to last for at least 15 years in immunocompetent individuals. To date there are no data to support the need for booster doses of HE vaccine in immunocompetent individuals who have responded to a primary course. All adequately vaccinated individuals have shown evidence of immunity in the form of persisting anti-Has and/or in vitro B-cell stimulation or an anamnestic response to a vaccine challenge. Nonetheless several countries and individuals currently have a policy of administering booster doses to certain:risk groups. Boosters may be used to provide reassurance of protective immunity against benign breakthrough infection. For immunocompromised patients, regular testing for anti-HBs, and a booster injection when the titre falls below 10 mIU/mL, is advised. Long-term monitoring should continue, to confirm the absence of clinically significant breakthrough episodes of hepatitis B and to find out if a carrier state develops after 15 years. Also, non-responders to a primary course should continue to be studied.	Guys Kings & St Thomas Hosp, Sch Med & Dent, London SE1 7EH, England	University of London; King's College London	Banatvala, J (corresponding author), Guys Kings & St Thomas Hosp, Sch Med & Dent, London SE1 7EH, England.		van damme, pierre/I-4846-2013	esteban, rafael/0000-0001-5280-392X; Franco, Elisabetta/0000-0002-1179-4411				[Anonymous], MMWR MORB MORTAL WKL; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BEASLEY RP, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P532; BOLAND GJ, 1995, HEPATOLOGY, V22, P873; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P1; CHIARAMONTE M, 1995, SCAND J GASTROENTERO, V30, P601, DOI 10.3109/00365529509089796; CROVARI P, 1988, VIRAL HEPATITIS LIVE, P1071; DAVIDSON M, 1986, J INFECTION, V13, P31, DOI 10.1016/S0163-4453(86)92653-8; GROB P, 1983, SCAND J INFECT DIS, P28; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; HADLER SC, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P766; *INT GROUP, 1988, LANCET, V1, P875; JILG W, 1988, J HEPATOL, V6, P201, DOI 10.1016/S0168-8278(88)80032-1; JILG W, 1988, J MED VIROL, V24, P377, DOI 10.1002/jmv.1890240404; JILG W, 1989, INFECTION, V17, P70, DOI 10.1007/BF01646879; JILG W, 1994, LANCET, V344, P458; Kane MA, 1998, VACCINE, V16, pS104, DOI 10.1016/S0264-410X(98)00308-9; LEE PI, 1995, J PEDIATR-US, V126, P716, DOI 10.1016/S0022-3476(95)70398-5; LEROUXROELS G, 1994, VACCINE, V12, P812, DOI 10.1016/0264-410X(94)90290-9; Liao SS, 1999, VACCINE, V17, P2661, DOI 10.1016/S0264-410X(99)00031-6; Lieming Ding, 1993, Clinical Infectious Diseases, V17, P475; RENZULLI G, 1992, P 35 C NAZ IG 21 24, P116; ROMERO R, 1994, SEMIN LIVER DIS, V14, P289, DOI 10.1055/s-2007-1007319; SALISBURY DM, 1996, IMMUNISATION INFECT, P95; STEVENS CE, 1984, VIRAL HEPATITIS LIVE, P275; TREADWELL TL, 1993, AM J MED, V95, P584, DOI 10.1016/0002-9343(93)90353-Q; VANDITZHUIJSEN TJM, 1988, AM J EPIDEMIOL, V128, P629, DOI 10.1093/oxfordjournals.aje.a115010; VANHATTUM J, 1992, VIRAL HEPATITIS LIVE, P774; Vellinga A, 1999, J MED VIROL, V57, P100, DOI 10.1002/(SICI)1096-9071(199902)57:2&lt;100::AID-JMV2&gt;3.0.CO;2-M; Vellinga A, 1999, VACCINE, V17, P602, DOI 10.1016/S0264-410X(98)00240-0; Wainwright RB, 1997, J INFECT DIS, V175, P674, DOI 10.1093/infdis/175.3.674; WEST DJ, 1994, PEDIATR INFECT DIS J, V13, P745, DOI 10.1097/00006454-199408000-00015; *WHO, 1991, WHOEPIGEN921; WHO, 1992, INF CONS QUADR DIPHT; WILLIG F, 1982, ADV ELECTROCHEMISTRY, V12, P1; WISMANS PJ, 1989, J HEPATOL, V8, P236, DOI 10.1016/0168-8278(89)90013-5; ZANETTI AR, 1990, J MED VIROL, V32, P219, DOI 10.1002/jmv.1890320405; Zuckerman JN, 1998, VIRAL HEPATITIS REV, V4, P43	38	425	436	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2000	355	9203					561	565						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10683019				2022-12-28	WOS:000085487400038
J	Davies, MK; Gibbs, CR; Lip, GYH				Davies, MK; Gibbs, CR; Lip, GYH			ABC of heart failure - Management: diuretics, ACE inhibitors, and nitrates	BRITISH MEDICAL JOURNAL			English	Review							ENALAPRIL		Selly Oak Hosp, Dept Cardiol, Birmingham B29 6JD, W Midlands, England; Univ Birmingham, City Hosp, Dept Med, Birmingham, W Midlands, England; Univ Birmingham, City Hosp, Dept Cardiol, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham	Davies, MK (corresponding author), Selly Oak Hosp, Dept Cardiol, Birmingham B29 6JD, W Midlands, England.							Cohn JN, 1997, CIRCULATION, V96, P856, DOI 10.1161/01.cir.96.3.856; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Remme WJ, 1997, EUR HEART J, V18, P736	6	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					428	431		10.1136/bmj.320.7232.428	http://dx.doi.org/10.1136/bmj.320.7232.428			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669450	Green Published			2022-12-28	WOS:000085377400026
J	Hemminki, E; McPherson, K				Hemminki, E; McPherson, K			Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease	LANCET			English	Article							REPLACEMENT THERAPY; CLINICAL-TRIALS; INFORMATION	Background In a previous study of pooled data from published trials, we found no evidence to support the claim that postmenopausal hormone therapy (PHT) is associated with a decrease in cardiovascular disease. The purpose of this study was to see whether reports of clinical trials attached to drug-licensing applications in Finland could be obtained for scientific purposes, whether they are useful for studying cardiovascular events resulting from PHT, and if so, whether these unpublished reports corroborate the results of published reports. Methods Since clinical trials in drug-licensing documents are confidential, we had to obtain special permission from the Ministry of Social Affairs and Health to use the data for research purposes. After permission was granted, we studied the clinical sections of licensing documents for PHT drugs sent by drug companies to the Finnish Drug Agency. We aimed to identify trials that compared PHT and a placebo (or no therapy, or vitamin-mineral drugs), and that reported on cardiovascular and thromboembolic events or superficial phlebitis. New trials were identified and their data were pooled with those of published trials. Findings 17 licensing applications for drugs used as PHT were found. The number, type, and quality of reporting of clinical trials varied widely between applications. The trials and their reporting of unanticipated adverse events were mostly inadequate. Six new trials tie, those fulfilling the inclusion criteria and not included in our earlier report) were found. The new trials added little to the conclusions of previously published studies: the calculated odds ratios of cardiovascular and thromboembolic events for women taking PHT versus those not taking it was 1.97 (95% CI 0.84-4.63), compared with 1.65 (0.65-4.21) in our previous study. Interpretation In this case, unpublished trials added only a little to the data available from published trials, mainly due to the type of clinical data used in the licensing applications. The new data did not change the previous conclusion that clinical trials do not support a beneficial effect of PHT on cardiovascular diseases.	Natl Res & Dev Ctr Welf & Hlth, Hlth Serv Res Unit, FIN-00531 Helsinki, Finland; London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Hemminki, E (corresponding author), Natl Res & Dev Ctr Welf & Hlth, Hlth Serv Res Unit, POB 220, FIN-00531 Helsinki, Finland.							Bardy AH, 1998, LANCET, V352, P1229, DOI 10.1016/S0140-6736(05)60576-4; Bardy AH, 1998, BRIT J CLIN PHARMACO, V46, P147, DOI 10.1046/j.1365-2125.1998.00759.x; Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; HEMMINKI E, 1980, BRIT MED J, V280, P833, DOI 10.1136/bmj.280.6217.833; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Josefson D, 1999, BRIT MED J, V318, P753, DOI 10.1136/bmj.318.7186.753; Meschia M, 1998, MENOPAUSE, V5, P157; Ollila E, 1996, Int J Risk Saf Med, V9, P161, DOI 10.3233/JRS-1996-9306; 1996, INT J RISK SAFETY ME, V9, P131	10	30	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					566	569		10.1016/S0140-6736(99)03432-7	http://dx.doi.org/10.1016/S0140-6736(99)03432-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10683020				2022-12-28	WOS:000085487400039
J	Lo, B; Alpers, A				Lo, B; Alpers, A			Uses and abuses of prescription drug information in pharmacy benefits management programs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPROVE HEALTH-CARE; PRIVACY	A 1998 incident in which patients' prescription information was used to advertise anew drug exemplifies the importance of confidentiality in the era of managed care and computers. The ethical concerns voiced about this incident can also apply to pharmacy benefits management programs. The use of personal health information in pharmacy benefits management is particularly important because of increased pressures to control rising drug costs. Specific confidentiality concerns include whether the goal of benefiting patients will be achieved and whether the means are appropriate. The means may be problematic because of financial conflicts of interest, lack of patient authorization, inappropriate access to information by third parties, and inadequate safeguards for confidentiality. Policies should be crafted that protect confidentiality while allowing appropriate use of personal health information in pharmacy benefits management. Sound policies should require clear evidence of benefit to patients, an oversight committee, patient authorization, disclosure or prohibition of conflicts of interest, additional safeguards for sensitive medical conditions, strong confidentiality protections, and restrictions on advertising.	Univ Calif San Francisco, Ctr AIDS Prevent Studies, Program Med Eth, San Francisco, CA USA; Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lo, B (corresponding author), Room C 126,521 Parnassus Ave, San Francisco, CA 94143 USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Appelbaum Paul S, 1994, ALMOST REVOLUTION ME, P17; BAKER DP, 1997, WASHINGTON POST 0130, pC1; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Comm. Maint. Priv. Secur. Health Care Appl. Natl. Inf. Infrastruct. Comm. Phys. Sci. Math. Appl.. Natl. Res. Counc, 1997, REC PROT EL HLTH INF; DONALDSON MS, 1994, HLTH DATA INFORMATIO, P5; Fuller LL, 1941, COLUMBIA LAW REV, V41, P799, DOI 10.2307/1117840; Goldman J, 1998, HEALTH AFFAIR, V17, P47, DOI 10.1377/hlthaff.17.6.47; GOSTIN LO, 1995, CORNELL LAW REV, V80, P451; HILZENRATH DS, 1997, WASH POST       0814, pE3; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; *HLTH PRIV PROJ, 1999, STAT HLTH PRIV UN TE; *HLTH PRIV WORK GR, 1999, BEST PRINC HLTH PRIV; HYMAN A, 1995, JAMA-J AM MED ASSOC, V273, P1781, DOI 10.1001/jama.273.22.1781; JIMENEZ R, 1998, BOSTON GLOBE NE 0614, P1; Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI 10.1056/NEJM199903043400903; KOLATA G, 1994, NY TIMES        0808, pD1; Kolata Gina, 1994, N Y Times Web, pA12; Latham SR, 1996, AM J LAW MED, V22, P399; Lipton HL, 1999, ANNU REV PUBL HEALTH, V20, P361, DOI 10.1146/annurev.publhealth.20.1.361; LO B, 1995, RESOLVING ETHICAL DI; Lowrance WW, 1997, PRIVACY HLTH RES REP; MCCARTHY R, 1999, DRUG BENEFIT TRENDS, V11, P26; *NAT BIOETH ADV CO, 1999, RES HUM STOR BIOL MA; *NAT C STAT LEG HL, 1999, PHARM MAN CAR DRUG F; *NAT COMM QUAL ASS, 1999, ACCR 2000 DRAFT STAN; OHARROW R, 1998, WASH POST       0308, pA1; OHARROW R, 1998, WASHINGTON POST 0219, pE1; Pearson SD, 1998, NEW ENGL J MED, V339, P689, DOI 10.1056/NEJM199809033391009; Rodwin M. A., 1993, MED MONEY MORALS PHY; ROSOFF AJ, 1998, ST LOUIS U LAW REV, V42, P1; Schulman KA, 1996, ANN INTERN MED, V124, P906, DOI 10.7326/0003-4819-124-10-199605150-00008; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; WEISS BD, 1982, JAMA-J AM MED ASSOC, V247, P2695, DOI 10.1001/jama.247.19.2695; 1999, FED REG, V64, P55918; 1998, MANAGED CARE, V3, P2; 1999, FED REG, V64, P59940; 1997, CAPITATION MANAG REP, V4, P153	41	16	17	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					801	806		10.1001/jama.283.6.801	http://dx.doi.org/10.1001/jama.283.6.801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	280XL	10683062				2022-12-28	WOS:000085129000035
J	Scully, AL; Kay, SA				Scully, AL; Kay, SA			Time flies for Drosophila	CELL			English	Review							CLOCK GENE; TRANSCRIPTION; CRYPTOCHROME; LOOP		Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, NSF Ctr Biol Timing, La Jolla, CA 92037 USA	Scripps Research Institute; National Science Foundation (NSF); Scripps Research Institute	Kay, SA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878				Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Devlin PF, 1999, TRENDS CELL BIOL, V9, P295, DOI 10.1016/S0962-8924(99)01611-6; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Glossop NRJ, 1999, SCIENCE, V286, P766, DOI 10.1126/science.286.5440.766; Hege DM, 1997, J BIOL RHYTHM, V12, P300, DOI 10.1177/074873049701200402; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Krishnan B, 1999, NATURE, V400, P375, DOI 10.1038/22566; Lee C, 1999, MOL CELL BIOL, V19, P5316; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Park JH, 1998, J BIOL RHYTHM, V13, P219, DOI 10.1177/074873098129000066; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4	19	53	55	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 4	2000	100	3					297	300		10.1016/S0092-8674(00)80665-0	http://dx.doi.org/10.1016/S0092-8674(00)80665-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676811	Bronze			2022-12-28	WOS:000085204400003
J	Wynn, R				Wynn, R			Saints and sinners: Women and the practice of medicine throughout the ages	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SURGERY		Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	Wynn, R (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.							ACHTERBERG J, 1990, WOMEN HEALER; BARANSKY B, 1999, JAMA-J AM MED ASSOC, V282, P840; BERNSTEIN DM, 1992, MINN MED, V75, P16; BRAUS P, 1994, AM DEMOGR, V16, P40; Brooke E., 1997, MED WOMEN PICTORIAL; Ferraris ZA, 1997, ANN THORAC SURG, V64, P1855, DOI 10.1016/S0003-4975(97)01079-5; FLEXNER A, 1910, MED ED US CANADA, P21; HURDMEAD KC, 1938, HIST WOMEN MED EARLI, P111; Kane-Berman J, 1997, S AFR MED J, V87, P1495; Longo M F, 1985, Curr Surg, V42, P91; MARKS G, 1972, WOMEN WHITE; PASTENA JA, 1993, ARCH SURG-CHICAGO, V128, P622; Rosenthal P A, 1982, J Am Med Womens Assoc (1972), V37, P129; SABATINI S, 1994, AM J NEPHROL, V14, P391, DOI 10.1159/000168754; Tamburrino M B, 1992, J Am Med Womens Assoc (1972), V47, P82; WALSH MR, 1990, NEW YORK STATE J MED, V90, P302	16	17	18	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					668	669		10.1001/jama.283.5.668	http://dx.doi.org/10.1001/jama.283.5.668			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665711	hybrid			2022-12-28	WOS:000084956500037
J	Graham, SM; Mtitimila, EI; Kamanga, HS; Walsh, AL; Hart, CA; Molyneux, ME				Graham, SM; Mtitimila, EI; Kamanga, HS; Walsh, AL; Hart, CA; Molyneux, ME			Clinical presentation and outcome of Pneumocystis carinii pneumonia in Malawian children	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RESPIRATORY-TRACT INFECTION; AFRICAN CHILDREN; INDUCED SPUTUM; HIV; DIAGNOSIS; ZIMBABWE; THERAPY; DISEASE; VIRUS	Background Necropsy studies from Africa have shown that Pneumocystis carinii pneumonia (PCP) is common in infants with HIV infection. We aimed to describe the rate, clinical presentation, and outcome of PCP in young Malawian children with acute severe pneumonia. Methods Children aged between 2 months and 5 years who were in hospital with a diagnosis of severe pneumonia were admitted to a study ward for clinical monitoring. We carried out blood culture, immunofluorescence on nasopharyngeal aspirate samples to test for PCP, polymerase chain reaction to detect HIV, and chest radiography. Findings 16 cases of PCP were identified among 150 children With radiologically confirmed severe pneumonia. All were HIV-positive and younger than 6 months. 21 children had bacterial pneumonia (including one who was also PCP positive) and 114 were not confirmed. The most common bacterial pathogens among children without PCP were Streptococcus pneumoniae (eight) and non-typhoidal salmonellae (seven). On admission, children with confirmed PCP had a lower mean age, body temperature, and oxygen saturation than children with bacterial pneumonia and were less likely to have a focal abnormality on auscultation. Oxygen requirements were much greater in children with PCP than those with bacterial pneumonias (96 of 105 hospital days vs 15 of 94, p<0.0001). Ten of 16 children with PCP and six of 21 with bacterial pneumonia died (relative risk 2.19 [95%. CI 1.0-4.7]). The overall case-fatality rate of severe pneumonia was 22%, In addition to a strong association with PCP, a fatal outcome was significantly and independently associated with HIV infection (2.98 [1.1-7.9]) and with age under 6 months (2.76 [1.0-5.2]). Interpretation PCP is common and contributes to the high mortality from pneumonia in Malawian infants, Clinical features are helpful in diagnosis. The study highlights the impact of HIV infection and difficult issues of management in countries with few resources.	Univ Liverpool, Dept Med Microbiol, Liverpool L69 3GA, Merseyside, England; Univ Malawi, Coll Med, Dept Paediat, Blantyre, Malawi; Univ Malawi, Coll Med, Wellcome Trust Res Labs, Blantyre, Malawi; Sch Trop Med, Liverpool, Merseyside, England	University of Liverpool; University of Malawi; University of Malawi; Liverpool School of Tropical Medicine	Graham, SM (corresponding author), Univ Liverpool, Dept Med Microbiol, 8th Floor,Duncan Bldg, Liverpool L69 3GA, Merseyside, England.	smgraham@liverpool.ac.uk		Graham, Stephen/0000-0003-3525-2294				AMUNDSON DE, 1989, SOUTHERN MED J, V82, P711, DOI 10.1097/00007611-198906000-00009; BLASER J, 1993, INFECTION, V21, P206, DOI 10.1007/BF01728888; BYE MR, 1987, PEDIATR PULM, V3, P425, DOI 10.1002/ppul.1950030609; *CDC, 1993, HIV AIDS SURV REP, P16; CHAUDHARY S, 1977, AM J DIS CHILD, V131, P902, DOI 10.1001/archpedi.1977.02120210080017; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; English M, 1996, T ROY SOC TROP MED H, V90, P658, DOI 10.1016/S0035-9203(96)90423-X; GIBB DM, 1994, ARCH DIS CHILD, V70, P241, DOI 10.1136/adc.70.3.241; HAGUE RA, 1990, ARCH DIS CHILD, V65, P1364, DOI 10.1136/adc.65.12.1364; Harries AD, 1997, INT J TUBERC LUNG D, V1, P346; Ikeogu MO, 1997, ARCH DIS CHILD, V76, P124, DOI 10.1136/adc.76.2.124; Jeena PM, 1997, ANN TROP PAEDIATR, V76, P124; Kamiya Y, 1997, ANN TROP PAEDIATR, V17, P121, DOI 10.1080/02724936.1997.11747874; Lepage P, 1998, PEDIATR INFECT DIS J, V17, P581, DOI 10.1097/00006454-199807000-00002; LIPSCHIK GY, 1992, LANCET, V340, P203, DOI 10.1016/0140-6736(92)90469-J; Lucas SB, 1996, BRIT MED J, V312, P335, DOI 10.1136/bmj.312.7027.335; MALIN AS, 1995, LANCET, V346, P1258, DOI 10.1016/S0140-6736(95)91862-0; MASUR H, 1990, NEW ENGL J MED, V323, P1500, DOI 10.1056/NEJM199011223232131; MCLAUGHLIN GE, 1995, J PEDIATR-US, V126, P821, DOI 10.1016/S0022-3476(95)70421-3; MIMICA I, 1971, AM J DIS CHILD, V122, P278, DOI 10.1001/archpedi.1971.02110040062002; MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506; *NAT COMM CLIN LAB, 1993, PERF STAND ANT SUSC; NATHOO KJ, 1993, ANN TROP PAEDIATR, V13, P253, DOI 10.1080/02724936.1993.11747655; OGNIBENE FP, 1989, J PEDIATR-US, V115, P430, DOI 10.1016/S0022-3476(89)80848-0; REDD SC, 1992, LANCET, V340, P1140, DOI 10.1016/0140-6736(92)93160-O; ROGERS MF, 1987, PEDIATRICS, V79, P1008; SHANN F, 1988, LANCET, V2, P1238; Shann F, 1995, CLIN INFECT DIS, V21, pS218, DOI 10.1093/clind/21.Supplement_3.S218; Shata AMA, 1996, ARCH DIS CHILD, V74, P535, DOI 10.1136/adc.74.6.535; SLEASMAN JW, 1993, AM J DIS CHILD, V147, P29, DOI 10.1001/archpedi.1993.02160250032012; Smyth A, 1997, ARCH DIS CHILD, V77, P227, DOI 10.1136/adc.77.3.227; STAGNO S, 1981, PEDIATRICS, V68, P322; VanDyke R.B., 1995, SEMIN PEDIAT INFECT, V6, P10, DOI 10.1016/S1045-1870(05)80018-4; Vetter KM, 1996, PEDIATR INFECT DIS J, V15, P438, DOI 10.1097/00006454-199605000-00011; WAKEFIELD AE, 1990, T ROY SOC TROP MED H, V84, P800, DOI 10.1016/0035-9203(90)90087-U; *WHO, 1993, WHOARI9328; *WHO PROGR CONTR A, 1994, WHOARI905 PROGR CONT	37	116	117	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	2000	355	9201					369	373		10.1016/S0140-6736(98)11074-7	http://dx.doi.org/10.1016/S0140-6736(98)11074-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665557				2022-12-28	WOS:000085122100013
J	McAlister, VC; Gao, ZH; Peltekian, K; Domingues, J; Mahalati, K; MacDonald, AS				McAlister, VC; Gao, ZH; Peltekian, K; Domingues, J; Mahalati, K; MacDonald, AS			Sirolimus-tacrolimus combination immunosuppression	LANCET			English	Article							TRANSPLANTATION; RAPAMYCIN	A series of 32 recipients of liver, kidney, or pancreas transplants who were treated with sirolimus and low-dose tacrolimus experienced a low rate of rejection and excellent graft function without drug-related toxic effects.	Queen Elizabeth Hlth Sci Ctr, Halifax, NS B3H 2Y9, Canada	Queen Elizabeth II Health Sciences Centre	McAlister, VC (corresponding author), Queen Elizabeth Hlth Sci Ctr, Halifax, NS B3H 2Y9, Canada.		McAlister, Vivian/B-9881-2008; Peltekian, Kevork M/D-1083-2010	McAlister, Vivian/0000-0002-2479-6862; Peltekian, Kevork M/0000-0002-9560-5576				DUMONT FJ, 1990, J IMMUNOL, V144, P1418; Groth CG, 1999, TRANSPLANTATION, V67, P1036, DOI 10.1097/00007890-199904150-00017; Kahan BD, 1998, TRANSPLANTATION, V66, P1040, DOI 10.1097/00007890-199810270-00013; Vu MD, 1997, TRANSPLANTATION, V64, P1853, DOI 10.1097/00007890-199712270-00039; Watson CJE, 1999, TRANSPLANTATION, V67, P505, DOI 10.1097/00007890-199902270-00002	5	234	247	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					376	377		10.1016/S0140-6736(99)03882-9	http://dx.doi.org/10.1016/S0140-6736(99)03882-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665560	Green Submitted			2022-12-28	WOS:000085122100016
J	Thisse, B; Wright, CVE; Thisse, C				Thisse, B; Wright, CVE; Thisse, C			Activin- and Nodal-related factors control antero-posterior patterning of the zebrafish embryo	NATURE			English	Article							NERVOUS-SYSTEM; FATE MAP; XENOPUS; EXPRESSION; SIGNALS; GENE; INDUCTION; SPECIFICATION; NOTOCHORD; MESODERM	Definition of cell fates along the dorso-ventral axis depends on an antagonistic relationship between ventralizing transforming growth factor-beta superfamily members, the bone morphogenetic proteins' and factors secreted from the dorsal organizer, such as Noggin and Chordin. The extracellular binding of the last group to the bone morphogenetic proteins prevents them from activating their receptors(2-4), and the relative ventralizer:antagonist ratio is thought to specify different dorso-ventral cell fates. Here, by taking advantage of a non-genetic interference method using a specific competitive inhibitor, the Lefty-related gene product Antivin(5), we provide evidence that cell fate along the anteroposterior axis of the zebrafish embryo is controlled by the morphogenetic activity of another transforming growth factor-beta superfamily subgroup-the Activin and Nodal-related faaors(6-9). Increasing antivin doses progressively deleted posterior fates within the ectoderm, eventually resulting in the removal of all fates except forebrain and eyes. In contrast, overexpression of activin or nodal-related factors converted ectoderm that was fated to be forebrain into more posterior ectodermal or mesendodermal fates, We propose that modulation of intercellular signalling by Antivin/Activin and Nodal-related factors provides a mechanism for the graded establishment of cell fates along the antero-posterior axis of the zebrafish embryo.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vanderbilt University	Thisse, C (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, France.			THISSE, Christine/0000-0002-8684-1681				ALTABA ARI, 1990, DEVELOPMENT, V108, P595; CHENG A, IN PRESS DEVELOPMENT; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GRISTMAN K, 1999, CELL, V97, P121; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Melby AE, 1996, DEVELOPMENT, V122, P2225; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Prince VE, 1998, DEV GENES EVOL, V208, P517, DOI 10.1007/s004270050210; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Reifers F, 1998, DEVELOPMENT, V125, P2381; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SPERMANN H, 1938, EMBRYONIC DEV INDUCT; THISSE C, 1994, DEV BIOL, V164, P420, DOI 10.1006/dbio.1994.1212; Thisse C, 1999, DEVELOPMENT, V126, P229; THISSE C, 1993, DEVELOPMENT, V119, P1203; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WOO K, 1995, DEVELOPMENT, V121, P2595; Woo K, 1997, SCIENCE, V277, P254, DOI 10.1126/science.277.5323.254; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	26	168	170	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					425	428		10.1038/35000200	http://dx.doi.org/10.1038/35000200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667793				2022-12-28	WOS:000085121100049
J	Gibbons, RD; Meltzer, D; Duan, NH				Gibbons, RD; Meltzer, D; Duan, NH		Inst Med Comm Organ Procurement &	Public Health: Waiting for organ transplantation	SCIENCE			English	Article									Univ Illinois, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gibbons, RD (corresponding author), Univ Illinois, Chicago, IL 60612 USA.		Meltzer, David/C-2926-2009	Meltzer, David/0000-0003-2790-7393; Duan, Naihua/0000-0001-9411-2924				Department of Health and Human Services, 1998, FED REG, V63, P16296; Institute of Medicine, 1999, ORG PROC TRANSPL ASS, DOI [10.17226/9628, DOI 10.17226/9628]; *UNOS, 1997, 1997 REP CTR SPEC GR, P15; *US GEN ACC OFF, 1997, GAOHEHS9826	4	36	37	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2000	287	5451					237	238		10.1126/science.287.5451.237	http://dx.doi.org/10.1126/science.287.5451.237			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10660422				2022-12-28	WOS:000084769600021
J	Braun, S; Pantel, K; Muller, P; Janni, W; Hepp, F; Kentenich, CRM; Gastroph, S; Wischnik, A; Dimpfl, T; Kindermann, G; Riethmuller, G; Schlimok, G				Braun, S; Pantel, K; Muller, P; Janni, W; Hepp, F; Kentenich, CRM; Gastroph, S; Wischnik, A; Dimpfl, T; Kindermann, G; Riethmuller, G; Schlimok, G			Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDIAN FOLLOW-UP; MONOCLONAL-ANTIBODIES; PROGNOSTIC-SIGNIFICANCE; PREMENOPAUSAL WOMEN; ANTI-CYTOKERATIN; PRIMARY SURGERY; NODAL STATUS; TUMOR-CELLS; MICROMETASTASES; CARCINOMA	Background: Cytokeratins are specific markers of epithelial cancer cells in bone marrow. We assessed the influence of cytokeratin-positive micrometastases in the bone marrow on the prognosis of women with breast cancer. Methods: We obtained bone marrow aspirates from both upper iliac crests of 552 patients with stage I, II, or III breast cancer who underwent complete resection of the tumor and 191 patients with nonmalignant disease. The specimens were stained with the monoclonal antibody A45-B/B3, which binds to an antigen on cytokeratins. The median follow-up was 38 months (range, 10 to 70). The primary end point was survival. Results: Cytokeratin-positive cells were detected in the bone marrow specimens of 2 of the 191 control patients with nonmalignant conditions (1 percent) and 199 of the 552 patients with breast cancer (36 percent). The presence of occult metastatic cells in bone marrow was unrelated to the presence or absence of lymph-node metastasis (P = 0.13). After four years of follow-up, the presence of micrometastases in bone marrow was associated with the occurrence of clinically overt distant metastasis and death from cancer-related causes (P<0.001), but not with locoregional relapse (P = 0.77). Of 199 patients with occult metastatic cells, 49 died of cancer, whereas of 353 patients without such cells, 22 died of cancer-related causes (P<0.001). Among the 301 women without lymph-node metastases, 14 of the 100 with bone marrow micrometastases died of cancer-related causes, as did 2 of the 201 without bone marrow micrometastases (P<0.001). The presence of occult metastatic cells in bone marrow, as compared with their absence, was an independent prognostic indicator of the risk of death from cancer (relative risk, 4.17; 95 percent confidence interval, 2.51 to 6.94; P<0.001), after adjustment for the use of systemic adjuvant chemotherapy. Conclusions: The presence of occult cytokeratin-positive metastatic cells in bone marrow increases the risk of relapse in patients with stage I, II, or III breast cancer. (N Engl J Med 2000;342:525-33.) (C)2000, Massachusetts Medical Society.	Univ Munich, Klinikum Innenstadt, Frauenklin 1, D-80337 Munich, Germany; Univ Munich, Klinikum Innenstadt, Inst Immunol, D-80337 Munich, Germany; Univ Hamburg, Krankenhaus Eppendorf, Frauenklin, D-2000 Hamburg, Germany; Zent Klinikum, Med Klin 2, Augsburg, Germany; Zent Klinikum, Frauenklin, Augsburg, Germany	University of Munich; University of Munich; University of Hamburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Braun, S (corresponding author), Univ Munich, Klinikum Innenstadt, Frauenklin 1, Maistr 11, D-80337 Munich, Germany.	sbraun@fk-i.med.uni-muenchen.de						[Anonymous], 1997, J CLIN PATHOL; Black, 1997, EUR J CANCER, V33, P2440; Black RJ, 1997, EUR J CANCER, V33, P1075, DOI 10.1016/S0959-8049(96)00492-3; Braun S, 1998, J NATL CANCER I, V90, P1099, DOI 10.1093/jnci/90.14.1099; Braun S, 2000, J CLIN ONCOL, V18, P80, DOI 10.1200/JCO.2000.18.1.80; Brugger W, 1999, J CLIN ONCOL, V17, P1535, DOI 10.1200/JCO.1999.17.5.1535; Cevatli BS, 1999, EUR J CANCER, V35, pS86, DOI 10.1016/S0959-8049(99)80716-3; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; COTE RJ, 1991, J CLIN ONCOL, V9, P1749, DOI 10.1200/JCO.1991.9.10.1749; COURTEMANCHE DJ, 1991, CAN J SURG, V34, P21; COX DR, 1972, J R STAT SOC B, V34, P187; DEARNALEY DP, 1981, BRIT J CANCER, V44, P85, DOI 10.1038/bjc.1981.152; DELSOL G, 1984, LANCET, V2, P1124; DEVITA VT, 1989, NEW ENGL J MED, V320, P527, DOI 10.1056/NEJM198902233200812; Diel IJ, 1996, JNCI-J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652; DOGLIONI C, 1990, VIRCHOWS ARCH A, V416, P479, DOI 10.1007/BF01600298; FISHER B, 1981, CANCER-AM CANCER SOC, V48, P1863, DOI 10.1002/1097-0142(19811015)48:8<1863::AID-CNCR2820480825>3.0.CO;2-U; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; HARBECK N, 1994, BRIT J CANCER, V69, P566, DOI 10.1038/bjc.1994.103; Hellman S, 1997, NEW ENGL J MED, V337, P996, DOI 10.1056/NEJM199710023371408; Jauch KW, 1996, J CLIN ONCOL, V14, P1810, DOI 10.1200/JCO.1996.14.6.1810; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASPER M, 1987, EUR J CANCER CLIN ON, V23, P137, DOI 10.1016/0277-5379(87)90007-1; Klein CA, 1999, P NATL ACAD SCI USA, V96, P4494, DOI 10.1073/pnas.96.8.4494; Landys K, 1998, BREAST CANCER RES TR, V49, P27, DOI 10.1023/A:1005980919916; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; Liu D., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P268; Mansi JL, 1999, LANCET, V354, P197, DOI 10.1016/S0140-6736(98)10175-7; MENARD S, 1994, BRIT J CANCER, V70, P709, DOI 10.1038/bjc.1994.379; Molino A, 1997, BREAST CANCER RES TR, V42, P23, DOI 10.1023/A:1005747711084; Mueller P, 1998, CANCER-AM CANCER SOC, V83, P538, DOI 10.1002/(SICI)1097-0142(19980801)83:3<538::AID-CNCR23>3.0.CO;2-W; Muller P, 1996, CANCER GENET CYTOGEN, V88, P8, DOI 10.1016/0165-4608(95)00189-1; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113; Pantel K, 1994, J Hematother, V3, P165, DOI 10.1089/scd.1.1994.3.165; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; Pantel K, 1996, LANCET, V347, P649, DOI 10.1016/S0140-6736(96)91203-9; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402; RIETHMULLER G, 1992, CURR OPIN IMMUNOL, V4, P647, DOI 10.1016/0952-7915(92)90041-C; SALVADORI B, 1990, EUR J CANCER, V26, P865, DOI 10.1016/0277-5379(90)90185-V; Schaller G, 1996, CLIN CANCER RES, V2, P1879; SCHLIMOK G, 1987, P NATL ACAD SCI USA, V84, P8672, DOI 10.1073/pnas.84.23.8672; Stigbrand T, 1998, TUMOR BIOL, V19, P132, DOI 10.1159/000029984; TAYLORPAPADIMITRIOU J, 1981, INT J CANCER, V28, P17, DOI 10.1002/ijc.2910280104; THOR A, 1988, BREAST CANCER RES TR, V11, P133, DOI 10.1007/BF01805837	45	766	805	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					525	533		10.1056/NEJM200002243420801	http://dx.doi.org/10.1056/NEJM200002243420801			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684910				2022-12-28	WOS:000085422400001
J	Groenewoud, JH; van der Heide, A; Onwuteaka-Philipsen, BD; Willems, DL; van der Maas, PJ; van der Wal, G				Groenewoud, JH; van der Heide, A; Onwuteaka-Philipsen, BD; Willems, DL; van der Maas, PJ; van der Wal, G			Clinical problems with the performance of euthanasia and physician-assisted suicide in the netherlands.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; ATTITUDES; LIFE; END; ONCOLOGISTS; DECISIONS; OREGON; DEATH	Background and Methods: The characteristics and frequency of clinical problems with the performance of euthanasia and physician-assisted suicide are uncertain. We analyzed data from two studies of euthanasia and physician-assisted suicide in the Netherlands (one conducted in 1990 and 1991 and the other in 1995 and 1996), with a total of 649 cases. We categorized clinical problems as technical problems, such as difficulty inserting an intravenous line; complications, such as myoclonus or vomiting; or problems with completion, such as a longer-than-expected interval between the administration of medications and death. Results: In 114 cases, the physician's intention was to provide assistance with suicide, and in 535, the intention was to perform euthanasia. Problems of any type were more frequent in cases of assisted suicide than in cases of euthanasia. Complications occurred in 7 percent of cases of assisted suicide, and problems with completion (a longer-than-expected time to death, failure to induce coma, or induction of coma followed by awakening of the patient) occurred in 16 percent of the cases; complications and problems with completion occurred in 3 percent and 6 percent of cases of euthanasia, respectively. The physician decided to administer a lethal medication in 21 of the cases of assisted suicide (18 percent), which thus became cases of euthanasia. The reasons for this decision included problems with completion (in 12 cases) and the inability of the patient to take all the medications (in 5). Conclusions: There may be clinical problems with the performance of euthanasia and physician-assisted suicide. In the Netherlands, physicians who intend to provide assistance with suicide sometimes end up administering a lethal medication themselves because of the patient's inability to take the medication or because of problems with the completion of physician-assisted suicide. (N Engl J Med 2000;342:551-6.) (C)2000, Massachusetts Medical Society.	Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Vrije Univ Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands; Vrije Univ Amsterdam, Dept Social Med, Amsterdam, Netherlands	Erasmus University Rotterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Groenewoud, JH (corresponding author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.							Asch DA, 1996, NEW ENGL J MED, V334, P1374, DOI 10.1056/NEJM199605233342106; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BAUME P, 1994, MED J AUSTRALIA, V161, P137, DOI 10.5694/j.1326-5377.1994.tb127345.x; BAUME P, 1994, MED J AUSTRALIA, V161, P142; BAUME P, 1994, MED J AUSTRALIA, V161, P140; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; Emanuel EJ, 1998, JAMA-J AM MED ASSOC, V280, P507, DOI 10.1001/jama.280.6.507; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; *GEN BOARD RDMA, 1996, EUTH NETH; Gevers S, 1996, BRIT MED BULL, V52, P326; *KON NED MAATSCH B, 1994, TOEP BER EUTH SGRAV; Kuhse H, 1997, MED J AUSTRALIA, V166, P191, DOI 10.5694/j.1326-5377.1997.tb140074.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; LEGEMAATE J, 1995, CAMB Q HEALTHC ETHIC, V4, P112; Matzo M L, 1997, Oncol Nurs Forum, V24, P1725; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MULLER MT, 1992, VOX HOSP, V16, P3; Onwuteaka-Philipsen B D, 1995, Arch Fam Med, V4, P951, DOI 10.1001/archfami.4.11.951; OnwuteakaPhilipsen BD, 1997, J AM GERIATR SOC, V45, P1208, DOI 10.1111/j.1532-5415.1997.tb03771.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; van der Wal G, 1992, Ned Tijdschr Geneeskd, V136, P1299; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; *WET I NED AP, 1998, MED CONTACT, V53, P1366; Woolfrey J, 1998, HASTINGS CENT REP, V28, P9, DOI 10.2307/3528645	28	123	123	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					551	556		10.1056/NEJM200002243420805	http://dx.doi.org/10.1056/NEJM200002243420805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684914	Green Published, Bronze			2022-12-28	WOS:000085422400005
J	Lavie, P; Herer, P; Hoffstein, V				Lavie, P; Herer, P; Hoffstein, V			Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study	BRITISH MEDICAL JOURNAL			English	Article							APNEA	Objective To assess whether sleep apnoea syndrome is an independent risk factor for hypertension. Design Population study Setting Sleep clinic in Toronto, Participants 2677 adults, aged 20-85 years, referred to the sleep clinic with suspected sleep apnoea syndrome. Outcome measures Medical history, demographic data, morning and evening blood pressure, and whole night polysomnography. Results Blood pressure and number of patients with hypertension increased linearly with severity of sleep apnoea, as shown by the apnoea-hypopnoea index. Multiple regression analysis of blood pressure levels of all patients not taking antihypertensives showed that apnoea was a significant predictor or both systolic and diastolic blood pressure after adjustment for age, body mass index, and sex. Multiple logistic I egression showed that each additional apnoeic event per hour of sleep increased the odds of hypertension by about 1%, whereas each 10% decrease in nocturnal oxygen saturation increased the odds by 13%. Conclusion Sleep apnoea syndrome is profoundly associated with hypertension independent of all relevant risk factors.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Sleep Lab, IL-31096 Haifa, Israel; Univ Toronto, St Michaels Hosp, Div Resp Med, Toronto, ON, Canada	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Lavie, P (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Sleep Lab, POB 9649, IL-31096 Haifa, Israel.		Lavie, Peretz/AAC-2736-2020					Fleiss L., 1981, STAT METHODS RATES P; FLETCHER EC, 1995, AM J MED, V98, P118, DOI 10.1016/S0002-9343(99)80395-7; HLA KM, 1994, ANN INTERN MED, V120, P382, DOI 10.7326/0003-4819-120-5-199403010-00005; HOLTSTEIN V, 1991, AM J MED, V91, P190; LAVIE P, 1995, SLEEP, V18, P149, DOI 10.1093/sleep/18.3.149; MARTIN CM, 1994, CIRCULATION, V90, P137; MILLMAN RP, 1991, CHEST, V99, P861, DOI 10.1378/chest.99.4.861; Silverberg DS, 1997, AM J HYPERTENS, V10, P1319, DOI 10.1016/S0895-7061(97)00322-1; Wright J, 1997, BRIT MED J, V314, P851; Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746; YOUNG T, 1996, SLEEP, V19, P202	11	646	688	1	23	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					479	482		10.1136/bmj.320.7233.479	http://dx.doi.org/10.1136/bmj.320.7233.479			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678860	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000085562200023
J	Lubbers, R; Grunsteudel, HF; Chumakov, AI; Wortmann, G				Lubbers, R; Grunsteudel, HF; Chumakov, AI; Wortmann, G			Density of phonon states in iron at high pressure	SCIENCE			English	Article							NUCLEAR RESONANT SCATTERING; X-RAY-DIFFRACTION; SYNCHROTRON-RADIATION; INNER-CORE; INELASTIC ABSORPTION; SINGLE-CRYSTAL; PHASE-DIAGRAM; TRAVEL-TIMES; EARTH-CORE; ANISOTROPY	The lattice dynamics of the hexagonal close-packed (hcp) phase of iron was studied with nuclear inelastic absorption of synchrotron radiation at pressures from 20 to 42 gigapascals. A variety of thermodynamic parameters were derived from the measured density of phonon states for hcp iron. such as Debye temperatures, Gruneisen parameter, mean sound velocities, and the Lattice contribution to entropy and specific heat. The results are of geophysical interest, because hcp iron is considered to be a major component of Earth's inner core.	Univ Gesamthsch Paderborn, Fachbereich Phys, D-33095 Paderborn, Germany; European Synchrotron Radiat Facil, F-38043 Grenoble, France	University of Paderborn; European Synchrotron Radiation Facility (ESRF)	Wortmann, G (corresponding author), Univ Gesamthsch Paderborn, Fachbereich Phys, D-33095 Paderborn, Germany.							Alfe D, 1999, NATURE, V401, P462, DOI 10.1038/46758; ALTHOFF JD, 1993, PHYS REV B, V48, P13253, DOI 10.1103/PhysRevB.48.13253; Anderson OL, 1997, SCIENCE, V278, P821, DOI 10.1126/science.278.5339.821; Brand RA, 1999, PHYS REV B, V59, pR14145, DOI 10.1103/PhysRevB.59.R14145; Chumakov A, 1998, HYPERFINE INTERACT, V113, P59, DOI 10.1023/A:1012659229533; Chumakov AI, 1996, PHYS REV B, V54, pR9596, DOI 10.1103/PhysRevB.54.R9596; CREAGER KC, 1992, NATURE, V356, P309, DOI 10.1038/356309a0; Creager KC, 1997, SCIENCE, V278, P1284, DOI 10.1126/science.278.5341.1284; FREUND AK, 1998, P SOC PHOTO-OPT INS, V3448, P1; Fultz B, 1997, PHYS REV LETT, V79, P937, DOI 10.1103/PhysRevLett.79.937; Grunsteudel HF, 1998, AUST J PHYS, V51, P453, DOI 10.1071/P97054; HASTINGS JB, 1991, PHYS REV LETT, V66, P770, DOI 10.1103/PhysRevLett.66.770; JAYARAMAN A, 1983, REV MOD PHYS, V55, P65, DOI 10.1103/RevModPhys.55.65; Jones W., 1985, THEORETICAL SOLID ST, V1, P237; Kohn VG, 1998, PHYS REV B, V58, P8437, DOI 10.1103/PhysRevB.58.8437; Mao HK, 1998, NATURE, V396, P741, DOI 10.1038/25506; Mao HK, 1999, NATURE, V399, P280, DOI 10.1038/20472; MAO HK, 1990, J GEOPHYS RES-SOLID, V95, P21737, DOI 10.1029/JB095iB13p21737; MINKIEWICZ VJ, 1967, PHYS REV, V162, P528, DOI 10.1103/PhysRev.162.528; RAMAKRISHNAN J, 1978, J GEOPHYS RES, V83, P3535, DOI 10.1029/JB083iB07p03535; Rohlsberger R, 1999, PHYSICA B, V263, P581, DOI 10.1016/S0921-4526(98)01259-9; SCHOBER HR, 1981, LANDOLTBORNSTEIN, V3, P53; SETO M, 1995, PHYS REV LETT, V74, P3828, DOI 10.1103/PhysRevLett.74.3828; Simmons G., 1971, SINGLE CRYSTAL ELAST; Singh AK, 1998, PHYS REV LETT, V80, P2157, DOI 10.1103/PhysRevLett.80.2157; SINGWI KS, 1960, PHYS REV, V120, P1093, DOI 10.1103/PhysRev.120.1093; Snigirev A, 1996, NATURE, V384, P49, DOI 10.1038/384049a0; Soderlind P, 1996, PHYS REV B, V53, P14063, DOI 10.1103/PhysRevB.53.14063; STIXRUDE L, 1995, SCIENCE, V267, P1972, DOI 10.1126/science.267.5206.1972; STURHAHN W, 1995, PHYS REV LETT, V74, P3832, DOI 10.1103/PhysRevLett.74.3832; VONBARGEN N, 1990, HIGH PRESSURE RES, V6, P113; YOO CS, 1995, SCIENCE, V270, P1473, DOI 10.1126/science.270.5241.1473	33	108	108	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1250	1253		10.1126/science.287.5456.1250	http://dx.doi.org/10.1126/science.287.5456.1250			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678829				2022-12-28	WOS:000085444700046
J	Hagan, PG; Nienaber, CA; Isselbacher, EM; Bruckman, D; Karavite, DJ; Russman, PL; Evangelista, A; Fattori, R; Suzuki, T; Oh, JK; Moore, AG; Malouf, JF; Pape, LA; Gaca, C; Sechtem, U; Lenferink, S; Deutsch, HJ; Diedrichs, H; Robles, JMY; Llovet, A; Gilon, D; Das, SK; Armstrong, WF; Deeb, GM; Eagle, KA				Hagan, PG; Nienaber, CA; Isselbacher, EM; Bruckman, D; Karavite, DJ; Russman, PL; Evangelista, A; Fattori, R; Suzuki, T; Oh, JK; Moore, AG; Malouf, JF; Pape, LA; Gaca, C; Sechtem, U; Lenferink, S; Deutsch, HJ; Diedrichs, H; Robles, JMY; Llovet, A; Gilon, D; Das, SK; Armstrong, WF; Deeb, GM; Eagle, KA			The International Registry of Acute Aortic Dissection (IRAD) - New insights into an old disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THORACIC AORTA; SURGICAL-MANAGEMENT; PERCUTANEOUS FENESTRATION; DIAGNOSIS; ANEURYSMS; CT; ECHOCARDIOGRAPHY; COMPLICATIONS; EXPERIENCE; NECROPSY	Context Acute aortic dissection is a life-threatening medical emergency associated with high rates of morbidity and mortality. Data are limited regarding the effect of recent imaging and therapeutic advances on patient care and outcomes in this setting. Objective To assess the presentation, management, and outcomes of acute aortic dissection. Design Case series with patients enrolled between January 1996 and December 1998. Data were collected at presentation and by physician review of hospital records. Setting The International Registry of Acute Aortic Dissection, consisting of 12 international referral centers. Participants A total of 464 patients (mean age, 63 years; 65.3% male), 62.3% of whom had type A dissection. Main Outcome Measures Presenting history, physical findings, management, and mortality, as assessed by history and physician review of hospital records. Results While sudden onset of severe sharp pain was the single most common presenting complaint, the clinical presentation was diverse. Classic physical findings such as aortic regurgitation and pulse deficit were noted in only 31.6% and 15.1% of patients, respectively, and initial chest radiograph and electrocardiogram were frequently not helpful (no abnormalities were noted in 12.4% and 31.3% of patients, respectively). Computed tomography was the initial imaging modality used in 61.1%, Overall in-hospital mortality was 27.4%, Mortality of patients with type A dissection managed surgically was 26%; among those not receiving surgery (typically because of advanced age and comorbidity), mortality was 58%. Mortality of patients with type B dissection treated medically was 10.7%. Surgery was performed in 20% of patients with type B dissection; mortality in this group was 31.4%. Conclusions Acute aortic dissection presents with a wide range of manifestations, and classic findings are often absent. A high clinical index of suspicion is necessary. Despite recent advances, in-hospital mortality rates remain high. Our data support the need for continued improvement in prevention, diagnosis, and management of acute aortic dissection.	Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Univ Massachusetts, Worcester, MA 01605 USA; Hosp Gen Univ Valle Hebron, Barcelona, Spain; Hosp 12 Octubre, E-28041 Madrid, Spain; Univ Hosp S Orsola, Bologna, Italy; Univ Tokyo, Tokyo, Japan; Mayo Clin, Rochester, MN USA; Univ Hamburg, Hosp Eppendorf, D-20246 Hamburg, Germany; Robert Bosch Krankenhaus, Stuttgart, Germany; Univ Cologne, Cologne, Germany; Hadassah Univ Hosp, IL-91120 Jerusalem, Israel	University of Michigan System; University of Michigan; Harvard University; Massachusetts General Hospital; University of Massachusetts System; University of Massachusetts Worcester; Hospital Universitari Vall d'Hebron; Hospital Universitario 12 de Octubre; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Tokyo; Mayo Clinic; University of Hamburg; Bosch; Robert Bosch Krankenhaus; University of Cologne; Hebrew University of Jerusalem	Eagle, KA (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	keagle@umich.edu	Fattori, Rossella/L-1017-2016	Karavite, Dean/0000-0003-0554-5715				Acierno Louis J., 1994, HIST CARDIOLOGY; *AM HEART ASS, 1998, 1998 HEART STROK STA; Armstrong WF, 1998, AM HEART J, V136, P1051, DOI 10.1016/S0002-8703(98)70162-0; BAER S, 1956, JAMA-J AM MED ASSOC, V161, P689, DOI 10.1001/jama.1956.02970080019007; BARNER HB, 1991, ANN THORAC SURG, V52, P1354, DOI 10.1016/0003-4975(91)90034-N; BAVARIA JE, 1995, ANN THORAC SURG, V60, P345, DOI 10.1016/0003-4975(95)00447-S; BICKERSTAFF LK, 1982, SURGERY, V92, P1103; BLANKENSHIP JC, 1989, J AM COLL CARDIOL, V14, P1579, DOI 10.1016/0735-1097(89)90402-6; BOGGS BR, 1987, J THORAC CARDIOV SUR, V93, P838; BUTLER J, 1990, BMJ-BRIT MED J, V300, P517, DOI 10.1136/bmj.300.6723.517; Chavan A, 1997, CIRCULATION, V96, P2124; CHIRILLO F, 1990, EUR HEART J, V11, P311, DOI 10.1093/oxfordjournals.eurheartj.a059703; CIGARROA JE, 1993, NEW ENGL J MED, V328, P35, DOI 10.1056/NEJM199301073280107; Daily P O, 1970, Ann Thorac Surg, V10, P237; Dake MD, 1999, NEW ENGL J MED, V340, P1546, DOI 10.1056/NEJM199905203402004; DEBAKEY ME, 1955, ANN SURG, V142, P586, DOI 10.1097/00000658-195510000-00005; EAGLE KA, 1989, CURR PROB CARDIOLOGY, V14, P225, DOI 10.1016/S0146-2806(89)80010-6; EAGLE KA, 1986, AM J CARDIOL, V57, P322, DOI 10.1016/0002-9149(86)90912-4; EARNEST F, 1979, MAYO CLIN PROC, V54, P43; ERBEL R, 1989, LANCET, V1, P457; FANN JI, 1995, CIRCULATION, V92, P113, DOI 10.1161/01.CIR.92.9.113; GODWIN JD, 1980, RADIOLOGY, V136, P125, DOI 10.1148/radiology.136.1.7384486; GRIEPP RB, 1975, J THORAC CARDIOV SUR, V70, P1051; HAMADA S, 1992, RADIOLOGY, V183, P155, DOI 10.1148/radiology.183.1.1549663; HIRST AE, 1958, MEDICINE, V37, P217, DOI 10.1097/00005792-195809000-00003; JAMIESON WRE, 1982, CAN J SURG, V25, P145; KHANDHERIA BK, 1993, CIRCULATION, V87, P1765, DOI 10.1161/01.CIR.87.5.1765; Kouchoukos NT, 1997, NEW ENGL J MED, V336, P1876, DOI 10.1056/NEJM199706263362606; LARSON EW, 1984, AM J CARDIOL, V53, P849, DOI 10.1016/0002-9149(84)90418-1; LEONARD JC, 1979, BRIT MED J, V2, P260, DOI 10.1136/bmj.2.6184.260; LINDSAY J, 1967, CIRCULATION, V35, P880, DOI 10.1161/01.CIR.35.5.880; NIENABER CA, 1995, CIRCULATION, V92, P1465, DOI 10.1161/01.CIR.92.6.1465; Nienaber CA, 1999, NEW ENGL J MED, V340, P1539, DOI 10.1056/NEJM199905203402003; NIENABER CA, 1992, CIRCULATION, V85, P434, DOI 10.1161/01.CIR.85.2.434; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; OGARA PT, 1995, CIRCULATION, V92, P1376, DOI 10.1161/01.CIR.92.6.1376; Pretre R, 1997, LANCET, V349, P1461, DOI 10.1016/S0140-6736(96)09372-5; ROBERTS CS, 1991, ANN SURG, V213, P356, DOI 10.1097/00000658-199104000-00011; ROBERTS WC, 1981, AM HEART J, V101, P195, DOI 10.1016/0002-8703(81)90666-9; SLATER EE, 1976, AM J MED, V60, P625, DOI 10.1016/0002-9343(76)90496-4; SPITTELL PC, 1993, MAYO CLIN PROC, V68, P642, DOI 10.1016/S0025-6196(12)60599-0; SVENSSON LG, 1990, CIRCULATION, V82, P24; SWAN HJC, 1970, NEW ENGL J MED, V283, P447, DOI 10.1056/NEJM197008272830902; WALKER PJ, 1993, J VASC SURG, V18, P1042, DOI 10.1016/0741-5214(93)90560-9; WARDEN HE, 1954, J THORAC SURG, V28, P331; WHEAT MW, 1965, J THORAC CARDIOV SUR, V50, P364, DOI 10.1016/S0022-5223(19)33192-7; WILLIAMS DM, 1990, RADIOLOGY, V174, P450, DOI 10.1148/radiology.174.2.2136956; WILSON SK, 1982, ARCH PATHOL LAB MED, V106, P175; WOLFE WG, 1977, CIRCULATION, V56, P503, DOI 10.1161/01.CIR.56.4.503; YAMADA T, 1988, RADIOLOGY, V168, P347, DOI 10.1148/radiology.168.2.3393653	50	2219	2450	5	116	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2000	283	7					897	903		10.1001/jama.283.7.897	http://dx.doi.org/10.1001/jama.283.7.897			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	281WT	10685714	Bronze			2022-12-28	WOS:000085185000028
J	Martyn, CN				Martyn, CN			Serum homocysteine and risk of coronary heart disease in UK Indian Asians	LANCET			English	Editorial Material							FOLATE		Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England	University of Southampton	Martyn, CN (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.							ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; Arnadottir M, 1996, SCAND J CLIN LAB INV, V56, P41, DOI 10.3109/00365519609088586; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BURDEN AC, 1992, DIABETIC MED, V9, P641, DOI 10.1111/j.1464-5491.1992.tb01860.x; Dudman NPB, 1999, LANCET, V354, P2072, DOI 10.1016/S0140-6736(99)03383-8; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; Ma J, 1996, CIRCULATION, V94, P2410, DOI 10.1161/01.CIR.94.10.2410; Obeid OA, 1998, LANCET, V352, P1829, DOI 10.1016/S0140-6736(05)79892-5; VANBOCKXMEER FM, 1996, CIRCULATION, V94, P3074	10	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					512	513		10.1016/S0140-6736(99)90439-7	http://dx.doi.org/10.1016/S0140-6736(99)90439-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10682996				2022-12-28	WOS:000085487400004
J	McPhillips, M; Hepper, PG; Mulhern, G				McPhillips, M; Hepper, PG; Mulhern, G			Effects of replicating primary-reflex movements on specific reading difficulties in children: a randomised, double-blind, controlled trial	LANCET			English	Article							DYSLEXIA; DISABILITIES; INFANTS	Background Children with specific reading difficulties have problems that extend beyond the range of underlying language-related deficits leg, they have difficulties with balance and mote, control). We investigated the role of persistent primary reflexes (Which are closely linked in the earliest months of life to the balance system) in disrupting the development of reading skills. Methods We assessed the efficacy of an intervention programme based on replicating the movements generated by the primary-reflex system during fetal and neonatal life. A randomised, individually matched, double-blind, placebo-controlled design was used and children (aged 8-11 years) with persistent primary reflexes and a poor standard of reading were enrolled into one of three treatment groups: experimental (children were given a specific movement sequence); placebo control (children were given non-specific movements); and control (no movements). Findings From an initial sample of 98 children, 60 children, 20 in each group were matched on age, sex, verbal intelligence quotient (IQ), reading ability, and persistent asymmetrical tonic neck reflex. For asymmetrical tonic neck-reflex levels there was a significant (group by time) interaction (p<0.001). The experimental group showed a significant decrease in the level of persistent reflex over the course of the study (mean change -1.8 [95% CI -2.4 to -1.2], p<0.001), whereas the changes in the placebo-control and control groups were not significant (-0.2 [-0.9 to 0.6] and -0.4 [-0.9 to 0.2]). Interpretation This study provides further evidence of a link between: reading difficulties and control of movement in children. In particular, our study highlights how the educational functioning of children may be linked to interference from an early neurodevelopmental system (the primary-reflex system). A new approach to the treatment of children with reading difficulties is proposed involving assessment of underlying neurological functioning, and appropriate remediation.	Queens Univ Belfast, Sch Psychol, Belfast BT7 1NN, Antrim, North Ireland	Queens University Belfast	McPhillips, M (corresponding author), Queens Univ Belfast, Sch Psychol, Belfast BT7 1NN, Antrim, North Ireland.		hepper, peter/D-1478-2009	McPhillips, Martin/0000-0003-0233-6619				BEARD R, 1993, TEACHING LIT BALANCI; BOBATH B, 1975, MOTOR DEV DIFFERENT; BOOKBINDER GE, 1976, MANUAL SALFORD SENTE; Bradley L., 1985, RHYME REASON READING; BRAITHWAITE GR, 1975, LANCHESTER SHORT STA; Capute A. J., 1981, LANGUAGE BEHAV INFAN, P157; CARTE E, 1984, J DEV BEHAV PEDIATR, V5, P189; CORNELISSEN P, 1995, VISION RES, V35, P1483, DOI 10.1016/0042-6989(95)98728-R; EDEN GF, 1994, VISION RES, V34, P1345, DOI 10.1016/0042-6989(94)90209-7; Fawcett AJ, 1996, ANN DYSLEXIA, V46, P259, DOI 10.1007/BF02648179; FAWCETT AJ, 1995, J MOTOR BEHAV, V27, P235, DOI 10.1080/00222895.1995.9941713; Frederickson N., 1995, PHONOLOGICAL ASSESSM; HASLUM MN, 1989, IRISH J PSYCHOL, V10, P622, DOI 10.1080/03033910.1989.10557776; Holt K. S., 1991, CHILD DEV DIAGNOSIS; Illingworth RS, 1987, DEV INFANT YOUNG CHI, V9th; KIBEL M, 1994, READING DEVELOPMENT AND DYSLEXIA, P105; LOVEGROVE W, 1991, VISUAL DYSLEXIA VISI, V13; Morrison D. C., 1985, NEUROBEHAVIOURAL PER; NEALE MD, 1989, NEALE ANAL READING A; NICOLSON RI, 1990, COGNITION, V35, P159, DOI 10.1016/0010-0277(90)90013-A; Olson R., 1990, READING ITS DEV COMP, P261; PAINE R S, 1964, Dev Med Child Neurol, V6, P345; Prechtl H., 1984, CONTINUITY NEURAL FU, P1; RILEY J, 1996, TEACHING READING; Rust J, 1993, WECHSLER OBJECTIVE R; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; SEIDEL UP, 1975, DEV MED CHILD NEUROL, V17, P563; SHAYWITZ SE, 1996, SCI AM, V275, P78; Snowling M., 2005, DYSLEXIA COGNITIVE D, V17, P4; STANOVICH KE, 1988, J LEARN DISABIL-US, V21, P590, DOI 10.1177/002221948802101003; Stein J, 1997, TRENDS NEUROSCI, V20, P147, DOI 10.1016/S0166-2236(96)01005-3; Stein JF, 1995, IRISH J PSYCHOL, V16, P220, DOI 10.1080/03033910.1995.10558058; TALLAL P, 1980, BRAIN LANG, V9, P182, DOI 10.1016/0093-934X(80)90139-X; THELEN E, 1983, J MOTOR BEHAV, V15, P353; THELEN E, 1979, ANIM BEHAV, V27, P699, DOI 10.1016/0003-3472(79)90006-X; YOUNG D, 1989, NONREADING INTELLIGE	36	66	67	0	25	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					537	541		10.1016/S0140-6736(99)02179-0	http://dx.doi.org/10.1016/S0140-6736(99)02179-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	287CN	10683004				2022-12-28	WOS:000085487400012
J	Laio, A; Bernard, S; Chiarotti, GL; Scandolo, S; Tosatti, E				Laio, A; Bernard, S; Chiarotti, GL; Scandolo, S; Tosatti, E			Physics of iron at Earth's core conditions	SCIENCE			English	Article							INNER-CORE; HIGH-PRESSURES; PHASE-TRANSITIONS; MELTING CURVE; TEMPERATURES; ENERGY; APPROXIMATION; OSCILLATIONS; ELASTICITY; ANISOTROPY	The bulk properties of iron at the pressure and temperature conditions of Earth's core were determined by a method that combines first-principles and classical molecular dynamic simulations. The theory indicates that (i) the iron melting temperature at inner-core boundary (ICB) pressure (330 gigapascals) is 5400 (+/-400) kelvin; (ii) Liquid iron at ICE conditions is about 6% denser than Earth's outer core; and (iii) the shear modulus of solid iron close to its melting tine is 140 gigapascals, consistent with the seismic value for the inner core. These results reconcile melting temperature estimates based on sound velocity shock wave data with those based on diamond anvil cell experiments.	Int Sch Adv Studies, I-34014 Trieste, Italy; Ist Nazl Fis Mat, I-34014 Trieste, Italy; CEA, DRIF, F-91680 Bruyeres Le Chatel, France; Int Ctr Theoret Phys, I-34014 Trieste, Italy	International School for Advanced Studies (SISSA); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua; CEA; Abdus Salam International Centre for Theoretical Physics (ICTP)	Chiarotti, GL (corresponding author), Int Sch Adv Studies, Via Beirut 2-4, I-34014 Trieste, Italy.		Scandolo, Sandro/AAC-9081-2019; Chiarotti, Guido/A-9909-2012; Laio, Alessandro/K-2117-2012	Scandolo, Sandro/0000-0003-3826-4813; Laio, Alessandro/0000-0001-9164-7907				Alfe D, 1999, NATURE, V401, P462, DOI 10.1038/46758; Allen M.P., 1991, COMPUTER SIMULATION; Anderson OL, 1997, J GEOPHYS RES-SOL EA, V102, P22659, DOI 10.1029/97JB01641; BASKES MI, 1992, PHYS REV B, V46, P2727, DOI 10.1103/PhysRevB.46.2727; BASSETT WA, 1994, SCIENCE, V266, P1662, DOI 10.1126/science.266.5191.1662; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; Belonoshko AB, 1997, SCIENCE, V275, P955, DOI 10.1126/science.275.5302.955; Belonoshko AB, 1997, PHYS EARTH PLANET IN, V102, P171, DOI 10.1016/S0031-9201(97)00014-9; BOEHLER R, 1993, NATURE, V363, P534, DOI 10.1038/363534a0; Boehler R, 1996, PHILOS T R SOC A, V354, P1265, DOI 10.1098/rsta.1996.0048; BONESS DA, 1990, J GEOPHYS RES-SOLID, V95, P21721, DOI 10.1029/JB095iB13p21721; Brandes E.A, 1983, SMITHELLS LIGHT META; BROWN JM, 1986, J GEOPHYS RES-SOLID, V91, P7485, DOI 10.1029/JB091iB07p07485; Cannon J. F., 1974, Journal of Physical and Chemical Reference Data, V3, P781, DOI 10.1063/1.3253148; de Wijs GA, 1998, NATURE, V392, P805, DOI 10.1038/33905; de Wijs GA, 1998, PHYS REV B, V57, P8223, DOI 10.1103/PhysRevB.57.8223; DZIEWONSKI AM, 1971, NATURE, V234, P465, DOI 10.1038/234465a0; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; JEANLOZ R, 1990, ANNU REV EARTH PL SC, V18, P357; JEPHCOAT A, 1987, NATURE, V325, P332, DOI 10.1038/325332a0; LIDE DR, 1993, CRC HDB CHEM PHYSICS; Mao HK, 1998, NATURE, V396, P741, DOI 10.1038/25506; Mao HK, 1999, NATURE, V399, P280, DOI 10.1038/20472; MAO HK, 1990, J GEOPHYS RES-SOLID, V95, P21737, DOI 10.1029/JB095iB13p21737; Matsui M, 1997, PHYS EARTH PLANET IN, V103, P55, DOI 10.1016/S0031-9201(97)00020-4; McQueen R.G., 1970, HIGH VELOCITY IMPACT, P293; MERMIN ND, 1965, PHYS REV, V137, P1441, DOI 10.1103/PhysRev.137.A1441; NGUYEN JH, 1999, INT C HIGH PRESS SCI; PARRINELLO M, 1982, J CHEM PHYS, V76, P2662, DOI 10.1063/1.443248; PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822; POIRIER JP, 1993, GEOPHYS J INT, V115, P147, DOI 10.1111/j.1365-246X.1993.tb05594.x; POIRIER JP, 1994, PHYS EARTH PLANET IN, V85, P319, DOI 10.1016/0031-9201(94)90120-1; SAXENA SK, 1994, SCIENCE, V264, P405, DOI 10.1126/science.264.5157.405; Shen GY, 1998, GEOPHYS RES LETT, V25, P373, DOI 10.1029/97GL03776; Soderlind P, 1996, PHYS REV B, V53, P14063, DOI 10.1103/PhysRevB.53.14063; STACEY FD, 1992, PHYSICS EARTH; Steinle-Neumann G, 1999, PHYS REV B, V60, P791, DOI 10.1103/PhysRevB.60.791; Stixrude L, 1997, J GEOPHYS RES-SOL EA, V102, P24729, DOI 10.1029/97JB02125; STIXRUDE L, 1995, SCIENCE, V267, P1972, DOI 10.1126/science.267.5206.1972; TALLON JL, 1979, PHILOS MAG A, V39, P151, DOI 10.1080/01418617908236889; Tomagnini O, 1996, PHYS REV LETT, V76, P1118, DOI 10.1103/PhysRevLett.76.1118; TROMP J, 1993, NATURE, V366, P678, DOI 10.1038/366678a0; WILLIAMS Q, 1987, SCIENCE, V236, P181, DOI 10.1126/science.236.4798.181; YOO CS, 1993, PHYS REV LETT, V70, P3931, DOI 10.1103/PhysRevLett.70.3931	44	273	281	0	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1027	1030		10.1126/science.287.5455.1027	http://dx.doi.org/10.1126/science.287.5455.1027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669412				2022-12-28	WOS:000085245400044
J	Kyne, L; Warny, M; Qamar, A; Kelly, CP				Kyne, L; Warny, M; Qamar, A; Kelly, CP			Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITALIZED-PATIENTS; RISK-FACTORS; DIARRHEA; INFECTION; COLITIS; COLONIZATION; ACQUISITION; COHORT; EPIDEMIOLOGY; PURIFICATION	Background: Clostridium difficile infection can result in asymptomatic carriage, mild diarrhea, or fulminant pseudomembranous colitis. We studied whether antibody responses to C. difficile toxins affect the risks of colonization, diarrhea, and asymptomatic carriage. Methods: We prospectively studied C. difficile infections in hospitalized patients who were receiving antibiotics. Serial stool samples were tested for C. difficile colonization by cytotoxin assay and culture. Serum antibody (IgA, IgG, and IgM) levels and fecal antibody (IgA and IgG) levels against C. difficile toxin A, toxin B, and nontoxin antigens were measured by an enzyme-linked immunosorbent assay (ELISA). Results: Of 271 patients, 37 (14 percent) were colonized with C. difficile at the time of admission, 18 of whom were asymptomatic carriers. An additional 47 patients (17 percent) became infected in the hospital, 19 of whom remained asymptomatic. The base-line antibody levels were similar in the patients who later became colonized and those who did not. After colonization, those who became asymptomatic carriers had significantly greater increases in serum levels of IgG antibody against toxin A than did the patients in whom C. difficile diarrhea developed (P<0.001). The adjusted odds ratio for diarrhea was 48.0 (95 percent confidence interval, 3.4 to 678) among patients with colonization who had a serum level of IgG antibody against toxin A of 3.00 ELISA units or less, as compared with patients with colonization who had a level of more than 3.00 ELISA units. Conclusions: We find no evidence of immune protection against colonization by C. difficile. However, after colonization there is an association between a systemic anamnestic response to toxin A, as evidenced by increased serum levels of IgG antibody against toxin A, and asymptomatic carriage of C. difficile. (N Engl J Med 2000;342:390-7.) (C)2000, Massachusetts Medical Society.	Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kelly, CP (corresponding author), Beth Israel Deaconess Med Ctr, Div Gastroenterol, Dana 601,330 Brookline Ave, Boston, MA 02215 USA.				NCRR NIH HHS [RR-01032] Funding Source: Medline; NIA NIH HHS [AG16956, AG08812] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG008812, R03AG016956, P30AG008812] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BACON AE, 1994, DIAGN MICR INFEC DIS, V18, P205, DOI 10.1016/0732-8893(94)90021-3; Bliss DZ, 1998, ANN INTERN MED, V129, P1012, DOI 10.7326/0003-4819-129-12-199812150-00004; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cheng SH, 1997, CLIN INFECT DIS, V25, P157, DOI 10.1086/516891; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; GEORGE WL, 1979, J CLIN MICROBIOL, V9, P214; GERDING DN, 1995, INFECT CONT HOSP EP, V16, P459; Guerrant R. L., 1990, REV INFECT DIS, V12, P41; HANFF PA, 1993, CLIN INFECT DIS, V16, pS245, DOI 10.1093/clinids/16.Supplement_4.S245; HOHMANN A, 1983, J IMMUNOL METHODS, V64, P199, DOI 10.1016/0022-1759(83)90398-8; HORN SD, 1983, MED CARE, V21, P14, DOI 10.1097/00005650-198301000-00002; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; JOHNSON S, 1992, J INFECT DIS, V166, P1287, DOI 10.1093/infdis/166.6.1287; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Kelly CP, 1996, ANTIMICROB AGENTS CH, V40, P373, DOI 10.1128/AAC.40.2.373; Kelly CP, 1996, EUR J GASTROEN HEPAT, V8, P1048, DOI 10.1097/00042737-199611000-00004; KELLY CP, 1992, GASTROENTEROLOGY, V102, P35, DOI 10.1016/0016-5085(92)91781-X; Kent KC, 1998, ANN SURG, V227, P296, DOI 10.1097/00000658-199802000-00021; Kyne L, 1999, AGE AGEING, V28, P107, DOI 10.1093/ageing/28.2.107; Kyne L, 1998, BIODRUGS, V10, P173, DOI 10.2165/00063030-199810030-00001; Kyne L, 1998, AGE AGEING, V27, P339, DOI 10.1093/ageing/27.3.339; LEUNG DYM, 1991, J PEDIATR-US, V118, P633, DOI 10.1016/S0022-3476(05)83393-1; MCFARLAND LV, 1991, INFECT IMMUN, V59, P2456, DOI 10.1128/IAI.59.7.2456-2462.1991; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MCFARLAND LV, 1987, J CLIN MICROBIOL, V25, P2241, DOI 10.1128/JCM.25.11.2241-2242.1987; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; MCFARLAND LV, 1995, AM J INFECT CONTROL, V23, P295, DOI 10.1016/0196-6553(95)90060-8; MULLIGAN ME, 1993, CLIN INFECT DIS, V16, pS239, DOI 10.1093/clinids/16.Supplement_4.S239; Pothoulakis C, 1996, EUR J GASTROEN HEPAT, V8, P1041, DOI 10.1097/00042737-199611000-00003; RIEGLER M, 1995, J CLIN INVEST, V95, P2004, DOI 10.1172/JCI117885; RUBIN MS, 1995, DIS COLON RECTUM, V38, P350, DOI 10.1007/BF02054220; Salcedo J, 1997, GUT, V41, P366, DOI 10.1136/gut.41.3.366; SAMORE MH, 1994, CLIN INFECT DIS, V18, P181, DOI 10.1093/clinids/18.2.181; Shim JK, 1998, LANCET, V351, P633, DOI 10.1016/S0140-6736(97)08062-8; Starr JM, 1997, LANCET, V349, P426, DOI 10.1016/S0140-6736(97)80053-0; SULLIVAN NM, 1982, INFECT IMMUN, V35, P1032, DOI 10.1128/IAI.35.3.1032-1040.1982; VISCIDI R, 1983, J INFECT DIS, V148, P93, DOI 10.1093/infdis/148.1.93; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; WARNY M, 1994, INFECT IMMUN, V62, P384, DOI 10.1128/IAI.62.2.384-389.1994	40	694	747	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					390	397		10.1056/NEJM200002103420604	http://dx.doi.org/10.1056/NEJM200002103420604			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666429				2022-12-28	WOS:000085205200004
J	Bello, YM; Phillips, TJ				Bello, YM; Phillips, TJ			Recent advances in wound healing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GROWTH FACTOR-BB; PRESSURE ULCERS; SKIN		Boston Univ, Sch Med, Boston, MA 02118 USA	Boston University	Phillips, TJ (corresponding author), 609 Albany St, Boston, MA 02118 USA.	skin@bu.edu		Phillips, Tania/0000-0003-2744-4931				Ashcroft GS, 1997, NAT MED, V3, P1209, DOI 10.1038/nm1197-1209; Association A.D., 1999, DIABETES CARE, V22, P1354, DOI DOI 10.2337/DIACARE.22.8.1354; Bello YM, 1999, WOUNDS, V11, P2; BERGSTROM N, 1994, AHCPR PUBLICATION; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; CULLUM N, 1999, COMPRESSION BANDAGES; DARKE SG, 1992, EUR J VASCULAR SURG, V6, P4, DOI 10.1016/S0950-821X(05)80086-6; Eaglstein WH, 1997, SURG CLIN N AM, V77, P689, DOI 10.1016/S0039-6109(05)70575-2; Falanga V, 1999, WOUND REPAIR REGEN, V7, P208, DOI 10.1046/j.1524-475X.1999.00208.x; Falanga V, 1998, ARCH DERMATOL, V134, P293, DOI 10.1001/archderm.134.3.293; Kanj LF, 1998, J AM ACAD DERMATOL, V38, P517, DOI 10.1016/S0190-9622(98)70113-6; LAZARUS GS, 1994, ARCH DERMATOL, V130, P489, DOI 10.1001/archderm.130.4.489; MASUDA EM, 1994, J VASC SURG, V19, P391, DOI 10.1016/S0741-5214(94)70066-4; MUSTOE TA, 1994, ARCH SURG-CHICAGO, V129, P213; OUAHES N, 1995, CURR PROBL DERMATOL, V7, P109; OVINGTON LG, 1999, OSTOMY WOUND MAN S1A, V45, P94; Pham HT, 1999, WOUNDS, V11, P79; Phillips TJ, 1998, ARCH DERMATOL, V134, P344, DOI 10.1001/archderm.134.3.344; Rees RS, 1999, WOUND REPAIR REGEN, V7, P141, DOI 10.1046/j.1524-475X.1999.00141.x; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Steed DL, 1996, J AM COLL SURGEONS, V183, P61; Whiteley MS, 1998, ANN ROY COLL SURG, V80, P104; Wieman TJ, 1998, DIABETES CARE, V21, P822, DOI 10.2337/diacare.21.5.822	23	84	90	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					716	718		10.1001/jama.283.6.716	http://dx.doi.org/10.1001/jama.283.6.716			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280XL	10683040	Green Submitted			2022-12-28	WOS:000085129000001
J	Fransz, PF; Armstrong, S; de Jong, JH; Parnell, LD; van Drunen, C; Dean, C; Zabel, P; Bisseling, T; Jones, GH				Fransz, PF; Armstrong, S; de Jong, JH; Parnell, LD; van Drunen, C; Dean, C; Zabel, P; Bisseling, T; Jones, GH			Integrated cytogenetic map of chromosome arm 4S of A-thaliana: Structural organization of heterochromatic knob and centromere region	CELL			English	Article							RECOMBINANT INBRED LINES; ARABIDOPSIS-THALIANA; REPETITIVE DNA; SEQUENCES; GENOME; RETROELEMENT; LIBRARY; MEIOSIS; MARKERS; ATHILA	We have constructed an integrated cytogenetic map of chromosome arm 4S of Arabidopsis thaliana. The map shows the detailed positions of various multicopy and unique sequences relative to euchromatin and heterochromatin segments. A quantitative analysis of the map positions at subsequent meiotic stages revealed a striking pattern of spatial and temporal variation in chromatin condensation for euchromatin and heterochromatin. For example, the centromere region consists of three domains with distinguishable structural, molecular, and functional properties. We also characterized a conspicuous heterochromatic knob of approximately 700 kb that accommodates a tandem repeat and several dispersed pericentromere-specific repeats. Moreover, our data provide evidence for an inversion event that relocated pericentromeric sequences to an interstitial position, resulting in the heterochromatic knob.	Univ Birmingham, Sch Biol Sci, Birmingham B15 2TT, W Midlands, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Amsterdam, EC Slater Inst Biochem Res, NL-1018 TV Amsterdam, Netherlands; John Innes Ctr Plant Sci Res, Dept Mol Genet, Norwich NR4 7UH, Norfolk, England	University of Birmingham; Cold Spring Harbor Laboratory; University of Amsterdam; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Fransz, PF (corresponding author), Inst Plant Genet & Crop Plant Res IPK, Corrensstr 3, D-06466 Gatersleben, Germany.	fransz@ipk-gatersleben.de	Bisseling, Ton/A-2421-2013	van Drunen, Cornelis M/0000-0001-5503-066X				Ananiev EV, 1998, GENETICS, V149, P2025; Brandes A, 1997, CHROMOSOME RES, V5, P238, DOI 10.1023/A:1018415502795; CAMPELL BR, 1992, GENE, V112, P225, DOI 10.1016/0378-1119(92)90380-8; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; Copenhaver GP, 1998, P NATL ACAD SCI USA, V95, P247, DOI 10.1073/pnas.95.1.247; Copenhaver GP, 1996, PLANT J, V9, P259, DOI 10.1046/j.1365-313X.1996.09020259.x; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; Dernburg AF, 1996, CELL, V86, P135, DOI 10.1016/S0092-8674(00)80084-7; Fransz P, 1998, PLANT J, V13, P867, DOI 10.1046/j.1365-313X.1998.00086.x; Fransz PF, 1996, PLANT J, V9, P421, DOI 10.1046/j.1365-313X.1996.09030421.x; Fuchs J, 1996, CHROMOSOMA, V104, P315, DOI 10.1007/s004120050121; Gasser SM, 1998, CELL MOL LIFE SCI, V54, P1, DOI 10.1007/s000180050120; GOLDSTEIN P, 1986, J CELL SCI, V82, P119; Hardtke CS, 1996, PLANT MOL BIOL, V32, P915, DOI 10.1007/BF00020488; Henikoff S, 1997, TRENDS GENET, V13, P293, DOI 10.1016/S0168-9525(97)01219-5; Heslop-Harrison JS, 1999, PLANT CELL, V11, P31, DOI 10.1105/tpc.11.1.31; HESLOPHARRISON JS, 1990, HEREDITY, V65, P385, DOI 10.1038/hdy.1990.108; Jackson SA, 1998, GENOME, V41, P566, DOI 10.1139/gen-41-4-566; Karpen GH, 1996, SCIENCE, V273, P118, DOI 10.1126/science.273.5271.118; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Kubo H, 1999, PLANT CELL, V11, P1217, DOI 10.1105/tpc.11.7.1217; LEUTWILER LS, 1984, MOL GEN GENET, V194, P15, DOI 10.1007/BF00383491; LIMADEFARIA A, 1983, MOL EVOLUTION ORG CH; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Liu YG, 1996, PLANT J, V10, P733, DOI 10.1046/j.1365-313X.1996.10040733.x; LOIDL J, 1991, CHROMOSOMA, V100, P221, DOI 10.1007/BF00344155; MALUSZYNSKA J, 1991, PLANT J, V1, P159, DOI 10.1111/j.1365-313X.1991.00159.x; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; McClintock B, 1929, SCIENCE, V69, P629, DOI 10.1126/science.69.1798.629; McCombie WR, 2000, CELL, V100, P377, DOI 10.1016/S0092-8674(00)80673-X; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; NEUFFER MG, 1997, MUTANTS MAIZE, P32; Pelissier T, 1995, PLANT MOL BIOL, V29, P441, DOI 10.1007/BF00020976; Pelissier T, 1996, GENETICA, V97, P141, DOI 10.1007/BF00054621; Ross KJ, 1996, CHROMOSOME RES, V4, P507, DOI 10.1007/BF02261778; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; SCHMIDT R, 1995, SCIENCE, V270, P480, DOI 10.1126/science.270.5235.480; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; Thompson HL, 1996, NUCLEIC ACIDS RES, V24, P3017, DOI 10.1093/nar/24.15.3017; VANBLOKLAND R, 1994, PLANT J, V6, P861, DOI 10.1046/j.1365-313X.1994.6060861.x; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4	46	250	276	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					367	376		10.1016/S0092-8674(00)80672-8	http://dx.doi.org/10.1016/S0092-8674(00)80672-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676818	Bronze			2022-12-28	WOS:000085204400010
J	Smith, MA; Brandt, J; Shadmehr, R				Smith, MA; Brandt, J; Shadmehr, R			Motor disorder in Huntington's disease begins as a dysfunction in error feedback control	NATURE			English	Article							SOMATOSENSORY EVOKED-POTENTIALS; STRIATAL GLUCOSE CONSUMPTION; BASAL GANGLIA VOLUME; GENE; CARRIERS; MEMORY; DYNAMICS; MODEL; RISK	A steady progression of motor dysfunction takes place in Huntington's disease(1) (HD), The origin of this disturbance with relation to the motor control process is not understood. Here we studied reaching movements in asymptomatic HD gene-carriers (AGCs) and subjects with manifest HD. We found that movement jerkiness, which characterizes the smoothness and efficiency of motion, was a sensitive indicator of presymptomatic HD progression. A large fraction of AGCs displayed elevated jerk even when more than seven years remained until predicted disease onset. Movement termination was disturbed much more than initiation and was highly variable from trial to trial. Analysis of this variability revealed that the sensitivity of end-movement jerk to subtle, self-generated early-movement errors was greater in HD subjects than in controls. Additionally, we found that HD corrective responses to externally-generated force pulses were greatly disturbed, indicating that HD subjects display aberrant responses to both external and self-generated errors. Because feedback corrections are driven by error and are delayed such that they predominantly affect movement termination, these findings suggest that a dysfunction in error correction characterizes the motor control deficit in early HD. This dysfunction may be observed years before clinical disease onset and grows worse as the disease progresses.	Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Smith, MA (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA.			Brandt, Jason/0000-0001-7381-6244; smith, maurice/0000-0003-4214-1277	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037422] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM007057] Funding Source: Medline; NINDS NIH HHS [R01 NS037422, R01 NS037422-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATKESON CG, 1985, J NEUROSCI, V5, P2318; Aylward EH, 1997, NEUROLOGY, V48, P394, DOI 10.1212/WNL.48.2.394; Aylward EH, 1996, ARCH NEUROL-CHICAGO, V53, P1293, DOI 10.1001/archneur.1996.00550120105023; Bhushan N, 1999, BIOL CYBERN, V81, P39, DOI 10.1007/s004220050543; BLACKMORE L, 1995, J MED GENET, V32, P358, DOI 10.1136/jmg.32.5.358; BRANDT J, 1984, J CLIN NEUROPSYCHOL, V6, P401, DOI 10.1080/01688638408401231; CORDO PJ, 1990, J NEUROPHYSIOL, V63, P161, DOI 10.1152/jn.1990.63.1.161; deBoo GM, 1997, ARCH NEUROL-CHICAGO, V54, P1353, DOI 10.1001/archneur.1997.00550230030012; FLASH T, 1985, J NEUROSCI, V5, P1688, DOI 10.1523/jneurosci.05-07-01688.1985; FOLSTEIN SE, 1989, HUNTIGNTONS DIS DISO; FOROUD T, 1995, ANN NEUROL, V37, P657, DOI 10.1002/ana.410370516; Gabrieli JDE, 1997, NEUROPSYCHOLOGY, V11, P272, DOI 10.1037/0894-4105.11.2.272; Hogan N., 1990, MULTIPLE MUSCLE SYST, P149, DOI [10.1007/978-1-4613-9030-5_9, DOI 10.1007/978-1-4613-9030-5_9]; KUWERT T, 1993, MOVEMENT DISORD, V8, P98, DOI 10.1002/mds.870080118; KUWERT T, 1993, J NEUROL, V241, P31, DOI 10.1007/BF00870669; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAZZIOTTA JC, 1987, NEW ENGL J MED, V316, P357, DOI 10.1056/NEJM198702123160701; MEYER BU, 1992, ELECTROEN CLIN NEURO, V85, P197, DOI 10.1016/0168-5597(92)90133-V; MIALL RC, 1986, BEHAV BRAIN RES, V20, P185, DOI 10.1016/0166-4328(86)90003-3; Miall RC, 1996, NEURAL NETWORKS, V9, P1265, DOI 10.1016/S0893-6080(96)00035-4; NOTH J, 1985, BRAIN, V108, P65, DOI 10.1093/brain/108.1.65; ROTHLIND JC, 1993, ARCH NEUROL-CHICAGO, V50, P799, DOI 10.1001/archneur.1993.00540080010005; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; Shadmehr R, 1997, J NEUROSCI, V17, P409, DOI 10.1523/JNEUROSCI.17-01-00409.1997; SHIDARA M, 1993, NATURE, V365, P50, DOI 10.1038/365050a0; Siemers E, 1996, ARCH NEUROL-CHICAGO, V53, P487, DOI 10.1001/archneur.1996.00550060029011; TOPPER R, 1993, BRAIN, V116, P87, DOI 10.1093/brain/116.1.87; WOLPERT DM, 1995, EXP BRAIN RES, V103, P460	29	262	262	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					544	549		10.1038/35000576	http://dx.doi.org/10.1038/35000576			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676962	Green Published, Green Accepted			2022-12-28	WOS:000085227300050
J	Schrag, D; Kuntz, KM; Garber, JE; Weeks, JC				Schrag, D; Kuntz, KM; Garber, JE; Weeks, JC			Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Conference of the Society-for-Medical-Decision-Making	OCT 24-28, 1998	BOSTON, MASSACHUSETTS	Soc Med Decis Making			CORONARY HEART-DISEASE; 20-YEAR FOLLOW-UP; OVARIAN-CANCER; DECISION-ANALYSIS; PROPHYLACTIC MASTECTOMY; COST-EFFECTIVENESS; RISK FACTOR; MORTALITY; SURVIVAL; CARCINOMA	Context Women with BRCA1- or BRCA2-associated breast cancer are at increased risk for contralateral breast cancer and ovarian cancer and therefore may consider secondary cancer prevention strategies, such as prophylactic surgery and tamoxifen therapy. It is not proven to what extent these strategies reduce risk of second cancers in such patients. Objective To examine the effect of tamoxifen therapy, bilateral prophylactic oophorectomy (PO), prophylactic contralateral mastectomy (PCM), and combinations of these strategies on life expectancy for women with unilateral breast cancer and a BRCA1 or BRCA2 gene mutation. Design and Setting Decision analysis using a Markov model. Probabilities for developing contralateral breast cancer and ovarian cancer, dying from these cancers, dying from primary breast cancer, and the reduction in cancer incidence and mortality due to prophylactic surgeries and/or tamoxifen were estimated from published studies. Participants Hypothetical breast cancer patients with BRCA1 or BRCA2 mutations facing decisions about secondary cancer prevention strategies. Interventions Seven strategies, including 5 years of tamoxifen use, PO, PCM, and combinations of these strategies, compared with careful surveillance. Main Outcome Measures Total and incremental life expectancy (LE) with each intervention strategy. Results Depending on the assumed penetrance of the BRCA mutation, compared with surveillance alone, 30-year-old early-stage breast cancer patients with BRCA mutations gain in LE 0.4 to 1.3 years from tamoxifen therapy, 0.2 to 1.8 years from PO, and 0.6 to 2.1 years from PCM, The magnitude of these gains is least for women with low-penetrance mutations (assumed contralateral breast cancer risk of 24% and ovarian cancer risk of 6%) and greatest for those with high-penetrance mutations (assumed contralateral breast cancer risk of 65% and ovarian cancer risk of 40%.) Older age and poorer prognosis from primary breast cancer further attenuate these gains. Conclusions Interventions to prevent second cancers, particularly PCM, may offer substantial LE gain for young women with BRCA-associated early-stage breast cancer. Estimates of LE gain may help women and their physicians consider the uncertainties, risks, and advantages of these interventions and lead to more informed choices about cancer prevention strategies.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health	Schrag, D (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, 1275 York Ave, New York, NY 10021 USA.		Kleibl, Zdenek/A-2009-2008	Kleibl, Zdenek/0000-0003-2050-9667				Abe O, 1998, LANCET, V352, P930; Bandera CA, 1998, OBSTET GYNECOL, V92, P596, DOI 10.1016/S0029-7844(98)00223-3; BARTLETT K, 1993, LANCET, V341, P1293; BROET P, 1995, J CLIN ONCOL, V13, P1578, DOI 10.1200/JCO.1995.13.7.1578; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; Clarke M, 1996, LANCET, V348, P1189; Clarke M, 1998, LANCET, V351, P1451; Colditz G A, 1997, Oncology (Williston Park), V11, P1491; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; Cooper GS, 1998, ANN EPIDEMIOL, V8, P229, DOI 10.1016/S1047-2797(97)00207-X; DePriest PD, 1997, GYNECOL ONCOL, V65, P408, DOI 10.1006/gyno.1997.4705; DISAIA PJ, 1995, CANCER, V76, P2075, DOI 10.1002/1097-0142(19951115)76:10+<2075::AID-CNCR2820761328>3.0.CO;2-2; EASTON DF, 1995, AM J HUM GENET, V56, P265; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; Fodor FH, 1998, AM J HUM GENET, V63, P45, DOI 10.1086/301903; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Grann VR, 1998, J CLIN ONCOL, V16, P979, DOI 10.1200/JCO.1998.16.3.979; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; HEALEY EA, 1993, J CLIN ONCOL, V11, P1545, DOI 10.1200/JCO.1993.11.8.1545; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; Johannsson OT, 1998, J CLIN ONCOL, V16, P397, DOI 10.1200/JCO.1998.16.2.397; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Khovidhunkit W, 1999, ANN INTERN MED, V130, P431, DOI 10.7326/0003-4819-130-5-199903020-00015; Lakhani SR, 1997, LANCET, V349, P1505; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Landis SH, 1998, CA-CANCER J CLIN, V48, P329; Landis SH, 1998, CA-CANCER J CLIN, V48, P192; Lee JS, 1999, JNCI-J NATL CANCER I, V91, P259, DOI 10.1093/jnci/91.3.259; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; LINDFORS KK, 1995, JAMA-J AM MED ASSOC, V274, P881, DOI 10.1001/jama.274.11.881; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; RIES LAG, 1993, CANCER-AM CANCER SOC, V71, P524; Rivkin SE, 1996, J CLIN ONCOL, V14, P46, DOI 10.1200/JCO.1996.14.1.46; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Robson M, 1998, J CLIN ONCOL, V16, P1642, DOI 10.1200/JCO.1998.16.5.1642; ROSEN PP, 1991, J CLIN ONCOL, V9, P1650, DOI 10.1200/JCO.1991.9.9.1650; ROSEN PP, 1989, SURGERY, V106, P904; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; Schairer C, 1997, INT J CANCER, V70, P150, DOI 10.1002/(SICI)1097-0215(19970117)70:2<150::AID-IJC2>3.0.CO;2-W; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; Smart CR, 1997, CA-CANCER J CLIN, V47, P134, DOI 10.3322/canjclin.47.3.134; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Struewing J P, 1995, J Natl Cancer Inst Monogr, P33; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tengs TO, 1998, MED DECIS MAKING, V18, P365, DOI 10.1177/0272989X9801800402; Thorlacius S, 1998, LANCET, V352, P1337, DOI 10.1016/S0140-6736(98)03300-5; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; *US SURV EP END RE, 1996, SEER PUBL US DAT 197; vanderSchouw YT, 1996, LANCET, V347, P714, DOI 10.1016/S0140-6736(96)90075-6; VENTURA SJ, 1998, NATL VITAL STAT REPO, V47, P1; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7; Whittemore AS, 1997, AM J HUM GENET, V60, P496; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606	57	158	160	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					617	624		10.1001/jama.283.5.617	http://dx.doi.org/10.1001/jama.283.5.617			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665701	Bronze			2022-12-28	WOS:000084956500027
J	Li, XP; Bjorkman, O; Shih, C; Grossman, AR; Rosenquist, M; Jansson, S; Niyogi, KK				Li, XP; Bjorkman, O; Shih, C; Grossman, AR; Rosenquist, M; Jansson, S; Niyogi, KK			A pigment-binding protein essential for regulation of photosynthetic light harvesting	NATURE			English	Article							PHOTOSYSTEM-II; ENERGY-DISSIPATION; XANTHOPHYLL CYCLE; CHLOROPHYLL FLUORESCENCE; VIOLAXANTHIN DEEPOXIDATION; CHLORINA MUTANTS; ANTENNA PROTEINS; HIGHER-PLANTS; GREEN PLANTS; S PROTEIN	Photosynthetic light harvesting in plants is regulated in response to changes in incident light intensity. Absorption of light that exceeds a plant's capacity for fixation of CO2 results in thermal dissipation of excitation energy in the pigment antenna of photosystem II by a poorly understood mechanism. This regulatory process, termed nonphotochemical quenching, maintains the balance between dissipation and utilization of light energy to minimize generation of oxidizing molecules, thereby protecting the plant against photo-oxidative damage. To identify specific proteins that are involved in nonphotochemical quenching, we have isolated mutants of Arabidopsis thaliana that cannot dissipate excess absorbed light energy. Here we show that the gene encoding PsbS, an intrinsic chlorophyll-binding protein of photosystem II, is necessary for nonphotochemical quenching but not for efficient light harvesting and photosynthesis, These results indicate that PsbS may be the site for nonphotochemical quenching, a finding that has implications for the functional evolution of pigment-binding proteins.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA; Umea Univ, Dept Plant Physiol, Umea Plant Sci Ctr, S-90187 Umea, Sweden	University of California System; University of California Berkeley; Carnegie Institution for Science; Umea University	Niyogi, KK (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	niyogi@nature.berkeley.edu	Jansson, Stefan/A-1119-2009	Jansson, Stefan/0000-0002-7906-6891; Rosenquist, Magnus/0000-0001-7795-9728				BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BELL WR, 1994, SEMIN HEMATOL, V31, P19; BILGER W, 1994, PLANTA, V193, P238, DOI 10.1007/BF00192536; Bossmann B, 1997, PHOTOSYNTH RES, V52, P127, DOI 10.1023/A:1005823711838; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; CROFTS AR, 1994, FEBS LETT, V352, P265, DOI 10.1016/0014-5793(94)00976-7; DAU H, 1994, J PHOTOCH PHOTOBIO B, V26, P3, DOI 10.1016/1011-1344(94)85032-1; Demmig-Adams B, 1998, PLANT CELL PHYSIOL, V39, P474, DOI 10.1093/oxfordjournals.pcp.a029394; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DEMMIGADAMS B, 1994, AUST J PLANT PHYSIOL, V21, P575, DOI 10.1071/PP9940575; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; Douglas SE, 1998, CURR OPIN GENET DEV, V8, P655, DOI 10.1016/S0959-437X(98)80033-6; Espineda CE, 1999, P NATL ACAD SCI USA, V96, P10507, DOI 10.1073/pnas.96.18.10507; FUNK C, 1995, J BIOL CHEM, V270, P30141; FUNK C, 1995, BIOCHEMISTRY-US, V34, P11133, DOI 10.1021/bi00035a019; GHANOTAKIS DF, 1987, PHOTOSYNTH RES, V14, P191, DOI 10.1007/BF00032704; Gilmore AM, 1996, PHOTOSYNTH RES, V48, P171, DOI 10.1007/BF00041007; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; GREEN BR, 1995, PHOTOSYNTH RES, V44, P139, DOI 10.1007/BF00018304; GREEN BR, 1994, PHOTOSYNTH RES, V39, P149, DOI 10.1007/BF00029382; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; HORTON P, 1991, FEBS LETT, V292, P1, DOI 10.1016/0014-5793(91)80819-O; HORTON P, 1992, PHOTOSYNTH RES, V34, P375, DOI 10.1007/BF00029812; Hurry V, 1997, PLANT PHYSIOL, V113, P639, DOI 10.1104/pp.113.2.639; JAHNS P, 1994, PLANTA, V192, P176, DOI 10.1007/BF01089032; Jansson S, 1997, BBA-BIOENERGETICS, V1320, P297, DOI 10.1016/S0005-2728(97)00033-9; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JOHNSON GN, 1993, PLANT CELL ENVIRON, V16, P673, DOI 10.1111/j.1365-3040.1993.tb00485.x; KIM KH, 1992, MED CHEM RES, V2, P22; KIM S, 1994, BBA-BIOENERGETICS, V1188, P339, DOI 10.1016/0005-2728(94)90054-X; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Niyogi KK, 1997, P NATL ACAD SCI USA, V94, P14162, DOI 10.1073/pnas.94.25.14162; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; OTTANDER C, 1995, PLANTA, V197, P176, DOI 10.1007/BF00239954; Owens T. G., 1994, PHOTOINHIBITION PHOT, P95; Phillip D, 1996, P NATL ACAD SCI USA, V93, P1492, DOI 10.1073/pnas.93.4.1492; Ruban AV, 1999, PLANT PHYSIOL, V119, P531, DOI 10.1104/pp.119.2.531; Ruban AV, 1996, BIOCHEMISTRY-US, V35, P674, DOI 10.1021/bi9524878; RUBAN AV, 1993, PLANT PHYSIOL, V102, P741, DOI 10.1104/pp.102.3.741; Tardy F, 1996, J PHOTOCH PHOTOBIO B, V34, P87, DOI 10.1016/1011-1344(95)07272-1; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; YAMAMOTO HY, 1972, BIOCHIM BIOPHYS ACTA, V267, P538, DOI 10.1016/0005-2728(72)90182-X	47	1129	1187	13	312	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					391	395		10.1038/35000131	http://dx.doi.org/10.1038/35000131			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667783				2022-12-28	WOS:000085121100039
J	von Dadelszen, P; Ornstein, MP; Bull, SB; Logan, AG; Koren, G; Magee, LA				von Dadelszen, P; Ornstein, MP; Bull, SB; Logan, AG; Koren, G; Magee, LA			Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; DOUBLE-BLIND; ANTIHYPERTENSIVE TREATMENT; INTRAUTERINE GROWTH; PREECLAMPSIA REMOTE; METHYLDOPA; LABETALOL; MANAGEMENT; ISRADIPINE; PINDOLOL	Background We investigated the relation between fetoplacental growth and the use of oral antihypertensive medication to treat mild-to-moderate pregnancy hypertension. Methods The study design was a metaregression analysis of published data from randomised controlled trials. Data from a paper that was regarded as an extreme statistical outliner were excluded from primary analyses. The change in (group) mean arterial pressure (MAP) from enrolment to delivery was compared with indicators of fetoplacental growth. Findings Greater mean difference in MAP with antihypertensive therapy was associated with the birth of a higher proportion of small-for-gestational-age (SGA) infants (slope: 0.09 [SD 0.03], r(2)=0.48, p=0.006, 14 trials) and lower mean birthweight significant after exclusion of data from another paper regarded as an extreme statistical outliner (slope: -14.49 [6.98] r(2)=0.16, p=0.049, 27). No relation with mean placental weight was seen (slope -2.01 [1.62], r(2)=0.15, p=0.25, 11 trials). Interpretation Treatment-induced falls in maternal blood pressure may adversely affect fetal growth. Given the small maternal benefits that are likely to be derived from therapy, new data are urgently needed to elucidate the relative maternal and fetal benefits and risks of oral antihypertensive drug treatment of mild-to-moderate pregnancy hypertension.	Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Paediat, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto	Magee, LA (corresponding author), 600 Univ Ave,Suite 428, Toronto, ON M5G 1X5, Canada.	laura.magee@utoronto.ca	von Dadelszen, Peter/AAP-7480-2021; Bull, Shelley B/A-1920-2013; Koren, Gideon/AAG-7726-2019; Logan, Alexander G/E-4626-2013	Koren, Gideon/0000-0002-9234-0875; von Dadelszen, Peter/0000-0003-4136-3070				[Anonymous], 1990, AM J OBSTET GYNECOL, V163, P1691; ARIAS F, 1979, OBSTET GYNECOL, V53, P489; BARKER DJP, 1995, P ROY SOC B-BIOL SCI, V262, P37, DOI 10.1098/rspb.1995.0173; BERLIN JA, 1994, ONLINE J CURR CLIN T, V3; BORZAK S, 1995, ANN INTERN MED, V123, P873, DOI 10.7326/0003-4819-123-11-199512010-00010; BOTTKANNER G, 1992, CLIN EXP HYPERTENS B, V11, P207, DOI 10.3109/10641959209031044; Briggs GG., 2008, DRUGS PREGNANCY LACT, P431; BUTTERS L, 1990, BMJ-BRIT MED J, V301, P587, DOI 10.1136/bmj.301.6752.587; Calder A, 1982, INT C SERIES, V591, P148; COLLINS R, 1994, PREGNANCY CHILDBIRTH; Cooper PA, 1997, S AFR MED J, V87, P314; CRUICKSHANK DJ, 1991, CLIN EXP HYPERTENS B, V10, P333, DOI 10.3109/10641959109012919; ELLENBOGEN A, 1986, INT J GYNECOL OBSTET, V24, P3, DOI 10.1016/0020-7292(86)90015-9; ELQARMALAWI AM, 1995, INT J GYNECOL OBSTET, V49, P125, DOI 10.1016/0020-7292(95)02351-C; FIDLER J, 1983, BMJ-BRIT MED J, V286, P1927, DOI 10.1136/bmj.286.6382.1927; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GALLERY EDM, 1985, BMJ-BRIT MED J, V291, P563, DOI 10.1136/bmj.291.6495.563; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248; HJERTBERG R, 1993, J PERINAT MED, V21, P69, DOI 10.1515/jpme.1993.21.1.69; HOGSTEDT S, 1984, CLIN EXP HYPERTENS B, V3, P152; HORVATH JS, 1985, OBSTET GYNECOL, V66, P634; JANNET D, 1994, OBSTET GYNECOL, V84, P354; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; LAMMING GD, 1980, CLIN EXP HYPERTENS, V2, P865, DOI 10.3109/10641968009037147; LARDOUX H, 1988, ARCH MAL COEUR VAISS, V81, P137; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; LEATHER HM, 1968, LANCET, V2, P488; Ley D, 1997, ACTA PAEDIATR, V86, P1090, DOI 10.1111/j.1651-2227.1997.tb14814.x; LIVINGSTONE I, 1983, CLIN EXP HYPERTENS B, V2, P341, DOI 10.3109/10641958309006092; Magee LA, 1999, BMJ-BRIT MED J, V318, P1332, DOI 10.1136/bmj.318.7194.1332; MARLETTINI MG, 1990, CURR THER RES CLIN E, V48, P684; MENZIES DN, 1964, BMJ-BRIT MED J, V1, P739, DOI 10.1136/bmj.1.5385.739; Montan S, 1996, J PERINAT MED, V24, P177, DOI 10.1515/jpme.1996.24.2.177; MONTAN S, 1992, BRIT MED J, V304, P946, DOI 10.1136/bmj.304.6832.946; Oumachigui A, 1992, Indian Heart J, V44, P39; PARAN E, 1995, INT J CLIN PHARM TH, V33, P119; PHIPPARD AF, 1991, MED J AUSTRALIA, V154, P378, DOI 10.5694/j.1326-5377.1991.tb121126.x; PICKLES CJ, 1989, BRIT J OBSTET GYNAEC, V96, P38, DOI 10.1111/j.1471-0528.1989.tb01574.x; PLOUIN PF, 1988, BRIT J OBSTET GYNAEC, V95, P868, DOI 10.1111/j.1471-0528.1988.tb06571.x; PLOUIN PF, 1990, BRIT J OBSTET GYNAEC, V97, P134, DOI 10.1111/j.1471-0528.1990.tb01738.x; Redman Christopher W. G., 1995, P182; Redman CW, 1978, INT C SERIES, V591, P101; REDMAN CWG, 1976, LANCET, V2, P753; REDMAN CWG, 1991, AM J KIDNEY DIS, V17, P149, DOI 10.1016/S0272-6386(12)81120-6; Rey E, 1997, CAN MED ASSOC J, V157, P1245; ROSENFELD JB, 1992, CLIN EXP HYPERTENS B, V11, P207; RUBIN PC, 1983, LANCET, V1, P431; SIBAI BM, 1987, OBSTET GYNECOL, V70, P323; SIBAI BM, 1990, AM J OBSTET GYNECOL, V162, P960, DOI 10.1016/0002-9378(90)91297-P; SIBAI BM, 1984, AM J OBSTET GYNECOL, V150, P831, DOI 10.1016/0002-9378(84)90458-7; Sibai BM, 1996, NEW ENGL J MED, V335, P257, DOI 10.1056/NEJM199607253350407; SIBAI BM, 1992, AM J OBSTET GYNECOL, V167, P879, DOI 10.1016/S0002-9378(12)80005-6; Steyn DW, 1997, LANCET, V350, P1267; TYSON JE, 1995, PEDIATRICS, V95, P534; VOTO LS, 1987, J CARDIOVASC PHARM, V10, pS101, DOI 10.1097/00005344-198700103-00025; WEITZ C, 1987, INT J GYNECOL OBSTET, V25, P35, DOI 10.1016/0020-7292(87)90181-0; WICHMAN K, 1984, SCAND J CLIN LAB INV, V44, P90, DOI 10.3109/00365518409085385; WIDESWENSSON D, 1993, AM J OBSTET GYNECOL, V169, P1581, DOI 10.1016/0002-9378(93)90440-T; WIDESWENSSON DH, 1995, AM J OBSTET GYNECOL, V173, P872, DOI 10.1016/0002-9378(95)90357-7; ZUSPAN FP, 1979, YB OBSTETRICS GYNECO, P11	60	290	311	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	2000	355	9198					87	92		10.1016/S0140-6736(98)08049-0	http://dx.doi.org/10.1016/S0140-6736(98)08049-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675164				2022-12-28	WOS:000085557200008
J	Dolk, H				Dolk, H			Commentary: Impact on health needs assessing from different angles	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Environm Epidemiol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Dolk, H (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Environm Epidemiol Unit, London WC1E 7HT, England.							Berry M, 1997, ENVIRON HEALTH PERSP, V105, P856, DOI 10.2307/3433704; Dolk H, 1998, LANCET, V352, P423, DOI 10.1016/S0140-6736(98)01352-X; GESCHWIND SA, 1992, AM J EPIDEMIOL, V135, P1197, DOI 10.1093/oxfordjournals.aje.a116226; MUKERJEE A, 1999, REPORT COMPLAINTS IL; SWAN SH, 1989, AM J EPIDEMIOL, V129, P885, DOI 10.1093/oxfordjournals.aje.a115222; VRIJHEID M, IN PRESS ENV HLTH PE	6	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					23	23						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10671039				2022-12-28	WOS:000084621600017
J	Frankel, S; Sterne, J; Smith, GD				Frankel, S; Sterne, J; Smith, GD			Mortality variations as a measure of general practitioner performance: implications of the Shipman case	BRITISH MEDICAL JOURNAL			English	Article									Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Frankel, S (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.		Sterne, Jonathan/Z-3106-2019; Davey Smith, George/A-7407-2013	Sterne, Jonathan/0000-0001-8496-6053; Davey Smith, George/0000-0002-1407-8314				*DEP HLTH, 2000, STAT GEN MED PRACT E; Rivett Geoffrey, 1998, CRADLE GRAVE 50 YEAR; SHAW M, 1999, WIDENING GAP HLTH IN; Smith R, 1999, BRIT MED J, V319, P1314, DOI 10.1136/bmj.319.7221.1314	4	32	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					489	489		10.1136/bmj.320.7233.489	http://dx.doi.org/10.1136/bmj.320.7233.489			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678864	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000085562200027
J	Henry, K				Henry, K			The case for more cautious, patient-focused antiretroviral therapy	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 INFECTION; REVERSE-TRANSCRIPTASE; PROTEASE-INHIBITOR; LYMPHOID-TISSUES; ZIDOVUDINE; PLASMA; LYMPHOCYTES; DIDANOSINE; RESISTANT	Many clinicians who care for patients with HIV infection are dissatisfied with the existing recommendations on antiretroviral therapy. Current practice focuses on the early suppression of viremia, yet the outcome of that approach may not be in the best interest of individual patients or populations. The major goal of HIV therapy is to maintain the long-term health of the patient while avoiding drug-related toxicity and preserving viable future treatment options. Recent studies have challenged the principles on which recommendations for early, aggressive treatment were based. Key studies that lead to licensure of antiretroviral medications usually involve short-term results in treatment-naive patients; it is difficult to apply these results to long-term management of therapy-experienced patients. Early, aggressive therapy often prematurely exposes patients to risks for medication-related side effects and resistance. A more cautious, patient-focused, long term approach to therapy would help foster studies of alternate strategies, such as delayed initiation of therapy, protease-sparing therapy, class-sparing therapy, planned drug interruptions, switches in therapy, and immune-based therapy. It is time for clinicians to rethink their approach to the treatment of HIV infection.	Reg Hosp, HIV Program, St Paul, MN 55101 USA; Univ Minnesota, AIDS Clin Trials Unit, St Paul, MN 55101 USA	University of Minnesota System; University of Minnesota Twin Cities	Henry, K (corresponding author), Reg Hosp, HIV Program, 640 Jackson,Suite 125N, St Paul, MN 55101 USA.	keithh6680@aol.com						Acosta EP, 1999, PHARMACOTHERAPY, V19, P708, DOI 10.1592/phco.19.9.708.31544; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Blanche S, 1999, LANCET, V354, P1084, DOI 10.1016/S0140-6736(99)07219-0; Boden D, 1999, JAMA-J AM MED ASSOC, V282, P1135, DOI 10.1001/jama.282.12.1135; Brinkman K, 1999, LANCET, V354, P1112, DOI 10.1016/S0140-6736(99)06102-4; Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004; CAMERON B, 1996, 3 C RETR OPP INF, pL86A; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Cooper DA, 1998, NEW ENGL J MED, V339, P1319, DOI 10.1056/NEJM199810293391810; DAVEY R, 1999, 39 INT C ANT AG CHEM, P689; DEEKS S, 1998, 5 C RETR OPP INF FEB, P419; DEMETER L, 1998, 5 C RETR OPP INF, P509; *DEP HLTH HUM SERV, 1998, MMWR-MORBID MORTAL W, V47, P43; Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205; Diez-Roux AV, 1999, AM J PUBLIC HEALTH, V89, P302, DOI 10.2105/AJPH.89.3.302; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Fauci AS, 1999, NEW ENGL J MED, V341, P1046, DOI 10.1056/NEJM199909303411406; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Fletcher CV, 1998, CLIN PHARMACOL THER, V64, P331, DOI 10.1016/S0009-9236(98)90182-5; FLETCHER CV, 1999, 39 INT C ANT AG CHEM, P322; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; GARRETT L, 1999, ESQUIRE, V313, P102; GAZZARD BG, 1999, 39 INT C ANT AG CHEM, P1888; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARRINGTON M, 1998, 12 WORLD AIDS C, P159; Havlir DV, 2000, JAMA-J AM MED ASSOC, V283, P229, DOI 10.1001/jama.283.2.229; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Henry K, 1998, LANCET, V351, P1328, DOI 10.1016/S0140-6736(05)79053-X; Henry K, 1998, LANCET, V352, P1031, DOI 10.1016/S0140-6736(98)00022-1; HENRY K, 1998, 5 C RETR OPP INF, P529; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hirsch VM, 1999, NAT MED, V5, P488, DOI 10.1038/8369; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Hockett RD, 1999, J EXP MED, V189, P1545, DOI 10.1084/jem.189.10.1545; HODAK SP, 1999, 39 INT C ANT AG CHEM, P1312; HOLMES SA, 1998, NY TIMES        0918, pA1; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KATZENSTEIN D, 1998, 12 WORLD AIDS C, V507, P12124; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; KEISER P, 1999, 39 INT C ANT AG CHEM, P602; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; Kimata JT, 1999, NAT MED, V5, P535, DOI 10.1038/8414; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Levy JA, 1998, LANCET, V352, P982, DOI 10.1016/S0140-6736(98)05391-4; Little SJ, 1999, JAMA-J AM MED ASSOC, V282, P1142, DOI 10.1001/jama.282.12.1142; Lori F, 1997, JAMA-J AM MED ASSOC, V277, P1437, DOI 10.1001/jama.277.18.1437; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; LYLES R, 1999, 6 C RETR OPP INF, P273; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Molina JM, 1999, J INFECT DIS, V180, P351, DOI 10.1086/314891; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Notermans DW, 1999, J INFECT DIS, V180, P1050, DOI 10.1086/315013; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PATERSON D, 1999, 6 C RETR OPP INF, P92; Pomerantz RJ, 1999, NEW ENGL J MED, V340, P1672, DOI 10.1056/NEJM199905273402110; Pomerantz RJ, 1999, JAMA-J AM MED ASSOC, V282, P1177, DOI 10.1001/jama.282.12.1177; RICHMAN DD, 1993, NATURE, V361, P588, DOI 10.1038/361588a0; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; SCRIBNER AN, 1999, 39 INT C ANT AG CHEM, P1311; Tebas P, 1999, AIDS, V13, pF23, DOI 10.1097/00002030-199902040-00002; *TREAT ACT GROUP, 1999, TAGLINE, V6, P1; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; Zhang ZQ, 1999, P NATL ACAD SCI USA, V96, P5169, DOI 10.1073/pnas.96.9.5169; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	74	50	50	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2000	132	4					306	311		10.7326/0003-4819-132-4-200002150-00009	http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285CY	10681286				2022-12-28	WOS:000085372900007
J	Josefson, D				Josefson, D			Radiation of the arteries can reduce narrowing	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					402	402						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669441				2022-12-28	WOS:000085377400018
J	Julien, JP; Bijker, N; Fentiman, IS; Peterse, JL; Delledonne, V; Rouanet, P; Avril, A; Sylvester, R; Mignolet, F; Bartelink, H; Van Dongen, JA				Julien, JP; Bijker, N; Fentiman, IS; Peterse, JL; Delledonne, V; Rouanet, P; Avril, A; Sylvester, R; Mignolet, F; Bartelink, H; Van Dongen, JA		EORTC Breast Canc Cooperat Grp; EORTC Radiotherapy Grp	Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853	LANCET			English	Article							RADIATION-THERAPY; IN-SITU; CANCER; LUMPECTOMY; IRRADIATION; MASTECTOMY; INSITU	Background Ductal carcinoma in situ (DCIS) of the breast is a disorder that has become more common since it may manifest as microcalcifications that can be detected by screening mammography. Since selected women with invasive cancer can be treated safely with breast-conservation therapy it is paradoxical that total mastectomy has remained the standard treatment for DCIS. We did a randomised phase III clinical trial to investigate the role of radiotherapy after complete local excision of DCIS. Methods Between 1986 and 1996, women with clinically or mammographically detected DCIS measuring less than or equal to 5 cm were treated by complete local excision of the lesion and then randomly assigned to either no further treatment (n=503) or to radiotherapy (n=507; 50 Gy in 5 weeks to the whole breast). The median duration of follow-up was 4.25 years (maximum 12.0 years). All analyses were by intention to treat. Findings 500 patients were followed up in the no further treatment group and 502 in the radiotherapy group. In the no further treatment group 83 women had local recurrence (44 recurrences of DCIS, and 40 invasive breast cancer). In the radiotherapy group 53 women had local recurrences (29 recurrences of DCIS, and 24 invasive breast cancer). The or year local relapse-free was 84% in the group treated with local excision alone compared with 91% in the women treated by local excision plus radiotherapy (log rank p=0.005; hazard ratio 0.62). Similar reductions in the risk of invasive (40%, p=0.04) and non-invasive (35%, p=0.06) local recurrence were seen. Conclusions Radiotherapy after local excision for DCIS, as compared with local excision alone, reduced the overall number of both invasive and non-invasive recurrences in the ipsilateral breast at a median follow-up of 4.25 years.	Ctr Henri Becquerel, Dept Surg, F-76038 Rouen, France; Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands; Guys Hosp, Clin Oncol Unit, London SE1 9RT, England; Ist Nazl Tumori, Dept Surg, I-20133 Milan, Italy; CRLC Val Daurelle, Dept Surg, F-34094 Montpellier, France; Inst Bergonie, Dept Surg, F-33076 Bordeaux, France; EORTC Data Ctr, B-1200 Brussels, Belgium; Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands; Dept Surg, NL-1066 CX Amsterdam, Netherlands	UNICANCER; Centre Henri Becquerel; Netherlands Cancer Institute; Guy's & St Thomas' NHS Foundation Trust; Fondazione IRCCS Istituto Nazionale Tumori Milan; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); UNICANCER; Institut Bergonie; European Organisation for Research & Treatment of Cancer	Julien, JP (corresponding author), Ctr Henri Becquerel, Dept Surg, Rue Damiens 1, F-76038 Rouen, France.	ajpjulien@aol.com	Fentiman, Ian/AAB-9886-2020; Fentiman, Ian S/I-7644-2019		NCI NIH HHS [2U10 CA11488-16, 5U10 CA11488-28] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DEJONG E, 1992, EUR J SURG ONCOL, V18, P64; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; JACOBSON JA, 1995, NEW ENGL J MED, V332, P907, DOI 10.1056/NEJM199504063321402; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Recht A., 1998, European Journal of Cancer, V34, P1664, DOI 10.1016/S0959-8049(98)00220-2; SCHNITT SJ, 1988, NEW ENGL J MED, V318, P898, DOI 10.1056/NEJM198804073181406; SHIRAGAI A, 1978, PHYS MED BIOL, V23, P245, DOI 10.1088/0031-9155/23/2/003; SILVERSTEIN MJ, 1995, EUR J CANCER, V31A, P1425, DOI 10.1016/0959-8049(95)00283-O; Silverstein MJ, 1996, CANCER-AM CANCER SOC, V77, P2267, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V; Silverstein MJ, 1999, NEW ENGL J MED, V340, P1455, DOI 10.1056/NEJM199905133401902; Solin LJ, 1996, J CLIN ONCOL, V14, P754, DOI 10.1200/JCO.1996.14.3.754; VANDONGEN JA, 1992, EUR J CANCER, V28A, P801, DOI 10.1016/0959-8049(92)90118-L; VERONESI U, 1995, EUR J CANCER, V31A, P1574, DOI 10.1016/0959-8049(95)00271-J	16	431	449	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2000	355	9203					528	533		10.1016/S0140-6736(99)06341-2	http://dx.doi.org/10.1016/S0140-6736(99)06341-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10683002				2022-12-28	WOS:000085487400010
J	Spurgeon, D				Spurgeon, D			Canada faces healthcare crisis	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					400	400						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669435				2022-12-28	WOS:000085377400012
J	Schon, JH; Berg, S; Kloc, C; Batlogg, B				Schon, JH; Berg, S; Kloc, C; Batlogg, B			RETRACTED: Ambipolar pentacene field-effect transistors and inverters (Retracted article. See vol 298, pg 961, 2002)	SCIENCE			English	Article; Retracted Publication							THIN-FILM TRANSISTORS; RING OSCILLATORS; CIRCUITS; CRYSTALS; MOBILITY; DEVICES	Organic field-effect transistors based on pentacene single crystals, prepared with an amorphous aluminum oxide gate insulator, are capable of ambipolar operation and can be used for the preparation of complementary inverter circuits. The field-effect mobilities of carriers in these transistors increase from 2.7 and 1.7 square centimeters per volt per second at room temperature up to 1200 and 320 square centimeters per volt per second at Low temperatures for hole and electron transport, respectively, following a power-law dependence. The possible simplification of the fabrication process of complementary Logic circuits with these transistors, together with the high carrier mobilities, may be seen as another step toward applications of plastic electronics.	Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T	Schon, JH (corresponding author), Lucent Technol, Bell Labs, Mt Ave, Murray Hill, NJ 07974 USA.	hendrik@lucent.com	Kloc, Christian/A-2255-2011; Berg, Steffen/AAG-7397-2021	Berg, Steffen/0000-0003-2441-7719				BROWN AR, 1995, SCIENCE, V270, P972, DOI 10.1126/science.270.5238.972; de Leeuw D, 1999, PHYS WORLD, V12, P31; Dimitrakopoulos CD, 1999, SCIENCE, V283, P822, DOI 10.1126/science.283.5403.822; Dimitrakopoulos CD, 1998, SYNTHETIC MET, V92, P47, DOI 10.1016/S0379-6779(98)80021-0; DODABALAPUR A, 1995, SCIENCE, V269, P1560, DOI 10.1126/science.269.5230.1560; Dodabalapur A, 1996, APPL PHYS LETT, V68, P1108, DOI 10.1063/1.115728; Dodabalapur A, 1998, APPL PHYS LETT, V73, P142, DOI 10.1063/1.121736; Drury CJ, 1998, APPL PHYS LETT, V73, P108, DOI 10.1063/1.121783; Garnier F, 1996, SYNTHETIC MET, V81, P163, DOI 10.1016/S0379-6779(96)03761-7; Horowitz G, 1998, ADV MATER, V10, P365, DOI 10.1002/(SICI)1521-4095(199803)10:5<365::AID-ADMA365>3.0.CO;2-U; Karl N., 1985, LANDOLTBORNSTEIN, V17i, P106; Katz H. E., 1998, HDB OLIGO POLYTHIOPH, P459; Klauk H, 1999, IEEE T ELECTRON DEV, V46, P1258, DOI 10.1109/16.766895; Klauk H, 1999, IEEE ELECTR DEVICE L, V20, P289, DOI 10.1109/55.767101; Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9; Lin YY, 1997, IEEE T ELECTRON DEV, V44, P1325, DOI 10.1109/16.605476; Lin YY, 1999, APPL PHYS LETT, V74, P2714, DOI 10.1063/1.123946; MATSUMURA M, 1980, J APPL PHYS, V51, P6443, DOI 10.1063/1.327599; Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205; NEUDECK GW, 1987, IEEE T ELECTRON DEV, V34, P344, DOI 10.1109/T-ED.1987.22928; Schon JH, 1999, APPL PHYS LETT, V74, P260, DOI 10.1063/1.123274; Schon JH, 1998, PHYS REV B, V58, P12952, DOI 10.1103/PhysRevB.58.12952; Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741; Sze S M, 1981, PHYS SEMICONDUCTOR D, P442; WARTA W, 1985, PHYS REV B, V32, P1172, DOI 10.1103/PhysRevB.32.1172	25	346	388	7	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2000	287	5455					1022	1023		10.1126/science.287.5455.1022	http://dx.doi.org/10.1126/science.287.5455.1022			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669410				2022-12-28	WOS:000085245400042
J	Gerhardt, A; Scharf, RE; Beckmann, MW; Struve, S; Bender, HG; Pillny, M; Sandmann, W; Zotz, RB				Gerhardt, A; Scharf, RE; Beckmann, MW; Struve, S; Bender, HG; Pillny, M; Sandmann, W; Zotz, RB			Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; ACTIVATED PROTEIN-C; COAGULATION-FACTOR-V; VENOUS THROMBOSIS; METHYLENETETRAHYDROFOLATE REDUCTASE; RISK FACTOR; ORAL-CONTRACEPTIVES; GENE; THROMBOEMBOLISM; LEIDEN	Background: Venous thromboembolism is a leading cause of morbidity and mortality during pregnancy and the puerperium. However, the role of mutations in the prothrombin and factor V genes and other thrombophilic abnormalities as risk factors for thromboembolism in women during pregnancy and the puerperium is not known. Methods: In a study of 119 women with a history of venous thromboembolism during pregnancy and the puerperium and 233 age-matched normal women, we measured the activity of antithrombin, protein C, protein S, and lupus anticoagulant. We also performed genetic analyses to detect the G1691A mutation in the factor V gene (factor V Leiden), the G20210A mutation in the prothrombin gene, and the C677T mutation in the methylenetetrahydrofolate reductase gene. Blood samples were obtained at least three months post partum or after the cessation of lactation. Results: Among the women with a history of venous thromboembolism, the prevalence of factor V Leiden was 43.7 percent, as compared with 7.7 percent among the normal women (relative risk of venous thromboembolism, 9.3; 95 percent confidence interval, 5.1 to 16.9); that of the G20210A prothrombin-gene mutation, 16.9 percent as compared with 1.3 percent (relative risk, 15.2; 95 percent confidence interval, 4.2 to 52.6); and that of both factor V Leiden and the G20210A prothrombin-gene mutation, 9.3 percent as compared with 0 (estimated odds ratio, 107). Assuming an overall risk of 1 in 1500 pregnancies, the risk of thrombosis among carriers of factor V Leiden was 0.2 percent, among carriers of the G20210A prothrombin-gene mutation, 0.5 percent, and among carriers of both defects, 4.6 percent, as calculated in a multivariate analysis. Conclusions: The G20210A prothrombin-gene mutation and factor V Leiden individually are associated with an increased risk of venous thromboembolism during pregnancy and the puerperium, and the risk among women with both mutations is disproportionately higher than that among women with only one mutation. (N Engl J Med 2000;342:374-80.) (C)2000, Massachusetts Medical Society.	Univ Dusseldorf, Med Ctr, Inst Haemostaseol & Transfus Med, Dept Hemostasis & Transfus Med, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Ctr, Dept Obstet & Gynecol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Ctr, Dept Vasc Surg & Kidney Transplantat, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Zotz, RB (corresponding author), Univ Dusseldorf, Med Ctr, Inst Haemostaseol & Transfus Med, Dept Hemostasis & Transfus Med, Moorenstr 5, D-40225 Dusseldorf, Germany.							BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Bokarewa MI, 1996, BRIT J HAEMATOL, V92, P473, DOI 10.1046/j.1365-2141.1996.d01-1496.x; Cumming AM, 1997, BRIT J HAEMATOL, V98, P353, DOI 10.1046/j.1365-2141.1997.2353052.x; DAHLBACK E, 1994, HAEMOSTASIS THROMBOS, V1, P671; DizonTownson DS, 1997, AM J OBSTET GYNECOL, V176, P883, DOI 10.1016/S0002-9378(97)70615-X; Eichinger S, 1998, THROMB HAEMOSTASIS, V80, P566; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GREEK D, 1994, PROF ENG, V7, P4; Hallak M, 1997, AM J OBSTET GYNECOL, V176, P889, DOI 10.1016/S0002-9378(97)70617-3; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; Hillarp A, 1997, THROMB HAEMOSTASIS, V78, P990; KIERKEGAARD A, 1983, ACTA OBSTET GYN SCAN, V62, P239, DOI 10.3109/00016348309155799; Kluijtmans LAJ, 1998, THROMB HAEMOSTASIS, V79, P254, DOI 10.1055/s-0037-1614974; KNIEMEYER HW, 1993, CLIN INVESTIGATOR, V72, P40; KNIEMEYER HW, 1990, GYNAKOLOGE, V23, P91; KNIEMEYER HW, 1990, KLIN WOCHENSCHR, V68, P1208, DOI 10.1007/BF01796511; KOLVENBACH R, 1991, GYNAKOLOGE, V24, P305; Leroyer C, 1998, THROMB HAEMOSTASIS, V80, P49; Margaglione M, 1998, THROMB HAEMOSTASIS, V79, P907; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RUTHERFORD S, 1991, American Journal of Obstetrics and Gynecology, V164, P286; TREFFERS PE, 1983, INT J GYNECOL OBSTET, V21, P327, DOI 10.1016/0020-7292(83)90024-3; Zotz RB, 1996, THROMB HAEMOSTASIS, V76, P53	26	360	373	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					374	380		10.1056/NEJM200002103420602	http://dx.doi.org/10.1056/NEJM200002103420602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666427				2022-12-28	WOS:000085205200002
J	Shannon, H; Duffy, H; Dahms, W; Mayer, L; Brillion, D; Lackaye, M; Whitehouse, F; Kruger, D; Bergenstal, R; Johnson, M; Jacobson, A; Doyle, J; Soroko, D; Nathan, D; Fritz, S; Godine, J; McKitrick, C; Service, J; Ziegler, G; Collwell, J; Wood, D; Mayfield, R; Garvey, T; Lyons, T; Smith, J; Hermayer, K; Molitch, M; Schaefer, B; Kolterman, O; Lorenzi, G; Sivitz, W; Bayless, M; Counts, D; Kowarski, A; Ostrowski, D; Greene, D; Martin, C; Herman, W; Bantle, J; Rogness, B; Goldstein, D; Hitt, S; Schade, D; Hornbeck, D; Schwartz, S; Maschak-Carey, BJ; Orchard, T; Silvers, N; Songer, T; Malone, J; Wetz, H; Kitabchi, A; Lambeth, H; Murphy, MB; Raskin, P; Strowig, S; Zinman, B; Barnic, A; Palmer, J; Van Ottingham, L; Dupre, J; Harth, J; May, M; Lorenz, R; Lipps, J; White, N; Santiago, J; Levandoski, L; Tamborlane, W; Gatcomb, P; Dahms, B; Corcoran, P; Quin, J; Lachin, J; Cleary, P; Kenny, D; Backlund, J; Diminick, L; Henry, A; Lamas, D; Cowic, C; Eastman, R; Davis, M; Hubbard, L; Geithman, P; Brickbauer, J; Kastorff, L; Neider, M; Steffes, M; Bucksa, J; Chavers, B; Weir, G; Clark, C; D'Agnostino, R; Espeland, M; Klein, B; Jacobson, H; Manolio, T; Rand, L; Singer, D; Stern, M; Genuth, S; Nathan, D; Nathan, D				Shannon, H; Duffy, H; Dahms, W; Mayer, L; Brillion, D; Lackaye, M; Whitehouse, F; Kruger, D; Bergenstal, R; Johnson, M; Jacobson, A; Doyle, J; Soroko, D; Nathan, D; Fritz, S; Godine, J; McKitrick, C; Service, J; Ziegler, G; Collwell, J; Wood, D; Mayfield, R; Garvey, T; Lyons, T; Smith, J; Hermayer, K; Molitch, M; Schaefer, B; Kolterman, O; Lorenzi, G; Sivitz, W; Bayless, M; Counts, D; Kowarski, A; Ostrowski, D; Greene, D; Martin, C; Herman, W; Bantle, J; Rogness, B; Goldstein, D; Hitt, S; Schade, D; Hornbeck, D; Schwartz, S; Maschak-Carey, BJ; Orchard, T; Silvers, N; Songer, T; Malone, J; Wetz, H; Kitabchi, A; Lambeth, H; Murphy, MB; Raskin, P; Strowig, S; Zinman, B; Barnic, A; Palmer, J; Van Ottingham, L; Dupre, J; Harth, J; May, M; Lorenz, R; Lipps, J; White, N; Santiago, J; Levandoski, L; Tamborlane, W; Gatcomb, P; Dahms, B; Corcoran, P; Quin, J; Lachin, J; Cleary, P; Kenny, D; Backlund, J; Diminick, L; Henry, A; Lamas, D; Cowic, C; Eastman, R; Davis, M; Hubbard, L; Geithman, P; Brickbauer, J; Kastorff, L; Neider, M; Steffes, M; Bucksa, J; Chavers, B; Weir, G; Clark, C; D'Agnostino, R; Espeland, M; Klein, B; Jacobson, H; Manolio, T; Rand, L; Singer, D; Stern, M; Genuth, S; Nathan, D; Nathan, D		Diabet Control Complications Trial	Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background: Among patients with type 1 diabetes mellitus, intensive therapy (with the aim of achieving near-normal blood glucose and glycosylated hemoglobin concentrations) markedly reduces the risk of microvascular complications as compared with conventional therapy. To assess whether these benefits persist, we compared the effects of former intensive and conventional therapy on the occurrence and severity of retinopathy and nephropathy for four years after the end of the Diabetes Control and Complications Trial (DCCT). Methods: At the end of the DCCT, the patients in the conventional-therapy group were offered intensive therapy, and the care of all patients was transferred to their own physicians. Retinopathy was evaluated on the basis of centrally graded fundus photographs in 1208 patients during the fourth year after the DCCT ended, and nephropathy was evaluated on the basis of urine specimens obtained from 1302 patients during the third or fourth year, approximately half of whom were from each treatment group. Results: The difference in the median glycosylated hemoglobin values between the conventional-therapy and intensive-therapy groups during the 6.5 years of the DCCT (average, 9.1 percent and 7.2 percent, respectively) narrowed during follow-up (median during 4 years, 8.2 percent and 7.9 percent, respectively; P<0.001). Nevertheless, the proportion of patients who had worsening retinopathy, including proliferative retinopathy, macular edema, and the need for laser therapy, was lower in the intensive-therapy group than in the conventional-therapy group (odds reduction, 72 percent to 87 percent; P<0.001). The proportion of patients with an increase in urinary albumin excretion was significantly lower in the intensive-therapy group. Conclusions: The reduction in the risk of progressive retinopathy and nephropathy resulting from intensive therapy in patients with type 1 diabetes persists for at least four years, despite increasing hyperglycemia. (N Engl J Med 2000;342:381-9.) (C)2000, Massachusetts Medical Society.	Epidemiol Diabet Intervent & Complicat Res Grp, Diabet Control & Complicat Trial, Bethesda, MD 20892 USA		Shannon, H (corresponding author), Epidemiol Diabet Intervent & Complicat Res Grp, Diabet Control & Complicat Trial, Box NDIC EDIC, Bethesda, MD 20892 USA.	nathan@gcrc.mgh.harvard.edu	Zinman, Bernard/E-7266-2013; Hramiak, Irene/G-3305-2011	Lachin, John/0000-0001-9838-2841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK062204] Funding Source: NIH RePORTER; NIDDK NIH HHS [N01 DK062204-007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRESTI A, 1990, CATEGORICAL DATA ANA, V80, P235; [Anonymous], 1991, OPHTHALMOLOGY, V98, P823; [Anonymous], 1996, DIABETES, V45, P1289; [Anonymous], 1995, DIABETES, V44, P968; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; *DIAB CONTR COMPL, 1998, ARCH OPHTHALMOL-CHIC, V116, P1469; Diabet Contr Complicat Trial Res Grp, 1998, ARCH OPHTHALMOL-CHIC, V116, P874; *EARL THER DIAB RE, 1985, PB85223006; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; Genuth S, 1999, DIABETES CARE, V22, P99; GOLDSTEIN DE, 1987, CLIN CHEM, V33, P2267; MOLITCH ME, 1993, KIDNEY INT, V43, P1196; Monnier VM, 1999, DIABETES, V48, P870, DOI 10.2337/diabetes.48.4.870; ODELL PM, 1992, BIOMETRICS, V48, P951, DOI 10.2307/2532360; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015; REICHARD P, 1995, J DIABETES COMPLICAT, V9, P25, DOI 10.1016/1056-8727(94)00008-C; *SAS I, 1989, SAS STAT US GUID VER; SHAMOON H, 1995, ARCH OPHTHALMOL-CHIC, V113, P36; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Snedecor GW, 1980, STAT METHODS, V7th; VLASSARA H, 1994, LAB INVEST, V70, P138	21	1112	1130	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					381	389						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666428				2022-12-28	WOS:000085205200003
J	Yacht, AC				Yacht, AC			Collective bargaining is the right step.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Med Ctr, Boston, MA 02118 USA	Boston Medical Center	Yacht, AC (corresponding author), Boston Med Ctr, Boston, MA 02118 USA.							*BOST MED CTR, BOST CIT HOSP MED DE; *BOST MED CTR, 1997, AGR BOST MED CTR HOU; IGLEHART J, 1997, NEW ENGL J MED, V341, P299	3	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					429	431		10.1056/NEJM200002103420613	http://dx.doi.org/10.1056/NEJM200002103420613			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666437				2022-12-28	WOS:000085205200012
J	Schlessinger, J				Schlessinger, J			New roles for Src kinases in control of cell survival and angiogenesis	CELL			English	Review							TYROSINE KINASE; RECEPTOR; FAMILY; PHOSPHORYLATION		NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst, New York, NY 10016 USA	New York University; New York University	Schlessinger, J (corresponding author), NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA.							Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	17	261	268	3	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 4	2000	100	3					293	296		10.1016/S0092-8674(00)80664-9	http://dx.doi.org/10.1016/S0092-8674(00)80664-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676810	Bronze			2022-12-28	WOS:000085204400002
J	Caramazza, A; Chialant, D; Capasso, R; Miceli, G				Caramazza, A; Chialant, D; Capasso, R; Miceli, G			Separable processing of consonants and vowels	NATURE			English	Article							PHONEMIC PARAPHASIA; SPEECH; ERRORS	There are two views about the nature of consonants and vowels. One view holds that they are categorically distinct objects that play a fundamental role in the construction of syllables in speech production(1-3). The other view is that they are convenient labels for distinguishing between peak (vowel) and non-peak (consonant) parts of a continuous stream of sound that varies in sonority (roughly the degree of openness of the vocal apparatus during speech)(4-6), or that they are summary labels for bundles of feature segments(7,8). Taking the latter view, consonants and vowels do not have an independent status in language processing. Here we provide evidence for the possible categorical distinction between consonants and vowels in the brain. We report the performance of two Italian-speaking aphasics who show contrasting, selective difficulties in producing vowels and consonants. Their performance in producing individual consonants is independent of the sonority value and feature properties of the consonants. This pattern of results suggests that consonants and vowels are processed by distinct neural mechanisms, thereby providing evidence for their independent status in language production.	Harvard Univ, Dept Psychol, Cognit Neuropsychol Lab, Cambridge, MA 02138 USA; Ist Ricovero & Cura Carattere Sci S Lucia, I-00179 Rome, Italy; Univ Cattolica, Dept Neurol, I-00168 Rome, Italy	Harvard University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Caramazza, A (corresponding author), Harvard Univ, Dept Psychol, Cognit Neuropsychol Lab, 33 Kirkland St, Cambridge, MA 02138 USA.		Miceli, Gabriele/J-8908-2014	Capasso, Rita/0000-0003-1523-7302				Beland R., 1990, J NEUROLINGUIST, V5, P125, DOI [10.1016/0911-6044(90)90009-N, DOI 10.1016/0911-6044(90)90009-N]; BLUMSTEIN SE, 1978, SYLLABLES SEGMENTS, P189; Boatman D, 1997, CORTEX, V33, P83, DOI 10.1016/S0010-9452(97)80006-8; BUCKINGHAM HW, 1986, COGNITIVE SCI, V10, P195, DOI 10.1207/s15516709cog1002_4; CANTER GJ, 1985, BRAIN LANG, V24, P204, DOI 10.1016/0093-934X(85)90131-2; CHRISTMAN SS, 1992, CLIN LINGUIST PHONET, V6, P219, DOI 10.3109/02699209208985532; CLEMENTS GN, 1983, MONOGRAPH SERIES MIT, V9; Goldsmith J., 1990, AUTOSEGMENTAL METRIC; Kenstowicz Michael, 1994, PHONOLOGY GENERATIVE; Levelt WJM, 1999, BEHAV BRAIN SCI, V22, P1; MacNeilage PF, 1998, BEHAV BRAIN SCI, V21, P499, DOI 10.1017/S0140525X98001265; MCCARTHY JJ, 1981, LINGUIST INQ, V12, P373; Miceli G., 2006, BATTERIA ANALISI DEF; NESPOT M, 1986, PRASODIC PHONOLOGY; Ramus F, 1999, J ACOUST SOC AM, V105, P512, DOI 10.1121/1.424522; Roelofs A, 1999, LANG COGNITIVE PROC, V14, P173, DOI 10.1080/016909699386338; Romani C, 1996, BRAIN LANG, V55, P144; Romani C, 1998, BRAIN LANG, V64, P83, DOI 10.1006/brln.1998.1958; Selkirk E. O., 1982, STRUCTURE PHONOLOG 2; Stevens Kenneth N., 1998, ACOUSTIC PHONETICS; YIP M, 1982, LINGUIST INQ, V13, P637	21	129	130	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					428	430		10.1038/35000206	http://dx.doi.org/10.1038/35000206			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	280UA	10667794				2022-12-28	WOS:000085121100050
J	Hillier, S; Cooper, C; Kellingray, S; Russell, G; Hughes, H; Coggon, D				Hillier, S; Cooper, C; Kellingray, S; Russell, G; Hughes, H; Coggon, D			Fluoride in drinking water and risk of hip fracture in the UK: a case-control study	LANCET			English	Article							PROXIMAL FEMUR; BONE; OSTEOPOROSIS; STRENGTH; WOMEN	Background Although the benefits of water fluoridation for dental health are widely accepted, concerns remain about possible adverse effects, particularly effects on bone. Several investigators have suggested increased rates of hip fracture in places with high concentrations of fluoride in drinking water, but this finding has not been consistent, possibly because of unrecognised confounding effects. Methods We did a case-control study of men and women aged 50 years and older from the English county of Cleveland, and compared patients with hip fracture with community controls. Current addresses were ascertained for all participants; for those who agreed to an interview and who passed a mental test, more detailed information was obtained about lifetime residential history and exposure to other known and suspected risk factors for hip fracture. Exposures to fluoride in water were estimated from the residential histories and from information provided by water suppliers. Analysis was by logistic regression. Findings 914 cases and 1196 controls were identified, of whom 514 and 527, respectively, were interviewed. Among those interviewed, hip fracture was strongly associated with low body-mass index (p for trend <0.001) and physical inactivity (p for trend <0.001). Estimated average lifetime exposure to fluoride in drinking water ranged from 0.15 to 1.79 ppm. Current residence in Hartlepool was a good indicator for high lifetime exposure to fluoride, After adjustment for potential confounders, the odds ratio associated with an average lifetime exposure to fluoride greater than or equal to 0.9 ppm was 1.0 [95% CI 0.7-1.5]. Interpretation There is a low risk of hip fracture for people ingesting fluoride in drinking water at concentrations of about 1 ppm. This low risk should not be a reason for withholding fluoridation of water supplies.	Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England; Univ Sheffield, Sch Med, Dept Human Metab & Clin Biochem, Sheffield S10 2RX, S Yorkshire, England	University of Southampton; University of Sheffield	Coggon, D (corresponding author), Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England.		Leary, Sam/B-4456-2016	Cooper, Cyrus/0000-0003-3510-0709; Russell, Robert Graham G/0000-0002-4136-1828; Leary, Sam/0000-0002-1706-0689				ALFFRAM PA, 1969, ACTA ORTHOP SCAND, V40, P137, DOI 10.3109/17453676908989494; ALHAVA EM, 1980, ACTA ORTHOP SCAND, V51, P413, DOI 10.3109/17453678008990817; ARNALA I, 1986, ACTA ORTHOP SCAND, V57, P344, DOI 10.3109/17453678608994408; CAULEY JA, 1995, J BONE MINER RES, V10, P1076; COOPER C, 1990, J EPIDEMIOL COMMUN H, V44, P17, DOI 10.1136/jech.44.1.17; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; COOPER C, 1991, JAMA-J AM MED ASSOC, V266, P513, DOI 10.1001/jama.266.4.513; DANIELSON C, 1992, JAMA-J AM MED ASSOC, V268, P746; Department of Health and Social Security Scottish Office Welsh Office, 1969, REP PUBL HLTH MED SU; GOGGIN JE, 1965, PUBLIC HEALTH REP, V80, P1005, DOI 10.2307/4592594; GORDON SL, 1992, OSTEOPOROSIS INT, V2, P109, DOI 10.1007/BF01623816; ISHIGURO K, 1993, CALCIFIED TISSUE INT, V52, P278, DOI 10.1007/BF00296652; Jacobsen S J, 1992, Ann Epidemiol, V2, P617, DOI 10.1016/1047-2797(92)90006-C; JACOBSEN SJ, 1993, AM J PUBLIC HEALTH, V83, P743, DOI 10.2105/AJPH.83.5.743; JACOBSEN SJ, 1990, JAMA-J AM MED ASSOC, V264, P500, DOI 10.1001/jama.264.4.500; JACQMINGADDA H, 1995, JAMA-J AM MED ASSOC, V273, P775, DOI 10.1001/jama.1995.03520340029026; KORNS RF, 1969, PUBLIC HEALTH REP, V84, P815, DOI 10.2307/4593687; LI Y, 1999, J DENT RES S1, V78, P263; MADANS J, 1983, AM J PUBLIC HEALTH, V73, P296, DOI 10.2105/AJPH.73.3.296; Martyn CN, 1999, LANCET, V353, P769, DOI 10.1016/S0140-6736(98)00390-0; Meunier PJ, 1996, INT CONGR SER, V1118, P305; QUERESHI KN, 1974, AGE AGEING, V3, P152; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SHERLOCK JC, 1984, J R SOC HLTH, V1, P34; SIMONEN O, 1985, LANCET, V2, P432; SUAREZALMAZOR ME, 1993, AM J PUBLIC HEALTH, V83, P689, DOI 10.2105/AJPH.83.5.689; WHITFORD GM, 1996, METABOLISM TOXICITY, P1	27	47	51	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					265	269		10.1016/S0140-6736(99)07161-5	http://dx.doi.org/10.1016/S0140-6736(99)07161-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	279LQ	10675073				2022-12-28	WOS:000085045600009
J	Vasioukhin, V; Bauer, C; Yin, M; Fuchs, E				Vasioukhin, V; Bauer, C; Yin, M; Fuchs, E			Directed actin polymerization is the driving force for epithelial cell-cell adhesion	CELL			English	Article							ALPHA-CATENIN; VINCULIN; PROTEIN; COMPLEX; FIBROBLASTS; CADHERINS; CONTACTS; MOTILITY; GTPASES; CDC42	We have found that epithelial cells engage in a process of cadherin-mediated intercellular adhesion that utilizes calcium and actin polymerization in unexpected ways. Calcium stimulates filopodia, which penetrate and embed into neighboring cells. E-cadherin complexes cluster at filopodia tips, generating a two-rowed zipper of embedded puncta. Opposing cell surfaces are clamped by desmosomes, while vinculin, zyxin, VASP, and Mena are recruited to adhesion zippers by a mechanism that requires alpha-catenin. Actin reorganizes and polymerizes to merge puncta into a single row and seal cell borders. In keratinocytes either null for alpha-catenin or blocked in VASP/Mena function, filopodia embed, but actin reorganization/polymerization is prevented, and membranes cannot seal. Taken together, a dynamic mechanism for intercellular adhesion is unveiled involving calcium-activated filopodia penetration and VASP/Mena-dependent actin reorganization/polymerization.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Fuchs, E (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	nliptak@midway.uchicago.edu	Fuchs, Elaine/G-1565-2016	Vasioukhin, Valeri/0000-0002-6730-0281	NIAMS NIH HHS [R01-AR27883] Funding Source: Medline; NIDCR NIH HHS [5P50DE11921] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011921] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; BERSHADSKY A, 1998, GUIDEBOOK EXTRACELLU, P3; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; GELGER B, 1992, COLD SPRING HARB SYM, V57, P631; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Laine RO, 1997, J CELL BIOL, V138, P1255, DOI 10.1083/jcb.138.6.1255; Lau PM, 1999, J CELL BIOL, V145, P1265, DOI 10.1083/jcb.145.6.1265; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; MCNEILL H, 1993, J CELL BIOL, V120, P1217, DOI 10.1083/jcb.120.5.1217; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; Stoffler HE, 1998, J CELL SCI, V111, P2779; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; YONEMURA S, 1995, J CELL SCI, V108, P127	39	909	928	1	93	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2000	100	2					209	219		10.1016/S0092-8674(00)81559-7	http://dx.doi.org/10.1016/S0092-8674(00)81559-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660044	Bronze			2022-12-28	WOS:000084932200005
J	del Camino, D; Holmgren, M; Liu, Y; Yellen, G				del Camino, D; Holmgren, M; Liu, Y; Yellen, G			Blocker protection in the pore of a voltage-gated K+ channel and its structural implications	NATURE			English	Article							SHAKER POTASSIUM CHANNELS; TETRAETHYLAMMONIUM ION; INACTIVATION; BINDING; SITE; MECHANISMS; REGION; CELLS	The structure of the bacterial potassium channel KcsA(1) has provided a framework for understanding the related voltage-gated potassium channels (Kv channels) that are used for signalling in neurons. Opening and closing of these Kv channels (gating) occurs at the intracellular entrance to the pore, and this is also the site at which many open channel blockers affect Kv channels(2-4). To learn more about the sites of blocker binding and about the structure of the open Ky channel, we investigated here. the ability of blockers to protect against chemical modification of cysteines introduced at sites in transmembrane segment S6, which contributes to the intracellular entrance. Within the intracellular half of S6 we found an abrupt cessation of protection for both large and small blockers that is inconsistent with the narrow 'inner pore' seen in the KcsA structure. These and other results are most readily explained by supposing that the structure of Ky channels differs from that of the non-voltage-gated bacterial channel by the introduction of a sharp bend in the inner (S6) helices. This bend would occur at a Pro-X-Pro sequence that is highly conserved in Ky channels, near the site of activation gating.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Yellen, G (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.			Yellen, Gary/0000-0003-4228-7866	NINDS NIH HHS [R01 NS029693] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029693] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; Baukrowitz T, 1996, P NATL ACAD SCI USA, V93, P13357, DOI 10.1073/pnas.93.23.13357; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; Gardner S, 1998, ACTA CRYSTALLOGR D, V54, P1071, DOI 10.1107/S0907444998007112; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; SWENSON RP, 1981, J GEN PHYSIOL, V77, P255, DOI 10.1085/jgp.77.3.255; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	27	279	281	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					321	325		10.1038/35002099	http://dx.doi.org/10.1038/35002099			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659852				2022-12-28	WOS:000084899700055
J	Ramer, MS; Priestley, JV; McMahon, SB				Ramer, MS; Priestley, JV; McMahon, SB			Functional regeneration of sensory axone into the adult spinal cord	NATURE			English	Article							DORSAL-ROOT AXONS; NERVE GROWTH-FACTOR; TRANSPLANTS; NEURONS; RAT; LESION; EXPRESSION; RECEPTORS; TARGETS; BRAIN	The arrest of dorsal root axonal regeneration at the transitional zone between the peripheral and central nervous system has been repeatedly described since the early twentieth century(1). Here we show that, with trophic support to damaged sensory axons, this regenerative barrier is surmountable. In adult rats with injured dorsal roots, treatment with nerve growth factor (NGF), neurotrophin-3 (NT3) and glial-cell-line-derived neurotrophic factor (GDNF), but not brain-derived neurotrophic factor (BDNF), resulted in selective regrowth of damaged axons across the dorsal root entry zone and into the spinal cord. Dorsal horn neurons were found to be synaptically driven by peripheral nerve stimulation in rats treated with NGF, NT3 and GDNF, demonstrating functional reconnection. In behavioural studies, rats treated with NGF and GDNF recovered sensitivity to noxious heat and pressure. The observed effects of neurotrophic factors corresponded to their known actions on distinct subpopulations of sensory neurons. Neurotrophic factor treatment may thus serve as a viable treatment in promoting recovery from root avulsion injuries.	Guys Kings & St Thomas Sch Biomed Sci, Neurosci Res Ctr, London SE1 7EH, England; Univ London Queen Mary & Westfield Coll, Div Biomed Sci, Neurosci Sect, London E1 4NS, England	University of London; King's College London; University of London; Queen Mary University London	Ramer, MS (corresponding author), Guys Kings & St Thomas Sch Biomed Sci, Neurosci Res Ctr, St Thomas Campus,Lambeth Palace Rd, London SE1 7EH, England.			McMahon, Stephen/0000-0003-4656-5536				AVERILL S, 1995, EUR J NEUROSCI, V7, P1484, DOI 10.1111/j.1460-9568.1995.tb01143.x; Bennett DLH, 1998, J NEUROSCI, V18, P3059; Bradbury EJ, 1998, MOL CELL NEUROSCI, V12, P256, DOI 10.1006/mcne.1998.0719; Bradbury EJ, 1999, EUR J NEUROSCI, V11, P3873, DOI 10.1046/j.1460-9568.1999.00809.x; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Cajal RS., 1928, DEGENERATION REGENER; Chong MS, 1999, J COMP NEUROL, V410, P42; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Dyer JK, 1998, EXP NEUROL, V154, P12, DOI 10.1006/exnr.1998.6905; Fraher JP, 1999, J ANAT, V194, P161, DOI 10.1046/j.1469-7580.1999.19420161.x; Houle JD, 1996, EXP NEUROL, V139, P278, DOI 10.1006/exnr.1996.0101; ITOH Y, 1990, J COMP NEUROL, V302, P272, DOI 10.1002/cne.903020207; Iwaya K, 1999, NEUROSURGERY, V44, P589, DOI 10.1097/00006123-199903000-00085; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11179, DOI 10.1073/pnas.93.20.11179; KOZLOVA EN, 1995, NEUROREPORT, V6, P269, DOI 10.1097/00001756-199501000-00011; MCMAHON SB, 1994, NEURON, V12, P1161, DOI 10.1016/0896-6273(94)90323-9; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; Oudega M, 1999, BRAIN RES, V818, P431, DOI 10.1016/S0006-8993(98)01314-6; RAMONCUETO A, 1994, EXP NEUROL, V127, P232, DOI 10.1006/exnr.1994.1099; ROSARIO CM, 1992, EXP NEUROL, V115, P158, DOI 10.1016/0014-4886(92)90241-H; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SIMS TJ, 1994, EXP BRAIN RES, V99, P25; TESSLER A, 1988, J COMP NEUROL, V270, P537, DOI 10.1002/cne.902700407; THOMPSON SWN, 1995, PAIN, V62, P219, DOI 10.1016/0304-3959(94)00271-F; Winkler J, 1997, ANN NEUROL, V41, P82, DOI 10.1002/ana.410410114; Zhang Y, 1998, J NEUROSCI RES, V54, P554; Zhou XF, 1999, EUR J NEUROSCI, V11, P1711, DOI 10.1046/j.1460-9568.1999.00589.x	27	405	441	1	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					312	316		10.1038/35002084	http://dx.doi.org/10.1038/35002084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659850				2022-12-28	WOS:000084899700053
J	de Koning, HJ				de Koning, HJ			Assessment of nationwide cancer-screening programmes	LANCET			English	Editorial Material							BREAST-CANCER; MORTALITY; QUALITY; TRIALS; WOMEN		Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	de Koning, HJ (corresponding author), Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands.		de+Koning, Harry/AAF-9062-2019	de+Koning, Harry/0000-0003-4682-3646				ALEXANDER F, 1989, J EPIDEMIOL COMMUN H, V43, P29, DOI 10.1136/jech.43.1.29; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; ANDERSSON I, 1995, J NATL CANCER I, V87, P1263; BAINES CJ, 1990, AM J ROENTGENOL, V155, P743, DOI 10.2214/ajr.155.4.2119103; DEHAES JCJM, 1991, INT J CANCER, V49, P538, DOI 10.1002/ijc.2910490411; DEKONING HJ, 1995, JNCI-J NATL CANCER I, V87, P1217; FAGERBERG G, 1985, ACTA ONCOL, V24, P465, DOI 10.3109/02841868509134418; FENTIMAN I, 1990, DETECTION TREATMENT, P618; Fracheboud J, 1998, INT J CANCER, V75, P694, DOI 10.1002/(SICI)1097-0215(19980302)75:5<694::AID-IJC6>3.0.CO;2-U; Hakama M, 1997, BRIT MED J, V314, P864; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; Moss S M, 1995, J Med Screen, V2, P186; Narod SA, 1997, LANCET, V349, P1846, DOI 10.1016/S0140-6736(05)61736-9; QUINN M, 1995, BRIT MED J, V311, P1391, DOI 10.1136/bmj.311.7017.1391; Sjonell G, 1999, Lakartidningen, V96, P904; TABAR L, 1981, RADIOLOGY, V138, P219, DOI 10.1148/radiology.138.1.7005939; van den Akker-van Marle E, 1999, J MED SCREEN, V6, P30, DOI 10.1136/jms.6.1.30	18	71	71	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					80	81		10.1016/S0140-6736(99)00419-5	http://dx.doi.org/10.1016/S0140-6736(99)00419-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675158				2022-12-28	WOS:000085557200002
J	Nicholson, KG				Nicholson, KG			Should staff in long-stay hospitals for elderly patients be vaccinated against influenza?	LANCET			English	Editorial Material							NURSING-HOME POPULATION; HEALTH-CARE WORKERS; OUTBREAKS; EPIDEMIC; MORTALITY		Leicester Royal Infirm, Infect Dis Unit, Leicester LE1 5WW, Leics, England	University of Leicester	Nicholson, KG (corresponding author), Leicester Royal Infirm, Infect Dis Unit, Leicester LE1 5WW, Leics, England.							Adal KA, 1996, INFECT CONT HOSP EP, V17, P641; AHMED AEH, 1995, LANCET, V346, P591, DOI 10.1016/S0140-6736(95)91434-X; COLES FB, 1992, J AM GERIATR SOC, V40, P589, DOI 10.1111/j.1532-5415.1992.tb02108.x; Drinka PJ, 1997, J FAM PRACTICE, V45, P509; Drinka PJ, 1998, ARCH INTERN MED, V158, P2155, DOI 10.1001/archinte.158.19.2155; Elder AG, 1996, BRIT MED J, V313, P1241, DOI 10.1136/bmj.313.7067.1241; NICHOLSON KG, 1995, VACCINE, V13, P365, DOI 10.1016/0264-410X(95)98258-C; ODELIN MF, 1993, GERONTOLOGY, V39, P109; PATRIARCA PA, 1986, AM J EPIDEMIOL, V124, P114, DOI 10.1093/oxfordjournals.aje.a114355; Potter J, 1997, J INFECT DIS, V175, P1, DOI 10.1093/infdis/175.1.1; WEINGARTEN S, 1988, J GEN INTERN MED, V3, P32, DOI 10.1007/BF02595754; Wilde JA, 1999, JAMA-J AM MED ASSOC, V281, P908, DOI 10.1001/jama.281.10.908; Yassi A, 1993, Can J Infect Dis, V4, P52; Yassi A, 1991, Can J Infect Dis, V2, P101	14	15	17	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					83	84		10.1016/S0140-6736(99)00310-4	http://dx.doi.org/10.1016/S0140-6736(99)00310-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675161				2022-12-28	WOS:000085557200005
J	Kilby, JM; Singh, S				Kilby, JM; Singh, S			Cytomegalovirus esophageal ulcers.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Alabama, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Kilby, JM (corresponding author), Univ Alabama, Birmingham, AL 35294 USA.			Kilby, J. Michael/0000-0003-3222-1003					0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2000	342	7					475	475		10.1056/NEJM200002173420705	http://dx.doi.org/10.1056/NEJM200002173420705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284FA	10675428				2022-12-28	WOS:000085319100005
J	Grote, JJ				Grote, JJ			Neonatal screening for hearing impairment	LANCET			English	Editorial Material							OTOACOUSTIC EMISSIONS		Leiden Univ, Med Ctr, Dept Ear Nose & Throat, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Grote, JJ (corresponding author), Leiden Univ, Med Ctr, Dept Ear Nose & Throat, NL-2300 RC Leiden, Netherlands.							BESS FH, 1994, PEDIATRICS, V93, P330; Davis A, 1997, HEALTH TECHNOL ASSES, V1, P1; *JOINT COMM INF HE, 1994, ASHA, V36, P38; KENNEDY CR, 1991, ARCH DIS CHILD-FETAL, V66, P1124, DOI 10.1136/adc.66.10_Spec_No.1124; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; Lutman ME, 1999, EUR J PEDIATR, V158, P95, DOI 10.1007/s004310051025; Miyamoto RT, 1999, ACTA OTO-LARYNGOL, V119, P219; *NIH, 1993, EARL ID HEAR IMP INF; Parving A, 1996, AUDIOLOGY, V35, P158; Salata JA, 1998, OTOLARYNG HEAD NECK, V118, P37, DOI 10.1016/S0194-5998(98)70372-9; Schoonhoven R, 1999, AUDIOLOGY, V38, P141; Watkin PM, 1999, ARCH DIS CHILD, V81, P380, DOI 10.1136/adc.81.5.380; Watkin PM, 1996, ARCH DIS CHILD-FETAL, V75, pF158, DOI 10.1136/fn.75.3.F158; WHITTAKER CK, 1993, AM J OTOL, V14, P1; Yoshinaga-Itano C, 1999, OTOLARYNG CLIN N AM, V32, P1089, DOI 10.1016/S0030-6665(05)70196-1	15	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					513	514		10.1016/S0140-6736(99)00393-1	http://dx.doi.org/10.1016/S0140-6736(99)00393-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10682997				2022-12-28	WOS:000085487400005
J	Loefler, IJP				Loefler, IJP			Are generalists still needed in a specialised world? The renaissance of general surgery	BRITISH MEDICAL JOURNAL			English	Article							VOLUME		Nairobi Hosp, Nairobi, Kenya		Loefler, IJP (corresponding author), Nairobi Hosp, POB 47964, Nairobi, Kenya.							BUCK N, 1987, REPORT CONFIDENTIAL, P38; DUDLEY H, 1990, PRIMARY SURG, V1; FERGUSON B, 1996, EFFECTIVE HLTH CARE, V2, P1; Jarhult J, 1996, EUR J SURG ONCOL, V22, P205, DOI 10.1016/S0748-7983(96)80002-3; King M., 1990, PRIMARY SURG, Vvol. 1; LOEFLER IJP, 1998, SURGERY, V16, P2; LOEFLER IJP, 1998, SURGERY, V16, P1; Richardson JD, 1998, J TRAUMA, V44, P266, DOI 10.1097/00005373-199802000-00004; Sarmiento A, 1998, J BONE JOINT SURG AM, V80A, P601, DOI 10.2106/00004623-199804000-00016; TAYLOR I, 1997, SURGERY, V15, P5; 1990, MED DIG, V16, P51; 1976, P ASS SURG E AFRICA, V23, P151; 1993, LANCET, V341, P597	13	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					436	438		10.1136/bmj.320.7232.436	http://dx.doi.org/10.1136/bmj.320.7232.436			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669452	Green Published			2022-12-28	WOS:000085377400028
J	Richards, T				Richards, T			UK launches initiative on global health	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					402	402						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669442				2022-12-28	WOS:000085377400019
J	Ciment, J				Ciment, J			Tube feeding bad for patients with dementia	BRITISH MEDICAL JOURNAL			English	News Item																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					335	335						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657322				2022-12-28	WOS:000085211400017
J	Mayer, W; Niveleau, A; Walter, J; Fundele, R; Haaf, T				Mayer, W; Niveleau, A; Walter, J; Fundele, R; Haaf, T			Embryogenesis - Demethylation of the zygotic paternal genome	NATURE			English	Article							DNA-REPLICATION; PREIMPLANTATION DEVELOPMENT; MOUSE EMBRYOS; METHYLATION		Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Grenoble 1, Mol & Struct Virol Unit, F-38706 La Tronche, France	Max Planck Society; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)								Adenot PG, 1997, DEVELOPMENT, V124, P4615; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BouniolBaly C, 1997, EXP CELL RES, V236, P201, DOI 10.1006/excr.1997.3708; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; HOWLETT SK, 1986, ROUX ARCH DEV BIOL, V195, P499, DOI 10.1007/BF00375890; MONK M, 1987, DEVELOPMENT, V99, P371; Olek A, 1997, NAT GENET, V17, P275, DOI 10.1038/ng1197-275; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; SCHEER U, 1987, EUR J CELL BIOL, V43, P358; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	10	1011	1066	0	91	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					501	502		10.1038/35000656	http://dx.doi.org/10.1038/35000656			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676950				2022-12-28	WOS:000085227300037
J	Mange, KC; Cizman, B; Joffe, M; Feldman, HI				Mange, KC; Cizman, B; Joffe, M; Feldman, HI			Arterial hypertension and renal allograft survival	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; DISEASE; PROGRESSION; RECIPIENTS; FAILURE	Context Several observational studies have investigated the significance of hypertension in renal allograft failure; however, these studies have been complicated by the lack of adjustment for baseline renal function, leaving the role of elevated blood pressure in allograft failure unclear. Objective To examine the relationship between blood pressure adjusted for renal function and survival after cadaveric allograft transplantation. Design Nonconcurrent historical cohort study conducted from 1985 through 1997. Setting University teaching hospital. Participants A total of 277 patients aged 18 years or older who underwent cadaveric renal transplantation without another simultaneous organ transplantation and whose allograft was functioning for a minimum of 1 year. Follow-up continued through 1997 (mean follow-up, 5.7 years). Main Outcome Measure Time to allograft failure (defined as death, return to dialysis, or retransplantation) by systolic, diastolic, and mean arterial blood pressure measurements at 1 year after transplantation. Results Multivariate Cox proportional hazards modeling demonstrated that nonwhite ethnicity, history of acute rejection, and nondiabetic kidney disease were significant predictors of failure (P = .01 for all), In addition, the calculated creatinine clearance at 1 year had an adjusted rate ratio (RR) for allograft failure per 10 mL/min (0.17 mL/s) of 0.74 (95% confidence interval [CI], 0.62-0.88). The RR per 10-mm Hg in crease in blood pressure measured at 1 year after transplantation, after adjustment for creatinine clearance, was 1.15 (95% CI, 1.02-1.30) for systolic pressure, 1.27 (95% CI, 1.01-1.60) for diastolic pressure, and 1.30 (95% CI, 1.05-1.61) for mean arterial pressure. Supplemental analyser that did not include death as a failure event or reduce the minimum allograft survival time for study subjects to 6 months yielded results consistent with the primary analysis. There was no evidence of modification of the blood pressure-allograft failure relationship by ethnicity or diabetes mellitus. Conclusions Systolic, diastolic, and mean arterial blood pressures at 1 year posttransplantation strongly predict allograft survival adjusted for baseline renal function. More aggressive control of blood pressure may prolong cadaveric allograft survival.	Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Feldman, HI (corresponding author), Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, 423 Guardian Dr,720 Blockley Hall, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007006, P50DK045191] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-07006, DK-45191] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAGNAC A, 1992, TRANSPLANTATION, V53, P766, DOI 10.1097/00007890-199204000-00012; Chertow GM, 1996, JAMA-J AM MED ASSOC, V276, P1732, DOI 10.1001/jama.276.21.1732; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; COSIO FG, 1995, KIDNEY INT, V47, P1136, DOI 10.1038/ki.1995.162; COX DR, 1972, J R STAT SOC B, V34, P187; Feldman HI, 1996, J AM SOC NEPHROL, V7, P151; Giatras I, 1997, ANN INTERN MED, V127, P337, DOI 10.7326/0003-4819-127-5-199709010-00001; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; LEE E, 1994, BIOMETRIKA, V81, P515; Opelz G, 1998, KIDNEY INT, V53, P217, DOI 10.1046/j.1523-1755.1998.00744.x; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; RUGGENENTI P, 1993, KIDNEY INT, V43, P706, DOI 10.1038/ki.1993.101; VIANELLO A, 1993, AM J KIDNEY DIS, V21, P79, DOI 10.1016/0272-6386(93)70099-K; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085	15	229	241	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					633	638		10.1001/jama.283.5.633	http://dx.doi.org/10.1001/jama.283.5.633			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665703				2022-12-28	WOS:000084956500029
J	D'Cruz, OF				D'Cruz, OF			Casting stones	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					441	442		10.1001/jama.283.4.441	http://dx.doi.org/10.1001/jama.283.4.441			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659858				2022-12-28	WOS:000084879800001
J	Fuller, R; Stanners, A				Fuller, R; Stanners, A			A cough, then respiratory failure	LANCET			English	Article							SYRINGOMYELIA; SCOLIOSIS		Pindersfield Gen Hosp, Med Rehabil Unit, Wakefield WF1 4DG, England	Pinderfields Hospital	Stanners, A (corresponding author), Pindersfield Gen Hosp, Med Rehabil Unit, Wakefield WF1 4DG, England.							ALCALA H, 1975, NEUROLOGY, V25, P875, DOI 10.1212/WNL.25.9.875; ALVAREZ D, 1995, EUR RESPIR J, V8, P661; ARAI S, 1993, SPINE, V18, P1591, DOI 10.1097/00007632-199309000-00004; KARNIK R, 1994, DEUT MED WOCHENSCHR, V119, P1771, DOI 10.1055/s-2008-1058899; Winter RB, 1997, SPINE, V22, P855, DOI 10.1097/00007632-199704150-00005	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					284	284		10.1016/S0140-6736(99)08502-5	http://dx.doi.org/10.1016/S0140-6736(99)08502-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675077				2022-12-28	WOS:000085045600013
J	Lata, R; Conway, JF; Cheng, NQ; Duda, RL; Hendrix, RW; Wikoff, WR; Johnson, JE; Tsuruta, H; Steven, AC				Lata, R; Conway, JF; Cheng, NQ; Duda, RL; Hendrix, RW; Wikoff, WR; Johnson, JE; Tsuruta, H; Steven, AC			Maturation dynamics of a viral capsid: Visualization of transitional intermediate states	CELL			English	Article							CRYOELECTRON MICROSCOPY; STRUCTURAL TRANSITIONS; BIOLOGICAL MACROMOLECULES; ELECTRON CRYOMICROSCOPY; CONFORMATIONAL-CHANGES; BACTERIAL-VIRUS; IN-VITRO; PROTEIN; DNA; BACTERIOPHAGE-T4	Typical of DNA bacteriophages and herpesviruses, HK97 assembles in two stages: polymerization and maturation. First, capsid protein polymerizes into closed shells; then, these precursors mature into larger, stabler particles. Maturation is initiated by proteolysis, producing a metastable particle primed for expansion-the major structural transition. We induced expansion in vitro by acidic pH and monitored the resulting changes by time-resolved X-ray diffraction and cryo-electron microscopy. The transition, which is not synchronized over the population, proceeds in a series of stochastically triggered subtransitions. Three distinct intermediates were identified, which are comparable to transitional states in protein folding. The intermediates' structures reveal the molecular events occurring during expansion. Integrated into a movie (see Dynamic Visualization below), they show capsid maturation as a dynamic process.	NIAMSD, Struct Biol Lab, Bethesda, MD 20892 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Stanford Univ, Stanford Linear Accelerator Ctr, SSRL, Palo Alto, CA 94309 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Scripps Research Institute; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Steven, AC (corresponding author), NIAMSD, Struct Biol Lab, Bethesda, MD 20892 USA.		Conway, James F/A-2296-2010	Conway, James F/0000-0002-6581-4748; Duda, Robert/0000-0002-9517-2731	NCRR NIH HHS [P41 RR01209] Funding Source: Medline; NIAID NIH HHS [R01 AI040101, R01 AI40101] Funding Source: Medline; NIGMS NIH HHS [R01 GM47795, R01 GM047795] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR027002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047795] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; BAYER ME, 1973, VIROLOGY, V54, P465, DOI 10.1016/0042-6822(73)90157-8; Belnap DM, 1997, J STRUCT BIOL, V120, P44, DOI 10.1006/jsbi.1997.3896; BERRIMAN J, 1994, ULTRAMICROSCOPY, V56, P241, DOI 10.1016/0304-3991(94)90012-4; Butcher SJ, 1997, EMBO J, V16, P4477, DOI 10.1093/emboj/16.14.4477; Conway JF, 1997, NATURE, V386, P91, DOI 10.1038/386091a0; CONWAY JF, 1995, J MOL BIOL, V253, P86, DOI 10.1006/jmbi.1995.0538; Conway JF, 1999, J STRUCT BIOL, V128, P106, DOI 10.1006/jsbi.1999.4168; COOKE R, 1995, FASEB J, V9, P636, DOI 10.1096/fasebj.9.8.7768355; DOKLAND T, 1993, J MOL BIOL, V233, P682, DOI 10.1006/jmbi.1993.1545; DUDA RL, 1995, J MOL BIOL, V247, P636, DOI 10.1006/jmbi.1994.0169; DUDA RL, 1995, J MOL BIOL, V247, P618, DOI 10.1016/S0022-2836(05)80143-3; Duda RL, 1998, CELL, V94, P55, DOI 10.1016/S0092-8674(00)81221-0; Flynn DL, 1997, CURR OPIN CHEM BIOL, V1, P190, DOI 10.1016/S1367-5931(97)80009-9; Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9; Fuller SD, 1996, J STRUCT BIOL, V116, P48, DOI 10.1006/jsbi.1996.0009; GALISTEO ML, 1993, BIOPHYS J, V65, P227, DOI 10.1016/S0006-3495(93)81073-7; Hendrix RW, 1998, ADV VIRUS RES, V50, P235, DOI 10.1016/S0065-3527(08)60810-6; HOHN B, 1983, P NATL ACAD SCI-BIOL, V80, P7456, DOI 10.1073/pnas.80.24.7456; Jardine PJ, 1998, J MOL BIOL, V284, P661, DOI 10.1006/jmbi.1998.2179; KING J, 1997, STRUCTURAL BIOL VIRU, P288; MULLER M, 1994, J STRUCT BIOL, V112, P199, DOI 10.1006/jsbi.1994.1021; Nermut MV, 1998, J STRUCT BIOL, V123, P143, DOI 10.1006/jsbi.1998.4024; Newcomb WW, 1996, J MOL BIOL, V263, P432, DOI 10.1006/jmbi.1996.0587; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SERWER P, 1978, J VIROL, V28, P917, DOI 10.1128/JVI.28.3.917-928.1978; SHIBATA H, 1987, J MOL BIOL, V196, P845, DOI 10.1016/0022-2836(87)90409-8; STEVEN AC, 1992, J MOL BIOL, V228, P870, DOI 10.1016/0022-2836(92)90871-G; STEVEN AC, 1990, BIOCHEMISTRY-US, V29, P5556, DOI 10.1021/bi00475a020; STEVEN AC, 1979, J SUPRAMOL STR CELL, V10, P1, DOI 10.1002/jss.400100102; Tao YZ, 1998, CELL, V95, P431, DOI 10.1016/S0092-8674(00)81773-0; Trus BL, 1997, NAT STRUCT BIOL, V4, P413, DOI 10.1038/nsb0597-413; Trus BL, 1996, J MOL BIOL, V263, P447, DOI 10.1016/S0022-2836(96)80018-0; Tsuruta H, 1998, J APPL CRYSTALLOGR, V31, P672, DOI 10.1107/S0021889898002702; Tuma R, 1996, BIOCHEMISTRY-US, V35, P4619, DOI 10.1021/bi952793l; Tuma R, 1998, P NATL ACAD SCI USA, V95, P9885, DOI 10.1073/pnas.95.17.9885; VALPUESTA JM, 1994, Q REV BIOPHYS, V27, P107, DOI 10.1017/S0033583500004510; WALKER M, 1995, BIOPHYS J, V68, pS87; White HE, 1997, NAT STRUCT BIOL, V4, P690, DOI 10.1038/nsb0997-690; Wikoff WR, 1998, VIROLOGY, V243, P113, DOI 10.1006/viro.1998.9040; Wikoff WR, 1999, ACTA CRYSTALLOGR D, V55, P763, DOI 10.1107/S0907444998017661; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; XIE ZH, 1995, J MOL BIOL, V253, P74, DOI 10.1006/jmbi.1995.0537; Yeager M, 1998, P NATL ACAD SCI USA, V95, P7299, DOI 10.1073/pnas.95.13.7299; Zlotnick A, 1996, BIOCHEMISTRY-US, V35, P7412, DOI 10.1021/bi9604800	46	120	127	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					253	263		10.1016/S0092-8674(00)81563-9	http://dx.doi.org/10.1016/S0092-8674(00)81563-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660048	Bronze			2022-12-28	WOS:000084932200009
J	Myatt, CJ; King, BE; Turchette, QA; Sackett, CA; Kielpinski, D; Itano, WM; Monroe, C; Wineland, DJ				Myatt, CJ; King, BE; Turchette, QA; Sackett, CA; Kielpinski, D; Itano, WM; Monroe, C; Wineland, DJ			Decoherence of quantum superpositions through coupling to engineered reservoirs	NATURE			English	Article							NONCLASSICAL MOTIONAL STATES; TRAPPED ION; ATOM; COHERENCE	The theory of quantum mechanics applies to closed systems. In such ideal situations, a single atom can, for example, exist simultaneously in a superposition of two different spatial locations, In contrast, real systems always interact with their environment, with the consequence that macroscopic quantum superpositions (as illustrated by the 'Schrodinger's cat' thought-experiment) are not observed, Moreover, macroscopic superpositions decay so quickly that even the dynamics of decoherence cannot,be observed, However, mesoscopic systems offer the possibility of observing the decoherence of such quantum superpositions, Here we present measurements of the decoherence of superposed motional states of a single trapped atom. Decoherence is induced by coupling the atom to engineered reservoirs, in which the coupling and state of the environment are controllable, we perform three experiments, finding that the decoherence rate scales with the square of a quantity describing the amplitude of the superposition state.	Natl Inst Stand & Technol, Div 847 10, Boulder, CO 80303 USA	National Institute of Standards & Technology (NIST) - USA	Wineland, DJ (corresponding author), Natl Inst Stand & Technol, Div 847 10, 325 Broadway, Boulder, CO 80303 USA.	dwineland@nist.gov	Monroe, Christopher R/G-8105-2011; Sackett, Charles/AAD-1452-2019; Itano, Wayne/AAV-8781-2020	Sackett, Charles/0000-0001-6741-0571; 				Brune M, 1996, PHYS REV LETT, V77, P4887, DOI 10.1103/PhysRevLett.77.4887; Buzek V., 1995, PROG OPTICS, V34, P1, DOI DOI 10.1016/S0079-6638(08)70324-X; CALDEIRA AO, 1985, PHYS REV A, V31, P1059, DOI 10.1103/PhysRevA.31.1059; CHAPMAN MS, 1995, PHYS REV LETT, V75, P3783, DOI 10.1103/PhysRevLett.75.3783; COLLETT MJ, 1988, PHYS REV A, V38, P2233, DOI 10.1103/PhysRevA.38.2233; deMatos RL, 1996, PHYS REV LETT, V76, P608, DOI 10.1103/PhysRevLett.76.608; Dirac P. A. M., 1958, PRINCIPLES QUANTUM M; Durr S, 1998, PHYS REV LETT, V81, P5705, DOI 10.1103/PhysRevLett.81.5705; Garraway BM, 1998, PHYS SCRIPTA, VT76, P152, DOI 10.1238/Physica.Topical.076a00152; GLAUBER RJ, 1963, PHYS REV, V131, P2766, DOI 10.1103/PhysRev.131.2766; Itano WM, 1997, P SOC PHOTO-OPT INS, V2995, P43, DOI 10.1117/12.273771; ITANO WM, 1990, PHYS REV A, V41, P2295, DOI 10.1103/PhysRevA.41.2295; MARZOLI I, 1994, PHYS REV A, V49, P2771, DOI 10.1103/PhysRevA.49.2771; Meekhof DM, 1996, PHYS REV LETT, V76, P1796, DOI 10.1103/PhysRevLett.76.1796; MONROE C, 1995, PHYS REV LETT, V75, P4011, DOI 10.1103/PhysRevLett.75.4011; Monroe C, 1996, SCIENCE, V272, P1131, DOI 10.1126/science.272.5265.1131; Murao M, 1998, PHYS REV A, V58, P663, DOI 10.1103/PhysRevA.58.663; MYATT CJ, IN PRESS LASER SPECT, V13; Poyatos JF, 1996, PHYS REV LETT, V77, P4728, DOI 10.1103/PhysRevLett.77.4728; Raimond JM, 1997, PHYS REV LETT, V79, P1964, DOI 10.1103/PhysRevLett.79.1964; RAIZEN MG, 1992, PHYS REV A, V45, P6493, DOI 10.1103/PhysRevA.45.6493; Schneider S, 1999, PHYS REV A, V59, P3766, DOI 10.1103/PhysRevA.59.3766; Schneider S, 1998, PHYS REV A, V57, P3748, DOI 10.1103/PhysRevA.57.3748; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P844, DOI 10.1007/BF01491987; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P807, DOI 10.1007/BF01491891; Schroedinger E., 1935, NATURWISSENSCHAFTEN, V23, P823, DOI [DOI 10.1007/BF01491914, 10.1007/BF01491914]; Thompson RC, 1999, AIP CONF PROC, V457, P388, DOI 10.1063/1.57449; Walls D. F., 1994, QUANTUM OPT; WALLS DF, 1985, PHYS REV A, V31, P2403, DOI 10.1103/PhysRevA.31.2403; Wilkinson SR, 1997, NATURE, V387, P575, DOI 10.1038/42418	32	583	588	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					269	273		10.1038/35002001	http://dx.doi.org/10.1038/35002001			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659838				2022-12-28	WOS:000084899700041
J	Miller, J; Petrie, J				Miller, J; Petrie, J			Development of practice guidelines	LANCET			English	Editorial Material							RECOMMENDATIONS		Royal Coll Phys, Scottish Intercollegiate Guidelines Network, Edinburgh EH2 1 Q, Midlothian, Scotland	Royal College of Physicians	Miller, J (corresponding author), Royal Coll Phys, Scottish Intercollegiate Guidelines Network, Edinburgh EH2 1 Q, Midlothian, Scotland.							*AGREE COLL GROUP, IN PRESS INT J TECHN; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; Institute of Medicine, 1992, GUID CLIN PRACT DEV; Leape L L, 1992, Qual Assur Health Care, V4, P151; *NAT HLTH MED RES, 1999, GUID DEV IMPL EV CLI; *SCOTT INT GUID NE, 1999, SIGN GUID INTR SIGN	7	56	58	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					82	83		10.1016/S0140-6736(99)90326-4	http://dx.doi.org/10.1016/S0140-6736(99)90326-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675160				2022-12-28	WOS:000085557200004
J	Clark, RH; Kueser, TJ; Walker, MW; Southgate, WM; Huckaby, JL; Perez, JA; Roy, BJ; Keszler, M; Kinsella, JP				Clark, RH; Kueser, TJ; Walker, MW; Southgate, WM; Huckaby, JL; Perez, JA; Roy, BJ; Keszler, M; Kinsella, JP		Clinical Inhaled Nitric Oxide Res	Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXTRACORPOREAL MEMBRANE-OXYGENATION; BLEEDING-TIME; PATHOPHYSIOLOGY; CIRCULATION; DISEASE; INJURY	Background: Inhaled nitric oxide improves gas exchange in neonates, but the efficacy of low-dose inhaled nitric oxide in reducing the need for extracorporeal membrane oxygenation has not been established. Methods: We conducted a clinical trial to determine whether low-dose inhaled nitric oxide would reduce the use of extracorporeal membrane oxygenation in neonates with pulmonary hypertension who were born after 34 weeks' gestation, were 4 days old or younger, required assisted ventilation, and had hypoxemic respiratory failure as defined by an oxygenation index of 25 or higher. The neonates who received nitric oxide were treated with 20 ppm for a maximum of 24 hours, followed by 5 ppm for no more than 96 hours. The primary end point of the study was the use of extracorporeal membrane oxygenation. Results: Of 248 neonates enrolled, 126 were randomly assigned to the nitric oxide group and 122 to the control group. Extracorporeal membrane oxygenation was used in 78 neonates in the control group (64 percent) and in 48 neonates in the nitric oxide group (38 percent) (P=0.001). The 30-day mortality rate in the two groups was similar (8 percent in the control group and 7 percent in the nitric oxide group). Chronic lung disease developed less often in neonates treated with nitric oxide than in those in the control group (7 percent vs. 20 percent, P=0.02). The efficacy of nitric oxide was independent of the base-line oxygenation index and the primary pulmonary diagnosis. Conclusions: Inhaled nitric oxide reduces the extent to which extracorporeal membrane oxygenation is needed in neonates with hypoxemic respiratory failure and pulmonary hypertension. (N Engl J Med 2000;342:469-74.) (C) 2000, Massachusetts Medical Society.	Duke Univ, Dept Pediat, Durham, NC 27706 USA; Carolinas Med Ctr, Div Neonatol, Charlotte, NC 28203 USA; Greenville Hosp Syst, Dept Neonatol, Greenville, SC USA; Med Univ S Carolina, Charleston, SC 29425 USA; Egleston Childrens Hosp, Atlanta, GA USA; Arnold Palmer Hosp, Orlando, FL USA; Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; Georgetown Univ Hosp, Div Neonatol, Washington, DC 20007 USA; Univ Colorado, Sch Med, Denver, CO USA	Duke University; Carolinas Medical Center; Greenville Health System; Medical University of South Carolina; Emory University; Georgetown University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Clark, RH (corresponding author), Pediatrix Med Grp, 1301 Concord Terr, Sunrise, FL 33323 USA.		Clark, Reese/L-5392-2019; Keszler, Martin/H-7260-2019	Clark, Reese/0000-0002-7363-4640; Keszler, Martin/0000-0002-9964-664X				ABMAN SH, 1990, AM J PHYSIOL, V259, pH1921, DOI 10.1152/ajpheart.1990.259.6.H1921; [Anonymous], 1997, NEW ENGL J MED, V337, P434; CORNISH JD, 1993, J PEDIATR-US, V122, P105, DOI 10.1016/S0022-3476(05)83501-2; Davidson D, 1998, PEDIATRICS, V101, P325, DOI 10.1542/peds.101.3.325; Field D, 1996, LANCET, V348, P75; Finer N, 1997, PEDIATRICS, V99, P838; FREEMAN B, 1994, CHEST, V105, pS79, DOI 10.1378/chest.105.3_Supplement.79S; Freeman B A, 1993, Res Rep Health Eff Inst, P1; GASTON B, 1994, PEDIATRICS, V94, P134; GEORGE TN, 1998, J PEDIATR, V132, P721; GLASS P, 1995, J PEDIATR-US, V127, P447, DOI 10.1016/S0022-3476(95)70082-X; Glass P, 1997, DEV MED CHILD NEUROL, V39, P441; Guidot DM, 1996, AM J PHYSIOL-LUNG C, V271, pL225, DOI 10.1152/ajplung.1996.271.2.L225; GUIDOT DM, 1995, AM J PHYSIOL-LUNG C, V269, pL2, DOI 10.1152/ajplung.1995.269.1.L2; Gutierrez HH, 1996, FREE RADICAL BIO MED, V21, P43, DOI 10.1016/0891-5849(95)02226-0; Hallman M, 1996, SEMIN PERINATOL, V20, P173, DOI 10.1016/S0146-0005(96)80046-2; HOGMAN M, 1994, ACTA PHYSIOL SCAND, V151, P125, DOI 10.1111/j.1748-1716.1994.tb09728.x; KANTO WP, 1994, J PEDIATR-US, V124, P335, DOI 10.1016/S0022-3476(94)70354-X; Kanto WP, 1998, CLIN PERINATOL, V25, P123, DOI 10.1016/S0095-5108(18)30140-4; Kinsella JP, 1997, PEDIATR RES, V41, P457, DOI 10.1203/00006450-199704000-00002; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; KINSELLA JP, 1995, J PEDIATR-US, V126, P853, DOI 10.1016/S0022-3476(95)70197-4; KINSELLA JP, 1992, AM J PHYSIOL, V263, pH875, DOI 10.1152/ajpheart.1992.263.3.H875; Luperchio S, 1996, FREE RADICAL BIO MED, V21, P513, DOI 10.1016/0891-5849(96)00219-5; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORIN FC, 1995, AM J RESP CRIT CARE, V151, P2010, DOI 10.1164/ajrccm.151.6.7767553; OROURKE PP, 1989, PEDIATRICS, V84, P957; Steinhorn RH, 1997, SEMIN PERINATOL, V21, P393, DOI 10.1016/S0146-0005(97)80005-5; Stork E, 1997, NEW ENGL J MED, V336, P597; UK Collaborative ECMO Group, 1998, PEDIATRICS, V101, P690; Vaucher YE, 1996, J PEDIATR-US, V128, P109, DOI 10.1016/S0022-3476(96)70439-0; WALSHSUKYS MC, 1994, J PEDIATR-US, V125, P104, DOI 10.1016/S0022-3476(94)70134-2; WESSEL DL, 1997, PEDIATRICS, V100, P888	34	471	498	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2000	342	7					469	474		10.1056/NEJM200002173420704	http://dx.doi.org/10.1056/NEJM200002173420704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284FA	10675427	Bronze			2022-12-28	WOS:000085319100004
J	Rabow, MW; Hardie, GE; Fair, JM; McPhee, SJ				Rabow, MW; Hardie, GE; Fair, JM; McPhee, SJ			End-of-life care content in 50 textbooks from multiple specialties	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Conference on Improving End-of-Life Care - A Conference of Nursing and Medical Textbook Publishers	MAR 12, 1999	OPEN SOC INST, NEW YORK, NY	Robert Wood Johnson Fdn, Last Acts Program	OPEN SOC INST		MEDICAL-EDUCATION; PALLIATIVE CARE; DYING PATIENTS; CHALLENGE; MODEL	Context Prior reviews of small numbers of medical textbooks suggest that end-of-life care is not well covered in textbooks. No broad study of end-of-life care content analysis has been performed on textbooks across a wide range of medical, pediatric, psychiatric, and surgical specialties. Objective To determine the quantity and rate the adequacy of information on end-of-life care in textbooks from multiple medical disciplines. Design and Sources A 1998 review of 50 top-selling textbooks from multiple specialties (cardiology, emergency medicine, family and primary care medicine, geriatrics, infectious disease and acquired immunodeficiency syndrome [AIDS], internal medicine, neurology, oncology and hematology, pediatrics, psychiatry, pulmonary medicine, and surgery) for the presence and adequacy of content in 13 end-of-life care domains. Main Outcome Measures Chapters on diseases commonly causing death and those devoted to end-of-life care were identified, read, rated, and compared by textbook specialty, chapter, and domain for the presence of helpful information in the 13 domains. Content for each domain was rated as absent, minimally present, or helpful. Textbook indexes were analyzed for the number of pages relevant to end-of-life care. Results Overall, helpful information was provided in 24.1% (range, 8.7%-44.2%) of the expected end-of-life content domains; in 19.1% (range, 6.2%-38.5%), expected content received minimal attention; and in 56.9% (range, 23.1%-77.9%), expected content was absent. As a group, the textbooks with the highest percentages of absent content were in surgery (71.8%), infectious diseases and AIDS (70%), and oncology and hematology (61.9%). Textbooks with the highest percentage of helpful end-of-life care content were in family medicine (34.4%), geriatrics (34.4%), and psychiatry (29.6%), In internal medicine textbooks, the content domains with the greatest amount of helpful information were epidemiology and natural history. Content domains covered least well were social, spiritual, ethical, and family issues, as well as physician after-death responsibilities. On average, textbook indexes cited 2% of their total pages as pertinent to end-of-life care. Conclusion Top-selling textbooks generally offered little helpful information on caring for patients at the end of life. Most disease-oriented chapters had no or minimal end-of-life care content. Specialty textbooks with information about particular diseases often did not contain helpful information on caring for patients dying from those diseases.	Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rabow, MW (corresponding author), Univ Calif San Francisco, Mt Zion, 1701 Divisadero St,5th Floor, San Francisco, CA 94115 USA.	mrabow@medicine.ucsf.edu						American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; BLANCHARD CG, 1981, CANCER, V47, P2756, DOI 10.1002/1097-0142(19810601)47:11<2756::AID-CNCR2820471135>3.0.CO;2-G; Block S D, 1998, J Palliat Med, V1, P347, DOI 10.1089/jpm.1998.1.347; Carron A T, 1999, Ann Intern Med, V130, P82; *CDCP, 1998, 10 LEAD CAUS DEATH U; Emanuel EJ, 1997, LANCET, V349, P1714, DOI 10.1016/S0140-6736(05)62952-2; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Ferrell B R, 1999, J Palliat Med, V2, P161, DOI 10.1089/jpm.1999.2.161; GIBSON R, 1998, J PALLIAT MED, V1, P415; HILL TP, 1995, ARCH INTERN MED, V155, P1265, DOI 10.1001/archinte.155.12.1265; Hill Wendy C., 1998, Pediatric Research, V43, p111A; HOLLEMAN WL, 1994, TEACH LEARN MED, V6, P260; *I MED COMM CAR EN, 1997, APPR DEATH IMPR CAR; Kaye J M, 1991, J Cancer Educ, V6, P21; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; *LOG BROTH CO INC, 1997, ORD FORM MOST POP TI; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MACDONALD N, 1991, CANADIAN PALLIATIVE; MCWHINNEY IR, 1994, CAN FAM PHYSICIAN, V40, P240; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; Plumb J D, 1992, Am J Hosp Palliat Care, V9, P32, DOI 10.1177/104990919200900311; Quill TE, 1998, ANN INTERN MED, V129, P590, DOI 10.7326/0003-4819-129-7-199810010-00026; Rabow M W, 1999, J Palliat Med, V2, P153, DOI 10.1089/jpm.1999.2.153; RAPPAPORT W, 1993, SURGERY, V113, P163; *RW JOHNS FDN LAST, 1999, C NURS MED TXB PUBL; SCHEIDERMAMN LJ, 1997, J FAM PRACTICE, V45, P259; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinmetz D, 1993, Arch Fam Med, V2, P753, DOI 10.1001/archfami.2.7.753; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; von Gunten C F, 1995, Am J Hosp Palliat Care, V12, P38, DOI 10.1177/104990919501200413; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; Woods NF., 1988, NURSING RES THEORY P	34	125	126	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					771	778		10.1001/jama.283.6.771	http://dx.doi.org/10.1001/jama.283.6.771			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	280XL	10683056				2022-12-28	WOS:000085129000029
J	Josefson, D				Josefson, D			Women taking combination HRT are at greater risk of breast cancer	BRITISH MEDICAL JOURNAL			English	News Item																		Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; 2000, JAME, V283, P534	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					333	333						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657316				2022-12-28	WOS:000085211400011
J	Kirby, RM				Kirby, RM			A memorable event - New doctors	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					375	375		10.1136/bmj.320.7231.375	http://dx.doi.org/10.1136/bmj.320.7231.375			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657340	Green Published			2022-12-28	WOS:000085211400039
J	Olesen, F; Dickinson, J; Hjortdahl, P				Olesen, F; Dickinson, J; Hjortdahl, P			General practice - time for a new definition	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE		Univ Aarhus, Res Unit Gen Practice, Vennelyst Blvd 6, DK-8000 Aarhus C, Denmark; Chinese Univ Hong Kong, Dept Community & Family Med, Hong Kong, Peoples R China; Univ Oslo, Dept Community & Family Med, Oslo, Norway	Aarhus University; Chinese University of Hong Kong; University of Oslo	Olesen, F (corresponding author), Univ Aarhus, Res Unit Gen Practice, Vennelyst Blvd 6, DK-8000 Aarhus C, Denmark.	fo@alm.au.dk						Anderson JM, 1996, SOC SCI MED, V43, P697, DOI 10.1016/0277-9536(96)00153-0; Antonowsky A, 1979, HLTH STRESS COPING; Brody H, 1999, J FAM PRACTICE, V48, P585; Dixon DM, 1999, BRIT J GEN PRACT, V49, P309; Donaldson M, 1996, PRIMARY CARE AM HLTH; Freeman G, 1997, BRIT MED J, V314, P1870, DOI 10.1136/bmj.314.7098.1870; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; HEATH I, 1995, MYSTER GEN PRACTICE; Heyrman J, 1987, VOCATIONAL TRAINING; Krasnik A, 1996, SCAND J SOC MED, V24, P2, DOI 10.1177/140349489602400102; LAMBERTS H, 1994, GEN PRACTICE RES DUT; MALTERUD K, 1995, THEOR MED, V16, P183, DOI 10.1007/BF00998544; McWhinney I, 1997, TXB FAMILY MED; McWhinney IR, 1996, BRIT J GEN PRACT, V46, P433; OLESEN F, 1998, EUR J GEN PRACT, V4, P81; Rosser WW, 1996, J FAM PRACTICE, V42, P139; Tuckett D., 1985, M EXPERTS APPROACH S; WEEL C, 1995, EUR J GEN PRACT, V1, P6; *WHO, 1994, MAK MED PRACT ED MOR	19	87	88	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2000	320	7231					354	357		10.1136/bmj.320.7231.354	http://dx.doi.org/10.1136/bmj.320.7231.354			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	282HC	10657333	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000085211400027
J	Kwan, P; Brodie, MJ				Kwan, P; Brodie, MJ			Early identification of refractory epilepsy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRACTABLE EPILEPSY; ANTIEPILEPTIC DRUGS; UNTREATED EPILEPSY; SEIZURES; REMISSION; PROGNOSIS; PREDICTORS; CHILDHOOD; COMMUNITY; SURGERY	Background: More than 30 percent of patients with epilepsy have inadequate control of seizures with drug therapy, but why this happens and whether it can be predicted are unknown. We studied the response to antiepileptic drugs in patients with newly diagnosed epilepsy to identify factors associated with subsequent poor control of seizures. Methods: We prospectively studied 525 patients (age, 9 to 93 years) who were given a diagnosis, treated, and followed up at a single center between 1984 and 1997. Epilepsy was classified as idiopathic (with a presumed genetic basis), symptomatic (resulting from a structural abnormality), or cryptogenic (resulting from an unknown underlying cause). Patients were considered to be seizure-free if they had not had any seizures for at least one year. Results: Among the 525 patients, 333 (63 percent) remained seizure-free during antiepileptic-drug treatment or after treatment was stopped. The prevalence of persistent seizures was higher in patients with symptomatic or cryptogenic epilepsy than in those with idiopathic epilepsy (40 percent vs. 26 percent, P=0.004) and in patients who had had more than 20 seizures before starting treatment than in those who had had fewer (51 percent vs. 29 percent, P<0.001). The seizure-free rate was similar in patients who were treated with a single established drug (67 percent) and patients who were treated with a single new drug (69 percent). Among 470 previously untreated patients, 222 (47 percent) became seizure-free during treatment with their first antiepileptic drug and 67 (14 percent) became seizure-free during treatment with a second or third drug. In 12 patients (3 percent) epilepsy was controlled by treatment with two drugs. Among patients who had no response to the first drug, the percentage who subsequently became seizure-free was smaller (11 percent) when treatment failure was due to lack of efficacy than when it was due to intolerable side effects (41 percent) or an idiosyncratic reaction (55 percent). Conclusions: Patients who have many seizures before therapy or who have an inadequate response to initial treatment with antiepileptic drugs are likely to have refractory epilepsy. (N Engl J Med 2000;342:314-9.) (C) 2000, Massachusetts Medical Society.	Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Brodie, MJ (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland.	martin.j.brodie@clinmed.gla.ac.uk		Kwan, Patrick/0000-0001-7310-276X				ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BEGHI E, 1992, EPILEPSIA, V33, P45; Berg AT, 1996, EPILEPSIA, V37, P24, DOI 10.1111/j.1528-1157.1996.tb00507.x; Berg AT, 1997, J CLIN NEUROPHYSIOL, V14, P102, DOI 10.1097/00004691-199703000-00003; Brodie MJ, 1997, EPILEPSIA, V38, P1245, DOI 10.1111/j.1528-1157.1997.tb01224.x; Brodie MJ, 1999, EPILEPSIA, V40, pS17, DOI 10.1111/j.1528-1157.1999.tb00928.x; Brodie MJ, 1999, EPILEPSY RES, V37, P81, DOI 10.1016/S0920-1211(99)00039-X; Brodie MJ, 1999, EPILEPSY RES, V34, P199, DOI 10.1016/S0920-1211(98)00110-7; Brodie MJ, 1996, LANCET, V347, P777, DOI 10.1016/S0140-6736(96)90863-6; Brodie MJ, 1997, EPILEPSY RES, V26, P423, DOI 10.1016/S0920-1211(96)01007-8; Brodie MJ, 1996, NEW ENGL J MED, V334, P479; BRODIE MJ, 1995, LANCET, V345, P662; Camfield C, 1996, NEUROLOGY, V46, P41, DOI 10.1212/WNL.46.1.41; COCKERELL OC, 1995, LANCET, V346, P140, DOI 10.1016/S0140-6736(95)91208-8; COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; Cockerell OC, 1996, J NEUROL NEUROSUR PS, V60, P247; Devinsky O, 1999, NEW ENGL J MED, V340, P1565, DOI 10.1056/NEJM199905203402008; DREIFUSS FE, 1998, EPILEPSY COMPREHENSI, V1, P517; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; *ILEA COMM, 1997, EPILEPSIA, V38, P614; KERANEN T, 1993, BRIT MED J, V307, P483, DOI 10.1136/bmj.307.6902.483; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; MCKEE PJW, 1993, THER DRUG MONIT, V15, P83, DOI 10.1097/00007691-199304000-00003; MCKEE PJW, 1990, BRIT MED J, V300, P978, DOI 10.1136/bmj.300.6730.978; Musicco M, 1997, NEUROLOGY, V49, P991, DOI 10.1212/WNL.49.4.991; Perucca E, 1998, CNS DRUGS, V10, P171, DOI 10.2165/00023210-199810030-00002; REYNOLDS EH, 1995, BRIT MED J, V310, P176, DOI 10.1136/bmj.310.6973.176; SANDER JWAS, 1993, EPILEPSIA, V34, P1007, DOI 10.1111/j.1528-1157.1993.tb02126.x; SCHMIDT D, 1995, CNS DRUGS, V3, P194, DOI 10.2165/00023210-199503030-00005; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; SHAFER SQ, 1988, EPILEPSIA, V29, P590, DOI 10.1111/j.1528-1157.1988.tb03767.x; Shorvon SD, 1996, EPILEPSIA, V37, pS1, DOI 10.1111/j.1528-1157.1996.tb06027.x; SILLANPAA M, 1993, EPILEPSIA, V34, P930, DOI 10.1111/j.1528-1157.1993.tb02114.x; Sillanpaa M, 1998, NEW ENGL J MED, V338, P1715, DOI 10.1056/NEJM199806113382402; TISHLER DM, 1995, EPILEPSIA, V36, P1, DOI 10.1111/j.1528-1157.1995.tb01657.x; Tobias E S, 1994, Seizure, V3, P37, DOI 10.1016/S1059-1311(05)80161-X; WATTS AE, 1992, EPILEPSIA, V33, P464, DOI 10.1111/j.1528-1157.1992.tb01692.x; Wieser HG, 1998, SEIZURE-EUR J EPILEP, V7, P173, DOI 10.1016/S1059-1311(98)80032-0; WOLF P, 1998, EPILEPSY COMPREHENSI, V1, P773	42	3295	3423	9	229	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2000	342	5					314	319		10.1056/NEJM200002033420503	http://dx.doi.org/10.1056/NEJM200002033420503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279XL	10660394				2022-12-28	WOS:000085070300003
J	Leonard, JV; Schapira, AHV				Leonard, JV; Schapira, AHV			Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects	LANCET			English	Review							LINKED SPASTIC PARAPLEGIA; C-OXIDASE DEFICIENCY; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; CYTOCHROME-C; PARKINSONS-DISEASE; MULTIPLE DELETIONS; FRIEDREICH-ATAXIA; LEIGHS SYNDROME; DNA	The first part of this review (Lancet 2000; 355: 299) covered primary disorders of mitochondrial DNA (mtDNA). This section will cover nuclear-encoded defects of the oxidative phosphorylation (OXPHOS) system, including mtDNA mutations that are secondary to nuclear gene mutations and nuclear gene defects responsible for secondary OXPHOS deficiency (panel). The latter group of diseases are predominantly neurodegenerative. The mitochondrion's role in apoptosis and its contribution to the pathogenesis of neurodegenerative diseases are also covered.	Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London NW3 2PF, England; UCL, Neurol Inst, London, England; Inst Child Hlth, Biochem Endocrine & Metab Unit, London, England	University of London; University College London; University of London; University College London; University of London; University College London	Schapira, AHV (corresponding author), Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, Rowland Hill St, London NW3 2PF, England.	schapira@rfhsm.ac.uk	Schapira, Anthony H V/A-1245-2010	Schapira, Anthony H V/0000-0002-3018-3966				Adams PL, 1997, ANN NEUROL, V41, P268, DOI 10.1002/ana.410410219; Arenas J, 1998, ANN NEUROL, V43, P397, DOI 10.1002/ana.410430321; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; Bonilla E, 1999, BBA-BIOENERGETICS, V1410, P171, DOI 10.1016/S0005-2728(98)00165-0; BOTS GTAM, 1981, ACTA NEUROPATHOL, V55, P21, DOI 10.1007/BF00691525; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; Briones P, 1997, J INHERIT METAB DIS, V20, P569, DOI 10.1023/A:1005303008439; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99; Chandrasekaran K, 1996, EXP NEUROL, V142, P80, DOI 10.1006/exnr.1996.0180; Cock H, 1999, EPILEPSIA, V40, P33, DOI 10.1111/j.1528-1157.1999.tb00897.x; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; De Michele G, 1998, AM J HUM GENET, V63, P135, DOI 10.1086/301930; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207; HALTIA M, 1992, BRAIN PATHOL, V2, P133, DOI 10.1111/j.1750-3639.1992.tb00681.x; HEVNER RF, 1993, J NEUROSCI, V13, P1805; Hirano M, 1997, P NATL ACAD SCI USA, V94, P14894, DOI 10.1073/pnas.94.26.14894; HUCKRIEDE A, 1994, BBA-MOL BASIS DIS, V1227, P200, DOI 10.1016/0925-4439(94)90096-5; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; Kaukonen JA, 1996, AM J HUM GENET, V58, P763; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Koroshetz WJ, 1997, ANN NEUROL, V41, P160, DOI 10.1002/ana.410410206; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492; Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154; Lutsenko S, 1998, P NATL ACAD SCI USA, V95, P6004, DOI 10.1073/pnas.95.11.6004; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; NICHOLLS DG, 1985, PROG BRAIN RES, V63, P97; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Priller J, 1997, ANN NEUROL, V42, P265, DOI 10.1002/ana.410420222; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; SANCHEZ-CASIS G, 1976, Canadian Journal of Neurological Sciences, V3, P349; SAUGIERVEBER P, 1994, NAT GENET, V6, P257, DOI 10.1038/ng0394-257; Schapira AHV, 1996, CURR OPIN NEUROL, V9, P260, DOI 10.1097/00019052-199608000-00003; Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SIMONIAN NA, 1994, J NEUROPATH EXP NEUR, V53, P508, DOI 10.1097/00005072-199409000-00010; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918; Swerdlow RH, 1998, ANN NEUROL, V44, P873, DOI 10.1002/ana.410440605; Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417; Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935; Tabrizi SJ, 2000, ANN NEUROL, V47, P80; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150; TIRANTI V, 1995, HUM MOL GENET, V4, P2017, DOI 10.1093/hmg/4.11.2017; Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	64	149	158	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	2000	355	9201					389	394		10.1016/S0140-6736(99)05226-5	http://dx.doi.org/10.1016/S0140-6736(99)05226-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665569				2022-12-28	WOS:000085122100037
J	Scanlon, JD; Lee, MSY				Scanlon, JD; Lee, MSY			The Pleistocene serpent Wonambi and the early evolution of snakes	NATURE			English	Article							ANATOMY	The Madtsoiidae were medium sized to gigantic snakes with a fossil record extending from the mid-Cretaceous to the Pleistocene, and spanning Europe, Africa, Madagascar, South America and Australia(1-3), This widely distributed group survived for about 90 million years (70% of known ophidian history), and potentially provides important insights into the origin and early evolution of snakes. However, madtsoiids are known mostly from their vertebrae, and their skull morphology and phylogenetic affinities have been enigmatic. Here we report new Australian material of Wonambi, one of the last-surviving madtsoiids(4-6), that allows the first detailed assessment of madtsoiid cranial anatomy and relationships, Despite its recent age, which could have overlapped with human history in Australia, Wonambi is one of the most primitive snakes known-as basal as the Cretaceous forms Pachyrhachis(7) and Dinilysia(8). None of these three primitive snake lineages shows features associated with burrowing, nor do any of the nearest lizard relatives of snakes (varanoids), These phylogenetic conclusions contradict the widely held 'subterranean' theory of snake origins(9-12), and instead imply that burrowing snakes (scolecophidians and anilioids) acquired their fossorial adaptations after the evolution of the snake body form and jaw apparatus in a large aquatic or (surface-active) terrestrial ancestor.	Univ Queensland, Dept Zool, Brisbane, Qld 4072, Australia; Univ New S Wales, Dept Biol Sci, Sydney, NSW 2052, Australia	University of Queensland; University of New South Wales Sydney	Scanlon, JD (corresponding author), Univ Queensland, Dept Zool, Brisbane, Qld 4072, Australia.	jscanlon@ultra.net.au						ARCHER M, 1997, C BIOCH 97, P131; BARRIE DJ, 1990, MEMOIRS QUEENSLAND M, V28, P139; BELLAIRS AD, 1951, BIOL REV, V26, P193, DOI 10.1111/j.1469-185X.1951.tb00646.x; CoPE E. D., 1869, P BOSTON SOC NATURAL, V12, P250; CUNDALL D, 1993, ZOOL J LINN SOC-LOND, V109, P275, DOI 10.1006/zjls.1993.1039; CUNDALL D, 1995, J ZOOL, V237, P353, DOI 10.1111/j.1469-7998.1995.tb02767.x; ESTES R, 1970, Bulletin of the Museum of Comparative Zoology, V140, P25; FRAZZETTA T H, 1970, Forma et Functio, V3, P205; Hecht MK., 1982, NEUES JB GEOLOGIE PA, P523; HEISE PJ, 1995, MOL BIOL EVOL, V12, P259; IANENSCH W, 1906, BEITR PALAEONT GEOL, V19, P1; Kluge A.G., 1991, MISCELLANEOUS PUBLIC, V178, P1; LaDuke T.C., 1991, CONTRIBUTIONS SCI NA, V424, P1, DOI [10.5962/p.226807, DOI 10.5962/P.226807]; Lee MSY, 1998, BIOL J LINN SOC, V65, P369, DOI 10.1111/j.1095-8312.1998.tb01148.x; Lee MSY, 1998, PHILOS T ROY SOC B, V353, P1521, DOI 10.1098/rstb.1998.0308; McDowell SB, 1987, SNAKES ECOLOGY EVOLU, P1; NOPESA F, 1923, PALAEONTOGRAPHICA, V65, P99; Rage Jean-Claude, 1998, Palaeovertebrata (Montpellier), V27, P109; RAGE JG, 1984, HDB PALAEHERPETOL 11; RIEPPEL O, 1988, EVOL BIOL, V22, P37; Scanlon John D., 1997, Memoirs of the Queensland Museum, V41, P393; Scanlon John D., 1995, Proceedings of the Linnean Society of New South Wales, V115, P233; SMITH M J, 1976, Transactions of the Royal Society of South Australia, V100, P39; SWOFFORD DL, 1999, PAUP VERSION 4 PHYLO; Underwood G., 1976, Linnean Soc Symp Ser, V3, P151; Underwood G., 1967, CONTRIBUTION CLASSIF; Wallach V, 1998, AMPHIBIA-REPTILIA, V19, P385, DOI 10.1163/156853898X00052; Walls G. L., 1940, COPEIA, V1940, P1; Woodward AS, 1901, P ZOOL SOC LOND, V1, P169; Zaher H, 1998, J VERTEBR PALEONTOL, V18, P1, DOI 10.1080/02724634.1998.10011029	30	100	102	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					416	420		10.1038/35000188	http://dx.doi.org/10.1038/35000188			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667791				2022-12-28	WOS:000085121100047
J	Silverberg, R				Silverberg, R			Pluto story - The discovery of extraterrestrial life was the key event of the third millennium.	NATURE			English	Article																			0	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					367	367		10.1038/35000306	http://dx.doi.org/10.1038/35000306			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667769	Bronze			2022-12-28	WOS:000085121100024
J	Cocchiarella, L; Turk, MA; Andersson, G				Cocchiarella, L; Turk, MA; Andersson, G			Improving the evaluation of permanent impairment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Amer Med Assoc, Chicago, IL 60610 USA; Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA; SUNY Upstate Med Univ, Dept Phys Med & Rehabil, Syracuse, NY USA	American Medical Association; Rush University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Cocchiarella, L (corresponding author), Amer Med Assoc, 515 N State St, Chicago, IL 60610 USA.		COCCHIARELLA, LUIGI/G-6878-2018	COCCHIARELLA, LUIGI/0000-0002-3201-4189				*AM MED ASS, IN PRESS GUID EV PER; American Medical Association, 1993, GUID EV PERM IMP; BARTH PS, 1999, PERMANENT PARTIAL DI; FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004; Goldstein B, 1997, JAMA-J AM MED ASSOC, V277, P1891; HSIAO WC, 1992, MED CARE, V30, pNS1, DOI 10.1097/00005650-199211001-00001; Institute of Medicine, 1997, EN AM ASS ROL REH SC; King PM, 1998, PHYS THER, V78, P852, DOI 10.1093/ptj/78.8.852; McDowell I., 1996, MEASURING HLTH GUIDE; *NAT COUNC DIS, 1999, NAT DIS POL PROGR RE; Spieler EA, 2000, JAMA-J AM MED ASSOC, V283, P519, DOI 10.1001/jama.283.4.519; 1999, INT CLASSIFICATION I	12	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					532	533		10.1001/jama.283.4.532	http://dx.doi.org/10.1001/jama.283.4.532			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659882				2022-12-28	WOS:000084879800035
J	Van Kampen, M; De Weerdt, W; Van Poppel, H; De Ridder, D; Feys, H; Baert, L				Van Kampen, M; De Weerdt, W; Van Poppel, H; De Ridder, D; Feys, H; Baert, L			Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial	LANCET			English	Article							RETROPUBIC PROSTATECTOMY; URINARY-INCONTINENCE; POSTPROSTATECTOMY INCONTINENCE; URODYNAMIC EVALUATION; CONTINENCE; EXPERIENCE; EXERCISES; MORBIDITY; SYMPTOMS	Background Urinary incontinence is a common long-term complication after radical prostatectomy. Spontaneous recovery of normal urinary control after surgery can take 1-2 years, We aimed to investigate whether there was any beneficial effect of pelvic-floor re-education for patients with urinary incontinence as a result of radical prostatectomy. Methods 102 consecutive incontinent patients who had had radical retropubic prostatectomy for clinically localised prostate cancer and who could comply with the ambulatory treatment schedule in our hospital were randomised, after catheter removal, into a treatment group (n=50) and a control group (n=52). Patients in the treatment group took part in a pelvic-floor re-education programme for as long as they were incontinent, and for a maximum of 1 year. The control group received placebo therapy. The primary endpoint was continence rate at 3 months. Incontinence was assessed objectively with the 1 h and 24 h pad tests and subjectively by the visual analogue scale, The groups were analysed on an intention-to-treat basis by ANOVA and chi(2)-test. Findings In the treatment group continence was achieved after 3 months in 43 (88%) of 48 patients. In the control group, continence returned after 3 months in 29 (56%) of 52 patients. At 1 year. the difference in proportion between treatment and control group was 14% (95% CI 2-27). In the treatment group improvement in both duration (log-rank test, p=0.0001) and degree of incontinence (Wald test. p=0.0010) was significantly better than in the control group. Interpretation Pelvic-floor re-education should be considered as a first-line option in curing incontinence after radical prostatectomy.	KU Leuven, Univ Hosp, Fac Educ & Physiotherapy, Dept Physiotherapy, Louvain, Belgium; KU Leuven, Univ Hosp, Div Urol, Louvain, Belgium; KU Leuven, Univ Hosp, Fac Phys Educ, Louvain, Belgium	KU Leuven; KU Leuven; KU Leuven	Van Kampen, M (corresponding author), KU Leuven, Univ Hosp, Fac Educ & Physiotherapy, Dept Physiotherapy, Louvain, Belgium.		De Ridder, Dirk JMK/G-2481-2010	De Ridder, Dirk JMK/0000-0001-6914-0077				BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; Bates TS, 1998, EUR UROL, V33, P165, DOI 10.1159/000019549; Bo K, 1996, OBSTET GYNECOL, V87, P261, DOI 10.1016/0029-7844(95)60375-1; BURGIO KL, 1989, J UROLOGY, V141, P303, DOI 10.1016/S0022-5347(17)40747-6; CAMMU H, 1995, UROLOGY, V45, P113, DOI 10.1016/S0090-4295(95)97180-7; CHAO R, 1995, J UROLOGY, V154, P16, DOI 10.1016/S0022-5347(01)67212-4; Donnellan SM, 1997, UROLOGY, V49, P225, DOI 10.1016/S0090-4295(96)00451-7; Eastham JA, 1996, J UROLOGY, V156, P1707, DOI 10.1016/S0022-5347(01)65488-0; ELDER JS, 1984, J UROLOGY, V132, P55, DOI 10.1016/S0022-5347(17)49462-6; Ficazzola MA, 1998, J UROLOGY, V160, P1317, DOI 10.1016/S0022-5347(01)62525-4; Goluboff ET, 1998, J UROLOGY, V159, P1276, DOI 10.1016/S0022-5347(01)63580-8; Gudziak MR, 1996, J UROLOGY, V156, P1131, DOI 10.1016/S0022-5347(01)65724-0; Haab F, 1996, UROL CLIN N AM, V23, P447, DOI 10.1016/S0094-0143(05)70324-4; HADLEY HR, 1986, CAMPBELLS UROLOGY, P2658; HAHN I, 1993, BRIT J UROL, V72, P421, DOI 10.1111/j.1464-410X.1993.tb16170.x; Hammerer P, 1997, J UROLOGY, V157, P233, DOI 10.1016/S0022-5347(01)65334-5; HAUTMANN RE, 1994, UROLOGY, V43, P47, DOI 10.1016/0090-4295(94)90218-6; HIRAOKA S, 1993, APCCHE CHEMECA 93 OF, V1, P353; JEYASSEELAN SM, 1997, CLIN GERONTOL, V7, P83; Leach GE, 1996, J UROLOGY, V155, P1256, DOI 10.1016/S0022-5347(01)66235-9; MEAGLIA JP, 1990, J UROLOGY, V144, P674, DOI 10.1016/S0022-5347(17)39551-4; MOURITSEN L, 1991, BRIT J UROL, V68, P32, DOI 10.1111/j.1464-410X.1991.tb15252.x; MYERS RP, 1995, EUR UROL SUPPL, V27, pS32; RUDY DC, 1984, J UROLOGY, V132, P708, DOI 10.1016/S0022-5347(17)49836-3; SCHUSSLER B, 1994, PELVIC FLOOR REEDUCA, P39; SERVOLL E, 1992, SCAND J UROL NEPHROL, V26, P231, DOI 10.3109/00365599209180874; SUTHERST J, 1981, LANCET, V1, P1128; Talcott JA, 1998, J CLIN ONCOL, V16, P275, DOI 10.1200/JCO.1998.16.1.275; Thiel R, 1997, EUR UROL, V31, P9; Van Kampen M, 1998, UROL INT, V60, P80, DOI 10.1159/000030216; WALSH PC, 1992, CAMPBELLS UROLOGY, P2865; WILSON JWL, 1996, J UROL S8, V156, pS16	32	192	201	1	32	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					98	102		10.1016/S0140-6736(99)03473-X	http://dx.doi.org/10.1016/S0140-6736(99)03473-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675166				2022-12-28	WOS:000085557200010
J	Porter, AMW				Porter, AMW			The death of a British officer-cadet from heat illness	LANCET			English	Editorial Material							MALIGNANT HYPERTHERMIA; HEATSTROKE		Radcrest, Heath Rise, Surrey GU15 2ER, England		Porter, AMW (corresponding author), Radcrest, Heath Rise, Surrey GU15 2ER, England.			Porter, Alan MW/0000-0001-5622-7288				ABRAHAM RB, 1998, POSTGRAD MED J, V74, P11; Allen GC, 1998, ANESTHESIOLOGY, V88, P579, DOI 10.1097/00000542-199803000-00006; BOURDON L, 1995, MED HYPOTHESES, V45, P268, DOI 10.1016/0306-9877(95)90116-7; BRAHAMS D, 1989, LANCET, V2, P814; BRICKNELL MCM, 1994, J R ARMY MED CORPS, V146, P67; BROWN JR, 1986, J R ARMY MED CORPS, V132, P181; Denborough M, 1998, LANCET, V352, P1131, DOI 10.1016/S0140-6736(98)03078-5; Epstein Y, 1999, MED SCI SPORT EXER, V31, P224, DOI 10.1097/00005768-199902000-00004; Gardner JW, 1996, MED SCI SPORT EXER, V28, P939, DOI 10.1097/00005768-199608000-00001; HOPKINS PM, 1991, LANCET, V338, P1491, DOI 10.1016/0140-6736(91)92304-K; Kark JA, 1996, AVIAT SPACE ENVIR MD, V67, P354; MCCARDLE WD, 1985, EXERCISE PHYSL, P441; PORTER A, 1986, LANCET, V1, P215; PORTER AM, 1993, MIL MED, V158, P606, DOI 10.1093/milmed/158.9.606; PUGH LGC, 1967, J APPL PHYSIOL, V23, P347, DOI 10.1152/jappl.1967.23.3.347; RUTBERG H, 1987, ANESTHESIOLOGY, V67, P308, DOI 10.1097/00000542-198709000-00005; SHIBOLET S, 1967, Q J MED, V36, P525; *US ARM CTR HLTH P, MED SURV MONTHL REP; 1989, LANCET, V2, P782; 1999, CAMBERLEY NEWS  0713	20	28	29	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					569	571		10.1016/S0140-6736(99)06407-7	http://dx.doi.org/10.1016/S0140-6736(99)06407-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10683021				2022-12-28	WOS:000085487400040
J	Vermeulen, EGJ; Stehouwer, CDA; Twisk, JWR; van den Berg, M; de Jong, SC; Mackaay, AJC; van Campen, CMC; Visser, FC; Jakobs, CAJM; Bulterijs, EJ; Rauwerda, JA				Vermeulen, EGJ; Stehouwer, CDA; Twisk, JWR; van den Berg, M; de Jong, SC; Mackaay, AJC; van Campen, CMC; Visser, FC; Jakobs, CAJM; Bulterijs, EJ; Rauwerda, JA			Effect of homocysteine-lowering treatment with folic acid plus vitamin B-6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial	LANCET			English	Article							CORONARY-ARTERY DISEASE; PLASMA HOMOCYSTEINE; VASCULAR-DISEASE; YOUNG-PATIENTS; RISK FACTOR; ARTERIOSCLEROSIS; HYPERHOMOCYSTEINEMIA; HOMOCYST(E)INE; POPULATION; SERUM	Background A high plasma homocysteine concentration is associated with increased risk of atherothrombotic disease. We investigated the effects of homocysteine-lowering treatment (folic acid plus vitamin B-6) on markers of subclinical atherosclerosis among healthy siblings of patients with premature atherothrombotic disease. Methods We did a randomised, placebo-controlled trial among 158 healthy siblings of 167 patients with premature atherothrombotic disease. 80 were assigned placebo and 78 were assigned 5 mg folic acid and 250 mg vitamin B-6 daily for 2 years. The primary endpoint was the development or progression of subclinical atherosclerosis as estimated from exercise electrocardiography, the ankle-brachial pressure index, and carotid and femoral ultrasonography, Findings Ten participants in the treatment group, and 14 in the placebo group dropped out. Vitamin treatment, compared with placebo,was associated with a decrease in fasting homocysteine concentration (from 14.7 to 7.4 mu mol/L vs from 14.7 to 12.0 mu mol/L), and in postmethionine homocysteine concentration (from 64.9 to 34.9 mu mol/L vs from 64.8 to 50.3 mu mol/L). It was also associated with a decreased rate of abnormal exercise electrocardiography tests (odds ratio 0.40 [0.17-0.93]; p=0.035). There was no apparent effect of vitamin treatment on ankle-brachial pressure indices (0.87 [0.56-1.33]), or on carotid and peripheral-arterial outcome variables (1.02 [0.26-4.05] and 0.86 [0.47-1.59], respectively). Interpretation Homocysteine-lowering treatment with folic acid plus vitamin Be in healthy siblings of patients with premature atherothrombotic disease is associated with a decreased occurrence of abnormal exercise electrocardiography tests, which is consistent with a decreased risk of atherosclerotic coronary events.	Univ Hosp Vrije Univ, Dept Internal Med, NL-1007 MB Amsterdam, Netherlands; Univ Hosp Vrije Univ, Dept Gen Surg, Vasc Surg Unit, NL-1007 MB Amsterdam, Netherlands; Univ Hosp Vrije Univ, Dept Cardiol, NL-1007 MB Amsterdam, Netherlands; Univ Hosp Vrije Univ, Dept Clin Chem, Metab Unit, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Inst Cardiovasc Res, Amsterdam, Netherlands; Inst Res Extramural Med, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Stehouwer, CDA (corresponding author), Univ Hosp Vrije Univ, Dept Internal Med, POB 7057, NL-1007 MB Amsterdam, Netherlands.		Stehouwer, Coen/AAB-3435-2021					ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; Aly S, 1998, BRIT J SURG, V85, P1099; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; BRUCE RA, 1980, AM J CARDIOL, V46, P371, DOI 10.1016/0002-9149(80)90003-X; De Jong SC, 1999, J INTERN MED, V246, P87, DOI 10.1046/j.1365-2796.1999.00541.x; deJong SC, 1997, ARTERIOSCL THROM VAS, V17, P2655, DOI 10.1161/01.ATV.17.11.2655; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; FOWKES FGR, 1988, INT J EPIDEMIOL, V17, P248, DOI 10.1093/ije/17.2.248; FOWKES FGR, 1988, J EPIDEMIOL COMMUN H, V42, P128, DOI 10.1136/jech.42.2.128; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; MACKAAY AJC, 1995, EUR J VASC ENDOVASC, V9, P170, DOI 10.1016/S1078-5884(05)80086-3; MCCULLY KS, 1970, AM J PATHOL, V61, P1; MONETA GL, 1993, J VASC SURG, V17, P152, DOI 10.1016/0741-5214(93)90019-I; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Peterson JC, 1998, LANCET, V351, P263, DOI 10.1016/S0140-6736(05)78275-1; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Stehouwer CDA, 1999, KIDNEY INT, V55, P308, DOI 10.1046/j.1523-1755.1999.00256.x; STRANDNESS DE, 1983, ARTERIOSCLEROSIS, V3, P103, DOI 10.1161/01.ATV.3.2.103; Twisk JWR, 1997, INT J SPORTS MED, V18, pS216, DOI 10.1055/s-2007-972718; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; vanCampen CMC, 1996, EUR HEART J, V17, P699; VANDENBERG M, 1994, J VASC SURG, V20, P933, DOI 10.1016/0741-5214(94)90230-5; vandenBerg M, 1996, ARTERIOSCL THROM VAS, V16, P165, DOI 10.1161/01.ATV.16.1.165; Verhaar MC, 1998, CIRCULATION, V97, P237, DOI 10.1161/01.CIR.97.3.237; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350; WILLIAMS MA, 1989, CARDIOVASCULAR APPLI, P247; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	33	253	271	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					517	522		10.1016/S0140-6736(99)07391-2	http://dx.doi.org/10.1016/S0140-6736(99)07391-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10683000				2022-12-28	WOS:000085487400008
J	[Anonymous]				[Anonymous]			Many medical chairs remain unfilled	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2000	320	7232					451	451						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669464				2022-12-28	WOS:000085377400062
J	Aronson, J				Aronson, J			When I use a word ... modern English abusage	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					357	357		10.1136/bmj.320.7231.357	http://dx.doi.org/10.1136/bmj.320.7231.357			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657334	Green Published			2022-12-28	WOS:000085211400028
J	Damoiseaux, RAMJ; van Balen, FAM; Hoes, AW; Verheij, TJM; de Melker, RA				Damoiseaux, RAMJ; van Balen, FAM; Hoes, AW; Verheij, TJM; de Melker, RA			Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years	BRITISH MEDICAL JOURNAL			English	Article							ANTIBIOTIC-TREATMENT; STREPTOCOCCUS-PNEUMONIAE; METAANALYSIS; EFFICACY; MYRINGOTOMY; NETWORK; EAR	Objective To determine the effect of antibiotic treatment for acute otitis media in children between 6 months and 2 years of age. Design Practice based, double blind, randomised, placebo controlled trial. Setting 53 general practices in the Netherlands. Subjects 240 children aged 6 months to 2 years with the diagnosis of acute otitis media. Intervention Amoxicillin 40 mg/kg/day in three doses. Main outcome measures Persistent symptoms at day four and duration of fever and pain or crying, or both. Otoscopy at days four and 11, tympanometry at six weeks, and use of analgesic. Results Persistent symptoms at day four were less common in the amoxicillin group (risk difference 13%; 95% confidence interval 1% to 25%). The median duration of fever was two days in the amoxicillin group versus three in die placebo group (P = 0.004). No significant difference was observed in duration of pain or crying, but analgesic consumption was higher in the placebo group during the first 10 days (4.1 v 2.3 doses, P = 0.004). In addition, no otoscopic differences were observed at days four and 11, and tympanometric findings at six weeks were similar in both groups. Conclusions Seven to eight children aged 6 to 24 months with acute otitis media needed to be treated with antibiotics to improve symptomatic outcome at day four in one child. This modest effect does not justify prescription of antibiotics at the first visit, provided close surveillance can be guaranteed.	Univ Med Ctr, Dept Gen Practice, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr, Juluis Ctr Patient Oriented Res, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Damoiseaux, RAMJ (corresponding author), Univ Med Ctr, Dept Gen Practice, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.			Damoiseaux, Roger/0000-0001-8052-0302				Alho OP, 1996, J FAM PRACTICE, V43, P258; APPELMAN CLM, 1991, BMJ-BRIT MED J, V303, P1450, DOI 10.1136/bmj.303.6815.1450; Appelman CLM, 1990, HUISARTS WET, V33, P242; BERMAN S, 1995, NEW ENGL J MED, V332, P1560, DOI 10.1056/NEJM199506083322307; BRUIJNZEELS MA, 1993, CHILD GEN PRACTICE D; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; Damoiseaux RAMJ, 1998, BRIT J GEN PRACT, V48, P1861; DelMar C, 1997, BRIT MED J, V314, P1526, DOI 10.1136/bmj.314.7093.1526; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; Froom J, 1997, BRIT MED J, V315, P98, DOI 10.1136/bmj.315.7100.98; HATHAWAY TJ, 1994, PEDIATRICS, V94, P143; Hermans PWM, 1997, J INFECT DIS, V175, P1413, DOI 10.1086/516474; Hoberman A, 1997, PEDIATR INFECT DIS J, V16, P463, DOI 10.1097/00006454-199705000-00002; IINO Y, 1993, ACTA OTO-LARYNGOL, V113, P761, DOI 10.3109/00016489309135897; JERGER J, 1970, ARCHIV OTOLARYNGOL, V92, P311; KALEIDA PH, 1991, PEDIATRICS, V87, P466; Kontiokari T, 1998, PEDIATR INFECT DIS J, V17, P676, DOI 10.1097/00006454-199808000-00003; LAXDAL OE, 1970, CAN MED ASSOC J, V102, P263; MANDEL EM, 1995, PEDIATRICS, V96, P5; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; Rothrock SG, 1997, PEDIATRICS, V99, P438, DOI 10.1542/peds.99.3.438; VANBUCHEM FL, 1981, LANCET, V2, P883; WORMALD PJ, 1995, CLIN OTOLARYNGOL, V20, P63, DOI 10.1111/j.1365-2273.1995.tb00014.x; ZIELHUIS G A, 1989, Scandinavian Journal of Primary Health Care, V7, P33, DOI 10.3109/02813438909103668	24	153	154	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					350	354		10.1136/bmj.320.7231.350	http://dx.doi.org/10.1136/bmj.320.7231.350			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657332	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000085211400026
J	Stark, H; Rodnina, MV; Wieden, HJ; van Heel, M; Wintermeyer, W				Stark, H; Rodnina, MV; Wieden, HJ; van Heel, M; Wintermeyer, W			Large-scale movement of elongation factor G and extensive conformational change of the ribosome during translocation	CELL			English	Article							FACTOR EF-G; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TRANSFER-RNA; MESSENGER-RNA; PROTEIN S4; FACTOR TU; 23S RNA; 16S; BINDING	Elongation factor (EF) G promotes tRNA translocation on the ribosome. We present three-dimensional reconstructions, obtained by cryo-electron microscopy, of EF-G-ribosome complexes before and after translocation. In the pretranslocation state, domain 1 of EF-G interacts with the L7/12 stalk on the 50S subunit, while domain 4 contacts the shoulder of the 30S subunit in the region where protein S4 is located. During translocation, EF-G experiences an extensive reorientation, such that, after translocation, domain 4 reaches into the decoding center. The factor assumes different conformations before and after translocation. The structure of the ribosome is changed substantially in the pretranslocation state, in particular at the head-to-body junction in the 30S subunit, suggesting a possible mechanism of translocation.	Univ Witten Herdecke, Inst Mol Biol, D-58448 Witten, Germany; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England	Witten Herdecke University; Imperial College London	Wintermeyer, W (corresponding author), Univ Witten Herdecke, Inst Mol Biol, D-58448 Witten, Germany.	winterme@uni-wh.de	Rodnina, Marina V./AAD-4667-2019	Rodnina, Marina V./0000-0003-0105-3879; Wieden, Hans-Joachim/0000-0001-5181-6059; Holger, Stark/0000-0002-6161-1118				AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Al-Karadaghi S, 1996, STRUCTURE, V4, P555, DOI 10.1016/S0969-2126(96)00061-5; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; BILGIN N, 1990, EMBO J, V9, P735, DOI 10.1002/j.1460-2075.1990.tb08167.x; Borowski C, 1996, P NATL ACAD SCI USA, V93, P4202, DOI 10.1073/pnas.93.9.4202; BRINK MF, 1994, NUCLEIC ACIDS RES, V22, P325, DOI 10.1093/nar/22.3.325; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Davies C, 1998, EMBO J, V17, P4545, DOI 10.1093/emboj/17.16.4545; DAVIES J, 1968, J BIOL CHEM, V243, P3312; Gabashvili IS, 1999, J MOL BIOL, V286, P1285, DOI 10.1006/jmbi.1999.2538; HARAUZ G, 1986, OPTIK, V73, P146; HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2; HEILEK GM, 1995, P NATL ACAD SCI USA, V92, P1113, DOI 10.1073/pnas.92.4.1113; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MODOLELL J, 1977, EUR J BIOCHEM, V81, P491, DOI 10.1111/j.1432-1033.1977.tb11974.x; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Mueller F, 1997, J MOL BIOL, V271, P545, DOI 10.1006/jmbi.1997.1211; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; OConnor M, 1995, BIOCHEM CELL BIOL, V73, P859, DOI 10.1139/o95-093; Oleinikov AV, 1998, P NATL ACAD SCI USA, V95, P4215, DOI 10.1073/pnas.95.8.4215; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; POWERS T, 1995, RNA, V1, P194; POWERS T, 1994, J MOL BIOL, V235, P156, DOI 10.1016/S0022-2836(05)80023-3; RAMAKRISHNAN V, 1992, NATURE, V358, P768, DOI 10.1038/358768a0; RODNINA MV, 1994, ANAL BIOCHEM, V219, P380, DOI 10.1006/abio.1994.1282; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; SAVELSBERGH A, IN PRESS J BIOL CHEM; SIGMUND CD, 1984, NUCLEIC ACIDS RES, V12, P4653, DOI 10.1093/nar/12.11.4653; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; SPIRIN AS, 1985, PROG NUCLEIC ACID RE, V32, P75, DOI 10.1016/S0079-6603(08)60346-3; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; VanLoock MS, 1999, J MOL BIOL, V285, P2069, DOI 10.1006/jmbi.1998.2442; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8	48	245	250	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					301	309		10.1016/S0092-8674(00)80666-2	http://dx.doi.org/10.1016/S0092-8674(00)80666-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676812	Green Published, Bronze			2022-12-28	WOS:000085204400004
J	Kirchner, JW; Feng, XH; Neal, C				Kirchner, JW; Feng, XH; Neal, C			Fractal stream chemistry and its implications for contaminant transport in catchments	NATURE			English	Article							DISPERSION-EQUATION; WATER; GROUNDWATER; PLYNLIMON; ISOTOPE; WALES	The time;it takes for rainfall to travel through a catchment and reach the stream is a fundamental hydraulic parameter that controls the retention of soluble contaminants and thus the downstream consequences of pollution episodes(1,2). Catchments with short flushing times will deliver brief, intense contaminant pulses to downstream waters, whereas catchments with longer flushing times will deliver less intense but more sustained contaminant fluxes. Here we analyse detailed time series of chloride, a natural tracer, in both rainfall and runoff from headwater catchments at Plynlimon, Wales. We show that, although the chloride concentrations in rainfall have a white noise spectrum, the chloride concentrations in streamflow exhibit fractal 1/f scaling over three orders of magnitude. The fractal fluctuations in tracer concentrations indicate that these catchments do not have characteristic flushing times. Instead, their travel times follow an approximate power-law distribution implying that they will retain a long chemical memory of past inputs. Contaminants will initially be flushed rapidly, but then low-level contamination will be delivered to streams for a surprisingly long time.	Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA; Dartmouth Coll, Dept Earth Sci, Hanover, NH 03755 USA; Inst Hydrol, Wallingford OX10 8BB, Oxon, England	University of California System; University of California Berkeley; Dartmouth College; UK Centre for Ecology & Hydrology (UKCEH)	Kirchner, JW (corresponding author), Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA.	kirchner@scismo.berkeley.edu	Kirchner, James W/B-6126-2009; Kirchner, James/AAC-4707-2019	Kirchner, James W/0000-0001-6577-3619; Kirchner, James/0000-0001-6577-3619				Avnir D, 1998, SCIENCE, V279, P39, DOI 10.1126/science.279.5347.39; BAIN L, 1983, ENCY STAT SCI, P292; BEVEN K, 1982, WATER RESOUR RES, V18, P1627, DOI 10.1029/WR018i006p01627; Bracewell RN, 2000, FOURIER TRANSFORM IT; BUTTLE JM, 1994, PROG PHYS GEOG, V18, P16, DOI 10.1177/030913339401800102; DUFFY CJ, 1986, WATER RESOUR RES, V22, P1115, DOI 10.1029/WR022i007p01115; DUFFY CJ, 1985, WATER RESOUR RES, V21, P1175, DOI 10.1029/WR021i008p01175; Gelhar L., 1993, STOCHASTIC SUBSURFAC; KAVANAUGH MC, 1994, ALTERNATIVES GROUND; KIRKBY C, 1991, 109 I HYDR; Korvin G., 1992, FRACTAL MODELS EARTH; KREFT A, 1978, CHEM ENG SCI, V33, P1471, DOI 10.1016/0009-2509(78)85196-3; Langmuir D., 1997, AQUEOUS ENV GEOCHEMI; NEAL C, 1988, HYDROL PROCESS, V2, P155, DOI 10.1002/hyp.3360020206; Neal C, 1997, HYDROL EARTH SYST SC, V1, P3, DOI 10.5194/hess-1-3-1997; Neal C, 1997, HYDROL EARTH SYST SC, V1, P583, DOI 10.5194/hess-1-583-1997; NEAL C, 1990, J HYDROL, V115, P269, DOI 10.1016/0022-1694(90)90209-G; Neal C, 1997, HYDROL EARTH SYST SC, V1, P687, DOI 10.5194/hess-1-687-1997; Neal C, 1997, HYDROL EARTH SYST SC, V1, P743, DOI 10.5194/hess-1-743-1997; NIEMI AJ, 1977, INT J APPL RADIAT IS, V28, P855, DOI 10.1016/0020-708X(77)90026-6; ROBSON AJ, 1993, J HYDROL, V144, P291, DOI 10.1016/0022-1694(93)90177-B; Rodhe A, 1996, WATER RESOUR RES, V32, P3497, DOI 10.1029/95WR01806; SCARGLE JD, 1982, APJ, V263, P835, DOI DOI 10.1086/160554; Schnoor J., 1996, ENV MODELING FATE TR; Sklash MG, 1996, HYDROL PROCESS, V10, P921, DOI 10.1002/(SICI)1099-1085(199607)10:7&lt;921::AID-HYP347&gt;3.0.CO;2-B; SPOSITO G, 1986, WATER RESOUR RES, V22, P255, DOI 10.1029/WR022i002p00255; STEWART MK, 1991, WATER RESOUR RES, V26, P3005; TURCOTTE DL, 1992, FRACTALS CHAOSS GEOL; Turner JV, 1998, ISOTOPE TRACERS IN CATCHMENT HYDROLOGY, P723	29	715	731	1	175	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 3	2000	403	6769					524	527		10.1038/35000537	http://dx.doi.org/10.1038/35000537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676956				2022-12-28	WOS:000085227300044
J	Burns, A				Burns, A			Might olfactory dysfunction be a marker of early Alzheimer's disease?	LANCET			English	Editorial Material							DEFICITS		Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England	University of Manchester	Burns, A (corresponding author), Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England.			Burns, Alistair/0000-0002-9837-0645				BERRIOS GE, 1984, BRIT J PSYCHIAT, V144, P662, DOI 10.1192/bjp.144.6.662; COOPER AF, 1976, BRIT J PSYCHIAT, V129, P216, DOI 10.1192/bjp.129.3.216; EICHENBAUM H, 1983, BRAIN RES B, V18, P597; Fox NC, 1996, LANCET, V348, P94, DOI 10.1016/S0140-6736(96)05228-2; Graves AB, 1999, NEUROLOGY, V53, P1480, DOI 10.1212/WNL.53.7.1480; KOSS E, 1988, NEUROLOGY, V38, P1228, DOI 10.1212/WNL.38.8.1228; Pearson RCA, 1996, NEURODEGENERATION, V5, P429, DOI 10.1006/neur.1996.0058; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Serby M, 1996, BIOL PSYCHIAT, V39, P375, DOI 10.1016/0006-3223(95)00472-6; SERBY M, 1991, AM J PSYCHIAT, V148, P357	10	18	19	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					84	85		10.1016/S0140-6736(99)90402-6	http://dx.doi.org/10.1016/S0140-6736(99)90402-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	288HT	10675162				2022-12-28	WOS:000085557200006
J	Fugh-Berman, A				Fugh-Berman, A			Herb-drug interactions	LANCET			English	Review							TRADITIONAL CHINESE MEDICINES; PLATELET ACTIVATING FACTOR; ST.-JOHNS-WORT; GINKGO-BILOBA; NEONATAL ANDROGENIZATION; GINSENG; PHARMACOKINETICS; INGESTION; PREDNISOLONE; WARFARIN	Concurrent use of herbs may mimic, magnify, or oppose the effect of drugs. Plausible cases of herb-drug interactions include: bleeding when warfarin is combined with ginkgo (Ginkgo biloba), garlic (Allium sativum), dong quai (Angelica sinensis), or danshen (Salvia miltiorrhiza); mild serotonin syndrome in patients who mix St John's wort (Hypericum perforatum) with serotonin-reuptake Inh biters; decreased bioavailability of digoxin, theophylline, cyclosporin, and phenprocoumon when these drugs are combined with St John's wort; induction of mania in depressed patients who mix antidepressants and Panax ginseng; exacerbation of extrapyramidal affects with neuroleptic drugs and betel nut (Areca catechu); increased risk of hypertension when tricyclic antidepressants are combined with yohimbine (Pausinystalia yohimbe); potentiation of oral and topical corticosteroids by liquorice (Glycyrrhiza glabra); decreased blood concentrations of prednisolone when taken with the Chinese herbal product xaio chai hu tang (sho-saiko-to); and decreased concentrations of phenytoin when combined with the Ayurvedic syrup shankhapushpi, Anthranoid-containing plants (including senna [Cassia senna] and cascara [Rhamnus purshiana]) and soluble fibres (including guar gum and psyllium) can decrease the absorption of drugs. Many reports of herb-drug interactions are sketchy and lack laboratory analysis of suspect preparations. Health-care practitioners should caution patients against mixing herbs and pharmaceutical drugs.	George Washington Univ, Sch Med & Hlth Sci, Dept Hlth Care Sci, Washington, DC 20037 USA	George Washington University	Fugh-Berman, A (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Hlth Care Sci, 2150 Penn Ave,NW, Washington, DC 20037 USA.	fughberman@aol.com		Fugh-Berman, Adriane/0000-0002-1717-7617				ASLAM M, 1979, LANCET, V1, P607, DOI 10.1016/S0140-6736(79)91028-6; AWANG DVC, 1991, JAMA-J AM MED ASSOC, V266, P363, DOI 10.1001/jama.1991.03470030063021; BAILEY CJ, 1989, DIABETES CARE, V12, P553, DOI 10.2337/diacare.12.8.553; Barnes J, 1998, BRIT J CLIN PHARMACO, V45, P496, DOI 10.1046/j.1365-2125.1998.00715.x; BERNARDI M, 1994, LIFE SCI, V55, P863, DOI 10.1016/0024-3205(94)90042-6; BON S, 1999, SCHWEITZER APOTHEKER, V16, P535; Bos R., 1997, ADVERS EFF HERB DRUG, V3, P165; BOURAOUI A, 1986, THERAPIE, V41, P467; BURNHAM BE, 1995, PLAST RECONSTR SURG, V95, P213, DOI 10.1097/00006534-199501000-00060; BUT PPH, 1994, J TROP MED HYG, V97, P371; CHAN K, 1995, J PHARM PHARMACOL, V47, P402, DOI 10.1111/j.2042-7158.1995.tb05819.x; CHEN MF, 1990, ENDOCRINOL JAPON, V37, P331; CHEN MF, 1991, ENDOCRINOL JAPON, V38, P167; Cheng TO, 1999, ANN THORAC SURG, V67, P894; CHUNG KF, 1987, LANCET, V1, P248; Cott JM, 1998, J NERV MENT DIS, V186, P500, DOI 10.1097/00005053-199808000-00008; DANDEKAR UP, 1992, J ETHNOPHARMACOL, V35, P285, DOI 10.1016/0378-8741(92)90026-N; DEAHL M, 1989, MOVEMENT DISORD, V4, P330, DOI 10.1002/mds.870040406; deKlerk GJ, 1997, BRIT MED J, V314, P731, DOI 10.1136/bmj.314.7082.731; DeMott K, 1998, CLIN PSYCHIAT NEWS, V26, P28; DESMET PAG, 1996, MECHANISMS DRUG INTE; DESMET PAGM, 1997, ADVERS EFF HERB DRUG, V3, P181; Doucet J, 1996, J AM GERIATR SOC, V44, P944, DOI 10.1111/j.1532-5415.1996.tb01865.x; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ellis GR, 1999, BRIT MED J, V319, P650; Ernst E, 1999, LANCET, V354, P2014, DOI 10.1016/S0140-6736(99)00418-3; Fugh-Berman A, 1999, PSYCHOSOM MED, V61, P712, DOI 10.1097/00006842-199909000-00012; GERMAN K, 1995, BRIT J UROL, V76, P518, DOI 10.1111/j.1464-410X.1995.tb07766.x; GERTNER E, 1995, ARTHRITIS RHEUM, V38, P614, DOI 10.1002/art.1780380506; Gilbert GJ, 1997, NEUROLOGY, V48, P1137, DOI 10.1212/WNL.48.4.1137; Gordon JB, 1998, AM FAM PHYSICIAN, V57, P950; HAKAS JF, 1990, ANN ALLERGY, V65, P322; HOMMA M, 1995, J PHARM PHARMACOL, V47, P687, DOI 10.1111/j.2042-7158.1995.tb05861.x; Huang WF, 1997, J CLIN PHARMACOL, V37, P344, DOI 10.1002/j.1552-4604.1997.tb04312.x; Izzat MB, 1998, ANN THORAC SURG, V66, P941, DOI 10.1016/S0003-4975(98)00624-9; Janetzky K, 1997, AM J HEALTH-SYST PH, V54, P692, DOI 10.1093/ajhp/54.6.692; Johne A, 1999, CLIN PHARMACOL THER, V66, P338, DOI 10.1053/cp.1999.v66.a101944; JONES BD, 1987, J CLIN PSYCHOPHARM, V7, P201, DOI 10.1097/00004714-198706000-00030; Ko RJ, 1998, NEW ENGL J MED, V339, P847, DOI 10.1056/NEJM199809173391214; KOREN G, 1990, JAMA-J AM MED ASSOC, V264, P2866, DOI 10.1001/jama.1990.03450220028007; LACOMBLEZ L, 1989, CLIN PHARMACOL THER, V45, P241, DOI 10.1038/clpt.1989.24; LAMANT V, 1987, BIOCHEM PHARMACOL, V36, P2749, DOI 10.1016/0006-2952(87)90259-0; Lantz MS, 1999, J GERIATR PSYCH NEUR, V12, P7, DOI 10.1177/089198879901200103; LEATHERDALE BA, 1981, BRIT MED J, V282, P1823, DOI 10.1136/bmj.282.6279.1823; LEE FC, 1987, CLIN EXP PHARMACOL P, V14, P543, DOI 10.1111/j.1440-1681.1987.tb01510.x; Matthews MK, 1998, NEUROLOGY, V50, P1933, DOI 10.1212/WNL.50.6.1933; MAURER A, 1999, EUR J CLIN PHARMACOL, V55, pA22; McRae S, 1996, CAN MED ASSOC J, V155, P293; Mustapha A, 1996, EUR J DRUG METAB PH, V21, P223, DOI 10.1007/BF03189717; Nebel A, 1999, ANN PHARMACOTHER, V33, P502, DOI 10.1345/aph.18252; Page RL, 1999, PHARMACOTHERAPY, V19, P870, DOI 10.1592/phco.19.10.870.31558; PERLMAN BB, 1990, LANCET, V335, P416, DOI 10.1016/0140-6736(90)90256-5; ROSE KD, 1990, NEUROSURGERY, V26, P880, DOI 10.1227/00006123-199005000-00026; Rosenblatt M, 1997, NEW ENGL J MED, V336, P1108, DOI 10.1056/NEJM199704103361518; Rowin J, 1996, NEUROLOGY, V46, P1775, DOI 10.1212/WNL.46.6.1775; SHADER RI, 1985, J CLIN PSYCHOPHARM, V5, P65, DOI 10.1097/00004714-198504000-00001; Shaw D, 1997, DRUG SAFETY, V17, P342, DOI 10.2165/00002018-199717050-00006; TAM LS, 1995, AUST NZ J MED, V25, P258, DOI 10.1111/j.1445-5994.1995.tb01540.x; TAYLOR RFH, 1992, LANCET, V339, P1134, DOI 10.1016/0140-6736(92)90732-I; TEELUCKSINGH S, 1990, LANCET, V335, P1060, DOI 10.1016/0140-6736(90)92633-S; Vale S, 1998, LANCET, V352, P36, DOI 10.1016/S0140-6736(05)79516-7; VANDERSTRICHT BI, 1994, BRIT MED J, V308, P1162, DOI 10.1136/bmj.308.6937.1162; WESTENDORF J, ADVERSE EFFECTS HERB, V2, P105; Yu CM, 1997, J INTERN MED, V241, P337, DOI 10.1046/j.1365-2796.1997.134137000.x; Zhu M, 1999, J PHARM PHARMACOL, V51, P175, DOI 10.1211/0022357991772105	65	782	820	4	301	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	2000	355	9198					134	138		10.1016/S0140-6736(99)06457-0	http://dx.doi.org/10.1016/S0140-6736(99)06457-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675182				2022-12-28	WOS:000085557200039
J	Gotzsche, PC; Olsen, O				Gotzsche, PC; Olsen, O			Is screening for breast cancer with mammography justifiable?	LANCET			English	Article							EDINBURGH RANDOMIZED TRIAL; CORONARY HEART-DISEASE; STAGE DISTRIBUTION; DEATH RATES; FOLLOW-UP; MORTALITY; WOMEN; EFFICACY; STOCKHOLM; QUALITY	Background A 1999 study found no decrease in breast-cancer mortality in Sweden, where screening has been recommended since 1985. We therefore reviewed the methodological quality of the mammography trials and an influential Swedish meta-analysis, and did a meta-analysis ourselves. Methods We searched the Cochrane Library for trials and asked the investigators for further details. Meta-analyses were done with Review Manager (version 4.0). Findings Baseline imbalances were shown for six of the eight identified trials, and inconsistencies in the number of women randomised were found in four. The two adequately randomised trials found no effect of screening on breast-cancer mortality (pooled relative risk 1.04 [95% CI 0.84-1.27]) or on total mortality (0.99 [0.94-1.05]). The pooled relative risk for breast-cancer mortality for the other trials was 0.75 (0.67-0.83), which was significantly different (p=0.005) from that for the unbiased trials. The Swedish meta-analysis showed a decrease in breast-cancer mortality but also an increase in total mortality (1.06 [1.04-1.08]); this increase disappeared after adjustment for an imbalance in age. Interpretation Screening for breast cancer with mammography is unjustified. If the Swedish trials are judged to be unbiased, the data show that for every 1000 women screened biennially throughout 12 years, one breast-cancer death is avoided whereas the total number of deaths is increased by six. If the Swedish trials (apart from the Malmo trial) are judged to be biased, there is no reliable evidence that screening decreases breast-cancer mortality.	Rigshosp, Nord Cochrane Ctr, Dept 7112, DK-2100 Copenhagen O, Denmark	Rigshospitalet	Gotzsche, PC (corresponding author), Rigshosp, Nord Cochrane Ctr, Dept 7112, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.	p.c.gotzsche@cochrane.dk						ALEXANDER FE, 1994, BRIT J CANCER, V70, P542, DOI 10.1038/bjc.1994.342; Alexander FE, 1999, LANCET, V353, P1903, DOI 10.1016/S0140-6736(98)07413-3; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; Andersson I, 1997, J Natl Cancer Inst Monogr, P63; ARON JL, 1986, INT J EPIDEMIOL, V15, P36, DOI 10.1093/ije/15.1.36; Bailar JC, 1997, CAN MED ASSOC J, V156, P193; BAINES CJ, 1994, ANN INTERN MED, V120, P326, DOI 10.7326/0003-4819-120-4-199402150-00011; Bjurstam N, 1997, CANCER, V80, P2091, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2091::AID-CNCR8>3.0.CO;2-#; CHU KC, 1988, JNCI-J NATL CANCER I, V80, P1125, DOI 10.1093/jnci/80.14.1125; Dickersin K, 1999, LANCET, V353, P1896, DOI 10.1016/S0140-6736(99)90074-0; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; FAGERBERG G, 1985, ACTA ONCOL, V24, P465, DOI 10.3109/02841868509134418; FINK R, 1972, AM J PUBLIC HEALTH N, V62, P328, DOI 10.2105/AJPH.62.3.328; FRINSELL J, 1991, BREAST CANC RES TREA, V18, P49; Frisell J, 1997, BREAST CANCER RES TR, V45, P263, DOI 10.1023/A:1005872617944; FRISELL J, 1986, BREAST CANCER RES TR, V8, P45, DOI 10.1007/BF01805924; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Miller A B, 1997, J Natl Cancer Inst Monogr, P37; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1981, CLIN INVEST MED, V4, P227; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Narod SA, 1997, LANCET, V349, P1846, DOI 10.1016/S0140-6736(05)61736-9; Nystrom L, 1996, J Med Screen, V3, P85; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; NYSTROM L, 1993, LANCET, V341, P1531; NYSTROM L, 1993, LANCET, V342, P550; Rehnqvist N, 1999, Lakartidningen, V96, P1050; ROBERTS MM, 1984, BRIT J CANCER, V50, P1, DOI 10.1038/bjc.1984.132; Rutqvist L E, 1999, Lakartidningen, V96, P1210; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Semiglazov V F, 1996, Vopr Onkol, V42, P49; SHAPIRO S, 1994, CANCER, V74, P231, DOI 10.1002/cncr.2820741306; SHAPIRO S, 1977, CANCER, V39, P2772, DOI 10.1002/1097-0142(197706)39:6<2772::AID-CNCR2820390665>3.0.CO;2-K; SHAPIRO S, 1966, J AMER MED ASSOC, V195, P731, DOI 10.1001/jama.195.9.731; Shapiro S., 1988, PERIODIC SCREENING B; Sjonell G, 1999, Lakartidningen, V96, P904; SKRABANEK P, 1993, LANCET, V341, P1531; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; SWIFT M, 1993, LANCET, V342, P549, DOI 10.1016/0140-6736(93)91672-9; TABAR L, 1985, DIAGN IMAG CLIN MED, V54, P158; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; TABAR L, 1995, CANCER, V75, P2507, DOI 10.1002/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-H	45	557	573	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	2000	355	9198					129	134		10.1016/S0140-6736(99)06065-1	http://dx.doi.org/10.1016/S0140-6736(99)06065-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675181				2022-12-28	WOS:000085557200038
J	Batey, RT; Rambo, RP; Lucast, L; Rha, B; Doudna, JA				Batey, RT; Rambo, RP; Lucast, L; Rha, B; Doudna, JA			Crystal structure of the ribonucleoprotein core of the signal recognition particle	SCIENCE			English	Article							METHIONINE-RICH DOMAIN; ESCHERICHIA-COLI; 4.5S RNA; PROTEIN TRANSLOCATION; NG DOMAIN; RECEPTOR; BINDING; SUBUNIT; GTPASE; SRP	The signal recognition particle (SRP), a protein-RNA complex conserved in all three kingdoms of Life, recognizes and transports specific proteins to cellular membranes for insertion or secretion. We describe here the 1.8 angstrom crystal structure of the universal core of the SRP, revealing protein recognition of a distorted RNA minor groove. Nucleotide analog interference mapping demonstrates the biological importance of observed interactions, and genetic results show that this core is functional in vivo. The structure explains why the conserved residues in the protein and RNA are required for SRP assembly and defines a signal sequence recognition surface composed of both protein and RNA.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA	Howard Hughes Medical Institute; Yale University; Yale University	Doudna, JA (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA.		Batey, Robert/A-8265-2009	Batey, Robert/0000-0002-1384-6625				Basu S, 1998, NAT STRUCT BIOL, V5, P986, DOI 10.1038/2960; Beavis RC, 1996, METHOD ENZYMOL, V270, P519; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BROWN S, 1989, J BACTERIOL, V171, P6517, DOI 10.1128/jb.171.12.6517-6520.1989; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; Gowda K, 1997, NUCLEIC ACIDS RES, V25, P2835, DOI 10.1093/nar/25.14.2835; Kurita K, 1996, J BIOL CHEM, V271, P13140, DOI 10.1074/jbc.271.22.13140; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lentzen G, 1996, RNA, V2, P244; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; Powers T, 1997, EMBO J, V16, P4880, DOI 10.1093/emboj/16.16.4880; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; Samuelsson T, 1999, NUCLEIC ACIDS RES, V27, P169, DOI 10.1093/nar/27.1.169; Schmitz U, 1996, RNA, V2, P1213; Schmitz U, 1999, NAT STRUCT BIOL, V6, P634, DOI 10.1038/10683; Schmitz U, 1999, RNA, V5, P1419, DOI 10.1017/S1355838299991458; Strobel SA, 1998, BIOPOLYMERS, V48, P65, DOI 10.1002/(SICI)1097-0282(1998)48:1<65::AID-BIP7>3.0.CO;2-D; Walter P., 1997, HARVEY LECT, V91, P115; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514; Zheng N, 1997, MOL CELL, V1, P79, DOI 10.1016/S1097-2765(00)80009-X; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	35	312	314	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1232	+		10.1126/science.287.5456.1232	http://dx.doi.org/10.1126/science.287.5456.1232			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678824				2022-12-28	WOS:000085444700041
J	Zhang, SN; Cui, W; Chen, W; Yao, YS; Zhang, XL; Sun, XJ; Wu, XB; Xu, HG				Zhang, SN; Cui, W; Chen, W; Yao, YS; Zhang, XL; Sun, XJ; Wu, XB; Xu, HG			Three-layered atmospheric structure in accretion disks around stellar-mass black holes	SCIENCE			English	Article							HIGH-ENERGY OBSERVATIONS; TRANSIENT GRO J1655-40; X-RAY BINARIES; SUPERLUMINAL SOURCE; SEYFERT-GALAXIES; JETS; COMPTONIZATION; MODEL	Modeling of the x-ray spectra of the Galactic superluminal jet sources GRS 1975 + 105 and GRO J7655-40 reveals a three-layered atmospheric structure in the inner region of their accretion disks. Above the cold and optically thick disk with a temperature of 0.2 to 0.5 kiloelectron volts, there is a warm Layer with a temperature of 1.0 to 1.5 kiloelectron volts and an optical depth around 10. Sometimes there is also a much hotter, optically thin corona above the warm layer, with a temperature of 100 kiloelectron volts or higher and an optical depth around unity. The structural similarity between the accretion disks and the solar atmosphere suggests that similar physical processes may be operating in these different systems.	Univ Alabama, Dept Phys, Huntsville, AL 35899 USA; NASA, Space Sci Lab, George C Marshall Space Flight Ctr, Huntsville, AL 35812 USA; MIT, Ctr Space Res, Cambridge, MA 02139 USA; Univ Maryland, Dept Astron, College Pk, MD 20742 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Chinese Acad Sci, Beijing Astron Observ, Beijing 100012, Peoples R China; Shanghai Jiao Tong Univ, Dept Appl Phys, Inst Space & Astrophys, Shanghai 200030, Peoples R China	University of Alabama System; University of Alabama Huntsville; National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; Massachusetts Institute of Technology (MIT); University System of Maryland; University of Maryland College Park; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Chinese Academy of Sciences; Shanghai Jiao Tong University	Zhang, SN (corresponding author), Univ Alabama, Dept Phys, Huntsville, AL 35899 USA.	zhangsn@email.uah.edu	Cui, Wei/Y-3279-2019	Cui, Wei/0000-0002-6324-5772				BLANDFORD RD, 1982, MON NOT R ASTRON SOC, V199, P883, DOI 10.1093/mnras/199.4.883; Blandford RD, 1999, MON NOT R ASTRON SOC, V303, pL1, DOI 10.1046/j.1365-8711.1999.02358.x; Borozdin K, 1999, ASTROPHYS J, V517, P367, DOI 10.1086/307186; CHAKRABARTI SK, 1995, ASTROPHYS J, V455, P623, DOI 10.1086/176610; Cui W, 1998, ASTROPHYS J, V492, pL53, DOI 10.1086/311092; Di Matteo T, 1999, MON NOT R ASTRON SOC, V304, P809, DOI 10.1046/j.1365-8711.1999.02375.x; Grove JE, 1998, ASTROPHYS J, V500, P899, DOI 10.1086/305746; Haardt F, 1997, ASTROPHYS J, V476, P620, DOI 10.1086/303656; HARMON BA, 1995, NATURE, V374, P703, DOI 10.1038/374703a0; Hawley JF, 1999, ASTROPHYS J, V518, P394, DOI 10.1086/307282; HJELLMING RM, 1995, NATURE, V375, P464, DOI 10.1038/375464a0; LEWIN WHG, 1995, XRAY BINARIES, P457; Liang EP, 1998, PHYS REP, V302, P66; LIANG EPT, 1977, ASTROPHYS J, V218, P247, DOI 10.1086/155677; Meier DL, 1997, NATURE, V388, P350, DOI 10.1038/41034; Meier DL, 1999, ASTROPHYS J, V522, P753, DOI 10.1086/307671; Mirabel IF, 1998, NATURE, V392, P673, DOI 10.1038/33603; MIRABEL IF, 1994, NATURE, V371, P46, DOI 10.1038/371046a0; Misra R, 1998, ASTROPHYS J, V495, P407, DOI 10.1086/305278; Nayakshin S, 1997, ASTROPHYS J, V490, pL13, DOI 10.1086/310998; Priest ER, 1999, ASTR SOC P, V158, P321; SCUDDER JD, 1992, ASTROPHYS J, V398, P319, DOI 10.1086/171859; SHAKURA NI, 1973, ASTRON ASTROPHYS, V24, P337; Sturrock PA, 1999, ASTROPHYS J, V521, P451, DOI 10.1086/307544; SUNYAEV RA, 1985, ASTRON ASTROPHYS, V143, P374; Tajima T., 1997, PLASMA ASTROPHYSICS, V98; TINGAY SJ, 1995, NATURE, V374, P141, DOI 10.1038/374141a0; TITARCHUK L, 1994, ASTROPHYS J, V434, P570, DOI 10.1086/174760; TORNSICK JA, 1999, ASTROPHYS J, V512, P892; Ueda Y, 1998, ASTROPHYS J, V492, P782, DOI 10.1086/305063; Van Paradijs J, 1998, NATO ADV SCI I C-MAT, V515, P279; Zhang SN, 1997, ASTROPHYS J, V479, P381, DOI 10.1086/303870; Zhang SN, 1997, ASTROPHYS J, V482, pL155, DOI 10.1086/310705; Zhang SN, 1997, AIP CONF PROC, P141, DOI 10.1063/1.54121; [No title captured]	35	53	55	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2000	287	5456					1239	1241		10.1126/science.287.5456.1239	http://dx.doi.org/10.1126/science.287.5456.1239			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678825				2022-12-28	WOS:000085444700042
J	Weinberg, A; Creed, F				Weinberg, A; Creed, F			Stress and psychiatric disorder in healthcare professionals and hospital staff	LANCET			English	Article							BRITISH CIVIL-SERVANTS; JOB STRESS; GENDER DIFFERENCES; SICKNESS ABSENCE; SOCIAL SUPPORT; WHITEHALL-II; WORK; PHYSICIANS; QUESTIONNAIRE; SATISFACTION	Background Previous studies of stress in healthcare staff have indicated a probable high prevalence of distress. Whether this distress can be attributed to the stressful nature of the work situation is not clear. No previous study has used a detailed interview method to ascertain the link between stress in and outside of work and anxiety and depressive disorders. Methods Doctors, nurses, and administrative and ancillary staff were screened using the general health questionnaire (GHQ). High scorers (GHQ>4) and matched individuals with low GHQ scores were interviewed by means of the clinical interview Schedule to ascertain definite anxiety and depressive disorders (cases). Cases and controls, matched for age, sex, and occupational group were interviewed with the life events and difficulties schedule classification and an objective measure of work stress to find out the amount of stress at work and outside of work. Sociodemographic and stress variables were entered into a logistic-regression analysis to find out. the variables associated with anxiety and depressive disorders. Findings 64 cases and 64 controls were matched. Cases and controls did not differ on demographic variables but cases were less likely to have a confidant (odds ratio 0.09 [95% CI 0.01-0.79]) and more likely to have had a previous episode of psychiatric disorder (3.07 [1.10-8.57]). Cases and controls worked similar hours and had similar responsibility but cases had a greater:number of objective stressful situations both in and out of work (severe event or substantial difficulty in and out of work-45 cases vs 18 controls 6.05 [2.81-13.00], p<0.001; severe chronic difficulty outside of work-27 vs 8, 5.12 [2.09-12.46], p<0.001). Cases had significantly more objective work problems than controls (median 6 vs 4, z=3.81, p<0.001). The logistic-regression analyses indicated that even after the effects of personal vulnerability to psychiatric disorder and ongoing social stress outside of work had been taken into account, stressful situations at work contributed to anxiety and depressive disorders. Interpretation Both stress at work and outside of work contribute to the anxiety and depressive disorders experienced by healthcare staff. Our findings suggest that the best way to decrease the prevalence of these disorders is individual treatment, which may focus on personal difficulties outside of work, combined with organisational attempts to reduce work stress. The latter may involve more assistance for staff who have a conflict between their managerial role and clinical role.	Univ Salford, Fac Hlth Care & Social Work Studies, Salford M6 6PU, Lancs, England	University of Salford	Weinberg, A (corresponding author), Univ Salford, Fac Hlth Care & Social Work Studies, Allerton Bldg, Salford M6 6PU, Lancs, England.	Ashley.Weinberg@man.ac.uk		weinberg, ashley/0000-0002-4676-4677				Aasland OG, 1997, SOC SCI MED, V45, P1615, DOI 10.1016/S0277-9536(97)00093-2; BEBBINGTON P, 1984, PSYCHOL MED, V14, P219, DOI 10.1017/S0033291700003251; BLENKIN H, 1995, BRIT MED J, V310, P534, DOI 10.1136/bmj.310.6978.534; Boey K W, 1999, Issues Ment Health Nurs, V20, P33, DOI 10.1080/016128499248772; Briner RB, 1997, J PSYCHOSOM RES, V43, P61, DOI 10.1016/S0022-3999(97)00010-X; Brown G., 1978, SOCIAL ORIGINS DEPRE; Brown GW, 1989, LIFE EVENTS ILLNESS, P49; Doncevic ST, 1998, SCAND J SOC MED, V26, P106, DOI 10.1177/14034948980260021001; Firth Cozens J, 1987, BRIT MED J, V295, P533; Goldberg D, 1972, DETECTION MINOR PSYC; Graham J, 1996, PALLIATIVE MED, V10, P185, DOI 10.1177/026921639601000302; Graham J, 1997, J PSYCHOSOM RES, V43, P227, DOI 10.1016/S0022-3999(97)00016-0; Gross EB, 1997, WOMEN HEALTH, V26, P1; Hardy GE, 1997, J PSYCHOSOM RES, V43, P83, DOI 10.1016/S0022-3999(97)00019-6; Hotopf M, 1997, J PSYCHOSOM RES, V43, P1, DOI 10.1016/S0022-3999(97)00115-3; HURRELL KK, 1998, J OCCUP HEALTH PSYCH, V3, P368; JEX SM, 1991, PSYCHOL REP, V69, P339, DOI 10.2466/PR0.69.5.339-349; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; LINN LS, 1986, MED CARE, V24, P830, DOI 10.1097/00005650-198609000-00004; McManus IC, 1999, LANCET, V354, P1358, DOI 10.1016/S0140-6736(99)02112-1; MELTZER H, 1995, 1 OFF POP CENS SURV; MOLASSIOTIS A, 1995, BONE MARROW TRANSPL, V15, P449; North FM, 1996, AM J PUBLIC HEALTH, V86, P332, DOI 10.2105/AJPH.86.3.332; PHELAN J, 1991, PSYCHOL MED, V21, P999, DOI 10.1017/S0033291700029998; Quine L, 1999, BRIT MED J, V318, P228, DOI 10.1136/bmj.318.7178.228; Reynolds S, 1997, J PSYCHOSOM RES, V43, P93, DOI 10.1016/S0022-3999(97)00023-8; RICHARDSEN AM, 1993, PSYCHOL REP, V72, P811, DOI 10.2466/pr0.1993.72.3.811; STANSFELD SA, 1992, PSYCHOL MED, V22, P739, DOI 10.1017/S0033291700038186; Stansfeld SA, 1997, PSYCHOL MED, V27, P35, DOI 10.1017/S0033291796004254; Stansfeld SA, 1998, PSYCHOSOM MED, V60, P247, DOI 10.1097/00006842-199805000-00004; vanWijk C, 1997, MIL MED, V162, P707, DOI 10.1093/milmed/162.10.707; Wall TD, 1997, BRIT J PSYCHIAT, V171, P519, DOI 10.1192/bjp.171.6.519; WHO, 2012, ICD 10 CLASS MENT BE; Williams S, 1998, IMPROVING HLTH NHS W	34	237	242	2	51	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2000	355	9203					533	537		10.1016/S0140-6736(99)07366-3	http://dx.doi.org/10.1016/S0140-6736(99)07366-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	287CN	10683003				2022-12-28	WOS:000085487400011
J	Scholl, A; Stohr, J; Luning, J; Seo, JW; Fompeyrine, J; Siegwart, H; Locquet, JP; Nolting, F; Anders, S; Fullerton, EE; Scheinfein, MR; Padmore, HA				Scholl, A; Stohr, J; Luning, J; Seo, JW; Fompeyrine, J; Siegwart, H; Locquet, JP; Nolting, F; Anders, S; Fullerton, EE; Scheinfein, MR; Padmore, HA			Observation of antiferromagnetic domains in epitaxial thin films	SCIENCE			English	Article							MAGNETIC DICHROISM; X-RAY; TEMPERATURE; MOMENTS	Antiferromagnetic domains in an epitaxial thin film, LaFeO3 on SrTiO3(100), were observed using a high-spatial-resolution photoelectron emission microscope with contrast generated by the large x-ray magnetic Linear dichroism effect at the multiplet-split L edge of Fe. The antiferromagnetic domains are linked to 90 degrees twinned crystallographic regions in the film. The Neel temperature of the thin film is reduced by 70 kelvin relative to the bulk material, and this reduction is attributed to epitaxial strain. These studies open the door for a microscopic understanding of the magnetic coupling across antiferromagnetic-ferromagnetic interfaces.	Univ Calif Berkeley, Adv Light Source, Berkeley, CA 94720 USA; IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA; IBM Corp, Div Res, Zurich Res Lab, CH-8803 Ruschlikon, Switzerland; Univ Neuchatel, Inst Phys, CH-2000 Neuchatel, Switzerland; Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; International Business Machines (IBM); International Business Machines (IBM); University of Neuchatel; Arizona State University; Arizona State University-Tempe	Scholl, A (corresponding author), Univ Calif Berkeley, Adv Light Source, 1 Cyclotron Rd, Berkeley, CA 94720 USA.	a_scholl@lbl.gov	Nolting, Frithjof/ABD-7373-2021; Nolting, Frithjof/J-4820-2017; Seo, Jin Won/J-3980-2013; Scholl, Andreas/K-4876-2012; Raoux, Simone/G-3920-2016; Fullerton, Eric E/H-8445-2013; Seo, Maria/L-9960-2018	Nolting, Frithjof/0000-0002-5679-5370; Nolting, Frithjof/0000-0002-5679-5370; Seo, Jin Won/0000-0003-4937-0769; Scholl, Andreas/0000-0002-1990-4769; Fullerton, Eric E/0000-0002-4725-9509; Seo, Maria/0000-0003-4937-0769; Locquet, Jean-Pierre/0000-0002-4214-7081				Abarra EN, 1996, PHYS REV LETT, V77, P3451, DOI 10.1103/PhysRevLett.77.3451; Alders D, 1998, PHYS REV B, V57, P11623, DOI 10.1103/PhysRevB.57.11623; Anders S, 1999, REV SCI INSTRUM, V70, P3973, DOI 10.1063/1.1150023; BARUCHEL J, 1993, PHYSICA B, V192, P79, DOI 10.1016/0921-4526(93)90110-R; EIBSCHUTZ M, 1967, PHYS REV, V156, P562, DOI 10.1103/PhysRev.156.562; FIEBIG M, 1995, APPL PHYS LETT, V66, P2906, DOI 10.1063/1.113699; Kortright JB, 1999, J MAGN MAGN MATER, V207, P7, DOI 10.1016/S0304-8853(99)00485-0; KUIPER P, 1993, PHYS REV LETT, V70, P1549, DOI 10.1103/PhysRevLett.70.1549; LOCQUET JP, 1994, APPL PHYS LETT, V64, P372, DOI 10.1063/1.111151; Locquet JP, 1998, NATURE, V394, P453, DOI 10.1038/28810; LUNING J, UNPUB; Lyubutin IS, 1999, J EXP THEOR PHYS+, V88, P590, DOI 10.1134/1.558833; MCMURDIE H, 1986, POWDER DIFFR, V1, P269; Nogues J, 1999, J MAGN MAGN MATER, V192, P203, DOI 10.1016/S0304-8853(98)00266-2; Prinz GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/science.282.5394.1660; ROTH WL, 1960, J APPL PHYS, V31, P2000, DOI 10.1063/1.1735486; SAITO S, 1980, J PHYS C SOLID STATE, V13, P1513, DOI 10.1088/0022-3719/13/8/020; Spanke D, 1998, PHYS REV B, V58, P5201, DOI 10.1103/PhysRevB.58.5201; STOHR J, 1993, SCIENCE, V259, P658, DOI 10.1126/science.259.5095.658; Stohr J, 1998, SURF REV LETT, V5, P1297, DOI 10.1142/S0218625X98001638; Stohr J, 1999, PHYS REV LETT, V83, P1862, DOI 10.1103/PhysRevLett.83.1862; THOLE BT, 1985, PHYS REV LETT, V55, P2086, DOI 10.1103/PhysRevLett.55.2086; WHITE RL, 1969, J APPL PHYS, V40, P1061, DOI 10.1063/1.1657530	23	278	280	2	155	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2000	287	5455					1014	1016		10.1126/science.287.5455.1014	http://dx.doi.org/10.1126/science.287.5455.1014			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669407				2022-12-28	WOS:000085245400039
J	Cohen, JJ				Cohen, JJ			White coats should not have union labels.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Assoc Amer Med Coll, Washington, DC 20037 USA	Association of American Medical Colleges	Cohen, JJ (corresponding author), Assoc Amer Med Coll, Washington, DC 20037 USA.							*AAMC EX COUNC, 1999, AAMC REPORTER, V9, P7; *ACCR COUNC GRAD M, 1998, I REQ; *ACCR COUNC GRAD M, 1999, PROC DEAL COMPL RES; [Anonymous], 1976, NLRB; *BOST MED CTR, 1999, NLRB, V330; *BOST MED CTR COMM, 1999, BOST MED CTR PET BRI, P44; *CED SIN MED CTR, 1976, LRRM, V91, P1398; Cohen JJ, 1999, ACAD MED, V74, P108, DOI 10.1097/00001888-199902000-00009; Cohen JJ, 1997, NEW ENGL J MED, V336, P1317, DOI 10.1056/NEJM199705013361811; Daugherty SR, 1996, ACAD MED, V71, pS93, DOI 10.1097/00001888-199601000-00054; Iglehart JK, 1999, NEW ENGL J MED, V341, P299, DOI 10.1056/NEJM199907223410424; KLEIN S, 1999, AM MEDI NEWS    0705, P34; KLEIN S, 1999, AM MED NEWS     1108, P5; KLEIN SA, 1999, AM MED NEWS     0927, P1; MARCHIONE M, 1998, MILWAUKEE J SEN 0712, P1; Marwick C, 1999, JAMA-J AM MED ASSOC, V281, P1781, DOI 10.1001/jama.281.19.1781; Richardson GS, 1996, SLEEP, V19, P718; 1998, USA TODAY       0528, pA12	18	12	12	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					431	434		10.1056/NEJM200002103420614	http://dx.doi.org/10.1056/NEJM200002103420614			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666438				2022-12-28	WOS:000085205200013
J	Berger, A				Berger, A			PAR2 antagonists-the next generation of anti-inflammatories?	BRITISH MEDICAL JOURNAL			English	News Item																		BUNNETT, 2000, NATURE MED, V6, P151	1	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					334	334		10.1136/bmj.320.7231.334	http://dx.doi.org/10.1136/bmj.320.7231.334			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657317	Green Published			2022-12-28	WOS:000085211400012
J	Fenwick, C; Na, SY; Voll, RE; Zhong, HH; Im, SY; Lee, JW; Ghosh, S				Fenwick, C; Na, SY; Voll, RE; Zhong, HH; Im, SY; Lee, JW; Ghosh, S			A subclass of Ras proteins that regulate the degradation of I kappa B	SCIENCE			English	Article							GTP-GAMMA-S; ACTIVATION; BETA; ALPHA; PHOSPHORYLATION; TRANSFORMATION; GTPASES; COMPLEX; FAMILY; GENE	Small guanosine triphosphatases, typified by the mammalian Ras proteins, play major roles in the regulation of numerous cellular pathways. A subclass of evolutionarily conserved Ras-Like proteins was identified, members of which differ from other Ras proteins in containing amino acids at positions 12 and 61 that are similar to those present in the oncogenic forms of Ras. These proteins, kappa B-Ras1 and kappa B-Ras2, interact with the PEST domains of I kappa B alpha and I kappa B beta [inhibitors of the transcription factor nuclear factor kappa B (NF-kappa B)] and decrease their rate of degradation. In cells, kappa B-Ras proteins are associated only with NF-kappa B:I kappa B beta complexes and therefore may provide an explanation for the slower rate of degradation of I kappa B beta compared with I kappa B alpha.	Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Microbiol, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea	Chonnam National University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Chonnam National University; Chonnam National University; Chonnam National University	Ghosh, S (corresponding author), Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea.			Fenwick, Craig/0000-0002-9435-0110				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FENWICK CW, UNPUB; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LAWRENCE PA, 1988, CELL, V54, P1, DOI 10.1016/0092-8674(88)90172-9; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Na SY, 1998, J BIOL CHEM, V273, P3212, DOI 10.1074/jbc.273.6.3212; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Raw AS, 1997, BIOCHEMISTRY-US, V36, P15660, DOI 10.1021/bi971912p; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Weil R, 1997, J BIOL CHEM, V272, P9942; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Winkler DG, 1997, J BIOL CHEM, V272, P24402, DOI 10.1074/jbc.272.39.24402; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	27	84	99	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					869	873		10.1126/science.287.5454.869	http://dx.doi.org/10.1126/science.287.5454.869			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657303				2022-12-28	WOS:000085136400050
J	Manoharan, HC; Lutz, CP; Eigler, DM				Manoharan, HC; Lutz, CP; Eigler, DM			Quantum mirages formed by coherent projection of electronic structure	NATURE			English	Article							SCANNING TUNNELING MICROSCOPE; METAL-SURFACE; SINGLE ATOMS; SPECTROSCOPY; SCATTERING	Image projection relies on classical wave mechanics and the use of natural or engineered structures such as lenses or resonant cavities. Well-known examples include the bending of light to create mirages in the atmosphere, and the focusing of sound by whispering galleries. However, the observation of analogous phenomena in condensed matter systems is a more recent development(1), facilitated by advances in nanofabrication. Here we report the projection of the electronic structure surrounding a magnetic Co atom to a remote location on the surface of a Cu crystal; electron partial waves scattered from the real Co atom are coherently refocused to form a spectral image or 'quantum mirage'. The focusing device is an elliptical quantum corral(2,3), assembled on the Cu surface. The corral acts as a quantum mechanical resonator, while the two-dimensional Cu surface-state electrons form the projection medium. When placed on the surface, Co atoms display a distinctive spectroscopic signature, known as the many-particle Kondo resonance(4-6), which arises from their magnetic moment. By positioning a Co atom at one focus of the ellipse, we detect a strong Kondo signature not only at the atom, but also at the empty focus. This behaviour contrasts with the usual spatially-decreasing response of an electron gas to a localized perturbation(7).	IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA	International Business Machines (IBM)	Manoharan, HC (corresponding author), IBM Corp, Almaden Res Ctr, Div Res, 650 Harry Rd, San Jose, CA 95120 USA.							Chan YS, 1997, PHYS REV LETT, V78, P2570, DOI 10.1103/PhysRevLett.78.2570; CROMMIE MF, 1993, NATURE, V363, P524, DOI 10.1038/363524a0; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; EVERSON MP, 1990, J VAC SCI TECHNOL A, V8, P3662, DOI 10.1116/1.576476; FANO U, 1961, PHYS REV, V124, P1866, DOI 10.1103/PhysRev.124.1866; HASEGAWA Y, 1993, PHYS REV LETT, V71, P1071, DOI 10.1103/PhysRevLett.71.1071; Heremans JJ, 1999, APPL PHYS LETT, V74, P1281, DOI 10.1063/1.123524; Hewson A. C., 1997, KONDO PROBLEM HEAVY, V2; KITTEL C, 1968, SOLID STATE PHYS, V22, P1; Kittel Ch., 1963, QUANTUM THEORY SOLID; KONDO J, 1964, PROG THEOR PHYS, V32, P37, DOI 10.1143/PTP.32.37; LANG ND, 1986, PHYS REV B, V34, P5947, DOI 10.1103/PhysRevB.34.5947; Li JT, 1998, PHYS REV LETT, V80, P2893, DOI 10.1103/PhysRevLett.80.2893; Madhavan V, 1998, SCIENCE, V280, P567, DOI 10.1126/science.280.5363.567; SPECTOR J, 1990, APPL PHYS LETT, V56, P1290, DOI 10.1063/1.102538; Stipe BC, 1998, SCIENCE, V280, P1732, DOI 10.1126/science.280.5370.1732; STROSCIO JA, 1991, SCIENCE, V254, P1319, DOI 10.1126/science.254.5036.1319; TOMSOVIC S, 1993, PHYS REV LETT, V70, P1405, DOI 10.1103/PhysRevLett.70.1405	19	725	732	4	221	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					512	515		10.1038/35000508	http://dx.doi.org/10.1038/35000508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676952				2022-12-28	WOS:000085227300040
J	Bickel, J; Clark, V				Bickel, J; Clark, V			Encouraging the advancement of women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CAREER		Assoc Amer Med Coll, Womens Programs, Washington, DC 20037 USA	Association of American Medical Colleges	Bickel, J (corresponding author), Assoc Amer Med Coll, Womens Programs, Washington, DC 20037 USA.							*ASS AM MED COLL, 1996, ACAD MED, V71, P800; BICKEL J, 1998, WOMEN US ACAD MED ST; Fried LP, 1996, JAMA-J AM MED ASSOC, V276, P898, DOI 10.1001/jama.276.11.898; Haapanen KJ, 1996, ACAD MED, V71, P794; Limacher MC, 1998, J AM COLL CARDIOL, V32, P827, DOI 10.1016/S0735-1097(98)00319-2; MILLER TB, 1996, NEW PSYCHOL WOMEN; TESCH B, 1997, J IRISH COLL PHYS SU, V26, P172; Valian V, 1998, WHY SO SLOW ADVANCEM; 1999, EXECUTIVE LEADERSHIP	9	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					671	671		10.1001/jama.283.5.671	http://dx.doi.org/10.1001/jama.283.5.671			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665713				2022-12-28	WOS:000084956500039
J	Catanzaro, A; Perry, S; Clarridge, JE; Dunbar, S; Goodnight-White, S; LoBue, PA; Peter, C; Pfyffer, GE; Sierra, MF; Weber, R; Woods, G; Mathews, G; Jonas, V; Smith, K; Della-Latta, P				Catanzaro, A; Perry, S; Clarridge, JE; Dunbar, S; Goodnight-White, S; LoBue, PA; Peter, C; Pfyffer, GE; Sierra, MF; Weber, R; Woods, G; Mathews, G; Jonas, V; Smith, K; Della-Latta, P			The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis - Results of a multicenter prospective trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; RESPIRATORY SPECIMENS; SYSTEM; AMPLIFICATION; COMPLEX; ASSAY; IDENTIFICATION; SENSITIVITY	Context In laboratory trials, nucleic acid amplification tests for the diagnosis of tuberculosis (TB) are more accurate than acid-fast bacilli (AFB) smear microscopy and are faster than culture. The impact of these tests on clinical diagnosis is not known. Objective To assess the performance of a nucleic acid amplification test, the enhanced Mycobacterium tuberculosis Direct (E-MTD) test, against a uniform clinical standard stratified by level of clinical suspicion. Design Prospective multicenter trial conducted between February and December 1996, documenting the clinical suspicion of TB at enrollment and using final comprehensive diagnosis as the criterion standard. Setting Six urban medical centers and 1 public health TB clinic. Patients A total of 338 patients with symptoms and signs consistent with active pulmonary TB and complete clinical diagnosis were stratified by the clinical investigators to be at low (less than or equal to 25%), intermediate (26%-75%), or high (>75%) relative risk of having TB. Main Outcome Measures Sensitivity, specificity, and positive and negative predictive values of the E-MTD test in clinical suspicion of groups with low (n = 224); intermediate (n = 68); and high (n = 46) clinical suspicion of TB. Results Based on comprehensive clinical diagnosis, sensitivity of the E-MTD test. was 83%, 75%, and 87% for low, intermediate, and high clinical suspicion of TB, respectively, and corresponding specificity was 97%, 100%, and 100% (P = .25). Positive predictive value of the E-MTD test was 59% (low), 100% (intermediate), and 100% (high) compared with 36% (low), 30% (intermediate), and 94% (high) for AFB smear. Corresponding negative predictive values were 99%, 91%,and 91% (E-MTD test) vs 96%, 71%, and 37% (AFB smear). Conclusions For complex diagnostic problems like TB, clinical risk assessments can provide important information regarding predictive values more likely to be experienced in clinical practice. For this series, a clincial suspicion of TB was helpful in targeting areas of the clinical spectrum in which nucleic acid amplification tests can make an important contribution.	Univ Calif San Diego, Med Ctr, San Diego, CA 92103 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA; San Diego Cty Publ Hlth Lab, San Diego, CA USA; Univ Zurich, Dept Med Microbiol, Swiss Natl Ctr Mycobacteria, Zurich, Switzerland; SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA; Univ Zurich Hosp, Div Infect Dis, CH-8091 Zurich, Switzerland; Univ Texas, Med Branch, Galveston, TX 77550 USA; Gen Probe Inc, San Diego, CA USA; Columbia Presbyterian Med Ctr, Dept Pathol, New York, NY 10032 USA	University of California System; University of California San Diego; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Zurich; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Zurich; University Zurich Hospital; University of Texas System; University of Texas Medical Branch Galveston; Columbia University; NewYork-Presbyterian Hospital	Catanzaro, A (corresponding author), Univ Calif San Diego, Med Ctr, 200 W Arbor Dr 8374, San Diego, CA 92103 USA.		Weber, Rainer/D-5175-2012; Sierra, Maria/GYU-1134-2022					ANKOBIAH W, 1996, CHEST, V110, pS229; [Anonymous], 1882, BERLINER KLIN WOCHEN, V19, P221; Ausina V, 1997, J CLIN MICROBIOL, V35, P1996, DOI 10.1128/JCM.35.8.1996-2002.1997; BARNES PF, 1988, J INFECT DIS, V158, P366, DOI 10.1093/infdis/158.2.366; Barnes PF, 1997, AM J RESP CRIT CARE, V155, P1497, DOI 10.1164/ajrccm.155.5.9154847; Bergmann JS, 1996, J CLIN MICROBIOL, V34, P1083, DOI 10.1128/JCM.34.5.1083-1085.1996; BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003; Bock NN, 1996, AM J RESP CRIT CARE, V154, P1468, DOI 10.1164/ajrccm.154.5.8912766; BOYD JC, 1975, ANN INTERN MED, V82, P489, DOI 10.7326/0003-4819-82-4-489; Bradley SP, 1996, AM J RESP CRIT CARE, V153, P1606, DOI 10.1164/ajrccm.153.5.8630609; Catanzaro A, 1997, AM J RESP CRIT CARE, V155, P1804, DOI 10.1164/ajrccm.155.5.9154896; Centers for Disease Control and Preventio, 1996, MMWR-MORBID MORTAL W, V45, P950; CHIN DP, 1995, AM J RESP CRIT CARE, V151, P1872, DOI 10.1164/ajrccm.151.6.7767534; CLARRIDGE JE, 1993, J CLIN MICROBIOL, V31, P2049, DOI 10.1128/JCM.31.8.2049-2056.1993; Cohen R, 1996, CHEST, V109, P420, DOI 10.1378/chest.109.2.420; Cohen RA, 1998, AM J RESP CRIT CARE, V157, P156, DOI 10.1164/ajrccm.157.1.97-06043; Crawford J T, 1994, Semin Respir Infect, V9, P62; DIAMOND GA, 1992, J CLIN EPIDEMIOL, V45, P9, DOI 10.1016/0895-4356(92)90181-L; EISENACH KD, 1991, AM REV RESPIR DIS, V144, P1160, DOI 10.1164/ajrccm/144.5.1160; El-Solh AA, 1998, CHEST, V114, P138, DOI 10.1378/chest.114.1.138; ElSolh A, 1997, AM J RESP CRIT CARE, V155, P1711, DOI 10.1164/ajrccm.155.5.9154881; GORDIN FM, 1989, AM REV RESPIR DIS, V139, P1090, DOI 10.1164/ajrccm/139.5.1090; JONAS V, 1993, J CLIN MICROBIOL, V31, P2410, DOI 10.1128/JCM.31.9.2410-2416.1993; Jonas V, 1997, CLIN LAB MED, V17, P119, DOI 10.1016/S0272-2712(18)30236-1; Mylotte JM, 1997, INFECT CONT HOSP EP, V18, P554; Nightingale SL, 1996, JAMA-J AM MED ASSOC, V275, P585, DOI 10.1001/jama.275.8.585; PFYFFER GE, 1994, J CLIN MICROBIOL, V32, P918, DOI 10.1128/JCM.32.4.918-923.1994; Pfyffer GE, 1997, J CLIN MICROBIOL, V35, P2229, DOI 10.1128/JCM.35.9.2229-2234.1997; Pfyffer GE, 1996, J CLIN MICROBIOL, V34, P834, DOI 10.1128/JCM.34.4.834-841.1996; Piersimoni C, 1997, J CLIN MICROBIOL, V35, P193, DOI 10.1128/JCM.35.1.193-196.1997; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; Rohner P, 1997, J CLIN MICROBIOL, V35, P3127, DOI 10.1128/JCM.35.12.3127-3131.1997; SCHULMAN KA, 1992, MED DECIS MAKING, V12, P109, DOI 10.1177/0272989X9201200203; SCOTT B, 1994, ARCH INTERN MED, V154, P326, DOI 10.1001/archinte.154.3.326; Smith JH, 1997, J CLIN MICROBIOL, V35, P1484, DOI 10.1128/JCM.35.6.1484-1491.1997; THIERRY D, 1990, NUCLEIC ACIDS RES, V18, P188, DOI 10.1093/nar/18.1.188; Tortoli E, 1998, J CLIN MICROBIOL, V36, P1378, DOI 10.1128/JCM.36.5.1378-1381.1998; Wobeser WL, 1996, J CLIN MICROBIOL, V34, P134, DOI 10.1128/JCM.34.1.134-139.1996; Wright PW, 1998, J CLIN MICROBIOL, V36, P1046, DOI 10.1128/JCM.36.4.1046-1049.1998	40	101	103	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					639	645		10.1001/jama.283.5.639	http://dx.doi.org/10.1001/jama.283.5.639			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665704	Bronze			2022-12-28	WOS:000084956500030
J	Goodman, KJ; Correa, P				Goodman, KJ; Correa, P			Transmission of Helicobacter pylori among siblings	LANCET			English	Article							UREA BREATH TEST; DUODENAL-ULCER; BIRTH-ORDER; INFECTION; RISK; CHILDREN; POPULATION; PREVALENCE; INFANCY; AGE	Background Helicobacter pylori infection causes chronic digestive diseases with a major public-health impact, yet the design of prevention measures is hampered by limited knowledge of transmission pathways. We studied the effect of family composition on H pylori prevalence among rural Colombian children aged 2-9 years. Methods 684 children were screened for H pylori with the UC-urea breath test, For each child, birth order, birth spacing, number of 2-9-year-old siblings, and number of H-pylori-positive 2-9-year-old siblings was recorded. Odds ratios were estimated by logistic regression, controlling for hygiene-related exposures, socioeconomic indicators, and the number of children in the household. Findings The odds of infection increased with the number of 2-9-year-old siblings in the household (odds ratios 1.4, 2.3, 2.6, and 4.3 for one, two, three, and four to five siblings, respectively). Compared with first-born children, odds ratios for children born second and third to ninth were 1.8 (95% CI 1.0-3.3) and 2.2(1.0-4.3), respectively. Compared with children born 10 or more years after the next older household member, those born within 4 years were 4.1 times (CI 2.0-8.6) more likely to be infected; the age gap to the next younger household member displayed a weaker effect. The number of H-pylori-positive 2-9-year-old siblings had particularly strong effect gradient (1.5, 3.2, 5.6, and 7.1, for one, two, three, and four positive siblings, respectively). Interpretation Among rural Andean children younger than 10 years, H pylori infection seems to be transmitted most readily among siblings who are close in age, and most frequently from older siblings to younger ones.	Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Houston, TX 77225 USA; Louisiana State Univ, Med Ctr, Dept Pathol, New Orleans, LA 70112 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Louisiana State University System	Goodman, KJ (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, POB 20186, Houston, TX 77225 USA.	kgoodman@utsph.sph.uth.tmc.edu	Goodman, Karen/D-6823-2013	Goodman, Karen/0000-0002-3790-3217	NATIONAL CANCER INSTITUTE [P01CA028842] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA28842] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashorn M, 1996, ARCH DIS CHILD-FETAL, V74, pF141, DOI 10.1136/fn.74.2.F141; Blaser MJ, 1998, GUT, V43, P721, DOI 10.1136/gut.43.5.721; BLASER MJ, 1995, CANCER RES, V55, P562; BLECKER U, 1994, J PEDIATR GASTR NUTR, V19, P87, DOI 10.1097/00005176-199407000-00014; Cadranel S, 1998, J PEDIATR GASTR NUTR, V27, P275, DOI 10.1097/00005176-199809000-00001; CORREA P, 1990, CANCER RES, V50, P4737; CORREA P, 1995, GASTROINTESTINAL OES, P485; CORREA P, 1989, PROGR SURGICAL PATHO, V10, P191; Delvin EE, 1999, J PEDIATR GASTR NUTR, V28, P59, DOI 10.1097/00005176-199901000-00014; Fall CHD, 1997, ARCH DIS CHILD, V77, P310, DOI 10.1136/adc.77.4.310; FOX JP, 1970, EPIDEMIOLOGY MAN DIS, P199; Gold BD, 1997, PEDIATR RES, V41, P641, DOI 10.1203/00006450-199705000-00007; Goodman, 1997, Cad Saude Publica, V13 Suppl 1, P15; Goodman KJ, 1996, AM J EPIDEMIOL, V144, P290, DOI 10.1093/oxfordjournals.aje.a008924; GOODMAN KJ, 1995, INT J EPIDEMIOL, V24, P875, DOI 10.1093/ije/24.5.875; GRAHAM DY, 1991, AM J GASTROENTEROL, V86, P1118; GUTENSOHN N, 1981, NEW ENGL J MED, V304, P135, DOI 10.1056/NEJM198101153040302; HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1115, DOI 10.1093/oxfordjournals.aje.a116577; *INT AG RES CANC, 1994, IARC MON EV CANC RIS, V61; ISAGER H, 1980, ACTA NEUROL SCAND, V61, P393; Kalach N, 1998, J PEDIATR GASTR NUTR, V26, P291, DOI 10.1097/00005176-199803000-00010; MACMAHON B, 1992, AM J EPIDEMIOL, V136, P916, DOI 10.1093/oxfordjournals.aje.a116564; PARSONNET J, 1995, ALIMENT PHARM THERAP, V9, P45; POUNDER RE, 1995, ALIMENT PHARM THERAP, V9, P33; REVES R, 1985, AM J EPIDEMIOL, V122, P112, DOI 10.1093/oxfordjournals.aje.a114070; Rothenbacher D, 1997, EPIDEMIOL INFECT, V119, P151, DOI 10.1017/S0950268897007905; Rothenbacher D, 1998, INT J EPIDEMIOL, V27, P135, DOI 10.1093/ije/27.1.135; Rowland M, 1997, J PEDIATR-US, V131, P815, DOI 10.1016/S0022-3476(97)70026-X; TAYLOR I, 1964, PRINCIPLES EPIDEMIOL, P304; TEH BH, 1994, ANTICANCER RES, V14, P1389; TSUGANE S, 1994, JPN J CANCER RES, V85, P474, DOI 10.1111/j.1349-7006.1994.tb02382.x; VANDENPLAS Y, 1992, PEDIATRICS, V90, P608; WANG JT, 1993, J INFECT DIS, V168, P1544, DOI 10.1093/infdis/168.6.1544; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	34	206	211	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	2000	355	9201					358	362		10.1016/S0140-6736(99)05273-3	http://dx.doi.org/10.1016/S0140-6736(99)05273-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665555				2022-12-28	WOS:000085122100011
J	Mol, CD; Izumi, T; Mitra, S; Tainer, JA				Mol, CD; Izumi, T; Mitra, S; Tainer, JA			DNA-bound structures and mutants reveal abasic DNA binding by APE1 DNA repair and coordination	NATURE			English	Article							HUMAN APURINIC ENDONUCLEASE; BASE EXCISION-REPAIR; POLYMERASE-BETA; SITES; DEOXYRIBOSE; RECOGNITION; DYNAMICS; PROTEIN; XRCC1; CELLS	Non-coding apurinic/apyrimidinic (AP) sites in DNA are continually created in cells both spontaneously and by damage-specific DNA glycosylases'. The biologically critical human base excision repair enzyme APE1 cleaves the DNA sugar-phosphate backbone at a position 5' of AP sites to prime DNA repair synthesis(2-4). Here we report three co-crystal structures of human APE1 bound to abasic DNA which show that APE1 uses a rigid, pre-formed, positively charged surface to kink the DNA helix and engulf the AP-DNA strand. APE1 inserts loops into both the DNA major and minor grooves and binds a flipped-out AP site in a pocket that excludes DNA bases and racemized beta-anomer AP sites. Both the APE1 active-site geometry and a complex with cleaved AP-DNA and Mn2+ support a testable structure-based catalytic mechanism. Alanine substitutions of the residues that penetrate the DNA helix unexpectedly show that human APE1 is structurally optimized to retain the cleaved DNA product. These structural and mutational results show how APE1 probably displaces bound glycosylases and retains the nicked DNA product, suggesting that APE1 acts in vivo to coordinate the orderly transfer of unstable DNA damage intermediates between the excision and synthesis steps of DNA repair.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	Scripps Research Institute; Scripps Research Institute; University of Texas System; University of Texas Medical Branch Galveston	Tainer, JA (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429				Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; Erzberger JP, 1999, J MOL BIOL, V290, P447, DOI 10.1006/jmbi.1999.2888; Erzberger JP, 1998, NUCLEIC ACIDS RES, V26, P2771, DOI 10.1093/nar/26.11.2771; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Izumi T, 1998, CARCINOGENESIS, V19, P525, DOI 10.1093/carcin/19.3.525; Izumi T, 1999, J MOL BIOL, V287, P47, DOI 10.1006/jmbi.1999.2573; KANE CM, 1981, J BIOL CHEM, V256, P3405; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Tsutakawa SE, 1999, CELL, V99, P615, DOI 10.1016/S0092-8674(00)81550-0; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017	30	583	603	12	90	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					451	456		10.1038/35000249	http://dx.doi.org/10.1038/35000249			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667800				2022-12-28	WOS:000085121100056
J	Ibrahim, NK; Sahin, AA; Dubrow, RA; Lynch, PN; Boehnke-Michaud, L; Valero, V; Buzdar, AU; Hortobagyi, GN				Ibrahim, NK; Sahin, AA; Dubrow, RA; Lynch, PN; Boehnke-Michaud, L; Valero, V; Buzdar, AU; Hortobagyi, GN			Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer	LANCET			English	Article							TYPHLITIS	Background Docetaxel and vinorelbine as combined treatment for metastatic breast cancer can have the dose-limiting toxic effects of mucositis and neutropenic fever. We report unexpected ischaemic colitis in six patients associated with docetaxel-based therapy, three of whom were treated in a phase I study designed to establish the maximum tolerated dose of this combination with the prophylactic use of granulocyte-colony-stimulating factor. Methods Between August, 1997, and December, 1998, 14 patients with metastatic breast cancer were treated with vinorelbine, docetaxel, and granulocyte-colony-stimulating factor in a phase I study. Three patients developed colitis similar to that seen in typhlitis. Three additional patients were identified during scheduled review of toxic effects in patients participating in clinical trials involving docetaxel. Findings Three patients on combined vinorelbine and docetaxel developed colitis-like symptoms. Two patients died, one from necrotic bower and the other from neutropenic fever and colitis, Two of the patients presented on day 7 and day 8 of chemotherapy, respectively, with neutropenic fever and abdominal pain; the third patient developed neutropenia without fever and abdominal pain on day 8. The other three patients were treated with docetaxel, docetaxel and pamidronate disodium, or docetaxel and cyclophosphamide. All three patients presented with abdominal pain on days 10, 5, and 4, respectively. One had non-neutropenic fever, another had neutropenic fever, and the third was afebrile and nonneutropenic at the time of presentation with abdominal pain. Three patients had blood in their diarrhoea, abdominal tenderness, or both. Computed tomography of the abdomen and pelvis showed features of colitis in three patients. Interpretation This serious complication may result from the use of docetaxel and may be exacerbated by its combination with vinorelbine. Study of hospital-based patients treated with taxane-based chemotherapy is underway to find out the frequency of such complications.	Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Oncol & Digest Dis, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pharm, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Ibrahim, NK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.							Cardenal F, 1996, J NATL CANCER I, V88, P1078, DOI 10.1093/jnci/88.15.1078; DOSIK GM, 1979, AM J MED, V67, P646, DOI 10.1016/0002-9343(79)90248-1; EPSTEIN M, 1998, CANC THER, V1, P174; HORTOBAGYI GN, 1989, CANCER, V63, P37, DOI 10.1002/1097-0142(19890101)63:1<37::AID-CNCR2820630106>3.0.CO;2-Z; KEIDAN RD, 1989, DIS COLON RECTUM, V32, P206, DOI 10.1007/BF02554529; Kennedy MJ, 1996, J CLIN ONCOL, V14, P783, DOI 10.1200/JCO.1996.14.3.783; PETALOZZI BC, 1993, CANCER, V71, P1797; Rolston Kenneth V. I., 1993, P2416	8	91	94	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					281	283		10.1016/S0140-6736(99)06195-4	http://dx.doi.org/10.1016/S0140-6736(99)06195-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675076				2022-12-28	WOS:000085045600012
J	McMahon, AP				McMahon, AP			More surprises in the Hedgehog signaling pathway	CELL			English	Review							SONIC HEDGEHOG; CHOLESTEROL; PROTEINS; GENE		Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	McMahon, AP (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.		McMahon, Andrew P/ABE-7520-2020					Aza-Blanc P, 1999, TRENDS GENET, V15, P458, DOI 10.1016/S0168-9525(99)01869-7; Beachy PA, 1997, COLD SPRING HARB SYM, V62, P191; Burke R, 1999, CELL, V99, P803, DOI 10.1016/S0092-8674(00)81677-3; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Osborne TF, 1998, CURR OPIN LIPIDOL, V9, P137, DOI 10.1097/00041433-199804000-00010; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Ramirez-Weber FA, 1999, CELL, V97, P599, DOI 10.1016/S0092-8674(00)80771-0; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2	19	169	179	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					185	188		10.1016/S0092-8674(00)81555-X	http://dx.doi.org/10.1016/S0092-8674(00)81555-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660040	Bronze			2022-12-28	WOS:000084932200001
J	Yla-Herttuala, S; Martin, JF				Yla-Herttuala, S; Martin, JF			Cardiovascular gene therapy	LANCET			English	Review							ENDOTHELIAL GROWTH-FACTOR; MUSCLE CELL-PROLIFERATION; ADENOVIRUS-MEDIATED TRANSFER; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; NITRIC-OXIDE SYNTHASE; RECEPTOR-DEFICIENT RABBITS; HUMAN LIPOPROTEIN-LIPASE; LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; ALTERS PLASMA HDL	Vascular gene transfer potentially offers new treatments for cardiovascular diseases. It can be used to overexpress therapeutically important proteins and correct genetic defects, and to test experimentally the effects of various genes in a local vascular compartment. Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) gene transfers have improved blood flow and collateral development in ischaemic limb and myocardium. Promising therapeutic effects have been obtained in animal models of restenosis or vein-graft thickening with the transfer of genes coding for VEGF, nitric-oxide synthase, thymidine kinase, retinoblastoma, growth arrest homoeobox, tissue inhibitor of metalloproteinases, cyclin or cyclin-dependent kinase inhibitors, fas ligand and hirudin, and antisense oligonucleotides against transcription factors or cell-cycle regulatory proteins. First experiences of VEGF gene transfer and decoy oligonucleotides in human beings have been reported. However, further developments in gene-transfer vectors, gene-delivery techniques and identification of effective treatment genes will be required before the full therapeutic potential of gene therapy in cardiovascular disease can be assessed.	Univ Kuopio, AI Virtanen Inst, Kuopio 70211, Finland; Univ Kuopio, Dept Med, Kuopio 70211, Finland; UCL, Dept Med, London, England	University of Eastern Finland; University of Eastern Finland; University of London; University College London	Yla-Herttuala, S (corresponding author), Univ Kuopio, AI Virtanen Inst, POB 1627, Kuopio 70211, Finland.	Seppo.YlaHerttuala@uku.fi		Yla-Herttuala, Seppo/0000-0001-7593-2708				Allaire E, 1998, J CLIN INVEST, V102, P1413, DOI 10.1172/JCI2909; ApplebaumBowden D, 1996, J CLIN INVEST, V97, P799, DOI 10.1172/JCI118479; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arras M, 1998, NAT BIOTECHNOL, V16, P159, DOI 10.1038/nbt0298-159; Bai H, 1998, GENE THER, V5, P761, DOI 10.1038/sj.gt.3300640; Bailey S R, 1996, Semin Interv Cardiol, V1, P17; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; Benoit P, 1999, CIRCULATION, V99, P105, DOI 10.1161/01.CIR.99.1.105; BILBAO G, 1998, TUMOR TARGET, V3, P59; Bittl JA, 1996, NEW ENGL J MED, V335, P1290, DOI 10.1056/NEJM199610243351707; Brousseau ME, 1998, J LIPID RES, V39, P1558; Burcin MM, 1999, P NATL ACAD SCI USA, V96, P355, DOI 10.1073/pnas.96.2.355; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHEN SJ, 1994, CIRCULATION, V89, P1922, DOI 10.1161/01.CIR.89.5.1922; Cheng L, 1998, CIRCULATION, V98, P2195, DOI 10.1161/01.CIR.98.20.2195; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; DeGeest B, 1997, CIRCULATION, V96, P4349; DeYoung MB, 1998, CIRC RES, V82, P306, DOI 10.1161/01.RES.82.3.306; Dugi KA, 1997, J LIPID RES, V38, P1822; Dunn PF, 1996, CIRCULATION, V93, P1439, DOI 10.1161/01.CIR.93.7.1439; Ehnholm S, 1998, J LIPID RES, V39, P1248; Excoffon KJDA, 1997, ARTERIOSCL THROM VAS, V17, P2532, DOI 10.1161/01.ATV.17.11.2532; Fabre JE, 1999, CIRCULATION, V99, P3043, DOI 10.1161/01.CIR.99.23.3043; Fan L, 1998, GENE THER, V5, P1434, DOI 10.1038/sj.gt.3300746; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Ferrara N, 1996, Curr Opin Nephrol Hypertens, V5, P35, DOI 10.1097/00041552-199601000-00008; FINKEL T, 1995, FASEB J, V9, P843, DOI 10.1096/fasebj.9.10.7615154; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; George SJ, 1998, HUM GENE THER, V9, P867, DOI 10.1089/hum.1998.9.6-867; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; Greeve J, 1996, J LIPID RES, V37, P2001; GRONDIN CM, 1984, CIRCULATION, V70, P208; GROSSMAN M, 1995, NAT MED, V1, P1148, DOI 10.1038/nm1195-1148; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; Hakumaki JM, 1999, NAT MED, V5, P1323, DOI 10.1038/15279; Harrell RL, 1997, CIRCULATION, V96, P621; Hart CE, 1999, CIRCULATION, V99, P564, DOI 10.1161/01.CIR.99.4.564; Hasty AH, 1999, CIRCULATION, V99, P2571, DOI 10.1161/01.CIR.99.19.2571; Henry Timothy D., 1999, Journal of the American College of Cardiology, V33, p384A; Iaccarino G, 1999, P NATL ACAD SCI USA, V96, P3945, DOI 10.1073/pnas.96.7.3945; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Isner JM, 1998, J VASC SURG, V28, P964, DOI 10.1016/S0741-5214(98)70022-9; Isner JM, 1997, GENE TRANSFER CARDIO, P307; Ito WD, 1997, CIRC RES, V80, P829; Janssens S, 1998, CIRCULATION, V97, P1274, DOI 10.1161/01.CIR.97.13.1274; Kanno S, 1999, CIRCULATION, V99, P2682, DOI 10.1161/01.CIR.99.20.2682; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOPFLER WP, 1994, CIRCULATION, V90, P1319, DOI 10.1161/01.CIR.90.3.1319; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Kozarsky KF, 1996, NAT GENET, V13, P54, DOI 10.1038/ng0596-54; Kozarsky KF, 1996, HUM GENE THER, V7, P943, DOI 10.1089/hum.1996.7.8-943; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; Kullo IJ, 1997, CIRCULATION, V96, P2254; Laham RJ, 1999, CIRCULATION, V100, P1865, DOI 10.1161/01.CIR.100.18.1865; Laham Roger J., 1999, Journal of the American College of Cardiology, V33, p383A; Laitinen M, 2000, HUM GENE THER, V11, P263, DOI 10.1089/10430340050016003; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Laitinen M, 1997, HUM GENE THER, V8, P1645, DOI 10.1089/hum.1997.8.14-1645; Lamping KG, 1997, AM J PHYSIOL-HEART C, V272, pH310, DOI 10.1152/ajpheart.1997.272.1.H310; Lan N, 1998, SCIENCE, V280, P1593, DOI 10.1126/science.280.5369.1593; Laukkanen J, 1998, CIRCULATION, V98, P108; Lawrie A, 1999, CIRCULATION, V99, P2617, DOI 10.1161/01.CIR.99.20.2617; Lazarous DF, 1998, CIRCULATION, V98, P456; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977; Leor J, 1997, CARDIOVASC RES, V35, P431, DOI 10.1016/S0008-6363(97)00159-4; Lindahl P, 1998, CURR OPIN LIPIDOL, V9, P407, DOI 10.1097/00041433-199810000-00004; Lindner V, 1996, ARTERIOSCL THROM VAS, V16, P1399, DOI 10.1161/01.ATV.16.11.1399; Lopez JJ, 1998, AM J PHYSIOL-HEART C, V274, pH930, DOI 10.1152/ajpheart.1998.274.3.H930; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Mack CA, 1998, J THORAC CARDIOV SUR, V115, P168, DOI 10.1016/S0022-5223(98)70455-6; Makinen K, 1999, CIRCULATION, V100, P770; Mann MJ, 1999, LANCET, V354, P1493, DOI 10.1016/S0140-6736(99)09405-2; Manninen HI, 1998, INVEST RADIOL, V33, P464, DOI 10.1097/00004424-199808000-00007; MARTINS RN, 1994, GROWTH FACTORS, V10, P299, DOI 10.3109/08977199409010996; Miwa K, 1997, CARDIOVASC RES, V36, P37, DOI 10.1016/S0008-6363(97)00143-0; MORGAN RA, 1993, ANNU REV BIOCHEM, V62, P191; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; Morishita R, 1998, CIRCULATION, V98, P1898, DOI 10.1161/01.CIR.98.18.1898; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; NABEL EG, 1994, ANNU REV PHYSIOL, V56, P741; Narins CR, 1998, CIRCULATION, V97, P1298, DOI 10.1161/01.CIR.97.13.1298; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Newman KD, 1995, J CLIN INVEST, V96, P2955, DOI 10.1172/JCI118367; Nikol S, 1999, GENE THER, V6, P737, DOI 10.1038/sj.gt.3300888; Nishida T, 1999, CIRC RES, V84, P1446; Numaguchi Y, 1999, ARTERIOSCL THROM VAS, V19, P727, DOI 10.1161/01.ATV.19.3.727; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; Pakkanen TM, 1999, GENE THER, V6, P34, DOI 10.1038/sj.gt.3300796; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Phillips MI, 1999, HYPERTENSION, V33, P8, DOI 10.1161/01.HYP.33.1.8; Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; PU LQ, 1993, CIRCULATION, V88, P208, DOI 10.1161/01.CIR.88.1.208; Rade JJ, 1996, NAT MED, V2, P293, DOI 10.1038/nm0396-293; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Safi J, 1997, J MOL CELL CARDIOL, V29, P2311, DOI 10.1006/jmcc.1997.0459; SANGHONG B, 1998, CIRC RES, V82, P295; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645; SeguretMace S, 1996, CIRCULATION, V94, P2177, DOI 10.1161/01.CIR.94.9.2177; Sellke FW, 1998, ANN THORAC SURG, V65, P1540, DOI 10.1016/S0003-4975(98)00340-3; Shah PK, 1998, CIRCULATION, V97, P780, DOI 10.1161/01.CIR.97.8.780; SHI CW, 1994, CIRC RES, V75, P199, DOI 10.1161/01.RES.75.2.199; Shyu KG, 1998, CIRCULATION, V98, P2081, DOI 10.1161/01.CIR.98.19.2081; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11; Stephan DJ, 1996, HUM GENE THER, V7, P1803, DOI 10.1089/hum.1996.7.15-1803; Svensson EC, 1999, CIRCULATION, V99, P201, DOI 10.1161/01.CIR.99.2.201; Symes JF, 1999, ANN THORAC SURG, V68, P830, DOI 10.1016/S0003-4975(99)00807-3; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; Tsukamoto K, 1997, J LIPID RES, V38, P1869; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; Tsurumi Y, 1996, CIRCULATION, V94, P3281, DOI 10.1161/01.CIR.94.12.3281; Turunen MP, 1999, GENE THER, V6, P6, DOI 10.1038/sj.gt.3300800; UNGER EF, 1994, AM J PHYSIOL, V266, pH1588, DOI 10.1152/ajpheart.1994.266.4.H1588; Van Belle E, 1998, CIRCULATION, V97, P381; VanBelle E, 1997, J AM COLL CARDIOL, V29, P1371, DOI 10.1016/S0735-1097(97)00049-1; vanderZee R, 1997, CIRCULATION, V95, P1030; Villanueva FS, 1998, CIRCULATION, V98, P1, DOI 10.1161/01.CIR.98.1.1; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; Waltenberger J, 1997, CIRCULATION, V96, P4083; Waugh JM, 1999, P NATL ACAD SCI USA, V96, P1065, DOI 10.1073/pnas.96.3.1065; Waugh JM, 1999, CIRC RES, V84, P84; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Wilson JM, 1996, NEW ENGL J MED, V334, P1185, DOI 10.1056/NEJM199605023341809; YANG ZY, 1996, P NATL ACAD SCI USA, V93, P9705; Ye XH, 1999, SCIENCE, V283, P88, DOI 10.1126/science.283.5398.88; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; YlaHerttuala S, 1997, CURR OPIN LIPIDOL, V8, P72; YLAHERTTUALA S, 1986, ARTERIOSCLEROSIS, V6, P230, DOI 10.1161/01.ATV.6.2.230; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; Yonemitsu Y, 1998, CIRC RES, V82, P147; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91; Zoldhelyi P, 1996, CIRCULATION, V93, P10, DOI 10.1161/01.CIR.93.1.10; Zsigmond E, 1997, HUM GENE THER, V8, P1921, DOI 10.1089/hum.1997.8.16-1921	153	290	333	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					213	222		10.1016/S0140-6736(99)04180-X	http://dx.doi.org/10.1016/S0140-6736(99)04180-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675133				2022-12-28	WOS:000084879700041
J	Britten, N; Stevenson, FA; Barry, CA; Barber, N; Bradley, CP				Britten, N; Stevenson, FA; Barry, CA; Barber, N; Bradley, CP			Misunderstandings in prescribing decisions in general practice: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EXPECTATIONS; PERCEPTIONS	Objectives To identify and describe misunderstandings between patients and doctors associated with prescribing decisions in general practice. Design Qualitative study. Setting 20 general practices in the West Midlands and south east England. Participants 20 general practitioners and 35 consulting patients. Main outcome measures Misunderstandings between patients and doctors that have potential or actual adverse consequences for taking medicine. Results 14 categories of misunderstanding were identified relating to patient information unknown to the doctor, doctor information unknown to the patient, conflicting information, disagreement about attribution of side effects, failure of communication about doctor's decision, and relationship factors. All the misunderstandings were associated wit lack of patients' participation in the consultation in terms of the voicing of expectations and preferences or the voicing of responses to doctors' decisions and actions. They were all associated with potential or actual adverse outcomes such as non-adherence to treatment. Many were based on inaccurate guesses and assumptions. In particular doctors seemed unaware of th relevance of patients' idea about medicines for successful prescribing. Conclusions Patients' participation in the consultation and the adverse consequences of lack of participation are important. The authors are developing an educational intervention that builds on these findings.	Kings Coll London, Guys Kings & St Thomas Dept Gen Practice & Primar, Concordance Unit, London SE11 6SP, England; Univ Birmingham, Dept Gen Practice, Birmingham B15 2TT, W Midlands, England; Univ London, Sch Pharm, London WC1N 1AX, England; Univ Coll Cork, Dept Gen Practice, Cork, Ireland	University of London; King's College London; University of Birmingham; University of London; University College London; University of London School of Pharmacy; University College Cork	Britten, N (corresponding author), Kings Coll London, Guys Kings & St Thomas Dept Gen Practice & Primar, Concordance Unit, London SE11 6SP, England.	nicky.britten@kcl.ac.uk	Stevenson, Fiona/AAJ-2727-2021	Stevenson, Fiona/0000-0003-2139-2309; Bradley, Colin/0000-0002-3595-9567				BARBER N, 1995, BRIT MED J, V310, P923, DOI 10.1136/bmj.310.6984.923; Barry CA, 1999, QUAL HEALTH RES, V9, P26, DOI 10.1177/104973299129121677; BARRY CA, IN PRESS BMJ; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BRITTEN N, 1994, FAM PRACT, V11, P62, DOI 10.1093/fampra/11.1.62; BRITTEN N, 1999, PRESCRIBER      0505, P13; BRITTEN N, BMJ, V15, P1506; Butler CC, 1998, BMJ-BRIT MED J, V317, P637, DOI 10.1136/bmj.317.7159.637; Cartwright Ann, 1967, PATIENTS THEIR DOCTO; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; GEOL R, 1999, FAM PRACT, V16, P4; Katon W, 1981, RELEVANCE SOCIAL SCI, P253; Richards T, 1999, BRIT MED J, V318, P277, DOI 10.1136/bmj.318.7179.277; *ROYAL PHARM SOC G, 1997, COMPL CONC REG SUPR; Stevenson FA, 2000, SOC SCI MED, V50, P829, DOI 10.1016/S0277-9536(99)00376-7; WILLIAMS S, 1995, FAM PRACT, V12, P193, DOI 10.1093/fampra/12.2.193	17	281	294	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	2000	320	7233					484	488		10.1136/bmj.320.7233.484	http://dx.doi.org/10.1136/bmj.320.7233.484			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	288KP	10678863	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000085562200026
J	Hak, AE; Pols, HAP; Visser, TJ; Drexhage, HA; Hofman, A; Witteman, JCM				Hak, AE; Pols, HAP; Visser, TJ; Drexhage, HA; Hofman, A; Witteman, JCM			Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam study	ANNALS OF INTERNAL MEDICINE			English	Article						hypothyroidism; autoimmune diseases; coronary arteriosclerosis; menopause; myocardial infarction	CORONARY HEART-DISEASE; THYROID-HORMONES; FOLLOW-UP; AUTOIMMUNE-THYROIDITIS; AORTIC ATHEROSCLEROSIS; NONTHYROIDAL ILLNESS; THYROTROPIN; CHOLESTEROL; PROGRESSION; LIPIDS	Background: Overt hypothyroidism has been found to be associated with cardiovascular disease. Whether subclinical hypothyroidism and thyroid autoimmunity are also risk factors for cardiovascular disease is controversial. Objective: To investigate whether subclinical hypothyroidism and thyroid autoimmunity are associated with aortic atherosclerosis and myocardial infarction in postmenopausal women. Design: Population-based cross-sectional study. Setting: A district of Rotterdam, the Netherlands. Participants: Random sample of 1149 women (mean age +/- SD, 69.0 +/- 7.5 years) participating in the Rotterdam Study. Measurements: Data on thyroid status, aortic atherosclerosis, and history of myocardial infarction were obtained at baseline. Subclinical hypothyroidism was defined as an elevated thyroid-stimulating hormone level (>4.0 mU/L) and a normal serum free thyroxine level (11 to 25 pmol/L [0.9 to 1.9 ng/d L]). In tests for antibodies to thyroid peroxidase, a serum level greater than 10 IU/mL was considered a positive result. Results: Subclinical hypothyroidism was present in 10.8% of participants and was associated with a greater age-adjusted prevalence of aortic atherosclerosis (odds ratio, 1.7 [95% CI, 1.1 to 2.6]) and myocardial infarction (odds ratio, 2.3 [CI, 1.3 to 4.0]). Additional adjustment for body mass index, total and high-density lipoprotein cholesterol level, blood pressure, and smoking status, as well as exclusion of women who took p-blockers, did not affect these estimates. Associations were slightly stronger in women who had subclinical hypothyroidism and antibodies to thyroid peroxidase (odds ratio for aortic atherosclerosis, 1.9 [CI, 1.1 to 3.6]; odds ratio for myocardial infarction, 3.1 [CI, 1.5 to 6.3]). No association was found between thyroid autoimmunity itself and cardiovascular disease. The population attributable risk percentage for subclinical hypothyroidism associated with myocardial infarction was within the range of that for known major risk factors for cardiovascular disease. Conclusion: Subclinical hypothyroidism is a strong indicator of risk for atherosclerosis and myocardial infarction in elderly women.	Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Witteman, JCM (corresponding author), Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, POB 1738, NL-3000 DR Rotterdam, Netherlands.	witteman@epib.fgg.eur.nl	Visser, Theo J/C-8059-2013	Visser, Theo J/0000-0002-6997-284X				ALTHAUS BU, 1988, CLIN ENDOCRINOL, V28, P157, DOI 10.1111/j.1365-2265.1988.tb03651.x; [Anonymous], 1992, INT STAT CLASS DIS R, V1-3; BASTENIE PA, 1977, LANCET, V2, P155; BASTENIE PA, 1967, LANCET, V2, P1221; BASTENIE PA, 1971, LANCET, V1, P203; BOTS ML, 1993, ATHEROSCLEROSIS, V102, P99, DOI 10.1016/0021-9150(93)90088-C; BRASS EP, 1984, DRUGS, V27, P447, DOI 10.2165/00003495-198427050-00004; BRENT GA, 1986, AM J MED, V81, P463, DOI 10.1016/0002-9343(86)90300-1; CARON P, 1990, CLIN ENDOCRINOL, V33, P519, DOI 10.1111/j.1365-2265.1990.tb03889.x; Chadarevian R, 1998, THROMB HAEMOSTASIS, V79, P99; DEAN JW, 1985, BRIT MED J, V290, P1555, DOI 10.1136/bmj.290.6481.1555; FOWLER PBS, 1970, LANCET, V2, P488; GASPAR IA, 1968, J AM GERIATR SOC, V16, P686, DOI 10.1111/j.1532-5415.1968.tb01278.x; GEUL KW, 1993, CLIN ENDOCRINOL, V39, P275, DOI 10.1111/j.1365-2265.1993.tb02366.x; Harjai KJ, 1997, ANN INTERN MED, V126, P63, DOI 10.7326/0003-4819-126-1-199701010-00009; HEINONEN OP, 1972, LANCET, V1, P785; Helfand M, 1998, ANN INTERN MED, V129, P144, DOI 10.7326/0003-4819-129-2-199807150-00020; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, V1; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HYMAN JB, 1954, AM HEART J, V48, P540, DOI 10.1016/0002-8703(54)90119-2; ISHIKAWA T, 1989, MOL PHARMACOL, V35, P760; Klein Irwin, 1996, P799; KOLTRINGER P, 1988, J ENDOCRINOL INVEST, V11, P267; KUNG AWC, 1995, CLIN ENDOCRINOL, V43, P445, DOI 10.1111/j.1365-2265.1995.tb02616.x; MAMIYA S, 1989, J BIOL CHEM, V264, P8575; MASAKI H, 1992, J CLIN ENDOCR METAB, V75, P721, DOI 10.1210/jc.75.3.721; MATHEWS JD, 1974, LANCET, V2, P1423; Miura S, 1996, ENDOCR J, V43, P657, DOI 10.1507/endocrj.43.657; Nedrebo BG, 1998, METABOLISM, V47, P89, DOI 10.1016/S0026-0495(98)90198-6; NILSSON G, 1976, ACTA MED SCAND, V200, P63; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PARLE JV, 1992, CLIN ENDOCRINOL, V37, P411, DOI 10.1111/j.1365-2265.1992.tb02351.x; POWELL J, 1987, BRIT J SURG, V74, P1139, DOI 10.1002/bjs.1800741220; ROBUSCHI G, 1987, ENDOCR REV, V8, P142, DOI 10.1210/edrv-8-2-142; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; STAUB JJ, 1992, AM J MED, V92, P631, DOI 10.1016/0002-9343(92)90782-7; STEINBERG AD, 1968, ANN INTERN MED, V68, P338, DOI 10.7326/0003-4819-68-2-338; Sundaram V, 1997, J CLIN ENDOCR METAB, V82, P3421, DOI 10.1210/jcem.82.10.4315; TIECHE M, 1981, BRIT HEART J, V46, P202, DOI 10.1136/hrt.46.2.202; TRANTOW T, 1994, METHOD FIND EXP CLIN, V16, P133; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P495, DOI 10.1111/j.1365-2265.1977.tb01341.x; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; VANBEMMEL JH, 1990, METHOD INFORM MED, V29, P346; Vanderpump MPJ, 1996, THYROID, V6, P155; VANGENT CM, 1977, CLIN CHIM ACTA, V75, P243, DOI 10.1016/0009-8981(77)90195-4; VANHAELST L, 1967, LANCET, V2, P800, DOI 10.1016/S0140-6736(67)92235-0; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; WITTEMAN JCM, 1986, LANCET, V2, P1120; WITTEMAN JCM, 1990, AM J CARDIOL, V66, P1060, DOI 10.1016/0002-9149(90)90505-U; WITTEMAN JCM, 1994, LANCET, V343, P504, DOI 10.1016/S0140-6736(94)91459-1; WITTEMAN JCM, 1993, CIRCULATION, V88, P2156, DOI 10.1161/01.CIR.88.5.2156; WONG ET, 1981, ARCH INTERN MED, V141, P873, DOI 10.1001/archinte.141.7.873	52	884	982	1	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2000	132	4					270	+		10.7326/0003-4819-132-4-200002150-00004	http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285CY	10681281	Green Published			2022-12-28	WOS:000085372900003
J	Jensen, SL				Jensen, SL			Double gloving - electrical resistance and surgeons' resistance	LANCET			English	Editorial Material							LATEX GLOVES; PROTECTION; VIRUSES		Aarhus Univ Hosp, Orthopaed Res Lab, DK-8000 Aarhus C, Denmark	Aarhus University	Jensen, SL (corresponding author), Aarhus Univ Hosp, Orthopaed Res Lab, DK-8000 Aarhus C, Denmark.							ARNOLD SG, 1988, NATURE, V335, P19, DOI 10.1038/335019c0; BENNETT NT, 1994, J AM COLL SURGEONS, V178, P107; BROUGH SJ, 1988, BRIT J SURG, V75, P317, DOI 10.1002/bjs.1800750408; Caillot JL, 1999, BRIT J SURG, V86, P1387, DOI 10.1046/j.1365-2168.1999.01266.x; COX MJ, 1994, J APPL BIOMATER, V5, P257, DOI 10.1002/jab.770050312; DOYLE PM, 1992, BRIT J OBSTET GYNAEC, V99, P83, DOI 10.1111/j.1471-0528.1992.tb14402.x; Fisher MD, 1999, J BIOMED MATER RES, V48, P797, DOI 10.1002/(SICI)1097-4636(1999)48:6<797::AID-JBM6>3.0.CO;2-4; Jensen SL, 1997, EUR J SURG, V163, P163; MarinBertolin S, 1997, PLAST RECONSTR SURG, V99, P956, DOI 10.1097/00006534-199704000-00003; Nelson J R, 1999, Am J Contact Dermat, V10, P183, DOI 10.1016/S1046-199X(99)90066-0; Novak CB, 1999, PLAST RECONSTR SURG, V103, P128, DOI 10.1097/00006534-199901000-00020; Patterson JMM, 1998, ANN SURG, V228, P266, DOI 10.1097/00000658-199808000-00017; WIGMORE SJ, 1994, BRIT J SURG, V81, P1480, DOI 10.1002/bjs.1800811026; WILLIAMS RE, 1994, J LONG-TERM EFF MED, V4, P193; ZBITNEW A, 1989, J ACQ IMMUN DEF SYND, V2, P201	15	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					514	515		10.1016/S0140-6736(99)00436-5	http://dx.doi.org/10.1016/S0140-6736(99)00436-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10682998				2022-12-28	WOS:000085487400006
J	Matricardi, PM; Rosmini, F; Riondino, S; Fortini, M; Ferrigno, L; Rapicetta, M; Bonini, S				Matricardi, PM; Rosmini, F; Riondino, S; Fortini, M; Ferrigno, L; Rapicetta, M; Bonini, S			Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FAMILY-SIZE; SERUM IGE; ASSOCIATION; INFECTIONS; PREVALENCE; CHILDHOOD; DISEASES; HYGIENE; CELLS; FLORA	Objective To investigate if markers of exposure to foodborne and orofecal microbes versus airborne viruses are associated with atopy and respiratory allergies. Design Retrospective case-control study. Participants 240 atopic cases and 240 non-atopic controls from a population sample of 1659 participants, all Italian male cadets aged 17-24. Setting Air force school in Caserta, Italy. Main outcome measures Serology for Toxoplasma gondii, Helicobacter pylori, hepatitis A virus, measles, mumps, rubella, chickenpox, cytomegalovirus, and herpes simplex virus type 1; skin sensitisation and IgE antibodies to relevant airborne allergens; total IgE concentration; and diagnosis of allergic asthma or rhinitis, Results Compared with controls there tvas a lower prevalence of T gondii (26% v 18%, P = 0.027), hepatitis A virus (30% v 16%, P = 0.004), and H pylori (18% v 15%, P = 0.325) in atopic participants. Adjusted odds ratios of atopy decreased with a gradient of exposure to H pylori, T gondii, and hepatitis A virus (none, odds ratio 1; one, 0.70; two or three, 0.37; P for trend = 0.000045) but not with cumulative exposure to the other viruses. Conversely, total IgE concentration was not independently associated with any infection. Allergic asthma was rare (1/245, 0.4%) and allergic rhinitis infrequent (16/245, 7%) among the participants (245/1659) exposed to at least two orofecal and foodborne infections (H pylori, T gondii, hepatitis A virus). Conclusion Respiratory allergy is less frequent in people heavily exposed to orofecal and foodborne microbes. Hygiene and a westernised, semisterile diet may facilitate atopy by influencing the overall pattern of commensals and pathogens that stimulate the gut associated lymphoid tissue thus contributing to the epidemic of allergic asthma and rhinitis in developed countries.	Div Aerea Studi Ric & Sperimentaz, Lab Immunol & Allergol, I-00040 Pomezia, Italy; Ist Super Sanita, Epidemiol & Biostat Lab, I-00161 Rome, Italy; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; CNR, Ist Med Sperimentale, I-00137 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR)	Matricardi, PM (corresponding author), Div Aerea Studi Ric & Sperimentaz, Lab Immunol & Allergol, I-00040 Pomezia, Italy.	matricardi.pm@mclink.it	Bonini, Sergio/T-6594-2019; Riondino, Silvia/AAV-7126-2020	Bonini, Sergio/0000-0003-0079-3031; Riondino, Silvia/0000-0002-2965-402X				AIM JS, 1997, LANCET, V350, P400; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; BEAMAN MH, 1995, PRINCIPLES PRACTICE, P2455; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; DIXON WJ, 1990, BMDP STAT SOFTWARE, V2; Dominici P, 1999, BRIT MED J, V319, P537, DOI 10.1136/bmj.319.7209.537; Dore MP, 1999, LANCET, V354, P132, DOI 10.1016/S0140-6736(99)01724-9; DURKIN HG, 1989, J IMMUNOL, V143, P1777; Goodwin CS, 1997, LANCET, V349, P265, DOI 10.1016/S0140-6736(96)07023-7; Grubel P, 1998, LANCET, V352, P788, DOI 10.1016/S0140-6736(05)60683-6; *GRUPP STUD INT SO, 1996, VACC IT; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holt PG, 1996, TOXICOL LETT, V86, P205, DOI 10.1016/0378-4274(96)03692-2; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; Matricardi PM, 1999, LANCET, V354, P430, DOI 10.1016/S0140-6736(05)75853-0; MATRICARDI PM, 1994, J ALLERGY CLIN IMMUN, V93, P68, DOI 10.1016/0091-6749(94)90234-8; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matricardi PM, 1997, ALLERGY, V52, P879, DOI 10.1111/j.1398-9995.1997.tb01246.x; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1999, LANCET, V353, P1457, DOI 10.1016/S0140-6736(99)90038-7; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Sudo N, 1997, J IMMUNOL, V159, P1739; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	36	501	520	0	50	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2000	320	7232					412	417		10.1136/bmj.320.7232.412	http://dx.doi.org/10.1136/bmj.320.7232.412			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669445	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000085377400022
J	Silverstein, MJ; Lagios, MD				Silverstein, MJ; Lagios, MD			Benefits of irradiation for DCIS: a Pyrrhic victory	LANCET			English	Editorial Material							CARCINOMA IN-SITU; SURGICAL ADJUVANT BREAST; RADIATION-THERAPY; B-17; LUMPECTOMY; CANCER		Univ So Calif, Dept Surg, Los Angeles, CA 90033 USA; St Marys Hosp, Breast Consultat Serv, San Francisco, CA USA	University of Southern California	Silverstein, MJ (corresponding author), Univ So Calif, Dept Surg, Los Angeles, CA 90033 USA.							FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; Fisher B, 1998, J CLIN ONCOL, V16, P441, DOI 10.1200/JCO.1998.16.2.441; FISHER ER, 1995, CANCER-AM CANCER SOC, V75, P1310, DOI 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G; Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y; FRAASS BA, 1985, INT J RADIAT ONCOL, V11, P485, DOI 10.1016/0360-3016(85)90179-8; LAGIOS MD, 1993, NEW ENGL J MED, V21, P1577; MULLERRUNKEL R, 1990, RADIOLOGY, V175, P873, DOI 10.1148/radiology.175.3.2343139; PAGE DL, 1995, CANCER, V75, P1219, DOI 10.1002/1097-0142(19950315)75:6<1219::AID-CNCR2820750602>3.0.CO;2-X; Silverstein MJ, 1996, CANCER-AM CANCER SOC, V77, P2267, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V; Silverstein MJ, 1999, NEW ENGL J MED, V340, P1455, DOI 10.1056/NEJM199905133401902; Solin LJ, 1996, J CLIN ONCOL, V14, P754, DOI 10.1200/JCO.1996.14.3.754	11	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					510	511		10.1016/S0140-6736(99)00421-3	http://dx.doi.org/10.1016/S0140-6736(99)00421-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10682994				2022-12-28	WOS:000085487400002
J	Ikonomidou, C; Bittigau, P; Ishimaru, MJ; Wozniak, DF; Koch, C; Genz, K; Price, MT; Stefovska, V; Horster, F; Tenkova, T; Dikranian, K; Olney, JW				Ikonomidou, C; Bittigau, P; Ishimaru, MJ; Wozniak, DF; Koch, C; Genz, K; Price, MT; Stefovska, V; Horster, F; Tenkova, T; Dikranian, K; Olney, JW			Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome	SCIENCE			English	Article							BRAIN GROWTH SPURT; PURKINJE-CELL LOSS; STEREOLOGICAL METHODS; EXPOSURE; NEURONS; DEATH; RATS	The deleterious effects of ethanol an the developing human brain are poorly understood. Here it is reported that ethanol, acting by a dual mechanism [blockade of N-methyl-D-aspartate (NMDA) glutamate receptors and excessive activation of GABA, receptors], triggers widespread apoptotic neurodegeneration in the developing rat forebrain. Vulnerability coincides with the period of synaptogenesis, which in humans extends from the sixth month of gestation to several years after birth. During this period, transient ethanol exposure can delete millions of neurons from the developing brain. This can explain the reduced brain mass and neurobehavioral disturbances associated with human fetal alcohol syndrome.	Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Humboldt Univ, Virchow Clin, Dept Pediat Neurol, D-13353 Berlin, Germany; Tokyo Med & Dent Univ, Med Res Inst, Chiyod Ku, Tokyo, Japan	Washington University (WUSTL); Humboldt University of Berlin; Tokyo Medical & Dental University (TMDU)	Olney, JW (corresponding author), Washington Univ, Sch Med, Dept Psychiat, 4940 Childrens Pl, St Louis, MO 63110 USA.				NIA NIH HHS [AG 11355] Funding Source: Medline; NIDA NIH HHS [DA 05072] Funding Source: Medline; NIMH NIH HHS [MH 38894] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG011355] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUERMOFFETT C, 1977, BRAIN RES, V119, P249, DOI 10.1016/0006-8993(77)90310-9; CLARREN SK, 1978, J PEDIATR-US, V92, P64, DOI 10.1016/S0022-3476(78)80072-9; CLARREN SK, 1978, NEW ENGL J MED, V298, P1063, DOI 10.1056/NEJM197805112981906; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Eckardt MJ, 1998, ALCOHOL CLIN EXP RES, V22, P998, DOI 10.1111/j.1530-0277.1998.tb03695.x; Faingold CL, 1998, PROG NEUROBIOL, V55, P509, DOI 10.1016/S0301-0082(98)00027-6; Famy C, 1998, AM J PSYCHIAT, V155, P552, DOI 10.1176/ajp.155.4.552; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goodlett C. R., 1992, MATERNAL SUBSTANCE A, P45; GOODLETT CR, 1990, ALCOHOL, V7, P107, DOI 10.1016/0741-8329(90)90070-S; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; JONES KL, 1973, LANCET, V1, P1267; JONES KL, 1973, LANCET, V2, P999; Kerns KA, 1997, J LEARN DISABIL-US, V30, P685, DOI 10.1177/002221949703000612; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; Paxinos G., 1991, ATLAS DEV RAT BRAIN; RYABININ AE, 1995, ALCOHOL CLIN EXP RES, V19, P784, DOI 10.1111/j.1530-0277.1995.tb01583.x; Sapp DW, 1998, J PHARMACOL EXP THER, V284, P768; SULIK KK, 1981, SCIENCE, V214, P936, DOI 10.1126/science.6795717; Swayze VW, 1997, PEDIATRICS, V99, P232, DOI 10.1542/peds.99.2.232; WEST JR, 1986, ALCOHOL CLIN EXP RES, V10, P190, DOI 10.1111/j.1530-0277.1986.tb05070.x; WEST JR, 1987, ALCOHOL DRUG RES, V7, P423; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; Wyllie A H, 1980, Int Rev Cytol, V68, P251	28	1081	1125	2	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1056	1060		10.1126/science.287.5455.1056	http://dx.doi.org/10.1126/science.287.5455.1056			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669420				2022-12-28	WOS:000085245400052
J	Shulz, DE; Sosnik, R; Ego, V; Haidarliu, S; Ahissar, E				Shulz, DE; Sosnik, R; Ego, V; Haidarliu, S; Ahissar, E			A neuronal analogue of state-dependent learning	NATURE			English	Article							LONG-TERM ENHANCEMENT; BASAL FOREBRAIN; AUDITORY-CORTEX; NUCLEUS BASALIS; BARREL CORTEX; CUTANEOUS RECEPTORS; EVOKED-POTENTIALS; GUINEA-PIG; RAT; PLASTICITY	State-dependent learning is a phenomenon in which the retrieval of newly acquired information is possible only if the subject is in the same sensory context and physiological state as during the encoding phase(1). In spite of extensive behavioural and pharmacological characterization(2), no cellular counterpart of this phenomenon has been reported, Here we describe a neuronal analogue of state-dependent learning in which cortical neurons show an acetylcholine-dependent expression of an acetylcholine-induced functional plasticity. This was demonstrated on neurons of rat somatosensory 'barrel' cortex, whose tunings to the temporal frequency of whisker deflections were modified by cellular conditioning. Pairing whisker stimulation with acetylcholine applied iontophoretically yielded selective lasting modification of responses, the expression of which depended on the presence of exogenous acetylcholine. Administration of acetylcholine during testing revealed frequency-specific changes in response that were not expressed when tested without acetylcholine or when the muscarinic antagonist, atropine, was applied concomitantly, Our results suggest that both acquisition and recall can be controlled by the cortical release of acetylcholine.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; CNRS, Inst Alfred Fessard, UNIC, Equipe Cognisci, F-91198 Gif Sur Yvette, France	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Shulz, DE (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.			Ego-Stengel, Valerie/0000-0002-9099-9051				Ahissar E, 1996, J PHYSIOL-PARIS, V90, P353, DOI 10.1016/S0928-4257(97)87919-3; Ahissar E, 1997, P NATL ACAD SCI USA, V94, P11633, DOI 10.1073/pnas.94.21.11633; Ahissar Ehud, 1994, Current Opinion in Neurobiology, V4, P580, DOI 10.1016/0959-4388(94)90060-4; Baskerville KA, 1997, NEUROSCIENCE, V80, P1159, DOI 10.1016/S0306-4522(97)00064-X; CARVELL GE, 1990, J NEUROSCI, V10, P2638; DELACOUR J, 1990, NEUROSCIENCE, V34, P1, DOI 10.1016/0306-4522(90)90299-J; Dykes RW, 1997, CAN J PHYSIOL PHARM, V75, P535, DOI 10.1139/cjpp-75-5-535; EDELINE JM, 1994, EXP BRAIN RES, V97, P373; Edeline JM, 1999, PROG NEUROBIOL, V57, P165, DOI 10.1016/S0301-0082(98)00042-2; GORDON WC, 1994, ANIMAL LEARNING COGN, P255; Haidarliu S, 1997, J COMP NEUROL, V385, P515, DOI 10.1002/(SICI)1096-9861(19970908)385:4<515::AID-CNE3>3.0.CO;2-6; Haidarliu S, 1996, PHYSIOL BEHAV, V60, P111, DOI 10.1016/0031-9384(95)02257-0; HAIDARLIU S, 1995, J NEUROSCI METH, V56, P125, DOI 10.1016/0165-0270(94)00114-V; HOWARD MA, 1994, EXP BRAIN RES, V102, P21; IZQUIERDO I, 1984, NEUROBIOLOGY LEARNIN, P333; JACOBS SE, 1995, J NEUROSCI, V15, P1099; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Kilgard MP, 1998, NAT NEUROSCI, V1, P727, DOI 10.1038/3729; Maalouf M, 1998, J NEUROPHYSIOL, V80, P529, DOI 10.1152/jn.1998.80.2.529; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; METHERATE R, 1989, BRAIN RES, V480, P372, DOI 10.1016/0006-8993(89)90210-2; RASMUSSON DD, 1988, EXP BRAIN RES, V70, P276; Richter L., 1988, CHILD CARE WORKER, V6, P11; Sachdev RNS, 1998, J NEUROPHYSIOL, V79, P3216, DOI 10.1152/jn.1998.79.6.3216; Shulz DE, 1997, EUR J NEUROSCI, V9, P396, DOI 10.1111/j.1460-9568.1997.tb01409.x; SINGER W, 1990, BRAIN ORG MEMORY CEL, P211; WEBSTER HH, 1991, BRAIN RES, V545, P292, DOI 10.1016/0006-8993(91)91300-P; WEINBERGER NM, 1995, ANNU REV NEUROSCI, V18, P129; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	29	122	126	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					549	553		10.1038/35000586	http://dx.doi.org/10.1038/35000586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676963				2022-12-28	WOS:000085227300051
J	Sze, JY; Victor, M; Loer, C; Shi, Y; Ruvkun, G				Sze, JY; Victor, M; Loer, C; Shi, Y; Ruvkun, G			Food and metabolic signaling defects in a Caenorhabditis elegans serotonin-synthesis mutant	NATURE			English	Article							C-ELEGANS; PROTEINS; EXPRESSION; LONGEVITY; GENETICS; NEURONS; LONG; PHEROMONE; BEHAVIOR; DAF-2	The functions of serotonin have been assigned through serotonin-receptor-specific drugs and mutants(1,2); however because a constellation of receptors remains when a single receptor subtype is inhibited, the coordinate responses to modulation of serotonin levels may be missed. Here we report the analysis of behavioural and neuroendocrine defects caused by a complete lack of serotonin signalling. Analysis of the C. elegans genome sequence showed that there is a single tryptophan hydroxylase gene (tph-1)-the key enzyme for serotonin biosynthesis. Animals bearing a tph-1 deletion mutation do not synthesize serotonin but are fully viable. The tph-1 mutant shows abnormalities in behaviour and metabolism that are normally coupled with the sensation and ingestion of food: rates of feeding and egg laying are decreased; large amounts of fat are stored; reproductive lifespan is increased; and some animals arrest at the metabolically inactive dauer stage. This metabolic dysregulation is, in part, due to downregulation of tranforming growth factor-beta and insulin-like neuroendocrine signals. The action of the C. elegans serotonergic system in metabolic control is similar to mammalian serotonergic input to metabolism and obesity.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ San Diego, Dept Biol, San Diego, CA 92110 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of San Diego	Ruvkun, G (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.	ruvkun@frodo.mgh.harvard.edu						[Anonymous], [No title captured]; AVERY L, 1993, GENETICS, V133, P897; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; Breum L, 1995, METABOLISM, V44, P1570, DOI 10.1016/0026-0495(95)90077-2; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; DSa CM, 1996, J NEUROCHEM, V67, P917; Duerr JS, 1999, J NEUROSCI, V19, P72, DOI 10.1523/JNEUROSCI.19-01-00072.1999; Duret L, 1998, GENOME RES, V8, P348, DOI 10.1101/gr.8.4.348; Gems D, 1998, GENETICS, V150, P129; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Leibowitz SF, 1998, BIOL PSYCHIAT, V44, P851, DOI 10.1016/S0006-3223(98)00186-3; Loer CM, 1999, J NEUROGENET, V13, P157, DOI 10.3109/01677069909083472; Nonogaki K, 1998, NAT MED, V4, P1152, DOI 10.1038/2647; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Patterson GI, 1997, GENE DEV, V11, P2679, DOI 10.1101/gad.11.20.2679; Peschke E, 1997, J PINEAL RES, V23, P156, DOI 10.1111/j.1600-079X.1997.tb00349.x; Rand James B., 1997, Cold Spring Harbor Monograph Series, V33, P611; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Riddle D.L., 1997, GENETIC ENV REGULATI, VII, P739; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; SULSTON J, 1975, J COMP NEUROL, V163, P215, DOI 10.1002/cne.901630207; Waggoner LE, 1998, NEURON, V21, P203, DOI 10.1016/S0896-6273(00)80527-9; WEINSHENKER D, 1995, J NEUROSCI, V15, P6975; Zwaal RR, 1997, GENETICS, V145, P715	30	460	482	0	80	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 3	2000	403	6769					560	564		10.1038/35000609	http://dx.doi.org/10.1038/35000609			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676966				2022-12-28	WOS:000085227300054
J	Berman, JM; Cheung, RJ; Weinberg, DS				Berman, JM; Cheung, RJ; Weinberg, DS			Surveillance after colorectal cancer resection	LANCET			English	Review							FOLLOW-UP PROGRAM; CARCINOEMBRYONIC ANTIGEN; CURATIVE RESECTION; COLON-CANCER; PULMONARY METASTASES; CARCINOMA METASTASES; RECTAL-CANCER; COST; CT; SURGERY		Thomas Jefferson Univ, Jefferson Med Coll, Div Gastroenterol & Hepatol, Philadelphia, PA 19107 USA	Jefferson University	Weinberg, DS (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Div Gastroenterol & Hepatol, 132 S 10th St,480 Main Bldg, Philadelphia, PA 19107 USA.							ARNAUD JP, 1980, DIS COLON RECTUM, V23, P141, DOI 10.1007/BF02587615; Audisio RA, 1996, ANN SURG ONCOL, V3, P349, DOI 10.1007/BF02305664; Bast RC, 1996, J CLIN ONCOL, V14, P2843; Bast RC, 1998, J CLIN ONCOL, V16, P793; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Bleday Ronald, 1995, P455; BRISTER SJ, 1988, DIS COLON RECTUM, V31, P786, DOI 10.1007/BF02560108; BRUINVELS DJ, 1994, ANN SURG, V219, P174, DOI 10.1097/00000658-199402000-00009; BUIE WD, 1993, GASTROINTEST ENDOSC, V3, P691; CAHAN WG, 1976, CANCER, V33, P414; CHARNSANGAVEJ C, 1993, CANCER, V71, P4236, DOI 10.1002/1097-0142(19930615)71:12+<4236::AID-CNCR2820711812>3.0.CO;2-5; CHEN YM, 1987, RADIOLOGY, V163, P307, DOI 10.1148/radiology.163.2.3562810; COOK DJ, 1992, CHEST S4, V102, P305; FLETCHER RH, 1986, ANN INTERN MED, V104, P66, DOI 10.7326/0003-4819-104-1-66; FLETCHER RH, 1993, JAMA-J AM MED ASSOC, V270, P987, DOI 10.1001/jama.270.8.987; Gerdes H, 1990, Gastroenterology, V99, P1849; Graham RA, 1998, ANN SURG, V228, P59, DOI 10.1097/00000658-199807000-00009; Graupe F, 1996, CHIRURG, V67, P604; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HIMAL HS, 1991, AM SURGEON, V5, P334; HUGHES KS, 1988, DIS COLON RECTUM, V31, P1, DOI 10.1007/BF02552560; HUGHES KS, 1988, SURGERY, V103, P278; KELLY CJ, 1992, CANCER-AM CANCER SOC, V70, P1397, DOI 10.1002/1097-0142(19920901)70:3+<1397::AID-CNCR2820701531>3.0.CO;2-A; KIEVIT J, 1990, CANCER, V65, P2580, DOI 10.1002/1097-0142(19900601)65:11<2580::AID-CNCR2820651131>3.0.CO;2-I; MAKELA JT, 1995, ARCH SURG-CHICAGO, V130, P1062; MCCALL JL, 1994, DIS COLON RECTUM, V37, P875, DOI 10.1007/BF02052591; MCCORMACK PM, 1979, DIS COLON RECTUM, V22, P553, DOI 10.1007/BF02587003; Michel P, 1999, GASTROENTEROLOGY, V117, P784, DOI 10.1016/S0016-5085(99)70335-5; MINTON JP, 1985, CANCER, V55, P1284, DOI 10.1002/1097-0142(19850315)55:6<1284::AID-CNCR2820550622>3.0.CO;2-B; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; MOSS AA, 1981, J COMPUT ASSIST TOMO, V5, P870, DOI 10.1097/00004728-198112000-00016; MULLER JM, 1994, ZBL CHIR, V119, P65; NELSON RL, 1995, SEMIN ONCOL, V22, P488; Norum J, 1997, ANN ONCOL, V8, P1081, DOI 10.1023/A:1008265614183; OHLSSON B, 1995, DIS COLON RECTUM, V38, P619, DOI 10.1007/BF02054122; PATCHETT SE, 1993, BRIT J SURG, V80, P1330, DOI 10.1002/bjs.1800801038; Pietra N, 1998, DIS COLON RECTUM, V41, P1127, DOI 10.1007/BF02239434; RICHERTBOE KE, 1995, CANCER-AM CANCER SOC, V75, P2605, DOI 10.1002/1097-0142(19950515)75:10<2605::AID-CNCR2820751031>3.0.CO;2-#; SANDLER RS, 1984, CANCER, V53, P93; Schoemaker D, 1998, GASTROENTEROLOGY, V114, P7, DOI 10.1016/S0016-5085(98)70626-2; STAAB HJ, 1978, AM J SURG, V136, P322, DOI 10.1016/0002-9610(78)90285-4; Stiggelbout AM, 1997, BRIT J CANCER, V75, P914, DOI 10.1038/bjc.1997.161; Stotland BR, 1997, HEMATOL ONCOL CLIN N, V11, P635, DOI 10.1016/S0889-8588(05)70454-8; SUGARBAKER PH, 1987, SURGERY, V102, P79; THOMPSON WM, 1986, AM J ROENTGENOL, V146, P703, DOI 10.2214/ajr.146.4.703; TURK PS, 1993, COLORECTAL CANC, P443; VIRGO KS, 1995, JAMA-J AM MED ASSOC, V273, P1837, DOI 10.1001/jama.273.23.1837; WANEBO HJ, 1987, ANN SURG, V205, P482, DOI 10.1097/00000658-198705000-00006; WANEBO HJ, 1978, NEW ENGL J MED, V299, P448, DOI 10.1056/NEJM197808312990904; WELCH JP, 1978, AM J SURG, V135, P505, DOI 10.1016/0002-9610(78)90028-4; YOSHIZAKO T, 1995, RADIOLOGY, V197, P282	51	82	83	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					395	399		10.1016/S0140-6736(99)06552-6	http://dx.doi.org/10.1016/S0140-6736(99)06552-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665570				2022-12-28	WOS:000085122100038
J	von Seidlein, L; Milligan, P; Pinder, M; Bojang, K; Anyalebechi, C; Gosling, R; Coleman, R; Ude, JI; Sadiq, A; Duraisingh, M; Warhurst, D; Alloueche, A; Targett, G; McAdam, K; Greenwood, B; Walraven, G; Olliaro, P; Doherty, T				von Seidlein, L; Milligan, P; Pinder, M; Bojang, K; Anyalebechi, C; Gosling, R; Coleman, R; Ude, JI; Sadiq, A; Duraisingh, M; Warhurst, D; Alloueche, A; Targett, G; McAdam, K; Greenwood, B; Walraven, G; Olliaro, P; Doherty, T			Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial	LANCET			English	Article							RESISTANT FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; ANTIMALARIAL; CHLOROQUINE; COMBINATIONS; SULFADOXINE; MEFLOQUINE; AFRICA; PCR	Background Resistance to cheap effective antimalarial drugs, especially to pyrimethamine-sulphadoxine (Fansidar), is likely to have a striking impact on childhood mortality in sub-Sharan Africa. The use of artesunate (sodium artesunate) in combination with pyrimethamine-sulphadoxine may delay or prevent resistance. We investigated the efficacy, safety, and tolerability of this combined treatment. Methods We did a double-blind, randomised, placebo-controlled trial in The Gambia. 600 children with acute uncomplicated Plasmodium falciparum malaria, aged 6 months to 10 years, at five health centres were randomly assigned pyrimethamine-sulphadoxine (25 mg/500 mg) with placebo; pyrimethamine-sulphadoxine plus one dose of artesunate (4mg/kg bodyweight); or pyrimethamine-sulphadoxine plus one dose 4 mg/kg bodyweight artesunate daily for 3 days. Children were visited at home each day after the start of treatment until parasitaemia had cleared. Findings The combined treatment was well tolerated. No adverse reactions attributable to treatment were recorded. By day 1, only 178 (47%) of 381 children treated with artesunate were still parasitaemic, compared with 157 (81%) of 195 children in the pyrimethamine-sulphadoxine alone group (relative risk 1.7 [95% CI 1.5-2.0], p<0.001). Treatment-failure rates at day 14 were 3.1% in the pyrimethamine sulphadoxine alone group, and 3.7% in the one-dose artesunate group (risk difference -0.6% [-4.2 to 3.0]) and 1.6% in the three-dose group (1.5 [1.5-4.5], p=0.048). Symptoms resolved faster in children who received artesunate, but there was no additional benefit for three doses of artesunate over one dose. Children given artesunate were less likely to be gametocytaemic after treatment. Interpretation The combined treatment was safe, well tolerated, and effective. The addition of artesunate to malaria treatment regimens in Africa results in lower gametocyte rates and may lower transmission rates.	MRC Labs, Farafenni Field Stn, Fajara, Senegal; London Sch Hyg & Trop Med, London, England; WHO, CH-1211 Geneva, Switzerland	University of London; London School of Hygiene & Tropical Medicine; World Health Organization	von Seidlein, L (corresponding author), MRC Labs, Farafenni Field Stn, Fajara, Senegal.		Milligan, Paul/D-8985-2017; warhurst, david c/C-3428-2013	Milligan, Paul/0000-0003-3430-3395; Bojang, Kalifa/0000-0001-7506-0938				Bojang KA, 1998, T ROY SOC TROP MED H, V92, P73, DOI 10.1016/S0035-9203(98)90962-2; Bunnag D, 1996, T ROY SOC TROP MED H, V90, P415, DOI 10.1016/S0035-9203(96)90529-5; Duraisingh MT, 1998, EXP PARASITOL, V89, P1, DOI 10.1006/expr.1998.4274; FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208; Irion A, 1998, TROP MED INT HEALTH, V3, P490, DOI 10.1046/j.1365-3156.1998.00253.x; Marsh K, 1998, LANCET, V352, P924, DOI 10.1016/S0140-6736(05)61510-3; Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x; NOSTEN F, 1994, J INFECT DIS, V170, P971, DOI 10.1093/infdis/170.4.971; Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9; Price RN, 1997, T ROY SOC TROP MED H, V91, P574, DOI 10.1016/S0035-9203(97)90032-8; Ronn AM, 1996, T ROY SOC TROP MED H, V90, P179, DOI 10.1016/S0035-9203(96)90129-7; SIXSMITH DG, 1984, AM J TROP MED HYG, V33, P772, DOI 10.4269/ajtmh.1984.33.772; Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7; Von Seidlein L, 1998, AM J TROP MED HYG, V58, P638; Watkins WM, 1997, PARASITOL TODAY, V13, P459, DOI 10.1016/S0169-4758(97)01124-1; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; White NJ, 1998, DRUG RESIST UPDATE, V1, P3, DOI 10.1016/S1368-7646(98)80208-2	17	155	155	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					352	357		10.1016/S0140-6736(99)10237-X	http://dx.doi.org/10.1016/S0140-6736(99)10237-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665554				2022-12-28	WOS:000085122100010
J	Kouwenhoven, L				Kouwenhoven, L			Nanotechnology - One photon seen by one electron	NATURE			English	Editorial Material							MILLIMETER		Delft Univ Technol, Dept Appl Phys, NL-2600 GA Delft, Netherlands; Delft Univ Technol, ERATO Mesoscop Correlat Project, NL-2600 GA Delft, Netherlands	Delft University of Technology; Delft University of Technology	Kouwenhoven, L (corresponding author), Delft Univ Technol, Dept Appl Phys, POB 5046, NL-2600 GA Delft, Netherlands.							CLELAND AN, 1992, APPL PHYS LETT, V61, P2820, DOI 10.1063/1.108048; GRABERT H, 1991, SINGLE CHARGE TUNN B, V294; Komiyama S, 2000, NATURE, V403, P405, DOI 10.1038/35000166; KOUWENHOVEN LP, 1997, ELECT TRANSPORT QU E, V435, P105; RICHARDS PL, 1994, J APPL PHYS, V76, P1, DOI 10.1063/1.357128; TUCKER JR, 1985, REV MOD PHYS, V57, P1055, DOI 10.1103/RevModPhys.57.1055	6	18	18	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					374	375		10.1038/35000322	http://dx.doi.org/10.1038/35000322			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667773				2022-12-28	WOS:000085121100029
J	Prinjha, R; Moore, SE; Vinson, M; Blake, S; Morrow, R; Christie, G; Michlovich, D; Simmons, DL; Walsh, FS				Prinjha, R; Moore, SE; Vinson, M; Blake, S; Morrow, R; Christie, G; Michlovich, D; Simmons, DL; Walsh, FS			Neurobiology - Inhibitor of neurite outgrowth in humans	NATURE			English	Article							SPINAL-CORD; GROWTH; MYELIN; IDENTIFICATION; ANTIBODY; PROTEINS; GENE		SmithKline Beecham Pharmaceut, Dept Neurosci Res, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Bioinformat, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline	Prinjha, R (corresponding author), SmithKline Beecham Pharmaceut, Dept Neurosci Res, New Frontiers Sci Pk N,3rd Ave, Harlow CM19 5AW, Essex, England.			Michalovich, David/0000-0003-4452-5776				BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Cajal S., 1928, DEGENERATION REGENER; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Geisler JG, 1998, MAMM GENOME, V9, P274, DOI 10.1007/s003359900748; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; RUBIN BP, 1994, J NEUROCYTOL, V23, P209, DOI 10.1007/BF01275525; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403	11	480	553	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					383	384		10.1038/35000287	http://dx.doi.org/10.1038/35000287			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667780				2022-12-28	WOS:000085121100036
J	Hartman, EE; Daley, J				Hartman, EE; Daley, J			A 73-year-old woman with osteoporosis, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Greenspan SL, 1999, JAMA-J AM MED ASSOC, V281, P1531, DOI 10.1001/jama.281.16.1531	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					531	531		10.1001/jama.283.4.531	http://dx.doi.org/10.1001/jama.283.4.531			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659881				2022-12-28	WOS:000084879800034
J	Rosen, CJ				Rosen, CJ			Fluoride and fractures: an ecological fallacy	LANCET			English	Editorial Material							DRINKING-WATER; WOMEN		St Joseph Hosp, Maine Ctr Osteoporosis Res & Educ, Bangor, ME 04401 USA; Jackson Lab, Bangor, ME USA	Jackson Laboratory	Rosen, CJ (corresponding author), St Joseph Hosp, Maine Ctr Osteoporosis Res & Educ, Bangor, ME 04401 USA.							CAULEY JA, 1995, J BONE MINER RES, V10, P1076; JACOBSEN SJ, 1990, JAMA-J AM MED ASSOC, V264, P500, DOI 10.1001/jama.264.4.500; KROGER H, 1994, BONE MINER, V27, P33, DOI 10.1016/S0169-6009(08)80184-5; *PHS, 1991, MMWR MORB MORTA SRR4, V40, P1; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; US Department of Health and Human Services, 1993, FLUOR CENS	6	9	9	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					247	248		10.1016/S0140-6736(99)00458-4	http://dx.doi.org/10.1016/S0140-6736(99)00458-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675067				2022-12-28	WOS:000085045600003
J	Ducy, P; Amling, M; Takeda, S; Priemel, M; Schilling, AF; Beil, FT; Shen, JH; Vinson, C; Rueger, JM; Karsenty, G				Ducy, P; Amling, M; Takeda, S; Priemel, M; Schilling, AF; Beil, FT; Shen, JH; Vinson, C; Rueger, JM; Karsenty, G			Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass	CELL			English	Article							OSTEOCLAST DIFFERENTIATION; INVOLUTIONAL OSTEOPOROSIS; POSTMENOPAUSAL WOMEN; RECEPTOR GENE; DIABETIC MICE; FEMALE MICE; DB/DB MICE; OB/OB MICE; OBESITY; MOUSE	Gonadal failure induces bone loss while obesity prevents it. This raises the possibility that bone mass, body weight, and gonadal function are regulated by common pathways. To test this hypothesis, we studied leptin-deficient and leptin receptor-deficient mice that are obese and hypogonadic. Both mutant mice have an increased bone formation leading to high bone mass despite hypogonadism and hypercortisolism. This phenotype is dominant, independent of the presence of fat, and specific for the absence of leptin signaling. There is no leptin signaling in osteoblasts but intracerebroventricular infusion of leptin causes bone loss in leptin-deficient and wild-type mice. This study identifies leptin as a potent inhibitor of bone formation acting through the central nervous system and therefore describes the central nature of bone mass control and its disorders.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Hamburg, Dept Trauma Surg, D-20246 Hamburg, Germany; NCI, Biochem Lab, Bethesda, MD 20892 USA	Baylor College of Medicine; University of Hamburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Karsenty, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	karsenty@bcm.tmc.edu	takeda, shu/B-5195-2012		NIAMS NIH HHS [AR45548] Funding Source: Medline; NIDCR NIH HHS [DE11290] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Ahima RS, 1999, ENDOCRINOLOGY, V140, P2755, DOI 10.1210/en.140.6.2755; Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982; Aschner B, 1912, PFLUG ARCH GES PHYS, V146, P1, DOI 10.1007/BF01681114; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1997, GENOMICS, V45, P264, DOI 10.1006/geno.1997.4962; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Cooper Cyrus, 1996, P419; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; EYRE DR, 1988, BIOCHEM J, V252, P495, DOI 10.1042/bj2520495; FELSON DT, 1993, J BONE MINER RES, V8, P567, DOI 10.1002/jbmr.5650080507; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; FROST HM, 1969, CALC TISS RES, V3, P211, DOI 10.1007/BF02058664; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; INOUE S, 1977, ENDOCRINOLOGY, V100, P108, DOI 10.1210/endo-100-1-108; Inui A, 1999, TRENDS NEUROSCI, V22, P62, DOI 10.1016/S0166-2236(98)01292-2; KAUFMAN JM, 1992, J CLIN ENDOCR METAB, V74, P118, DOI 10.1210/jc.74.1.118; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levy JB, 1996, ENDOCRINOLOGY, V137, P1159, DOI 10.1210/en.137.4.1159; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; Namae M, 1998, LAB ANIM SCI, V48, P103; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PECK WA, 1993, AM J MED, V94, P646; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; Ravn P, 1999, J BONE MINER RES, V14, P1622, DOI 10.1359/jbmr.1999.14.9.1622; Reid IR, 1997, NEW ENGL J MED, V337, P420, DOI 10.1056/NEJM199708073370609; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; TREMOLLIERES FA, 1993, J CLIN ENDOCR METAB, V77, P683, DOI 10.1210/jc.77.3.683; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	50	1589	1700	2	62	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2000	100	2					197	207		10.1016/S0092-8674(00)81558-5	http://dx.doi.org/10.1016/S0092-8674(00)81558-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660043	Bronze			2022-12-28	WOS:000084932200004
J	Wallace, AJ; Stillman, TJ; Atkins, A; Jamieson, SJ; Bullough, PA; Green, J; Artymiuk, PJ				Wallace, AJ; Stillman, TJ; Atkins, A; Jamieson, SJ; Bullough, PA; Green, J; Artymiuk, PJ			E-coli hemolysin E (HlyE, ClyA, SheA): X-ray crystal structure of the toxin and observation of membrane pores by electron microscopy	CELL			English	Article							ESCHERICHIA-COLI; ANGSTROM RESOLUTION; RTX TOXIN; PROTEIN; MODEL; WATER; SLYA	Hemolysin E (HlyE) is a novel pore-forming toxin of Escherichia coli, Salmonella typhi, and Shigella flexneri. Here we report the X-ray crystal structure of the water-soluble form of E. coli HlyE at 2.0 Angstrom resolution and the visualization of the lipid-associated form of the toxin in projection at low resolution by electron microscopy. The crystal structure reveals HlyE to be the first member of a new family of toxin structures, consisting of an elaborated helical bundle some 100 Angstrom long. The electron micrographs show how HlyE oligomerizes in the presence of lipid to form transmembrane pores. Taken together, the data from these two structural techniques allow us to propose a simple model for the structure of the pore and for membrane interaction.	Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Artymiuk, PJ (corresponding author), Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.			Bullough, Per/0000-0001-8147-1127				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GL, 1993, PROTEIN ENG, V6, P13; Bauer ME, 1996, INFECT IMMUN, V64, P167, DOI 10.1128/IAI.64.1.167-175.1996; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; delCastillo FJ, 1997, MOL MICROBIOL, V25, P107, DOI 10.1046/j.1365-2958.1997.4391813.x; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Green J, 1997, MOL MICROBIOL, V24, P593, DOI 10.1046/j.1365-2958.1997.3801737.x; GRINDLEY HM, 1993, J MOL BIOL, V229, P707, DOI 10.1006/jmbi.1993.1074; Harbury PAB, 1998, STRUCT FOLD DES, V6, P1487, DOI 10.1016/S0969-2126(98)00147-6; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KREUSCH A, 1994, PROTEIN SCI, V3, P58; LESLIE AGW, 1994, PROTEIN CRYSTALLOGR, V26; Li J, 1996, J MOL BIOL, V257, P129, DOI 10.1006/jmbi.1996.0152; Ludwig A, 1995, MOL GEN GENET, V249, P474, DOI 10.1007/BF00290573; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; O'brien A., 1996, E COLI SALMONELLA CE, V2, P2788; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Oscarsson J, 1999, MOL MICROBIOL, V32, P1226, DOI 10.1046/j.1365-2958.1999.01435.x; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; Ralph ET, 1998, P NATL ACAD SCI USA, V95, P10449, DOI 10.1073/pnas.95.18.10449; Reingold J, 1999, VET MICROBIOL, V66, P125, DOI 10.1016/S0378-1135(98)00310-1; Rigaud JL, 1997, J STRUCT BIOL, V118, P226, DOI 10.1006/jsbi.1997.3848; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; ROWE GE, 1994, METHOD ENZYMOL, V235, P657; SALYERS AA, 1994, BACTERIAL PATHOGENES; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; [No title captured]	45	175	195	3	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					265	276		10.1016/S0092-8674(00)81564-0	http://dx.doi.org/10.1016/S0092-8674(00)81564-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660049	Bronze			2022-12-28	WOS:000084932200010
J	Wyckoff, GJ; Wang, W; Wu, CI				Wyckoff, GJ; Wang, W; Wu, CI			Rapid evolution of male reproductive genes in the descent of man	NATURE			English	Article							POSITIVE SELECTION; PROTEIN EVOLUTION; DROSOPHILA; PRIMATES; SUBSTITUTION; POLYMORPHISM; NUCLEOTIDE; SEQUENCES; SPERM; RATES	A diverse body of morphological and genetic evidence has suggested that traits pertaining to male reproduction may have evolved much more rapidly than other types of character(1-3). Recently, DNA sequence comparisons have also shown a very high level of divergence in male reproductive proteins between closely related Drosophila species(4-6), among marine invertebrates(7,8) and between mouse and rat(9). Here we show that rapid evolution of male reproductive genes is observable in primates and is quite notable in the lineages to human and chimpanzee. Nevertheless, rapid evolution by itself is not necessarily an indication of positive darwinian selection; relaxation of negative selection is often equally compatible with the DNA sequence data. By taking three statistical approaches, we show that positive darwinian selection is often the driving force behind this rapid evolution. These results open up opportunities to test the hypothesis that sexual selection plays some role in the molecular evolution of higher primates.	Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Wu, CI (corresponding author), Univ Chicago, Comm Genet, 1101 E 57th St, Chicago, IL 60637 USA.			Wyckoff, Gerald/0000-0003-2604-2666				COULTHART MB, 1988, MOL BIOL EVOL, V5, P167; Darwin C., 1871, P475; Dixson AF, 1998, PRIMATE SEXUALITY; Eberhard W.G., 1985, SEXUAL SELECTION ANI; Fisher R.A., 1930, GENETICAL THEORY NAT; Gould K.G., 1980, International Review of Cytology, V63, P323, DOI 10.1016/S0074-7696(08)61761-1; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; Kimura M., 1983, NEUTRAL THEORY MOL E; LEE Y, 1995, MOL BIOL EVOL, V6, P424; Li W. H, 1997, MOL EVOLUTION; LI WH, 1985, MOL BIOL EVOL, V2, P150; LI WH, 1984, J MOL EVOL, V21, P58, DOI 10.1007/BF02100628; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; MAEDA N, 1988, MOL BIOL EVOL, V5, P1; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Metz EC, 1996, MOL BIOL EVOL, V13, P397, DOI 10.1093/oxfordjournals.molbev.a025598; NELSON JE, 1993, J BIOL CHEM, V268, P2932; Nurminsky DI, 1998, NATURE, V396, P572, DOI 10.1038/25126; QUERALT R, 1993, J FORENSIC SCI, V38, P1491; RETIEF JD, 1993, J MOL EVOL, V37, P426; RETIEF JD, 1993, EUR J BIOCHEM, V214, P609, DOI 10.1111/j.1432-1033.1993.tb17960.x; Rooney AP, 1999, MOL BIOL EVOL, V16, P706, DOI 10.1093/oxfordjournals.molbev.a026153; SCHLICKER M, 1994, HUM REPROD, V9, P2313, DOI 10.1093/oxfordjournals.humrep.a138444; SHIMMIN LC, 1993, NATURE, V362, P745, DOI 10.1038/362745a0; SILLENTULLBERG B, 1993, AM NAT, V141, P1, DOI 10.1086/285458; Sutton KA, 1997, J MOL EVOL, V45, P579, DOI 10.1007/PL00006262; Ting CT, 1998, SCIENCE, V282, P1501, DOI 10.1126/science.282.5393.1501; Tsaur SC, 1998, MOL BIOL EVOL, V15, P1040, DOI 10.1093/oxfordjournals.molbev.a026002; Wu CI, 1996, TRENDS ECOL EVOL, V11, P281, DOI 10.1016/0169-5347(96)10033-1; Yang ZH, 1998, MOL BIOL EVOL, V15, P1600, DOI 10.1093/oxfordjournals.molbev.a025888	30	429	454	2	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					304	309		10.1038/35002070	http://dx.doi.org/10.1038/35002070			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659848				2022-12-28	WOS:000084899700051
J	Grilli, R; Magrini, N; Penna, A; Mura, G; Liberati, A				Grilli, R; Magrini, N; Penna, A; Mura, G; Liberati, A			Practice guidelines developed by specialty societies: the need for a critical appraisal	LANCET			English	Article							QUALITY; TRIALS	Background There is increasing concern about the quality, reliability, and independence of practice guidelines. Because no information is available on the methodological quality of the guidelines developed by specialty societies, we undertook a survey on those published in peer-reviewed journals. Methods Practice guidelines produced by specialty societies and published in English between January, 1988, and July, 1998, where identified through MEDLINE, Their quality was assessed in terms of whether they reported: the type of professionals and stakeholders involved in the development process; the strategy to identify primary evidence; and an explicit grading of recommendations according to the quality of supporting evidence. Findings Overall, 431 guidelines were eligible for the study. Most did not meet the criteria: 67% did not report any description of the type of stakeholders, 88% gave no information on searches for published studies, and 82% did not give any explicit grading of the strength of recommendations. There was improvement over time for searches (from 2% to 18%, p<0.001) and explicit grading of evidence (from 6% to 27%, p<0.001). All three criteria for quality were met in only 22 (5%) guidelines. Interpretation Despite improvement over time, the quality of practice guidelines developed by specialty societies is unsatisfactory. Explicit methodological criteria for the production of guidelines shared among public agencies, scientific societies, and patients' associations need to be set up. Common standards of reporting, following the same principles that led to the CONSORT statement for randomised clinical trials, should be promoted.	Ist Ric Farmacol Mario Negri, Milan, Italy; Ctr Valutaz Efficacia Assistenza Sanit, Modena, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Grilli, R (corresponding author), Agenzia Serv Sanit Reg, Piazzale Marconi 25, I-00144 Rome, Italy.	webmaster@assr.it	Grilli, Roberto/AAN-9249-2021; Grilli, Roberto/K-1444-2016	Grilli, Roberto/0000-0001-9425-7170; Grilli, Roberto/0000-0001-9425-7170				Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Cluzeau F, 1994, Qual Health Care, V3, P121, DOI 10.1136/qshc.3.3.121; Cluzeau FA, 1999, INT J QUAL HEALTH C, V11, P21, DOI 10.1093/intqhc/11.1.21; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1839, DOI 10.1001/jama.263.13.1839; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Hibble A, 1998, BRIT MED J, V317, P862, DOI 10.1136/bmj.317.7162.862; Institute of Medicine, 1992, GUID CLIN PRACT DEV; Jackson R, 1998, BRIT MED J, V317, P427; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; LITTLEJOHNS P, 1997, PROMOTING RIGOROUS D; MOHER D, 1996, LANCET, V347, P263; MURPHY MK, 1998, HEALTH TECHNOL ASSES, P2; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; SMITH BJ, 1992, MED J AUSTRALIA, V157, P603, DOI 10.5694/j.1326-5377.1992.tb137403.x; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; Thomson R, 1998, BRIT MED J, V316, P509, DOI 10.1136/bmj.316.7130.509; Unwin N, 1998, BMJ-BRIT MED J, V317, P1125; Varonen H, 1997, QUAL HEALTH CARE, V6, P75, DOI 10.1136/qshc.6.2.75; Woodman R, 1999, BRIT MED J, V318, P893, DOI 10.1136/bmj.318.7188.893b	20	455	487	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	2000	355	9198					103	106		10.1016/S0140-6736(99)02171-6	http://dx.doi.org/10.1016/S0140-6736(99)02171-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675167				2022-12-28	WOS:000085557200011
J	Masliah, E; Rockenstein, E; Veinbergs, I; Mallory, M; Hashimoto, M; Takeda, A; Sagara, Y; Sisk, A; Mucke, L				Masliah, E; Rockenstein, E; Veinbergs, I; Mallory, M; Hashimoto, M; Takeda, A; Sagara, Y; Sisk, A; Mucke, L			Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; TRANSGENIC MICE; LEWY BODIES; NACP/ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; BETA; AGGREGATION; MUTATION; GENE	To elucidate the role of the synaptic protein alpha-synuclein in neurodegenerative disorders, transgenic mice expressing wild-type human alpha-synuclein were generated. Neuronal expression of human alpha-synuclein resulted in progressive accumulation of alpha-synuclein-and ubiquitin-immunoreactive inclusions in neurons in the neocortex, hippocampus, and substantia nigra. Ultrastructural analysis revealed both electron-dense intranuclear deposits and cytoplasmic inclusions. These alterations were associated with Loss of dopaminergic terminals in the basal ganglia and with motor impairments. These results suggest that accumulation of wild-type alpha-synuclein may play a causal role in Parkinson's disease and related conditions.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Yokohama City Univ, Sch Med, Dept Psychiat, Yokohama, Kanagawa 236, Japan; Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94141 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Yokohama City University; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Masliah, E (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE ON AGING [R01AG011385, R37AG011385, R01AG010689] Funding Source: NIH RePORTER; NIA NIH HHS [AG10689, AG11385, AG5131] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHEN XH, 1995, GENOMICS, V26, P425, DOI 10.1016/0888-7543(95)80237-G; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DICKSON DW, 1989, ACTA NEUROPATHOL, V78, P572, DOI 10.1007/BF00691284; Forster MJ, 1999, NEUROBIOL AGING, V20, P167, DOI 10.1016/S0197-4580(99)00041-X; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GAUTHIER S, 1982, PROG NEURO-PSYCHOPH, V6, P595, DOI 10.1016/S0278-5846(82)80154-1; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KOSAKA K, 1978, ACTA NEUROPATHOL, V42, P127, DOI 10.1007/BF00690978; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Masliah E, 1996, J NEUROSCI, V16, P5795; MASLIAH E, 1998, NEUROSCI NEWS, V1, P14; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takeda A, 1998, AM J PATHOL, V152, P367; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141	24	1457	1564	2	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1265	1269		10.1126/science.287.5456.1265	http://dx.doi.org/10.1126/science.287.5456.1265			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678833				2022-12-28	WOS:000085444700050
J	Henzen, C; Suter, A; Lerch, E; Urbinelli, R; Schorno, XH; Briner, VA				Henzen, C; Suter, A; Lerch, E; Urbinelli, R; Schorno, XH; Briner, VA			Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment	LANCET			English	Article							ADRENOCORTICOTROPIN STIMULATION TEST; CORTICOSTEROID-THERAPY; PITUITARY DISEASE; SHORT SYNACTHEN; AXIS; INSUFFICIENCY; ACTH; HORMONE	Background Suppression of the adrenal response is an unpredictable consequence of glucocorticoid treatment. To investigate the kinetics of the adrenal response after shortterm, high-dose glucocorticoid treatment, we measured the adrenal response to the low-dose (1 mu g) corticotropin stimulation test. Methods We studied 75 patients who received the equivalent of at least 25 mg prednisone daily for between 5 days and 30 days. After discontinuation of glucocorticoid treatment, 1 mu g corticotropin was administered intravenously, and stimulated plasma cortisol concentrations were measured 30 min later. In patients with a suppressed response to 1 mu g corticotropin, the test was repeated until stimulated plasma cortisol concentrations reached the normal range. Findings The adrenal response to 1 mu g corticotropin was suppressed in 34 patients and normal in 41. Subsequent low-dose corticotropin tests showed a steady recovery of the adrenal response within 14 days. In two patients, the adrenal response remained suppressed for several months. There was no correlation between plasma cortisol concentrations and the duration or dose of glucocorticoid treatment. Interpretation Suppression of the adrenal response is common after short-term, high-dose glucocorticoid treatment. The low-dose corticotropin test is a sensitive and simple test to assess the adrenal response after such treatment.	Kantonsspital Lucerne, Dept Med, CH-6000 Lucerne 16, Switzerland	Lucerne Cantonal Hospital	Henzen, C (corresponding author), Kantonsspital Lucerne, Dept Med, CH-6000 Lucerne 16, Switzerland.							Abdu TAM, 1999, J CLIN ENDOCR METAB, V84, P838, DOI 10.1210/jc.84.3.838; BORST GC, 1982, NEW ENGL J MED, V306, P1462, DOI 10.1056/NEJM198206173062405; BROIDE J, 1995, J CLIN ENDOCR METAB, V80, P1243, DOI 10.1210/jc.80.4.1243; CHRISTY NP, 1992, NEW ENGL J MED, V326, P266, DOI 10.1056/NEJM199201233260410; Clayton RN, 1996, CLIN ENDOCRINOL, V44, P147, DOI 10.1046/j.1365-2265.1996.666478.x; DAIDOH H, 1995, CLIN ENDOCRINOL, V43, P311, DOI 10.1111/j.1365-2265.1995.tb02037.x; Darmon P, 1999, EUR J ENDOCRINOL, V140, P51, DOI 10.1530/eje.0.1400051; Dickstein G, 1998, J CLIN ENDOCR METAB, V83, P4531, DOI 10.1210/jc.83.12.4531; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; EDWARDS CRW, 1974, J CLIN ENDOCR METAB, V3, P475; FIAD TM, 1994, CLIN ENDOCRINOL, V40, P603, DOI 10.1111/j.1365-2265.1994.tb03011.x; Ford LR, 1997, J PEDIATR-US, V131, P722, DOI 10.1016/S0022-3476(97)70100-8; GRINSPOON SK, 1994, J CLIN ENDOCR METAB, V79, P923, DOI 10.1210/jc.79.4.923; HAGG E, 1987, CLIN ENDOCRINOL, V26, P221, DOI 10.1111/j.1365-2265.1987.tb00780.x; Hurel SJ, 1996, CLIN ENDOCRINOL, V44, P141, DOI 10.1046/j.1365-2265.1996.555381.x; JONES SL, 1994, CLIN ENDOCRINOL, V41, P123, DOI 10.1111/j.1365-2265.1994.tb03793.x; KEHLET H, 1973, BRIT J ANAESTH, V45, P1043, DOI 10.1093/bja/45.10.1043; Lamberts SWJ, 1997, NEW ENGL J MED, V337, P1285, DOI 10.1056/NEJM199710303371807; LIVANOU T, 1967, LANCET, V2, P856; Mayenknecht J, 1998, J CLIN ENDOCR METAB, V83, P1558, DOI 10.1210/jc.83.5.1558; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MELBY JC, 1974, ANN INTERN MED, V81, P505, DOI 10.7326/0003-4819-81-4-505; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; Rasmuson S, 1996, CLIN ENDOCRINOL, V44, P151, DOI 10.1046/j.1365-2265.1996.600482.x; SALASSA RM, 1953, JAMA-J AM MED ASSOC, V152, P1509, DOI 10.1001/jama.1953.03690160009004; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; Talwar V, 1998, QJM-MON J ASSOC PHYS, V91, P285, DOI 10.1093/qjmed/91.4.285; Thaler LM, 1998, J CLIN ENDOCR METAB, V83, P2726, DOI 10.1210/jc.83.8.2726; TORDJMAN K, 1995, J CLIN ENDOCR METAB, V80, P1301, DOI 10.1210/jc.80.4.1301	29	194	200	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					542	545		10.1016/S0140-6736(99)06290-X	http://dx.doi.org/10.1016/S0140-6736(99)06290-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10683005				2022-12-28	WOS:000085487400013
J	Tomasec, P; Braud, VM; Rickards, C; Powell, MB; McSharry, BP; Gadola, S; Cerundolo, V; Borysiewicz, LK; McMichael, AJ; Wilkinson, GWG				Tomasec, P; Braud, VM; Rickards, C; Powell, MB; McSharry, BP; Gadola, S; Cerundolo, V; Borysiewicz, LK; McMichael, AJ; Wilkinson, GWG			Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I HOMOLOG; SEQUENCE-DERIVED PEPTIDES; E BINDS; REPLICATION; RECEPTOR; LYSIS; TAP; TRANSLOCATION; TRANSPORTER	The nonclassical major histocompatibility complex (MHC) class I molecule HLA-E inhibits natural killer (NK) cell-mediated lysis by interacting with CD94/ NKG2A receptors. Surface expression of HLA-E depends on binding of conserved peptides derived from MHC class I molecules. The same peptide is present in the leader sequence of the human cytomegalovirus (HCMV) glycoprotein UL40 (gpUL40). It is shown that, independently of the transporter associated with antigen processing, gpUL40 can up-regulate expression of HLA-E, which protects targets from NK cell Lysis. While classical MHC class I molecules are down-regulated, HLA-E is up-regulated by HCMV. induction of HLA-E surface expression by gpUL40 may represent an escape route for HCMV.	John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England; Univ Wales, Coll Med, Dept Med, Cardiff CF14 4XN, S Glam, Wales	University of Oxford; Cardiff University	Braud, VM (corresponding author), John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.		braud, veronique M/I-4597-2013; McSharry, Brian/AAE-3351-2019; Wilkinson, Gavin WG/J-6388-2015	braud, veronique M/0000-0001-8213-3947; McSharry, Brian/0000-0003-0473-2789; Wilkinson, Gavin WG/0000-0002-5623-0126; Cerundolo, Vincenzo/0000-0003-0040-3793				Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Biron CA, 1997, CURR OPIN IMMUNOL, V9, P24, DOI 10.1016/S0952-7915(97)80155-0; Borrego F, 1998, J EXP MED, V187, P813, DOI 10.1084/jem.187.5.813; BORYSIEWICZ LK, 1985, J IMMUNOL, V134, P2695; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brown MG, 1999, J IMMUNOL, V163, P1991; BROWNE H, 1992, J VIROL, V66, P6784, DOI 10.1128/JVI.66.11.6784-6787.1992; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; Cretney E, 1999, J EXP MED, V190, P435, DOI 10.1084/jem.190.3.435; Farrell HE, 1997, NATURE, V386, P510, DOI 10.1038/386510a0; Fletcher JM, 1998, J IMMUNOL, V161, P2365; Hengel H, 1997, IMMUNITY, V6, P623, DOI 10.1016/S1074-7613(00)80350-7; Kubota A, 1999, CELL IMMUNOL, V191, P145, DOI 10.1006/cimm.1998.1424; Lee N, 1998, J IMMUNOL, V160, P4951; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; Leong CC, 1998, J EXP MED, V187, P1681, DOI 10.1084/jem.187.10.1681; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; Moins-Teisserenc HT, 1999, LANCET, V354, P1598, DOI 10.1016/S0140-6736(99)04206-3; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Plachter B, 1996, ADV VIRUS RES, V46, P195, DOI 10.1016/S0065-3527(08)60073-1; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Polic B, 1998, J EXP MED, V188, P1047, DOI 10.1084/jem.188.6.1047; Reyburn HT, 1997, NATURE, V386, P514, DOI 10.1038/386514a0; Robertson MJ, 1996, EXP HEMATOL, V24, P406; SCALZO AA, 1992, J IMMUNOL, V149, P581; SCALZO AA, 1990, J EXP MED, V171, P1469, DOI 10.1084/jem.171.5.1469; TOMASEC P, UNPUB; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; [No title captured]	34	478	496	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1031	1033		10.1126/science.287.5455.1031	http://dx.doi.org/10.1126/science.287.5455.1031			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669413				2022-12-28	WOS:000085245400045
J	Roberts, C; Sarangi, S; Southgate, L; Wakeford, R; Wass, V				Roberts, C; Sarangi, S; Southgate, L; Wakeford, R; Wass, V			Oral examinations-equal opportunities, ethnicity, and fairness in the MRCGP	BRITISH MEDICAL JOURNAL			English	Article									UCL, Ctr Hlth Informat & Multiprofess Educ, London N19 5NF, England; Thames Valley Univ, Ctr Appl Linguist Res, London W5 5AA, England; Cardiff Univ, Ctr Language & Commun Res, Cardiff CF1 3XB, S Glam, Wales; Univ Cambridge, Cambridge CB2 1TT, England; Guys Kings & St Thomas Med Sch, Dept Gen Practice & Primary Care, London SE11 6PT, England	University of London; University College London; University of West London; Cardiff University; University of Cambridge; University of London; King's College London	Southgate, L (corresponding author), UCL, Ctr Hlth Informat & Multiprofess Educ, London N19 5NF, England.	L.Southgate@chime.ucl.ac.uk						Atkinson M.J., 1984, STRUCTURES SOCIAL AC; Atkinson P, 1995, MED TALK MED WORK; Elwyn G, 1999, BMJ-BRIT MED J, V318, P186, DOI 10.1136/bmj.318.7177.186; EVANS LR, 1966, J MED EDUC, V41, P651; Fairclough Norman, 1989, LANGUAGE POWER, V3rd; Goffman E., 1981, FORM TALK; Gumperz John J., 1982, DISCOURSE STRATEGIES; HAMMERSLEY M, 1991, ETHNOGRAPHY PRINCIPL; KVALE S, 1996, UNDERSTANDING PRACTI, P473; Roberts C., 1992, LANGUAGE DISCRIMINAT; Roberts C, 1999, TALK WORK I ORDER DI, P473; ROBERTS C, 1995, MULTILINGUA, V14, P363, DOI DOI 10.1515/MULT.1995.14.4.363; SARABIA L, 1994, TRAC-TREND ANAL CHEM, V13, P1, DOI 10.1016/0165-9936(94)85052-6; Scollon R., 1995, INTERCULTURAL COMMUN; THOMAS CS, 1993, MED EDUC, V27, P433, DOI 10.1111/j.1365-2923.1993.tb00297.x; WAKEFORD R, 1992, BRIT MED J, V305, P92, DOI 10.1136/bmj.305.6845.92; WAKEFORD R, 1995, BRIT MED J, V311, P331; WAKEFORD R, 1992, GEN POLICIES, V1, P53; WAKEFORD RE, 1986, P ANN C RES MED ED W, P339	19	79	79	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					370	374		10.1136/bmj.320.7231.370	http://dx.doi.org/10.1136/bmj.320.7231.370			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657339	Green Published			2022-12-28	WOS:000085211400037
J	Stallard, S; Litherland, JC; Cordiner, C; Dobson, HM; George, WD; Mallon, EA; Hole, D				Stallard, S; Litherland, JC; Cordiner, C; Dobson, HM; George, WD; Mallon, EA; Hole, D			Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									N Glasgow Hosp Univ NHS Trust, Univ Dept Surg, Glasgow G11 6NT, Lanark, Scotland; N Glasgow Hosp Univ NHS Trust, Univ Dept Pathol, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Dept Publ Hlth, W Scotland Canc Surveillance Unit, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Stallard, S (corresponding author), N Glasgow Hosp Univ NHS Trust, Univ Dept Surg, Glasgow G11 6NT, Lanark, Scotland.							Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; GAMBRELL RD, 1992, AM FAM PHYSICIAN S5, V46, P87; Harding C, 1996, BRIT MED J, V312, P1646, DOI 10.1136/bmj.312.7047.1646; Litherland JC, 1999, CLIN RADIOL, V54, P285, DOI 10.1016/S0009-9260(99)90555-X	5	33	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					348	349		10.1136/bmj.320.7231.348	http://dx.doi.org/10.1136/bmj.320.7231.348			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657329	Green Submitted, Green Published, Green Accepted, Bronze			2022-12-28	WOS:000085211400025
J	Baxter, S				Baxter, S			From Caribbean to Clementine - The road to the stars begins in the ocean depths.	NATURE			English	Article																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					485	485		10.1038/35000671	http://dx.doi.org/10.1038/35000671			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676939	Bronze			2022-12-28	WOS:000085227300024
J	Eiler, JM; Schiano, P; Kitchen, N; Stolper, EM				Eiler, JM; Schiano, P; Kitchen, N; Stolper, EM			Oxygen-isotype evidence for recycled crust in the sources of mid-ocean-ridge basalts	NATURE			English	Article							ELEMENT GEOCHEMISTRY; UPPER-MANTLE; ISOTOPE; HETEROGENEITY; ORIGIN; GEODYNAMICS; SYSTEMATICS; SCALE; H2O	Mid-ocean-ridge basalts (MORBs) are the most abundant terrestrial magmas and are believed to form by partial melting of a globally extensive reservoir of ultramafic rocks in the upper mantle(1). MORBs vary in their abundances of incompatible elements (that is, those that partition into silicate liquids during partial melting) and in the isotopic ratios of several radiogenic isotope systems(2-4). These variations define a spectrum between 'depleted' and 'enriched' compositions, characterized by respectively low and high abundances of incompatible elements(5,6). Compositional variations in the sources of MORBs could reflect recycling of subducted crustal materials into the source reservoir(7), or any of a number of processes of intramantle differentiation(8-10). Variations in (18)O/(16)O (principally sensitive to the interaction of rocks with the Earth's hydrosphere) offer a test of these alternatives. Here we show that (18)O/(16)O ratios of MORBs are correlated with aspects of their incompatible-element chemistry. These correlations are consistent with control of the oxygen-isotope and incompatible-element geochemistry of MORBs by a component of recycled crust that is variably distributed throughout their upper mantle sources.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Inst Phys Globe, Lab Geochim Cosmochim, F-75252 Paris 05, France; Univ Clermont Ferrand, Unite Mixte Rech Magmas & Volcans 6524, F-63038 Clermont Ferrand, France	California Institute of Technology; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Clermont Auvergne (UCA); Universite Jean Monnet	Eiler, JM (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.	eiler@gps.caltech.edu						ALLEGRE CJ, 1987, EARTH PLANET SC LETT, V86, P175, DOI 10.1016/0012-821X(87)90220-2; ARMSTRONG RL, 1968, REV GEOPHYS, V6, P175, DOI 10.1029/RG006i002p00175; Arthur M.A., 1983, SEPM SHORT COURSE, V10, P1; CRISP JA, 1984, J VOLCANOL GEOTH RES, V20, P177, DOI 10.1016/0377-0273(84)90039-8; DEPAOLO DJ, 1976, GEOPHYS RES LETT, V3, P743, DOI 10.1029/GL003i012p00743; GREEN DH, 1971, PHILOS TR R SOC S-A, V268, P707, DOI 10.1098/rsta.1971.0022; HARMON RS, 1995, CONTRIB MINERAL PETR, V120, P95, DOI 10.1007/BF00311010; HART SR, 1984, NATURE, V309, P753, DOI 10.1038/309753a0; HOFMANN AW, 1982, EARTH PLANET SC LETT, V57, P421, DOI 10.1016/0012-821X(82)90161-3; KAY R, 1970, J GEOPHYS RES, V75, P1585, DOI 10.1029/JB075i008p01585; LANGMUIR CH, 1992, GEOPH MONOG SERIES, V71, P183; MAHONEY J, 1992, J GEOPHYS RES-SOL EA, V97, P19771, DOI 10.1029/92JB01424; MATTHEWS A., 1998, MINERAL MAG A, V62A, P971; MCKENZIE D, 1983, NATURE, V301, P229, DOI 10.1038/301229a0; MCKENZIE D, 1991, J PETROL, V32, P1021, DOI 10.1093/petrology/32.5.1021; MICHAEL P, 1995, EARTH PLANET SC LETT, V131, P301, DOI 10.1016/0012-821X(95)00023-6; MUEHLENBACHS K, 1986, REV MINERAL, V16, P425; ONIONS RK, 1977, EARTH PLANET SC LETT, V34, P13, DOI 10.1016/0012-821X(77)90100-5; PALLISTER JS, 1981, J GEOPHYS RES, V86, P2673, DOI 10.1029/JB086iB04p02673; POLI S, 1995, J GEOPHYS RES-SOL EA, V100, P22299, DOI 10.1029/95JB01570; Schiano P, 1997, EARTH PLANET SC LETT, V150, P363, DOI 10.1016/S0012-821X(97)00098-8; SCHILLING JG, 1973, NATURE, V242, P565, DOI 10.1038/242565a0; SHAW DM, 1970, GEOCHIM COSMOCHIM AC, V34, P237, DOI 10.1016/0016-7037(70)90009-8; Sun S.-S., 1989, GEOLOGICAL SOC LONDO, V42, P323, DOI [10.1144/GSL.SP.1989.042.01.19, DOI 10.1144/GSL.SP.1989.042.01.19]; SUN SS, 1979, EARTH PLANET SC LETT, V44, P119, DOI 10.1016/0012-821X(79)90013-X; TATSUMOTO M, 1966, SCIENCE, V153, P1094, DOI 10.1126/science.153.3740.1094; WOOD JA, 1981, BASALTIC VOLCANISM T, P631; ZINDLER A, 1984, EARTH PLANET SC LETT, V70, P175, DOI 10.1016/0012-821X(84)90004-9; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425	29	190	198	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					530	534		10.1038/35000553	http://dx.doi.org/10.1038/35000553			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676958				2022-12-28	WOS:000085227300046
J	Heller, E				Heller, E			Condensed-matter physics - Electrons in the looking glass	NATURE			English	Editorial Material							QUANTUM CORRALS; SCATTERING; SURFACE; WAVES		Harvard Univ, Dept Phys, Lyman Lab, Cambridge, MA 02138 USA; Harvard Univ, Dept Chem, Lyman Lab, Cambridge, MA 02138 USA	Harvard University; Harvard University	Heller, E (corresponding author), Harvard Univ, Dept Phys, Lyman Lab, 17 Oxford St, Cambridge, MA 02138 USA.							CROMMIE MF, 1993, NATURE, V363, P524, DOI 10.1038/363524a0; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; HELLER EJ, 1994, NATURE, V369, P464, DOI 10.1038/369464a0; Li JT, 1998, PHYS REV LETT, V80, P2893, DOI 10.1103/PhysRevLett.80.2893; Madhavan V, 1998, SCIENCE, V280, P567, DOI 10.1126/science.280.5363.567; Manoharan HC, 2000, NATURE, V403, P512, DOI 10.1038/35000508; WEBER EH, 1925, WELLENLEHRE EXPT GEG; 1993, PHYSICS TODAY    NOV	8	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					489	+		10.1038/35000681	http://dx.doi.org/10.1038/35000681			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676942				2022-12-28	WOS:000085227300027
J	Rice, SA				Rice, SA			Molecular dynamics - Optical control of reactions	NATURE			English	Editorial Material							FEMTOSECOND LASER-PULSES; COHERENT CONTROL; ADIABATIC PASSAGE; QUANTUM STATE; SELECTIVITY; PHOTODISSOCIATION; SEMICONDUCTORS		Univ Chicago, James Franck Inst, Chicago, IL 60637 USA	University of Chicago	Rice, SA (corresponding author), Univ Chicago, James Franck Inst, 5640 S Ellis Ave, Chicago, IL 60637 USA.							Abrashkevich A, 1998, PHYS REV LETT, V81, P3789, DOI 10.1103/PhysRevLett.81.3789; Assion A, 1998, SCIENCE, V282, P919, DOI 10.1126/science.282.5390.919; Baumert T, 1997, ADV CHEM PHYS, V101, P47, DOI 10.1002/9780470141601.ch2; Bonadeo NH, 1998, SCIENCE, V282, P1473, DOI 10.1126/science.282.5393.1473; CHARRON E, 1995, PHYS REV LETT, V75, P2815, DOI 10.1103/PhysRevLett.75.2815; DUPONT E, 1995, PHYS REV LETT, V74, P3596, DOI 10.1103/PhysRevLett.74.3596; Fiss JA, 1998, CHEM PHYS, V233, P335, DOI 10.1016/S0301-0104(98)00142-6; Frohnmeyer T, 1999, CHEM PHYS LETT, V312, P447, DOI 10.1016/S0009-2614(99)00895-7; Kobrak MN, 1998, PHYS REV A, V57, P2885, DOI 10.1103/PhysRevA.57.2885; Kobrak MN, 1998, J CHEM PHYS, V109, P1, DOI 10.1063/1.476550; KOSLOFF R, 1989, CHEM PHYS, V139, P201, DOI 10.1016/0301-0104(89)90012-8; KURIZKI G, 1989, PHYS REV B, V39, P3435, DOI 10.1103/PhysRevB.39.3435; MANZ J, 1993, J PHYS CHEM-US, V97, P12625, DOI 10.1021/j100150a026; PEIRCE AP, 1988, PHYS REV A, V37, P4950, DOI 10.1103/PhysRevA.37.4950; SHAPIRO M, 1986, J CHEM PHYS, V84, P4103, DOI 10.1063/1.450074; Shapiro M, 1997, CHEM PHYS, V217, P325, DOI 10.1016/S0301-0104(97)00058-X; Shnitman A, 1996, PHYS REV LETT, V76, P2886, DOI 10.1103/PhysRevLett.76.2886; TANNOR DJ, 1986, J CHEM PHYS, V85, P5805, DOI 10.1063/1.451542; TANNOR DJ, 1985, J CHEM PHYS, V83, P5013, DOI 10.1063/1.449767	19	23	28	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					496	497		10.1038/35000695	http://dx.doi.org/10.1038/35000695			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676947				2022-12-28	WOS:000085227300032
J	Zeidler, M; Hughes, T; Zeman, A				Zeidler, M; Hughes, T; Zeman, A			Confused by arteritis	LANCET			English	Article							TEMPORAL ARTERITIS		Western Gen Hosp, Dept Clin Neurol, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Wales Hosp, Dept Clin Neurol, Cardiff CF4 4XW, S Glam, Wales	University of Edinburgh; Cardiff University	Zeidler, M (corresponding author), Western Gen Hosp, Dept Clin Neurol, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.			Zeman, Adam/0000-0003-4875-658X				BUTTNER T, 1994, EUR NEUROL, V34, P162, DOI 10.1159/000117031; CASELLI RJ, 1990, NEUROLOGY, V40, P753, DOI 10.1212/WNL.40.5.753; CASELLI RJ, 1988, NEUROLOGY, V38, P352, DOI 10.1212/WNL.38.3.352; COLLAZOS J, 1994, POSTGRAD MED J, V70, P228, DOI 10.1136/pgmj.70.821.228; WILKINSON IM, 1972, ARCH NEUROL-CHICAGO, V27, P378, DOI 10.1001/archneur.1972.00490170010003	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					374	374		10.1016/S0140-6736(99)11011-0	http://dx.doi.org/10.1016/S0140-6736(99)11011-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665558				2022-12-28	WOS:000085122100014
J	Wickware, P				Wickware, P			Insiders advise on first steps to a career	NATURE			English	Article																			0	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					466	466		10.1038/35000347	http://dx.doi.org/10.1038/35000347			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667804	Bronze			2022-12-28	WOS:000085121100061
J	Malouf, AJ; Norton, CS; Engel, AF; Nicholls, RJ; Kamm, MA				Malouf, AJ; Norton, CS; Engel, AF; Nicholls, RJ; Kamm, MA			Long-term results of overlapping anterior anal-sphincter repair for obstetric trauma	LANCET			English	Article							POSTOBSTETRIC FECAL INCONTINENCE; ENDOSONOGRAPHY; DEFECTS; INJURY; ULTRASOUND; NEUROPATHY; SURGERY	Background Anterior structural damage to the anal sphincter occurs in up to a third of women at first vaginal delivery, and of these a third have new bowel symptoms. The standard treatment for such structural damage is anterior overlapping anal-sphincter repair. We aimed to assess the long-term results of this operation. Methods We assessed the long-term results in 55 consecutive patients who had had repair a minimum of 5 years (median 77 months [range 60-96]) previously. Questionnaire and telephone interview assessed current bowel function and continence, restriction in activities related to bowel control, and overall satisfaction with the results of surgery, 42 of these patients had been continent of solid and liquid stool at a median of 15 months after the repair. Findings We were able to contact 47 (86%) of the 55 patients. One of these patients had required a proctectomy and end ileostomy for Crohn's disease. Of the remaining 46 patients, 27 reported improved bowel control without the need for further surgery, and 23 rated their symptom improvement as 50% or greater. Seven patients had undergone further surgery for incontinence and one patient had not had a covering stoma closed. Thus, the rang-term functional outcome of the sphincter repair alone could be assessed in 38 patients. Of these patients, none was fully continent to both stool and flatus; only four were totally continent to solid and liquid stool; six had no faecal urgency; and eight had no passive soiling. Of the 38 patients, 20 still wore a pad for incontinence and 25 reported lifestyle restriction. 14 reported the onset of a new evacuation disorder after sphincter repair. 23 of the 46 patients contacted had a successful long-term outcome (defined as no further surgery and urge faecal incontinence monthly or less). Interpretation The results of overlapping sphincter repair for obstetric anal-sphincter damage seem to deteriorate with time. Preoperative counselling should emphasise that although most patients will improve after the procedure, continence is rarely perfect, many have residual symptoms, and some may develop new evacuation disorders.	St Marks Hosp, Harrow HA1 3UJ, Middx, England	Imperial College London	Kamm, MA (corresponding author), St Marks Hosp, Harrow HA1 3UJ, Middx, England.							Briel JW, 1998, DIS COLON RECTUM, V41, P209, DOI 10.1007/BF02238250; BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; Cook TA, 1998, BRIT J SURG, V85, P293; CTERCTEKO G C, 1988, Australian and New Zealand Journal of Surgery, V58, P703, DOI 10.1111/j.1445-2197.1988.tb01100.x; DEEN KI, 1993, ANN SURG, V218, P201, DOI 10.1097/00000658-199308000-00013; ENGEL AF, 1994, BRIT J SURG, V81, P1231, DOI 10.1002/bjs.1800810853; FLESHMAN JW, 1991, DIS COLON RECTUM, V34, P1061, DOI 10.1007/BF02050062; GEE AS, 1995, BRIT J SURG, V82, P1179, DOI 10.1002/bjs.1800820910; Gilliland R, 1998, DIS COLON RECTUM, V41, P1516, DOI 10.1007/BF02237299; Jensen LL, 1997, DIS COLON RECTUM, V40, P197, DOI 10.1007/BF02054988; Korsgen S, 1997, DIS COLON RECTUM, V40, P835, DOI 10.1007/BF02055443; LONDONOSCHIMMER EE, 1994, INT J COLORECTAL DIS, V9, P110, DOI 10.1007/BF00699424; MARCIO J, 1993, DIS COLON RECTUM, V36, P77; Meyenberger C, 1996, ENDOSCOPY, V28, P217, DOI 10.1055/s-2007-1005431; Norton C, 1999, BRIT J SURG, V86, P1159, DOI 10.1046/j.1365-2168.1999.01215.x; PARKS AG, 1977, GUT, V18, P656, DOI 10.1136/gut.18.8.656; Peterli R, 1997, Swiss Surg, V3, P112; Romano G, 1996, BRIT J RADIOL, V69, P6, DOI 10.1259/0007-1285-69-817-6; SANGALLI MR, 1994, J AM COLL SURGEONS, V179, P583; Sentovich SM, 1997, DIS COLON RECTUM, V40, P1430, DOI 10.1007/BF02070707; Sitzler PJ, 1996, DIS COLON RECTUM, V39, P1356, DOI 10.1007/BF02054524; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1994, BRIT J SURG, V81, P463, DOI 10.1002/bjs.1800810349; Vaizey CJ, 1999, GUT, V44, P77, DOI 10.1136/gut.44.1.77; Young CJ, 1998, DIS COLON RECTUM, V41, P344, DOI 10.1007/BF02237489	25	298	302	1	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					260	265		10.1016/S0140-6736(99)05218-6	http://dx.doi.org/10.1016/S0140-6736(99)05218-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675072				2022-12-28	WOS:000085045600008
J	Fu, HX; Cohen, RE				Fu, HX; Cohen, RE			Polarization rotation mechanism for ultrahigh electromechanical response in single-crystal piezoelectrics	NATURE			English	Article							FIRST-PRINCIPLES; BEHAVIOR; OXIDES; BATIO3	Piezoelectric materials, which convert mechanical to electrical energy(and vice versa), are crucial in medical imaging, telecommunication and ultrasonic devices(1,2). A new generation of single-crystal materials(3), such as Pb(Zn1/3Nb2/3) O-3-PbTiO3 (PZN-PT) and Pb(Mg1/3Nb2/3)O-3-PbTiO3 (PMN-PT), exhibit a piezoelectric effect that is ten times larger than conventional ceramics, and may revolutionize(4) these applications. However, the mechanism underlying the ultrahigh performance of these new materials-and consequently the possibilities for further improvements-are not at present clear. Here we report a first-principles study of the ferroelectric perovskite, BaTiO3, which is similar(5) to single-crystal PZN-PT but is a simpler system to analyse. We show that a large piezoelectric response can be driven by polarization rotation induced by an external electric field; Out computations suggest how to design materials with better performance, and may stimulate further interest in the fundamental theory of dielectric systems in finite electric fields.	Carnegie Inst Sci, Washington, DC 20015 USA	Carnegie Institution for Science	Cohen, RE (corresponding author), Carnegie Inst Sci, 5251 Broad Branch Rd NW, Washington, DC 20015 USA.	cohen@gl.ciw.edu	Cohen, Ronald/B-3784-2010; Cohen, Ronald/AAY-2570-2020	Cohen, Ronald/0000-0001-5871-2359; 				COHEN RE, 1992, NATURE, V358, P136, DOI 10.1038/358136a0; Durbin MK, 1999, APPL PHYS LETT, V74, P2848, DOI 10.1063/1.124034; Egami T, 1998, AIP CONF PROC, P1, DOI 10.1063/1.56286; Garcia A, 1998, APPL PHYS LETT, V72, P2981, DOI 10.1063/1.121514; Ghosez P, 1998, PHYS REV B, V58, P6224, DOI 10.1103/PhysRevB.58.6224; Glass A.M., 1979, PRINCIPLES APPL FERR; KINGSMITH RD, 1993, PHYS REV B, V47, P1651, DOI 10.1103/PhysRevB.47.1651; Martin RM, 1997, PHYS REV B, V56, P1124, DOI 10.1103/PhysRevB.56.1124; MITSUI T, 1981, LANDOLTBORNSTEIN N A, V16; Park SE, 1997, J APPL PHYS, V82, P1804, DOI 10.1063/1.365983; PARK SE, UNPUB J APPL PHYS; RESTA R, 1994, REV MOD PHYS, V66, P899, DOI 10.1103/RevModPhys.66.899; Saghi-Szabo G, 1998, PHYS REV LETT, V80, P4321, DOI 10.1103/PhysRevLett.80.4321; Service RF, 1997, SCIENCE, V275, P1878, DOI 10.1126/science.275.5308.1878; Singh D.J., 2006, PLANEWAVES PSEUDOPOT, Vsecond; Uchino K, 1996, PIEZOELECTRIC ACTUAT; WEI SH, 1985, PHYS REV LETT, V55, P1200, DOI 10.1103/PhysRevLett.55.1200; ZGONIK M, 1994, PHYS REV B, V50, P5941, DOI 10.1103/PhysRevB.50.5941	18	1777	1820	33	991	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2000	403	6767					281	283		10.1038/35002022	http://dx.doi.org/10.1038/35002022			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659840				2022-12-28	WOS:000084899700043
J	Carey, JC; Klebanoff, MA; Hauth, JC; Hillier, SL; Thom, EA; Ernest, JM; Heine, RP; Nugent, RP; Fischer, ML; Leveno, KJ; Wapner, R; Varner, M				Carey, JC; Klebanoff, MA; Hauth, JC; Hillier, SL; Thom, EA; Ernest, JM; Heine, RP; Nugent, RP; Fischer, ML; Leveno, KJ; Wapner, R; Varner, M		Natl Inst Child Hlth Human Dev Net	Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BIRTH-WEIGHT; CONTROLLED TRIAL; INFECTION; PREMATURITY; LABOR	Background: Bacterial vaginosis has been associated with preterm birth. In clinical trials, the treatment of bacterial vaginosis in pregnant women who previously had a preterm delivery reduced the risk of recurrence. Methods: To determine whether treating women in a general obstetrical population who have asymptomatic bacterial vaginosis (as diagnosed on the basis of vaginal Gram's staining and pH) prevents preterm delivery, we randomly assigned 1953 women who were 16 to less than 24 weeks pregnant to receive two 2-g doses of metronidazole or placebo. The diagnostic studies were repeated and a second treatment was administered to all the women at 24 to less than 30 weeks' gestation. The primary outcome was the rate of delivery before 37 weeks' gestation. Results: Bacterial vaginosis resolved in 657 of 845 women who had follow-up Gram's staining in the metronidazole group (77.8 percent) and 321 of 859 women in the placebo group (37.4 percent). Data on the time and characteristics of delivery were available for 953 women in the metronidazole group and 966 in the placebo group. Preterm delivery occurred in 116 women in the metronidazole group (12.2 percent) and 121 women in the placebo group (12.5 percent) (relative risk, 1.0; 95 percent confidence interval, 0.8 to 1.2). Treatment did not prevent preterm deliveries that resulted from spontaneous labor (5.1 percent in the metronidazole group vs. 5.7 percent in the placebo group) or spontaneous rupture of the membranes (4.2 percent vs. 3.7 percent), nor did it prevent delivery before 32 weeks (2.3 percent vs. 2.7 percent). Treatment with metronidazole did not reduce the occurrence of preterm labor, intraamniotic or postpartum infections, neonatal sepsis, or admission of the infant to the neonatal intensive care unit. Conclusions: The treatment of asymptomatic bacterial vaginosis in pregnant women does not reduce the occurrence of preterm delivery or other adverse perinatal outcomes. (N Engl J Med 2000;342:534-40.) (C)2000, Massachusetts Medical Society.	Univ Oklahoma, Dept Obstet & Gynecol, Oklahoma City, OK USA; NICHHD, NIH, Bethesda, MD 20892 USA; Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA; Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; George Washington Univ, Ctr Biostat, Rockville, MD USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Obstet & Gynecol, Winston Salem, NC 27103 USA; Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Dallas, TX 75235 USA; Thomas Jefferson Univ, Dept Obstet & Gynecol, Philadelphia, PA USA; Univ Utah, Dept Obstet & Gynecol, Salt Lake City, UT USA; Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA; Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; Univ Tennessee, Dept Obstet & Gynecol, Memphis, TN 38103 USA; Univ Cincinnati, Dept Obstet & Gynecol, Cincinnati, OH USA; Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA; Univ Miami, Dept Obstet & Gynecol, Miami, FL 33152 USA; Med Univ S Carolina, Dept Obstet & Gynecol, Charleston, SC 29425 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; George Washington University; Wake Forest University; Wake Forest Baptist Medical Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Jefferson University; Utah System of Higher Education; University of Utah; University System of Ohio; Ohio State University; University of Chicago; University of Tennessee System; University of Tennessee Health Science Center; University System of Ohio; University of Cincinnati; Wayne State University; University of Miami; Medical University of South Carolina	Klebanoff, MA (corresponding author), NICHHD, NIH, 6100 Execut Blvd,Rm 7B03 MSC 7510, Bethesda, MD 20892 USA.		Heine, R. Phillips/AAR-1189-2020; Varner, Michael/K-9890-2013	Varner, Michael/0000-0001-9455-3973	NICHD NIH HHS [U10 HD27869, U10 HD21410, U10 HD21414] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021410, U10HD027869] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD002535, U10HD021414, Z01HD002535] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CNAAN A, 1989, STAT MED, V8, P1255, DOI 10.1002/sim.4780081009; DRISCOLL S G, 1979, Clinical Obstetrics and Gynecology, V22, P339, DOI 10.1097/00003081-197906000-00011; GIBBS RS, 1992, AM J OBSTET GYNECOL, V166, P1515, DOI 10.1016/0002-9378(92)91628-N; Goldenberg RL, 1996, AM J PUBLIC HEALTH, V86, P781, DOI 10.2105/AJPH.86.6.781; Goldenberg RL, 1997, CLIN PERINATOL, V24, P23, DOI 10.1016/S0095-5108(18)30182-9; GRAVETT MG, 1986, JAMA-J AM MED ASSOC, V256, P1899; Hauth JC, 1998, PRENAT NEONAT MED, V3, P86; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; JOESOEF MR, 1995, AM J OBSTET GYNECOL, V173, P1527, DOI 10.1016/0002-9378(95)90644-4; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LUGOMIRO VI, 1992, JAMA-J AM MED ASSOC, V268, P92, DOI 10.1001/jama.268.1.92; MCDONALD HM, 1992, BRIT J OBSTET GYNAEC, V99, P190, DOI 10.1111/j.1471-0528.1992.tb14497.x; McDonald HM, 1997, BRIT J OBSTET GYNAEC, V104, P1391, DOI 10.1111/j.1471-0528.1997.tb11009.x; MCGREGOR JA, 1994, AM J OBSTET GYNECOL, V170, P1048, DOI 10.1016/S0002-9378(94)70098-2; MEIS PJ, 1995, AM J OBSTET GYNECOL, V173, P1231, DOI 10.1016/0002-9378(95)91360-2; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; ROMERO R, 1988, CLIN OBSTET GYNECOL, V31, P553, DOI 10.1097/00003081-198809000-00006; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7	21	417	438	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					534	540		10.1056/NEJM200002243420802	http://dx.doi.org/10.1056/NEJM200002243420802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684911				2022-12-28	WOS:000085422400002
J	Dulipsingh, L; Lassman, MN				Dulipsingh, L; Lassman, MN			Pituitary apoplexy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									New Britain Gen Hosp, New Britain, CT 06053 USA; St Francis Hosp & Med Ctr, Hartford, CT 06105 USA	Saint Francis Hospital & Medical Center	Dulipsingh, L (corresponding author), New Britain Gen Hosp, New Britain, CT 06053 USA.								0	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					550	550		10.1056/NEJM200002243420804	http://dx.doi.org/10.1056/NEJM200002243420804			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684913				2022-12-28	WOS:000085422400004
J	Ernst, E; White, AR				Ernst, E; White, AR			Acupuncture may be associated with serious adverse events	BRITISH MEDICAL JOURNAL			English	Letter									Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England	University of Exeter	Ernst, E (corresponding author), Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England.							Ernst E, 1999, BRIT MED J, V318, P536, DOI 10.1136/bmj.318.7182.536; Ernst E, 1997, BRIT MED J, V314, P1362; Onizuka T, 1998, Kansenshogaku Zasshi, V72, P776; Vickers A, 1999, BRIT MED J, V319, P973, DOI 10.1136/bmj.319.7215.973	4	15	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					513	514		10.1136/bmj.320.7233.513	http://dx.doi.org/10.1136/bmj.320.7233.513			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678876	Green Published			2022-12-28	WOS:000085562200046
J	Guntupalli, KK; Fromm, RE				Guntupalli, KK; Fromm, RE			Update in critical care medicine	ANNALS OF INTERNAL MEDICINE			English	Review							TRIALS		Ben Taub Gen Hosp, Baylor Coll Med, Dept Pulm, Houston, TX 77030 USA	Baylor College of Medicine	Guntupalli, KK (corresponding author), Ben Taub Gen Hosp, Baylor Coll Med, Dept Pulm, 1502 Taub Loop, Houston, TX 77030 USA.							D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2000	132	4					288	295		10.7326/0003-4819-132-4-200002150-00007	http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285CY	10681284				2022-12-28	WOS:000085372900006
J	Moss, AJ; Daubert, JP				Moss, AJ; Daubert, JP			Internal ventricular defibrillation.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Rochester, Med Ctr, Rochester, NY 14642 USA	University of Rochester	Moss, AJ (corresponding author), Univ Rochester, Med Ctr, Rochester, NY 14642 USA.		Daubert, James P./ABC-1476-2021						0	5	5	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					398	398		10.1056/NEJM200002103420605	http://dx.doi.org/10.1056/NEJM200002103420605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666430				2022-12-28	WOS:000085205200005
J	Corey, L; Handsfield, HH				Corey, L; Handsfield, HH			Genital herpes and public health - Addressing a global problem	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SIMPLEX VIRUS; RISK FACTOR; TYPE-2 INFECTION; CONTROLLED TRIAL; ULCER DISEASE; ACYCLOVIR; TRANSMISSION; ASSOCIATION; SUPPRESSION	Genital herpes can be caused by herpes simplex virus 2 (HSV-2) or, less commonly, by herpes simplex virus 1 (HSV-1). With a seroprevalence of antibodies to HSV-2 of 22% in the general population, genital herpes is 1 of the 3 most prevalent sexually transmitted diseases (STDs) in the United States, A central issue in the public health problem of genital herpes is the high proportion of genital HSV infections that are unrecognized by both patients and clinicians. Persons who are HSV-2 seropositive may be symptomatic but nevertheless fail to recognize genital herpes; they serve as reservoirs for transmission. Physicians and patients must be aware of the subclinical presentation of genital herpes and the potential these patients have for transmitting HSV, Serious consequences of HSV infection include neonatal herpes and increased risk of human immunodeficiency virus transmission. Recommendations to physicians for prevention include using type-specific tests for HSV when screening for other STDs and testing for HSV when evaluating patients with genital ulcers. Researchers must evaluate the performance of type-specific tests and strategies to prevent transmission.	Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Publ Hlth Seattle & King Cty, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, Program Infect Dis, 1100 Fairview Ave N D3-100, Seattle, WA 98109 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI-30731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashley RL, 1999, J CLIN MICROBIOL, V37, P1632, DOI 10.1128/JCM.37.5.1632-1633.1999; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; Benedetti JK, 1999, ANN INTERN MED, V131, P14, DOI 10.7326/0003-4819-131-1-199907060-00004; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; Brown ZA, 1997, NEW ENGL J MED, V337, P509, DOI 10.1056/NEJM199708213370801; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; CATOTTI DN, 1993, SEX TRANSM DIS, V20, P77, DOI 10.1097/00007435-199303000-00004; Corey L, 1998, SEX TRANSM DIS, V25, P58, DOI 10.1097/00007435-199802000-00002; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; Corey L, 1999, SEX TRANSM DIS, V3rd, P285; Diamond C, 1999, SEX TRANSM DIS, V26, P221, DOI 10.1097/00007435-199904000-00007; Dickerson MC, 1996, SEX TRANSM DIS, V23, P429, DOI 10.1097/00007435-199609000-00015; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; FORSGREN M, 1990, SCAND J INFECT DIS, P37; GREENBLATT RM, 1988, AIDS, V2, P47, DOI 10.1097/00002030-198802000-00008; Gwanzura L, 1998, J INFECT DIS, V177, P481, DOI 10.1086/517381; Handsfield HH, 1999, SEX TRANSM DIS, V26, P228, DOI 10.1097/00007435-199904000-00009; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; HOOK EW, 1992, J INFECT DIS, V165, P251, DOI 10.1093/infdis/165.2.251; *INT HERP MAN FOR, 1999, HERPES, V6, P1; JOHNSON RE, 1990, NEW ENGL J MED, V321, P8; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; Langenberg AGM, 1999, NEW ENGL J MED, V341, P1432, DOI 10.1056/NEJM199911043411904; MARAZZO JM, 1997, INFECT DIS OBSTET GY, V5, P29; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; Mertz KJ, 1998, J INFECT DIS, V178, P1795, DOI 10.1086/314502; Mole L, 1997, J INFECT DIS, V176, P766, DOI 10.1086/517297; Morse SA, 1997, J INFECT DIS, V175, P583, DOI 10.1093/infdis/175.3.583; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; ROSS JDC, 1993, GENITOURIN MED, V69, P381; Schacker T, 1998, J INFECT DIS, V178, P1616, DOI 10.1086/314486; Schacker T, 1998, ANN INTERN MED, V128, P21, DOI 10.7326/0003-4819-128-1-199801010-00004; Schacker T, 1998, JAMA-J AM MED ASSOC, V280, P61, DOI 10.1001/jama.280.1.61; Wald A, 1996, ANN INTERN MED, V124, P8, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00002; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; WHITLEY RJ, 1980, PEDIATRICS, V66, P495; WHITLEY RJ, 1995, INFECT DIS FETUS NEW, P354	42	174	183	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					791	794		10.1001/jama.283.6.791	http://dx.doi.org/10.1001/jama.283.6.791			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280XL	10683059				2022-12-28	WOS:000085129000032
J	Henney, JE				Henney, JE			Sertraline approved for posttraumatic stress disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Commissioner Food & Drugs, Rockville, MD 20857 USA		Henney, JE (corresponding author), Commissioner Food & Drugs, HF 1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					596	596		10.1001/jama.283.5.596-b	http://dx.doi.org/10.1001/jama.283.5.596-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665687				2022-12-28	WOS:000084956500007
J	Wentz, FJ; Schabel, M				Wentz, FJ; Schabel, M			Precise climate monitoring using complementary satellite data sets	NATURE			English	Article							SEA-SURFACE TEMPERATURE; TROPOSPHERIC WATER-VAPOR; TRENDS; RECORDS; OCEANS	Observations from Earth-orbiting satellites have been a key component in monitoring climate change for the past two decades. This has become possible with the availability of air temperatures from the Microwave Sounding Unit (MSU)(1) since 1979, sea surface temperatures from the Advanced Very High Resolution Radiometer (AVHRR)(2) since 1982 and, most recently, measurements of atmospheric water vapour content from the Special Sensor Microwave Imager (SSM/I)(3) since 1987. Here we present a detailed comparison of each pair of these three time series, focusing on both interannual and decadal variations in climate. We find a strong association between sea surface temperature, lower-tropospheric air temperature and total column water-vapour content over large oceanic regions on both time scales. This lends observational support to the idea of a constant; relative humidity model having a moist adiabatic lapse rate. On the decadal timescale, the combination of data sets shows a consistent warming and moistening trend of the marine atmosphere for 1987-1998.	Remote Sensing Syst, Santa Rosa, CA 95401 USA		Wentz, FJ (corresponding author), Remote Sensing Syst, 438 1st St,Suite 200, Santa Rosa, CA 95401 USA.		Schabel, Matthias C./H-4647-2019					BONY S, 1995, CLIM DYNAM, V11, P307, DOI 10.1007/BF00211682; Christy JR, 1998, J CLIMATE, V11, P2016, DOI 10.1175/1520-0442-11.8.2016; GAFFEN DJ, 1992, GEOPHYS RES LETT, V19, P1839, DOI 10.1029/92GL02001; Gutzler DS, 1996, J ATMOS SCI, V53, P2773, DOI 10.1175/1520-0469(1996)053<2773:LFOAVA>2.0.CO;2; Hurrell JW, 1997, NATURE, V386, P164, DOI 10.1038/386164a0; Hurrell JW, 1998, J CLIMATE, V11, P945, DOI 10.1175/1520-0442(1998)011<0945:DIORTT>2.0.CO;2; JACKSON DL, 1995, J CLIMATE, V8, P2025, DOI 10.1175/1520-0442(1995)008<2025:ASOSDC>2.0.CO;2; PEIXOTO JP, 1991, PHYSICS CLIMATE; Randel DL, 1996, B AM METEOROL SOC, V77, P1233, DOI 10.1175/1520-0477(1996)077<1233:ANGWVD>2.0.CO;2; REYNOLDS RW, 1994, J CLIMATE, V7, P929, DOI 10.1175/1520-0442(1994)007<0929:IGSSTA>2.0.CO;2; REYNOLDS RW, 1993, J CLIMATE, V6, P768, DOI 10.1175/1520-0442(1993)006<0768:IOMPAO>2.0.CO;2; Ross RJ, 1998, GEOPHYS RES LETT, V25, P4357, DOI 10.1029/1998GL900169; Ross RJ, 1996, J CLIMATE, V9, P3561, DOI 10.1175/1520-0442(1996)009<3561:TWVCAT>2.0.CO;2; Schroeder SR, 1998, GEOPHYS RES LETT, V25, P1301, DOI 10.1029/98GL01029; SPENCER RW, 1992, J CLIMATE, V5, P858, DOI 10.1175/1520-0442(1992)005<0858:PARVOS>2.0.CO;2; SPENCER RW, 1990, SCIENCE, V247, P1558, DOI 10.1126/science.247.4950.1558; STEPHENS GL, 1990, J CLIMATE, V3, P634, DOI 10.1175/1520-0442(1990)003<0634:OTRBWV>2.0.CO;2; STONE PH, 1979, J ATMOS SCI, V36, P415, DOI 10.1175/1520-0469(1979)036<0415:ALRRAT>2.0.CO;2; Wentz FJ, 1998, NATURE, V394, P661, DOI 10.1038/29267; Wentz FJ, 1997, J GEOPHYS RES-OCEANS, V102, P8703, DOI 10.1029/96JC01751; Wilks A. A., 1995, STAT METHODS ATMOSPH; Zhai PM, 1997, J CLIMATE, V10, P2643, DOI 10.1175/1520-0442(1997)010<2643:AWVOC>2.0.CO;2	22	162	166	2	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					414	416		10.1038/35000184	http://dx.doi.org/10.1038/35000184			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667790				2022-12-28	WOS:000085121100046
J	Wrana, JL				Wrana, JL			Regulation of Smad activity	CELL			English	Review							PROTEIN		Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Wrana, JL (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Wrana, Jeffrey/F-8857-2013					Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DONG C, 2000, IN PRESS MOL CELL; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	20	340	371	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					189	192		10.1016/S0092-8674(00)81556-1	http://dx.doi.org/10.1016/S0092-8674(00)81556-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660041	Bronze			2022-12-28	WOS:000084932200002
J	Johnson, GJ				Johnson, GJ			Improving outcome of cataract surgery in developing countries	LANCET			English	Editorial Material							OF-LIFE OUTCOMES		UCL, Int Ctr Eye Hlth, London EC1V 9EL, England	University of London; London School of Hygiene & Tropical Medicine; University College London	Johnson, GJ (corresponding author), UCL, Int Ctr Eye Hlth, London EC1V 9EL, England.							DADA VK, 1999, CATARACT BLINDNESS S; Kapoor H, 1999, BRIT J OPHTHALMOL, V83, P343, DOI 10.1136/bjo.83.3.343; Limburg H, 1999, B WORLD HEALTH ORGAN, V77, P455; Pokharel GP, 1998, BRIT J OPHTHALMOL, V82, P606, DOI 10.1136/bjo.82.6.606; REIDY A, 1991, BRIT J OPHTHALMOL, V75, P102, DOI 10.1136/bjo.75.2.102; Zhao JL, 1998, AM J OPHTHALMOL, V126, P515, DOI 10.1016/S0002-9394(98)00274-8	6	16	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					158	159		10.1016/S0140-6736(99)00404-3	http://dx.doi.org/10.1016/S0140-6736(99)00404-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675108				2022-12-28	WOS:000084879700002
J	Soto, C; Kascsak, RJ; Saborio, GP; Aucouturier, P; Wisniewski, T; Prelli, F; Kascsak, R; Mendez, E; Harris, DA; Ironside, J; Tagliavini, F; Carp, RI; Frangione, B				Soto, C; Kascsak, RJ; Saborio, GP; Aucouturier, P; Wisniewski, T; Prelli, F; Kascsak, R; Mendez, E; Harris, DA; Ironside, J; Tagliavini, F; Carp, RI; Frangione, B			Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides	LANCET			English	Article							SCRAPIE AGENT; AMYLOIDOSIS; INHIBITION; MICE; CJD	Background Transmissible spongiform encephalopathies are associated with a structural transition in the prion protein that results in the conversion of the physiological PrPc to pathological PrPSc. We investigated whether this conformational transition can be inhibited and reversed by peptides homologous to the PrP fragments implicated in the abnormal folding. which contain specific residues acting as beta-sheet blockers (beta-sheet breaker peptides). Methods We studied the effect of a 13-residue beta-sheet breaker peptide (iPrP13) on the reversion of the abnormal structure and properties of PrPSc; purified from the brains of mice with experimental scrapie and from human beings affected by sporadic and variant Creutzfeldt-Jakob disease. In a cellular model of familial prion disease, we studied the effect of the peptide in the production of the abnormal form of PrP in intact cells. The influence of the peptide on prion infectivity was studied in vivo by incubation time assays in mice with experimental scrapie. Findings The beta-sheet breaker peptide partly reversed in-vitro PrPSc to a biochemical and structural state similar to that of PrPc. The effect of the peptide was also detected in intact cells. Treatment of prion infectious material with iPrP13 delayed the appearance of clinical symptoms and decreased infectivity by 90-95% in mice with experimental scrapie. Interpretation beta-sheet breaker peptides reverse PrP conformational changes implicated in the pathogenesis of spongiform encephalopathies, These peptides or their derivatives provide a useful tool to study the role of PrP conformation and might represent a novel therapeutic approach for prion-related disorders.	Serono Pharmaceut Res Inst, Dept Cellular Biochem, Geneva, Switzerland; NYU, Med Ctr, New York, NY 10016 USA; New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA; CSIC, Ctr Nacl Biotecnol, Madrid, Spain; Washington Univ, Sch Med, St Louis, MO USA; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; Ist Nazl Neurol Carlo Besta, Milan, Italy	New York University; Institute for Basic Research in Developmental Disabilities; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Washington University (WUSTL); University of Edinburgh; IRCCS Istituto Neurologico Besta	Soto, C (corresponding author), Serono Pharmaceut Res Inst, Dept Cellular Biochem, Geneva, Switzerland.		Tagliavini, Fabrizio/AAO-7891-2021; Wisniewski, Thomas/Q-6525-2019	Tagliavini, Fabrizio/0000-0003-1039-7315; Wisniewski, Thomas/0000-0002-3379-8966; Ironside, James/0000-0001-5869-2108; Harris, David/0000-0002-6985-5790	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR002594, R01AR002594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035496] Funding Source: NIH RePORTER; NIAMS NIH HHS [ARD2594] Funding Source: Medline; NINDS NIH HHS [NS35496] Funding Source: Medline; PHS HHS [M56472] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adjou KT, 1998, CNS DRUGS, V10, P83, DOI 10.2165/00023210-199810020-00001; Aucouturier P, 1999, NEUROSCI LETT, V274, P33, DOI 10.1016/S0304-3940(99)00659-X; Brown P, 1990, ANTIVIR CHEM CHEMOTH, V1, P75, DOI 10.1177/095632029000100201; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; CARP RI, 1994, ANN NY ACAD SCI, V724, P221, DOI 10.1111/j.1749-6632.1994.tb38912.x; CARP RI, 1984, INTERVIROLOGY, V21, P61, DOI 10.1159/000149503; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; DICKINSON AG, 1988, CIBA F SYMP, V135, P63; FAUCHERE JL, 1992, ADV DRUG RES, V23, P127; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; Haywood AM, 1997, NEW ENGL J MED, V337, P1821, DOI 10.1056/NEJM199712183372508; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Kascsak RJ, 1997, IMMUNOL INVEST, V26, P259, DOI 10.3109/08820139709048931; KIMBERLIN RH, 1976, SCI PROGRESS-UK, V63, P461; Li SC, 1996, P NATL ACAD SCI USA, V93, P6676, DOI 10.1073/pnas.93.13.6676; MOORE GJ, 1994, TRENDS PHARMACOL SCI, V15, P124, DOI 10.1016/0165-6147(94)90049-3; Narwa R, 1999, BIOCHEMISTRY-US, V38, P8770, DOI 10.1021/bi990736c; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Soto C, 1999, CNS DRUGS, V12, P347, DOI 10.2165/00023210-199912050-00002; WILL RG, 1996, LANCET, V347, P925; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	30	242	267	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					192	197		10.1016/S0140-6736(99)11419-3	http://dx.doi.org/10.1016/S0140-6736(99)11419-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675119				2022-12-28	WOS:000084879700013
J	Yamey, G				Yamey, G			Nestle accused of breaking international code	BRITISH MEDICAL JOURNAL			English	News Item																		Launer J, 1999, BRIT MED J, V318, P117, DOI 10.1136/bmj.318.7176.117; 1997, BRIT MED J, V314, P165	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					468	468						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678855				2022-12-28	WOS:000085562200016
J	Muth, CM; Shank, ES				Muth, CM; Shank, ES			Primary care: Gas embolism.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CEREBRAL AIR-EMBOLISM; HYPERBARIC-OXYGEN; BLOOD-FLOW; ISCHEMIA; LIDOCAINE; THERAPY; ECHOCARDIOGRAPHY; PHYSIOLOGY; MANAGEMENT; CATHETER		Univ Saarland, Univ Hosp Homburg, Druckkammerzentrum Homburg, D-6650 Homburg, Germany; Massachusetts Gen Hosp, Dept Anesthesiol & Crit Care, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Anesthesiol, Boston, MA USA	Saarland University; Universitatsklinikum des Saarlandes; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Muth, CM (corresponding author), Univ Saarlandes Kliniken, Druckkammerzentrum Homburg, D-66424 Homburg, Germany.							Albin MS, 1997, TXB NEUROANESTHESIA, P1009; ANNANE D, 1994, CRIT CARE MED, V22, P851, DOI 10.1097/00003246-199405000-00023; Bennett P B, 1990, DIVING ACCIDENT MANA, P366; Bleck TP, 1999, EPILEPSIA, V40, pS59, DOI 10.1111/j.1528-1157.1999.tb00880.x; BUTLER BD, 1979, J APPL PHYSIOL, V47, P537, DOI 10.1152/jappl.1979.47.3.537; DEANGELIS J, 1975, ANESTHESIOLOGY, V43, P110, DOI 10.1097/00000542-197507000-00025; Dexter F, 1997, ANESTH ANALG, V84, P1203, DOI 10.1097/00000539-199706000-00006; DONLON JV, 1990, ANESTHESIA, V2, P2001; DURANT TM, 1947, AM HEART J, V33, P269, DOI 10.1016/0002-8703(47)90656-X; DUTKA AJ, 1992, STROKE, V23, P1515, DOI 10.1161/01.STR.23.10.1515; DUTKA AJ, 1992, UNDERSEA BIOMED RES, V19, P131; DUTKA AJ, 1985, UNDERSEA BIOMED RES, V12, P403; EVANS DE, 1989, J NEUROSURG, V70, P97, DOI 10.3171/jns.1989.70.1.0097; EVANS DE, 1981, STROKE, V12, P338; EVANS DE, 1984, J NEUROSURG, V60, P257, DOI 10.3171/jns.1984.60.2.0257; GANSHIRT H, 1983, EUR NEUROL, V22, P78, DOI 10.1159/000115654; GILDENBERG PL, 1981, J NEUROSURG, V54, P75, DOI 10.3171/jns.1981.54.1.0075; GRONERT GA, 1979, ANESTHESIOLOGY, V50, P548, DOI 10.1097/00000542-197906000-00018; HALLIDAY P, 1994, BRIT J SURG, V81, P71, DOI 10.1002/bjs.1800810123; HILL BF, 1993, AM J EMERG MED, V11, P155, DOI 10.1016/0735-6757(93)90111-N; Hoffman WE, 1998, NEUROSURGERY, V43, P1050, DOI 10.1097/00006123-199811000-00026; KATZ J, 1988, BRIT J ANAESTH, V61, P200, DOI 10.1093/bja/61.2.200; KIZER KW, 1981, ANN EMERG MED, V10, P485, DOI 10.1016/S0196-0644(81)80285-5; LYNCH JJ, 1984, AM J CARDIOL, V53, P1478, DOI 10.1016/S0002-9149(84)91617-5; Mammoto T, 1998, ACTA ANAESTH SCAND, V42, P643, DOI 10.1111/j.1399-6576.1998.tb05295.x; MCDERMOTT JJ, 1990, UNDERSEA BIOMED RES, V17, P525; MILLER JD, 1970, J NEUROL NEUROSUR PS, V33, P745, DOI 10.1136/jnnp.33.6.745; MINK RB, 1995, STROKE, V26, P2307, DOI 10.1161/01.STR.26.12.2307; Mitchell SJ, 1999, ANN THORAC SURG, V67, P1117, DOI 10.1016/S0003-4975(99)00057-0; Moon R E, 1999, Respir Care Clin N Am, V5, P93; Moon R.E., 1996, HDB HYPERBARIC MED, P229; MURPHY BP, 1985, ANN SURG, V201, P242, DOI 10.1097/00000658-198502000-00019; Palmon SC, 1997, J CLIN ANESTH, V9, P251, DOI 10.1016/S0952-8180(97)00024-X; Patel PM, 1998, ANESTH ANALG, V86, P773, DOI 10.1097/00000539-199804000-00018; PEIRCE EC, 1980, ANN THORAC SURG, V29, P300, DOI 10.1016/S0003-4975(10)61474-9; Porter JM, 1999, BRIT J ANAESTH, V82, P117, DOI 10.1093/bja/82.1.117; Reasoner DK, 1996, ANESTH ANALG, V82, P61, DOI 10.1097/00000539-199601000-00011; Ryu KH, 1996, STROKE, V27, P303, DOI 10.1161/01.STR.27.2.303; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; SHAPIRO HM, 1990, ANESTHESIA, V2, P1737; Smith Robert M., 1994, Journal of Emergency Medicine, V12, P147, DOI 10.1016/0736-4679(94)90691-2; SPENCER MP, 1971, AEROSPACE MED, V42, P822; Thom SR, 1997, AM J PHYSIOL-CELL PH, V272, pC770, DOI 10.1152/ajpcell.1997.272.3.C770; Tommasino C, 1996, J NEUROSURG ANESTH, V8, P30, DOI 10.1097/00008506-199601000-00008; TOVAR EA, 1995, ANN THORAC SURG, V60, P1138, DOI 10.1016/0003-4975(95)00531-O; VANLIEW HD, 1993, AVIAT SPACE ENVIR MD, V64, P859; VIK A, 1990, J APPL PHYSIOL, V69, P237, DOI 10.1152/jappl.1990.69.1.237; VOORHIES RM, 1984, J NEUROSURG, V60, P177, DOI 10.3171/jns.1984.60.1.0177; Weissman A, 1996, J REPROD MED, V41, P103; Yu ASL, 1997, AM J KIDNEY DIS, V29, P453, DOI 10.1016/S0272-6386(97)90209-2; Ziser A, 1999, J THORAC CARDIOV SUR, V117, P818, DOI 10.1016/S0022-5223(99)70304-1	51	597	612	2	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2000	342	7					476	482		10.1056/NEJM200002173420706	http://dx.doi.org/10.1056/NEJM200002173420706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284FA	10675429				2022-12-28	WOS:000085319100006
J	Peck, C; McCall, M; McLaren, B; Rotem, T				Peck, C; McCall, M; McLaren, B; Rotem, T			Continuing medical education and continuing professional development: international comparisons	BRITISH MEDICAL JOURNAL			English	Article									Hlth Media Net, London EC1R 3DB, England; Royal Australasian Coll Phys, Sydney, NSW 2000, Australia		Peck, C (corresponding author), Hlth Media Net, London EC1R 3DB, England.							*AMA, 1999, PHYS REC AW; Fox RD, 1998, BRIT MED J, V316, P466, DOI 10.1136/bmj.316.7129.466; GRANT J, 1998, EFFECTIVENESS CONTIN, P21; *JOINT CTR ED MED, 1999, GOOD CPD GUID, P23; PARBOOSINGH J, 1999, TOWNHALL SESSION MAI; *ROYAL AUSTR COLL, 1999, REV MAINT PROF STAND; *ROYAL COLL PHYS S, 1999, ANN REP ROYAL COLL P	7	149	153	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					432	435		10.1136/bmj.320.7232.432	http://dx.doi.org/10.1136/bmj.320.7232.432			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669451	Green Published			2022-12-28	WOS:000085377400027
J	Roberts, CJ; Nelson, B; Marton, MJ; Stoughton, R; Meyer, MR; Bennett, HA; He, YDD; Dai, HY; Walker, WL; Hughes, TR; Tyers, M; Boone, C; Friend, SH				Roberts, CJ; Nelson, B; Marton, MJ; Stoughton, R; Meyer, MR; Bennett, HA; He, YDD; Dai, HY; Walker, WL; Hughes, TR; Tyers, M; Boone, C; Friend, SH			Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE PATHWAY; POLARIZED CELL-GROWTH; FILAMENTOUS-GROWTH; ACTIN CYTOSKELETON; INVASIVE GROWTH; REGULATED GENES; SHUTTLE VECTORS; MATING FACTOR; PHEROMONE	Genome-wide transcript profiling was used to monitor signal transduction during yeast pheromone response. Genetic manipulations allowed analysis of changes in gene expression underlying pheromone signaling, cell cycle control, and polarized morphogenesis. A two-dimensional hierarchical clustered matrix, covering 383 of the most highly regulated genes, was constructed from 46 diverse experimental conditions. Diagnostic subsets of coexpressed genes reflected signaling activity, cross talk, and overlap of multiple mitogen-activated protein kinase (MAPK) pathways. Analysis of the profiles specified by two different MAPKs-Fus3p and Kss1p-revealed functional overlap of the filamentous growth and mating responses. Global transcript analysis reflects biological responses associated with the activation and perturbation of signal transduction pathways.	Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; Rosetta Inpharmat, Kirkland, WA 98034 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada	Queens University - Canada; Merck & Company; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Boone, C (corresponding author), Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada.		Tyers, Michael/ABE-3194-2021; Pillay, Nischalan/F-9536-2012					Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; Blanco P, 1998, FEMS MICROBIOL LETT, V164, P249, DOI 10.1016/S0378-1097(98)00220-1; Brachmann CB, 1998, YEAST, V14, P115; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; Buehrer BM, 1997, MOL CELL BIOL, V17, P6517, DOI 10.1128/MCB.17.11.6517; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Chen GC, 1997, GENE DEV, V11, P2958, DOI 10.1101/gad.11.22.2958; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; ERDMAN S, COMMUNICATION; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FIELDS S, 1988, MOL CELL BIOL, V8, P551, DOI 10.1128/MCB.8.2.551; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gognies S, 1999, YEAST, V15, P11, DOI 10.1002/(SICI)1097-0061(19990115)15:1<11::AID-YEA336>3.0.CO;2-O; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Gray JV, 1997, EMBO J, V16, P4924, DOI 10.1093/emboj/16.16.4924; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; Hartigan J., 1975, CLUSTERING ALGORITHM; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hung W, 1997, EUR J BIOCHEM, V245, P241, DOI 10.1111/j.1432-1033.1997.00241.x; HWANGSHUM JJ, 1991, MOL GEN GENET, V227, P197, DOI 10.1007/BF00259671; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Karos M, 1999, MOL GEN GENET, V260, P510, DOI 10.1007/s004380050924; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Kuo MH, 1997, MOL CELL BIOL, V17, P819, DOI 10.1128/MCB.17.2.819; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Liu HP, 1996, GENETICS, V144, P967; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Madhani HD, 1999, P NATL ACAD SCI USA, V96, P12530, DOI 10.1073/pnas.96.22.12530; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Mosch HU, 1999, MOL BIOL CELL, V10, P1325, DOI 10.1091/mbc.10.5.1325; NAIR PB, UNPUB; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Robertson LS, 1998, P NATL ACAD SCI USA, V95, P13783, DOI 10.1073/pnas.95.23.13783; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SIKORSKI RS, 1989, GENETICS, V122, P19; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WATANABE Y, 1995, MOL CELL BIOL, V15, P5740; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; XUE CB, 1989, BIOCHEM BIOPH RES CO, V162, P253, DOI 10.1016/0006-291X(89)91989-X; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	78	701	733	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					873	880		10.1126/science.287.5454.873	http://dx.doi.org/10.1126/science.287.5454.873			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657304				2022-12-28	WOS:000085136400051
J	Alizadeh, AA; Eisen, MB; Davis, RE; Ma, C; Lossos, IS; Rosenwald, A; Boldrick, JG; Sabet, H; Tran, T; Yu, X; Powell, JI; Yang, LM; Marti, GE; Moore, T; Hudson, J; Lu, LS; Lewis, DB; Tibshirani, R; Sherlock, G; Chan, WC; Greiner, TC; Weisenburger, DD; Armitage, JO; Warnke, R; Levy, R; Wilson, W; Grever, MR; Byrd, JC; Botstein, D; Brown, PO; Staudt, LM				Alizadeh, AA; Eisen, MB; Davis, RE; Ma, C; Lossos, IS; Rosenwald, A; Boldrick, JG; Sabet, H; Tran, T; Yu, X; Powell, JI; Yang, LM; Marti, GE; Moore, T; Hudson, J; Lu, LS; Lewis, DB; Tibshirani, R; Sherlock, G; Chan, WC; Greiner, TC; Weisenburger, DD; Armitage, JO; Warnke, R; Levy, R; Wilson, W; Grever, MR; Byrd, JC; Botstein, D; Brown, PO; Staudt, LM			Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling	NATURE			English	Article							NON-HODGKINS-LYMPHOMA; GERMINAL-CENTER FORMATION; CHROMOSOMAL TRANSLOCATION; PROGNOSTIC-SIGNIFICANCE; PROTEIN EXPRESSION; MOLECULAR-CLONING; BCL-6 EXPRESSION; ANTIGEN; CLASSIFICATION; TRANSCRIPTION	Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in natural history reflects unrecognized molecular heterogeneity in the tumours, Using DNA microarrays, we have conducted a systematic characterization of gene expression in B-cell malignancies. Here we show that there is diversity in gene expression among the tumours of DLBCL patients, apparently reflecting the variation in tumour proliferation rate, host response and differentiation state of the tumour. We identified two molecularly distinct forms of DLBCL which had gene expression patterns indicative of different stages of B-cell differentiation. One type expressed genes characteristic of germinal centre B cells ('germinal centre B-like DLBCL'); the second type expressed genes normally induced during in vitro activation of peripheral blood B cells ('activated B-like DLBCL'), Patients with germinal centre B-like DLBCL had a significantly better overall survival than those with activated B-like DLBCL, The molecular classification of tumours on the basis of gene expression can thus identify previously undetected and clinically significant subtypes of cancer.	NCI, Metab Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Hlth Res & Policy Stat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; NIH, Bioinformat & Mol Anal Sect, CBEL, CIT, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; Res Genet Inc, Huntsville, AL 35801 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA; NCI, Med Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); US Food & Drug Administration (FDA); University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Medicine; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Staudt, LM (corresponding author), NCI, Metab Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA.		Sherlock, Gavin J/B-1831-2009; B, shaizimah/AAS-2555-2020; Sherlock, Gavin J/E-9110-2012; Alizadeh, Ash A/C-5594-2009; Staudt, Louis/AAC-5324-2019	Alizadeh, Ash A/0000-0002-5153-5625; Sherlock, Gavin/0000-0002-1692-4983; Levy, Ronald/0000-0003-2061-0650	CENTER FOR INFORMATION TECHNOLOGY [Z01CT000260, ZIACT000260] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT))		Alizadeh A, 1998, J CLIN IMMUNOL, V18, P373, DOI 10.1023/A:1023293621057; ALIZADEH AA, IN PRESS COLD SPRING; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; BAHLER DW, 1992, P NATL ACAD SCI USA, V89, P6770, DOI 10.1073/pnas.89.15.6770; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Chan WC, 1997, BLOOD, V89, P3909; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DeRisi J, 1996, NAT GENET, V14, P457; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FLENGHI L, 1995, AM J PATHOL, V147, P405; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Gascoyne RD, 1997, BLOOD, V90, P244; GOLAY J, 1994, J IMMUNOL, V153, P543; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GROGAN TM, 1988, BLOOD, V71, P1157; Harada S, 1999, LEUKEMIA, V13, P1441, DOI 10.1038/sj.leu.2401487; HARRIS NL, 1994, BLOOD, V84, P1361; Hodgkin, 1832, Med Chir Trans, V17, P68; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; JALKANEN S, 1991, J CLIN INVEST, V87, P1835, DOI 10.1172/JCI115205; Khan J, 1998, CANCER RES, V58, P5009; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Klein U, 1998, IMMUNOL REV, V162, P261; Kramer MHH, 1996, J CLIN ONCOL, V14, P2131, DOI 10.1200/JCO.1996.14.7.2131; Kramer MHH, 1998, BLOOD, V92, P3152, DOI 10.1182/blood.V92.9.3152.421a07_3152_3162; Kuo FC, 1997, J EXP MED, V186, P1547, DOI 10.1084/jem.186.9.1547; Liu J, 1996, Biomed Environ Sci, V9, P1; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Pittaluga S, 1996, J PATHOL, V179, P145; Preti HA, 1997, ANN INTERN MED, V127, P186, DOI 10.7326/0003-4819-127-3-199708010-00002; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Reed D., 1902, JOHNS HOPKINS HOS RE, V10, P133; ROSENBERG SA, 1994, BLOOD, V84, P1359; SCHEINER SM, 1995, ACADEME, V81, P4; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Staudt L M, 1999, Int Rev Immunol, V18, P381, DOI 10.3109/08830189909088490; Sternberg C. U., 1898, Z HEILK, V19, P21; Tangye SG, 1998, J EXP MED, V188, P1691, DOI 10.1084/jem.188.9.1691; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Vose UM, 1998, SEMIN ONCOL, V25, P483; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Zani VJ, 1996, BLOOD, V87, P3124, DOI 10.1182/blood.V87.8.3124.bloodjournal8783124	50	7082	7533	11	558	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					503	511		10.1038/35000501	http://dx.doi.org/10.1038/35000501			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676951				2022-12-28	WOS:000085227300039
J	Ludwig, MZ; Bergman, C; Patel, NH; Kreitman, M				Ludwig, MZ; Bergman, C; Patel, NH; Kreitman, M			Evidence for stabilizing selection in a eukaryotic enhancer element	NATURE			English	Article							EVEN-SKIPPED PROMOTER; DROSOPHILA EMBRYO; EXPRESSION; EVOLUTION; STRIPE; PATTERNS; REGION; SITES	Eukaryotic gene expression is mediated by compact cis-regulatory modules, or enhancers, which are bound by specific sets of transcription factors(1). The combinatorial interaction of these bound transcription factors determines time- and tissue-specific gene activation or repression. The even-skipped stripe 2 element controls the expression of the second transverse stripe of a even-skipped messenger RNA in Drosophila melanogaster embryos, and is one of the best characterized eukaryotic enhancers(2-4). Although even-skipped stripe 2 expression is strongly conserved in Drosophila, the stripe 2 element itself has undergone considerable evolutionary change in its binding-site sequences and the spacing between them. We have investigated this apparent contradiction, and here we show that two chimaeric enhancers, constructed by swapping the 5' and 3' halves of the native stripe 2 elements of two species, no longer drive expression of a reporter gene in the wildtype pattern. Sequence differences between species have functional consequences, therefore, but they are masked by other coevolved differences. On the basis of these results, we present a model for the evolution of eukaryotic regulatory sequences.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Ludwig, MZ (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.		Bergman, Casey/F-7854-2010	Bergman, Casey/0000-0002-5462-9854; Patel, Nipam/0000-0003-4328-654X				Arnone MI, 1997, DEVELOPMENT, V124, P1851; Arnosti DN, 1996, DEVELOPMENT, V122, P205; BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; Gibson G, 1996, SCIENCE, V271, P200, DOI 10.1126/science.271.5246.200; GOTO T, 1989, CELL, V57, P413, DOI 10.1016/0092-8674(89)90916-1; HARDING K, 1989, EMBO J, V8, P1205, DOI 10.1002/j.1460-2075.1989.tb03493.x; Hewitt GF, 1999, DEVELOPMENT, V126, P1201; KIMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P5773, DOI 10.1073/pnas.78.9.5773; Kimura M., 1983, NEUTRAL THEORY MOL E; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Long AD, 1998, GENETICS, V149, P999; Ludwig MZ, 1998, DEVELOPMENT, V125, P949; LUDWIG MZ, 1995, MOL BIOL EVOL, V12, P1002; OHTA T, 1990, GENETICS, V126, P219; SMALL S, 1993, DEVELOPMENT, V119, P767; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715	19	435	448	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					564	567		10.1038/35000615	http://dx.doi.org/10.1038/35000615			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676967				2022-12-28	WOS:000085227300055
J	Lundstrom, CC				Lundstrom, CC			Rapid diffusive infiltration of sodium into partially molten peridotite	NATURE			English	Article							OCEAN-RIDGE BASALT; ABYSSAL PERIDOTITES; UPWELLING MANTLE; SILICATE MELTS; ORIGIN; MECHANISMS; XENOLITHS; PYROXENE; BEHAVIOR; ALKALIS	Recent seismological, geochemical and experimental observations suggest that, as mantle peridotite melts, the resulting basaltic liquid forms an interconnected network, culminating in the rapid ascent of the basalt relative to the surrounding solid matrix(1-3) Mantle melting is therefore a polybaric process, with melts produced over a range of pressures having differing chemical characteristics(4-6). Modelling and peridotite-melting experiments designed to simulate polybaric mantle melting generally assume that there is no interaction between melts generated at greater pressures and the overlying solid mantle at lower pressures(5,7). Beneath mid-ocean ridges, melts derived from greater depth are probably channelized during ascent, so preventing direct re-equilibration with shallow peridotites, as required by geochemical observations(6,9). I show here, however, that sodium in ascending melts will quickly diffuse into the melt formed within nearby peridotite at lower pressures. This process fundamentally changes the manner by which the peridotite melts, and can account for both the creation of silica-rich glass inclusions in mantle xenoliths and the anomalous melting modes recorded by abyssal peridotites, Increased melting of lithosphere and upwelling asthenosphere could result from this process without the need to invoke higher mantle temperatures.	Brown Univ, Dept Geol Sci, Providence, RI 02912 USA	Brown University	Lundstrom, CC (corresponding author), Univ Illinois, Dept Geol, Urbana, IL 61801 USA.							BAKER MB, 1995, NATURE, V375, P308, DOI 10.1038/375308a0; DICK HJB, 1984, EARTH PLANET SC LETT, V69, P88, DOI 10.1016/0012-821X(84)90076-1; Draper DS, 1997, J PETROL, V38, P1187, DOI 10.1093/petrology/38.9.1187; ELTHON D, 1992, J GEOPHYS RES-SOL EA, V97, P9015, DOI 10.1029/92JB00723; FREY FA, 1974, GEOCHIM COSMOCHIM AC, V38, P1023, DOI 10.1016/0016-7037(74)90003-9; HIROSE K, 1993, EARTH PLANET SC LETT, V114, P477, DOI 10.1016/0012-821X(93)90077-M; Hirose K, 1998, PHYS EARTH PLANET IN, V107, P111, DOI 10.1016/S0031-9201(97)00129-5; Hirschmann MM, 1998, GEOCHIM COSMOCHIM AC, V62, P883, DOI 10.1016/S0016-7037(98)00028-3; JOHNSON KTM, 1990, J GEOPHYS RES-SOLID, V95, P2661, DOI 10.1029/JB095iB03p02661; Kelemen PB, 1997, PHILOS T R SOC A, V355, P283, DOI 10.1098/rsta.1997.0010; KELEMEN PB, 1995, NATURE, V375, P747, DOI 10.1038/375747a0; KINZLER RJ, 1992, J GEOPHYS RES-SOL EA, V97, P6907, DOI 10.1029/91JB02841; KLEIN EM, 1987, J GEOPHYS RES-SOLID, V92, P8089, DOI 10.1029/JB092iB08p08089; KUSHIRO I, 1975, AM J SCI, V275, P411, DOI 10.2475/ajs.275.4.411; LANGMUIR CH, 1980, PHILOS T R SOC A, V297, P383, DOI 10.1098/rsta.1980.0223; LESHER CE, 1994, J GEOPHYS RES-SOL EA, V99, P9585, DOI 10.1029/94JB00469; Lundstrom CC, 2000, CHEM GEOL, V162, P105, DOI 10.1016/S0009-2541(99)00122-9; MCKENZIE D, 1984, J PETROL, V25, P713, DOI 10.1093/petrology/25.3.713; Niu YL, 1997, EARTH PLANET SC LETT, V152, P251, DOI 10.1016/S0012-821X(97)00119-2; Robinson JAC, 1998, EARTH PLANET SC LETT, V155, P97, DOI 10.1016/S0012-821X(97)00162-3; RYERSON FJ, 1985, GEOCHIM COSMOCHIM AC, V49, P637, DOI 10.1016/0016-7037(85)90159-0; Shaw CSJ, 1998, CONTRIB MINERAL PETR, V132, P354, DOI 10.1007/s004100050429; STOLPER E, 1980, CONTRIB MINERAL PETR, V74, P13, DOI 10.1007/BF00375485; TAKAHASHI E, 1986, J GEOPHYS RES-SOLID, V91, P9367, DOI 10.1029/JB091iB09p09367; Toomey DR, 1998, SCIENCE, V280, P1224, DOI 10.1126/science.280.5367.1224; Vannucci R, 1998, EARTH PLANET SC LETT, V158, P39, DOI 10.1016/S0012-821X(98)00040-5; WAFF HS, 1979, J GEOPHYS RES, V84, P6109, DOI 10.1029/JB084iB11p06109; WALTER MJ, 1994, J PETROL, V35, P329, DOI 10.1093/petrology/35.2.329; WATSON EB, 1984, J GEOL, V92, P121, DOI 10.1086/628843; WATSON EB, 1982, CONTRIB MINERAL PETR, V80, P73, DOI 10.1007/BF00376736	30	48	50	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					527	530		10.1038/35000546	http://dx.doi.org/10.1038/35000546			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676957				2022-12-28	WOS:000085227300045
J	Roger, VL; Farkouh, ME; Weston, SA; Reeder, GS; Jacobsen, SJ; Zinsmeister, AR; Yawn, BP; Kopecky, SL; Gabriel, SE				Roger, VL; Farkouh, ME; Weston, SA; Reeder, GS; Jacobsen, SJ; Zinsmeister, AR; Yawn, BP; Kopecky, SL; Gabriel, SE			Sex differences in evaluation and outcome of unstable angina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; GENDER-RELATED DIFFERENCES; EMERGENCY ROOM; CHEST PAIN; CARDIAC PROCEDURES; BYPASS-SURGERY; BIAS; MANAGEMENT; MORTALITY	Context The existence of sex bias in the delivery of cardiac care is controversial,and little is known about the association between sex and delivery of care and outcomes at an early point in the diagnostic sequence, such as when patients present for the evaluation of chest pain. Objective To test the hypothesis that female sex is negatively associated with care delivered to and outcomes of persons diagnosed as having unstable angina. Design Inception population-based cohort study with an average of 6 years of follow-up. Setting Emergency departments (EDs) in Olmsted County, Minnesota. Patients A total of 2271 Olmsted County residents (1306 men and 965 women) who presented to the ED for the first time with symptoms meeting criteria for unstable angina between 1985 and 1992, Main Outcome Measures Use of cardiac procedures within 90 days of ED visit, overall mortality, and cardiac events (cardiac death, nonfatal myocardial infarction, nonfatal cardiac arrest, and congestive heart failure), com pared by sex and Agency for Health Care Policy and Research cardiovascular risk category (low, intermediate, or high). Results Women were older (P<.001), more likely to have a history of hypertension (P=.001), and less likely to present with typical angina (P=.004) than men. Men were more likely than women to undergo noninvasive cardiac tests (relative risk [RR], 1.27; 95% confidence interval [CI], 1.14-1.40) as well as invasive cardiac procedures (RR, 1.72; 95% CI, 1.51-1.97). After adjustment, male sex was associated with a 24% increase in the use of cardiac procedures. Survival of both men and women in the high and intermediate risk categories was significantly lower than expected per the general population (P<.001). Women had a worse outcome than men, but after multivariate adjustment, male sex was associated with a trend toward an increase in the risk of death (RR, 1.23; 95% CI, 0.99-1.54) and significantly associated with increased risk of cardiac events (RR, 1.21;95% CI, 1.03-1.42). Conclusions Our population-based data indicate that after an ED visit for symptoms of unstable angina, the use of cardiac procedures was lower in women, but after taking into account baseline characteristics, men experienced worse outcomes.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Epidemiol Sect, Rochester, MN 55905 USA; Olmsted Med Ctr, Dept Res, Rochester, MN USA; Mt Sinai Med Ctr, Cardiovasc Inst, Div Cardiol, New York, NY 10029 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Olmsted Medical Center; Icahn School of Medicine at Mount Sinai	Roger, VL (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.		Roger, Veronique/AAV-5951-2020	Jacobsen, Steven/0000-0002-8174-8533	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59205] Funding Source: Medline; NIAMS NIH HHS [AR30582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Braunwald E, 1994, UNSTABLE ANGINA DIAG; CHIRIBOGA DE, 1993, AM J CARDIOL, V71, P268, DOI 10.1016/0002-9149(93)90789-F; DEWINTER RJ, 1995, CIRCULATION, V92, P3401, DOI 10.1161/01.CIR.92.12.3401; FUNK M, 1994, AM J CARDIOL, V74, P1170, DOI 10.1016/0002-9149(94)90475-8; HACHAMOVITCH R, 1995, J AM COLL CARDIOL, V26, P1457, DOI 10.1016/0735-1097(95)00356-8; HANLEY PC, 1989, J AM COLL CARDIOL, V13, P624, DOI 10.1016/0735-1097(89)90603-7; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; HILTON TC, 1994, J AM COLL CARDIOL, V23, P1016, DOI 10.1016/0735-1097(94)90584-3; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; Karlson BW, 1996, CORONARY ARTERY DIS, V7, P231; KARLSON BW, 1993, CORONARY ARTERY DIS, V4, P761, DOI 10.1097/00019501-199309000-00002; Karlson BW, 1997, AM J EMERG MED, V15, P1, DOI 10.1016/S0735-6757(97)90038-3; Katz DA, 1996, JAMA-J AM MED ASSOC, V276, P1568; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; MAIR J, 1995, CHEST, V108, P1502, DOI 10.1378/chest.108.6.1502; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; Maynard C, 1996, CIRCULATION, V94, P93; MELTON LJ, 1985, MAYO CLIN PROC, V60, P880, DOI 10.1016/S0025-6196(12)64794-6; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; Roger VL, 1997, CIRCULATION, V95, P405; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; SHAW LJ, 1994, ANN INTERN MED, V120, P559, DOI 10.7326/0003-4819-120-7-199404010-00005; SKETCH MH, 1975, AM J CARDIOL, V36, P169, DOI 10.1016/0002-9149(75)90521-4; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; Stussman BJ, 1997, DHHS PUBLICATION; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; VARETTO T, 1993, J AM COLL CARDIOL, V22, P1804, DOI 10.1016/0735-1097(93)90761-O; WEINER DA, 1979, NEW ENGL J MED, V301, P230, DOI 10.1056/NEJM197908023010502	32	116	116	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					646	652		10.1001/jama.283.5.646	http://dx.doi.org/10.1001/jama.283.5.646			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665705	Bronze			2022-12-28	WOS:000084956500031
J	Rossi, DJ; Oshima, T; Attwell, D				Rossi, DJ; Oshima, T; Attwell, D			Glutamate release in severe brain ischaemia is mainly by reversed uptake	NATURE			English	Article							RAT HIPPOCAMPAL SLICES; METHYL-D-ASPARTATE; NEURONAL DEATH; IN-VITRO; ISCHEMIA; ACTIVATION; TRANSPORT; CALCIUM; ANOXIA; MECHANISMS	The release of glutamate during brain anoxia or ischaemia triggers the death of neurons', causing mental or physical handicap. The mechanism of glutamate release is controversial, however. Four release mechanisms have been postulated: vesicular release dependent on external calcium(2) or Ca(2+) released from intracellular stores(3); release through swelling-activated onion channels(4); an indomethacin-sensitive process in astrocytes(5-7); and reversed operation of glutamate transporters(8,9). Here we have mimicked severe ischaemia in hippocampal slices and monitored glutamate release as a receptor-gated current in the CA1 pyramidal cells that are killed preferentially in ischaemic hippocampus. Using blockers of the different release mechanisms, we demonstrate that glutamate release is largely by reversed operation of neuronal glutamate transporters, and that it plays a key role in generating the anoxic depolarization that abolishes information processing in the central nervous system a few minutes after the start of ischaemia. A mathematical model incorporating K(+) channels, reversible uptake carriers and NMDA (N-methyl-D-aspartate) receptor channels reproduces the main features of the response to ischaemia. Thus, transporter-mediated glutamate homeostasis fails dramatically in ischaemia: instead of removing extracellular glutamate to protect neurons, transporters release glutamate, triggering neuronal death.	UCL, Dept Physiol, London WC1E 6BT, England; Shionogi & Co Ltd, Toyonaka, Osaka 561, Japan	University of London; University College London; Shionogi & Company Limited	Attwell, D (corresponding author), UCL, Dept Physiol, Gower St, London WC1E 6BT, England.	D.Attwell@ucl.ac.uk	Attwell, David/ABE-6750-2020					ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Basarsky TA, 1999, J NEUROSCI, V19, P6439; BEDNAR M M, 1992, Neurological Research, V14, P53; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Billups B, 1996, NATURE, V379, P171, DOI 10.1038/379171a0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; FRIEDMAN JE, 1994, BRAIN RES, V663, P329, DOI 10.1016/0006-8993(94)91281-5; GUNDERSEN V, 1993, NEUROSCIENCE, V57, P97, DOI 10.1016/0306-4522(93)90114-U; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; JAHR CE, 1990, J NEUROSCI, V10, P3178; KATCHMAN AN, 1993, J NEUROPHYSIOL, V70, P1; LERMA J, 1992, MOL PHARMACOL, V41, P217; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; MADL JE, 1993, J NEUROSCI, V13, P4429; MCBAIN CJ, 1990, SCIENCE, V249, P674, DOI 10.1126/science.2382142; Nowicky AV, 1998, J PHYSIOL-LONDON, V507, P131, DOI 10.1111/j.1469-7793.1998.131bu.x; PARPURA V, 1909, NATURE, V28, P159; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; RALEY KM, 1990, NEUROSCI LETT, V110, P118, DOI 10.1016/0304-3940(90)90798-E; Roettger V, 1996, NEUROSCIENCE, V75, P677, DOI 10.1016/0306-4522(96)00314-4; SAH P, 1988, J GEN PHYSIOL, V92, P263, DOI 10.1085/jgp.92.2.263; SARANTIS M, 1993, NEURON, V11, P541, DOI 10.1016/0896-6273(93)90158-N; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; STORMMATHISEN J, 1992, PROG BRAIN RES, V94, P225; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; WALZ W, 1993, DEV NEUROSCI-BASEL, V15, P216, DOI 10.1159/000111337; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	30	870	909	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					316	321		10.1038/35002090	http://dx.doi.org/10.1038/35002090			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659851				2022-12-28	WOS:000084899700054
J	Yokouchi, Y; Noijiri, Y; Barrie, LA; Toom-Sauntry, D; Machida, T; Inuzuka, Y; Akimoto, H; Li, HJ; Fujinuma, Y; Aoki, S				Yokouchi, Y; Noijiri, Y; Barrie, LA; Toom-Sauntry, D; Machida, T; Inuzuka, Y; Akimoto, H; Li, HJ; Fujinuma, Y; Aoki, S			A strong source of methyl chloride to the atmosphere from tropical coastal land	NATURE			English	Article							SOUTH-ATLANTIC; BIOSYNTHESIS; HALOMETHANES; METHANETHIOL; HALIDES	Methyl chloride (CH3Cl), the most abundant halocarbon in the atmosphere, has received much attention as a natural source of chlorine :atoms in the stratosphere(1,2). The annual global flux of CH3Cl has been estimated to be around 3.5 Tg on the grounds that this must balance the loss through reaction with OH radicals (which gives a lifetime for atmospheric CH3Cl of 1.5 yr)(3-5), The most likely main source of methyl chloride has been thought to be oceanic emission(2,6-8), with biomass burning the second largest source(9). But recent seawater measurements(10) indicate that oceanic fluxes cannot account for more than 12% of the estimated global flux of CH3Cl, raising the question of where the remainder comes from. Here we report evidence of significant CH3Cl emission from warm coastal land, particularly from tropical islands. This conclusion is based on a global monitoring study and spot measurements, which show enhancement of atmospheric CH3Cl in the tropics, a close correlation between CH3Cl concentrations and those of biogenic compounds emitted by terrestrial plants, and OH-linked seasonality of CH3Cl concentrations in middle and high latitudes, A strong, equatorially located source of this nature would explain why the distribution of CH3Cl is uniform between the Northern and Southern hemispheres, despite their differences in ocean and land area.	Natl Inst Environm Studies, Tsukuba, Ibaraki 3050053, Japan; Atmospher Environm Serv, Toronto, ON M3H 5T4, Canada; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan; Tohoku Univ, Ctr Atmospher & Ocean Studies, Aoba Ku, Sendai, Miyagi 9800845, Japan	National Institute for Environmental Studies - Japan; Environment & Climate Change Canada; Meteorological Service of Canada; University of Tokyo; Tohoku University	Yokouchi, Y (corresponding author), Natl Inst Environm Studies, 16-2 Onogawa, Tsukuba, Ibaraki 3050053, Japan.		Machida, Toshinobu/H-6526-2018; 陽子, 横内/E-8041-2010; Nojiri, Yukihiro/D-1999-2010	Machida, Toshinobu/0000-0003-3312-8775; Nojiri, Yukihiro/0000-0001-9885-9195				ATLAS E, 1993, J GEOPHYS RES-ATMOS, V98, P16933, DOI 10.1029/93JD01005; ATTIEH JM, 1995, J BIOL CHEM, V270, P9250, DOI 10.1074/jbc.270.16.9250; Blake NJ, 1996, J GEOPHYS RES-ATMOS, V101, P24151, DOI 10.1029/96JD00561; CICERONE RJ, 1981, REV GEOPHYS, V19, P123, DOI 10.1029/RG019i001p00123; Fabian P., 1986, AIR POLLUTION, P23, DOI [10.1007/978-3-540-39222-4_2, DOI 10.1007/978-3-540-39222-4_2]; GRAEDEL TE, 1995, GLOBAL BIOGEOCHEM CY, V9, P47, DOI 10.1029/94GB03103; HARPER DB, 1985, NATURE, V315, P55, DOI 10.1038/315055a0; Khalil MAK, 1999, ATMOS ENVIRON, V33, P1305, DOI 10.1016/S1352-2310(98)00234-9; KOPPMANN R, 1993, J GEOPHYS RES-ATMOS, V98, P20517, DOI 10.1029/93JD01864; Li HJ, 1999, ATMOS ENVIRON, V33, P1881, DOI 10.1016/S1352-2310(98)00303-3; LOGAN JA, 1981, J GEOPHYS RES-OCEANS, V86, P7210, DOI 10.1029/JC086iC08p07210; Moore RM, 1996, J GEOPHYS RES-OCEANS, V101, P28529, DOI 10.1029/96JC02915; RASMUSSEN RA, 1980, J GEOPHYS RES-OCEANS, V85, P7350, DOI 10.1029/JC085iC12p07350; SAINI HS, 1995, PLANT CELL ENVIRON, V18, P1027, DOI 10.1111/j.1365-3040.1995.tb00613.x; SINGH HB, 1983, J GEOPHYS RES-OCEANS, V88, P3684, DOI 10.1029/JC088iC06p03684; Yokouchi Y, 1999, J GEOPHYS RES-ATMOS, V104, P8067, DOI 10.1029/1998JD100013; YOKOUCHI Y, 1981, J CHROMATOGR, V209, P293, DOI 10.1016/S0021-9673(00)81591-5; Zimmerman P. R., 1979, EPA450479004	18	115	120	2	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					295	298		10.1038/35002049	http://dx.doi.org/10.1038/35002049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659845				2022-12-28	WOS:000084899700048
J	Ramsay, S				Ramsay, S			Embryo splitting produces primate "clone"	LANCET			English	News Item																		Chan AWS, 2000, SCIENCE, V287, P317, DOI 10.1126/science.287.5451.317	1	0	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					205	205		10.1016/S0140-6736(00)00006-4	http://dx.doi.org/10.1016/S0140-6736(00)00006-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675128				2022-12-28	WOS:000084879700022
J	Gould, SJ				Gould, SJ			Deconstructing the "science wars" by reconstructing an old mold	SCIENCE			English	Article									Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA; NYU, New York, NY USA	Harvard University; New York University	Gould, SJ (corresponding author), Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA.							CHIOCCO A, 1622, MUSAEUM FC VERONENSI, P407; DARGENVILLE D, HIST NATURELLE ECLAI; DARWIN C, 1903, MORE LETT C DARWIN, V1, P195; DARWIN F, 1888, LIFE LETT C DARWIN I, V1, P83; DEPERET C, 1909, TRANSFORMATIONS ANIA, P4; DRAPERS JW, 1874, HIST CONFLICT SCI RE; GOULD SJ, 1990, RK MERTON CONSENSUS, P35; Gruber H., 1974, DARWIN MAN; MERTON Robert King, 1965, SHOULDERS GIANTS SHA; Snow C., 1959, 2 CULTURES SCI REVOL; WATS G, 1674, ADV PROFICIENCIE LEA, P17; WHITE AD, 1896, HIST WARFARE SCI THE; WORM O, 1655, MUSEUM WORMIANUM SEU, P84	13	46	46	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2000	287	5451					253	+		10.1126/science.287.5451.253	http://dx.doi.org/10.1126/science.287.5451.253			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10660425				2022-12-28	WOS:000084769600028
J	Garg, A; Radvan, J; Hopkinson, N				Garg, A; Radvan, J; Hopkinson, N			Clopidogrel associated with acute arthritis	BRITISH MEDICAL JOURNAL			English	Article									Royal Bournemouth Hosp, Dept Cardiol, Bournemouth BH8 8DH, Dorset, England		Garg, A (corresponding author), Royal Bournemouth Hosp, Dept Cardiol, Bournemouth BH8 8DH, Dorset, England.								0	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					483	483						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678862				2022-12-28	WOS:000085562200025
J	Hider, JD; Shehab, Z; Courteney-Harris, R				Hider, JD; Shehab, Z; Courteney-Harris, R			Effectiveness of modified release isosorbide mononitrate affected by incorrect use	BRITISH MEDICAL JOURNAL			English	Article									City Gen Hosp, Dept Ear Nose & Throat, Newcastle Under Lyme, Staffs, England		Hider, JD (corresponding author), City Gen Hosp, Dept Ear Nose & Throat, Newcastle Under Lyme, Staffs, England.								0	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					483	483		10.1136/bmj.320.7233.483	http://dx.doi.org/10.1136/bmj.320.7233.483			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678861	Bronze, Green Submitted			2022-12-28	WOS:000085562200024
J	Lovelady, CA; Garner, KE; Moreno, KL; Williams, JP				Lovelady, CA; Garner, KE; Moreno, KL; Williams, JP			The effect of weight loss in overweight, lactating women on the growth of their infants.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background: The retention of weight gained during pregnancy may contribute to obesity. Lactation should promote weight loss, but weight loss is highly variable among lactating women. The risks associated with the restriction of energy intake during lactation have not been adequately evaluated. The purpose of this study was to determine whether weight loss by women during lactation affects the growth of their infants. Methods: We randomly assigned 40 breast-feeding women who were overweight (defined as a body-mass index [the weight in kilograms divided by the square of the height in meters] of 25 to 30) at 4 weeks post partum either to restrict their energy intake by 500 kcal per day and to exercise for 45 minutes per day for 4 days per week (the diet-and-exercise group) or to maintain their usual dietary intake and not exercise more than once per week for 10 weeks (the control group). We measured the weight and fat mass of the women and the weight and length of the infants before, during, and at the end of the study period. Results: The mean (+/-SD) energy intake decreased by 544+/-471 kcal per day in the diet-and-exercise group. As compared with the control group, the women in the diet-and-exercise group lost more weight (4.8+/-1.7 kg vs. 0.8+/-2.3 kg, P<0.001) and fat mass (4.0+/-2.0 kg vs. 0.3+/-1.8 kg, P<0.001). The gains in weight and length of the infants whose mothers were in the diet-and-exercise group (1925+/-500 g and 7.8+/-2.0 cm, respectively) were not significantly different from those of the infants whose mothers were in the control group (1861+/-576 g and 7.3+/-1.7 cm). Conclusions: Weight loss of approximately 0.5 kg per week between 4 and 14 weeks post partum in overweight women who are exclusively breast-feeding does not affect the growth of their infants. (N Engl J Med 2000;342:449-53.) (C)2000, Massachusetts Medical Society.	Univ N Carolina, Dept Nutr & Foodserv Syst, Greensboro, NC 27402 USA	University of North Carolina; University of North Carolina Greensboro	Lovelady, CA (corresponding author), Univ N Carolina, Dept Nutr & Foodserv Syst, POB 26170, Greensboro, NC 27402 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R15HD034222] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 34222] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		*AM COLL SPORT MED, 1993, ACSMS RES MAN GUID E; *AM COLL SPORTS ME, 1995, ACSMS GUID EX TEST P; [Anonymous], 1991, NUTR LACTATION; BROZEK J, 1963, ANN NY ACAD SCI, V110, P113, DOI 10.1111/j.1749-6632.1963.tb17079.x; Butte NF, 1998, J NUTR, V128, p381S, DOI 10.1093/jn/128.2.381S; Daniel WW, 1987, BIOSTATISTICS FDN AN, V4; DUSDIEKER LB, 1994, AM J CLIN NUTR, V59, P833, DOI 10.1093/ajcn/59.4.833; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Harris J. A., 1919, PUBLICATION CARNEGIE, V279; Lohman T. G., 1988, ANTHROPOMETRIC STAND, V3, p[3, 43]; McCrory MA, 1999, AM J CLIN NUTR, V69, P959; National Research Council Subcommittee on the Tenth Edition of the Recommended Dietary Allowances, 1989, REC DIET ALL, V10th; NELSON SE, 1989, EARLY HUM DEV, V19, P223, DOI 10.1016/0378-3782(89)90057-1; Pennington JA, 1994, BOWES CHURCHS FOOD V; *SPSS, 1998, SPSS PC SOFTW VERS 8; STRODE MA, 1986, ACTA PAEDIATR SCAND, V75, P222, DOI 10.1111/j.1651-2227.1986.tb10188.x; *WHO WORK GROUP IN, 1994, EV INF GROWTH SUMM A, P165; WILMORE JH, 1969, J APPL PHYSIOL, V27, P96, DOI 10.1152/jappl.1969.27.1.96	18	132	141	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2000	342	7					449	453		10.1056/NEJM200002173420701	http://dx.doi.org/10.1056/NEJM200002173420701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284FA	10675424	Bronze			2022-12-28	WOS:000085319100001
J	El-Serag, HB; Inadomi, JM; Kowdley, KV				El-Serag, HB; Inadomi, JM; Kowdley, KV			Screening for hereditary hemochromatosis in siblings and children of affected patients - A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article						genetic screening; hemochromatosis; cost-benefit analysis; transferrin; ferritin	IDIOPATHIC HEMOCHROMATOSIS; GENETIC HEMOCHROMATOSIS; HLA-H; DIAGNOSIS; SURVIVAL; MUTATION	Background: Screening for hereditary hemochromatosis is traditionally done by using serum iron studies. However, mutation analysis of the hemochromatosis-associated HFE gene has recently become available. Objective: To compare the cost-effectiveness of no screening with four screening strategies that incorporate HFE gene testing or serum iron studies. Design: Cost-effectiveness analysis. Data Sources: Published literature. Target Population: Siblings and children of an affected proband. Time Horizon: Lifetime from 10 years of age (children) or 45 years of age (siblings). Perspective: Societal. Intervention: 1) Serum iron studies. 2) Gene testing of the proband. If the proband is homozygous (C282Y+/+), the spouse undergoes gene testing; if he or she is heterozygous (C282Y+/-), the children undergo gene testing. 3) Gene testing of the proband; if he or she is homozygous, relatives undergo gene testing. 4) Direct gene testing of relatives. Outcome Measures: Cost per life-year saved and incremental cost-effectiveness ratio. Results of Base-Case Analysis: In children, HFE gene testing of the proband was the most cost-effective strategy for screening one child (incremental cost-effectiveness ratio, $508 per life-year saved). HFE gene testing of the proband followed by testing of the spouse was the most cost-effective strategy for screening two or more children (incremental cost-effectiveness ratio, $3665 per life-year saved). In siblings, all screening strategies were dominant compared with no screening. Strategies using HFE gene testing were less costly than serum iron studies. Results of Sensitivity Analysis: Despite varying the prevalence of mutations and regardless of the cost of the genetic test in one- and two-way sensitivity analyses, HFE gene testing remained cost-effective. Conclusions: HFE gene testing for the C282Y mutation is a cost-effective method of screening relatives of patients With hereditary hemochromatosis.	Vet Affairs Med Ctr, Div Gastroenterol, Ann Arbor, MI 48105 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Michigan, Med Ctr, Ann Arbor, MI USA; Univ Washington, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; University of Michigan System; University of Michigan; University of Washington; University of Washington Seattle	Inadomi, JM (corresponding author), Vet Affairs Med Ctr, Div Gastroenterol, 2215 Fuller Rd 111-D, Ann Arbor, MI 48105 USA.	jinadomi@umich.edu	Inadomi, John/A-6221-2014; Kowdley, Kris/AAF-5202-2019	Inadomi, John/0000-0001-6776-8661; 				Adams PC, 1995, HEPATOLOGY, V22, P1720, DOI 10.1016/0270-9139(95)90197-3; Adams PC, 1998, CLIN GENET, V53, P176; ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; Adams PC, 1999, AM J GASTROENTEROL, V94, P1593; Adams PC, 1999, HEPATOLOGY, V29, P1324, DOI 10.1002/hep.510290425; Adams PC, 1998, GASTROENTEROLOGY, V114, P319, DOI 10.1016/S0016-5085(98)70483-4; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; ADAMS PC, 1992, DIGEST DIS SCI, V37, P361, DOI 10.1007/BF01307728; Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; Barton JC, 1998, ANN INTERN MED, V129, P932, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00003; BASSETT ML, 1984, GASTROENTEROLOGY, V87, P628; BASSETT ML, 1982, HUM GENET, V60, P352, DOI 10.1007/BF00569217; Bennett WG, 1997, ANN INTERN MED, V127, P855, DOI 10.7326/0003-4819-127-10-199711150-00001; BEUTLER E, 1995, BLOOD CELL MOL DIS, V22, P187; BLUMBERG RS, 1988, GASTROENTEROLOGY, V95, P1399, DOI 10.1016/0016-5085(88)90379-4; Bulaj ZJ, 1996, NEW ENGL J MED, V335, P1799, DOI 10.1056/NEJM199612123352403; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Carella M, 1997, AM J HUM GENET, V60, P828; Crawford DHG, 1998, GASTROENTEROLOGY, V114, P1003, DOI 10.1016/S0016-5085(98)70320-8; EDWARDS CQ, 1977, NEW ENGL J MED, V297, P7, DOI 10.1056/NEJM197707072970102; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GOLD MR, 1996, COST EFFECTIVENESS H, P27; Inadomi J, 1997, GASTROENTEROLOGY, V113, P1289, DOI 10.1053/gast.1997.v113.pm9322524; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; KIRSCHNER CG, 1994, PHYSICIANS CURRENT P; MOLRAND R, 1999, GASTROENTEROLOGY, V116, P372; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; Powell LW, 1996, SEMIN LIVER DIS, V16, P55, DOI 10.1055/s-2007-1007219; Powell LW, 1998, ANN INTERN MED, V129, P925, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00002; POWELL LW, 1986, HEPATOLOGY, V6, P1423, DOI 10.1002/hep.1840060636; Robson KJH, 1997, GUT, V41, P841; Smith BN, 1997, HEPATOLOGY, V25, P1439, DOI 10.1002/hep.510250622; Weinstein MC, 1980, CLIN DECISION ANAL, P92; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Wong LL, 1997, ARCH INTERN MED, V157, P1429, DOI 10.1001/archinte.157.13.1429	38	55	57	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2000	132	4					261	+		10.7326/0003-4819-132-4-200002150-00003	http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285CY	10681280				2022-12-28	WOS:000085372900002
J	Goldberg, D				Goldberg, D			MMR, autism, and Adam	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					389	389		10.1136/bmj.320.7231.389	http://dx.doi.org/10.1136/bmj.320.7231.389			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657358	Green Published			2022-12-28	WOS:000085211400076
J	Saether, BE; Tufto, J; Engen, S; Jerstad, K; Rostad, OW; Skatan, JE				Saether, BE; Tufto, J; Engen, S; Jerstad, K; Rostad, OW; Skatan, JE			Population dynamical consequences of climate change for a small temperate songbird	SCIENCE			English	Article							NORTH-ATLANTIC OSCILLATION; ENVIRONMENTAL STOCHASTICITY	Predicting the effects of an expected climatic change requires estimates and modeling of stochastic factors as well as density-dependent effects in the population dynamics. In a population of a small songbird, the dipper (Cinclus cinclus), environmental stochasticity and density dependence both influenced the population growth rate. About half of the environmental variance was explained by variation in mean winter temperature. Including these results in a stochastic model shows that an expected change In climate will strongly affect the dynamics of the population, Leading to a nonlinear increase in the carrying capacity and in the expected mean population size.	Norwegian Univ Sci & Technol, Dept Zool, N-7491 Trondheim, Norway; Norwegian Univ Sci & Technol, Dept Math Sci, N-7491 Trondheim, Norway; Aurebekk, N-4500 Mandal, Norway; Agr Univ Norway, Dept Biol & Nat Conservat, N-1432 As, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Life Sciences	Saether, BE (corresponding author), Norwegian Univ Sci & Technol, Dept Zool, N-7491 Trondheim, Norway.	Bernt-Erik.Sathere@chembio.ntnu.no	Tufto, Jarle/I-4817-2013					ATHREYA KB, 1971, ANN MATH STAT, V42, P1499, DOI 10.1214/aoms/1177693150; Bartlett MS., 1960, STOCHASTIC POPULATIO; Berger J.O., 1995, STAT DECISION THEORY, V2nd ed; Bjornstad ON, 1999, TRENDS ECOL EVOL, V14, P427, DOI 10.1016/S0169-5347(99)01677-8; Chatfield C., 2016, ANAL TIME SERIES INT; Corti S, 1999, NATURE, V398, P799, DOI 10.1038/19745; Crick HQP, 1997, NATURE, V388, P526, DOI 10.1038/41453; DUNHAM AE, 1993, BIOTIC INTERACTIONS AND GLOBAL CHANGE, P95; Engen S, 1998, OIKOS, V83, P345, DOI 10.2307/3546848; Forchhammer MC, 1998, NATURE, V391, P29, DOI 10.1038/34070; Gilks W. R., 1996, MARKOV CHAIN MONTE C, P1, DOI DOI 10.1201/B14835; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Hurrell JW, 1997, CLIMATIC CHANGE, V36, P301, DOI 10.1023/A:1005314315270; Intergovernmental Panel on Climate Change, 1996, CLIM CHANG 1995 SCI; IVES AR, 1993, BIOTIC INTERACTIONS AND GLOBAL CHANGE, P120; LAMB PJ, 1987, B AM METEOROL SOC, V68, P1218, DOI 10.1175/1520-0477(1987)068<1218:NAOCAA>2.0.CO;2; Lande R, 1999, AM NAT, V154, P271, DOI 10.1086/303240; Lande R, 1998, OIKOS, V83, P353, DOI 10.2307/3546849; MAY RM, 1973, AM NAT, V107, P621, DOI 10.1086/282863; McCleery RH, 1998, NATURE, V391, P30, DOI 10.1038/34073; Newton I., 1998, POPULATION LIMITATIO; ORMEROD SJ, 1994, DIPPERS; Post E, 1999, ECOLOGY, V80, P1322, DOI 10.1890/0012-9658(1999)080[1322:CVPPAN]2.0.CO;2; Ranta E, 1998, ENVIRONM INTELL UNIT, P47; ROGERS JC, 1984, MON WEATHER REV, V112, P1999, DOI 10.1175/1520-0493(1984)112<1999:TABTNA>2.0.CO;2; Saether BE, 1997, TRENDS ECOL EVOL, V12, P143, DOI 10.1016/S0169-5347(96)10068-9; Saether BE, 1998, AM NAT, V151, P441, DOI 10.1086/286131; SCHLESINGER ME, 1994, NATURE, V367, P723, DOI 10.1038/367723a0; Shindell DT, 1999, NATURE, V399, P452, DOI 10.1038/20905; Solbreck Christer, 1995, P279, DOI 10.1016/B978-012159270-7/50015-4; SPIEGELHALTER DJ, 1996, BUGS 5 0 BAYESIAN IN; Tufto J, 2000, OIKOS, V88, P273, DOI 10.1034/j.1600-0706.2000.880205.x; Turchin Peter, 1995, P19, DOI 10.1016/B978-012159270-7/50003-8	33	252	256	1	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2000	287	5454					854	856		10.1126/science.287.5454.854	http://dx.doi.org/10.1126/science.287.5454.854			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657299				2022-12-28	WOS:000085136400046
J	Chen, CK; Burns, ME; He, W; Wensel, TG; Baylor, DA; Simon, MI				Chen, CK; Burns, ME; He, W; Wensel, TG; Baylor, DA; Simon, MI			Slowed recovery of rod photoresponse in mice lacking the GTPase accelerating protein RGS9-1	NATURE			English	Article							PHOTORECEPTOR G-PROTEIN; CGMP PHOSPHODIESTERASE; TARGET ENZYME; GAMMA-SUBUNIT; RETINAL RODS; TRANSDUCIN; PHOTOTRANSDUCTION; DEACTIVATION; ACTIVATION; EXPRESSION	Timely deactivation of the alpha-subunit of the rod G-protein transducin (G alpha t) is essential for the temporal resolution of rod vision(1). Regulators of G-protein signalling (RGS) proteins accelerate hydrolysis of GTP by the alpha-subunits of heterotrimeric G proteins(2-4) in vitro. Several retinal RGS proteins can act in vitro as GTPase accelerating proteins (GAP) for G alpha t(5-8). Recent reconstitution experiments indicate that one of these, RGS9-1, may account for much of the G alpha t GAP activity in rod outer segments (ROS)(8,9). Here we report that ROS membranes from mice lacking RGS9-1 hydrolyse GTP more slowly than ROS membranes from control mice. The G beta 5-L protein that forms a complex with RGS9-1 (ref. 10) was absent from RGS9(-/-) retinas, although G beta 5-L messenger RNA was still present. The flash responses of RGS9(-/-) rods rose normally, but recovered much more slowly than normal. We conclude that RGS9-1, probably in a complex with G beta 5-L, is essential for acceleration of hydrolysis of GTP by G alpha t and for normal recovery of the photoresponse.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Stanford Univ, Med Ctr, Dept Neurobiol, Stanford, CA 94305 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA	California Institute of Technology; Stanford University; Baylor College of Medicine	Simon, MI (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.			Wensel, Theodore/0000-0003-3518-9352				ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; Makino CL, 1998, PHOTOSTASIS AND RELATED PHENOMENA, P129; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; PAGES F, 1992, J BIOL CHEM, V267, P22018; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rieke F, 1998, REV MOD PHYS, V70, P1027, DOI 10.1103/RevModPhys.70.1027; Sagoo MS, 1997, NATURE, V389, P392, DOI 10.1038/38750; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; Wieland T, 1997, J BIOL CHEM, V272, P8853; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068	30	315	320	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					557	560		10.1038/35000601	http://dx.doi.org/10.1038/35000601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676965				2022-12-28	WOS:000085227300053
J	Koide, S; Huang, XL; Link, K; Koide, A; Bu, ZM; Engelman, DM				Koide, S; Huang, XL; Link, K; Koide, A; Bu, ZM; Engelman, DM			Design of single-layer beta-sheets without a hydrophobic core	NATURE			English	Article							ROTATIONAL DIFFUSION ANISOTROPY; HETERONUCLEAR NMR-SPECTROSCOPY; BORRELIA-BURGDORFERI OSPA; PROTEIN DESIGN; STRUCTURAL CHARACTERIZATION; BACKBONE DYNAMICS; RELAXATION; N-15; SCATTERING; DOMAIN	The hydrophobic effect is the main thermodynamic driving force in the folding of water-soluble proteins(1,2), Exclusion of nonpolar moieties from aqueous solvent results in the formation of a hydrophobic core in a protein, which has been generally considered essential for specifying and stabilizing the folded structures of proteins(1-6). Outer surface protein A (OspA) from Borrelia burgdorferi contains a three-stranded beta-sheet segment which connects two globular domains(7). Although this single-layer beta- sheet segment is exposed to solvent on both faces and thus does not contain a hydrophobic core, the segment has a high conformational stability(8), Here we report the engineering of OspA variants that contain larger single-layer beta-sheets (comprising five and seven beta-strands) by duplicating a beta-hairpin unit within the beta-sheet, Nuclear magnetic resonance and small-angle X-ray scattering analyses reveal that these extended single-layer beta-sheets are formed as designed, and amide hydrogen-deuterium exchange and chemical denaturation show that they are stable. Thus, interactions within the beta-hairpin unit and those between adjacent units, which do not involve the formation of a hydrophobic core, are sufficient to specify and stabilize the single-layer beta-sheet structure. Our results provide an expanded view of protein folding, misfolding and design.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA	University of Rochester; Yale University	Koide, S (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.							Beasley JR, 1997, J BIOL CHEM, V272, P2031, DOI 10.1074/jbc.272.4.2031; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Bu ZM, 1998, PROTEIN SCI, V7, P2681, DOI 10.1002/pro.5560071223; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; Kataoka M, 1997, PROTEIN SCI, V6, P422; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Koepf EK, 1999, PROTEIN SCI, V8, P841, DOI 10.1110/ps.8.4.841; Koide S, 1999, BIOCHEMISTRY-US, V38, P4757, DOI 10.1021/bi982443+; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lacroix E, 1999, CURR OPIN STRUC BIOL, V9, P487, DOI 10.1016/S0959-440X(99)80069-4; LATTMAN EE, 1994, CURR OPIN STRUC BIOL, V4, P87, DOI 10.1016/S0959-440X(94)90064-7; Lee LK, 1997, J BIOMOL NMR, V9, P287, DOI 10.1023/A:1018631009583; Li H, 1997, P NATL ACAD SCI USA, V94, P3584, DOI 10.1073/pnas.94.8.3584; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Pham TN, 1998, NAT STRUCT BIOL, V5, P115, DOI 10.1038/nsb0298-115; Pham TN, 1998, J BIOMOL NMR, V11, P407, DOI 10.1023/A:1008246908142; Tjandra N, 1997, NAT STRUCT BIOL, V4, P443, DOI 10.1038/nsb0697-443; WISCHART DS, 1994, J BIOMOL NMR, V4, P171	30	47	49	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					456	460		10.1038/35000255	http://dx.doi.org/10.1038/35000255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667801				2022-12-28	WOS:000085121100057
J	Sun, LF; Xie, SS; Liu, W; Zhou, WY; Liu, ZQ; Tang, DS; Wang, G; Qian, LX				Sun, LF; Xie, SS; Liu, W; Zhou, WY; Liu, ZQ; Tang, DS; Wang, G; Qian, LX			Materials - Creating the narrowest carbon nanotubes	NATURE			English	Article									Chinese Acad Sci, Inst Phys, Ctr Condensed Matter Phys, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Physics, CAS	Sun, LF (corresponding author), Chinese Acad Sci, Inst Phys, Ctr Condensed Matter Phys, POB 603, Beijing 100080, Peoples R China.							AJAYAN PM, 1992, NATURE, V358, P23, DOI 10.1038/358023a0; Chang BH, 1998, SCI CHINA SER A, V41, P431, DOI 10.1007/BF02879035; Endo M., 1996, CARBON NANOTUBES; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Piskoti C, 1998, NATURE, V393, P771, DOI 10.1038/31668; SAITO R, 1992, APPL PHYS LETT, V60, P2204, DOI 10.1063/1.107080; SAWADA S, 1992, SOLID STATE COMMUN, V83, P917, DOI 10.1016/0038-1098(92)90911-R	7	136	153	4	77	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					384	384		10.1038/35000290	http://dx.doi.org/10.1038/35000290			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667781	Bronze			2022-12-28	WOS:000085121100037
J	Singh, AJ; Garner, P; Floyd, K				Singh, AJ; Garner, P; Floyd, K			Cost-effectiveness of public-funded options for cataract surgery in Mysore, India	LANCET			English	Article							INTRAOCULAR-LENS IMPLANTATION; OF-LIFE OUTCOMES; VISUAL-ACUITY; EXTRACTION; NEPAL; COMPLICATIONS; BLINDNESS	Background In India 3.8 million people become blind due to cataracts every year. We assessed the cost-effectiveness of public-funded options for delivering cataract surgery in Mysore, Karnataka State, India. Methods Three types of delivery of cataract surgery were studied: mobile government camps, walk-in services at a state medical college hospital, and patients transported in from satellite clinics to a non-governmental hospital. We assessed outcomes in a systematic sample of patients operated on in 1996-97 by follow-up at home; average costs by provider derived from actual expenditures during the year. Findings Almost half the patients operated on in government camps were dissatisfied with the outcome (34/70, 49% [95% CI 36-61]), More than one third were blind in the operated eye (25/70, 36% [25-48]), User satisfaction was higher with other providers (medical college hospital 82% [63-94]; nongovernment hospital 85% [72-93]), and fewer patients remained blind, Camps were a low-cost option, but the poor outcomes reduced their cost-effectiveness to US$97 per patient. The state medical college hospital was least cost-effective, at US$176 per patient, and the non-governmental hospital was the most cost-effective at US$54 per patient. Interpretation The government of India should review its policy for government camp surgery, and consider alternatives, such as transporting patients to better permanent facilities. India and other developing countries should monitor outcomes in cataract surgery programmes, as well as throughput.	Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool	Singh, AJ (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.	a.j.singh@liv.ac.uk	Garner, Paul/Y-8385-2019; Garner, Paul/HII-5856-2022	Garner, Paul/0000-0002-0607-6941; 				ALFARAN MF, 1990, BRIT J OPHTHALMOL, V74, P141, DOI 10.1136/bjo.74.3.141; BOHAN M, 1992, SURVEY BLINDNESS IND; Cook NJ, 1996, BRIT J OPHTHALMOL, V80, P698, DOI 10.1136/bjo.80.8.698; Dandona L, 1999, AM J OPHTHALMOL, V127, P650, DOI 10.1016/S0002-9394(99)00044-6; Dandona L, 1998, LANCET, V351, P1312, DOI 10.1016/S0140-6736(97)09509-3; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Drummond MF, 2015, METHODS EC EVALUATIO; EGBERT PR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1764, DOI 10.1001/archopht.1991.01080120148046; Gold MR, 1996, COST EFFECTIVENESS H; HENNIG A, 1992, ACTA OPHTHALMOL, V70, P402; HOGEWEG M, 1992, ACTA OPHTHALMOL, V70, P407; JOSE R, 1997, INDIAN J COMMUNITY H, V3, P5; Kapoor H, 1999, BRIT J OPHTHALMOL, V83, P343, DOI 10.1136/bjo.83.3.343; Limburg H, 1999, B WORLD HEALTH ORGAN, V77, P455; Marseille E, 1996, B WORLD HEALTH ORGAN, V74, P319; MINASSIAN DC, 1990, BRIT J OPHTHALMOL, V74, P341, DOI 10.1136/bjo.74.6.341; Murthy GVS, 1996, ACTA OPHTHALMOL SCAN, V74, P60; MURTHY GVS, 1995, J TROP MED HYG, V98, P84; Pararajasegaram R, 1999, AM J OPHTHALMOL, V128, P359; Pokharel GP, 1998, BRIT J OPHTHALMOL, V82, P606, DOI 10.1136/bjo.82.6.606; POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P239, DOI 10.1001/archopht.1994.01090140115033; Prajna  NV, 1998, AM J OPHTHALMOL, V125, P14, DOI 10.1016/S0002-9394(99)80230-X; REIDY A, 1991, BRIT J OPHTHALMOL, V75, P102, DOI 10.1136/bjo.75.2.102; Salem MA, 1987, BR J OPHTHALMOL, V71, P458; SNELLINGEN T, 1995, BRIT J OPHTHALMOL, V79, P1029; Thylefors B, 1996, B WORLD HEALTH ORGAN, V74, P319; Verma L, 1996, TROP MED INT HEALTH, V1, P342, DOI 10.1046/j.1365-3156.1996.d01-45.x; *WORLD BANK, 1994, CAT BLINDN CONTR PRO; Zhao JL, 1998, AM J OPHTHALMOL, V126, P515, DOI 10.1016/S0002-9394(98)00274-8	29	49	51	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2000	355	9199					180	184		10.1016/S0140-6736(99)07430-9	http://dx.doi.org/10.1016/S0140-6736(99)07430-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675117				2022-12-28	WOS:000084879700011
J	Mani, SK; Fienberg, AA; O'Callaghan, JP; Snyder, GL; Allen, PB; Dash, PK; Moore, AN; Mitchell, AJ; Bibb, J; Greengard, P; O'Malley, BW				Mani, SK; Fienberg, AA; O'Callaghan, JP; Snyder, GL; Allen, PB; Dash, PK; Moore, AN; Mitchell, AJ; Bibb, J; Greengard, P; O'Malley, BW			Requirement for DARPP-32 in progesterone-facilitated sexual receptivity in female rats and mice	SCIENCE			English	Article							REGULATED NEURONAL PHOSPHOPROTEIN; CYCLIC-AMP; PROTEIN PHOSPHATASE-1; OVARIECTOMIZED RATS; DOPAMINE; BEHAVIOR; RECEPTOR; PHOSPHORYLATION; ACTIVATION; LORDOSIS	DARPP-32, a dopamine- and adenosine 3',5'-monophosphate (cAMP)-regulated phosphoprotein (32 kilodaltons in size), is an obligate intermediate in progesterone (P)-facilitated sexual receptivity in female rats and mice. The facilitative effect of P on sexual receptivity in female rats was blocked by antisense oligonucleotides to DARPP-32. Homozygous mice carrying a null mutation for the DARPP-32 gene exhibited minimal levels of P-facilitated sexual receptivity when compared to their wild-type Littermates. P significantly increased hypothalamic cAMP levels and cAMP-dependent protein kinase activity. These increases were not inhibited by a D-1 subclass dopamine receptor antagonist. P also enhanced phosphorylation of DARPP-32 on threonine 34 in the hypothalamus of mice. DARPP-32 activation is thus an obligatory step in progestin receptor regulation of sexual receptivity in rats and mice.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA	Baylor College of Medicine; Rockefeller University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University of Texas System	Mani, SK (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	smani@bcm.tmc.edu	O'Callaghan, James/O-2958-2013		NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH057442, R01MH057442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035457] Funding Source: NIH RePORTER; NIMH NIH HHS [MH49662, MH57442] Funding Source: Medline; NINDS NIH HHS [NS 35457] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN PB, UNPUB; Apostolakis EM, 1996, J NEUROSCI, V16, P4823; BEYER C, 1986, ANN NY ACAD SCI, V474, P270, DOI 10.1111/j.1749-6632.1986.tb28018.x; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Greengard P, 1998, BRAIN RES REV, V26, P274, DOI 10.1016/S0165-0173(97)00057-X; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; KIMURA F, 1980, ENDOCRINOLOGY, V106, P631, DOI 10.1210/endo-106-2-631; Kohlert JG, 1997, HORM BEHAV, V32, P143, DOI 10.1006/hbeh.1997.1415; Kow L, 1994, NEUROSCI BIOBEHAV R, V18, P1; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANI SK, 1994, ENDOCRINOLOGY, V135, P1409, DOI 10.1210/en.135.4.1409; MANI SK, 1994, SCIENCE, V265, P1246, DOI 10.1126/science.7915049; Mani SK, 1996, MOL ENDOCRINOL, V10, P1728, DOI 10.1210/me.10.12.1728; Meredith JM, 1998, J NEUROSCI, V18, P10189; Moore AN, 1996, J BIOL CHEM, V271, P14214, DOI 10.1074/jbc.271.24.14214; Nairn A C, 1992, Curr Opin Neurobiol, V2, P296, DOI 10.1016/0959-4388(92)90118-5; Nishi A, 1997, J NEUROSCI, V17, P8147; OCALLAGHAN JP, 1983, BRAIN RES BULL, V11, P31, DOI 10.1016/0361-9230(83)90054-0; OGAWA S, 1994, J NEUROSCI, V14, P1766, DOI 10.1523/JNEUROSCI.14-03-01766.1994; POLLIO G, 1993, MOL BRAIN RES, V19, P135, DOI 10.1016/0169-328X(93)90158-L; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Roberson ED, 1996, J BIOL CHEM, V271, P30436, DOI 10.1074/jbc.271.48.30436; SNYDER GL, 1994, J NEUROCHEM, V63, P1766; VATHY I, 1989, J NEUROENDOCRINOL, V1, P383, DOI 10.1111/j.1365-2826.1989.tb00133.x; WHALEN RE, 1986, NEUROSCI BIOBEHAV R, V10, P47, DOI 10.1016/0149-7634(86)90032-1; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; WISE PM, 1981, ENDOCRINOLOGY, V108, P2186, DOI 10.1210/endo-108-6-2186	29	105	130	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2000	287	5455					1053	1056		10.1126/science.287.5455.1053	http://dx.doi.org/10.1126/science.287.5455.1053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669419				2022-12-28	WOS:000085245400051
J	Hoffman, GR; Nassar, N; Cerione, RA				Hoffman, GR; Nassar, N; Cerione, RA			Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI	CELL			English	Article							GDP-DISSOCIATION INHIBITOR; GUANINE-NUCLEOTIDE EXCHANGE; CRYSTAL-STRUCTURE; RAS; GTPASES; PROGRAM; DOMAIN; CYTOSKELETON; ACTIVATION; ANALOG	The RhoGDI proteins serve as key multifunctional regulators of Rho family GTP-binding proteins. The 2.6 Angstrom X-ray crystallographic structure of the Cdc42/RhoGDI complex reveals two important sites of interaction between GDI and Cdc42. First, the amino-terminal regulatory arm of the GDI binds to the switch I and II domains of Cdc42 leading to the inhibition of both GDP dissociation and GTP hydrolysis. Second, the geranylgeranyl moiety of Cdc42 inserts into a hydrophobic pocket within the immunoglobulin-like domain of the GDI molecule leading to membrane release. The structural data demonstrate how GDIs serve as negative regulators of small GTP-binding proteins and how the isoprenoid moeity is utilized in this critical regulatory interaction.	Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Cerione, RA (corresponding author), Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01646] Funding Source: Medline; NEI NIH HHS [EY-06429] Funding Source: Medline; NIGMS NIH HHS [GM-47458] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Gillilan R. E., 1995, Computer Graphics, V29, P55, DOI 10.1145/204362.204376; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; HORI Y, 1991, ONCOGENE, V6, P515; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Longenecker K, 1999, ACTA CRYSTALLOGR D, V55, P1503, DOI 10.1107/S090744499900801X; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Nomanbhoy TK, 1999, BIOCHEMISTRY-US, V38, P1744, DOI 10.1021/bi982198u; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; PLATKO JV, 1995, P NATL ACAD SCI USA, V92, P2974, DOI 10.1073/pnas.92.7.2974; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Wu WJ, 1997, J BIOL CHEM, V272, P26153, DOI 10.1074/jbc.272.42.26153	40	411	420	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					345	356		10.1016/S0092-8674(00)80670-4	http://dx.doi.org/10.1016/S0092-8674(00)80670-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676816	Bronze			2022-12-28	WOS:000085204400008
J	Richens, J; Imrie, J; Copas, A				Richens, J; Imrie, J; Copas, A			Condoms and seat belts: the parallels and the lessons	LANCET			English	Editorial Material							BEHAVIORAL INTERVENTIONS; HIV-INFECTION; LEGISLATION; THAILAND; MEN; PREVENTION; DECLINE; SEX; GAY		UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, Mortimer Market Ctr, London WC1E 6AU, England	University of London; University College London; UCL Medical School	Richens, J (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, Mortimer Market Ctr, Mortimer Market, London WC1E 6AU, England.	jrichens@gum.ucl.ac.uk	Richens, John/C-1876-2008	Copas, Andrew/0000-0001-8968-5963				Adams J., 1995, RISK, V1st ed.; Adams J., 1985, RISK FREEDOM RECORD; ADAMS JGU, 1994, SAFETY SCI, V18, P135, DOI 10.1016/0925-7535(94)90022-1; Aral SO, 1998, LANCET, V351, P33; Aral SO, 1996, INT J STD AIDS, V7, P30, DOI 10.1258/0956462961917753; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; Brody S, 1996, NEW ENGL J MED, V335, P1998, DOI 10.1056/NEJM199612263352614; COHEN DA, 1992, SEX TRANSM DIS, V19, P245, DOI 10.1097/00007435-199209000-00002; Dilley JW, 1997, NEW ENGL J MED, V337, P501, DOI 10.1056/NEJM199708143370715; Evans L., 1991, TRAFFIC SAFETY DRIVE; HARVEY AC, 1986, J ROY STAT SOC A STA, V149, P187, DOI 10.2307/2981553; Hopperus Buma A. P. C. C., 1995, Genitourinary Medicine, V71, P172; Janssen W, 1991, 1991C15 IZF TNO I PE; Kalichman SC, 1998, AM J PREV MED, V15, P120, DOI 10.1016/S0749-3797(98)00037-3; Kelly JA, 1998, AIDS, V12, pF91, DOI 10.1097/00002030-199810000-00001; MCCARTHY M, 1989, J EPIDEMIOL COMMUN H, V43, P218, DOI 10.1136/jech.43.3.218; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; Organization for Economic Cooperation and Development, 1990, BEH AD CHANG ROAD TR; OTTEN MW, 1993, AM J PUBLIC HEALTH, V83, P529, DOI 10.2105/AJPH.83.4.529; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; Rothenberg RB, 1998, AIDS, V12, P2095, DOI 10.1097/00002030-199816000-00004; SHRADERFRESHETT.KS, 1990, RISK HLTH SAFETY ENV, V1, P34; Smeed R. J., 1970, TRAFFIC ENG CONTROL, V12, P150; Wasserheit JN, 1996, J INFECT DIS, V174, pS201, DOI 10.1093/infdis/174.Supplement_2.S201; Wilde G. J. S., 1994, TARGET RISK; 1986, LANCET, V1, P75	26	100	101	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					400	403		10.1016/S0140-6736(99)09109-6	http://dx.doi.org/10.1016/S0140-6736(99)09109-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665571				2022-12-28	WOS:000085122100039
J	Hayflick, L				Hayflick, L			New approaches to old age - To truly understand ageing, we must look beyond the diseases of old age.	NATURE			English	Editorial Material									Univ Calif San Francisco, Dept Anat, Sea Ranch, CA 95497 USA	University of California System; University of California San Francisco	Hayflick, L (corresponding author), Univ Calif San Francisco, Dept Anat, POB 89, Sea Ranch, CA 95497 USA.		Hayflick, Leonard/AAW-2460-2020						0	39	44	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					365	365		10.1038/35000303	http://dx.doi.org/10.1038/35000303			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667768	Bronze			2022-12-28	WOS:000085121100023
J	Santoso, A; Chien, P; Osherovich, LZ; Weissman, JS				Santoso, A; Chien, P; Osherovich, LZ; Weissman, JS			Molecular basis of a yeast prion species barrier	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; SUP35 GENE; AMYLOID FIBRILS; RELEASE FACTOR; IN-VITRO; PROTEIN; PSI; PROPAGATION; DETERMINANT; MICROSCOPY	The yeast [PSI+] factor is inherited by a prion mechanism involving self-propagating Sup35p aggregates. We find that Sup35p prion function is conserved among distantly related yeasts. As with mammalian prions, a species barrier inhibits prion induction between Sup35p from different yeast species. This barrier is faithfully reproduced in vitro where, remarkably, ongoing polymerization of one Sup35p species does not affect conversion of another. Chimeric analysis identifies a short domain sufficient to allow foreign Sup35p to cross this barrier. These observations argue that the species barrier results from specificity in the growing aggregate, mediated by a well-defined epitope on the amyloid surface and, together with our identification of a novel yeast prion domain, show that multiple prion-based heritable states can propagate independently within one cell.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	jsw1@itsa.ucsf.edu		Weissman, Jonathan/0000-0003-2445-670X				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bailleul PA, 1999, GENETICS, V153, P81; Bates GP, 1998, BIOCHEM SOC T, V26, P471, DOI 10.1042/bst0260471; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Derkatch IL, 1996, GENETICS, V144, P1375; DOEL SM, 1994, GENETICS, V137, P659; Eaglestone SS, 1999, EMBO J, V18, P1974, DOI 10.1093/emboj/18.7.1974; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Ito K, 1998, RNA, V4, P958, DOI 10.1017/S1355838298971874; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; KURTZMAN CP, 1994, YEAST, V10, P1727, DOI 10.1002/yea.320101306; KUSHNIROV VV, 1990, YEAST, V6, P461, DOI 10.1002/yea.320060603; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; TUITE MF, 1981, GENETICS, V98, P691; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1995, YEAST, V11, P1671, DOI 10.1002/yea.320111609; Zhou P, 1999, EMBO J, V18, P1182, DOI 10.1093/emboj/18.5.1182	37	231	235	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2000	100	2					277	288		10.1016/S0092-8674(00)81565-2	http://dx.doi.org/10.1016/S0092-8674(00)81565-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660050	Bronze			2022-12-28	WOS:000084932200011
J	Bamber, JL; Vaughan, DG; Joughin, I				Bamber, JL; Vaughan, DG; Joughin, I			Widespread complex flow in the interior of the Antarctic ice sheet	SCIENCE			English	Article							MASS-BALANCE; DYNAMICS; STREAMS; GREENLAND	It has been suggested that as much as 90% of the discharge from the Antarctic Ice Sheet is drained through a small number of fast-moving ice streams and outlet glaciers fed by relatively stable and inactive catchment areas. Here, evidence obtained from balance velocity estimates suggests that each major drainage basin is fed by complex systems of tributaries that penetrate up to 1000 kilometers from the grounding line into the interior of the ice sheet. This finding has important consequences for the modeled or estimated dynamic response time of past and present ice sheets to climate forcing.	Univ Bristol, Sch Geog Sci, Bristol Glaciol Ctr, Bristol BS8 1SS, Avon, England; British Antarctic Survey High Cross, Cambridge CB3 0ET, England; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of Bristol; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Bamber, JL (corresponding author), Univ Bristol, Sch Geog Sci, Bristol Glaciol Ctr, Univ Rd, Bristol BS8 1SS, Avon, England.	j.l.bamber@bristol.ac.uk	Joughin, Ian R/A-2998-2008; Joughin, Ian/AAR-7778-2021; Bamber, Jonathan/C-7608-2011; Vaughan, David/C-8348-2011	Joughin, Ian R/0000-0001-6229-679X; Joughin, Ian/0000-0001-6229-679X; Bamber, Jonathan/0000-0002-2280-2819; Vaughan, David/0000-0002-9065-0570				Bamber J.L., 1996, ANN GLACIOL, V23, P364; Bamber JL, 1997, ANN GLACIOL, V25, P439, DOI 10.3189/S0260305500014427; BAMBER L, IN PRESS J GLACIOL; BENTLEY CR, 1987, J GEOPHYS RES-SOLID, V92, P8843, DOI 10.1029/JB092iB09p08843; Bindschadler R, 1996, J GLACIOL, V42, P461, DOI 10.3189/S0022143000003452; BUDD WF, 1996, ANN GLACIOL, V23, P21; Drewry DJ., 1983, ANTARCTICA GLACIOLOG; FAHNESTOCK M, 1993, SCIENCE, V262, P1530, DOI 10.1126/science.262.5139.1530; Hughes B., 1973, J IND RELAT, V15, P1; Huybrechts P, 1999, J CLIMATE, V12, P2169, DOI 10.1175/1520-0442(1999)012<2169:TDROTG>2.0.CO;2; JONES M, 1996, 11 INT WORKSH FILCHN; Joughin I, 1999, SCIENCE, V286, P283, DOI 10.1126/science.286.5438.283; Marshall SJ, 1997, J GEOPHYS RES-SOL EA, V102, P20615, DOI 10.1029/97JB01189; MCINTYRE NF, 1985, J GLACIOL, V31, P99, DOI 10.3189/S0022143000006328; NYE JF, 1963, GEOPHYS J ROY ASTR S, V7, P431, DOI 10.1111/j.1365-246X.1963.tb07087.x; Patterson W.S.B, 1994, PHYS GLACIERS, Vthird, P496; Payne AJ, 1998, GEOPHYS RES LETT, V25, P3173, DOI 10.1029/98GL52327; STENOIEN MD, 1998, THESIS U WISCONSIN M; Vaughan DG, 1999, J CLIMATE, V12, P933, DOI 10.1175/1520-0442(1999)012<0933:RONSMB>2.0.CO;2; Wingham DJ, 1998, SCIENCE, V282, P456, DOI 10.1126/science.282.5388.456	20	268	273	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2000	287	5456					1248	1250		10.1126/science.287.5456.1248	http://dx.doi.org/10.1126/science.287.5456.1248			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678828				2022-12-28	WOS:000085444700045
J	McNally, JG; Muller, WG; Walker, D; Wolford, R; Hager, GL				McNally, JG; Muller, WG; Walker, D; Wolford, R; Hager, GL			The glucocorticoid receptor: Rapid exchange with regulatory sites in living cells	SCIENCE			English	Article							TRANSCRIPTION FACTORS; MMTV PROMOTER; IN-VIVO; GENES; ACTIVATION; CHROMATIN; INTERPLAY; INVIVO	Steroid receptors bind to site-specific response elements in chromatin and modulate gene expression in a hormone-dependent fashion. With the use of a tandem array of mouse mammary tumor virus reporter elements and a form of glucocorticoid receptor labeled with green fluorescent protein, targeting of the receptor to response elements in live mouse cells was observed. Photobleaching experiments provide direct evidence that the hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment. Thus, the interaction of regulatory proteins with target sites in chromatin is a more dynamic process than previously believed.	NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hager, GL (corresponding author), NCI, Lab Receptor Biol & Gene Express, Bldg 41,Room B602, Bethesda, MD 20892 USA.	hagerg@exchange.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC010027, ZIABC010027] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; BELMONT A, 1996, J CELL BIOL, V135, P1685; Carmi I, 1998, NATURE, V396, P168, DOI 10.1038/24164; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; De Angelis DA, 1998, P NATL ACAD SCI USA, V95, P12312, DOI 10.1073/pnas.95.21.12312; ELLENBERG J, UNPUB; FLETCHER TM, UNPUBHER TM; Fragoso G, 1997, METHODS, V11, P246, DOI 10.1006/meth.1996.0411; Fragoso G, 1998, MOL CELL BIOL, V18, P3633, DOI 10.1128/MCB.18.6.3633; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GRONEMEYER H, 1993, STEROID HORMONE ACTI, P94; Hager GL, 1999, METHOD ENZYMOL, V302, P73, DOI 10.1016/S0076-6879(99)02011-X; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Kramer PR, 1999, J BIOL CHEM, V274, P28590, DOI 10.1074/jbc.274.40.28590; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; OSTROWSKI MC, 1983, MOL CELL BIOL, V3, P2045, DOI 10.1128/MCB.3.11.2045; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; TRUSS M, 1992, J STEROID BIOCHEM, V43, P365, DOI 10.1016/0960-0760(92)90071-P; Walker D, 1999, METHODS, V19, P386, DOI 10.1006/meth.1999.0874; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	34	629	642	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2000	287	5456					1262	1265		10.1126/science.287.5456.1262	http://dx.doi.org/10.1126/science.287.5456.1262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678832				2022-12-28	WOS:000085444700049
J	Williams, A				Williams, A			A paper that changed my practice - A more helpful technique	BRITISH MEDICAL JOURNAL			English	Article																		AHMAD T, 1991, LANCET, V338, P674, DOI 10.1016/0140-6736(91)91242-M	1	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					377	377		10.1136/bmj.320.7231.377	http://dx.doi.org/10.1136/bmj.320.7231.377			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657342	Green Published			2022-12-28	WOS:000085211400041
J	Song, HW; Mugnier, P; Das, AK; Webb, HM; Evans, DR; Tuite, MF; Hemmings, BA; Barford, D				Song, HW; Mugnier, P; Das, AK; Webb, HM; Evans, DR; Tuite, MF; Hemmings, BA; Barford, D			The crystal structure of human eukaryotic release factor eRF1 - Mechanism of stop codon recognition and peptidyl-tRNA hydrolysis	CELL			English	Article							ELONGATION-FACTOR-G; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; TRANSLATION TERMINATION; TRANSFER-RNA; CHAIN TERMINATION; BINDING-SITE; FACTORS RF1; IN-VITRO; YEAST	The release factor eRF1 terminates protein biosynthesis by recognizing stop codons at the A site of the ribosome and stimulating peptidyl-tRNA bond hydrolysis at the peptidyl transferase center. The crystal structure of human eRF1 to 2.8 Angstrom resolution, combined with mutagenesis analyses of the universal GGQ motif, reveals the molecular mechanism of release factor activity. The overall shape and dimensions of eRF1 resemble a tRNA molecule with domains 1, 2, and 3 of eRF1 corresponding to the anticodon loop, aminoacyl acceptor stem, and T stem of a tRNA molecule, respectively. The position of the essential GGQ motif at an exposed tip of domain 2 suggests that the Gin residue coordinates a water molecule to mediate the hydrolytic activity at the peptidyl transferase center. A conserved groove on domain 1, 80 Angstrom from the GGQ motif, is proposed to form the codon recognition site.	Inst Canc Res, Sect Struct Biol, London SW3 6JB, England; Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Oxford; University of Kent; Friedrich Miescher Institute for Biomedical Research	Barford, D (corresponding author), Inst Canc Res, Sect Struct Biol, 237 Fulham Rd, London SW3 6JB, England.	dbarford@icr.ac.uk	Tuite, Mick/ABC-7909-2020; song, haiwei/H-6082-2011	Tuite, Mick/0000-0002-5214-540X; 				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BARTON GJ, 1990, METHOD ENZYMOL, V183, P403; BONETTI B, 1995, J MOL BIOL, V251, P334, DOI 10.1006/jmbi.1995.0438; BROWN CM, 1994, J BIOL CHEM, V269, P33164; BROWN CM, 1990, NUCLEIC ACIDS RES, V18, P2079, DOI 10.1093/nar/18.8.2079; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buckingham RH, 1997, MOL MICROBIOL, V24, P449, DOI 10.1046/j.1365-2958.1997.3711734.x; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; EGGERTSSON G, 1988, MICROBIOL REV, V52, P354, DOI 10.1128/MMBR.52.3.354-374.1988; Eurwilaichitr L, 1999, MOL MICROBIOL, V32, P485, DOI 10.1046/j.1365-2958.1999.01346.x; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Frolova L, 1996, RNA, V2, P334; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; Frolova LY, 1999, RNA, V5, P1014, DOI 10.1017/S135583829999043X; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; GOLDSTEIN JL, 1970, P NATL ACAD SCI USA, V67, P99, DOI 10.1073/pnas.67.1.99; Grentzmann G, 1997, J BIOL CHEM, V272, P12300, DOI 10.1074/jbc.272.19.12300; GRENTZMANN G, 1994, P NATL ACAD SCI USA, V91, P5848, DOI 10.1073/pnas.91.13.5848; Ito K, 1996, P NATL ACAD SCI USA, V93, P5443, DOI 10.1073/pnas.93.11.5443; Ito K, 1998, RNA, V4, P958, DOI 10.1017/S1355838298971874; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KONECKI DS, 1977, J BIOL CHEM, V252, P4514; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; McCaughan KK, 1998, BIOL CHEM, V379, P857, DOI 10.1515/bchm.1998.379.7.857; Merkulova TI, 1999, FEBS LETT, V443, P41, DOI 10.1016/S0014-5793(98)01669-X; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIKUNI O, 1994, P NATL ACAD SCI USA, V91, P5798, DOI 10.1073/pnas.91.13.5798; MILMAN G, 1969, P NATL ACAD SCI USA, V63, P183, DOI 10.1073/pnas.63.1.183; MIRONOVA LN, 1986, GENETIKA+, V22, P200; MOFFAT JG, 1994, J BIOL CHEM, V269, P18899; Mottagui-Tabar S, 1998, EUR J BIOCHEM, V257, P249, DOI 10.1046/j.1432-1327.1998.2570249.x; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Nakamura Y, 1998, GENES CELLS, V3, P265, DOI 10.1046/j.1365-2443.1998.00191.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Poole ES, 1997, RNA, V3, P974; POOLE ES, 1995, EMBO J, V14, P151, DOI 10.1002/j.1460-2075.1995.tb06985.x; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; SIKORSKI RS, 1989, GENETICS, V122, P19; STANSFIELD I, 1995, CURR GENET, V27, P417, DOI 10.1007/BF00311210; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Stansfield I, 1997, EUR J BIOCHEM, V245, P557, DOI 10.1111/j.1432-1033.1997.00557.x; Stansfield I, 1996, MOL MICROBIOL, V20, P1135, DOI 10.1111/j.1365-2958.1996.tb02634.x; TATE W, 1990, NUCLEIC ACIDS RES, V18, P6537, DOI 10.1093/nar/18.22.6537; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	58	367	394	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					311	321		10.1016/S0092-8674(00)80667-4	http://dx.doi.org/10.1016/S0092-8674(00)80667-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676813	Bronze			2022-12-28	WOS:000085204400005
J	Davies, HTO; Marshall, MN				Davies, HTO; Marshall, MN			UK and US health-care systems: divided by more than a common language	LANCET			English	Editorial Material									Univ St Andrews, Dept Management, St Andrews KY16 9AL, Fife, Scotland; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of St Andrews; University of Manchester	Davies, HTO (corresponding author), Univ St Andrews, Dept Management, St Andrews KY16 9AL, Fife, Scotland.							BLENDON RJ, 1998, COMMONWEALTH FUNDS 1; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Horton R, 1999, LANCET, V353, P610, DOI 10.1016/S0140-6736(99)00057-4; INGLEHART JK, 1999, HLTH AFFAIRS, V18, P7; LeRoy L, 1999, HEALTH AFFAIR, V18, P234, DOI 10.1377/hlthaff.18.3.234	5	11	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					336	336		10.1016/S0140-6736(99)00416-X	http://dx.doi.org/10.1016/S0140-6736(99)00416-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665551				2022-12-28	WOS:000085122100007
J	Goldring, SR				Goldring, SR			A 55-year-old woman with rheumatoid arthritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DRUG-THERAPY; FOLLOW-UP; METHOTREXATE; DISEASE; DESTRUCTION; PATHOPHYSIOLOGY; QUESTIONNAIRE; DEGRADATION; COMBINATION; EXPRESSION		Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; New England Baptist Hosp, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; New England Baptist Hospital	Goldring, SR (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							ANDERSON JJ, 1989, ARTHRITIS RHEUM, V32, P1093, DOI 10.1002/anr.1780320907; Arend WP, 1997, ARTHRITIS RHEUM, V40, P595, DOI 10.1002/art.1780400402; AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BELLAMY N, 1992, ANN RHEUM DIS, V51, P588, DOI 10.1136/ard.51.5.588; BRADLEY LA, 1987, ARTHRITIS RHEUM, V30, P1105, DOI 10.1002/art.1780301004; CASH JM, 1994, NEW ENGL J MED, V330, P1368; da Camara CC, 1998, ANN PHARMACOTHER, V32, P580, DOI 10.1345/aph.17214; EPSTEIN WV, 1994, SEMIN ARTHRITIS RHEU, V23, P32, DOI 10.1016/0049-0172(94)90082-5; ERHARDT CC, 1989, ANN RHEUM DIS, V48, P7, DOI 10.1136/ard.48.1.7; FASSBENDER HG, 1983, COLLAGEN REL RES, V3, P141; FELDMANN M, 1990, ANN RHEUM DIS, P480; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FIRESTEIN GS, 1990, J IMMUNOL, V144, P3347; Fox DA, 1997, ARTHRITIS RHEUM, V40, P598, DOI 10.1002/art.1780400403; FUCHS HA, 1989, J RHEUMATOL, V16, P585; Goldring SR, 1998, METABOLIC BONE DIS, P621; Gravallese EM, 1998, AM J PATHOL, V152, P943; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HOCHBERG MC, 1992, ARTHRITIS RHEUM, V35, P498, DOI 10.1002/art.1780350502; Hochberg MC, 1996, ARTHRITIS RHEUM-US, V39, P1791; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D; Koopman WJ, 1998, ANN INTERN MED, V128, P231, DOI 10.7326/0003-4819-128-3-199802010-00010; KRANE SM, 1990, ANN NY ACAD SCI, V580, P340, DOI 10.1111/j.1749-6632.1990.tb17943.x; KREMER JM, 1992, ARTHRITIS RHEUM, V35, P138, DOI 10.1002/art.1780350203; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; MEENAN RF, 1992, ARTHRITIS RHEUM, V35, P1, DOI 10.1002/art.1780350102; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Needleman P, 1997, J RHEUMATOL, V24, P6; Nepom BS, 1995, ARTHRITIS RHEUM, V38, P1715, DOI 10.1002/art.1780381202; O'Dell JR, 1999, NEW ENGL J MED, V340, P310, DOI 10.1056/NEJM199901283400411; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; PAGET SA, 1997, PRIMER RHEUMATIC DIS, P168; PINCUS T, 1992, J RHEUMATOL, V19, P1885; PINCUS T, 1993, RHEUM DIS CLIN N AM, V19, P123; POLEKSIC L, 1993, SKELETAL RADIOL, V22, P577; Reginster JY, 1999, ARTHRITIS RHEUM, V42, pS400; Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502; SAAG KG, 1994, AM J MED, V96, P115, DOI 10.1016/0002-9343(94)90131-7; SCOTT DL, 1987, LANCET, V1, P1108; SHMERLING RH, 1991, AM J MED, V91, P528, DOI 10.1016/0002-9343(91)90190-9; Silas S, 1999, B RHEUM DIS, V48, P1; Simms RW, 1996, ARTHRITIS RHEUM-US, V39, P723; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3; Stein CM, 1997, ARTHRITIS RHEUM, V40, P1843, DOI 10.1002/art.1780401018; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; VANDERHEIJDE DMFM, 1992, ARTHRITIS RHEUM-US, V35, P26; Ward MM, 1998, J RHEUMATOL, V25, P408; Weaver A, 1998, ARTHRITIS RHEUM, V41, pS131; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; WEYAND CM, 1995, J CLIN INVEST, V95, P2120, DOI 10.1172/JCI117900; WEYAND CM, 1992, ANN INTERN MED, V117, P801, DOI 10.7326/0003-4819-117-10-801; WOLFE F, 1988, J RHEUMATOL, V15, P1480; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408; Woolley DE, 1997, ANN RHEUM DIS, V56, P151, DOI 10.1136/ard.56.3.151	59	6	7	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					524	531		10.1001/jama.283.4.524	http://dx.doi.org/10.1001/jama.283.4.524			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659880				2022-12-28	WOS:000084879800033
J	Tricot, G				Tricot, G			New insights into role of microenvironment in multiple myeloma	LANCET			English	Editorial Material							EXPRESSION; CELLS; OSTEOPROTEGERIN; ACTIVATION; BCL-X(L); BCL-2		Arkansas Canc Res Ctr, Little Rock, AR 72205 USA		Tricot, G (corresponding author), Arkansas Canc Res Ctr, Little Rock, AR 72205 USA.							Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; CherbonnelLasserre C, 1996, ONCOGENE, V13, P1489; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Deaglio S, 1998, J IMMUNOL, V160, P395; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Tu YP, 1996, BLOOD, V88, P1805, DOI 10.1182/blood.V88.5.1805.bloodjournal8851805; Vacca A, 1999, BLOOD, V93, P3064; Vallario A, 1999, BRIT J HAEMATOL, V105, P441, DOI 10.1046/j.1365-2141.1999.01321.x; Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015	18	110	114	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					248	250		10.1016/S0140-6736(00)00019-2	http://dx.doi.org/10.1016/S0140-6736(00)00019-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675068				2022-12-28	WOS:000085045600004
J	Raucher, D; Stauffer, T; Chen, W; Shen, K; Guo, SL; York, JD; Sheetz, MP; Meyer, T				Raucher, D; Stauffer, T; Chen, W; Shen, K; Guo, SL; York, JD; Sheetz, MP; Meyer, T			Phosphatidylinositol 4,5-bisphoshate functions as a second messenger that regulates cytoskeleton-plasma membrane adhesion	CELL			English	Article							PANCREATIC ACINAR-CELLS; ACTIN POLYMERIZATION; F-ACTIN; IN-VIVO; BINDING; GROWTH; U73122; POLYPHOSPHOINOSITIDES; JASPLAKINOLIDE; TETHERS	Binding interactions between the plasma membrane and the cytoskeleton define cell functions such as cell shape, formation of cell processes, cell movement, and endocytosis. Here we use optical tweezers tether force measurements and show that plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2) acts as a second messenger that regulates the adhesion energy between the cytoskeleton and the plasma membrane. Receptor stimuli that hydrolyze PIP2 lowered adhesion energy, a process that could be mimicked by expressing PH domains that sequester PIP2 or by targeting a 5'-PIP2-phosphatase to the plasma membrane to selectively lower plasma membrane PIP2 concentration. Our study suggests that plasma membrane PIP2 controls dynamic membrane functions and cell shape by locally increasing and decreasing the adhesion between the actin-based cortical cytoskeleton and the plasma membrane.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University	Meyer, T (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.		Raucher, Drazen/AAE-4540-2022	Meyer, Tobias/0000-0003-4339-3804	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048113, R55GM048113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55672] Funding Source: Medline; NIGMS NIH HHS [GM 48113, GM 362277] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERK DA, 1992, BIOPHYS J, V61, P9, DOI 10.1016/S0006-3495(92)81811-8; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; DAI J, 1999, IN PRESS BIOPHYS J; DAI JW, 1995, BIOPHYS J, V68, P988, DOI 10.1016/S0006-3495(95)80274-2; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Hochmuth RM, 1996, BIOPHYS J, V70, P358, DOI 10.1016/S0006-3495(96)79577-2; Holzinger A, 1997, CELL MOTIL CYTOSKEL, V38, P365, DOI 10.1002/(SICI)1097-0169(1997)38:4<365::AID-CM6>3.0.CO;2-2; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1995, CHEM BIOL, V2, P61, DOI 10.1016/1074-5521(95)90276-7; JIN WZ, 1994, BRAIN RES, V642, P237, DOI 10.1016/0006-8993(94)90927-X; Kandzari D E, 1996, Subcell Biochem, V26, P97; Keller H, 1998, CELL MOTIL CYTOSKEL, V41, P181, DOI 10.1002/(SICI)1097-0169(1998)41:2<181::AID-CM8>3.3.CO;2-M; KLEINIG H, 1970, J CELL BIOL, V46, P396, DOI 10.1083/jcb.46.2.396; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; Lee E, 1998, CELL MOTIL CYTOSKEL, V39, P122, DOI 10.1002/(SICI)1097-0169(1998)39:2<122::AID-CM3>3.0.CO;2-8; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; Mogami H, 1997, BIOCHEM J, V324, P645, DOI 10.1042/bj3240645; Raucher D, 1999, J CELL BIOL, V144, P497, DOI 10.1083/jcb.144.3.497; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; TRAN D, 1993, CELL SIGNAL, V5, P565, DOI 10.1016/0898-6568(93)90052-N; WAUGH RE, 1995, ANN BIOMED ENG, V23, P308, DOI 10.1007/BF02584431; WAUGH RE, 1987, BIOPHYS J, V52, P391, DOI 10.1016/S0006-3495(87)83227-7; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YULE DI, 1992, J BIOL CHEM, V267, P13830	30	560	571	1	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					221	228		10.1016/S0092-8674(00)81560-3	http://dx.doi.org/10.1016/S0092-8674(00)81560-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660045				2022-12-28	WOS:000084932200006
J	Belin, P; Zatorre, RJ; Lafaille, P; Ahad, P; Pike, B				Belin, P; Zatorre, RJ; Lafaille, P; Ahad, P; Pike, B			Voice-selective areas in human auditory cortex	NATURE			English	Article							RHESUS-MONKEY; PERCEPTION; SPEAKER	The human voice contains in its acoustic structure a wealth of information on the speaker's identity and emotional state which we perceive with remarkable ease and accuracy(1-3). Although the perception of speaker-related features of voice plays a major role in human communication, little is known about its neural basis(4-7) Here:we show, using functional magnetic resonance imaging in human volunteers, that voice-selective regions can be found bilaterally along the upper bank of the superior temporal sulcus (STS), These regions showed greater neuronal activity when subjects listened passively to vocal sounds, whether speech or non-speech, than to non-vocal environmental sounds. Central STS regions also displayed a high degree of selectivity by responding significantly more to vocal sounds than to matched control stimuli, including scrambled voices and amplitude-modulated noise. Moreover, their response to stimuli degraded by frequency filtering paralleled the subjects' behavioural performance in voice-perception tasks that used these stimuli. The voice-selective areas in the STS may represent the counterpart of the face-selective areas in human visual cortex(8,9); their existence sheds new light on the functional architecture of the human auditory cortex.	McGill Univ, Montreal Neurol Inst, Neuropsychol Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Psychol, Montreal, PQ H3A 2B4, Canada; McGill Univ, McConnel Brain Imaging Ctr, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University; McGill University	Belin, P (corresponding author), McGill Univ, Montreal Neurol Inst, Neuropsychol Cognit Neurosci Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	pascal@bic.mni.mcgill.ca	Belin, Pascal/C-6247-2009; Pike, Bruce/K-5562-2014	Belin, Pascal/0000-0002-7578-6365; Pike, Bruce/0000-0001-8924-683X				ASSAL G, 1981, REV NEUROL, V137, P255; Belin P, 1999, NEUROIMAGE, V10, P417, DOI 10.1006/nimg.1999.0480; BINDER JR, 1999, J COGNITIVE NEUROS S, V11, P99; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Dehaene S, 1997, NEUROREPORT, V8, P3809, DOI 10.1097/00001756-199712010-00030; DOEHRING DG, 1971, NEUROPSYCHOLOGIA, V9, P425, DOI 10.1016/0028-3932(71)90006-6; Ellis A.W., 1989, HDB RES FACE PROCESS, P207; Hall DA, 1999, HUM BRAIN MAPP, V7, P213, DOI 10.1002/(SICI)1097-0193(1999)7:3<213::AID-HBM5>3.0.CO;2-N; Imaizumi S, 1997, NEUROREPORT, V8, P2809, DOI 10.1097/00001756-199708180-00031; JONES EG, 1995, J COMP NEUROL, V362, P153, DOI 10.1002/cne.903620202; Kaas JH, 1999, CURR OPIN NEUROBIOL, V9, P164, DOI 10.1016/S0959-4388(99)80022-1; Kanwisher N, 1997, J NEUROSCI, V17, P4302; KLATT DH, 1990, J ACOUST SOC AM, V87, P820, DOI 10.1121/1.398894; McCarthy G, 1997, J COGNITIVE NEUROSCI, V9, P605, DOI 10.1162/jocn.1997.9.5.605; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; PANDYA DN, 1995, REV NEUROL, V151, P486; PAPCUN G, 1989, J ACOUST SOC AM, V85, P913, DOI 10.1121/1.397564; Rauschecker JP, 1998, AUDIOL NEURO-OTOL, V3, P86, DOI 10.1159/000013784; Rendall D, 1998, J ACOUST SOC AM, V103, P602, DOI 10.1121/1.421104; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; Talairach J., 1988, COPLANAR STEREOTAXIC; TURNER R, 1994, FUNCTIONAL NEUROIMAG, P69; Van Lancker D R, 1982, Brain Cogn, V1, P185, DOI 10.1016/0278-2626(82)90016-1; VANDOMMELEN WA, 1990, LANG SPEECH, V33, P259, DOI 10.1177/002383099003300302; VANLANCKER DR, 1989, J CLIN EXP NEUROPSYC, V11, P665, DOI 10.1080/01688638908400923; WATZLAWICKI P, 1967, STUDY INTERACTIONAL; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767	28	1232	1249	7	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2000	403	6767					309	312		10.1038/35002078	http://dx.doi.org/10.1038/35002078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	276VU	10659849				2022-12-28	WOS:000084899700052
J	Gardner, TS; Cantor, CR; Collins, JJ				Gardner, TS; Cantor, CR; Collins, JJ			Construction of a genetic toggle switch in Escherichia coli	NATURE			English	Article							LOGICAL ANALYSIS; NETWORKS; DYNAMICS; EXPRESSION; CIRCUITS; SYSTEMS; LAMBDA	It has been proposed(1) that gene-regulatory circuits with virtually any desired property can be constructed from networks of simple regulatory elements. These properties, which include multistability and oscillations, have been found in specialized gene circuits such as the bacteriophage lambda switch(2) and the Cyanobacteria circadian oscillator(3), However, these behaviours have not been demonstrated in networks of non-specialized regulatory components. Here we present the construction of a genetic toggle switch-a synthetic, bistable gene-regulatory network-in Escherichia coli and provide a simple theory that predicts the conditions necessary for bistability, The toggle is constructed from any two repressible promoters arranged in a mutually inhibitory network. It is flipped between stable states using transient chemical or thermal induction and exhibits a nearly ideal switching threshold. As a practical device, the toggle switch forms a synthetic, addressable cellular memory unit and has implications for biotechnology, biocomputing and gene therapy.	Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA; Boston Univ, Ctr BioDynam, Boston, MA 02215 USA; Boston Univ, Ctr Adv Biotechnol, Boston, MA 02215 USA	Boston University; Boston University; Boston University	Collins, JJ (corresponding author), Boston Univ, Dept Biomed Engn, 44 Cummington St, Boston, MA 02215 USA.	jcollins@bu.edu						Arkin A, 1998, GENETICS, V149, P1633; ARKIN A, 1994, BIOPHYS J, V67, P560, DOI 10.1016/S0006-3495(94)80516-8; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Edelstein-Keshet L., 1988, MATH MODELS BIOL; GLASS L, 1973, J THEOR BIOL, V39, P103, DOI 10.1016/0022-5193(73)90208-7; GLASS L, 1975, J THEOR BIOL, V54, P85, DOI 10.1016/S0022-5193(75)80056-7; GLASS L, 1975, J CHEM PHYS, V63, P1325, DOI 10.1063/1.431518; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; KAPLAN D, 1995, UNDERSTANDING NONLIN; KAUFFMAN S, 1974, J THEOR BIOL, V44, P167, DOI 10.1016/S0022-5193(74)80037-8; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; McAdams HH, 1998, ANNU REV BIOPH BIOM, V27, P199, DOI 10.1146/annurev.biophys.27.1.199; MODOD J, 1961, COLD SPRING HARB SYM, V26, P389; Ptashne M, 1992, GENETIC SWITCH PHAGE; Rubinow S. I., 2002, INTRO MATH BIOL, VDover; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schellenberger W, 1980, Adv Enzyme Regul, V19, P257; SHEA MA, 1985, J MOL BIOL, V181, P211, DOI 10.1016/0022-2836(85)90086-5; SMITH TF, 1977, MATH BIOSCI, V36, P61, DOI 10.1016/0025-5564(77)90016-5; TCHURAEV RN, 1991, J THEOR BIOL, V151, P71, DOI 10.1016/S0022-5193(05)80144-4; THOMAS R, 1978, J THEOR BIOL, V73, P631, DOI 10.1016/0022-5193(78)90127-3; THOMAS R, 1991, J THEOR BIOL, V153, P1, DOI 10.1016/S0022-5193(05)80350-9; YAGIL G, 1971, BIOPHYS J, V11, P11, DOI 10.1016/S0006-3495(71)86192-1	26	2840	3020	47	705	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2000	403	6767					339	342		10.1038/35002131	http://dx.doi.org/10.1038/35002131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659857				2022-12-28	WOS:000084899700060
J	Keppler, F; Eiden, R; Niedan, V; Pracht, J; Scholer, HF				Keppler, F; Eiden, R; Niedan, V; Pracht, J; Scholer, HF			Halocarbons produced by natural oxidation processes during degradation of organic matter	NATURE			English	Article								Volatile halogenated organic compounds (VHOC) play an important role in atmospheric chemical processes-contributing, for example, to stratospheric ozone depletion(1-4), For anthropogenic VHOC whose sources are well known(5), the global atmospheric input can be estimated from industrial production data. Halogenated compounds of natural origin can also contribute significantly to the levels of VHOC in the atmosphere(6). The oceans have been implicated as one of the main natural sources(7-10), where organisms such as macroalgae and microalgae can release large quantities of VHOC to the atmosphere(11,12), Some terrestrial sources have also been identified, such as wood-rotting fungi(13), biomass burning(14) and volcanic emissions(15). Here we report the identification of a different terrestrial source of naturally occurring VHOC, We find that, in soils and sediments, halide ions can be alkylated during the oxidation of organic matter by an electron acceptor such as Fe(III): sunlight or microbial mediation are not required for these reactions. When the available halide ion is chloride, the reaction products are CH3Cl, C2H5Cl, C3H7Cl and C4H9Cl. (The corresponding alkyl bromides or alkyl iodides are produced when bromide or iodide are present.) Such abiotic processes could make a significant contribution to the budget of the important atmospheric compounds CH3Cl, CH3Br and CH3I.	Univ Heidelberg, Inst Environm Geochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Keppler, F (corresponding author), Univ Heidelberg, Inst Environm Geochem, Neuenheimer Feld 236, D-69120 Heidelberg, Germany.		Keppler, Frank/F-4401-2012	Keppler, Frank/0000-0003-2766-8812				ANDERSON JG, 1991, SCIENCE, V251, P39, DOI 10.1126/science.251.4989.39; Andreae MO, 1996, J GEOPHYS RES-ATMOS, V101, P23603, DOI 10.1029/95JD01733; Butler JH, 1999, NATURE, V399, P749, DOI 10.1038/21586; CLASS TH, 1988, J ATMOS CHEM, V6, P35, DOI 10.1007/BF00048330; CRUTZEN PJ, 1986, NATURE, V324, P651, DOI 10.1038/324651a0; Desjardins S, 1999, J SOIL CONTAM, V8, P175; GRIBBLE GW, 1992, J NAT PROD, V55, P1353, DOI 10.1021/np50088a001; HARPER DB, 1985, NATURE, V315, P55, DOI 10.1038/315055a0; HOEKSTRA EJ, 1993, NATURALLY PRODUCED O, P149; Laturnus F, 1998, GEOPHYS RES LETT, V25, P773, DOI 10.1029/98GL00490; LOVELOCK JE, 1975, NATURE, V256, P193, DOI 10.1038/256193a0; LOVLEY DR, 1991, MICROBIOL REV, V55, P259, DOI 10.1128/MMBR.55.2.259-287.1991; Moore RM, 1996, J GEOPHYS RES-OCEANS, V101, P28529, DOI 10.1029/96JC02915; POST WM, 1982, NATURE, V298, P156, DOI 10.1038/298156a0; RASMUSSEN RA, 1980, J GEOPHYS RES-OCEANS, V85, P7350, DOI 10.1029/JC085iC12p07350; SINGH AK, 1984, THORAC CARDIOV SURG, V32, P89, DOI 10.1055/s-2007-1023355; SOLOMON S, 1990, NATURE, V347, P347, DOI 10.1038/347347a0; STURGES WT, 1993, TELLUS B, V45, P120, DOI 10.1034/j.1600-0889.1993.t01-1-00004.x; WEVER R, 1988, SCIENCE, V355, P501	19	272	288	6	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					298	301		10.1038/35002055	http://dx.doi.org/10.1038/35002055			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659846				2022-12-28	WOS:000084899700049
J	Uchide, K; Ueno, H; Inoue, M; Suzuki, M				Uchide, K; Ueno, H; Inoue, M; Suzuki, M			A cause of pre-eclampsia?	LANCET			English	Article									Kanazawa Univ, Sch Med, Dept Obstet & Gynaecol, Kanazawa, Ishikawa 9208641, Japan; Kanazawa Univ, Sch Med, Dept Radiol Technol, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University; Kanazawa University	Uchide, K (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynaecol, Takara Machi 13-1, Kanazawa, Ishikawa 9208641, Japan.							Dekker GA, 1998, AM J OBSTET GYNECOL, V179, P1359, DOI 10.1016/S0002-9378(98)70160-7; Gibo M, 1998, CLIN IMAG, V22, P422, DOI 10.1016/S0899-7071(98)00067-9; Roberts JM, 1998, LANCET, V352, P22; Satyapal KS, 1999, SURG RADIOL ANAT, V21, P77, DOI 10.1007/BF01635058	4	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					114	114		10.1016/S0140-6736(99)10384-2	http://dx.doi.org/10.1016/S0140-6736(99)10384-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675170				2022-12-28	WOS:000085557200014
J	Hambrecht, R; Wolf, A; Gielen, S; Linke, A; Hofer, J; Erbs, S; Schoene, N; Schuler, G				Hambrecht, R; Wolf, A; Gielen, S; Linke, A; Hofer, J; Erbs, S; Schoene, N; Schuler, G			Effect of exercise on coronary endothelial function in patients with coronary artery disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-FAT DIET; INTENSIVE PHYSICAL EXERCISE; SHEAR-STRESS; DYSFUNCTION; ATHEROSCLEROSIS; EXPRESSION; REDUCTION; PERFUSION; CAPACITY; HEART	Background: Studies of the cardioprotective effects of exercise training in patients with coronary artery disease have yielded contradictory results. Exercise training has been associated with improvement in myocardial perfusion even in patients who have progression of coronary atherosclerosis. We therefore conducted a prospective study of the effect of exercise training on endothelial function in patients with coronary artery disease. Methods: We randomly assigned 19 patients with coronary endothelial dysfunction, indicated by abnormal acetylcholine-induced vasoconstriction, to an exercise-training group (10 patients) or a control group (9 patients). To reduce confounding, patients with coronary risk factors that could be influenced by exercise training (such as diabetes, hypertension, hypercholesterolemia, and smoking) were excluded. In an initial study and after four weeks, the changes in vascular diameter in response to the intracoronary infusion of increasing doses of acetylcholine (0.072, 0.72, and 7.2 microg per minute) were assessed. The mean peak flow velocity was measured by Doppler velocimetry, and the diameter of epicardial coronary vessels was measured by quantitative coronary angiography. Results: In the initial study, the two groups had similar vasoconstrictive responses to acetylcholine. After four weeks of exercise training, coronary-artery constriction in response to acetylcholine at a dose of 7.2 microg per minute was reduced by 54 percent (from a mean [+/-SE] decrease in the luminal diameter of 0.41+/-0.05 mm in the initial study to a decrease of 0.19+/-0.07 mm at four weeks; P<0.05 for the comparison with the change in the control group). In the exercise-training group, the increases in mean peak flow velocity in response to 0.072, 0.72, and 7.2 microg of acetylcholine per minute were 12+/-7, 36+/-11, and 78+/-16 percent, respectively, in the initial study. After four weeks of exercise, the increases in response to acetylcholine were 27+/-7, 73+/-19, and 142+/-28 percent (P<0.01 for the comparison with the control group). Coronary blood-flow reserve (the ratio of the mean peak flow velocity after adenosine infusion to the resting velocity) increased by 29 percent after four weeks of exercise (from 2.8+/-0.2 in the initial study to 3.6+/-0.2 after four weeks; P<0.01 for the comparison with the control group). Conclusions: Exercise training improves endothelium-dependent vasodilatation both in epicardial coronary vessels and in resistance vessels in patients with coronary artery disease. (N Engl J Med 2000;342:454-60.) (C)2000, Massachusetts Medical Society.	Univ Leipzig, Herzzentrum, Dept Med & Cardiol, D-04289 Leipzig, Germany	Heart Center Leipzig GMBH; Leipzig University	Hambrecht, R (corresponding author), Univ Leipzig, Herzzentrum, Dept Med & Cardiol, Russenstr 19, D-04289 Leipzig, Germany.							Andrews TC, 1997, CIRCULATION, V95, P324; COHEN MV, 1982, J APPL PHYSIOL, V52, P664, DOI 10.1152/jappl.1982.52.3.664; EHSANI AA, 1981, CIRCULATION, V64, P1116, DOI 10.1161/01.CIR.64.6.1116; ERNST E, 1987, EUR HEART J, V8, P59, DOI 10.1093/eurheartj/8.suppl_G.59; Ferguson R J, 1974, Am J Cardiol, V34, P764, DOI 10.1016/0002-9149(74)90693-6; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GOULD KL, 1994, CIRCULATION, V89, P1530, DOI 10.1161/01.CIR.89.4.1530; Hambrecht R, 1998, CIRCULATION, V98, P2709, DOI 10.1161/01.CIR.98.24.2709; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; HASKELL WL, 1993, CIRCULATION, V87, P1076, DOI 10.1161/01.CIR.87.4.1076; Inoue N, 1996, CIRC RES, V79, P32, DOI 10.1161/01.RES.79.1.32; LAUGHLIN MH, 1992, J APPL PHYSIOL, V73, P2209, DOI 10.1152/jappl.1992.73.6.2209; MANCINI GB, 1996, CIRCULATION, V94, P1490; Mancini GBJ, 1996, CIRCULATION, V94, P258, DOI 10.1161/01.CIR.94.3.258; MULLER JM, 1994, CIRCULATION, V89, P2308, DOI 10.1161/01.CIR.89.5.2308; NIEBAUER J, 1995, AM J CARDIOL, V76, P771, DOI 10.1016/S0002-9149(99)80224-0; Reinhart WH, 1998, AM HEART J, V135, P379, DOI 10.1016/S0002-8703(98)70311-4; Rieder MJ, 1997, CIRC RES, V80, P312, DOI 10.1161/01.RES.80.3.312; SCHEEL KW, 1981, CIRC RES, V48, P523, DOI 10.1161/01.RES.48.4.523; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SCHULER G, 1992, J AM COLL CARDIOL, V19, P34, DOI 10.1016/0735-1097(92)90048-R; Solzbach U, 1997, CIRCULATION, V96, P1513, DOI 10.1161/01.CIR.96.5.1513; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; White FC, 1998, J APPL PHYSIOL, V85, P1160, DOI 10.1152/jappl.1998.85.3.1160; WILSON RF, 1985, CIRCULATION, V72, P82, DOI 10.1161/01.CIR.72.1.82; Woodman Christopher R., 1997, American Journal of Physiology, V273, pH2575; ZEIHER AM, 1993, J CLIN INVEST, V92, P652, DOI 10.1172/JCI116634	27	896	939	1	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2000	342	7					454	460		10.1056/NEJM200002173420702	http://dx.doi.org/10.1056/NEJM200002173420702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284FA	10675425				2022-12-28	WOS:000085319100002
J	Balasekaran, R; Porter, JL; Santa Ana, CA; Fordtran, JS				Balasekaran, R; Porter, JL; Santa Ana, CA; Fordtran, JS			Positive results on tests for steatorrhea in persons consuming olestra potato chips	ANNALS OF INTERNAL MEDICINE			English	Article							INGESTED OLESTRA; HUMAN GUT; DISPOSITION; DIARRHEA; RESIDUE	Background: Olestra is a nonabsorbable fat substitute that consists of fatty acids esterified to a sucrose molecule. Objective: To determine the effect of olestra consumption on measurements of fecal fat excretion. Design: Controlled cross-over trial. Setting: Clinical research center and outpatient research laboratory. Participants: 10 healthy volunteers. Intervention: On days 1 to 6 of the study, participants consumed 5 oz of conventional potato chips per day; on days 7 to 12, they consumed 5 oz of potato chips containing 40 g of olestra per day. Measurements: Quantitative measurement of fecal fat by the van de Kamer titration, van de Kamer gravimetric, and Jeejeebhoy gravimetric methods and qualitative assessment of fecal fat by Sudan III staining. Results: Excellent correlation was seen among the three quantitative assays, but the van de Kamer titration method yielded lower measurements than the two gravimetric methods. When participants consumed 40 g of olestra per day, the excretion of fecal fat increased to levels observed in patients with steatorrhea caused by the malabsorption syndrome. Conclusion: Consumption of olestra can cause false-positive results on tests for steatorrhea and may therefore lead to an erroneous diagnosis of the malabsorption syndrome.	Baylor Univ, Med Ctr, Dallas, TX 75246 USA	Baylor University; Baylor University Medical Center	Fordtran, JS (corresponding author), Baylor Univ, Med Ctr, 2nd Floor HOB,3500 Gaston Ave, Dallas, TX 75246 USA.				NIDDK NIH HHS [5-RO1-DK37172-13] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037172] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aichbichler BW, 1998, DIGEST DIS SCI, V43, P2353, DOI 10.1023/A:1026699525487; BARTKO JJ, 1994, STAT MED, V13, P737, DOI 10.1002/sim.4780130534; BOLINN GW, 1984, GASTROENTEROLOGY, V87, P319; CUMMINGS JH, 1976, GUT, V17, P210, DOI 10.1136/gut.17.3.210; Daher GC, 1996, FOOD CHEM TOXICOL, V34, P693, DOI 10.1016/0278-6915(96)00042-7; Daher GC, 1997, FUND APPL TOXICOL, V39, P138, DOI 10.1006/faat.1997.2359; DITCHBURN RK, 1971, J CLIN PATHOL, V24, P506, DOI 10.1136/jcp.24.6.506; DRUMMEY GD, 1961, NEW ENGL J MED, V264, P85, DOI 10.1056/NEJM196101122640207; FINE KD, 1992, GASTROENTEROLOGY, V102, P1936, DOI 10.1016/0016-5085(92)90316-Q; GLANNELLA R, 1998, GASTROENTEROLOGY, V114, pA372; JEEJEEBHOY KN, 1970, CLIN BIOCHEM, V3, P157, DOI 10.1016/S0009-9120(70)80021-2; KESTER JJ, 1993, SCI FOOD IND 21 CENT, P37; MATTSON FH, 1972, J NUTR, V102, P1171, DOI 10.1093/jn/102.9.1171; McRorie J, 1998, GASTROENTEROLOGY, V114, pA396, DOI 10.1016/S0016-5085(98)81605-3; MILLER KW, 1995, FUND APPL TOXICOL, V24, P229, DOI 10.1006/faat.1995.1026; VANDEKAMER JH, 1949, J BIOL CHEM, V177, P347; WEBB DR, 1997, J NUTR, V127, pS1574; WENZL HH, 1995, GASTROENTEROLOGY, V108, P1729, DOI 10.1016/0016-5085(95)90134-5; WIGGINS HS, 1976, GUT, V17, P1007, DOI 10.1136/gut.17.12.1007	19	11	11	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2000	132	4					279	282		10.7326/0003-4819-132-4-200002150-00005	http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285CY	10681282				2022-12-28	WOS:000085372900004
J	Coninx, R; Maher, D; Reyes, H; Grzemska, M				Coninx, R; Maher, D; Reyes, H; Grzemska, M			Tuberculosis in prisons in countries with high prevalence	BRITISH MEDICAL JOURNAL			English	Article							INFECTION		Int Comm Red Cross, Unit Med & Community Hlth Care, CH-1202 Geneva, Switzerland; WHO, Communicable Dis Prevent & Control, CH-1202 Geneva, Switzerland; Columbia Univ, Ctr Study Soc & Med, New York, NY 10032 USA	World Health Organization; Columbia University	Coninx, R (corresponding author), Int Comm Red Cross, Unit Med & Community Hlth Care, 19 Ave Paix, CH-1202 Geneva, Switzerland.			Maher, Dermot/0000-0003-0466-1976				AERTS A, 1998, INT J TUBERCULOSI S2, V2, pS193; Auregan G., 1995, Archives de l'Institut Pasteur de Madagascar, V62, P18; BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228; CONINX R, 1995, LANCET, V346, P1238, DOI 10.1016/S0140-6736(95)92952-5; DROBNIEWSKI F, 1995, LANCET, V346, P948, DOI 10.1016/S0140-6736(95)91562-1; GOLDFARB A, 1999, PUBLIC HLTH RES I SO; Koffi N, 1997, INT J TUBERC LUNG D, V1, P250; MacIntyre CR, 1997, CLIN INFECT DIS, V24, P1060, DOI 10.1086/513632; Maher D, 1997, TREATMENT TUBERCULOS; Maher D, 1998, GUIDELINES CONTROL T; Nyangulu DS, 1997, LANCET, V350, P1284, DOI 10.1016/S0140-6736(97)05023-X; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Reyes H, 1997, BRIT MED J, V315, P1447, DOI 10.1136/bmj.315.7120.1447; Wares DF, 1997, LANCET, V350, P957, DOI 10.1016/S0140-6736(05)63295-3; *WHO, 1997, GLOB TUB PROGR GLOB	15	70	76	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					440	442		10.1136/bmj.320.7232.440	http://dx.doi.org/10.1136/bmj.320.7232.440			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669453	Green Published			2022-12-28	WOS:000085377400030
J	Hui, JYH; Woo, PCY; Kan, PS; Tang, APY				Hui, JYH; Woo, PCY; Kan, PS; Tang, APY			A woman with ascites and abdominal masses	LANCET			English	Article									Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Alice Ho Miu Ling Nethersole Hosp, Dept Diagnost Radiol, Tai Po, Hong Kong, Peoples R China	University of Hong Kong; Alice Ho Miu Ling Nethersole Hospital	Woo, PCY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.		Woo, Patrick Chiu Yat/C-4449-2009	Woo, Patrick Chiu Yat/0000-0001-9401-1832				ADEBAMOWO CA, 1993, TROP GEOGR MED, V45, P86; FORMIGARAMOS CC, 1980, AM J TROP MED HYG, V29, P795, DOI 10.4269/ajtmh.1980.29.795; IHEKWABA FN, 1979, BRIT J SURG, V66, P132, DOI 10.1002/bjs.1800660215; LAURENT F, 1991, GASTROINTEST RADIOL, V16, P115, DOI 10.1007/BF01887323; MYLVAGAN.C, 1969, J TROP MED HYG, V72, P98	5	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2000	355	9203					546	546		10.1016/S0140-6736(99)09107-2	http://dx.doi.org/10.1016/S0140-6736(99)09107-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10683006				2022-12-28	WOS:000085487400014
J	Maron, BJ; Shen, WK; Link, MS; Epstein, AE; Almquist, AK; Daubert, JP; Bardy, GH; Favale, S; Rea, RF; Boriani, G; Estes, NAM; Spirito, P				Maron, BJ; Shen, WK; Link, MS; Epstein, AE; Almquist, AK; Daubert, JP; Bardy, GH; Favale, S; Rea, RF; Boriani, G; Estes, NAM; Spirito, P			Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; VENTRICULAR-TACHYCARDIA; IMPROVED SURVIVAL; HIGH-RISK; MANAGEMENT; CARDIOLOGY; PROGNOSIS; SPECTRUM; DISEASE; YOUNG	Background: Hypertrophic cardiomyopathy is a genetic disease associated with a risk of ventricular tachyarrhythmias and sudden death, especially in young patients. Methods: We conducted a retrospective multicenter study of the efficacy of implantable cardioverter-defibrillators in preventing sudden death in 128 patients with hypertrophic cardiomyopathy who were judged to be at high risk for sudden death. Results: At the time of the implantation of the defibrillator, the patients were 8 to 82 years old (mean [+/-SD], 40+/-16), and 69 patients (54 percent) were less than 41 years old. The average follow-up period was 3.1 years. Defibrillators were activated appropriately in 29 patients (23 percent), by providing defibrillation shocks or antitachycardia pacing, with the restoration of sinus rhythm; the average age at the time of the intervention was 41 years. The rate of appropriate defibrillator discharge was 7 percent per year. A total of 32 patients (25 percent) had episodes of inappropriate discharges. In the group of 43 patients who received defibrillators for secondary prevention (after cardiac arrest or sustained ventricular tachycardia), the devices were activated appropriately in 19 patients (11 percent per year). Of 85 patients who had prophylactic implants because of risk factors (i.e., for primary prevention), 10 had appropriate interventions (5 percent per year). The interval between implantation and the first appropriate discharge was highly variable but was substantially prolonged (four to nine years) in six patients. In all 21 patients with stored electrographic data and appropriate interventions, the interventions were triggered by ventricular tachycardia or fibrillation. Conclusions: Ventricular tachycardia or fibrillation appears to be the principal mechanism of sudden death in patients with hypertrophic cardiomyopathy. In high-risk patients with hypertrophic cardiomyopathy, implantable defibrillators are highly effective in terminating such arrhythmias, indicating that these devices have a role in the primary and secondary prevention of sudden death. (N Engl J Med 2000;342:365-73.) (C)2000, Massachusetts Medical Society.	Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA; Mayo Clin, Rochester, MN USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Rochester, Med Ctr, Rochester, NY 14642 USA; Univ Washington, Med Ctr, Seattle, WA 98195 USA; Univ Bari, Bari, Italy; Univ Bologna, Bologna, Italy; Ente Osped Osped Galliera, Genoa, Italy	Minneapolis Heart Institute Foundation; Mayo Clinic; Tufts Medical Center; Tufts University; University of Alabama System; University of Alabama Birmingham; University of Rochester; University of Washington; University of Washington Seattle; Universita degli Studi di Bari Aldo Moro; University of Bologna; Ente Ospedaliero Ospedali Galliera	Maron, BJ (corresponding author), Minneapolis Heart Inst Fdn, 920 E 28th St,Suite 40, Minneapolis, MN 55407 USA.	gencvres@skypoint.com	Boriani, Giuseppe/AAC-3406-2022; Boriani, Giuseppe/A-4852-2015; Daubert, James P./ABC-1476-2021	Boriani, Giuseppe/0000-0002-9820-4815; Boriani, Giuseppe/0000-0002-9820-4815; Betocchi, Sandro/0000-0002-8701-2463; favale, stefano/0000-0002-9833-9576				Borggrefe M, 1998, J AM COLL CARDIOL, V31, P1086; CECCHI F, 1989, J AM COLL CARDIOL, V13, P1283, DOI 10.1016/0735-1097(89)90302-1; Credner SC, 1998, J AM COLL CARDIOL, V32, P1909, DOI 10.1016/S0735-1097(98)00495-1; Elliott PM, 1999, J AM COLL CARDIOL, V33, P1596, DOI 10.1016/S0735-1097(99)00056-X; FIDDLER GI, 1978, AM J CARDIOL, V42, P793, DOI 10.1016/0002-9149(78)90099-1; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLUES HG, 1995, J AM COLL CARDIOL, V26, P1699, DOI 10.1016/0735-1097(95)00390-8; LOUIE EK, 1994, PROG CARDIOVASC DIS, V36, P275, DOI 10.1016/S0033-0620(05)80036-2; MARON B, 1950, JAMA-J AM MED ASSOC, V281, P2288; MARON BJ, 1976, CIRCULATION, V53, P9, DOI 10.1161/01.CIR.53.1.9; Maron BJ, 1997, LANCET, V350, P1330; Maron BJ, 1998, CIRCULATION, V98, P1460, DOI 10.1161/01.CIR.98.14.1460; Maron BJ, 1999, JAMA-J AM MED ASSOC, V281, P650, DOI 10.1001/jama.281.7.650; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; Maron BJ, 1998, AM J CARDIOL, V81, P1339; MARON BJ, 1979, CIRCULATION, V59, P689, DOI 10.1161/01.CIR.59.4.689; Maron BJ, 1999, J CARDIOVASC ELECTR, V10, P263; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MCKENNA WJ, 1984, ARCH DIS CHILD, V59, P971, DOI 10.1136/adc.59.10.971; MCKENNA WJ, 1985, BRIT HEART J, V53, P412; MCKENNA WJ, 1989, CIRCULATION, V80, P1489, DOI 10.1161/01.CIR.80.5.1489; MIROWSKI M, 1980, NEW ENGL J MED, V303, P322, DOI 10.1056/NEJM198008073030607; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; MYERBURG RJ, 1989, J AM COLL CARDIOL, V14, P508, DOI 10.1016/0735-1097(89)90209-X; NICOD P, 1988, NEW ENGL J MED, V318, P1255, DOI 10.1056/NEJM198805123181907; Olivotto I, 1999, J AM COLL CARDIOL, V33, P2044, DOI 10.1016/S0735-1097(99)00094-7; Pires LA, 1999, J AM COLL CARDIOL, V33, P24, DOI 10.1016/S0735-1097(98)00519-1; Primo J, 1998, J AM COLL CARDIOL, V31, P1081, DOI 10.1016/S0735-1097(98)00037-0; Ruppel R, 1998, J AM COLL CARDIOL, V32, P1724, DOI 10.1016/S0735-1097(98)00430-6; Sadoul N, 1997, CIRCULATION, V96, P2987, DOI 10.1161/01.CIR.96.9.2987; Schaumann A, 1998, CIRCULATION, V97, P66, DOI 10.1161/01.CIR.97.1.66; SHAH PM, 1974, CIRC RES, V35, P179; SILKA MJ, 1993, CIRCULATION, V87, P800, DOI 10.1161/01.CIR.87.3.800; SPIRITO P, 1994, CIRCULATION, V90, P2743, DOI 10.1161/01.CIR.90.6.2743; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; TEARE D, 1958, BRIT HEART J, V20, P1; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; Zhu DWX, 1998, PACE, V21, P299, DOI 10.1111/j.1540-8159.1998.tb01109.x; ZIPES DP, 1995, CIRCULATION, V92, P59, DOI 10.1161/01.CIR.92.1.59	42	631	649	2	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					365	373		10.1056/NEJM200002103420601	http://dx.doi.org/10.1056/NEJM200002103420601			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666426				2022-12-28	WOS:000085205200001
J	Cowen, RK; Lwiza, KMM; Sponaugle, S; Paris, CB; Olson, DB				Cowen, RK; Lwiza, KMM; Sponaugle, S; Paris, CB; Olson, DB			Connectivity of marine populations: Open or closed?	SCIENCE			English	Article							GREAT-BARRIER-REEF; LARVAL FISHES; CORAL-REEFS; WEST-INDIES; RECRUITMENT; DIFFUSION; DISPERSAL; PACIFIC; DISTRIBUTIONS; CIRCULATION	Most marine populations are thought to be well connected via long-distance dispersal of larval stages. Eulerian and Lagrangian flow models, coupled with Linear mortality estimates, were used to examine this assumption. The findings show that when simple advection models are used, Larval exchange rates may be overestimated; such simplistic models fail to account for a decrease of up to nine orders of magnitude in larval concentrations resulting from diffusion and mortality. The alternative process of larval retention near local populations is shown to exist and may be of great importance in the maintenance of marine population structure and management of coastal marine resources.	Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; SUNY Stony Brook, Marine Sci Res Ctr, Stony Brook, NY 11794 USA	University of Miami; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Cowen, RK (corresponding author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, 4600 Rickenbacker Causeway, Miami, FL 33149 USA.			Olson, Donald/0000-0001-7180-5672; Paris-Limouzy, Claire Beatrix/0000-0002-0637-1334; Lwiza, Kamazima/0000-0003-2790-9284				BLACK KP, 1991, MAR ECOL PROG SER, V74, P1, DOI 10.3354/meps074001; BOEHLERT GW, 1992, DEEP-SEA RES, V39, P439, DOI 10.1016/0198-0149(92)90082-5; BOEHLERT GW, 1987, ESTUAR COAST SHELF S, V25, P261, DOI 10.1016/0272-7714(87)90071-0; CARR MH, 1993, CAN J FISH AQUAT SCI, V50, P2019, DOI 10.1139/f93-226; CHOAT JH, 1988, 6 INT COR REEF S EX, P149; COWEN RK, 1985, J MAR RES, V43, P719, DOI 10.1357/002224085788440376; COWEN RK, 1994, B MAR SCI, V54, P228; DOHERTY PJ, 1995, ECOLOGY, V76, P2373, DOI 10.2307/2265814; DORSEY S, UNPUB; DUTKIEWICZ S, 1993, J GEOPHYS RES-OCEANS, V98, P16487, DOI 10.1029/93JC01364; Govoni John J., 1994, Fisheries Oceanography, V3, P120, DOI 10.1111/j.1365-2419.1994.tb00054.x; Helbig JA, 1998, CAN J FISH AQUAT SCI, V55, P2206, DOI 10.1139/cjfas-55-10-2206; HILL AE, 1991, MAR ECOL PROG SER, V70, P117, DOI 10.3354/meps070117; HOUDE ED, 1989, FISH B-NOAA, V87, P471; JOHNS WE, 1990, J GEOPHYS RES-OCEANS, V95, P22103, DOI 10.1029/JC095iC12p22103; Jones GP, 1999, NATURE, V402, P802, DOI 10.1038/45538; Lee TN, 1999, B MAR SCI, V64, P35; Leis JM, 1997, MAR ECOL PROG SER, V159, P165, DOI 10.3354/meps159165; LEIS JM, 1991, MAR BIOL, V109, P157, DOI 10.1007/BF01320243; MEEKAN MG, 1993, MAR ECOL PROG SER, V93, P217, DOI 10.3354/meps093217; MORSE WW, 1989, FISH B-NOAA, V87, P417; OKUBO A, 1971, DEEP-SEA RES, V18, P789, DOI 10.1016/0011-7471(71)90046-5; OLSON DB, 1985, J MAR RES, V43, P113, DOI 10.1357/002224085788437325; Paiva AM, 1999, J MARINE SYST, V21, P307, DOI 10.1016/S0924-7963(99)00020-2; Polovina JJ, 1999, FISH B-NOAA, V97, P132; RICHARDSON PL, 1994, J GEOPHYS RES-OCEANS, V99, P5081, DOI 10.1029/93JC03486; Roberts CM, 1997, SCIENCE, V278, P1454, DOI 10.1126/science.278.5342.1454; Robertson DR, 1996, CORAL REEFS, V15, P121, DOI 10.1007/s003380050032; ROSENBLATT RH, 1986, COPEIA, P275, DOI 10.2307/1444988; ROUGHGARDEN J, 1985, ECOLOGY, V66, P54, DOI 10.2307/1941306; SCHELTEMA RS, 1986, B MAR SCI, V39, P290; SCHULTZ ET, 1994, MAR ECOL PROG SER, V109, P15, DOI 10.3354/meps109015; SHULMAN MJ, 1995, EVOLUTION, V49, P897, DOI 10.1111/j.1558-5646.1995.tb02325.x; Sinclair M, 1988, MARINE POPULATIONS E; Sponaugle S, 1996, MAR FRESHWATER RES, V47, P433, DOI 10.1071/MF9960433; Stansfield KL, 1995, J GEOPHYS RES-OCEANS, V100, P24819, DOI 10.1029/95JC02749; Stobutzki IC, 1997, MAR ECOL PROG SER, V149, P35, DOI 10.3354/meps149035; Swearer SE, 1999, NATURE, V402, P799, DOI 10.1038/45533; Taggart C.T., 1990, P151; THORSON G, 1950, MEDD DOMM DAN FISK P, V4, P1; WARNER RR, 1988, P 6 INT COR REEF S T, V1; Werner Francisco E., 1993, Fisheries Oceanography, V2, P43, DOI 10.1111/j.1365-2419.1993.tb00120.x; Wing SR, 1998, LIMNOL OCEANOGR, V43, P1710, DOI 10.4319/lo.1998.43.7.1710; Wolanski E, 1997, NATURWISSENSCHAFTEN, V84, P262, DOI 10.1007/s001140050394	44	905	922	2	245	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					857	859		10.1126/science.287.5454.857	http://dx.doi.org/10.1126/science.287.5454.857			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657300				2022-12-28	WOS:000085136400047
J	Xue, YQ; Sherman, DH				Xue, YQ; Sherman, DH			Alternative modular polyketide synthase expression controls macrolactone structure	NATURE			English	Article							STREPTOMYCES-VENEZUELAE; BIOSYNTHESIS; ACID	Modular polyketide synthases are giant multifunctional enzymes that catalyse the condensation of small carboxylic acids such as acetate and propionate into structurally diverse polyketides that possess a spectrum of biological activities(1,2). In a modular polyketide synthase, an enzymatic domain catalyses a specific reaction, and three to six enzymatic domains involved in a condensation-processing cycle are organized into a module(3). A fundamental aspect of a modular polyketide synthase is that its module arrangement linearly specifies the structure of its polyketide product(3). Here we report a natural example in which alternative expression of the pikromycin polyketide synthase results in the generation of two macrolactone structures. Expression of the full-length modular polyketide synthase PikAIV in Streptomyces venezuelae generates the 11-membered ring macrolactone narbonolide, whereas expression of the amino-terminal truncated form of PikAIV leads to 'skipping' of the final condensation cycle in polyketide biosynthesis to generate the 12-membered ring macrolactone 10-deoxymethynolide. Our findings provide insight into the structure and function of modular polyketide synthases, as well as a new set of tools to generate structural diversity in polyketide natural products.	Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Minnesota, Biol Proc Technol Inst, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Sherman, DH (corresponding author), Univ Minnesota, Dept Microbiol, Box 196,1460 Mayo Mem Bldg, Minneapolis, MN 55455 USA.			Xue, Alex/0000-0002-7388-6899				Bisang C, 1999, NATURE, V401, P502, DOI 10.1038/46829; Butler AR, 1999, CHEM BIOL, V6, P287, DOI 10.1016/S1074-5521(99)80074-X; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Gokhale RS, 1999, SCIENCE, V284, P482, DOI 10.1126/science.284.5413.482; Gokhale RS, 1999, CHEM BIOL, V6, P117, DOI 10.1016/S1074-5521(99)80008-8; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HORI T, 1971, J CHEM SOC CHEM COMM, P304, DOI 10.1039/c29710000304; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; LAMBALOT RH, 1992, J ANTIBIOT, V45, P1981, DOI 10.7164/antibiotics.45.1981; LYDIATE DJ, 1985, GENE, V35, P223, DOI 10.1016/0378-1119(85)90001-0; Rangaswamy V, 1998, J BACTERIOL, V180, P3330, DOI 10.1128/JB.180.13.3330-3338.1998; Sambrook J., 2002, MOL CLONING LAB MANU; Schneider A, 1998, ARCH MICROBIOL, V169, P404, DOI 10.1007/s002030050590; SHERMAN DH, 1988, P 8 INT BIOT S SOC F, V1, P123; Staunton J, 1996, NAT STRUCT BIOL, V3, P188, DOI 10.1038/nsb0296-188; Tang L, 1999, CHEM BIOL, V6, P553, DOI 10.1016/S1074-5521(99)80087-8; Xue YQ, 1998, CHEM BIOL, V5, P661, DOI 10.1016/S1074-5521(98)90293-9; Xue YQ, 1998, P NATL ACAD SCI USA, V95, P12111, DOI 10.1073/pnas.95.21.12111	21	90	95	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					571	575		10.1038/35000624	http://dx.doi.org/10.1038/35000624			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676969				2022-12-28	WOS:000085227300057
J	Strauss, RS				Strauss, RS			Adult functional outcome of those born small for gestational age - Twenty-six-year follow-up of the 1970 British Birth Cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; INTRAUTERINE GROWTH-RETARDATION; CHILDREN BORN; SCHOOL-AGE; INFANTS; WEIGHT; RISK; ADOLESCENCE; INTERVENTION; DISABILITY	Context Although studies have documented cognitive impairment in children who were born small for gestational age (SCA), other studies have not demonstrated differences in IQ or other cognitive scores. The need exists for long-term studies of such children to assess functional outcomes not measurable with standardized testing. Objective To determine the long-term functional outcome of SGA infants. Design Prospective cohort study. Setting and Participants A total of 14 189 full-term infants born in the United Kingdom on April 5 through 11, 1970, were studied as part of the 1970 British Birth Cohort; 1064 were SCA (birth weight less than the fifth percentile for age at term). Follow-up at 5, 10, 16, and 26 years was 93%, 80%, 72%, and 53%, respectively. Main Outcome Measures School performance and achievement, assessed at 5, 10, and 16 years; and years of education, occupational status, income, marital status, life satisfaction, disability, and height, assessed at 26 years, comparing persons born SCA with those who were not. Results At 5, 10, and 16 years of age, those born SCA demonstrated small but significant deficits in academic achievement. In addition, teachers were less likely to rate those born SGA in the top 15th percentile of the class at 16 years (13% vs 20%, P<.01) and more likely to recommend special education (4.9% vs 2.3%; P<.01) compared with those born at normal birth weight (NBW). At age 26 years, adults who were SGA did not demonstrate any differences in years of education, employment, hours of work per week, marital status, or satisfaction with life. However, adults who were SCA were less likely to have professional or managerial jobs (8.7% vs 16.4%; P<.01) and reported significantly lower levels of weekly income (mean [SD], 185 [91] vs 206 [102] pound; P<.01) than adults who were NEW. Adults who were SCA also reported significant height deficits compared with those who were NEW (mean [SD] z score, -0.55 [0.98] vs 0.08 [1.02]; P<.001), Similar results were also obtained after adjusting for social class, sex, region of birth, and the presence of fetal or neonatal distress. Conclusions In this cohort, adults who were born SGA had significant differences in academic achievement and professional attainment compared with adults who were NEW. However, there were no long-term social or emotional consequences of being SGA: these adults were as likely to be employed, married, and satisfied with life.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, Div Pediat Gastroenterol & Nutr, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Strauss, RS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, Div Pediat Gastroenterol & Nutr, 1 Robert Wood Johnson Pl,CN-19, New Brunswick, NJ 08903 USA.							BABSON SG, 1969, AM J DIS CHILD, V117, P553, DOI 10.1001/archpedi.1969.02100030555009; BENDERSKY M, 1994, DEV PSYCHOL, V30, P484, DOI 10.1037/0012-1649.30.4.484; Berlin LJ, 1998, PREV MED, V27, P238, DOI 10.1006/pmed.1998.0282; Brimer MA, 1962, ENGLISH PICTURE VOCA; COLE S, 1981, HEAD CIRCUMFERENCE L; DAVIE R, 1972, BIRTH 7 REPORT NATL; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DOUGLAS JWB, 1976, ARCH DIS CHILD, V51, P820, DOI 10.1136/adc.51.11.820; ESCALONA SK, 1982, PEDIATRICS, V70, P670; FITZHARDINGE PM, 1972, PEDIATRICS, V50, P50; FORBES JF, 1983, BRIT J OBSTET GYNAEC, V90, P297, DOI 10.1111/j.1471-0528.1983.tb08913.x; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; GOLDENBERG, 1998, EUR J CLIN NUTR, V52, pS100; Goldthorpe J. H., 1974, SOCIAL GRADING OCCUP; HACK M, 1991, NEW ENGL J MED, V325, P231, DOI 10.1056/NEJM199107253250403; Hardy JB., 1979, 1 YEAR LIFE; Harris, 1963, CHILDRENS DRAWINGS M; HARVEY D, 1982, PEDIATRICS, V69, P296; HERTZIG ME, 1981, DEV MED CHILD NEUROL, V23, P778; KALVERBOER, 1972, PROFILE TEST SPACIAL; KIMMEL PL, 1995, J AM SOC NEPHROL, V6, P1418; LOW JA, 1992, AM J OBSTET GYNECOL, V167, P1499, DOI 10.1016/0002-9378(92)91727-R; LOW JA, 1982, AM J OBSTET GYNECOL, V142, P670, DOI 10.1016/S0002-9378(16)32439-5; McCormick MC, 1996, PEDIATRICS, V97, P18; McIntire DD, 1999, NEW ENGL J MED, V340, P1234, DOI 10.1056/NEJM199904223401603; MITCHELL RG, 1980, DEV MED CHILD NEUROL, V22, P1; MYERS DG, 1995, PSYCHOL SCI, V6, P10, DOI 10.1111/j.1467-9280.1995.tb00298.x; NILSEN ST, 1988, BRIT J OBSTET GYNAEC, V91, P122; PAZ I, 1993, AM J DIS CHILD, V147, P337, DOI 10.1001/archpedi.1993.02160270099030; PAZ I, 1995, OBSTET GYNECOL, V85, P452; PRYOR J, 1995, J PAEDIATR CHILD H, V31, P403, DOI 10.1111/j.1440-1754.1995.tb00847.x; RUBIN RA, 1973, PEDIATRICS, V52, P352; Saigal S, 1996, JAMA-J AM MED ASSOC, V276, P453, DOI 10.1001/jama.276.6.453; SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162; STEIN Z, 1972, SCIENCE, V178, P708, DOI 10.1126/science.178.4062.708; Sternberg R. J, 1998, SCI AM, V9, P12; STEWART AL, 1982, J CHRON DIS, V35, P295, DOI 10.1016/0021-9681(82)90085-6; Strauss RS, 1997, J PEDIATR-US, V130, P95, DOI 10.1016/S0022-3476(97)70316-0; Strauss RS, 1998, J PEDIATR-US, V133, P67, DOI 10.1016/S0022-3476(98)70180-5; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; Tate DG, 1997, ARCH PHYS MED REHAB, V78, pS18, DOI 10.1016/S0003-9993(97)90217-3; Tin W, 1998, ARCH DIS CHILD-FETAL, V79, pF83, DOI 10.1136/fn.79.2.F83; VILLAR J, 1984, PEDIATRICS, V74, P783; Weikart DP, 1998, PREV MED, V27, P233, DOI 10.1006/pmed.1998.0280; WESTWOOD M, 1983, PEDIATRICS, V71, P376	45	301	320	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					625	632		10.1001/jama.283.5.625	http://dx.doi.org/10.1001/jama.283.5.625			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	277WL	10665702	Bronze			2022-12-28	WOS:000084956500028
J	Bodelier, PLE; Roslev, P; Henckel, T; Frenzel, P				Bodelier, PLE; Roslev, P; Henckel, T; Frenzel, P			Stimulation by ammonium-based fertilizers of methane oxidation in soil around rice roots	NATURE			English	Article							METHANOTROPHIC BACTERIA; ORYZA-SATIVA; FOREST SOILS; INHIBITION; CONSUMPTION; KINETICS; PLANTS	Methane is involved in a number of chemical and physical processes in the Earths atmosphere, including global warming(1), Atmospheric methane originates mainly from biogenic sources, such as rice paddies and natural wetlands; the former account for at least 30% of the global annual emission of methane to the atmosphere(2). As an increase of rice production by 60% is the most appropriate way to sustain the estimated increase of the human population during the next three decades(3), intensified global fertilizer application will be necessary(3): but it is known that an increase of the commonly used ammonium-based fertilizers can enhance methane emission from rice agriculture. Approximately 10-30% of the methane produced by methanogens in rice paddies is consumed by methane-oxidizing bacteria associated with the roots of rice(4,5); these bacteria are generally thought to be inhibited by ammonium-based fertilizers, as tvas demonstrated for soils(6-8) and sediments(9,10). In contrast, we show here that the activity and growth of such bacteria in the root zone of rice plants are stimulated after fertilization. Using a combination of radioactive fingerprinting(11) and molecular biology(12) techniques, we identify the bacteria responsible for this effect. We expect that our results will make necessary a re-evaluation of the link between fertilizer use and methane emissions, with effects on global warming studies.	Netherlands Inst Ecol, Ctr Limnol, NL-3631 AC Nieuwersluis, Netherlands; Max Planck Inst Terr Microbiol, Dept Biogeochem, D-35043 Marburg, Germany; Univ Aalborg, Environm Engn Lab, DK-9000 Aalborg, Denmark	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); Max Planck Society; Aalborg University	Bodelier, PLE (corresponding author), Netherlands Inst Ecol, Ctr Limnol, Rijksstr Weg 6, NL-3631 AC Nieuwersluis, Netherlands.		Bodelier, Paul/AAF-8353-2020; Bodelier, Paul L/A-9591-2011	Bodelier, Paul/0000-0002-5757-5572; Bodelier, Paul L/0000-0002-5757-5572				Banik A, 1996, BIOL FERT SOILS, V21, P319, DOI 10.1007/BF00334910; Bodelier PLE, 1999, APPL ENVIRON MICROB, V65, P1826; Bodelier PLE, 1997, PLANT SOIL, V190, P91, DOI 10.1023/A:1004212814097; BODELIER PLE, UNPUB BIOGEOCHEMISTR; BOSSE U, 1993, FEMS MICROBIOL ECOL, V13, P123, DOI 10.1016/0168-6496(93)90030-B; Bosse U, 1997, APPL ENVIRON MICROB, V63, P1199, DOI 10.1128/AEM.63.4.1199-1207.1997; Cassman KG, 1998, FIELD CROP RES, V56, P7, DOI 10.1016/S0378-4290(97)00140-8; CRUTZEN PJ, RUMINANT PHYSL DIGES, P291; DUNFIELD P, 1995, APPL ENVIRON MICROB, V61, P3129, DOI 10.1128/AEM.61.8.3129-3135.1995; Gilbert B, 1998, SOIL BIOL BIOCHEM, V30, P1903, DOI 10.1016/S0038-0717(98)00061-3; Gulledge J, 1997, SOIL BIOL BIOCHEM, V29, P13, DOI 10.1016/S0038-0717(96)00265-9; Gulledge J, 1998, APPL ENVIRON MICROB, V64, P4291; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; Henckel T, 1999, APPL ENVIRON MICROB, V65, P1980; King GM, 1998, APPL ENVIRON MICROB, V64, P253; KING GM, 1994, APPL ENVIRON MICROB, V60, P3220, DOI 10.1128/AEM.60.9.3220-3227.1994; KING GM, 1994, NATURE, V370, P282, DOI 10.1038/370282a0; LINDAU CW, 1991, PLANT SOIL, V136, P195, DOI 10.1007/BF02150050; Ludwig W, 1998, ELECTROPHORESIS, V19, P554, DOI 10.1002/elps.1150190416; Neue HU, 1997, SOIL USE MANAGE, V13, P258, DOI 10.1111/j.1475-2743.1997.tb00597.x; Roslev P, 1999, APPL ENVIRON MICROB, V65, P4064; Roslev P, 1998, J MICROBIOL METH, V31, P99, DOI 10.1016/S0167-7012(97)00094-8; STEUDLER PA, 1989, NATURE, V341, P314, DOI 10.1038/341314a0; Strunk O, 1996, ARB SOFTWARE ENV SEQ; SUNDH I, 1995, FEMS MICROBIOL ECOL, V18, P103, DOI 10.1111/j.1574-6941.1995.tb00167.x; vanderGon HACD, 1996, BIOL FERT SOILS, V22, P359, DOI 10.1007/BF00334584; vanderNat FJWA, 1997, APPL ENVIRON MICROB, V63, P4734, DOI 10.1128/AEM.63.12.4734-4740.1997	27	371	419	10	204	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					421	424		10.1038/35000193	http://dx.doi.org/10.1038/35000193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667792				2022-12-28	WOS:000085121100048
J	Brenner, MP				Brenner, MP			Fluid mechanics - Jets from a singular surface	NATURE			English	Editorial Material							COLLAPSING CAVITIES; WAVES		MIT, Dept Math, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Brenner, MP (corresponding author), MIT, Dept Math, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							CHOPTUIK MW, 1993, PHYS REV LETT, V70, P9, DOI 10.1103/PhysRevLett.70.9; COOKER MJ, 1990, P 6 INT WORKSH WAT W, P49; KELLER JB, 1983, SIAM J APPL MATH, V43, P268, DOI 10.1137/0143018; LARSON RB, 1969, MON NOT R ASTRON SOC, V145, P271, DOI 10.1093/mnras/145.3.271; LONGUETHIGGINS MS, 1995, J FLUID MECH, V290, P183, DOI 10.1017/S0022112095002461; LonguetHiggins MS, 1997, PHILOS T R SOC A, V355, P625, DOI 10.1098/rsta.1997.0029; PLESSET MS, 1977, ANNU REV FLUID MECH, V9, P145, DOI 10.1146/annurev.fl.09.010177.001045; TAYLOR G, 1950, PROC R SOC LON SER-A, V201, P159, DOI 10.1098/rspa.1950.0049; Zeff BW, 2000, NATURE, V403, P401, DOI 10.1038/35000151	10	12	14	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					377	378		10.1038/35000330	http://dx.doi.org/10.1038/35000330			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667775				2022-12-28	WOS:000085121100031
J	Sekiyama, A; Iwasaki, T; Matsuda, K; Saitoh, Y; Onuki, Y; Suga, S				Sekiyama, A; Iwasaki, T; Matsuda, K; Saitoh, Y; Onuki, Y; Suga, S			Probing bulk states of correlated electron systems by high-resolution resonance photoemission	NATURE			English	Article							CE COMPOUNDS; MODEL; SPECTROSCOPY; CERIUM; CERU2SI2; METAL	Electron correlations are known to play an important role in determining the unusual physical properties of a variety of compounds. Such properties include high-temperature superconductivity(1), heavy fermion behaviour(2,3) and metal-to-insulator transitions(4,5). High-resolution photoelectron spectroscopy (PES) provides a means of directly probing the electronic states (particularly those near the Fermi level) in these materials, but the; short photoelectron mean free paths(6) (less than or equal to 5 Angstrom) associated with the low excitation energies conventionally used (less than or equal to 120 eV) make this a surface-sensitive technique. Now that high-resolution PES is possible at much higher energies(7), with mean free paths as long as 15 Angstrom (ref. 6), it should become feasible to probe the bulk electronic states in these materials. Here we demonstrate the power of this technique by applying it to the cerium compounds CeRu2Si2 and CeRu2. Previous PES studies of these compounds revealed very similar spectra for the Ce 4f electronic states(8-13), yet it is expected that such states should be different owing to their differing degrees of hybridization with other valence bands. Our determination of the bulk Ce 4f electronic states of these compounds resolves these differences.	Osaka Univ, Grad Sch Engn Sci, Dept Mat Phys, Osaka 5608531, Japan; Japan Atom Energy Res Inst, Kansai Res Esteb, Dept Synchrotron Res, Mikazuki, Hyogo 6795148, Japan; Osaka Univ, Grad Sch Sci, Dept Phys, Osaka 5600043, Japan	Osaka University; Japan Atomic Energy Agency; Osaka University	Sekiyama, A (corresponding author), Osaka Univ, Grad Sch Engn Sci, Dept Mat Phys, Osaka 5608531, Japan.		Sekiyama, Akira/G-1851-2016					ALLEN JW, 1986, ADV PHYS, V35, P275, DOI 10.1080/00018738600101901; AMATO A, 1988, J MAGN MAGN MATER, V76-7, P263, DOI 10.1016/0304-8853(88)90389-7; AMATO A, 1988, J MAGN MAGN MAT, V77; AOKI H, 1992, J PHYS SOC JPN, V61, P3457, DOI 10.1143/JPSJ.61.3457; BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701; BICKERS NE, 1985, PHYS REV LETT, V54, P230, DOI 10.1103/PhysRevLett.54.230; DUO L, 1996, PHYS REV B, V54, pR1736; Garnier M, 1997, PHYS REV LETT, V78, P4127, DOI 10.1103/PhysRevLett.78.4127; GUNNARSSON O, 1983, PHYS REV LETT, V50, P604, DOI 10.1103/PhysRevLett.50.604; Hedo M, 1998, PHILOS MAG B, V77, P975, DOI 10.1080/13642819808206399; JOYCE JJ, 1992, PHYS REV LETT, V68, P236, DOI 10.1103/PhysRevLett.68.236; KAINDL G, 1992, REV SCI INSTRUM, V63, P1234, DOI 10.1063/1.1143090; Kang JS, 1999, PHYS REV B, V60, P5348, DOI 10.1103/PhysRevB.60.5348; KUWAHARA H, 1995, SCIENCE, V270, P961, DOI 10.1126/science.270.5238.961; NAKAMURA M, 1994, PHYS REV LETT, V73, P2891, DOI 10.1103/PhysRevLett.73.2891; ONUKI Y, 1987, J MAGN MAGN MATER, V63-4, P281, DOI 10.1016/0304-8853(87)90587-7; ONUKI Y, 1987, J MAGN MAGN MAT, V64; PATTHEY F, 1990, PHYS REV B, V42, P8864, DOI 10.1103/PhysRevB.42.8864; Saitoh Y, 1998, J SYNCHROTRON RADIAT, V5, P542, DOI 10.1107/S090904959701902X; SATO N, 1984, J PHYS SOC JPN, V53, P3967, DOI 10.1143/JPSJ.53.3967; TANUMA S, 1987, SURF SCI, V192, pL849, DOI 10.1016/S0039-6028(87)81156-1; WESCHKE E, 1991, PHYS REV B, V44, P8304, DOI 10.1103/PhysRevB.44.8304; Witkowski N, 1997, PHYS REV B, V56, P12054, DOI 10.1103/PhysRevB.56.12054; Yang SH, 1996, PHYS REV B, V53, P11946, DOI 10.1103/PhysRevB.53.R11946; YEH JJ, 1985, ATOM DATA NUCL DATA, V32, P1, DOI 10.1016/0092-640X(85)90016-6	25	250	251	3	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					396	398		10.1038/35000140	http://dx.doi.org/10.1038/35000140			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667784				2022-12-28	WOS:000085121100040
J	Morrow, M; Schnitt, SJ				Morrow, M; Schnitt, SJ			Treatment selection in ductal carcinoma in situ	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BREAST-CANCER; IN-SITU; INSITU; LESIONS; AUTOPSY; THERAPY		Northwestern Univ, Sch Med, Dept Surg, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Lynn Sage Comprehens Breast Ctr, Chicago, IL USA; Harvard Univ, Sch Med, Beth Israel Hosp, Dept Pathol, Boston, MA USA	Northwestern University; Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Morrow, M (corresponding author), NW Mem Hosp, Lynn Sage Comprehens Breast Ctr, 251 E Huron St,Galter 13-174, Chicago, IL 60611 USA.							BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher B, 1998, J CLIN ONCOL, V16, P441, DOI 10.1200/JCO.1998.16.2.441; Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y; Gapstur SM, 1999, JAMA-J AM MED ASSOC, V281, P2091, DOI 10.1001/jama.281.22.2091; Hiramatsu H, 1995, Cancer J Sci Am, V1, P55; HOLLAND R, 1990, LANCET, V335, P519, DOI 10.1016/0140-6736(90)90747-S; Jordan VC, 1999, ENDOCR REV, V20, P253, DOI 10.1210/edrv.20.3.0368; KINNE DW, 1989, ARCH SURG-CHICAGO, V124, P33; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; MORROW M, 2000, DIS BREAST, P383; NIELSEN M, 1984, CANCER-AM CANCER SOC, V54, P612, DOI 10.1002/1097-0142(1984)54:4<612::AID-CNCR2820540403>3.0.CO;2-B; Pandya S, 1998, BREAST J, V4, P146; Ravdin PM, 1998, J CLIN ONCOL, V16, P515, DOI 10.1200/JCO.1998.16.2.515; ROSNER D, 1980, ANN SURG, V192, P139, DOI 10.1097/00000658-198008000-00001; Silverstein MJ, 1999, NEW ENGL J MED, V340, P1455, DOI 10.1056/NEJM199905133401902; SILVERSTEIN MJ, 1997, DUCTAL CARCINOMA IN, P443; Solin LJ, 1996, J CLIN ONCOL, V14, P754, DOI 10.1200/JCO.1996.14.3.754	19	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					453	455		10.1001/jama.283.4.453	http://dx.doi.org/10.1001/jama.283.4.453			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659859				2022-12-28	WOS:000084879800002
J	Schlissel, MS				Schlissel, MS			Transcription - A tail of histone acetylation and DNA recombination	SCIENCE			English	Editorial Material									Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Schlissel, MS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 439 LSA, Berkeley, CA 94720 USA.							ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Golding A, 1999, EMBO J, V18, P3712, DOI 10.1093/emboj/18.13.3712; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kwon J, 1998, MOL CELL, V2, P829, DOI 10.1016/S1097-2765(00)80297-X; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; McMurry MT, 2000, SCIENCE, V287, P495, DOI 10.1126/science.287.5452.495; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	10	33	33	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					438	440		10.1126/science.287.5452.438	http://dx.doi.org/10.1126/science.287.5452.438			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10671173				2022-12-28	WOS:000084929900031
J	Bergman, R; Swenson, J				Bergman, R; Swenson, J			Dynamics of supercooled water in confined geometry	NATURE			English	Article							LOW-FREQUENCY DISPERSION; GLASS-TRANSITION; DIELECTRIC-RELAXATION; LIQUIDS	As with most liquids, it is possible to supercool(1-4) water; this generally involves cooling the liquid below its melting temperature I(avoiding crystallization) until it eventually forms a glass. The viscosity and related relaxation times (tau) of glass-forming liquids typically show non-Arrhenius temperature (T) dependencies: Liquids with highly non-Arrhenius behaviour in the supercooled region are termed 'fragile', In contrast, liquids whose behaviour is close to the Arrhenius law (ln tau proportional to 1/T) are termed 'strong' (ref. 5). A unique 'fragile-strong' transition around 228 K has been proposed(6) for supercooled water; however, experimental studies of hulk supercooled water in this temperature range are generally hampered because crystallization occurs. Here we use broad-band dielectric spectroscopy to study the relaxation dynamics of supercooled water in a wide temperature range, including the usually inaccessible temperature region. This is possible because the supercooled water is held within a layered vermiculite clay-the geometrical confinement and presence of intercalated sodium ions prevent(7) most of the water from crystallizing. We find a relaxational process with an Arrhenius temperature dependence, consistent with the proposed strong nature of deeply supercooled bulk water. Because water that is less supercooled has been established(6) as highly fragile, our results support the existence of a fragile-strong transition.	Chalmers Univ Technol, Dept Expt Phys, SE-41296 Gothenburg, Sweden; Chalmers Univ Technol, Dept Appl Phys, SE-41296 Gothenburg, Sweden	Chalmers University of Technology; Chalmers University of Technology	Bergman, R (corresponding author), Chalmers Univ Technol, Dept Expt Phys, SE-41296 Gothenburg, Sweden.		VIEILLARD, Philippe/B-8544-2008; Swenson, Jan/H-6653-2018	VIEILLARD, Philippe/0000-0003-0394-7999; Swenson, Jan/0000-0001-5640-4766				ANGELL C.A., 1982, WATER COMPREHENSIVE, P1; ANGELL CA, 1988, NATURE, V331, P206, DOI 10.1038/331206a0; ANGELL CA, 1991, J NON-CRYST SOLIDS, V131, P13, DOI 10.1016/0022-3093(91)90266-9; Arndt M, 1997, PHYS REV LETT, V79, P2077, DOI 10.1103/PhysRevLett.79.2077; Barut G, 1998, PHYS REV LETT, V80, P3543, DOI 10.1103/PhysRevLett.80.3543; BERGMAN R, UNPUB J CHEM PHYS; BJERRUM N, 1952, SCIENCE, V115, P385, DOI 10.1126/science.115.2989.385; BOHMER R, 1993, J CHEM PHYS, V99, P4201, DOI 10.1063/1.466117; HANDA YP, 1988, J PHYS CHEM-US, V92, P3323, DOI 10.1021/j100323a005; HUNTER RJ, 1971, NATURE-PHYS SCI, V230, P192, DOI 10.1038/physci230192b0; Ito K, 1999, NATURE, V398, P492, DOI 10.1038/19042; Jeevanandam P, 1998, J CHEM PHYS, V108, P1206, DOI 10.1063/1.475482; Johari GP, 1996, J CHEM PHYS, V105, P7079, DOI 10.1063/1.472509; JOHARI GP, 1987, NATURE, V330, P552, DOI 10.1038/330552a0; JONSCHER AK, 1978, PHILOS MAG B, V38, P587, DOI 10.1080/13642817808246336; Mishima O, 1998, NATURE, V396, P329, DOI 10.1038/24540; Mizoguchi K, 1998, J CHEM PHYS, V109, P1867, DOI 10.1063/1.476763; NAGAI KL, 1998, J NONCRYST SOLIDS, P235; Okada K, 1999, J CHEM PHYS, V110, P3026, DOI 10.1063/1.477897; OLEJNIK S, 1972, NATURE-PHYS SCI, V236, P15, DOI 10.1038/physci236015b0; Ronne C, 1999, PHYS REV LETT, V82, P2888, DOI 10.1103/PhysRevLett.82.2888; Sillescu H, 1999, J NON-CRYST SOLIDS, V243, P81, DOI 10.1016/S0022-3093(98)00831-X; SKIPPER NT, 1991, J CHEM PHYS, V94, P5751, DOI 10.1063/1.460457; Smith RS, 1999, NATURE, V398, P788, DOI 10.1038/19725; SPEEDY RJ, 1976, J CHEM PHYS, V65, P851, DOI 10.1063/1.433153; Stanley HE, 1999, MRS BULL, V24, P22, DOI 10.1557/S0883769400052295; SWENSON J, UNPUB J CHEM PHYS; Tanaka H, 1996, NATURE, V380, P328, DOI 10.1038/380328a0; TUCK JJ, 1984, J CHEM SOC FARAD T 1, V80, P309, DOI 10.1039/f19848000309	29	299	300	0	101	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					283	286		10.1038/35002027	http://dx.doi.org/10.1038/35002027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659841				2022-12-28	WOS:000084899700044
J	Gingerich, O				Gingerich, O			Tycho and the ton of gold	NATURE			English	Editorial Material									Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Gingerich, O (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.								0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					251	251		10.1038/35002212	http://dx.doi.org/10.1038/35002212			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659828	Bronze			2022-12-28	WOS:000084899700028
J	Yan, YF; Pennycook, SJ				Yan, YF; Pennycook, SJ			Alloys - Atomic structure of the quasicrystal Al72Ni20Co8	NATURE			English	Article							TILINGS		Oak Ridge Natl Lab, Div Solid State, Oak Ridge, TN 37831 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory	Yan, YF (corresponding author), Natl Renewable Energy Lab, Golden, CO 80401 USA.		Pennycook, Stephen/AAA-1112-2019	Pennycook, Stephen/0000-0002-3210-6323				Gummelt P, 1996, GEOMETRIAE DEDICATA, V62, P1, DOI 10.1007/bf00239998; Jeong HC, 1997, PHYS REV B, V55, P3520, DOI 10.1103/PhysRevB.55.3520; Steinhardt PJ, 1998, NATURE, V396, P55, DOI 10.1038/23902; Steinhardt PJ, 1999, NATURE, V399, P84, DOI 10.1038/20005; STEINHARDT PJ, 1996, NATURE, V382, P433; YAN Y, IN PRESS MATER SCI E	6	19	19	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					266	267		10.1038/35002251	http://dx.doi.org/10.1038/35002251			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659836				2022-12-28	WOS:000084899700038
J	Alderman, MH				Alderman, MH			Measures and meaning of blood pressure	LANCET			English	Editorial Material									Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Alderman, MH (corresponding author), Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA.							ALDERMAN MH, 1993, ANN INTERN MED, V119, P329, DOI 10.7326/0003-4819-119-4-199308150-00013; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Chalmers J, 1999, J HYPERTENS, V17, P151; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; PROBSTFIELD JL, 1991, JAMA-J AM MED ASSOC, V265, P3255; SWALE SJD, 1985, PLATT VERSUS PICKERI	7	10	10	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2000	355	9199					159	159		10.1016/S0140-6736(99)00409-2	http://dx.doi.org/10.1016/S0140-6736(99)00409-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675109				2022-12-28	WOS:000084879700003
J	Ginsburg, J; Prelevic, GM				Ginsburg, J; Prelevic, GM			Lack of significant hormonal effects and controlled trials of phyto-oestrogens	LANCET			English	Editorial Material							SOY; MENOPAUSE; ESTROGEN; WOMEN		UCL Royal Free & Univ Coll, Sch Med, Dept Med, London NW3 2QG, England	University of London; University College London; UCL Medical School	Ginsburg, J (corresponding author), UCL Royal Free & Univ Coll, Sch Med, Dept Med, London NW3 2QG, England.							ALDERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; BAIRD DD, 1995, J CLIN ENDOCR METAB, V80, P1685, DOI 10.1210/jc.80.5.1685; BOULET MJ, 1994, MATURITAS, V19, P157, DOI 10.1016/0378-5122(94)90068-X; Duncan AM, 1999, J CLIN ENDOCR METAB, V84, P3479, DOI 10.1210/jc.84.10.3479; HUNTER MS, 1990, PSYCHOSOM MED, V52, P357, DOI 10.1097/00006842-199005000-00009; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Martini MC, 1999, NUTR CANCER, V34, P133, DOI 10.1207/S15327914NC3402_2; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; Nestel PJ, 1999, J CLIN ENDOCR METAB, V84, P895, DOI 10.1210/jc.84.3.895; TANG DG, 1993, PROSTAG OTH LIPID M, V45, P249, DOI 10.1016/0090-6980(93)90051-8; Xu X, 1998, CANCER EPIDEM BIOMAR, V7, P1101	12	28	29	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					163	164		10.1016/S0140-6736(99)00428-6	http://dx.doi.org/10.1016/S0140-6736(99)00428-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675113				2022-12-28	WOS:000084879700007
J	Averof, M; Rokas, A; Wolfe, KH; Sharp, PM				Averof, M; Rokas, A; Wolfe, KH; Sharp, PM			Evidence for a high frequency of simultaneous double-nucleotide substitutions	SCIENCE			English	Article							NONSYNONYMOUS SUBSTITUTIONS; MOLECULAR EVOLUTION; UBIQUITIN GENES; 2 SERINES; SEQUENCE; DNA; DIVERGENCE; ALIGNMENT; MUTATION; GENOME	Point mutations are generally assumed to involve changes of single nucleotides. Nevertheless, the nature and known mechanisms of mutation do not exclude the possibility that several adjacent nucleotides may change simultaneously in a single mutational event. Two independent approaches are used here to estimate the frequency of simultaneous double-nucleotide substitutions. The first examines switches between TCN and ACY (where N is any nucleotide and Y is a pyrimidine) codons encoding absolutely conserved serine residues in a number of proteins from diverse organisms. The second reveals double-nucleotide substitutions in primate noncoding sequences. These two complementary approaches provide similar high estimates for the rate of doublet substitutions, on the order of 0.1 per site per billion years.	FORTH, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Dublin Trinity Coll, Dept Genet, Dublin 2, Ireland; Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England	Foundation for Research & Technology - Hellas (FORTH); University of Edinburgh; Trinity College Dublin; University of Nottingham	Averof, M (corresponding author), FORTH, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece.		Rokas, Antonis/A-9775-2008; Sharp, Paul M/F-5783-2010; Wolfe, Kenneth H/B-4653-2009; Sharp, Paul M/GPX-1497-2022; Sharp, Paul/Y-3787-2019	Rokas, Antonis/0000-0002-7248-6551; Sharp, Paul M/0000-0001-9771-543X; Sharp, Paul M/0000-0001-9771-543X; Averof, Michalis/0000-0002-6803-7251; Wolfe, Kenneth/0000-0003-4992-4979				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; Bailey WJ, 1992, MOL PHYLOGENET EVOL, V1, P97, DOI 10.1016/1055-7903(92)90024-B; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; Comeron JM, 1998, GENETICS, V150, P767; DIAZLAZCOZ Y, 1995, J MOL BIOL, V250, P123, DOI 10.1006/jmbi.1995.0363; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; Gaut BS, 1998, EVOL BIOL, V30, P93; GOLDFARB PS, 1988, NATURE, V336, P429, DOI 10.1038/336429a0; GOLDING GB, 1985, P NATL ACAD SCI USA, V82, P8577, DOI 10.1073/pnas.82.24.8577; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; HAMPSEY DM, 1988, J MOL BIOL, V201, P471, DOI 10.1016/0022-2836(88)90629-8; IRWIN DM, 1988, NATURE, V336, P429, DOI 10.1038/336429b0; Kimura M., 1985, POPULATION GENETICS, P19; KOONIN EV, 1989, NATURE, V338, P467, DOI 10.1038/338467b0; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Li W. H, 1997, MOL EVOLUTION; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; MIYAMOTO MM, 1988, P NATL ACAD SCI USA, V85, P7627, DOI 10.1073/pnas.85.20.7627; MOUCHIROUD D, 1995, J MOL EVOL, V40, P107, DOI 10.1007/BF00166602; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; PALMER JD, 1988, ANN MO BOT GARD, V75, P1180, DOI 10.2307/2399279; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHARP PM, 1987, J MOL EVOL, V25, P58, DOI 10.1007/BF02100041; SHARP PM, 1995, PHILOS T R SOC B, V349, P241, DOI 10.1098/rstb.1995.0108; SHARP PM, 1987, TRENDS ECOL EVOL, V2, P328, DOI 10.1016/0169-5347(87)90108-X; Smith NGC, 1999, GENETICS, V153, P1395; SWOFFORD DL, 1990, PAUP PHYLOGENETIC AN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; WOLFE KH, 1993, J MOL EVOL, V37, P441, DOI 10.1007/BF00178874	38	91	96	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1283	1286		10.1126/science.287.5456.1283	http://dx.doi.org/10.1126/science.287.5456.1283			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678838				2022-12-28	WOS:000085444700055
J	Fine, SL; Berger, JW; Maguire, MG; Ho, AC				Fine, SL; Berger, JW; Maguire, MG; Ho, AC			Drug therapy: Age-related macular degeneration.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BEAVER-DAM-EYE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; NUTRITION EXAMINATION SURVEY; LASER PHOTOCOAGULATION; CIGARETTE-SMOKING; 5-YEAR INCIDENCE; NATIONAL-HEALTH; MACULOPATHY; PREVALENCE; ABNORMALITIES		Univ Penn Hlth Syst, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Wills Eye Hosp, Dept Ophthalmol, Philadelphia, PA 19107 USA	University of Pennsylvania; Pennsylvania Medicine; Jefferson University	Fine, SL (corresponding author), Univ Penn Hlth Syst, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.			Ho, Allen/0000-0003-3921-608X				Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; [Anonymous], 1991, Arch Ophthalmol, V109, P1109; [Anonymous], 1998, Ophthalmology, V105, P11; BENNETT J, 1999, AGE RELATED MACULAR, P395; Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; BISCHOFF PM, 1985, DOC OPHTHALMOL, V60, P235, DOI 10.1007/BF00157827; BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329; BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1557, DOI 10.1001/archopht.1995.01100120087016; CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265; Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147; CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X; Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9; FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624; FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001; FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513; Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169; Gass JDM., 1997, DIAGNOSIS TREATMENT, V4th edition; GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023; Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865; HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200; HAWKINS BS, 1992, ARCH OPHTHALMOL-CHIC, V110, P761; Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6; HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522; Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006; HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629; Kaplan HJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1168, DOI 10.1001/archopht.1997.01100160338012; Klein R, 1998, AM J EPIDEMIOL, V147, P103; Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6; KLEIN R, 1995, OPHTHALMOLOGY, V102, P371; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; KLEIN R, 1995, OPHTHALMOLOGY, V102, P1126, DOI 10.1016/S0161-6420(13)30905-1; Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045; Leibowitz H M, 1980, Surv Ophthalmol, V24, P335; Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9; MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956; Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741; MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480; Maguire MG, 1999, AGE RELATED MACULAR, P17; MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048; MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450; *NAT EYE I, 1993, NIH PUBL; NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192; REGILLO CD, 1994, OPHTHALMOLOGY, V101, P280; Rizzo JF, 1997, NEUROSCIENTIST, V3, P251, DOI 10.1177/107385849700300413; SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500; Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141; Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0; SEDDON JM, 1995, JAMA-J AM MED ASSOC, V273, P622; SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; SPERDUTO RD, 1990, ARCH OPHTHALMOL-CHIC, V108, P1403, DOI 10.1001/archopht.1990.01070120051026; STEINBERG JD, 1999, AGE RELATED MACULAR, P433; STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549; Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722; Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7; TIELSCH JA, 1994, PREVENT BLINDNESS AM; VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625; VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205; YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701; 1998, SCIENCE, V279, P1107	65	374	401	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2000	342	7					483	492		10.1056/NEJM200002173420707	http://dx.doi.org/10.1056/NEJM200002173420707			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284FA	10675430				2022-12-28	WOS:000085319100007
J	Hall, S; Bobrow, M; Marteau, TM				Hall, S; Bobrow, M; Marteau, TM			Psychological consequences for parents of false negative results on prenatal screening for Down's syndrome: retrospective interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NATIONAL REGISTER; ENGLAND; CHILD; WALES	Objective To determine the psychological consequences for parents of children with Down's syndrome of having received a false negative result on prenatal screening. Design Comparison of adjustment of parents who received a false negative result with that of parents not offered a test and those who declined a test. Setting Parents were interviewed in their own homes. Participants Parents of 179 children with Down's syndrome (mean age 4 (range 2-6) years). Main outcome measures Anxiety, depression, parenting stress, attitudes towards the child, and attributions of blame for the birth of the affected child. Results Overall, regardless of screening history, parents adjusted well to having a child with Down's syndrome. Compared with mothers who declined a test, mothers in the false negative group had higher parenting stress (mean score 81.2 v 71.8, P = 0.016, 95% confidence interval for the difference 1.8 to 17.0) and more negative attitudes towards their children (124.9 v 134.2, P = 0.009, -16.2 to -2.4). Fathers in the false negative group had higher parenting stress test scores (77.8 v 70.0, P = 0.046, 1.5 to 14.2) than fathers not offered a test Mothers in the false negative group were more likely to blame others for the outcome than mothers who had not been offered the test (28% v 13%, P = 0.032, 3% to 27%). Mothers and fathers in the false negative group were more likely to blame others for this outcome than parents who had declined a test (mothers 28% v 0%, P = 0.001, 19% to 37%; fathers 27% v 0%, P = 0.004, 17% to 38%). Blaming others was associated with poorer adjustment for mothers and fathers. Conclusions A false negative result on prenatal screening seems to have a small adverse effect on parental adjustment evident two to six years after the birth of an affected child.	Guys Kings Coll, Psychol & Genet Res Grp, London SE1 9RT, England; St Thomass Sch Med, London SE1 9RT, England; Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of London; King's College London; University of London; King's College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Marteau, TM (corresponding author), Guys Kings Coll, Psychol & Genet Res Grp, Thomas Guy House,Guys Campus, London SE1 9RT, England.	theresa.marteau@kcl.ac.uk	Hall, Sue/C-3584-2009; Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Marteau, Theresa/0000-0003-3025-1129				Abidin RR., 1990, PARENTING STRESS IND, DOI [10.4236/psych.2018.97104, DOI 10.4236/PSYCH.2018.97104]; Allanson A, 1997, J Med Screen, V4, P21; Cockburn J, 1995, J Med Screen, V2, P224; GARDNER SB, 1989, STAT CONFIDENCE; Hall S, 1997, PSYCHOL HEALTH, V12, P579, DOI 10.1080/08870449708406733; JUDSON SL, 1980, CHILD CARE HLTH DEV, V6, P47, DOI 10.1111/j.1365-2214.1980.tb00796.x; MARTEAU TM, 1992, PUBLIC HEALTH, V106, P131, DOI 10.1016/S0033-3506(05)80390-7; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; MUTTON DE, 1991, BRIT MED J, V303, P1295, DOI 10.1136/bmj.303.6813.1295; MUTTON DE, 1993, BRIT MED J, V306, P431, DOI 10.1136/bmj.306.6875.431; PARSONS L, 1992, BRIT MED J, V305, P1228, DOI 10.1136/bmj.305.6863.1228-a; PETTIGREW M, IN PRESS HLTH TECHNO; QUINE L, 1991, J COMMUNITY APPL SOC, V1, P57, DOI 10.1002/casp.2450010109; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SMITH DK, 1994, BRIT MED J, V309, P776, DOI 10.1136/bmj.309.6957.776; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; TENNEN H, 1990, PSYCHOL BULL, V108, P209, DOI 10.1037/0033-2909.108.2.209; Wald N J, 1997, J Med Screen, V4, P181; Wald NJ, 1999, LANCET, V354, P1264, DOI 10.1016/S0140-6736(99)03819-2	19	51	51	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2000	320	7232					407	412		10.1136/bmj.320.7232.407	http://dx.doi.org/10.1136/bmj.320.7232.407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	285EU	10669444	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000085377400021
J	Klimov, VI; Mikhailovsky, AA; McBranch, DW; Leatherdale, CA; Bawendi, MG				Klimov, VI; Mikhailovsky, AA; McBranch, DW; Leatherdale, CA; Bawendi, MG			Quantization of multiparticle Auger rates in semiconductor quantum dots	SCIENCE			English	Article							NANOCRYSTALS; SPECTRUM	We have resolved single-exponential relaxation dynamics of the 2-, 3-, and 4-electron-hole pair states in nearly monodisperse cadmium selenide quantum dots with radii ranging from 1 to 4 nanometers. Comparison of the discrete relaxation constants measured for different multiple-pair states indicates that the carrier decay rate is cubic in carrier concentration, which is characteristic of an Auger process. We observe that in the quantum-confined regime, the. Auger constant is strongly size-dependent and decreases with decreasing the quantum dot size as the radius cubed.	Univ Calif Los Alamos Natl Lab, Chem Sci & Technol Div, Los Alamos, NM 87545 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Klimov, VI (corresponding author), Univ Calif Los Alamos Natl Lab, Chem Sci & Technol Div, CST 6,MS J585, Los Alamos, NM 87545 USA.		Klimov, Victor/Y-2823-2019	Klimov, Victor/0000-0003-1158-3179				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; CHATTERJI D, 1976, THEORY AUGER TRANSIT; CHEPIC DI, 1990, J LUMIN, V47, P113, DOI 10.1016/0022-2313(90)90007-X; DELERUE C, 1995, PHYS REV LETT, V75, P2228, DOI 10.1103/PhysRevLett.75.2228; Efros AL, 1997, PHYS REV LETT, V78, P1110, DOI 10.1103/PhysRevLett.78.1110; EFROS AL, 1995, SOLID STATE COMMUN, V93, P281, DOI 10.1016/0038-1098(94)00780-2; Gammon D, 1996, SCIENCE, V273, P87, DOI 10.1126/science.273.5271.87; GHANASSI M, 1993, APPL PHYS LETT, V62, P78, DOI 10.1063/1.108833; Hunsche S, 1996, APPL PHYS B-LASERS O, V62, P3, DOI 10.1007/BF01081240; Klimov VI, 1999, PHYS REV B, V60, P13740, DOI 10.1103/PhysRevB.60.13740; Klimov VI, 1998, OPT LETT, V23, P277, DOI 10.1364/OL.23.000277; Klimov VI, 1997, PHYS REV B, V55, P13173, DOI 10.1103/PhysRevB.55.13173; Klimov VI, 1998, PHYS REV LETT, V80, P4028, DOI 10.1103/PhysRevLett.80.4028; Landsberg P., 1991, RECOMBINATION SEMICO; NORRIS DJ, 1994, PHYS REV LETT, V72, P2612, DOI 10.1103/PhysRevLett.72.2612; PAN JL, 1992, PHYS REV B, V46, P3977, DOI 10.1103/PhysRevB.46.3977	16	1175	1201	12	392	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1011	1013		10.1126/science.287.5455.1011	http://dx.doi.org/10.1126/science.287.5455.1011			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669406				2022-12-28	WOS:000085245400038
J	Petrov, DA; Sangster, TA; Johnston, JS; Hartl, DL; Shaw, KL				Petrov, DA; Sangster, TA; Johnston, JS; Hartl, DL; Shaw, KL			Evidence for DNA loss as a determinant of genome size	SCIENCE			English	Article							DROSOPHILA; EVOLUTION; PSEUDOGENES; RETROTRANSPOSONS; GENES	Eukaryotic genome sizes range over five orders of magnitude. This variation cannot be explained by differences in organismic complexity (the C value paradox). To test the hypothesis that some variation in genome size can be attributed to differences in the patterns of insertion and deletion (indel) mutations among organisms, this study examines the indel spectrum in Laupala crickets, which have a genome size 11 times larger than that of Drosophila. Consistent with the hypothesis. DNA Loss is more than 40 times slower in Laupala than in Drosophila.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA	Harvard University; Texas A&M University System; Texas A&M University College Station	Petrov, DA (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.			Petrov, Dmitri/0000-0002-3664-9130				BELDA JE, 1991, CYTOBIOS, V67, P13; CAVALIERSMITH T, 1985, EVOLUTION GENOME SIZ, P523; Charlesworth B, 1996, NATURE, V384, P315, DOI 10.1038/384315a0; Elgar G, 1996, TRENDS GENET, V12, P145, DOI 10.1016/0168-9525(96)10018-4; HUGHES AL, 1995, NATURE, V377, P391, DOI 10.1038/377391a0; JEFFS P, 1991, P ROY SOC B-BIOL SCI, V244, P151, DOI 10.1098/rspb.1991.0064; JOHN B, 1988, EUKARYOTIC GENOME DE; LI WH, 1981, NATURE, V292, P237, DOI 10.1038/292237a0; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MIRSKY AE, 1951, J GEN PHYSIOL, V34, P451, DOI 10.1085/jgp.34.4.451; MORIYAMA E, 1997, MOL BIOL EVOL, V15, P770; Ogata H, 1996, FEBS LETT, V390, P99, DOI 10.1016/0014-5793(96)00636-9; PETROV D, UNPUB; Petrov DA, 1998, MOL BIOL EVOL, V15, P1562, DOI 10.1093/oxfordjournals.molbev.a025883; Petrov DA, 1997, GENE, V205, P279, DOI 10.1016/S0378-1119(97)00516-7; Petrov DA, 1998, MOL BIOL EVOL, V15, P293, DOI 10.1093/oxfordjournals.molbev.a025926; Petrov DA, 1996, NATURE, V384, P346, DOI 10.1038/384346a0; RUDKIN GT, 1969, GENETICS, V61, P227; SanMiguel P, 1998, NAT GENET, V20, P43, DOI 10.1038/1695; SHARP PM, 1989, J MOL EVOL, V28, P398, DOI 10.1007/BF02603075; Shaw KL, 1996, EVOLUTION, V50, P237, DOI 10.1111/j.1558-5646.1996.tb04488.x; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; THINDWA HP, 1994, SOUTHWEST ENTOMOL, V19, P371; THOMAS CA, 1971, ANNU REV GENET, V5, P237, DOI 10.1146/annurev.ge.05.120171.001321; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; Wright DA, 1996, GENETICS, V142, P569; [No title captured]	27	256	271	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1060	1062		10.1126/science.287.5455.1060	http://dx.doi.org/10.1126/science.287.5455.1060			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669421				2022-12-28	WOS:000085245400053
J	Beckett, WS				Beckett, WS			Current concepts: Occupational respiratory diseases.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INDUCED ASTHMA; UNITED-STATES; LUNG-FUNCTION; WORKERS; EXPOSURES; SYMPTOMS; ASBESTOS; BRONCHITIS; INDUSTRY; ALLERGY		Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Div Pulm & Crit Care, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Beckett, WS (corresponding author), Univ Rochester, Sch Med & Dent, Dept Environm Med, Box EHSC,575 Elmwood Ave, Rochester, NY 14642 USA.	bill_beckett@urmc.rochester.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES01247] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AM IND HYG ASS ME, 1999, CIH NAM DES CERT IND; ANDREWS JL, 1969, AM REV RESPIR DIS, V100, P791; Barker RD, 1998, OCCUP ENVIRON MED, V55, P684, DOI 10.1136/oem.55.10.684; Bascom R, 1996, FUND APPL TOXICOL, V29, P86, DOI 10.1006/faat.1996.0009; BASCOM R, 1999, LUNG BIOL HEALTH DIS, V123, P65; BECKETT WS, 1994, OCCUP ENVIRON MED, V51, P14, DOI 10.1136/oem.51.1.14; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; BLANC P, 1991, ANN INTERN MED, V114, P930, DOI 10.7326/0003-4819-114-11-930; BOUHUYS A, 1967, NEW ENGL J MED, V277, P170, DOI 10.1056/NEJM196707272770402; Brooks SM, 1998, CHEST, V113, P42, DOI 10.1378/chest.113.1.42; BRUBAKER RE, 1977, J OCCUP ENVIRON MED, V19, P693, DOI 10.1097/00043764-197710000-00013; BURGE PS, 1982, EUR J RESPIR DIS, V63, P47; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; CHANYEUNG M, 1995, CHEST, V108, P1084, DOI 10.1378/chest.108.4.1084; CHRISTIANI DC, 1994, AM J RESP CRIT CARE, V150, P1250, DOI 10.1164/ajrccm.150.5.7952548; Chuwers P, 1997, AM J RESP CRIT CARE, V155, P1066, DOI 10.1164/ajrccm.155.3.9116988; Cowie RL, 1998, CHEST, V113, P340, DOI 10.1378/chest.113.2.340; Cullen M R, 1981, Am J Ind Med, V2, P51, DOI 10.1002/ajim.4700020109; DAVISON AG, 1988, LANCET, V1, P663, DOI 10.1016/S0140-6736(88)91474-2; DEHALLER R, 1965, MED THORAC, V22, P549; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Fishwick D, 1997, AM J RESP CRIT CARE, V156, P1440, DOI 10.1164/ajrccm.156.5.97-03007; FREUND E, 1989, JAMA-J AM MED ASSOC, V262, P3041, DOI 10.1001/jama.262.21.3041; Harber P, 1996, AM J RESP CRIT CARE, V154, P1153, DOI 10.1164/ajrccm.154.4.8887621; Hendrick DJ, 1996, THORAX, V51, P947, DOI 10.1136/thx.51.9.947; HIMMELSTEIN JS, 1985, NEW ENGL J MED, V312, P687, DOI 10.1056/NEJM198503143121104; Hirvonen A, 1996, J NATL CANCER I, V88, P1853, DOI 10.1093/jnci/88.24.1853; IMBUS HR, 1987, J OCCUP ENVIRON MED, V29, P734; Kern DG, 1998, ANN INTERN MED, V129, P261, DOI 10.7326/0003-4819-129-4-199808150-00001; Kern DG, 1999, ANN INTERN MED, V130, P246; KORN RJ, 1987, AM REV RESPIR DIS, V136, P298, DOI 10.1164/ajrccm/136.2.298; LILIENFELD DE, 1988, BRIT J IND MED, V45, P283; LITOVITZ TL, 1991, AM J EMERG MED, V9, P461, DOI 10.1016/0735-6757(91)90216-7; MCKUSICK VA, 1984, JAMA-J AM MED ASSOC, V252, P1041, DOI 10.1001/jama.252.8.1041; Menzies D, 1997, NEW ENGL J MED, V337, P1524, DOI 10.1056/NEJM199711203372107; MORGAN WKC, 1978, BRIT J IND MED, V35, P285; MORGAN WKC, 1988, AM REV RESPIR DIS, V138, P813, DOI 10.1164/ajrccm/138.4.813; MOSCATO G, 1995, EUR RESPIR J, V8, P1605; Naclerio R, 1997, JAMA-J AM MED ASSOC, V278, P1842, DOI 10.1001/jama.278.22.1842; National Institute for Occupational Safety and Health, 1996, DHHS NIOSH PUBL, V96-110; National Toxicology Program, 1998, REP CARC; NEWMAN LS, 1995, NEW ENGL J MED, V333, P1128, DOI 10.1056/NEJM199510263331707; Newman LS, 1997, NEW ENGL J MED, V337, P139; PAGGIARO PL, 1994, EUR RESPIR J, V7, P761, DOI 10.1183/09031936.94.07040761; Perkner JJ, 1998, J OCCUP ENVIRON MED, V40, P136, DOI 10.1097/00043764-199802000-00009; PETO J, 1995, LANCET, V345, P535, DOI 10.1016/S0140-6736(95)90462-X; PICKERING CAC, 1982, EUR J RESPIR DIS, V63, P104; REYNOLDS HY, 1991, LUNG, V169, pS109; Ross DJ, 1999, CLIN EXP ALLERGY, V29, P750; Steenland K, 1996, AM J IND MED, V29, P474, DOI 10.1002/(SICI)1097-0274(199605)29:5<474::AID-AJIM6>3.0.CO;2-M; Sunyer J, 1998, AM J RESP CRIT CARE, V157, P512, DOI 10.1164/ajrccm.157.2.9705029; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43, DOI 10.7326/0003-4819-122-1-199501010-00007; TAYLOR AN, 1978, BRIT MED J, V2, P94, DOI 10.1136/bmj.2.6130.94; VIEGI G, 1991, AM REV RESPIR DIS, V143, P510, DOI 10.1164/ajrccm/143.3.510; WEISS W, 1984, AM REV RESPIR DIS, V130, P293; Woodin MA, 1998, AM J RESP CRIT CARE, V158, P182, DOI 10.1164/ajrccm.158.1.9711054; WRIGHT JL, 1993, CLIN CHEST MED, V14, P635; 1990, INT AGENCY RES CANC, V49, P447; 1997, MMWR MORB MORTAL WKL, V46, P897; 1991, MMWR MORB MORTAL WKL, V40, P646; 1991, MMWR MORB MORTAL WKL, V40, P619; 1991, MMWR MORB MORTAL WKL, V40, P819; 1997, MMWR MORB MORTAL WKL, V46, P974	64	99	104	2	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					406	413		10.1056/NEJM200002103420607	http://dx.doi.org/10.1056/NEJM200002103420607			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666432				2022-12-28	WOS:000085205200007
J	Gausche, M; Lewis, RJ; Stratton, SJ; Haynes, BE; Gunter, CS; Goodrich, SM; Poore, PD; McCollough, MD; Henderson, DP; Pratt, FD; Seidel, JS				Gausche, M; Lewis, RJ; Stratton, SJ; Haynes, BE; Gunter, CS; Goodrich, SM; Poore, PD; McCollough, MD; Henderson, DP; Pratt, FD; Seidel, JS			Effect of out-of-hospital pediatric endotracheal intubation on survival and neurological outcome - A controlled clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREHOSPITAL CARE; PARAMEDICS; CHILDREN; PREDICTORS	Context Endotracheal intubation (ETI) is widely used for airway management of children in the out-of-hospital setting, despite a lack of controlled trials demonstrating a positive effect on survival or neurological outcome. Objective To compare the survival and neurological outcomes of pediatric patients treated with bag-valve-mask ventilation (BVM) with those of patients treated with BVM followed by ETI. Design Controlled clinical trial, in which patients were assigned to interventions by calendar day from March 15, 1994, through January 1, 1997. Setting Two large, urban, rapid-transport emergency medical services (EMS) systems. Participants A total of 830 consecutive patients aged 12 years or younger or estimated to weigh less than 40 kg who required airway management; 820 were available for follow-up. Interventions Patients were assigned to receive either BVM (odd days; n = 410) or BVM followed by ETI (even days; n = 420). Main Outcome Measures Survival to hospital discharge and neurological status at discharge from an acute care hospital compared by treatment group. Results There was no significant difference in survival between the BVM group (123/ 404 [30%]) and the ETI group (110/416 [26%]) (odds ratio [OR], 0.82; 95% confidence interval [CI], 0.61-1.11) or in the rate of achieving a good neurological outcome (BVM, 92/404 [23%] vs ETI, 85/416 [20%]) (OR, 0.87; 95% CI, 0.62-1.22). Conclusion These results indicate that the addition of out-of-hospital ETI to a paramedic scope of practice that already includes BVM did not improve survival or neurological outcome of pediatric patients treated in an urban EMS system.	Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA; Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90509 USA; Harbor UCLA Res & Educ Inst, Torrance, CA USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90024 USA; USC, Sch Educ, Div Learning & Instruct, Los Angeles, CA USA; Los Angeles Cty Fire Dept, Los Angeles, CA USA; Los Angeles Cty Emergency Med Serv Agcy, Torrance, CA USA; Orange Cty Emergency Med Serv Agcy, Santa Ana, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California	Gausche, M (corresponding author), Harbor UCLA Med Ctr, Dept Emergency Med, 1000 W Carson St,Box 21, Torrance, CA 90509 USA.	mgausche@emedharbor.edu		Stratton, Samuel/0000-0002-2505-115X	AHRQ HHS [1RO1 HS9166] Funding Source: Medline; PHS HHS [MCH-064004] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIJIAN P, 1989, ANN EMERG MED, V18, P489, DOI 10.1016/S0196-0644(89)80830-3; Brownstein D, 1996, ANN EMERG MED, V28, P34, DOI 10.1016/S0196-0644(96)70136-1; Doran J V, 1995, Prehosp Disaster Med, V10, P259; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Gausche M, 1996, ACAD EMERG MED, V3, P564, DOI 10.1111/j.1553-2712.1996.tb03464.x; GAUSCHE M, 1997, INSTRUCTOR MANUAL AD; GAUSCHE M, IN PRESS ANN EMERG M; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; Kumar VR, 1997, ANN EMERG MED, V29, P743, DOI 10.1016/S0196-0644(97)70195-1; LEWIS RJ, 1993, ANN EMERG MED, V22, P1463, DOI 10.1016/S0196-0644(05)81997-3; LEWIS RJ, 1994, J AM STAT ASSOC, V89, P1528, DOI 10.2307/2291016; *LOS ANG COUNT EM, 1992, EM MED SERV PLAN LOS; *LOS ANG PED SOC, 1984, INF HDB EM DEP APPR; LOSEK J D, 1989, Pediatric Emergency Care, V5, P1, DOI 10.1097/00006565-198903000-00001; LOSEK JD, 1987, AM J EMERG MED, V5, P370, DOI 10.1016/0735-6757(87)90383-4; MOGAYZEL C, 1995, ANN EMERG MED, V25, P484, DOI 10.1016/S0196-0644(95)70263-6; NAKAYAMA DK, 1990, ANN SURG, V211, P218, DOI 10.1097/00000658-199002000-00015; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; *OR COUNT EM MED S, 1992, EM MED SERV PLAN OR; POINTER JE, 1989, AM J EMERG MED, V7, P364, DOI 10.1016/0735-6757(89)90039-9; QUAN L, 1992, PEDIATRICS, V90, P909; QUAN L, 1990, PEDIATRICS, V86, P586; Rumball C J, 1997, Prehosp Emerg Care, V1, P1, DOI 10.1080/10903129708958776; SEIDEL JS, 1991, PEDIATRICS, V88, P681; SEIDEL JSS, 1992, PLANNING MANAGING SY, P267; SHEA S, 1992, PEDIAT ENDOTRACHEAL; Sirbaugh PE, 1999, ANN EMERG MED, V33, P174, DOI 10.1016/S0196-0644(99)70391-4; Stratton S J, 1993, Prehosp Disaster Med, V8, P323; STRATTON SJ, 1991, ANN EMERG MED, V20, P1314, DOI 10.1016/S0196-0644(05)81073-X; TSAI A, 1987, ANN EMERG MED, V16, P284; *US DEP TRANSP, 1994, PUBL DOT HS	31	534	544	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					783	790		10.1001/jama.283.6.783	http://dx.doi.org/10.1001/jama.283.6.783			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280XL	10683058	Bronze			2022-12-28	WOS:000085129000031
J	Gilbert, RB; Kaan, R; Lipkin, DH; Lepp, M				Gilbert, RB; Kaan, R; Lipkin, DH; Lepp, M			Chronic fatigue: Syndrome or disease?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Chron Fatigue Syndrome Soc Illinois, Skokie, IL USA		Gilbert, RB (corresponding author), Chron Fatigue Syndrome Soc Illinois, Skokie, IL USA.							EHRLICH GE, 1999, JAMA-J AM MED ASSOC, V282, P1095; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; SHARPE M, 1991, BRIT MED BULL, V47, P989, DOI 10.1093/oxfordjournals.bmb.a072525; STRAUS SE, 1994, J INFECT DIS, V170, P1, DOI 10.1093/infdis/170.1.1; WESSELY S, 1990, PSYCHOL MED, V20, P35, DOI 10.1017/S0033291700013210	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					744	744		10.1001/jama.283.6.744	http://dx.doi.org/10.1001/jama.283.6.744			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280XL	10683049				2022-12-28	WOS:000085129000017
J	Hou, SB; Larsen, RW; Boudko, D; Riley, CW; Karatan, E; Zimmer, M; Ordal, GW; Alam, M				Hou, SB; Larsen, RW; Boudko, D; Riley, CW; Karatan, E; Zimmer, M; Ordal, GW; Alam, M			Myoglobin-like aerotaxis transducers in Archaea and Bacteria	NATURE			English	Article							AMINO-ACID-SEQUENCES; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; HALOBACTERIUM-SALINARIUM; SERINE CHEMORECEPTOR; RHIZOBIUM-MELILOTI; GENE-EXPRESSION; PROTEINS; OXYGEN; METHYLATION	Haem-containing proteins such as haemoglobin and myoglobin play an essential role in oxygen transport and storage. Comparison of the amino-acid sequences of globins from Bacteria and Eukarya suggests that they share an early common ancestor, even though the proteins perform different functions in these two kingdoms(1-6). Until now, no members of the globin family have been found in the third kingdom, Archaea. Recent studies of biological signalling in the Bacteria and Eukarya have revealed a new class of haem-containing proteins that serve as sensors(7). Until now, no haem-based sensor has been described in the Archaea. Here we report the first myoglobin-like, haem-containing protein in the Archaea, and the first haem-based aerotactic transducer in the Bacteria (termed HemAT-Hs for the archaeon Halobacterium salinarum, and HemAT-Bs for Bacillus subtilis). These proteins exhibit spectral properties similar to those of myoglobin and trigger aerotactic responses.	Univ Hawaii, Dept Microbiol, Honolulu, HI 96822 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Hawaii, Dept Chem, Honolulu, HI 96822 USA	University of Hawaii System; University of Illinois System; University of Illinois Urbana-Champaign; University of Hawaii System	Alam, M (corresponding author), Univ Hawaii, Dept Microbiol, Snyder Hall 207,2538 Mall, Honolulu, HI 96822 USA.			Hou, Shaobin/0000-0003-3467-8242; Boudko, Dmitri/0000-0002-1899-044X				ALAM M, 1991, J BACTERIOL, V173, P5837, DOI 10.1128/jb.173.18.5837-5842.1991; Andersson CR, 1996, P NATL ACAD SCI USA, V93, P5682, DOI 10.1073/pnas.93.12.5682; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; BOYD A, 1983, NATURE, V301, P623, DOI 10.1038/301623a0; Brooun A, 1998, J BACTERIOL, V180, P1642, DOI 10.1128/JB.180.7.1642-1646.1998; BROOUN A, 1997, PRIMARY STRUCTURES F; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Hardison R, 1999, AM SCI, V87, P126, DOI 10.1511/1999.20.809; Hardison R, 1998, J EXP BIOL, V201, P1099; IHARA K, 1991, ARCH BIOCHEM BIOPHYS, V286, P111, DOI 10.1016/0003-9861(91)90015-B; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LEONHARDT H, 1988, J GEN MICROBIOL, V134, P605; LINDBECK JC, 1995, MICROBIOL-SGM, V141, P2945, DOI 10.1099/13500872-141-11-2945; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; Rebbapragada A, 1997, P NATL ACAD SCI USA, V94, P10541, DOI 10.1073/pnas.94.20.10541; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Suzuki T, 1998, CELL MOL LIFE SCI, V54, P979, DOI 10.1007/s000180050227; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VINOGRADOV SN, 1992, COMP BIOCHEM PHYS B, V103, P759, DOI 10.1016/0305-0491(92)90193-U; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; WONG LS, 1995, J BACTERIOL, V177, P3985, DOI 10.1128/jb.177.14.3985-3991.1995; Zhang WS, 1996, P NATL ACAD SCI USA, V93, P4649, DOI 10.1073/pnas.93.10.4649; Zhulin IB, 1998, MOL MICROBIOL, V29, P1522; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	28	229	238	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					540	544		10.1038/35000570	http://dx.doi.org/10.1038/35000570			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676961				2022-12-28	WOS:000085227300049
J	Davis, E				Davis, E			Earth science - Volcanic action at Axial Seamount	NATURE			English	Editorial Material									Geol Survey Canada, Pacific Geosci Ctr, Sidney, BC V8L 4B2, Canada	Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada	Davis, E (corresponding author), Geol Survey Canada, Pacific Geosci Ctr, Box 6000, Sidney, BC V8L 4B2, Canada.	davis@pgc.nrcan.gc.ca						Baker ET, 1999, GEOPHYS RES LETT, V26, P3445, DOI 10.1029/1999GL002331; Chadwick WW, 1999, GEOPHYS RES LETT, V26, P3441, DOI 10.1029/1999GL900498; Dziak RP, 1999, GEOPHYS RES LETT, V26, P3429, DOI 10.1029/1999GL002332; Embley RW, 1999, GEOPHYS RES LETT, V26, P3425, DOI 10.1029/1999GL002328; Fox CG, 1999, GEOPHYS RES LETT, V26, P3437, DOI 10.1029/1999GL900491; Lupton J, 1999, GEOPHYS RES LETT, V26, P3449, DOI 10.1029/1999GL002330; McLaughlin-West EA, 1999, GEOPHYS RES LETT, V26, P3453, DOI 10.1029/1999GL002336; Sohn RA, 1999, GEOPHYS RES LETT, V26, P3433, DOI 10.1029/1999GL900505	8	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					379	380		10.1038/35000335	http://dx.doi.org/10.1038/35000335			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667777				2022-12-28	WOS:000085121100033
J	Chaturvedi, N				Chaturvedi, N			HOPE and extension of the indications for ACE inhibitors?	LANCET			English	Editorial Material							HYPERTENSION; ENALAPRIL		UCL, Dept Med, London WC1E 6BT, England	University of London; University College London	Chaturvedi, N (corresponding author), UCL, Dept Med, London WC1E 6BT, England.							Black HR, 1997, ARCH INTERN MED, V157, P2413; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; DEVITA C, 1994, LANCET, V343, P1115; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Nielsen S, 1997, NEPHROL DIAL TRANSPL, V12, P19; Stearne MR, 1998, BRIT MED J, V317, P713; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2000, NEW ENGL J MED, V342, P145	12	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					246	247		10.1016/S0140-6736(90)00006-3	http://dx.doi.org/10.1016/S0140-6736(90)00006-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675066				2022-12-28	WOS:000085045600002
J	Hata, A; Seoane, J; Lagna, G; Montalvo, E; Hemmati-Brivanlou, A; Massague, J				Hata, A; Seoane, J; Lagna, G; Montalvo, E; Hemmati-Brivanlou, A; Massague, J			OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways	CELL			English	Article							BONE MORPHOGENETIC PROTEINS; TGF-BETA; CRYSTAL-STRUCTURE; GENE-EXPRESSION; HOMEOBOX GENE; FUNCTIONAL-CHARACTERIZATION; TUMOR-SUPPRESSOR; XENOPUS MESODERM; TRANSCRIPTION; REGULATORS	We have identified the 30-zinc finger protein OAZ as a DNA-binding factor that associates with Smads in response to BMP2, forming a complex that transcriptionally activates the homeobox regulator of Xenopus mesoderm and neural development, Xvent-2. OAZ contains a BMP signaling module formed by two clusters of fingers that bind Smads and the Xvent-2 BMP response element, respectively. Previously implicated as a transcriptional partner of Olf-1/EBF in olfactory epithelium and lymphocyte development in the rat, OAZ fulfills this role through clusters of fingers that are separate from the BMP signaling module. The mutually exclusive use of OAZ by the BMP-smad and Olf pathways illustrates the dual role of a multi-zinc finger protein in signal transduction during development.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Rockefeller University	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.		Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974; Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA34610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA034610, R01CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HemmatiBrivanlou A, 1997, ANNU REV NEUROSCI, V20, P43, DOI 10.1146/annurev.neuro.20.1.43; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Klug A, 1999, J MOL BIOL, V293, P215, DOI 10.1006/jmbi.1999.3007; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Peters H, 1999, TRENDS GENET, V15, P59, DOI 10.1016/S0168-9525(98)01662-X; Rastegar S, 1999, MECH DEVELOP, V81, P139, DOI 10.1016/S0925-4773(98)00239-1; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shou J, 1999, NAT NEUROSCI, V2, P339, DOI 10.1038/7251; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Tang SJ, 1998, DEVELOPMENT, V125, P1877; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang ZJ, 1998, RNA, V4, P394; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	46	353	379	2	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					229	240		10.1016/S0092-8674(00)81561-5	http://dx.doi.org/10.1016/S0092-8674(00)81561-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660046	Bronze			2022-12-28	WOS:000084932200007
J	Barnes, DM; Miles, DW				Barnes, DM; Miles, DW			Response of metastatic breast cancer to trastuzumab?	LANCET			English	Editorial Material							MONOCLONAL-ANTIBODY; NEU ONCOGENE; PHASE-II		Guys Hosp, Imperial Canc Res Fund, Breast Pathol Lab, London SE1 9RT, England; Guys Hosp, Imperial Canc Res Fund, Breast Biol Grp, London SE1 9RT, England	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust	Barnes, DM (corresponding author), Guys Hosp, Imperial Canc Res Fund, Breast Pathol Lab, London SE1 9RT, England.							Allred DC, 1998, MODERN PATHOL, V11, P155; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Brenner T L, 1999, J Am Pharm Assoc (Wash), V39, P236; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Goldenberg MM, 1999, CLIN THER, V21, P309, DOI 10.1016/S0149-2918(00)88288-0; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; Jacobs TW, 1999, J CLIN ONCOL, V17, P1974, DOI 10.1200/JCO.1999.17.7.1974; Jacobs TW, 1999, J CLIN ONCOL, V17, P1983, DOI 10.1200/JCO.1999.17.7.1983; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; McNeil C, 1999, J NATL CANCER I, V91, P110, DOI 10.1093/jnci/91.2.110; NAINGGOLAN L, 1999, SCRIP, V2493, P21; NORTON L, 1999, P AM SOC CLIN ONCOL, V18; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Wisecarver JL, 1999, AM J CLIN PATHOL, V111, P299	16	15	17	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					160	161		10.1016/S0140-6736(99)00430-4	http://dx.doi.org/10.1016/S0140-6736(99)00430-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675110				2022-12-28	WOS:000084879700004
J	Miles, R				Miles, R			Neurobiology - Diversity in inhibition	SCIENCE			English	Editorial Material							RECEPTOR ACTIVATION; SUBUNIT COMPOSITION; RAT HIPPOCAMPUS; AMPA RECEPTORS; PYRAMIDAL CELL; NEURONS; INTERNEURONS; POTENTIALS; CHANNEL		Inst Pasteur, Lab Neurobiol Cellulaire, INSERM, U261, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Miles, R (corresponding author), Inst Pasteur, Lab Neurobiol Cellulaire, INSERM, U261, Paris, France.							Angulo MC, 1997, J NEUROSCI, V17, P6685; BAIRNBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303; BOCHET P, 1994, NEURON, V12, P383, DOI 10.1016/0896-6273(94)90279-8; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Csicsvari J, 1998, NEURON, V21, P179, DOI 10.1016/S0896-6273(00)80525-5; Du J, 1996, J NEUROSCI, V16, P506; FREUND TF, 1990, P NATL ACAD SCI USA, V87, P8501, DOI 10.1073/pnas.87.21.8501; Galarreta M, 1999, NATURE, V402, P72, DOI 10.1038/47029; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; Gibson JR, 1999, NATURE, V402, P75, DOI 10.1038/47035; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; HAUSSER M, 1995, NEURON, V15, P637, DOI 10.1016/0896-6273(95)90152-3; Katona I, 1999, NEUROSCIENCE, V88, P37, DOI 10.1016/S0306-4522(98)00302-9; Martina M, 1998, J NEUROSCI, V18, P8111; Martina M, 2000, SCIENCE, V287, P295, DOI 10.1126/science.287.5451.295; McBain CJ, 1999, TRENDS NEUROSCI, V22, P228, DOI 10.1016/S0166-2236(98)01347-2; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; Parra P, 1998, NEURON, V20, P983, DOI 10.1016/S0896-6273(00)80479-1; Sik A, 1998, P NATL ACAD SCI USA, V95, P3245, DOI 10.1073/pnas.95.6.3245; Traub RD, 1995, J COMPUT NEUROSCI, V2, P291, DOI 10.1007/BF00961441; Watanabe D, 1998, CELL, V95, P17, DOI 10.1016/S0092-8674(00)81779-1; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0	23	29	31	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2000	287	5451					244	246		10.1126/science.287.5451.244	http://dx.doi.org/10.1126/science.287.5451.244			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10660424				2022-12-28	WOS:000084769600025
J	Chung, DY; Hogan, T; Brazis, P; Rocci-Lane, M; Kannewurf, C; Bastea, M; Uher, C; Kanatzidis, MG				Chung, DY; Hogan, T; Brazis, P; Rocci-Lane, M; Kannewurf, C; Bastea, M; Uher, C; Kanatzidis, MG			CsBi4Te6: A high-performance thermoelectric material for low-temperature applications	SCIENCE			English	Article							BISMUTH SULFIDES KBI6.33S10; ANTISITE DEFECTS; BI2TE3; K2BI8S13; CRYSTALS; SYSTEM; MERIT; ZR; HF	Thermoelectric (Peltier) heat pumps are capable of refrigerating solid or fluid objects, and unlike conventional vapor compressor systems, they can be miniaturized without Loss of efficiency. More efficient thermoelectric materials need to be identified, especially for Low-temperature applications in electronics and devices. The material CsBi4Te6 has been synthesized and its properties have been studied. When doped appropriately, it exhibits a high thermoelectric figure of merit below room temperature (ZT(max) similar to 0.8 at 225 kelvin). At cryogenic temperatures, the thermoelectric properties of CsBi4Te6 appear to match or exceed those of Bi2-xSbxTe3-ySey alloys.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Ctr Fundamental Mat Res, E Lansing, MI 48824 USA; Michigan State Univ, Dept Phys, E Lansing, MI 48824 USA; Northwestern Univ, Dept Elect Engn & Comp Sci, Evanston, IL 60208 USA	Michigan State University; Michigan State University; Northwestern University	Kanatzidis, MG (corresponding author), Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.		Uher, Ctirad/M-9966-2014	Chung, Duck Young/0000-0002-1315-2631				BORKOWSKI K, 1987, MATER RES BULL, V22, P381, DOI 10.1016/0025-5408(87)90056-0; Chen BX, 1997, PHYS REV B, V55, P1476, DOI 10.1103/PhysRevB.55.1476; Chen BX, 1997, CHEM MATER, V9, P1655, DOI 10.1021/cm970033m; CHIZHEVSKAYA SN, 1995, INORG MATER+, V31, P1083; Chung DY, 1997, MATER RES SOC SYMP P, V478, P333, DOI 10.1557/PROC-478-333; Chung DY, 1997, CHEM MATER, V9, P3060, DOI 10.1021/cm970397e; Chung DY, 1997, PROCEEDINGS ICT'97 - XVI INTERNATIONAL CONFERENCE ON THERMOELECTRICS, P459, DOI 10.1109/ICT.1997.667185; DiSalvo FJ, 1999, SCIENCE, V285, P703, DOI 10.1126/science.285.5428.703; Goldsmid HJ, 1999, J ELECTRON MATER, V28, P869, DOI 10.1007/s11664-999-0211-y; Hohl H, 1999, J PHYS-CONDENS MAT, V11, P1697, DOI 10.1088/0953-8984/11/7/004; HORAK J, 1986, J PHYS CHEM SOLIDS, V47, P805, DOI 10.1016/0022-3697(86)90010-7; JEON HH, 1991, J PHYS CHEM SOLIDS, V4, P579; Kafer W, 1998, INST PHYS CONF SER, V152, P185; Kanatzidis MG, 1996, CHEM MATER, V8, P1465, DOI 10.1021/cm9600182; Kittel C, 1986, INTRO SOLID STATE PH, P150; LARSON P, UNPUB; Littleton RT, 1998, APPL PHYS LETT, V72, P2056, DOI 10.1063/1.121406; LOSTAK P, 1983, PHYS STATUS SOLIDI A, V76, pK71, DOI 10.1002/pssa.2210760165; LYDING JW, 1988, IEEE T INSTRUM MEAS, V37, P76, DOI 10.1109/19.2668; Nolas GS, 1998, APPL PHYS LETT, V73, P178, DOI 10.1063/1.121747; Sales BC, 1996, SCIENCE, V272, P1325, DOI 10.1126/science.272.5266.1325; Schindler JL, 1997, MATER RES SOC SYMP P, V478, P327, DOI 10.1557/PROC-478-327; SHELDRICK GM, 1994, STRUCTURE SOLUTION R; Slack G.A., 1995, CRC HDB THERMOELECTR, P407; SLACK GA, 1997, SOLID STATE PHYS, V34, P1; STORDEUR M, 1990, PHYS STATUS SOLIDI B, V161, P831, DOI 10.1002/pssb.2221610237; SUSSMANN H, 1982, KTB SERIES, P100; TESTARDI LR, 1962, J PHYS CHEM SOLIDS, V23, P1209, DOI 10.1016/0022-3697(62)90168-3; Tritt TM, 1999, SCIENCE, V283, P804, DOI 10.1126/science.283.5403.804; TRITT TM, 1997, MAT RES SOC S P, V478; Uher C, 1999, PHYS REV B, V59, P8615, DOI 10.1103/PhysRevB.59.8615; Vedernikov MV, 1997, PROCEEDINGS ICT'97 - XVI INTERNATIONAL CONFERENCE ON THERMOELECTRICS, P56, DOI 10.1109/ICT.1997.666974; Yim WM, 1966, J MATER SCI, V1, P52, DOI 10.1007/BF00549720; YIM WM, 1968, J ELECTROCHEM SOC, V115, P556, DOI 10.1149/1.2411329; ZAIAR SM, 1962, ADV ENERG CONVERS, V2, P105; 1986, ENCY MAT SCI ENG, P4968	36	766	806	20	509	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1024	1027		10.1126/science.287.5455.1024	http://dx.doi.org/10.1126/science.287.5455.1024			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669411	Green Submitted			2022-12-28	WOS:000085245400043
J	Dietl, T; Ohno, H; Matsukura, F; Cibert, J; Ferrand, D				Dietl, T; Ohno, H; Matsukura, F; Cibert, J; Ferrand, D			Zener model description of ferromagnetism in zinc-blende magnetic semiconductors	SCIENCE			English	Article							TRANSPORT-PROPERTIES; GA1-XMNXAS; TRANSITION; ZN1-XMNXTE; (GA,MN)AS; GAAS	Ferromagnetism in manganese compound semiconductors not only opens prospects for tailoring magnetic and spin-related phenomena in semiconductors with a precision specific to III-V compounds but also addresses a question about the origin of the magnetic interactions that Lead to a Curie temperature (T-C) as high as 110 K for a manganese concentration of just 5%, Zener's model of ferromagnetism, originally proposed for transition metals in 1950, can explain T-C of Ga1-xMnxAs and that of its II-VI counterpart Zn1-xMnxTe and is used to predict materials with T-C exceeding room temperature, an important step toward semiconductor electronics that use both charge and spin.	Tohoku Univ, Elect Commun Res Inst, Sendai, Miyagi 9808577, Japan; Polish Acad Sci, Inst Phys, PL-02668 Warsaw, Poland; Polish Acad Sci, Coll Sci, PL-02668 Warsaw, Poland; Univ Grenoble 1, CNRS, UMR 5588, Spectrometrie Phys Lab, F-38402 St Martin Dheres, France	Tohoku University; Polish Academy of Sciences; Institute of Physics - Polish Academy of Sciences; Polish Academy of Sciences; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Dietl, T (corresponding author), Tohoku Univ, Elect Commun Res Inst, Katahira 2-1-1, Sendai, Miyagi 9808577, Japan.	dietl@ifpan.edu.pl; ohno@riec.tohoku.ac.jp	Dietl, Tomasz/C-9537-2013; Cibert, Joël/D-4992-2017; Ma, Jun/D-8971-2011; Ohno, Hideo/E-6453-2010	Dietl, Tomasz/0000-0003-1090-4380; Cibert, Joël/0000-0002-4506-9613; Ohno, Hideo/0000-0001-9688-8259				AVERKIEV NS, 1987, SOV PHYS SEMICOND+, V21, P1119; Beschoten B, 1999, PHYS REV LETT, V83, P3073, DOI 10.1103/PhysRevLett.83.3073; BIMBERG D, 1982, LANDOLTBORNSTEIN A, V17; Bir GL., 1974, SYMMETRY STRAIN INDU; BLACHNIK R, 1999, LANDOLTBORNSTEIN B, V41; BLINOWSKI J, 1997, HIGH MAGNETIC FIELDS, V2, P861; BROSER I, 1982, LANDOLTBORNSTEIN B, V17; de Boeck J, 1999, PHYS WORLD, V12, P27; Dietl T, 1997, PHYS REV B, V55, pR3347, DOI 10.1103/PhysRevB.55.R3347; DIETL T, UNPUB; DiVincenzo DP, 1999, J APPL PHYS, V85, P4785, DOI 10.1063/1.370481; FERRAND D, IN PRESS J CRYSTAL G; FURDYNA JK, 1988, J APPL PHYS, V64, pR29, DOI 10.1063/1.341700; GLOD P, 1994, PHYSICA B, V194, P995, DOI 10.1016/0921-4526(94)90827-3; Julien FH, 1998, SCIENCE, V282, P1429, DOI 10.1126/science.282.5393.1429; Jungwirth T, 1999, PHYS REV B, V59, P9818, DOI 10.1103/PhysRevB.59.9818; Kim K, 1997, PHYS REV B, V56, P7363, DOI 10.1103/PhysRevB.56.7363; LAGUILLAUME CBA, 1992, PHYS REV B, V46, P9853, DOI 10.1103/PhysRevB.46.9853; Linnarsson M, 1997, PHYS REV B, V55, P6938, DOI 10.1103/PhysRevB.55.6938; MADELUNG O, 1987, LANDOLTBORNSTEIN, V22; Matsukura F, 1998, PHYS REV B, V57, pR2037, DOI 10.1103/PhysRevB.57.R2037; Mott N.F., 1940, P ROYAL SOC LONDON S, V175, P382; Ohno H, 1996, APPL PHYS LETT, V69, P363, DOI 10.1063/1.118061; Ohno H, 1999, J APPL PHYS, V85, P4277, DOI 10.1063/1.370343; Ohno H, 1998, SCIENCE, V281, P951, DOI 10.1126/science.281.5379.951; OHNO H, 1992, PHYS REV LETT, V68, P2664, DOI 10.1103/PhysRevLett.68.2664; OHNO H, 1996, P 23 INT C PHYS SEM, P405; Oiwa A, 1997, SOLID STATE COMMUN, V103, P209, DOI 10.1016/S0038-1098(97)00178-6; Okabayashi J, 1998, PHYS REV B, V58, pR4211, DOI 10.1103/PhysRevB.58.R4211; PAALANEN MA, 1991, PHYSICA B, V169, P223, DOI 10.1016/0921-4526(91)90233-5; Prinz GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/science.282.5394.1660; RARITY J, 1996, MICROCAVITIES PHOTON; Sarma Sankar Das, 1997, PERSPECTIVES QUANTUM; SAWICKI M, 1986, PHYS REV LETT, V56, P508, DOI 10.1103/PhysRevLett.56.508; SHAPIRA Y, 1986, PHYS REV B, V33, P356, DOI 10.1103/PhysRevB.33.356; Shi J, 1996, SCIENCE, V271, P937, DOI 10.1126/science.271.5251.937; Shimizu H, 1999, APPL PHYS LETT, V74, P398, DOI 10.1063/1.123082; Shioda R, 1998, PHYS REV B, V58, P1100, DOI 10.1103/PhysRevB.58.1100; Stolpe I, 1998, PHYSICA B, V256, P659, DOI 10.1016/S0921-4526(98)00598-5; TWARDOWSKI A, 1984, SOLID STATE COMMUN, V50, P509, DOI 10.1016/0038-1098(84)90318-1; VanEsch A, 1997, PHYS REV B, V56, P13103, DOI 10.1103/PhysRevB.56.13103; Vogel D, 1996, PHYS REV B, V54, P5495, DOI 10.1103/PhysRevB.54.5495; ZENER C, 1951, PHYS REV, V81, P440, DOI 10.1103/PhysRev.81.440; ZENER C, 1951, PHYS REV, V83, P299, DOI 10.1103/PhysRev.83.299	44	7237	7456	21	885	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2000	287	5455					1019	1022		10.1126/science.287.5455.1019	http://dx.doi.org/10.1126/science.287.5455.1019			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669409				2022-12-28	WOS:000085245400041
J	Servant, G; Weiner, OD; Herzmark, P; Balla, T; Sedat, JW; Bourne, HR				Servant, G; Weiner, OD; Herzmark, P; Balla, T; Sedat, JW; Bourne, HR			Polarization of chemoattractant receptor signaling during neutrophil chemotaxis	SCIENCE			English	Article							PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN POLYMERIZATION; BINDING; ACTIVATION; CDC42; CELLS; PHOSPHOINOSITIDES; LEUKOCYTES	Morphologic polarity is necessary for chemotaxis of mammalian cells. As a probe of intracellular signals responsible for this asymmetry, the pleckstrin homology domain of the AKT protein kinase (or protein kinase B), tagged with the green fluorescent protein (PHAKT-GFP), was expressed in neutrophils. Upon exposure of cells to chemoattractant, PHAKT-GFP is recruited selectively to membrane at the cell's leading edge, indicating an internal signaling gradient that is much steeper than that of the chemoattractant. Translocation of PHAKT-GFP is inhibited by toxin-B from Clostridium difficile, indicating that it requires activity of one or more Rho guanosine triphosphatases.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; NICHHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bourne, HR (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.		Weiner, Orion D/F-2576-2011	Weiner, Orion D/0000-0002-1778-6543; Balla, Tamas/0000-0002-9077-3335	NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-25101, GM-27800, R01 GM027800-27] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R01GM025101, R37GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Cassimeris L, 1990, Semin Cell Biol, V1, P125; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOWNEY GP, 1994, CURR OPIN IMMUNOL, V6, P113, DOI 10.1016/0952-7915(94)90042-6; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Ma L, 1998, J CELL BIOL, V140, P1125; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; SERVANT G, UNPUB; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; ZIGMOND SH, 1977, J CELL BIOL, V75, P606, DOI 10.1083/jcb.75.2.606; Zigmond SH, 1998, J CELL BIOL, V142, P1001, DOI 10.1083/jcb.142.4.1001; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	48	703	717	4	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1037	1040		10.1126/science.287.5455.1037	http://dx.doi.org/10.1126/science.287.5455.1037			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669415	Green Accepted			2022-12-28	WOS:000085245400047
J	Nonnemaker, L				Nonnemaker, L			Women physicians in academic medicine: New insights from cohort studies.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNAL MEDICINE; SEX-DIFFERENCES; MEN; ADVANCEMENT; PROMOTION; FACULTY	Background: I conducted a study to determine whether women who graduate from medical schools are more or less likely than their male counterparts to pursue full-time careers in academic medicine and to advance to the senior ranks of medical school faculties. Methods: The rates of advancement to the ranks of assistant, associate, and full professor for all U.S. medical school graduates from 1979 through 1993 and for all members of U.S. medical school faculties from 1979 through 1997 were studied. Cohorts were defined on the basis of the year of graduation from medical school, track (tenure or nontenure), and academic department. Within each cohort, the number of women who advanced to a senior rank was compared with the number that would be expected on the basis of parity between men and women, and 95 percent confidence intervals were calculated. Results: Women were significantly more likely than men to pursue an academic career. During the study period, 634 more women became faculty members than expected. The numbers were higher in the older cohorts than in the younger cohorts. The numbers of women who advanced to the ranks of associate and full professor were significantly lower than the expected numbers. This was true for both tenure and nontenure tracks, even after adjustment for the department. A total of 334 fewer women advanced to associate professor than expected, and 44 fewer women advanced to full professor than expected. Conclusions: Disparities persist in the advancement of men and women on medical school faculties. However, the numbers of women physicians at all levels of academic medicine are increasing. (N Engl J Med 2000;342:399-405.) (C)2000, Massachusetts Medical Society.	Assoc Amer Med Coll, Ctr Assessment & Management Change Acad Med, Washington, DC 20037 USA	Association of American Medical Colleges	Nonnemaker, L (corresponding author), Assoc Amer Med Coll, Ctr Assessment & Management Change Acad Med, 2450 N St NW, Washington, DC 20037 USA.							*ASS AM MED COLL, 1988, WOM MIN US MED SCH F; *ASS AM MED COLL, 1999, AAMC DAT BOOK; BICKEL J, 1988, NEW ENGL J MED, V319, P1579, DOI 10.1056/NEJM198812153192405; BICKEL J, 1991, ACAD MED, V66, P497, DOI 10.1097/00001888-199108000-00025; Bickel J., 1988, WOMEN MED STAT; CARR PL, 1993, ANN INTERN MED, V119, P908, DOI 10.7326/0003-4819-119-9-199311010-00008; DEANGELIS CD, 1995, JAMA-J AM MED ASSOC, V273, P1056; DIAL TH, 1989, ACAD MED, V64, P198, DOI 10.1097/00001888-198904000-00007; DiPrete TA, 1997, AM SOCIOL REV, V62, P386, DOI 10.2307/2657312; Donoghue G D, 1988, J Am Med Womens Assoc (1972), V43, P28; Kaplan SH, 1996, NEW ENGL J MED, V335, P1282, DOI 10.1056/NEJM199610243351706; Kvaerner KJ, 1999, BRIT MED J, V318, P91; LEVEY BA, 1990, ACAD MED, V65, P102, DOI 10.1097/00001888-199002000-00011; NICKERSON KG, 1990, JAMA-J AM MED ASSOC, V264, P1813, DOI 10.1001/jama.264.14.1813; TESCH B, 1997, J IRISH COLL PHYS SU, V26, P172; TESCH BJ, 1995, JAMA-J AM MED ASSOC, V273, P1022, DOI 10.1001/jama.273.13.1022; WALLIS LA, 1981, JAMA-J AM MED ASSOC, V246, P2350, DOI 10.1001/jama.246.20.2350; WHITE LJ, 1991, ANN INTERN MED, V114, P63, DOI 10.7326/0003-4819-114-1-63; WHITING BE, 1990, ACAD MED, V65, P277, DOI 10.1097/00001888-199004000-00013; WILKINSON CJ, 1986, ANESTHESIOLOGY, V64, P496, DOI 10.1097/00000542-198604000-00014; 1981, MIT FAC NEWSLETT MAR, V56, P151	21	351	354	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					399	405		10.1056/NEJM200002103420606	http://dx.doi.org/10.1056/NEJM200002103420606			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666431				2022-12-28	WOS:000085205200006
J	Oderda, G; Rapa, A; Ronchi, B; Lerro, P; Pastore, M; Staiano, A; de'Angelis, GL; Strisciuglio, P				Oderda, G; Rapa, A; Ronchi, B; Lerro, P; Pastore, M; Staiano, A; de'Angelis, GL; Strisciuglio, P			Detection of Helicobacter pylori in stool specimens by non-invasive antigen enzyme immunoassay in children: multicentre Italian study	BRITISH MEDICAL JOURNAL			English	Article									Paediat Endoscopy Unit, Catanzaro 88100, Italy; Paediat Endoscopy Unit, Catanzaro 88100, Italy; Univ Parma, Paediat Endoscopy Unit, I-43100 Parma, Italy; Univ Piemonte Orientale, Paediat Endoscopy Unit, I-28100 Novara, Italy; Univ Piemonte Orientale, Paediat Res Lab, I-28100 Novara, Italy; Univ Turin, Paediat Endoscopy Unit, I-10126 Turin, Italy; Paediat Endoscopy Unit, I-71013 San Giovanni Rotondo, Italy; Univ Naples, Paediat Endoscopy Unit, I-80131 Naples, Italy	University of Parma; University of Eastern Piedmont Amedeo Avogadro; University of Eastern Piedmont Amedeo Avogadro; University of Turin; University of Naples Federico II	Oderda, G (corresponding author), Univ Piemonte Orientale, Paediat Endoscopy Unit, I-28100 Novara, Italy.		Rapa, Anna/B-8878-2013; Rapa, Anna/R-5678-2019; de'Angelis, Gian Luigi/AAC-7901-2021; Staiano, Annamaria/H-3026-2011	Rapa, Anna/0000-0002-5523-5224; de'Angelis, Gian Luigi/0000-0002-8254-6917; Staiano, Annamaria/0000-0003-0586-1339				BLASER MJ, 1995, CANCER RES, V55, P562; Makristathis A, 1998, J CLIN MICROBIOL, V36, P2772, DOI 10.1128/JCM.36.9.2772-2774.1998; Vaira D, 1999, LANCET, V354, P30, DOI 10.1016/S0140-6736(98)08103-3	3	126	130	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					347	348		10.1136/bmj.320.7231.347	http://dx.doi.org/10.1136/bmj.320.7231.347			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657328	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000085211400024
J	Yung, M				Yung, M			A memorable patient - For want of a bag of blood	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					365	365		10.1136/bmj.320.7231.365	http://dx.doi.org/10.1136/bmj.320.7231.365			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657337	Green Published			2022-12-28	WOS:000085211400035
J	Bjerre, LM; LeLorier, J				Bjerre, LM; LeLorier, J			Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed"	BRITISH MEDICAL JOURNAL			English	Article							DRUGS; RISK	Results of epidemiological studies need to be expressed in understandable terms if they are to be of practical use to clinicians and policy makers Case-control studies are often used to stud) adverse effects of treatment; odds ratios from these are used to express the magnitude of adverse effects, but ar-e not intuitively understandable estimates of risk A more understandable and informative means of expressing the risk of adverse events in case-control studies is "the number of patients needed to be treated for one additional patient to be harmed" This is calculated from the odds ratio and the unexposed event rate-that is, the rate of occurrence of the adverse event of interest in people not exposed to the treatment.	CHU Montreal, Ctr Rech, Pharmacoepidemiol & Pharmacoecon Res Unit, Montreal, PQ H2W 1T8, Canada; McGill Univ, Fac Med, Dept Epidemiol & Biostat, Montreal, PQ H3A 1A2, Canada	Universite de Montreal; McGill University	LeLorier, J (corresponding author), CHU Montreal, Ctr Rech, Pharmacoepidemiol & Pharmacoecon Res Unit, Campus Hotel-Dieu, Montreal, PQ H2W 1T8, Canada.			Bjerre, Lise M./0000-0003-3634-3585				Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; FARLEY TMM, 1995, LANCET, V346, P1582; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SACKETT DL, 1997, EVIDENCE BASED MED; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Sackett DL, 1996, EVIDENCE BASED MED, V1, P164, DOI DOI 10.1136/EBM.1996.1.164; Spitzer WO, 1996, BRIT MED J, V312, P83	11	59	59	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					503	506		10.1136/bmj.320.7233.503	http://dx.doi.org/10.1136/bmj.320.7233.503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678870	Green Published			2022-12-28	WOS:000085562200033
J	Murray, HW; Pepin, J; Nutman, TB; Hoffman, SL; Mahmoud, AAF				Murray, HW; Pepin, J; Nutman, TB; Hoffman, SL; Mahmoud, AAF			Tropical medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CUTANEOUS LEISHMANIASIS; PLASMODIUM-FALCIPARUM; MALARIA; DIAGNOSIS; INFECTION; VACCINE		Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; Univ Sherbrooke, Ctr Int Hlth, Sherbrooke, PQ J1H 5N4, Canada; NIH, Helminth Immunol Sect, Bethesda, MD 20892 USA; NIH, Clin Parasitol Unit, Parasit Dis Lab, Bethesda, MD 20892 USA; USN, Med Res Ctr, Rockville, MD 20852 USA; Merck Vaccines, Whitehouse Stn, NJ 08889 USA	Cornell University; University of Sherbrooke; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; United States Department of Defense; United States Navy; Merck & Company	Murray, HW (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA.	hwmurray@mail.med.cornell.edu	Murray, Heather/GQY-8016-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016963, R56AI016963, Z01AI000439] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 16963, R56 AI016963, R01 AI016963] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADDISS DA, 1999, LYMPHATIC FILARIASIS, P151; Alvar J, 1997, CLIN MICROBIOL REV, V10, P298, DOI 10.1128/CMR.10.2.298; BAILEY JW, 1994, TROP DOCT, V24, P54, DOI 10.1177/004947559402400204; Baird JK, 1999, MED CLIN N AM, V83, P923; BEADLE C, 1994, LANCET, V343, P564, DOI 10.1016/S0140-6736(94)91520-2; BRONNER U, 1991, T ROY SOC TROP MED H, V85, P608, DOI 10.1016/0035-9203(91)90364-5; BURRI C, 1993, CHEMOTHERAPY, V39, P225, DOI 10.1159/000239130; Dessein AJ, 1999, AM J HUM GENET, V65, P709, DOI 10.1086/302526; DOCHRINGSCHWERD.E, 1995, MEM I O CRUZ, V90, P141; DREVER G, 1999, T R SOC TROP MED HYG, V93, P413; Ekwanzala M, 1996, LANCET, V348, P1427, DOI 10.1016/S0140-6736(96)06088-6; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gilles HM, 1998, BRIT MED BULL, V54, P269; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Hoffman SL, 1996, NEW ENGL J MED, V335, P124, DOI 10.1056/NEJM199607113350209; Karp CL, 1999, CLIN INFECT DIS, V28, P947, DOI 10.1086/514745; Lopez-Jaramillo P, 1998, LANCET, V351, P1176, DOI 10.1016/S0140-6736(05)79119-4; MAHMOUD AAP, TROPICAL MED SCI PRA; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; MCCARTHY JS, 1999, LYMPHATIC FILARIASIS, P127; Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520; Nabarro DN, 1998, SCIENCE, V280, P2067, DOI 10.1126/science.280.5372.2067; Noroes J, 1996, T ROY SOC TROP MED H, V90, P55, DOI 10.1016/S0035-9203(96)90478-2; Ottesen EA, 1999, PARASITOL TODAY, V15, P382, DOI 10.1016/S0169-4758(99)01486-6; Ottesen EA, 1997, B WORLD HEALTH ORGAN, V75, P491; PEPIN J, IN PRESS B WHO; Schofield CJ, 1999, ADV PARASIT, V42, P1, DOI 10.1016/S0065-308X(08)60147-5; Sharifi I, 1998, LANCET, V351, P1540, DOI 10.1016/S0140-6736(98)09552-X; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Sundar S, 1998, LANCET, V351, P563, DOI 10.1016/S0140-6736(97)04350-X; Sundar S, 1999, ANN TROP MED PARASIT, V93, P589, DOI 10.1080/00034989958096; Trouiller P, 1998, Int J Infect Dis, V3, P61, DOI 10.1016/S1201-9712(99)90010-3; Tsang VCW, 1997, IMMUNOL INVEST, V26, P175, DOI 10.3109/08820139709048925; Weatherall D, 1998, BRIT MED BULL, V54, P489; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X	35	17	17	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	2000	320	7233					490	494		10.1136/bmj.320.7233.490	http://dx.doi.org/10.1136/bmj.320.7233.490			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678866	Green Published			2022-12-28	WOS:000085562200028
J	Quint, DJ				Quint, DJ			Indications for emergent MRI of the central nervous system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VERTEBRAL ARTERY DISSECTIONS; DIFFUSION-WEIGHTED MR; SUBARACHNOID HEMORRHAGE; ACUTE STROKE; CT; ANGIOGRAPHY; INFARCTION; DIAGNOSIS; THROMBOSIS; ETIOLOGY		Univ Michigan, Med Ctr, Dept Neuroradiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Quint, DJ (corresponding author), Univ Michigan, Med Ctr, Dept Neuroradiol, 1500 E Med Ctr Dr,B1D520,Box 30, Ann Arbor, MI 48109 USA.	djquint@umich.edu						Adams HP, 1996, STROKE, V27, P1711; Adams HP, 1996, NEUROLOGY, V47, P835; Auer F, 1998, J NEUROL NEUROSUR PS, V64, P474, DOI 10.1136/jnnp.64.4.474; BACH F, 1990, ACTA NEUROCHIR, V107, P37, DOI 10.1007/BF01402610; BANNAN PE, 1992, CURR OPIN NEUROL NEU, V5, P540; Beauchamp NJ, 1998, RADIOGRAPHICS, V18, P1269, DOI 10.1148/radiographics.18.5.9747619; Beauchamp NJ, 1998, AM J ROENTGENOL, V171, P73, DOI 10.2214/ajr.171.1.9648768; Burdette JH, 1998, AM J ROENTGENOL, V171, P791, DOI 10.2214/ajr.171.3.9725318; DEMAEREL P, 1992, NEURORADIOLOGY, V34, P490, DOI 10.1007/BF00598957; Desfontaines P, 1995, ACTA NEUROL BELG, V95, P226; ELKHOURY GY, 1995, AM J ROENTGENOL, V164, P43, DOI 10.2214/ajr.164.1.7998567; Ginsberg MD, 1997, AM J NEURORADIOL, V18, P1435; Gonzalez RG, 1999, RADIOLOGY, V210, P155, DOI 10.1148/radiology.210.1.r99ja02155; Haley GH, 1997, ANN EMERG MED, V30, P676, DOI 10.1016/S0196-0644(97)99996-0; HURST RW, 1994, SEMIN NEUROL, V14, P320, DOI 10.1055/s-2008-1041092; Jacobs A, 1997, J NEUROL SCI, V147, P27, DOI 10.1016/S0022-510X(96)05300-2; Kasner SE, 1997, STROKE, V28, P1993, DOI 10.1161/01.STR.28.10.1993; KLUFAS RA, 1995, AM J ROENTGENOL, V164, P673, DOI 10.2214/ajr.164.3.7863892; Lovblad KO, 1998, AM J NEURORADIOL, V19, P1061; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Noguchi K, 1997, RADIOLOGY, V203, P257, DOI 10.1148/radiology.203.1.9122404; Patel M R, 1996, Top Magn Reson Imaging, V8, P345; Provenzale JM, 1997, AM J ROENTGENOL, V169, P1161, DOI 10.2214/ajr.169.4.9308483; Provenzale JM, 1998, AM J ROENTGENOL, V170, P777, DOI 10.2214/ajr.170.3.9490973; Russell EJ, 1997, RADIOLOGY, V205, P315, DOI 10.1148/radiology.205.2.9356608; Singer MB, 1998, RADIOLOGY, V208, P417, DOI 10.1148/radiology.208.2.9680570; Velthuis BK, 1998, RADIOLOGY, V208, P423, DOI 10.1148/radiology.208.2.9680571; Villringer A, 1997, New Horiz, V5, P332; VILLRINGER A, 1994, J NEURORADIOLOGY, V21, P72	29	18	19	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2000	283	7					853	855		10.1001/jama.283.7.853	http://dx.doi.org/10.1001/jama.283.7.853			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	281WT	10685696				2022-12-28	WOS:000085185000001
J	Maclean, J				Maclean, J			It could be you	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					455	455		10.1136/bmj.320.7232.455	http://dx.doi.org/10.1136/bmj.320.7232.455			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669471	Green Published			2022-12-28	WOS:000085377400067
J	Jin, T; Zhang, N; Long, Y; Parent, CA; Devreotes, PN				Jin, T; Zhang, N; Long, Y; Parent, CA; Devreotes, PN			Localization of the G protein beta gamma complex in living cells during chemotaxis	SCIENCE			English	Article							DICTYOSTELIUM-DISCOIDEUM; TEMPORAL MECHANISM; RECEPTORS; SUBUNIT; LEUKOCYTES; GRADIENTS; RESPONSES; FREQUENCY; DIMERS; AMEBAE	Gradients of chemoattractants elicit signaling events at the Leading edge of a cell even though chemoattractant receptors are uniformly distributed on the cell surface. In highly polarized Dictyostelium discoideum amoebas, membrane-associated beta gamma subunits of heterotrimeric guanine nucleotide-binding proteins (G proteins) were localized in a shallow anterior-posterior gradient. A uniformly applied chemoattractant generated binding sites for pleckstrin homology (PH) domains on the inner surface of the membrane in a pattern similar to that of the G beta gamma subunits. Loss of cell polarity resulted in uniform distribution of both the G beta gamma subunits and the sensitivity of PH domain recruitment. There observations indicate that G beta gamma subunits are not sufficiently localized to restrict signaling events to the Leading edge but that their distribution may determine the relative chemotactic sensitivity of polarized cells.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Devreotes, PN (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.				NIGMS NIH HHS [GM-28007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010418, ZIABC010418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028007, R37GM028007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; BOURNE H, COMMUNICATION; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; FISHER PR, 1989, J CELL BIOL, V108, P973, DOI 10.1083/jcb.108.3.973; Jin T, 1998, EMBO J, V17, P5076, DOI 10.1093/emboj/17.17.5076; Jin T, 1998, MOL BIOL CELL, V9, P2949, DOI 10.1091/mbc.9.10.2949; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; MEDEN U, 1995, J BIOL CHEM, V270, P15892; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Meinhardt H, 1999, J CELL SCI, V112, P2867; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SWANSON JA, 1982, CELL, V28, P225, DOI 10.1016/0092-8674(82)90340-3; VARNUMFINNEY B, 1987, CELL MOTIL CYTOSKEL, V8, P7, DOI 10.1002/cm.970080103; VARNUMFINNEY BJ, 1987, CELL MOTIL CYTOSKEL, V8, P18, DOI 10.1002/cm.970080104; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; Zhang N.F., UNPUB; ZIGMOND SH, 1981, J CELL BIOL, V89, P585, DOI 10.1083/jcb.89.3.585; ZIGMOND SH, 1977, J CELL BIOL, V75, P606, DOI 10.1083/jcb.75.2.606	26	234	240	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1034	1036		10.1126/science.287.5455.1034	http://dx.doi.org/10.1126/science.287.5455.1034			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669414				2022-12-28	WOS:000085245400046
J	Blumenthal, SJ				Blumenthal, SJ			Critical women's health issues in the 21st century	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US PHS, US Dept HHS, Washington, DC 20201 USA	United States Public Health Service	Blumenthal, SJ (corresponding author), US PHS, US Dept HHS, Washington, DC 20201 USA.							*ASS AM MED COLL, 1999, WOM US AC MED STAT 1; BLUMENTHAL SJ, 1995, WOMENS COMPLETE HLTH, P3; *CDCP, 1998, HLTH US 1998 SOC STA; National Institutes of Health, 1992, NIH PUBL; U.S. Census Bureau, 1967, TABLE 4 YEARS SCH CO; *US DEP HHS, 1997, US DEP HLTH HUM SERV	6	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					667	667		10.1001/jama.283.5.667	http://dx.doi.org/10.1001/jama.283.5.667			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665710	hybrid			2022-12-28	WOS:000084956500036
J	Chen, MS; Huber, AB; van der Haar, ME; Frank, M; Schnell, L; Spillmann, AA; Christ, F; Schwab, ME				Chen, MS; Huber, AB; van der Haar, ME; Frank, M; Schnell, L; Spillmann, AA; Christ, F; Schwab, ME			Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1	NATURE			English	Article							GROWTH-INHIBITORS; GENE; RAT; EXPRESSION; PROTEIN; IDENTIFICATION; TRANSCRIPTS; RECOVERY; SEQUENCE; CLONING	The capacity of the adult brain and spinal cord to repair lesions by axonal regeneration or compensatory fibre growth is extremely Limited. A monoclonal antibody (IN-1) raised against NI-220/250, a myelin protein that is a potent inhibitor of neurite growth, promoted axonal regeneration and compensatory plasticity following lesions of the central nervous system (CNS) in adult rats(1-4). Here we report the cloning of nogo A, the rat complementary DNA encoding NI-220/250. The nogo gene encodes at least three major protein products (Nogo-A, -B and -C), Recombinant Nogo-A is recognized by monoclonal antibody IN-1, and it inhibits neurite outgrowth from dorsal root ganglia and spreading of 3T3 fibroblasts in an IN-1-sensitive manner. Antibodies against Nogo-A stain CNS myelin and oligodendrocytes and allow dorsal root ganglion neurites to grow on CNS myelin and into optic nerve explants. These data show that Nogo-A is a potent inhibitor of neurite growth and an IN-1 antigen produced by oligodendrocytes, and may allow the generation of new reagents to enhance CNS regeneration and plasticity.	Univ Zurich, Inst Brain Res, Dept Neuromorphol, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, CH-8057 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Schwab, ME (corresponding author), Univ Zurich, Inst Brain Res, Dept Neuromorphol, CH-8057 Zurich, Switzerland.		Schwab, Martin E/B-6818-2016					BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen M. S., 1999, Society for Neuroscience Abstracts, V25, P2030; Geisler JG, 1998, MAMM GENOME, V9, P274, DOI 10.1007/s003359900748; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; Morris NJ, 1999, BBA-PROTEIN STRUCT M, V1431, P525, DOI 10.1016/S0167-4838(99)00068-0; NAGASE T, 1998, DNA RES, V5, P169; Ninkina NN, 1997, GENE, V184, P205, DOI 10.1016/S0378-1119(96)00596-3; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; Roebroek AJM, 1996, GENOMICS, V32, P191, DOI 10.1006/geno.1996.0105; RUBIN BP, 1994, J NEUROCYTOL, V23, P209, DOI 10.1007/BF01275525; SCHAERENWIEMERS N, 1995, J NEUROSCI, V15, P5753; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WIECZOREK DF, 1991, MOL BRAIN RES, V10, P33, DOI 10.1016/0169-328X(91)90053-Z	19	1168	1347	2	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					434	439		10.1038/35000219	http://dx.doi.org/10.1038/35000219			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667796				2022-12-28	WOS:000085121100052
J	Gambaro, G; Anglani, F; D'Angelo, A				Gambaro, G; Anglani, F; D'Angelo, A			Association studies of genetic polymorphisms and complex disease	LANCET			English	Editorial Material							ANGIOTENSIN-CONVERTING ENZYME; CARDIOVASCULAR HOMEOSTASIS; DELETION POLYMORPHISM; BLOOD PRESSURES; EXPRESSION; RISK		Univ Padua, Dept Med & Surg Sci, I-35128 Padua, Italy; Univ Padua, Sch Med, Sect Mol Med, I-35128 Padua, Italy	University of Padua; University of Padua	D'Angelo, A (corresponding author), Univ Padua, Dept Med & Surg Sci, Via Guistiniant, I-35128 Padua, Italy.		Cappuccio, Francesco Paolo/ABF-1094-2020; Anglani, Franca/F-9045-2017	Cappuccio, Francesco Paolo/0000-0002-7842-5493; Anglani, Franca/0000-0003-1534-4458; Gambaro, Giovanni/0000-0001-5733-2370				CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; KIDD KK, 1993, AM J MED GENET, V48, P71, DOI 10.1002/ajmg.1320480202; Krege JH, 1997, HYPERTENSION, V29, P150, DOI 10.1161/01.HYP.29.1.150; MIZUIRI S, 1997, J AM SOC NEPHROL, V8, pA115; Morgan L, 1996, HUM GENET, V98, P194, DOI 10.1007/s004390050189; Muller DN, 1997, HYPERTENSION, V29, P98, DOI 10.1161/01.HYP.29.1.98; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; Staessen JA, 1997, J HYPERTENS, V15, P1579, DOI 10.1097/00004872-199715120-00059; STRACHAN T, 1996, HUM MOL GENET, P499; Tian BH, 1997, HYPERTENSION, V30, P128, DOI 10.1161/01.HYP.30.1.128; Yoshida H, 1997, J AM SOC NEPHROL, V8, p633A	13	170	173	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					308	311		10.1016/S0140-6736(99)07202-5	http://dx.doi.org/10.1016/S0140-6736(99)07202-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675088				2022-12-28	WOS:000085045600040
J	Johanson, R				Johanson, R			Perineal massage for prevention of perineal trauma in childbirth	LANCET			English	Editorial Material							EPISIOTOMY; LACERATION		N Staffordshire Matern Hosp, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England	University Hospital of North Staffordshire NHS Trust	Johanson, R (corresponding author), N Staffordshire Matern Hosp, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England.							AVERY MD, 1987, J NURSE-MIDWIFERY, V32, P181, DOI 10.1016/0091-2182(87)90095-4; AVERY MD, 1986, J NURSE-MIDWIFERY, V31, P128, DOI 10.1016/0091-2182(86)90148-5; CARROLI G, 1999, COCHRANE LIB; Graham I. D., 1997, EPISIOTOMY CHALLENGI; KETTLE C, 1999, PERINEAL TEARS; KETTLE C, 1999, CLIN EVID, V2, P522; Klein MC, 1997, AM J OBSTET GYNECOL, V176, P403, DOI 10.1016/S0002-9378(97)70506-4; KLEIN MC, 1994, AM J OBSTET GYNECOL, V171, P591, DOI 10.1016/0002-9378(94)90070-1; Labrecque M, 1999, AM J OBSTET GYNECOL, V180, P593, DOI 10.1016/S0002-9378(99)70260-7; LABRECQUE M, 1994, BIRTH-ISS PERINAT C, V21, P20, DOI 10.1111/j.1523-536X.1994.tb00911.x; McCandlish R, 1998, BRIT J OBSTET GYNAEC, V105, P1262, DOI 10.1111/j.1471-0528.1998.tb10004.x; Renfrew MJ, 1998, BIRTH-ISS PERINAT C, V25, P143; Shipman MK, 1997, BRIT J OBSTET GYNAEC, V104, P787, DOI 10.1111/j.1471-0528.1997.tb12021.x	13	25	27	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					250	251		10.1016/S0140-6736(00)00020-9	http://dx.doi.org/10.1016/S0140-6736(00)00020-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	279LQ	10675069				2022-12-28	WOS:000085045600005
J	Mariani-Costantini, R; Catalano, P; di Gennaro, F; di Tota, G; Angeletti, LR				Mariani-Costantini, R; Catalano, P; di Gennaro, F; di Tota, G; Angeletti, LR			New light on cranial surgery in ancient Rome	LANCET			English	Review							P53		Univ Gabriele Dannunzio, Sect Mol Pathol, Dept Oncol & Neurosci, I-66013 Chieti 1, Italy; Natl Archeol Museum, Lab Anthropol, Chieti, Italy; Archeol Superintendence Rome, Rome, Italy; Univ La Sapienza, Dept Expt Med & Pathol, Sect Hist Med, Rome, Italy	G d'Annunzio University of Chieti-Pescara; Sapienza University Rome	Mariani-Costantini, R (corresponding author), Univ Gabriele Dannunzio, Sect Mol Pathol, Dept Oncol & Neurosci, Via Vestini 1, I-66013 Chieti 1, Italy.		Mariani-Costantini, Renato/B-6637-2012	Mariani-Costantini, Renato/0000-0002-4440-1848				Alt KW, 1997, NATURE, V387, P360, DOI 10.1038/387360a0; BLAMIRES TL, 1992, EYE, V6, P90, DOI 10.1038/eye.1992.18; Brothwell Donald R., 1967, DIS ANTIQUITY, P673; BROTHWELL DR, 1974, J ARCHAEOL SCI, V1, P209, DOI 10.1016/0305-4403(74)90044-2; CAMPILLO D, 1993, J PALEOPATHOL, V3, P137; Capasso L, 1995, P 9 EUR M PAL ASS BA, P103; *CELS, 1971, MED 3, V8, P1; CLAUDII GALENI, 1965, OPERA OMNIA 10, V6; Cuscianna N, 1996, J PALEOPATHOL, V8, P85; *EL MED, CMG; Germana Franco, 1992, TRAPANAZIONI CRANIOT; GOODMAN AH, 1992, J PALEOPATHOLOGY MON, V2; GRAHAM DI, 1997, GREENFIELDS NEUROPAT; *HIPP, 1988, HIPP 5, V2, P1; *HIPP, 1994, HIPP 6, V5, P16; Jackson R., 1990, J ROMAN ARCHAEOL, V3, P5, DOI DOI 10.1017/S1047759400010813; Jackson Ralph, 1988, DOCTORS DIS ROMAN EM; JOLLY KW, 1994, ONCOGENE, V9, P97; Kleihues P, 1997, AM J PATHOL, V150, P1; KRUG A, 1990, MED MONDO CLASSICO; Lisowski F. P, 1967, DIS ANTIQUITY, P651; Majno G., 1975, HEALING HAND; MARCHESINI BB, 1986, B COMMISSIONE ARCHEO, V91, P698; MCLEONDON RE, 1998, RUSSEL RUBINSTEINS P; Merbs CF, 1989, RECONSTRUCTION LIFE, P161; Parker S., 1986, OSSA, V12, P141; Piggott S., 1940, P PREHIST SOC, V6, P112, DOI 10.1017/S0079497X00020430; PLINY ELDER, 1974, HIST NATURELLE, V25, pR7; ROSAI J, 1989, ACKERMANS SURG PATHO, P1713; WELLS C, 1964, BONES BODIES DIS, P141; WELLS C, 1967, DISEASES ANTIQUITY, P390	31	33	33	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					305	307		10.1016/S0140-6736(99)05064-3	http://dx.doi.org/10.1016/S0140-6736(99)05064-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675087				2022-12-28	WOS:000085045600039
J	Daily, GC; Walker, BH				Daily, GC; Walker, BH			Seeking the great transition	NATURE			English	Editorial Material									Stanford Univ, Dept Biol Sci, Ctr Conservat Biol, Stanford, CA 94305 USA; CSIRO, Canberra, ACT 2601, Australia	Stanford University; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Daily, GC (corresponding author), Stanford Univ, Dept Biol Sci, Ctr Conservat Biol, Stanford, CA 94305 USA.		Walker, Brian H/F-2386-2011					Daily GC, 1996, ECOL APPL, V6, P991, DOI 10.2307/2269582; DAILY GC, UNPUB SCI; Daily GC, 1997, NATURES SERVICES SOC, DOI DOI 10.12987/9780300188479-039; Dunphy D. C., 1998, SUSTAINABLE CORPORAT; ELKINGTON J, 1999, PEOPLE PLANET, V8, P10; Hackel JD, 1999, CONSERV BIOL, V13, P726, DOI 10.1046/j.1523-1739.1999.98210.x; Hawken Paul, 2010, NATURAL CAPITALISM C; Hawken Paul, 2011, ECOLOGY COMMERCE DEC; James AN, 1999, NATURE, V401, P323, DOI 10.1038/43774; Levin S., 1999, FRAGILE DOMINION; MCNEELY JA, 1999, MOBILIZING BROADER S; Myers Norman, 1998, PERVERSE SUBSIDIES T; National Research Council, 1999, OUR COMM JOURN TRANS; RAVEN PH, IN PRESS FRONTIERS M; Rees W.E., 1996, OUR ECOLOGICAL FOOTP; Richards D. J, 1997, IND GREEN GAME IMPLI; Romm Joseph J., 1999, COOL COMPANIES BEST; ROSENBLATT R, 1999, CONSUMING DESIRES CO; SASSEVILLE DR, 1997, ISO 14000 ANSWER BOO; Schmidheiny S., 1992, CHANGING COURSE GLOB; Schulze PC, 1999, MEASURES ENV PERFORM, P1; *SIERR BUS COUNC, 1996, SIERR NEV WEALTH IND; Socolow R, 1994, IND ECOLOGY GLOBAL C; Wilkinson P, 1998, NATURE, V396, P511, DOI 10.1038/24979	24	23	26	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					243	245		10.1038/35002194	http://dx.doi.org/10.1038/35002194			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659827				2022-12-28	WOS:000084899700022
J	Rhew, RC; Miller, BR; Weiss, RF				Rhew, RC; Miller, BR; Weiss, RF			Natural methyl bromide and methyl chloride emissions from coastal salt marshes	NATURE			English	Article							HIGHER-PLANTS; BIOSYNTHESIS; METHANE; HALOMETHANES; FLUX	Atmospheric methyl bromide (CH3Br) and methyl chloride (CH3Cl), compounds that are involved in stratospheric ozone depletion, originate from both natural and anthropogenic sources. Current estimates of CH3Br and CH3Cl emissions from oceanic sources, terrestrial plants and fungi, biomass burning and anthropogenic inputs do not balance their losses owing to oxidation by hydroxyl radicals, oceanic degradation, and consumption in soils, suggesting that additional natural terrestrial sources may be important(1). Here we show that CH3Br and CH3Cl are released to the atmosphere from all vegetation zones of two coastal salt marshes. We see very large fluxes of CH3Br and CH3Cl per unit area: up to 42 and 570 mu mol m(-2) d(-1), respectively. The fluxes show large diurnal, seasonal and spatial variabilities, but there is a strong correlation between the fluxes of CH3Br and those of CH3Cl, with an average molar flux ratio of roughly 1:20. If our measurements are typical of salt marshes globally, they suggest that such ecosystems, even though they constitute less than 0.1% of the global surface area(2), may produce roughly 10% of the total fluxes of atmospheric CH3Br and CH3Cl.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Rhew, RC (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.		Rhew, Robert C/M-8110-2016	Rhew, Robert C/0000-0001-6358-2050; Miller, Benjamin/0000-0003-1647-0122				ALONGI D, 1998, COASTAL ECOSYSTEM PR; ATTIEH JM, 1995, J BIOL CHEM, V270, P9250, DOI 10.1074/jbc.270.16.9250; BARTLETT KB, 1985, J GEOPHYS RES-ATMOS, V90, P5710, DOI 10.1029/JD090iD03p05710; DELAUNE RD, 1983, TELLUS B, V35, P8, DOI 10.1111/j.1600-0889.1983.tb00002.x; Gan J, 1998, GEOPHYS RES LETT, V25, P3595, DOI 10.1029/98GL52697; HARPER DB, 1985, NATURE, V315, P55, DOI 10.1038/315055a0; Kurylo MJ, 1999, SCI ASSESSMENT OZONE, P21; Livingston G., 1995, BIOGENIC TRACE GASES, P14; MANLEY SL, 1988, MAR BIOL, V98, P477, DOI 10.1007/BF00391538; Miller BR, 1998, J GEOPHYS RES-ATMOS, V103, P13237, DOI 10.1029/98JD00771; MILLER BR, 1998, THESIS U CALIFORNIA; SAINI HS, 1995, PLANT CELL ENVIRON, V18, P1027, DOI 10.1111/j.1365-3040.1995.tb00613.x; Saxena D, 1998, APPL ENVIRON MICROB, V64, P2831; Scarratt MG, 1996, MAR CHEM, V54, P263, DOI 10.1016/0304-4203(96)00036-9; STEELE LP, 1987, J ATMOS CHEM, V5, P125, DOI 10.1007/BF00048857; Varner RK, 1999, GEOPHYS RES LETT, V26, P2433, DOI 10.1029/1999GL900587; Watling R, 1998, MYCOL RES, V102, P769, DOI 10.1017/S0953756298006157; Wingenter OW, 1998, GEOPHYS RES LETT, V25, P2797, DOI 10.1029/98GL02179; WOODWELL GM, 1973, BROOKHAVEN S BIOL SE, V24, P221; WUOSMAA AM, 1990, SCIENCE, V249, P160, DOI 10.1126/science.2371563; Zedler, 1982, FWSOBS8154 US FISH W	21	206	219	6	65	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					292	295		10.1038/35002043	http://dx.doi.org/10.1038/35002043			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659844				2022-12-28	WOS:000084899700047
J	Yack, JE; Fullard, JH				Yack, JE; Fullard, JH			Ultrasonic hearing in nocturnal butterflies	NATURE			English	Article									Carleton Univ, Dept Biol, Ottawa, ON K1S 5B6, Canada; Carleton Univ, Coll Nat Sci, Ottawa, ON K1S 5B6, Canada; Univ Toronto, Dept Zool, Mississauga, ON L5L 1C6, Canada; Univ Toronto, Erindale Coll, Mississauga, ON L5L 1C6, Canada	Carleton University; Carleton University; University of Toronto; University Toronto Mississauga; University of Toronto; University Toronto Mississauga	Yack, JE (corresponding author), Carleton Univ, Dept Biol, Ottawa, ON K1S 5B6, Canada.	jyack@ccs.carleton.ca						Conner WE, 1999, J EXP BIOL, V202, P1711; FULALRD JH, 1998, COMP HEARING INSECTS, P279; HOY R, 1989, J EXP BIOL, V146, P287; Jacobs K, 1999, J EXP ZOOL, V283, P270, DOI 10.1002/(SICI)1097-010X(19990215)283:3&lt;270::AID-JEZ5&gt;3.0.CO;2-C; Kristensen NP., 1998, HDB ZOOLOGY, VIV, P7; NOVACEK MJ, 1985, NATURE, V315, P140, DOI 10.1038/315140a0; OTERO LD, 1990, B ENTOMOL VENEZ, V5, P128; Ribaric Darja, 1996, Acta Entomologica Slovenica, V4, P5; Scoble M.J., 1986, Bulletin of the British Museum (Natural History) Entomology, V53, P251; SCOBLE MJ, 1990, J NAT HIST, V24, P159, DOI 10.1080/00222939000770101; SILBERGLIED RE, 1984, BIOL BUTTERFLIES, P207; Vogel R, 1912, Z WISS ZOOL ABT A, V100, P210; YACK JE, 1993, ANN ENTOMOL SOC AM, V86, P677, DOI 10.1093/aesa/86.6.677	13	49	51	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2000	403	6767					265	266		10.1038/35002247	http://dx.doi.org/10.1038/35002247			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659835				2022-12-28	WOS:000084899700037
J	Maeshima, E; Yamada, Y; Yukawa, S				Maeshima, E; Yamada, Y; Yukawa, S			Fever and leucopenia with steroids	LANCET			English	Article									Wakayama Med Coll, Dept Internal Med 3, Wakayama 6410012, Japan	Wakayama Medical University	Maeshima, E (corresponding author), Wakayama Med Coll, Dept Internal Med 3, 811-1 Kimiidera, Wakayama 6410012, Japan.							FRANCISCO P, 1993, DUBOIS LUPUS ERYTHEM, P574; ROKSETH R, 1960, LANCET, V26, P680; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	3	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					198	198		10.1016/S0140-6736(99)09005-4	http://dx.doi.org/10.1016/S0140-6736(99)09005-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675120				2022-12-28	WOS:000084879700014
J	Thompson, C; Kinmonth, AL; Stevens, L; Peveler, RC; Stevens, A; Ostler, KJ; Pickering, RM; Baker, NG; Henson, A; Preece, J; Cooper, D; Campbell, MJ				Thompson, C; Kinmonth, AL; Stevens, L; Peveler, RC; Stevens, A; Ostler, KJ; Pickering, RM; Baker, NG; Henson, A; Preece, J; Cooper, D; Campbell, MJ			Effects of a clinical-practice guideline and practice-based education on detection and outcome of depression in primary care: Hampshire Depression Project randomised controlled trial	LANCET			English	Article							GENERAL-PRACTITIONERS; HOSPITAL ANXIETY; MAJOR DEPRESSION; HEALTH-CARE; IMPROVE; SCALE; AMITRIPTYLINE; RECOGNITION; MANAGEMENT; STATEMENT	Background Depression is a major individual and public-health burden throughout the world and is managed mainly in primary care. The most effective strategy to reduce this burden has been believed to be education of primary-care practitioners. We tested this assumption by assessing the effectiveness of an educational programme based on a clinical-practice guideline in improving the recognition and outcome of primary-care depression. Methods We carried out a randomised controlled trial in a representative sample of 60 primary-care practices (26% of the total) in an English health district. Education was delivered to practice teams and quality tested by feedback from participants and expert raters, The primary endpoints were recognition of depression, defined by the hospital anxiety and depression (HAD) scale, and improvement. Analysis was by intention to treat. Findings The education was well received by participants, 80% of whom thought it would change their management of patients with depression. 21 409 patients were screened, of whom 4192 were classified as depressed by the HAD scale. The sensitivity of physicians to depressive symptoms was 39% in the intervention group and 36% in the control group after education (odds ratio 1.2 [95% CI 0.88-1.61]). The outcome of depressed patients as a whole at 6 weeks or 6 months after the assessment did not significantly Improve. Interpretation Although well received, this in-practice programme, which was designed to convey the current consensus on best practice for the care of depression, did not deliver improvements in recognition of or recovery from depression.	Univ Southampton, Royal S Hants Hosp, Dept Mental Hlth, Community Clin Sci Res Div, Southampton SO14 0PE, Hants, England; Univ Cambridge, Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Cambridge, England; Univ Southampton, Dept Primary Med Care, Southampton, Hants, England; Univ Birmingham, Dept Publ Hlth & Epidemiol, Birmingham, W Midlands, England; Univ Southampton, Dept Med Stat & Comp, Southampton, Hants, England; Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Cambridge; University of Southampton; University of Birmingham; University of Southampton; University of Sheffield	Thompson, C (corresponding author), Univ Southampton, Royal S Hants Hosp, Dept Mental Hlth, Community Clin Sci Res Div, Brintons Terrace, Southampton SO14 0PE, Hants, England.		Campbell, Michael J/I-4253-2014	Campbell, Michael J/0000-0003-3529-2739; Stevens, Andrew/0000-0003-2079-3397				Altman DG, 1996, BRIT MED J, V313, P570; *AM PSYCH ASS, 1996, PRACT GUID MAJ DEPR, P79; [Anonymous], 1989, J AFFECT DISORDERS, V17, P197; [Anonymous], 1994, BMJ, V308, P313; Armstrong E, 1997, PRIMARY MENTAL HLTH; COULTER A, 1994, BRIT MED J, V308, P308; Docherty JP, 1997, J CLIN PSYCHIAT, V58, P5; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; EISENBERG L, 1992, NEW ENGL J MED, V326, P1080, DOI 10.1056/NEJM199204163261610; Fleiss J. L., 1981, STAT METHODS RATES P, V2; GASK L, 1987, MED EDUC, V21, P362, DOI 10.1111/j.1365-2923.1987.tb00377.x; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; Hannaford PC, 1996, BRIT J GEN PRACT, V46, P333; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; HOLLYMAN JA, 1988, J ROY COLL GEN PRACT, V38, P393; Howe A, 1996, BRIT J GEN PRACT, V46, P407; JOHNSTONE M, 1995, PREVENTING CORONARY; Judd LL, 1996, AM J PSYCHIAT, V153, P1411; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KENDRICK T, 1995, BRIT MED J, V311, P93, DOI 10.1136/bmj.311.6997.93; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; PADGETT D, 1988, J CLIN EPIDEMIOL, V41, P1007, DOI 10.1016/0895-4356(88)90040-6; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V79, P19, DOI 10.1111/j.1600-0447.1989.tb09229.x; RUTZ W, 1996, INT J METHODS PSY S1, V6, P178; Schulberg HC, 1996, ARCH GEN PSYCHIAT, V53, P913; SIMON G, 1995, AM J PSYCHIAT, V152, P352; Stevens L, 1997, MED EDUC, V31, P375, DOI 10.1046/j.1365-2923.1997.00670.x; STEVENS LC, 1995, PRIMARY CARE PSYCH S, V1, P45; THOMPSON C, 1989, Human Psychopharmacology, V4, P91, DOI 10.1002/hup.470040204; UPADHYAYA AK, 1993, BRIT J GEN PRACT, V43, P349; USTUN TB, 1995, MENTAL ILLNESS GEN H; WHITE PT, 1989, J ROY COLL GEN PRACT, V39, P182; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	34	364	371	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2000	355	9199					185	191		10.1016/S0140-6736(99)03171-2	http://dx.doi.org/10.1016/S0140-6736(99)03171-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	276LR	10675118				2022-12-28	WOS:000084879700012
J	Hirsch, E; Katanaev, VL; Garlanda, C; Azzolino, O; Pirola, L; Silengo, L; Sozzani, S; Mantovani, A; Altruda, F; Wymann, MP				Hirsch, E; Katanaev, VL; Garlanda, C; Azzolino, O; Pirola, L; Silengo, L; Sozzani, S; Mantovani, A; Altruda, F; Wymann, MP			Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation	SCIENCE			English	Article							INDUCED RESPIRATORY BURST; KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN-NEUTROPHILS; ACTIVATION; WORTMANNIN; CHEMOKINES; MIGRATION; INHIBITION; RECEPTORS	Phosphoinositide 3-kinase (PI3K) activity is crucial for Leukocyte function, but the roles of the four receptor-activated isoforms are unclear. Mice Lacking heterotrimeric guanine nucleotide-binding protein (G protein)-coupled PI3K gamma were viable and had fully differentiated neutrophils and macrophages. Chemoattractant-stimulated PI3K gamma(-/-) neutrophils did not produce phosphatidylinositol 3,4,5-trisphosphate, did not activate protein kinase B, and displayed impaired respiratory burst and motility. Peritoneal PI3K gamma-null macrophages showed a reduced migration toward a wide range of chemotactic stimuli and a severely defective accumulation in a septic peritonitis model. These results demonstrate that PI3K gamma is a crucial signaling molecule required for macrophage accumulation in inflammation.	Univ Turin, Dept Genet Biol & Biochem, Turin, Italy; Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland; Ist Ric Farmacol Mario Negri, Milan, Italy; Univ Brescia, Sect Gen Pathol, Brescia, Italy	University of Turin; University of Fribourg; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Brescia	Hirsch, E (corresponding author), Univ Turin, Dept Genet Biol & Biochem, Turin, Italy.	hirsch@molinette.unito.it; matthiaspaul.wymann@unifr.ch	Katanaev, Vladimir/F-9480-2014; Garlanda, Cecilia/K-4601-2016; Mantovani, Alberto/HCI-7449-2022; Sozzani, Silvano/C-1447-2009; Hirsch, Emilio/F-4848-2013; Pirola, Luciano/I-5250-2018; Wymann, Matthias P/C-3227-2008	Katanaev, Vladimir/0000-0002-7909-5617; Garlanda, Cecilia/0000-0002-1510-7703; Mantovani, Alberto/0000-0001-5578-236X; Sozzani, Silvano/0000-0002-3144-8743; Hirsch, Emilio/0000-0002-9073-6024; Wymann, Matthias P/0000-0003-3349-4281; Pirola, Luciano/0000-0001-6539-5435	Telethon [E.0635] Funding Source: Medline	Telethon(Fondazione Telethon)		Al-Aoukaty A, 1999, J IMMUNOL, V162, P3249; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Aratani Y, 1999, INFECT IMMUN, V67, P1828; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernstein HG, 1998, CELL MOL BIOL, V44, P973; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; Frevert CW, 1998, J IMMUNOL METHODS, V213, P41, DOI 10.1016/S0022-1759(98)00016-7; HIRSCH E, UNPUB; KOWNATZKI E, 1988, CLIN EXP IMMUNOL, V74, P143; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; OKADA T, 1994, J BIOL CHEM, V269, P3568; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Test S T, 1986, Methods Enzymol, V132, P401; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	28	1046	1130	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2000	287	5455					1049	1053		10.1126/science.287.5455.1049	http://dx.doi.org/10.1126/science.287.5455.1049			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669418				2022-12-28	WOS:000085245400050
J	Alderson, P; Roberts, I				Alderson, P; Roberts, I			Should journals publish systematic reviews that find no evidence to guide practice? Examples from injury research	BRITISH MEDICAL JOURNAL			English	Article							CARE MANAGEMENT; INTENSIVE-CARE; HEAD-INJURY	Many systematic reviews are inconclusive and reinforce the message that there is clinical uncertainty. Phil Alderson and Ian Roberts argue that journals should make a point of publishing such reviews rather than waiting for reviews that show marked benefit or harm. Some experts disagree, however, but we failed to persuade them to commit their views to print.	UK Cochrane Ctr, NHS Res & Dev Programme, Oxford OX2 7LG, England; UCL, Inst Child Hlth, Child Hlth Monitoring Unit, London WC1N 1EH, England	Cochrane Centre; University of London; University College London	Alderson, P (corresponding author), UK Cochrane Ctr, NHS Res & Dev Programme, Oxford OX2 7LG, England.	palderson@cochrane.co.uk						Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; MAATA B, 1996, CRIT CARE MED, V24, P1743; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Roberts I, 1998, BMJ-BRIT MED J, V317, P235	9	53	55	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					376	377		10.1136/bmj.320.7231.376	http://dx.doi.org/10.1136/bmj.320.7231.376			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657341	Green Published			2022-12-28	WOS:000085211400040
J	Crone, B; Dodabalapur, A; Lin, YY; Filas, RW; Bao, Z; LaDuca, A; Sarpeshkar, R; Katz, HE; Li, W				Crone, B; Dodabalapur, A; Lin, YY; Filas, RW; Bao, Z; LaDuca, A; Sarpeshkar, R; Katz, HE; Li, W			Large-scale complementary integrated circuits based on organic transistors	NATURE			English	Article							THIN-FILM TRANSISTORS	Thin-film transistors based on molecular and polymeric organic materials have been proposed for a number of applications, such as displays(1-3) and radio-frequency identification tags(4-6). The main factors motivating investigations of organic transistors are their lower cost and simpler packaging, relative to conventional inorganic electronics, and their compatibility with flexible substrates(7,8). In most digital circuitry, minimal power dissipation and stability of performance against transistor parameter variations are crucial. In silicon-based microelectronics, these are achieved through the use of complementary logic-which incorporates both p- and n-type transistors-and it is therefore reasonable to suppose that adoption of such an approach with organic semiconductors will similarly result in reduced power dissipation, improved noise margins and greater operational stability. Complementary inverters and ring oscillators have already been reported(9,10). Here we show that such an approach can realize much larger scales of integration (in the present case, up to 864 transistors per circuit) and operation speeds of similar to 1 kHz in clocked sequential complementary circuits.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Lucent Technol, Allentown, PA 18103 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Alcatel-Lucent; Lucent Technologies	Dodabalapur, A (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.	ananth@bell-labs.com	Dodabalapur, Ananth/H-3043-2012; Katz, Howard E/A-3352-2010; Bao, Zhenan/AAC-5044-2019	Bao, Zhenan/0000-0002-0972-1715				Bao ZA, 1998, J AM CHEM SOC, V120, P207, DOI 10.1021/ja9727629; Bao ZN, 1997, CHEM MATER, V9, P1299, DOI 10.1021/cm9701163; BONSE M, 1988, IEDM PISC, P249; BROWN AR, 1995, SCIENCE, V270, P972, DOI 10.1126/science.270.5238.972; Dimitrakopoulos CD, 1999, SCIENCE, V283, P822, DOI 10.1126/science.283.5403.822; DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270; DODABALAPUR A, 1995, SCIENCE, V269, P1560, DOI 10.1126/science.269.5230.1560; Dodabalapur A, 1996, APPL PHYS LETT, V69, P4227, DOI 10.1063/1.116953; Dodabalapur A, 1998, APPL PHYS LETT, V73, P142, DOI 10.1063/1.121736; Dodabalapur A, 1996, APPL PHYS LETT, V68, P2246, DOI 10.1063/1.115873; Drury CJ, 1998, APPL PHYS LETT, V73, P108, DOI 10.1063/1.121783; FILAS RW, 1997, ADV ELECT PACKAGING, V1, P1265; Garnier F, 1998, CHEM PHYS, V227, P253, DOI 10.1016/S0301-0104(97)00308-X; Jackson TN, 1998, IEEE J SEL TOP QUANT, V4, P100, DOI 10.1109/2944.669475; Katz HE, 1995, CHEM MATER, V7, P2235, DOI 10.1021/cm00060a007; Lin YY, 1999, APPL PHYS LETT, V74, P2714, DOI 10.1063/1.123946; RABAY JM, 1996, DIGITAL INTEGRATED C, pCH6; Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741; Ziemelis K, 1998, NATURE, V393, P619, DOI 10.1038/31333	19	1171	1251	6	494	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2000	403	6769					521	523		10.1038/35000530	http://dx.doi.org/10.1038/35000530			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676955				2022-12-28	WOS:000085227300043
J	Prakash, B; Praefcke, GJK; Renault, L; Wittinghofer, A; Herrmann, C				Prakash, B; Praefcke, GJK; Renault, L; Wittinghofer, A; Herrmann, C			Structure of human guanylate-binding protein 1 representing a unique class of GTP-binding proteins	NATURE			English	Article							INTERFERON; GTPASES; PROGRAM; MOTIF; RAS; GMP	Interferon-gamma is an immunomodulatory substance that induces the expression of many genes to orchestrate a cellular response and establish the antiviral state of the cell. Among the most abundant antiviral proteins induced by interferon-gamma are guanylate-binding proteins such as GBP1 and GBP2 (refs 1, 2). These are large GTP-binding proteins of relative molecular mass 67,000 with a high-turnover GTPase activity(3) and an antiviral effect(4). Here we have determined the crystal structure of full-length human GBP1 to 1.8 Angstrom resolution. The amino-terminal 278 residues constitute a modified G domain with a number of insertions compared to the canonical pas structure, and the carboxy-terminal part is an extended helical domain with unique features. From the structure and biochemical experiments reported here, GBP1 appears to belong to the group of large GTP-binding proteins that includes Mx and dynamin, the common property of which is the ability to undergo oligomerization with a high concentration-dependent GTPase activity(5).	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Max Planck Society	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	alfred.wittinghofer@mpi-dortmund.mpg.de; christian.herrmann@mpi-dortmund.mpg.de	BS, Prakash/D-2337-2010	RENAULT, Louis/0000-0003-1722-074X; Praefcke, Gerrit/0000-0001-8818-1499				Anderson SL, 1999, VIROLOGY, V256, P8, DOI 10.1006/viro.1999.9614; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boehm U, 1998, J IMMUNOL, V161, P6715; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; CHENG YSE, 1983, J BIOL CHEM, V258, P7746; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kochs G, 1999, J BIOL CHEM, V274, P4370, DOI 10.1074/jbc.274.7.4370; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Praefcke GJK, 1999, J MOL BIOL, V292, P321, DOI 10.1006/jmbi.1999.3062; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899	30	251	257	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2000	403	6769					567	571		10.1038/35000617	http://dx.doi.org/10.1038/35000617			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676968				2022-12-28	WOS:000085227300056
J	Singer, CD				Singer, CD			Good Fridays	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					576	577		10.1001/jama.283.5.576	http://dx.doi.org/10.1001/jama.283.5.576			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665683				2022-12-28	WOS:000084956500001
J	Heeschen, C; Hamm, CW				Heeschen, C; Hamm, CW			Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists	LANCET			English	Editorial Material									Stanford Univ, Sch Med, Dept Cardiovasc Med, Stanford, CA 94305 USA; Kerckhoff Heart Ctr, Bad Nauheim, Germany	Stanford University; Kerckhoff Clinic	Heeschen, C (corresponding author), Stanford Univ, Sch Med, Dept Cardiovasc Med, Stanford, CA 94305 USA.		Guba, Markus/M-4309-2019; Hamm, Christian W./I-3155-2017	Hamm, Christian W./0000-0001-6763-4161; Heeschen, Christopher/0000-0002-1158-8554				AKKERHUIS M, 1999, 72 ANN SCI SESS AM H; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; CANNON C, 1999, 48 ANN SCI SESS AM C; Cannon CP, 1998, CIRCULATION, V97, P340; Hamm CW, 1999, NEW ENGL J MED, V340, P1623, DOI 10.1056/NEJM199905273402103; Heeschen C, 1999, LANCET, V354, P1757, DOI 10.1016/S0140-6736(99)10285-X; ONEILL WW, 1999, 48 ANN SCI SESS AM C; Simoons ML, 1997, LANCET, V349, P1429; Smith JW, 1999, CIRCULATION, V99, P620, DOI 10.1161/01.CIR.99.5.620; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol E, 1998, CIRCULATION, V97, P2386	12	30	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	2000	355	9201					330	331		10.1016/S0140-6736(99)00464-X	http://dx.doi.org/10.1016/S0140-6736(99)00464-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665546				2022-12-28	WOS:000085122100002
J	Leonard, JV; Schapira, AHV				Leonard, JV; Schapira, AHV			Mitochondrial respiratory chain disorders I: mitochondrial DNA defects	LANCET			English	Review							HEREDITARY OPTIC NEUROPATHY; STROKE-LIKE EPISODES; CLINICAL-FEATURES; LACTIC-ACIDOSIS; MUTATION LOAD; MELAS; DELETIONS; MYOPATHY; MTDNA; DISEASE	Mitochondria have a pivotal role in cell metabolism, being the major site of ATP production via oxidative phosphorylation (OXPHOS); they have a critical role in apoptotic cell death; and they also contribute to human genetics since mitochondria have a functional genome separate from that of nuclear DNA. Defects of mitochondrial metabolism are associated with a wide spectrum of disease. An important part of this spectrum is caused by mutations of mitochondrial DNA (mtDNA). These class I OXPHOS diseases are covered in part I of this two-part review. Dysfunction of mitochondrial OXPHOS has also emerged as an important component of a range of predominantly neurodegenerative diseases in which the mitochondrial abnormality is most probably secondary. These class Il OXPHOS diseases are due to mutations of genes not encoding OXPHOS subunits or are caused by exogenous or endogenous OXPHOS toxins. Class II mitochondrial diseases and the mitochondrion's role in apoptosis are covered in part II.	Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London NW3 2PF, England; UCL, Dept Neurol, London WC1E 6BT, England; Inst Child Hlth, Biochem Endocrine & Metab Unit, London, England	University of London; University College London; University of London; University College London; University of London; University College London	Schapira, AHV (corresponding author), Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, Rowland Hill St, London NW3 2PF, England.	schapira@rfhms.ac.uk	Schapira, Anthony H V/A-1245-2010	Schapira, Anthony H V/0000-0002-3018-3966				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Brown GK, 1997, J INHERIT METAB DIS, V20, P2, DOI 10.1023/A:1005336903888; CAMPOS Y, 1995, PEDIATR NEUROL, V13, P69, DOI 10.1016/0887-8994(95)00082-Q; Chalmers RM, 1996, J NEUROL SCI, V135, P173, DOI 10.1016/0022-510X(95)00286-B; Chalmers RM, 1996, AM J HUM GENET, V59, P103; Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889; Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; Clark KM, 1998, J CLIN INVEST, V102, P2090, DOI 10.1172/JCI944; Cock HR, 1999, J NEUROL SCI, V165, P10, DOI 10.1016/S0022-510X(99)00088-X; Cock HR, 1998, ANN NEUROL, V44, P187, DOI 10.1002/ana.410440208; DeVries DD, 1996, AM J HUM GENET, V58, P703; GOVAN GG, 1994, J NEUROL SCI, V126, P193, DOI 10.1016/0022-510X(94)90272-0; HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617; HARDING AE, 1992, BRAIN, V115, P979, DOI 10.1093/brain/115.4.979; HARDING AE, 1995, AM J HUM GENET, V57, P77; HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606; HAUSWIRTH WW, 1982, P NATL ACAD SCI-BIOL, V79, P4686, DOI 10.1073/pnas.79.15.4686; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106; JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206; MACKEY D, 1992, AM J HUM GENET, V51, P1218; Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208; MCSHANE MA, 1991, AM J HUM GENET, V48, P39; Morris AAM, 1996, J INHERIT METAB DIS, V19, P573, DOI 10.1007/BF01799117; POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23; Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311; RIORDANEVA P, 1995, BRAIN, V118, P319, DOI 10.1093/brain/118.2.319; Servidei S, 1998, NEUROMUSCULAR DISORD, V8, pXIII; SMITH PR, 1995, J NEUROL SCI, V130, P134, DOI 10.1016/0022-510X(95)00021-S; Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Taylor RW, 1997, J BIOENERG BIOMEMBR, V29, P195, DOI 10.1023/A:1022646215643	34	266	277	1	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2000	355	9200					299	304		10.1016/S0140-6736(99)05225-3	http://dx.doi.org/10.1016/S0140-6736(99)05225-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675086				2022-12-28	WOS:000085045600038
J	Cha, JN; Stucky, GD; Morse, DE; Deming, TJ				Cha, JN; Stucky, GD; Morse, DE; Deming, TJ			Biomimetic synthesis of ordered silica structures mediated by block copolypeptides	NATURE			English	Article							MESOPOROUS SILICA; PROTEIN; DIATOM; ACID	In biological systems such as diatoms and sponges, the formation of solid silica structures with precisely controlled morphologies is directed by proteins and polysaccharides and occurs in water at neutral:pH and ambient temperature(1-4). Laboratory methods, in contrast, have to rely on extreme pH conditions and/or surfactants to induce the condensation of silica precursors into specific morphologies or patterned structures(5-10), This contrast in processing conditions and the growing demand for benign synthesis methods that minimize adverse environmental effects have spurred much interest in biomimetic approaches in materials science(4,5), The recent demonstration that silicatein-a protein found in the silica spicules of the sponge Tethya aurantia(11)-can hydrolyse and condense the precursor molecule tetraethoxysilane to form silica structures with controlled shapes at ambient conditions(12-14) seems particularly promising in this context, Here we describe synthetic cysteine-lysine block copolypeptides that mimic the properties of silicatein: the copolypeptides self-assemble into structured aggregates that hydrolyse tetraethoxysilane while simultaneously directing the formation of ordered silica morphologies. We find that oxidation of the cysteine sulphydryl groups, which is known to affect the assembly of the block copolypeptide(15), allows us to produce different structures: hard silica spheres and well-defined columns of amorphous silica are produced using the fully reduced and the oxidized forms of the copolymer, respectively.	Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Deming, TJ (corresponding author), Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA.		Deming, Timothy/I-5411-2013	Deming, Timothy/0000-0002-0594-5025				Bamford C.H.E.A., 1956, SYNTHETIC POLYPEPTID; BERGER A, 1956, J AM CHEM SOC, V78, P4483, DOI 10.1021/ja01598a080; BRZEZINSKI MA, 1986, MAR CHEM, V19, P139, DOI 10.1016/0304-4203(86)90045-9; Cha JN, 1999, P NATL ACAD SCI USA, V96, P361, DOI 10.1073/pnas.96.2.361; Deming TJ, 1997, NATURE, V390, P386, DOI 10.1038/37084; Huo QS, 1997, CHEM MATER, V9, P14, DOI 10.1021/cm960464p; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Kroger N, 1997, EUR J BIOCHEM, V250, P99, DOI 10.1111/j.1432-1033.1997.00099.x; Liff MI, 1998, POLYM INT, V47, P375, DOI 10.1002/(SICI)1097-0126(199811)47:3<375::AID-PI73>3.0.CO;2-D; Lukens WW, 1999, LANGMUIR, V15, P5403, DOI 10.1021/la990209u; MANN S, 1995, J MATER CHEM, V5, P935, DOI 10.1039/jm9950500935; Mizutani T, 1998, B CHEM SOC JPN, V71, P2017, DOI 10.1246/bcsj.71.2017; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; Morse DE, 1999, TRENDS BIOTECHNOL, V17, P230, DOI 10.1016/S0167-7799(99)01309-8; MORSE DE, IN PRESS ORGANOSILIC, V4; OLIVER S, 1995, NATURE, V378, P47, DOI 10.1038/378047a0; Shimizu K, 1998, P NATL ACAD SCI USA, V95, P6234, DOI 10.1073/pnas.95.11.6234; SIMPSON TL, 1981, SILICON SILICEOUS ST; Strickland J.D.H., 1972, PRACTICAL HDB SEWATE, DOI [10.2307/1979241, DOI 10.2307/1979241]; Vrieling EG, 1999, J BIOTECHNOL, V70, P39, DOI 10.1016/S0168-1656(99)00056-5; Ying JY, 1999, ANGEW CHEM INT EDIT, V38, P56, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<56::AID-ANIE56>3.0.CO;2-E; Zhang LF, 1996, SCIENCE, V272, P1777, DOI 10.1126/science.272.5269.1777; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548; Zhao DY, 1998, CURR OPIN SOLID ST M, V3, P111, DOI 10.1016/S1359-0286(98)80073-9; Zhou Y, 1999, ANGEW CHEM INT EDIT, V38, P780	25	600	628	4	293	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					289	292		10.1038/35002038	http://dx.doi.org/10.1038/35002038			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659843				2022-12-28	WOS:000084899700046
J	Hasle, H; Clemmensen, IH; Mikkelsen, M				Hasle, H; Clemmensen, IH; Mikkelsen, M			Risks of leukaemia and solid tumours in individuals with Down's syndrome	LANCET			English	Article							ACUTE MEGAKARYOBLASTIC LEUKEMIA; CANCER INCIDENCE; CHILDREN; GENE; MALFORMATIONS; DISORDER; WOMEN	Background Individuals with Down's syndrome have a greater risk for leukaemia than the general population, but reliable estimates of the age-specific risk are lacking and little is known about the risk of solid tumours. Methods We identified 2814 individuals with Down's syndrome from the Danish Cytogenetic Register, and linked the data to the Danish Cancer Registry. The number of person-years at risk was 48 453. Standardised incidence ratio (SIR) and 95% CI were calculated of the basis of cancer rates specific for age and sex in the general population. Findings 60 cases of cancer were found, with 49.8 expected (SIR 1.20 [95% CI 0.92-1.55]). Leukaemia constituted 60% of cases of malignant disease overall and 97% of cases in children. The SIR for leukaemia varied with age, being 56 (38-81) at age 0-4 years and 10 (4-20) at 5-29 years. No cases of leukaemia were seen after the age of 29 years. The SIR for acute myeloid leukaemia was 3.8 (1.7-8.4) times higher than that for acute lymphoblastic leukaemia in children aged 0-4 years. The cumulative risk for leukaemia by the age of 5 years was 2.1% and that by 30 years was 2.7%. Only 24 solid tumours were seen, with 47.8 expected (0.50 [0.32-0.75]). No cases of breast cancer were found, with 7.3 expected (p=0.0007). Higher than expected numbers of testicular cancers, ovarian cancers, and retinoblastomas were seen but were not significant. Intrepretation The occurrence of cancer in Down's syndrome is unique with a high risk of leukaemia in children and a decreased risk of solid tumours in all age-groups. The distinctive pattern of malignant diseases may provide clues in the search for leukaemogenic genes and tumour-suppressor genes on chromosome 21.	Aarhus Univ Hosp Skejby, Dept Paediat, DK-8200 Aarhus N, Denmark; Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; John F Kennedy Inst, DK-2600 Glostrup, Denmark	Aarhus University; Danish Cancer Society	Hasle, H (corresponding author), Aarhus Univ Hosp Skejby, Dept Paediat, DK-8200 Aarhus N, Denmark.			Hasle, Henrik/0000-0003-3976-9231				AVETLOISEAU H, 1995, J PEDIAT HEMATOL ONC, V17, P19, DOI 10.1097/00043426-199502000-00003; BAIN B, 1991, LEUKEMIA LYMPHOMA, V3, P309, DOI 10.3109/10428199109070274; BALARAJAN R, 1982, J EPIDEMIOL COMMUN H, V36, P127, DOI 10.1136/jech.36.2.127; BENTLEY D, 1975, PEDIATRICS, V56, P131; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Chik KW, 1999, J PEDIAT HEMATOL ONC, V21, P149, DOI 10.1097/00043426-199903000-00012; DelaTorre R, 1996, EXPERIENTIA, V52, P871; FABIA J, 1970, PEDIATRICS, V45, P60; FESTER A, 1986, CANCER GENET CYTOGEN, V20, P109; FONG C, 1987, CANCER GENET CYTOGEN, V28, P55, DOI 10.1016/0165-4608(87)90354-2; GERICKE GS, 1977, S AFR MED J, V51, P369; Hasle H, 1996, BRIT J CANCER, V73, P1156, DOI 10.1038/bjc.1996.222; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; HASLE H, 1995, LEUKEMIA, V9, P1569; HAYASHI Y, 1988, BLOOD, V72, P15; Ho CY, 1996, BLOOD, V87, P5218, DOI 10.1182/blood.V87.12.5218.bloodjournal87125218; ISELIUS L, 1990, HUM GENET, V85, P477; Ives JH, 1998, GENE CHROMOSOME CANC, V23, P61, DOI 10.1002/(SICI)1098-2264(199809)23:1<61::AID-GCC9>3.3.CO;2-F; Kohno T, 1998, GENE CHROMOSOME CANC, V21, P236, DOI 10.1002/(SICI)1098-2264(199803)21:3<236::AID-GCC8>3.0.CO;2-0; KRIVIT W, 1957, AMA J DIS CHILD, V94, P289, DOI 10.1001/archpedi.1957.04030040075012; NAROD SA, 1991, BRIT J CANCER, V63, P993, DOI 10.1038/bjc.1991.216; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; OLSON JM, 1995, MED PEDIATR ONCOL, V24, P305, DOI 10.1002/mpo.2950240507; OSTER J, 1975, ACTA PAEDIATR SCAND, V64, P322, DOI 10.1111/j.1651-2227.1975.tb03842.x; ROBISON LL, 1984, J PEDIATR-US, V105, P235, DOI 10.1016/S0022-3476(84)80119-5; Sakata K, 1997, GENE CHROMOSOME CANC, V18, P318, DOI 10.1002/(SICI)1098-2264(199704)18:4<318::AID-GCC12>3.3.CO;2-#; SALO MK, 1979, SCAND J CLIN LAB INV, V39, P485, DOI 10.3109/00365517909106135; SARGE D, 1996, PATHOL RES PRACT, V192, P1266; Satge D, 1998, CANCER RES, V58, P448; Satge D, 1998, AM J MED GENET, V78, P207, DOI 10.1002/(SICI)1096-8628(19980707)78:3<207::AID-AJMG1>3.3.CO;2-Q; Satge D, 1997, CANCER, V80, P929; SCHOLL T, 1982, DEV MED CHILD NEUROL, V24, P817; Schupf N, 1997, J INTELL DISABIL RES, V41, P264, DOI 10.1111/j.1365-2788.1997.tb00706.x; SHEN JJ, 1995, AM J HUM GENET, V56, P915; SIMON JH, 1987, CANCER-AM CANCER SOC, V60, P2515, DOI 10.1002/1097-0142(19871115)60:10<2515::AID-CNCR2820601028>3.0.CO;2-F; SLORDAHL SH, 1993, MED PEDIATR ONCOL, V21, P254, DOI 10.1002/mpo.2950210404; STORM HH, 1997, DAN MED B, V44, P549; WINDHAM GC, 1985, AM J EPIDEMIOL, V121, P49, DOI 10.1093/oxfordjournals.aje.a113982; ZIPURSKY A, 1994, LEUKEMIA RES, V18, P163, DOI 10.1016/0145-2126(94)90111-2; ZIPURSKY A, 1992, PEDIATR HEMAT ONCOL, V9, P139, DOI 10.3109/08880019209018329	41	544	560	1	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					165	169		10.1016/S0140-6736(99)05264-2	http://dx.doi.org/10.1016/S0140-6736(99)05264-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675114				2022-12-28	WOS:000084879700008
J	Weinshenker, BG				Weinshenker, BG			Progressive forms of MS: classification streamlined or consensus overturned?	LANCET			English	Editorial Material							MULTIPLE-SCLEROSIS; NATURAL-HISTORY		Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55902 USA	Mayo Clinic	Weinshenker, BG (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol, 200 1St St Sw, Rochester, MN 55902 USA.		Weinshenker, Brian G/ABH-6146-2020	Weinshenker, Brian G/0000-0001-5806-6203				Andersson PB, 1999, ARCH NEUROL-CHICAGO, V56, P1138, DOI 10.1001/archneur.56.9.1138; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; Kremenchutzky M, 1999, BRAIN, V122, P1941, DOI 10.1093/brain/122.10.1941; KURTZKE JF, 1977, J CHRON DIS, V30, P819, DOI 10.1016/0021-9681(77)90010-8; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Lucchinetti C, 1999, BRAIN, V122, P2279, DOI 10.1093/brain/122.12.2279; Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x; Lucchinetti CF, 1998, SEMIN NEUROL, V18, P337, DOI 10.1055/s-2008-1040885; Matthews PM, 1998, SEMIN NEUROL, V18, P327, DOI 10.1055/s-2008-1040884; McAlpine D., 1955, MULT SCLER J; OLERUP O, 1989, P NATL ACAD SCI USA, V86, P7113, DOI 10.1073/pnas.86.18.7113; RUNMARKER B, 1993, BRAIN, V116, P117, DOI 10.1093/brain/116.1.117; Thompson AJ, 1997, BRAIN, V120, P1085, DOI 10.1093/brain/120.6.1085; Thompson AJ, 1999, ANN NEUROL, V46, P471; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Weinshenker BG, 1998, NEUROLOGY, V51, P742, DOI 10.1212/WNL.51.3.742; Weinshenker BG, 1999, ANN NEUROL, V46, P878, DOI 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q; WEINSHENKER BG, 1991, BRAIN, V114, P1045, DOI 10.1093/brain/114.2.1045	19	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2000	355	9199					162	163		10.1016/S0140-6736(99)00356-6	http://dx.doi.org/10.1016/S0140-6736(99)00356-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675112				2022-12-28	WOS:000084879700006
J	Carman, WF; Elder, AG; Wallace, LA; McAulay, K; Walker, A; Murray, GD; Stott, DJ				Carman, WF; Elder, AG; Wallace, LA; McAulay, K; Walker, A; Murray, GD; Stott, DJ			Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial	LANCET			English	Article							VIRUSES; DISEASE; PCR	Background Vaccination of health-care workers has been claimed to prevent nosocomial influenza infection of elderly patients in long-term care. Data are, however, limited on this strategy. We aimed to find out whether vaccination of healthcare workers lowers mortality and the frequency of virologically proven influenza in such patients. Methods In a parallel-group study, healthcare workers in 20 long-term elderly-care hospitals (range 44-105 patients) were randomly offered or not offered influenza vaccine (cluster randomisation, stratified for policy for vaccination of patients and hospital size). All deaths among patients were recorded over 6 months In the winter of 1996-97. We selected a random sample of 50% of patients for virological surveillance for influenza, with combined nasal and throat swabs taken every 2 weeks during the epidemic period, Swabs were tested by tissue culture and PCR for influenza viruses A and B. Findings Influenza vaccine uptake in healthcare workers was 50.9% in hospitals in which they were routinely offered vaccine, compared with 4.9% in those in which they were not. The uncorrected rate of mortality in patients was 102 (13.6%) of 749 in vaccine hospitals compared with 154 (22.4%) of 688 in no-vaccine hospitals (odds ratio 0.58 [95% CI 0.40-0.84], p=0.014). The two groups did not differ for proportions of patients positive for influenza infection (5.4% and 6.7%, respectively); at necropsy, PCR was positive in none of 17 patients from vaccine hospitals and six (20%) of 30 from no-vaccine hospitals (p=0.055). Interpretation Vaccination of healthcare workers was associated with a substantial decrease in mortality among patients. However, virological surveillance showed no associated decrease in non-fatal influenza infection in patients.	Univ Glasgow, Glasgow Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland; Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland; Greater Glasgow Hlth Board, Glasgow, Lanark, Scotland; Bellshill Hosp, Dept Occupat Hlth, Bellshill, Lanark, Scotland; Univ Glasgow, Inst Virol, Glasgow G4 0SF, Lanark, Scotland	University of Glasgow; University of Edinburgh; University of Glasgow	Stott, DJ (corresponding author), Univ Glasgow, Glasgow Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland.			Murray, Gordon/0000-0001-9866-4734				[Anonymous], 1996, IMMUNISATION INFECT; Deulofeu F, 1998, J AM GERIATR SOC, V46, P14, DOI 10.1111/j.1532-5415.1998.tb01007.x; EIDER AG, 1996, BRIT MED J, V313, P1241; Ellis JS, 1997, J CLIN MICROBIOL, V35, P2076, DOI 10.1128/JCM.35.8.2076-2082.1997; GROSS PA, 1989, VACCINE, V7, P303, DOI 10.1016/0264-410X(89)90190-4; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Kerry SM, 1998, BMJ-BRIT MED J, V316, P54, DOI 10.1136/bmj.316.7124.54; LENNOX IM, 1990, AGE AGEING, V19, P169, DOI 10.1093/ageing/19.3.169; MAHONEY F I, 1965, Md State Med J, V14, P61; Murray DM, 1998, DESIGN ANAL GROUP RA; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060; Potter J, 1997, J INFECT DIS, V175, P1, DOI 10.1093/infdis/175.1.1; Potter JM, 1999, AGE AGEING, V28, P141, DOI 10.1093/ageing/28.2.141; Pregliasco F, 1998, J MED VIROL, V56, P168, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;168::AID-JMV11&gt;3.0.CO;2-C; Simonsen L, 1998, J INFECT DIS, V178, P53, DOI 10.1086/515616; STOTT D J, 1990, Health Bulletin (Edinburgh), V48, P17; THOMAS DR, 1993, J AM GERIATR SOC, V41, P928, DOI 10.1111/j.1532-5415.1993.tb06757.x; ZHANG WD, 1991, J VIROL METHODS, V33, P165, DOI 10.1016/0166-0934(91)90017-T; 1996, ANN PHARMACOTHER, V30, P906; 1996, SCIEH WEEKLY REPORT, V31, P268	21	616	639	0	57	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					93	97		10.1016/S0140-6736(99)05190-9	http://dx.doi.org/10.1016/S0140-6736(99)05190-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675165				2022-12-28	WOS:000085557200009
J	Peterson, S; Sanga, A; Eklof, H; Bunga, B; Taube, A; Gebre-Medhin, M; Rosling, H				Peterson, S; Sanga, A; Eklof, H; Bunga, B; Taube, A; Gebre-Medhin, M; Rosling, H			Classification of thyroid size by palpation and ultrasonography in field surveys	LANCET			English	Article							VOLUME; ULTRASOUND; IODINE	Background Goitre surveys are used to assess the degree of iodine deficiency in a population. The change of goitre classification made by WHO in 1994 implied that a smaller thyroid size should be regarded as goitre. Furthermore, the acceptable goitre prevalence was lowered from 10% to 5%, and ultrasonography was recommended as a more precise method for diagnosis of goitre. We studied the effects of the change of palpation system, and compared the precision of the old and new systems ultrasonographic examination. Methods We studied 225 schoolchildren (aged 7-14 years) in a highland village in Tanzania. The size of the thyroid was assessed in duplicate by ultrasonography and by WHO's 1960 and 1994 palpation systems. The latter were done by three examiners. Variations within and between examination methods and examiners were assessed. and measurement errors by ultrasonography were assessed from duplicate examinations. The sensitivity and specificity of the two palpation systems were calculated, with diagnosis by ultrasonography as the gold standard. Apparent palpation prevalences were calculated at a "true" 5% prevalence. Findings The lowered criterion for goitre resulted in an extra 20-33% of children being diagnosed as having goitre by palpation. The variation between repeat examinations was only slightly smaller by ultrasonography (kappa=0.63) than by experienced examiners (kappa=0.57-0.58). The variation between thyroid volume estimation by ultrasonography and the true volume was about 50% due to both measurement error and variation in the shape of thyroid lobes. The new goitre criterion decreased specificity from 76% to 29%, whereas sensitivity rose from 56% to 80%. In contrast, a suggested sharpening of the old criterion increased specificity to 90%. Interpretation A return to the old (1960) palpation criterion for goitre: "lobes larger than the terminal phalanxes of thumbs" and to an accepted palpation goitre prevalence of 10% can allow affordable monitoring of thyroid size through palpation in field surveys.	Karolinska Inst, Dept Publ Hlth Sci, Div Int Hlth, SE-17176 Stockholm, Sweden; Tanzania Food & Nutr Ctr, Dar Es Salaam, Tanzania; Univ Uppsala, Dept Womens & Childrens Hlth, S-75105 Uppsala, Sweden; Univ Uppsala, Dept Radiol, S-75105 Uppsala, Sweden; Univ Uppsala, Dept Stat, S-75105 Uppsala, Sweden	Karolinska Institutet; Uppsala University; Uppsala University; Uppsala University	Rosling, H (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, Div Int Hlth, SE-17176 Stockholm, Sweden.			Peterson, Stefan/0000-0001-7203-3096				AGHINILOMBARDI F, 1995, THYROID S1, V5, pS36; BRUNN J, 1981, DEUT MED WOCHENSCHR, V106, P1338, DOI 10.1055/s-2008-1070506; CHANOINE JP, 1991, EUR J PEDIATR, V150, P395, DOI 10.1007/BF02093716; Delange F, 1997, EUR J ENDOCRINOL, V136, P180, DOI 10.1530/eje.0.1360180; Delange F, 1999, EUR J ENDOCRINOL, V140, P486, DOI 10.1530/eje.0.1400486; Delange F, 1997, B WORLD HEALTH ORGAN, V75, P95; Delange F, 1986, PAHO WHO SCI PUBLICA, P373; Demaeyer EM, 1979, CONTROL ENDEMIC GOIT; Foo LC, 1999, EUR J ENDOCRINOL, V140, P491, DOI 10.1530/eje.0.1400491; GUTEKUNST R, 1986, ACTA ENDOCRINOL-COP, V112, P494, DOI 10.1530/acta.0.1120494; GUTEKUNST R, 1993, IODINE DEFICIENCY EU; HETZEL BS, 1988, ACC SCN STATE ART SE; MACLENNAN R, 1974, ENDEMIC GOITER CRETI, P195; MACLENNAN R, 1969, ENDEMIC GOITER, P67; Nordmeyer JP, 1997, EXP CLIN ENDOCR DIAB, V105, P366, DOI 10.1055/s-0029-1211781; Perez C, 1960, ENDEMIC GOITRE, P369; PETERSON S, 1999, HLTH POLICY PLANN, V14, P400; QUERIDO A, 1974, Pan American Health Organization Scientific Publication, V292, P267; Taube A., 1995, Archives d'Anatomie et de Cytologie Pathologiques, V43, P227; TAUBE A, 1990, ACTA ONCOL, V29, P1; Tonglet Rene, 1994, Food and Nutrition Bulletin, V15, P64; 1993, METHODS MEASURING IO; VITTI P, 1994, J CLIN ENDOCR METAB, V79, P600, DOI 10.1210/jc.79.2.600; WHO/UNICEF/ICCIDD, 1994, IND ASS IOD DEF DIS; World Health Organization, 1997, WHO GLOB DAT CHILD G	25	55	60	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 8	2000	355	9198					106	110		10.1016/S0140-6736(99)07221-9	http://dx.doi.org/10.1016/S0140-6736(99)07221-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675168				2022-12-28	WOS:000085557200012
J	Gaffen, DJ; Santer, BD; Boyle, JS; Christy, JR; Graham, NE; Ross, RJ				Gaffen, DJ; Santer, BD; Boyle, JS; Christy, JR; Graham, NE; Ross, RJ			Multidecadal changes in the vertical temperature structure of the tropical troposphere	SCIENCE			English	Article							SURFACE-TEMPERATURE; SATELLITE; TRENDS; RECORDS; CARDS	Trends in global lower tropospheric temperature derived from satellite observations since 1979 show Less warming than trends based on surface meteorological observations. Independent radiosonde observations of surface and tropospheric temperatures confirm that, since 1979, there has been greater warming at the surface than aloft in the tropics. Associated lapse-rate changes show a decrease in the static stability of the atmosphere, which exceeds unforced static stability variations in climate simulations with state-of-the-art coupled ocean-atmosphere models, The differential temperature trends and Lapse-rate changes seen during the satellite era are not sustained back to 1960.	NOAA, Air Resources Lab, RARL, Silver Spring, MD 20910 USA; Lawrence Livermore Natl Lab, Program Climate Model Diagnost & Intercomparison, Livermore, CA 94550 USA; Univ Alabama, Earth Syst Sci Lab, Huntsville, AL 35899 USA; Univ Calif San Diego, Scripps Inst Oceanog, Div Climate Res, La Jolla, CA 92093 USA	National Oceanic Atmospheric Admin (NOAA) - USA; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of Alabama System; University of Alabama Huntsville; University of California System; University of California San Diego; Scripps Institution of Oceanography	Gaffen, DJ (corresponding author), NOAA, Air Resources Lab, RARL, 1315 East West Highway, Silver Spring, MD 20910 USA.	dian.gaffen@noaa.gov	Santer, Benjamin D/F-9781-2011; Santer, Ben/ABA-1099-2021					Angell JK, 1999, GEOPHYS RES LETT, V26, P2761, DOI 10.1029/1999GL900375; Bengtsson L, 1999, J GEOPHYS RES-ATMOS, V104, P3865, DOI 10.1029/1998JD200046; Boville BA, 1998, J CLIMATE, V11, P1115, DOI 10.1175/1520-0442(1998)011<1115:TNCSMV>2.0.CO;2; Christy JR, 1998, J CLIMATE, V11, P2016, DOI 10.1175/1520-0442-11.8.2016; CHRISTY JR, 1995, ATMOS ENVIRON, V29, P1957, DOI 10.1016/1352-2310(94)00240-L; Diaz HF, 1996, NATURE, V383, P152, DOI 10.1038/383152a0; ESKRIDGE RE, 1995, B AM METEOROL SOC, V76, P1759, DOI 10.1175/1520-0477(1995)076<1759:ACARDS>2.0.CO;2; Gaffen DJ, 1998, NATURE, V394, P615, DOI 10.1038/29163; GAFFEN DJ, 1934, J GEOPHYS RES, V99, P3667; GAFFEN MA, IN PRESS J CLIM; Gutzler DS, 1996, J ATMOS SCI, V53, P2773, DOI 10.1175/1520-0469(1996)053<2773:LFOAVA>2.0.CO;2; Hansen J, 1999, J GEOPHYS RES-ATMOS, V104, P30997, DOI 10.1029/1999JD900835; HANSEN J, 1995, CLIMATIC CHANGE, V30, P103, DOI 10.1007/BF01093228; Hansen J, 1997, J GEOPHYS RES-ATMOS, V102, P25679, DOI 10.1029/97JD01495; Hurrell JW, 1997, NATURE, V386, P164, DOI 10.1038/386164a0; Hurrell JW, 1998, J CLIMATE, V11, P945, DOI 10.1175/1520-0442(1998)011<0945:DIORTT>2.0.CO;2; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; Kattenberg A, 1995, CLIMATE CHANGE 1995: THE SCIENCE OF CLIMATE CHANGE, P285; Molnar P, 1999, J GEOPHYS RES-ATMOS, V104, P24265, DOI 10.1029/1999JD900485; RAMASWAMY V, 1994, J GEOPHYS RES-ATMOS, V99, P18909, DOI 10.1029/94JD01310; ROECKNER EK, 1992, 93 M PLANCK I MET HA; Santer BD, 1999, J GEOPHYS RES-ATMOS, V104, P6305, DOI 10.1029/1998JD200096; Santer BD, 2000, SCIENCE, V287, P1227, DOI 10.1126/science.287.5456.1227; SANTER BD, IN PRESS J GEOPHYS R; SPENCER RW, 1990, SCIENCE, V247, P1558, DOI 10.1126/science.247.4950.1558; STONE PH, 1979, J ATMOS SCI, V36, P415, DOI 10.1175/1520-0469(1979)036<0415:ALRRAT>2.0.CO;2; Stouffer RJ, 2000, J CLIMATE, V13, P513, DOI 10.1175/1520-0442(2000)013<0513:ACOSAT>2.0.CO;2; THOMPSON LG, 1993, GLOBAL PLANET CHANGE, V7, P145, DOI 10.1016/0921-8181(93)90046-Q; Thompson LG, 2000, QUATERNARY SCI REV, V19, P19, DOI 10.1016/S0277-3791(99)00052-9; Toumi R, 1999, GEOPHYS RES LETT, V26, P1751, DOI 10.1029/1999GL900351; Wallis TWR, 1998, J CLIMATE, V11, P272, DOI 10.1175/1520-0442(1998)011<0272:ASOCSF>2.0.CO;2; WASHINGTON WM, IN PRESS CLIM DYN; Wentz FJ, 1998, NATURE, V394, P661, DOI 10.1038/29267	33	86	88	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2000	287	5456					1242	1245		10.1126/science.287.5456.1242	http://dx.doi.org/10.1126/science.287.5456.1242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678826				2022-12-28	WOS:000085444700043
J	Vinje, WE; Gallant, JL				Vinje, WE; Gallant, JL			Sparse coding and decorrelation in primary visual cortex during natural vision	SCIENCE			English	Article							RECEPTIVE-FIELD; STRIATE CORTEX; CORTICAL DYNAMICS; RESPONSES; SCENES; NORMALIZATION; INTEGRATION; MECHANISMS; PATTERNS; NEURONS	Theoretical studies suggest that primary visual cortex (area V1) uses a sparse code to efficiently represent natural scenes. This issue was investigated by recording from V1 neurons in awake behaving macaques during both free viewing of natural scenes and conditions simulating natural vision. Stimulation of the nonclassical receptive field increases the selectivity and sparseness of individual V1 neurons, increases the sparseness of the population response distribution, and strongly decorrelates the responses of neuron pairs. These effects are due to both excitatory and suppressive modulation of the classical receptive field by the nonclassical receptive field and do not depend critically on the spatiotemporal structure of the stimuli. During natural vision, the classical and nonclassical receptive fields function together to form a sparse representation of the visual world. This sparse code may be computationally efficient for both early vision and higher visual processing.	Univ Calif Berkeley, Program Neurosci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Gallant, JL (corresponding author), Univ Calif Berkeley, Program Neurosci, Berkeley, CA 94720 USA.		Gallant, Jack L/C-4426-2011					ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P153; Baddeley R, 1997, P ROY SOC B-BIOL SCI, V264, P1775, DOI 10.1098/rspb.1997.0246; Barlow HB, 1989, NEURAL COMPUT, V1, P295, DOI 10.1162/neco.1989.1.3.295; Barlow H. B., 1961, SENS COMMUN, P217, DOI DOI 10.7551/MITPRESS/9780262518420.003.0013; Bell AJ, 1997, VISION RES, V37, P3327, DOI 10.1016/S0042-6989(97)00121-1; Carandini M, 1997, J NEUROSCI, V17, P8621; Conner CE, 1997, J NEUROSCI, V17, P3201; Dan Y, 1996, J NEUROSCI, V16, P3351; DAUGMAN JG, 1989, IEEE T BIO-MED ENG, V36, P107, DOI 10.1109/10.16456; DILORENZO PM, 1989, J NEUROPHYSIOL, V62, P823, DOI 10.1152/jn.1989.62.4.823; FIELD DJ, 1994, NEURAL COMPUT, V6, P559, DOI 10.1162/neco.1994.6.4.559; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; FOLDIAK P, 1995, HDB BRAIN THEORY NEU, P895; Gallant JL, 1998, NEUROREPORT, V9, P2153, DOI 10.1097/00001756-199806220-00045; GILBERT CD, 1992, NEURON, V9, P1, DOI 10.1016/0896-6273(92)90215-Y; Gilbert CD, 1996, P NATL ACAD SCI USA, V93, P615, DOI 10.1073/pnas.93.2.615; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; JUDGE SJ, 1980, J NEUROPHYSIOL, V43, P1133, DOI 10.1152/jn.1980.43.4.1133; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; Laughlin SB, 1998, NAT NEUROSCI, V1, P36, DOI 10.1038/236; Levy WB, 1996, NEURAL COMPUT, V8, P531, DOI 10.1162/neco.1996.8.3.531; Lewicki MS, 1998, ADV NEUR IN, V10, P815; Manly BFJ., 2017, RANDOMIZATION MONTE, DOI 10.1201/9781315273075; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; Olshausen BA, 1997, VISION RES, V37, P3311, DOI 10.1016/S0042-6989(97)00169-7; Olshausen BA, 1996, NATURE, V381, P607, DOI 10.1038/381607a0; Ringach DL, 1997, NATURE, V387, P281, DOI 10.1038/387281a0; ROLLS ET, 1995, J NEUROPHYSIOL, V73, P713, DOI 10.1152/jn.1995.73.2.713; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; SIMONCELLI EP, 1998, ADV NEURAL INFORMATI, V11; SNODDERLY DM, 1995, J NEUROPHYSIOL, V74, P2100, DOI 10.1152/jn.1995.74.5.2100; Walker GA, 1999, J NEUROSCI, V19, P10536; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577	34	828	852	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1273	1276		10.1126/science.287.5456.1273	http://dx.doi.org/10.1126/science.287.5456.1273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678835				2022-12-28	WOS:000085444700052
J	Leder, BZ; Longcope, C; Catlin, DH; Ahrens, B; Schoenfeld, DA; Finkelstein, JS				Leder, BZ; Longcope, C; Catlin, DH; Ahrens, B; Schoenfeld, DA; Finkelstein, JS			Oral androstenedione administration and serum testosterone concentrations in young men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANABOLIC-STEROIDS; ADIPOSE-TISSUE; MUSCLE; AROMATIZATION; ANDROGENS; AGE	Context Androstenedione, a steroid hormone and the major precursor to testosterone, is available without prescription and is purported to increase strength and athletic performance. The hormonal effects of androstenedione, however, are unknown. Objective To determine if oral administration of androstenedione increases serum testosterone levels in healthy men. Design Open-label randomized controlled trial conducted between October 1998 and April 1999. Setting General clinical research center of a tertiary-care, university-affiliate hospital. Participants Forty-two healthy men aged 20 to 40 years, Intervention Subjects were randomized to receive oral androstenedione (either 100 mg/d [n = 15] or 300 mg/d [n = 14]) or no androstenedione (n = 13) for 7 days. Main Outcome Measures Changes in serum testosterone, androstenedione, estrone, and estradiol levels, measured by frequent blood sampling, compared among the 3 treatment groups. Results Mean (SE) changes in the area under the curve (AUC) for serum testosterone concentrations were -2% (7%), -4% (4%), and 34% (14%) in the groups receiving 0, 100, and 300 mg/d of androstenedione, respectively. When compared with the control group, the change in testosterone AUC was significant for the 300-mg/d group (P<.001) but not for the 100-mg/d group (P = .48). Baseline testosterone levels, drawn 24 hours after androstenedione administration, did not change. Mean (SE) changes in the AUC for serum estradiol concentrations were 4% (6%), 42% (12%), and 128% (24%) in the groups receiving 0, 100, and 300 mg/d of androstenedione, respectively. When compared with the control group, the change in the estradiol AUC was significant for both the 300-mg/d (P<.001) and 100-mg/d (P = .002) groups. There was marked variability in individual responses for all measured sex steroids. Conclusions Our data suggest that oral androstenedione, when given in dosages of 300 mg/d, increases serum testosterone and estradiol concentrations in some healthy men.	Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA; Univ Massachusetts, Sch Med, Dept Obstet & Gynecol, Worcester, MA USA; Univ Calif Los Angeles, Dept Med, Olymp Analyt Lab, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Finkelstein, JS (corresponding author), Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Bulfinch 327, Boston, MA 02114 USA.		Finkelstein, Joel/M-6463-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002759] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline; NIDDK NIH HHS [5 R29 DK443341, K24 DK02759] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RA, 1995, CONTRACEPTION, V52, P115, DOI 10.1016/S0010-7824(95)00136-0; BAGHERI SA, 1974, ANN INTERN MED, V81, P610, DOI 10.7326/0003-4819-81-5-610; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; BOURGUIGNON JP, 1988, ENDOCR REV, V9, P467, DOI 10.1210/edrv-9-4-467; DICKERMAN RD, 1995, CARDIOLOGY, V86, P172, DOI 10.1159/000176867; FORNEY JP, 1981, J CLIN ENDOCR METAB, V53, P192, DOI 10.1210/jcem-53-1-192; HORTON R, 1966, J CLIN INVEST, V45, P301, DOI 10.1172/JCI105344; ISHAK KG, 1987, SEMIN LIVER DIS, V7, P230, DOI 10.1055/s-2008-1040579; King DS, 1999, JAMA-J AM MED ASSOC, V281, P2020, DOI 10.1001/jama.281.21.2020; LABRIE F, 1994, BAILLIERE CLIN ENDOC, V8, P451, DOI 10.1016/S0950-351X(05)80261-7; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; LINDBERG MC, 1966, AM J OBSTET GYNECOL, V95, P743, DOI 10.1016/0002-9378(66)90073-1; LONGCOPE C, 1969, J CLIN INVEST, V48, P2191, DOI 10.1172/JCI106185; LONGCOPE C, 1976, STEROIDS, V28, P521, DOI 10.1016/0039-128X(76)90021-0; MAHESH VB, 1962, ACTA ENDOCRINOL-COP, V41, P400, DOI 10.1530/acta.0.0410400; MATSUMINE H, 1986, J CLIN ENDOCR METAB, V63, P717, DOI 10.1210/jcem-63-3-717; MCNUTT RA, 1988, AM J CARDIOL, V62, P164, DOI 10.1016/0002-9149(88)91390-2; ORTH DN, 1998, WILLIAMS TXB ENDOCRI, P517; PRADER A, 1978, PEDIATRICS, V62, P1202; Simpson ER, 1997, RECENT PROG HORM RES, V52, P185; WEINSTEIN RL, 1974, J CLIN INVEST, V53, P1, DOI 10.1172/JCI107526; Yesalis CE, 1999, JAMA-J AM MED ASSOC, V281, P2043, DOI 10.1001/jama.281.21.2043; Yesalis CE, 1997, ARCH PEDIAT ADOL MED, V151, P1197, DOI 10.1001/archpedi.1997.02170490023005	23	93	95	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					779	782		10.1001/jama.283.6.779	http://dx.doi.org/10.1001/jama.283.6.779			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280XL	10683057				2022-12-28	WOS:000085129000030
J	Henney, JE				Henney, JE			Alternative supply of penicillin G	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Commissioner Food & Drugs, Rockville, MD 20857 USA		Henney, JE (corresponding author), Commissioner Food & Drugs, HF 1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					596	596		10.1001/jama.283.5.596-b	http://dx.doi.org/10.1001/jama.283.5.596-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665687				2022-12-28	WOS:000084956500005
J	Seltzer, EG; Gerber, MA; Cartter, ML; Freudigman, K; Shapiro, ED				Seltzer, EG; Gerber, MA; Cartter, ML; Freudigman, K; Shapiro, ED			Long-term outcomes of persons with Lyme disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BORRELIA-BURGDORFERI; INCORRECT DIAGNOSIS; SEROLOGIC TESTS; ARTHRITIS; CHILDREN; FIBROMYALGIA; OVERDIAGNOSIS; MISDIAGNOSIS; CONNECTICUT; POPULATION	Context Few data exist about the long-term outcomes of patients with Lyme disease. Objective To assess the long-term outcomes of patients with Lyme disease. Design Two-part project including a community-based longitudinal cohort study and a matched cohort study, Setting and Participants Six hundred seventy-eight patients identified from a random sample of all reports of Connecticut residents with suspected Lyme disease submitted to the Connecticut Department of Public Health from 1984-1991 were evaluated in the longitudinal study; for a random subsample of 212 patients from the larger study, 212 age-matched controls without Lyme disease also were enrolled. Main Outcome Measures Self-reports or parents' reports of symptoms and ability to perform certain daily activities since diagnosis of Lyme disease; scores on the 36-item Short-Form Health Survey and the Center for Epidemiologic Studies-Depression scale, for adults, by case-definition status and between patients and controls. Results Of the 678 patients, 51.6% were female, 34.4% were children, and 64.3% met the national surveillance case definition for Lyme disease. Most patients (85.5%) were treated with antimicrobial agents, Interviews were conducted a median of 51 months after diagnosis (range, 15-135 months). An increased frequency of symptoms (eg, pain, fatigue) or of difficulty with daily activities (eg, performing housework, exercising) was reported by 69% of the patients, although few (19%) of these problems were attributed to Lyme disease. Whenever there was a statistically significant difference in the frequencies of either increased symptoms or increased difficulties with typical activities between those who did or did not meet the surveillance case definition, in all instances the greater frequency of problems was in the group that did not meet the case definition. The frequencies of reports of both increased symptoms and increased difficulties with typical activities among patients who had been diagnosed as having Lyme disease were similar to those among age-matched controls without Lyme disease. Conclusions: In this cohort, although many patients reported increases in symptoms and/or increased difficulties with typical daily activities between 1 and 11 years after diagnosis of Lyme disease, the frequencies of these reports were similar to the frequencies of such reports among age-matched controls without Lyme disease.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Childrens Clin Res Ctr, New Haven, CT 06520 USA; Univ Connecticut, Sch Med, Dept Pediat, Farmington, CT 06032 USA; Connecticut Dept Publ Hlth & Addict Serv, Hartford, CT 06106 USA	Yale University; Yale University; Yale University; Yale University; University of Connecticut	Shapiro, ED (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St, New Haven, CT 06520 USA.							Adams WV, 1999, J RHEUMATOL, V26, P1190; Bakken LL, 1997, J CLIN MICROBIOL, V35, P537, DOI 10.1128/JCM.35.3.537-543.1997; BURLINGTON DB, 1997, PUBLICATION FDA PUBL; *CDCP BACT ZOON BR, 1991, LYME DIS SURVEILL SU, V2, P1; CROFT P, 1993, J RHEUMATOL, V20, P710; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; Gerber MA, 1998, PEDIATRICS, V102, P905, DOI 10.1542/peds.102.4.905; Gerber MA, 1996, NEW ENGL J MED, V335, P1270, DOI 10.1056/NEJM199610243351703; GERBER MA, 1992, 5 INT C LYM BORR MAY; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; GUSTAFSON TL, 1994, TRUE EPISTAT; HEDBERG CW, 1990, ARCH INTERN MED, V150, P732; HSU VM, 1993, ARTHRITIS RHEUM, V36, P1493, DOI 10.1002/art.1780361103; ITOMAA M, 1998, SCAND J INFECT DIS, V30, P269; LIGHTFOOT RW, 1993, ANN INTERN MED, V119, P503, DOI 10.7326/0003-4819-119-6-199309150-00010; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; LUFT BJ, 1993, ANN INTERN MED, V119, P518; MacDonald KL, 1996, AM J MED, V100, P548, DOI 10.1016/S0002-9343(96)00017-4; MEHTA C, 1991, STATXACT COMPUTER PR; PETERSEN LR, 1989, YALE J BIOL MED, V62, P253; [Prevention Centers for Disease C], 1998, MMWR-MORBID MORTAL W, V46, P3; Radloff LS, 1977, APPL PSYCH MEAS, V1, P385, DOI DOI 10.1177/014662167700100306; Reid MC, 1998, ANN INTERN MED, V128, P354, DOI 10.7326/0003-4819-128-5-199803010-00003; ROSE CD, 1994, CLIN PEDIATR, V33, P663, DOI 10.1177/000992289403301105; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; Seltzer EG, 1996, PEDIATR INFECT DIS J, V15, P762, DOI 10.1097/00006454-199609000-00003; SELVIN S, 1996, STAT ANAL EPIDEMIOLO, P197; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; Shadick NA, 1999, ANN INTERN MED, V131, P919, DOI 10.7326/0003-4819-131-12-199912210-00003; SIGAL LH, 1992, PEDIATRICS, V90, P523; Sigal LH, 1996, ARCH INTERN MED, V156, P1493, DOI 10.1001/archinte.156.14.1493; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SIGAL LH, 1994, AM J MED, V96, P365, DOI 10.1016/0002-9343(94)90068-X; SIGAL LH, 1995, AM J MED, V98, pS74, DOI 10.1016/S0002-9343(99)80048-5; SIGAL LH, 1998, NEW ENGL J MED, V339, P571; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; TUKEY JW, 1977, SCIENCE, V198, P679, DOI 10.1126/science.333584; Wang TJ, 1998, J RHEUMATOL, V25, P2249; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; [No title captured]	43	113	116	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					609	616		10.1001/jama.283.5.609	http://dx.doi.org/10.1001/jama.283.5.609			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665700	Bronze			2022-12-28	WOS:000084956500026
J	Wickware, P				Wickware, P			Progress from a fragile start	NATURE			English	Article																			0	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					466	466		10.1038/35000347	http://dx.doi.org/10.1038/35000347			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667804	Bronze			2022-12-28	WOS:000085121100060
J	Spieler, EA; Barth, PS; Burton, JF; Himmelstein, J; Rudolph, L				Spieler, EA; Barth, PS; Burton, JF; Himmelstein, J; Rudolph, L			Recommendations to Guide Revision of the Guides to the Evaluation of Permanent Impairment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The American Medical Association's Guides to the Evaluation of Permanent Impairment, Fourth Edition, is the most commonly used tool in the United States for rating permanent impairments for disability systems. The Guides, currently undergoing revision, has been the focus of considerable controversy. Criticisms have focused on 2 areas: internal deficiencies, including the lack of a comprehensive, valid, reliable, unbiased, and evidence-based system for rating impairments; and the way in which workers' compensation systems use the ratings, resulting in inappropriate compensation. We focus on the internal deficiencies and recommend that the Guides remains a tool for evaluation of permanent impairment, not disability. To maintain wide acceptance of the Guides, its authors need to improve the validity, internal consistency, and comprehensiveness of the ratings; document reliability and reproducibility of the results; and make the Guides easily comprehensible and accessible to physicians.	W Virginia Univ, Coll Law, Morgantown, WV 26506 USA; Univ Connecticut, Dept Econ, Storrs, CT 06268 USA; Rutgers State Univ, Sch Management & Labor Relat, New Brunswick, NJ USA; Univ Massachusetts, Dept Family Med & Community Hlth, Worcester, MA 01605 USA; Univ Massachusetts, Ctr Hlth Policy & Res, Worcester, MA 01605 USA; Calif Dept Ind Relat, Div Workers Compensat, San Francisco, CA USA	West Virginia University; University of Connecticut; Rutgers State University New Brunswick; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Spieler, EA (corresponding author), W Virginia Univ, Coll Law, POB 6130, Morgantown, WV 26506 USA.	espieler@wvu.edu						*AM MED ASS, 1988, GUID EV PERM IMP; *AM MED ASS, 1971, GUID EV PERM IMP; *AM MED ASS, 1984, GUID EV PERM IMP; American Medical Association, 1990, GUID EV PERM IMP; American Medical Association, 1993, GUID EV PERM IMP; BATTISTA ME, 1989, JAMA-J AM MED ASSOC, V261, P2558; BAVON A, 1993, USE IMPAIRMENT RATIN; Berkowitz M, 1987, PERMANENT DISABILITY; Bigos S, 1994, AHCPR PUBLICATION; Burkhauser RV, 1996, DISABILITY, WORK AND CASH BENEFITS, P59; DEMBE AE, 1999, OCCUPATIONAL MUSCULO; ENGELBERG AL, GUIDES EVALUATION PE; ENGELBERG AL, 1998, ENV OCCUPATIONAL MED, P67; GAW DW, 1996, J TENNESSEE MED ASS, V9, P77; GLOSS DS, 1982, JAMA-J AM MED ASSOC, V248, P2292, DOI 10.1001/jama.248.18.2292; HADLER N, 1990, WORKERS COMPENSATION, V3, P14; HADLER N, 1990, WORKERS COMPENSATION, V3, P4; HANKINSON JL, 1993, OCCUP MED, V8, P353; HARBER P, 1994, TXB CLIN OCCUPATIONA, P92; HIMMELSTEIN JS, 1999, OCCUPATIONAL HLTH RE, P257; Howards I., 1980, DISABILITY SOCIAL PR; KESSLER HH, 1970, DISABILITY DETERMINA; LIPOLD AG, 1998, BNAS WORKERS COMPENS, V9, P545; Matheson L. N., 1996, DISABILITY EVALUATIO, P168; McCarthy ML, 1998, J BONE JOINT SURG AM, V80A, P1034, DOI 10.2106/00004623-199807000-00012; McDowell I., 1996, MEASURING HLTH GUIDE; MULVANY P, 1998, J LAW MED, V6, P136; Nagi SZ, 1965, SOCIOLOGY REHABILITA, P100; Nagi SZ, 1991, DISABILITY AM NATL A, P309, DOI DOI 10.17226/1579; National Center for Medical Rehabilitation Research, 1993, RES PLAN NAT CTR MED; Nitschke JE, 1999, SPINE, V24, P262, DOI 10.1097/00007632-199902010-00013; Pope A., 1991, DISABILITY AM NATL A, P1; Pope A. M, 1997, ENABLING AM ASSESSIN; PRYOR ES, 1990, HARVARD LAW REV, V103, P964, DOI 10.2307/1341483; PRYOR ES, 1995, 19 ANN NAT S WORK CO; Rondinelli RD, 1997, ARCH PHYS MED REHAB, V78, P1358, DOI 10.1016/S0003-9993(97)90310-5; SINCLAIR S, 1997, WORKERS COMPENSATION, V10, P13; SINCLAIR S, 1994, WORKERS COMPENSATION, V7, P1; Stewart AL, 1992, MEASURING FUNCTIONIN; Stone D., 1984, DISABLED STATE; STREETON JA, 1994, MED J AUSTRALIA, V160, P658, DOI 10.5694/j.1326-5377.1994.tb125886.x; Streiner DL., 1995, HLTH MEASUREMENT SCA, V2nd ed.; *WHO, 1998, INT CLASS IMP ACT PA	43	34	35	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					519	523		10.1001/jama.283.4.519	http://dx.doi.org/10.1001/jama.283.4.519			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659879				2022-12-28	WOS:000084879800032
J	Ellis, J				Ellis, J			There's a place for the theory of everything	NATURE			English	Letter									CERN, European Lab Particle Phys, Div Theoret Phys, CH-1211 Geneva 23, Switzerland	European Organization for Nuclear Research (CERN)	Ellis, J (corresponding author), CERN, European Lab Particle Phys, Div Theoret Phys, CH-1211 Geneva 23, Switzerland.							Ellis G, 1999, NATURE, V401, P527, DOI 10.1038/44009; ELLIS J, 1986, NATURE, V323, P595, DOI 10.1038/323595a0; KLEIN E, QUEST UNITY	3	1	1	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					241	242		10.1038/35002186	http://dx.doi.org/10.1038/35002186			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659823	Bronze			2022-12-28	WOS:000084899700017
J	Graves, LM; Guy, HI; Kozlowski, P; Huang, M; Lazarowski, E; Pope, RM; Collins, MA; Dahlstrand, EN; Earp, HS; Evans, DR				Graves, LM; Guy, HI; Kozlowski, P; Huang, M; Lazarowski, E; Pope, RM; Collins, MA; Dahlstrand, EN; Earp, HS; Evans, DR			Regulation of carbamoyl phosphate synthetase by MAP kinase	NATURE			English	Article							PYRIMIDINE NUCLEOTIDE BIOSYNTHESIS; PROTEIN-KINASE; MULTIFUNCTIONAL PROTEIN; ESCHERICHIA-COLI; PHOSPHORYLATION; ACTIVATION; CELLS; ENZYMES; CAD	The de novo synthesis of pyrimidine nucleotides is required for mammalian cells to proliferate. The rate-limiting step in this pathway is catalysed by carbamoyl phosphate synthetase (CPS II), part of the multifunctional enzyme CAD(1,2). Here we describe the regulation of CAD by the mitogen-activated protein (MAP) kinase cascade. When phosphorylated by MAP kinase in vitro or activated by epidermal growth factor in vivo, CAD lost its feedback inhibition (which is dependent on uridine triphosphate) and became more sensitive to activation (which depends upon phosphoribosyl pyrophosphate). Both these allosteric regulatory changes favour biosynthesis of pyrimidines for growth(2). They were accompanied by increased epidermal growth factor-dependent phosphorylation of CAD in vivo and were prevented by inhibition of MAP kinase. Mutation of a consensus MAP kinase phosphorylation site abolished the changes in CAD allosteric regulation that were stimulated by growth factors. Finally, consistent with an effect of MAP kinase signalling on CPS II activity, epidermal growth factor increased cellular uridine triphosphate and this increase was reversed by inhibition of MAP kinase. Hence these studies may indicate a direct link between activation of the MAP kinase cascade and de novo biosynthesis of pyrimidine nucleotides.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University	Graves, LM (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.		Graves, Lee/AAG-5470-2021		NIGMS NIH HHS [R01 GM060371] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060371] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; AOKI T, 1981, SCIENCE, V212, P463, DOI 10.1126/science.7209543; Banerjei LC, 1997, SOMAT CELL MOLEC GEN, V23, P37, DOI 10.1007/BF02679954; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Evans D.R., 1986, MULTIDOMAIN PROTEINS, P283; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GUY HI, 1994, J BIOL CHEM, V269, P23808; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; PATTERSON D, 1977, SOMAT CELL GENET, V3, P483, DOI 10.1007/BF01539120; Resing KA, 1997, METHOD ENZYMOL, V283, P29; Sahay N, 1998, J BIOL CHEM, V273, P31195, DOI 10.1074/jbc.273.47.31195; SHAW SM, 1992, EUR J BIOCHEM, V207, P957, DOI 10.1111/j.1432-1033.1992.tb17130.x; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SMITH KA, 1995, PHILOS T ROY SOC B, V347, P49, DOI 10.1098/rstb.1995.0008; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173	23	163	170	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					328	332		10.1038/35002111	http://dx.doi.org/10.1038/35002111			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659854				2022-12-28	WOS:000084899700057
J	Katz, A; Davis, ME				Katz, A; Davis, ME			Molecular imprinting of bulk, microporous silica	NATURE			English	Article							TRANSESTERIFICATION; RECOGNITION; POLYMERS	Molecular imprinting aims to create solid materials containing chemical functionalities that are spatially organized by covalent(1) or non-covalent(2) interactions with imprint (or template) molecules during the synthesis process. Subsequent removal of the imprint molecules leaves behind designed sites for the recognition of small molecules, making the material ideally suited for applications such as separations, chemical sensing and catalysis(2-5). Until now, the molecular imprinting of bulk polymers(2-5) and polymer(6,7) and silica(8,9) surfaces has been reported, but the extension of these methods to a wider range of materials remains problematic. For example, the formation of substrate-specific cavities within bulk silica, while conceptually straightforward(10), has been difficult to accomplish experimentally(11,12). Here we describe the imprinting of bulk amorphous silicas with single aromatic rings carrying up to three 3-aminopropyltriethoxysilane side groups; this generates and occupies microporosity and attaches functional organic groups to the pore walls in a controlled fashion. The triethoxysilane part of the molecules' side groups is incorporated into the silica framework during sol-gel synthesis, and subsequent removal of the aromatic core creates a cavity with spatially organized aminopropyl groups covalently anchored to the pore walls. We find that the imprinted silicas act as shape-selective base catalysts. Our strategy can be extended to imprint other functional groups, which should give access to a wide range of functionalized materials.	CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Davis, ME (corresponding author), CALTECH, Pasadena, CA 91125 USA.							Ahmad WR, 1996, CATAL LETT, V40, P109, DOI 10.1007/BF00807466; BRINKER CJ, 1982, J NON-CRYST SOLIDS, V48, P47, DOI 10.1016/0022-3093(82)90245-9; D'Souza SM, 1999, NATURE, V398, P312, DOI 10.1038/18636; Dai S, 1999, ANGEW CHEM INT EDIT, V38, P1235, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1235::AID-ANIE1235>3.0.CO;2-X; Davis ME, 1996, CHEM MATER, V8, P1820, DOI 10.1021/cm960019u; DUNN D, 1997, CHEM MATER, V4, P2280; Fuji K, 1999, J AM CHEM SOC, V121, P3807, DOI 10.1021/ja9836444; HEILMANN J, 1994, ANGEW CHEM INT EDIT, V33, P471, DOI 10.1002/anie.199404711; HOUK J, 1987, J AM CHEM SOC, V109, P6825, DOI 10.1021/ja00256a040; Jones CW, 1998, NATURE, V393, P52, DOI 10.1038/29959; Katz A, 1999, MACROMOLECULES, V32, P4113, DOI 10.1021/ma981445z; Maier WF, 1997, CATAL LETT, V46, P137, DOI 10.1023/A:1019013022688; SHEA KJ, 1994, TRENDS POLYM SCI, V2, P166; Shi HQ, 1999, NATURE, V398, P593, DOI 10.1038/19267; VLATAKIS G, 1993, NATURE, V361, P645, DOI 10.1038/361645a0; WHITCOMBE MJ, 1995, J AM CHEM SOC, V117, P7105, DOI 10.1021/ja00132a010; WULFF G, 1986, J AM CHEM SOC, V108, P1089, DOI 10.1021/ja00265a045; WULFF G, 1995, ANGEW CHEM INT EDIT, V34, P1812, DOI 10.1002/anie.199518121	18	450	466	10	299	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					286	289		10.1038/35002032	http://dx.doi.org/10.1038/35002032			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659842				2022-12-28	WOS:000084899700045
J	Reichhardt, T				Reichhardt, T			NASA ponders termination of gamma-ray observatory	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					232	232		10.1038/35002151	http://dx.doi.org/10.1038/35002151			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659814	Bronze			2022-12-28	WOS:000084899700005
J	Hart, JT				Hart, JT			Commentary: Three decades of the inverse care law	BRITISH MEDICAL JOURNAL			English	Editorial Material							COMMUNITY; HEALTH		Univ Glamorgan, Welsh Inst Hlth & Social Care, Pontypridd CF37 1DL, M Glam, Wales	University of South Wales	Hart, JT (corresponding author), Univ Glamorgan, Welsh Inst Hlth & Social Care, Glyntaff Campus, Pontypridd CF37 1DL, M Glam, Wales.							BUNKER JP, 1994, MILBANK Q, V72, P225, DOI 10.2307/3350295; HART JT, 1991, BMJ-BRIT MED J, V302, P1509, DOI 10.1136/bmj.302.6791.1509; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; McKeown Thomas, 1979, ROLE MED; NOYCE J, 1974, LANCET, V1, P554; Smith R, 1999, BRIT MED J, V318, P209; WILKINSON R, 1996, UNHEALTHY SOC AFFICT	7	48	50	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					18	19						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10671038				2022-12-28	WOS:000084621600015
J	Haynes, RB				Haynes, RB			Commentary: A warning to complementary medicine practitioners: get empirical or else	BRITISH MEDICAL JOURNAL			English	Editorial Material									McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Haynes, RB (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada.			Haynes, Robert Brian/0000-0002-1453-3196				HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802	2	9	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1632	1632						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10660326				2022-12-28	WOS:000084562600026
J	Armstrong, K; Eisen, A; Weber, B				Armstrong, K; Eisen, A; Weber, B			Assessing the risk of breast cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HORMONE REPLACEMENT THERAPY; FAMILY HISTORY; POSTMENOPAUSAL WOMEN; SCREENING MAMMOGRAPHY; POOLED ANALYSIS; BRCA1; MUTATIONS; TAMOXIFEN; MORTALITY; VALIDATION		Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Armstrong, K (corresponding author), 1233 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	karmstro@mail.med.upenn.edu			NCI NIH HHS [CA73619] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DE, 1985, CANCER, V56, P383, DOI 10.1002/1097-0142(19850715)56:2<383::AID-CNCR2820560230>3.0.CO;2-0; BONDY ML, 1994, J NATL CANCER I, V86, P620, DOI 10.1093/jnci/86.8.620; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; Chlebowski RT, 1999, J CLIN ONCOL, V17, P1939, DOI 10.1200/JCO.1999.17.6.1939; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; Colditz GA, 1996, J NATL CANCER I, V88, P365, DOI 10.1093/jnci/88.6.365; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Costantino JP, 1999, J NATL CANCER I, V91, P1541, DOI 10.1093/jnci/91.18.1541; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128; FORD D, 1995, AM J HUM GENET, V57, P1457; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Freudenheim JL, 1997, AM J EPIDEMIOL, V146, P932, DOI 10.1093/oxfordjournals.aje.a009219; Gail M, 1999, J CLIN ONCOL, V17, P740; Gail M, 1998, J CLIN ONCOL, V16, P3105, DOI 10.1200/JCO.1998.16.9.3105; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GAIL MH, 1992, CANC PREVENTION, P1; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; Hendrick R E, 1997, J Natl Cancer Inst Monogr, P87; HILDRETH NG, 1989, NEW ENGL J MED, V321, P1281, DOI 10.1056/NEJM198911093211901; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; Lindfors KK, 1996, JAMA-J AM MED ASSOC, V275, P112; MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681; McGuigan KA, 1996, J NATL CANCER I, V88, P1315, DOI 10.1093/jnci/88.18.1315; Mettler FA, 1996, CANCER, V77, P903, DOI 10.1002/(SICI)1097-0142(19960301)77:5<903::AID-CNCR15>3.0.CO;2-7; Michels KB, 1996, EPIDEMIOLOGY, V7, P521, DOI 10.1097/00001648-199609000-00012; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; *NAT COMM CLIN LAB, 1997, M27A NAT COMM CLIN L, P1; OFFIT K, 1994, J CLIN ONCOL, V12, P1724, DOI 10.1200/JCO.1994.12.8.1724; OTTMAN R, 1983, LANCET, V2, P556; Powles T, 1998, LANCET, V352, P98; *PREV SERV TASK FO, 1996, SCREEN BREAST CANC G, P73; Ries L. A. G., 1999, SEER CANC STAT REV 1; Rockhill B, 1998, AM J EPIDEMIOL, V147, P826, DOI 10.1093/oxfordjournals.aje.a009535; Rosenberg L, 1996, AM J EPIDEMIOL, V143, P25; Rosser EM, 1996, J MED GENET, V33, P977, DOI 10.1136/jmg.33.12.977; Rowe PM, 1997, LANCET, V349, P928, DOI 10.1016/S0140-6736(05)62704-3; Salzmann P, 1998, ANN INTERN MED, V128, P878, DOI 10.7326/0003-4819-127-11-199712010-00001; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; Schrag D, 1997, NEW ENGL J MED, V337, P434; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; Sellers TA, 1997, ANN INTERN MED, V127, P973, DOI 10.7326/0003-4819-127-11-199712010-00004; ShattuckEidens D, 1997, JAMA-J AM MED ASSOC, V278, P1242, DOI 10.1001/jama.278.15.1242; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; SPIEGELMAN D, 1994, J NATL CANCER I, V86, P600, DOI 10.1093/jnci/86.8.600; STEFANEK ME, 1995, NIH PUBLICATION, P37; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TAPLIN SH, 1990, CANCER, V66, P812, DOI 10.1002/1097-0142(19900815)66:4<812::AID-CNCR2820660436>3.0.CO;2-1; TAPLIN SH, 1991, CANCER, V67, P2400; Veronesi U, 1998, LANCET, V352, P93; Vogel V G, 1996, Oncology (Williston Park), V10, P1451; VOGEL VG, 1996, ONCOLOGY HUNTINGT, V10, P1461; Wooster R, 1996, NATURE, V379, P749, DOI 10.1038/379749a0; 1999, ARCH INTERN MED, V159, P1458	68	206	215	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					564	571		10.1056/NEJM200002243420807	http://dx.doi.org/10.1056/NEJM200002243420807			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684916				2022-12-28	WOS:000085422400007
J	Bostom, AG; Garber, C				Bostom, AG; Garber, C			Endpoints for homocysteine-lowering trials	LANCET			English	Editorial Material							DISEASE		Mem Hosp Rhode Isl, Div Gen Internal Med, Providence, RI 02860 USA; Mem Hosp Rhode Isl, Div Cardiol, Human Performance Lab, Providence, RI 02860 USA		Bostom, AG (corresponding author), Mem Hosp Rhode Isl, Div Gen Internal Med, Providence, RI 02860 USA.		Garber, Carol/ABD-4375-2021	Garber, Carol/0000-0002-1268-576X				ADAMS MR, 1995, CIRCULATION, V92, P2127, DOI 10.1161/01.CIR.92.8.2127; Bostom AG, 2000, J AM SOC NEPHROL, V11, P149, DOI 10.1681/ASN.V111149; Bostom AG, 1999, ANN INTERN MED, V131, P352, DOI 10.7326/0003-4819-131-5-199909070-00006; Clarke R, 1998, J Cardiovasc Risk, V5, P249, DOI 10.1097/00043798-199808000-00007; Froelicher VF, 1999, CHEST, V116, P1442, DOI 10.1378/chest.116.5.1442; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; Malinow MR, 1999, CIRCULATION, V99, P178, DOI 10.1161/01.CIR.99.1.178; McQuillan BM, 1999, CIRCULATION, V99, P2383, DOI 10.1161/01.CIR.99.18.2383; MUDD SH, 1985, AM J HUM GENET, V37, P1; Omenn GS, 1998, CIRCULATION, V97, P421; PROBSTFIELD JL, 1993, CIRCULATION, V87, P74; Taylor LM, 1999, J VASC SURG, V29, P8, DOI 10.1016/S0741-5214(99)70345-9	13	23	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2000	355	9203					511	512		10.1016/S0140-6736(99)00437-7	http://dx.doi.org/10.1016/S0140-6736(99)00437-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10682995				2022-12-28	WOS:000085487400003
J	Copas, JB; Shi, JQ				Copas, JB; Shi, JQ			Reanalysis of epidemiological evidence on lung cancer and passive smoking	BRITISH MEDICAL JOURNAL			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; METAANALYSIS; BIAS	Objective To assess the epidemiological evidence for an increase in the risk of lung cancer resulting from exposure to environmental tobacco smoke. Design Reanalysis of 37 published epidemiological studies previously included in a meta-analysis allowing for the possibility of publication bias. Main outcome measure Relative risk of lung cancer among female lifelong non-smokers, according to whether her partner was a current smoker or a lifelong non-smoker. Results If it is assumed that all studies that have ever been carried out are included, or that those selected for review are truly representative of all such studies, then the estimated excess risk of lung cancer is 24%, as previously reported (95% confidence interval 13% to 36%, P < 0.001). However, a significant correlation between study outcome and study size suggests the presence of publication bias. Adjustment for such bias implies that the risk has been overestimated. For example, if only 60% of studies have been included, the estimate of excess risk falls from 24% to 15%. Conclusion A modest degree of publication bias leads to a substantial reduction in the relative risk and to a weaker level of significance, suggesting that the published estimate of the increased risk of lung cancer associated with environmental tobacco smoke needs to be interpreted with caution.	Univ Warwick, Dept Stat, Coventry CV4 7AL, W Midlands, England	University of Warwick	Copas, JB (corresponding author), Univ Warwick, Dept Stat, Coventry CV4 7AL, W Midlands, England.							BERO LA, 1994, JAMA-J AM MED ASSOC, V272, P133, DOI 10.1001/jama.272.2.133; Copas J, 1999, J R STAT SOC A STAT, V162, P95, DOI 10.1111/1467-985X.00123; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980	5	33	34	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					417	418		10.1136/bmj.320.7232.417	http://dx.doi.org/10.1136/bmj.320.7232.417			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669446	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000085377400023
J	Willenheimer, R; Erhardt, LR				Willenheimer, R; Erhardt, LR			Value of 6-min-walk test for assessment of severity and prognosis of heart failure	LANCET			English	Editorial Material							LEFT-VENTRICULAR DYSFUNCTION; 6-MINUTE WALK TEST; QUALITY-OF-LIFE; OXYGEN-UPTAKE		Univ Lund, Malmo Univ Hosp, Dept Cardiol, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Willenheimer, R (corresponding author), Univ Lund, Malmo Univ Hosp, Dept Cardiol, SE-20502 Malmo, Sweden.							BENGE W, 1980, CIRCULATION, V61, P955, DOI 10.1161/01.CIR.61.5.955; BITTNER V, 1993, CIRCULATION, V88, P590; BITTNER V, 1993, JAMA-J AM MED ASSOC, V270, P1702, DOI 10.1001/jama.270.14.1702; Cahalin LP, 1996, CHEST, V110, P325, DOI 10.1378/chest.110.2.325; COHN JN, 1993, CIRCULATION, V87, P1; DRACUP K, 1992, J HEART LUNG TRANSPL, V11, P273; Faggiano P, 1997, AM HEART J, V134, P203, DOI 10.1016/S0002-8703(97)70125-X; GORKIN L, 1993, AM J CARDIOL, V71, P1069, DOI 10.1016/0002-9149(93)90575-W; Lucas C, 1999, AM HEART J, V138, P618, DOI 10.1016/S0002-8703(99)70174-2; RILEY M, 1992, EUR HEART J, V13, P789, DOI 10.1093/oxfordjournals.eurheartj.a060258; Roul G, 1998, AM HEART J, V136, P449, DOI 10.1016/S0002-8703(98)70219-4; Stevenson L., 1996, EXERCISE GAS EXCHANG, P271; Zugck C, 1998, CIRCULATION, V98, P157	13	22	25	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					515	516		10.1016/S0140-6736(99)00445-6	http://dx.doi.org/10.1016/S0140-6736(99)00445-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287CN	10682999				2022-12-28	WOS:000085487400007
J	Li, GY; Weis, RM				Li, GY; Weis, RM			Covalent modification regulates ligand binding to receptor complexes in the chemosensory system of Escherichia coli	CELL			English	Article							BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; KINASE CHEA; SERINE CHEMORECEPTOR; CYTOPLASMIC FRAGMENT; RESPONSE REGULATOR; ASPARTATE RECEPTOR; SENSORY RECEPTOR; PROTEIN; METHYLATION	In the Escherichia coli chemosensory pathway, receptor modification mediates adaptation to ligand. Evidence is presented that covalent modification influences ligand binding to receptors in complexes with CheW and the kinase CheA. Kinase inhibition was measured with serine receptor complexes in different modification levels; K-i for serine-mediated inhibition increased 10,000-fold from the lowest to the highest level. Without CheA and CheW, ligand binding is unaffected by covalent modification; thus, the influence of covalent modification is mediated only in the receptor complex, a conclusion supported by an analogy to allosteric enzymes and the observation of cooperative kinase inhibition. Also, the finding that a subsaturating serine concentration accelerates active receptor-kinase complex assembly implies that the assembly/disassembly process may also contribute to kinase regulation.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA; Univ Massachusetts, Grad Program Mol & Cellular Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Weis, RM (corresponding author), Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.	rmweis@chem.umass.edu			NIGMS NIH HHS [R01 GM53210] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053210] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1969, SCIENCE, V166, P1588, DOI 10.1126/science.166.3913.1588; Barnakov AN, 1998, J BACTERIOL, V180, P6713, DOI 10.1128/JB.180.24.6713-6718.1998; BORKOVICH KA, 1991, METHOD ENZYMOL, V200, P205; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; Bray D, 1998, ANNU REV BIOPH BIOM, V27, P59, DOI 10.1146/annurev.biophys.27.1.59; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Bren A, 1998, J MOL BIOL, V278, P507, DOI 10.1006/jmbi.1998.1730; CONLEY MP, 1989, J BACTERIOL, V171, P5190, DOI 10.1128/jb.171.9.5190-5193.1989; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hill AV, 1913, BIOCHEM J, V7, P471, DOI 10.1042/bj0070471; Iwama T, 1997, J BIOL CHEM, V272, P13810, DOI 10.1074/jbc.272.21.13810; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LeMoual H, 1997, BIOCHEMISTRY-US, V36, P13441, DOI 10.1021/bi9713207; Levit MN, 1998, MOL MICROBIOL, V30, P459, DOI 10.1046/j.1365-2958.1998.01066.x; Levit MN, 1999, BIOCHEMISTRY-US, V38, P6651, DOI 10.1021/bi982839l; Li JY, 1997, BIOCHEMISTRY-US, V36, P11851, DOI 10.1021/bi971510h; LI JY, 1995, BIOCHEMISTRY-US, V34, P14626, DOI 10.1021/bi00045a003; LIN LN, 1994, BIOCHEMISTRY-US, V33, P6564, DOI 10.1021/bi00187a025; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; MADDOCK JR, 1993, SCIENCE, V259, P1717; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NINFA EG, 1991, J BIOL CHEM, V266, P9764; Osborn M J, 1974, Methods Enzymol, V31, P642; RICE MS, 1991, J BIOL CHEM, V266, P9746; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Seeley SK, 1996, BIOCHEMISTRY-US, V35, P16336, DOI 10.1021/bi961749i; SLOCUM MK, 1983, J BACTERIOL, V155, P565, DOI 10.1128/JB.155.2.565-577.1983; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; Wyman J, 1968, Q Rev Biophys, V1, P35; YONEKAWA H, 1986, FEBS LETT, V198, P21, DOI 10.1016/0014-5793(86)81176-0	42	163	165	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 4	2000	100	3					357	365		10.1016/S0092-8674(00)80671-6	http://dx.doi.org/10.1016/S0092-8674(00)80671-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	282ET	10676817	Bronze			2022-12-28	WOS:000085204400009
J	Abrahamson, J; Dinniss, J				Abrahamson, J; Dinniss, J			Ball lightning caused by oxidation of nanoparticle networks from normal lightning strikes on soil	NATURE			English	Article							SILICON	Observations of ball lightning have been reported for centuries, but the origin of this phenomenon remains an enigma. The 'average' ball lightning appears as a sphere with a diameter of 300 mm, a lifetime of about 10 s, and a luminosity similar to a 100-W lamp(1). It floats freely in the air, and ends either in an explosion, or by simply fading from view. It almost invariably occurs during stormy weather(2,3). Several energy sources have been proposed(2-4) to explain the light, but none of these models has succeeded in explaining all of the observed characteristics. Here we report a model that potentially accounts for all of those properties, and which has some experimental support. When normal lightning strikes soil, chemical energy is stored in nanoparticles of Si, SiO or SiC, which are ejected into the air as a filamentary network, As the particles are slowly oxidized in air, the stored energy is released as heat and light. We investigated this basic process by exposing soil samples to a lightning-like discharge, which produced chain aggregates of nanoparticles: these particles oxidize at a rate appropriate for explaining the lifetime of ball lightning.	Univ Canterbury, Dept Chem & Proc Engn, Christchurch 1, New Zealand	University of Canterbury	Abrahamson, J (corresponding author), Univ Canterbury, Dept Chem & Proc Engn, Private Bag 4800, Christchurch 1, New Zealand.							Aleksandrov V. Ya., 1982, Soviet Physics - Technical Physics, V27, P527; ALEKSANDROV VY, 1983, NATURE, V27, P1221; Andrianov A. M., 1977, Soviet Physics - Technical Physics, V22, P1342; Barry J.D, 1980, BALL LIGHTNING BEAD; Bohren C., 2008, ABSORPTION SCATTERIN; Cawood W, 1931, NATURE, V128, P150, DOI 10.1038/128150a0; DEAL BE, 1965, J APPL PHYS, V36, P3770, DOI 10.1063/1.1713945; ESSENE EJ, 1986, SCIENCE, V234, P189, DOI 10.1126/science.234.4773.189; Fortov VE, 1997, J EXP THEOR PHYS+, V84, P256, DOI 10.1134/1.558112; Friedlander SK, 1998, APPL PHYS LETT, V72, P173, DOI 10.1063/1.120676; HUTCHISON SG, 1988, METALL TRANS B, V19, P249, DOI 10.1007/BF02654209; *I EL ENG, 1988, INSPEC PROP SIL 75, P938; JACOBSON NS, 1993, J AM CERAM SOC, V76, P3, DOI 10.1111/j.1151-2916.1993.tb03684.x; LITTAU KA, 1993, J PHYS CHEM-US, V97, P1224, DOI 10.1021/j100108a019; LOWKE JJ, 1969, J GEOPHYS RES, V74, P6887, DOI 10.1029/JC074i028p06887; LUDWIG MH, 1997, HDB OPTICAL PROPERTI, V2, P103; MASSOUD HZ, 1987, J APPL PHYS, V62, P3416, DOI 10.1063/1.339305; NAGAMORI M, 1995, J NON-CRYST SOLIDS, V189, P270, DOI 10.1016/0022-3093(95)00239-1; Palik E D, 1985, HDB OPTICAL CONSTANT; PEMBERTON ST, 1984, CHEM ENG SCI, V39, P829, DOI 10.1016/0009-2509(84)85052-6; Rayle W.D., 1966, D3188 NASA TN; SIEGEL RW, 1998, PHYSICS NEW MAT, P66; Singer S., 1971, NATURE BALL LIGHTNIN; SMIRNOV BM, 1987, PHYS REP, V152, P177, DOI 10.1016/0370-1573(87)90142-6; TURNER DJ, 1994, PHILOS T R SOC A, V347, P83, DOI 10.1098/rsta.1994.0040	25	107	108	2	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2000	403	6769					519	521		10.1038/35000525	http://dx.doi.org/10.1038/35000525			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676954				2022-12-28	WOS:000085227300042
J	Horton, B				Horton, B			Bioengineering programmes rise to meet the challenge of a young science - When biology met engineering, they created a new field for scientists who don't want to be hedged into one discipline	NATURE			English	Article																			0	2	2	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					463	465		10.1038/35000341	http://dx.doi.org/10.1038/35000341			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667802				2022-12-28	WOS:000085121100058
J	Ryu, WS; Berry, RM; Berg, HC				Ryu, WS; Berry, RM; Berg, HC			Torque-generating units of the flagellar motor of Escherichia coli have a high duty ratio	NATURE			English	Article							OPTICAL TWEEZERS; ROTATION; MOVEMENT; MOTILITY; DOMAIN; MODEL	Rotation of the bacterial flagellar motor is driven by an ensemble of torque-generating units containing the proteins MotA and; MotB(1-3). Here, by inducing expression of MotA in motA(-) cells under conditions of low viscous load, we show that the limiting speed of the motor is independent of the number of units: at vanishing load, one unit turns the motor as rapidly as many. This result indicates that each unit may remain attached to the rotor for most of its mechanochemical cycle, that is, that it has a high duty ratio(4). Thus, torque generators behave more like kinesin, the protein that moves vesicles along microtubules, than myosin, the protein that powers muscle. However, their translation rates, stepping frequencies and power outputs are much higher, being greater than 30 mu m s(-1), 12 Hz and 1.5 x 10(5) pN nm s(-1) respectively.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Rowland Inst Sci Inc, Cambridge, MA 02142 USA; Kings Coll London, Randall Ctr, London SE1 1UL, England	Harvard University; University of London; King's College London	Berg, HC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.							ARMSTRONG JB, 1967, GENETICS, V56, P363; BERG HC, 1993, BIOPHYS J, V65, P2201, DOI 10.1016/S0006-3495(93)81278-5; Berry RM, 1999, BIOPHYS J, V76, P580, DOI 10.1016/S0006-3495(99)77226-7; Berry RM, 1999, ADV MICROB PHYSIOL, V41, P291, DOI 10.1016/S0065-2911(08)60169-1; Berry RM, 1997, P NATL ACAD SCI USA, V94, P14433, DOI 10.1073/pnas.94.26.14433; BLAIR DF, 1988, SCIENCE, V242, P1678, DOI 10.1126/science.2849208; BLOCK SM, 1984, NATURE, V309, P470, DOI 10.1038/309470a0; BLOCK SM, 1991, CYTOMETRY, V12, P492, DOI 10.1002/cyto.990120605; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; CHEN X, IN PRESS BIOPHYS J; DeRosier DJ, 1998, CELL, V93, P17, DOI 10.1016/S0092-8674(00)81141-1; FUNG DCY, 1994, THESIS HARVARD U; Gittes F, 1998, OPT LETT, V23, P7, DOI 10.1364/OL.23.000007; Happel J, 1991, LOW REYNOLDS NUMBER; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; KUWAJIMA G, 1988, J BACTERIOL, V170, P485, DOI 10.1128/jb.170.1.485-488.1988; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; MACNAB RM, 1977, P NATL ACAD SCI USA, V74, P221, DOI 10.1073/pnas.74.1.221; Macnab RM, 1996, ESCHERICHIA COLI SAL, V1, P123; MAURER L, 1987, J BACTERIOL, V169, P640, DOI 10.1128/jb.169.2.640-645.1987; MURAMOTO K, 1995, J MOL BIOL, V251, P50, DOI 10.1006/jmbi.1995.0415; Samuel ADT, 1996, BIOPHYS J, V71, P918, DOI 10.1016/S0006-3495(96)79295-0; SILVERMAN M, 1974, NATURE, V249, P73, DOI 10.1038/249073a0; SILVERMAN M, 1976, NATURE, V264, P577, DOI 10.1038/264577a0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; [No title captured]	30	183	186	3	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					444	447		10.1038/35000233	http://dx.doi.org/10.1038/35000233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667798				2022-12-28	WOS:000085121100054
J	Zeff, BW; Kleber, B; Fineberg, J; Lathrop, DP				Zeff, BW; Kleber, B; Fineberg, J; Lathrop, DP			Singularity dynamics in curvature collapse and jet eruption on a fluid surface	NATURE			English	Article							PINCHOFF; CAVITIES; BUBBLES; WAVES	Finite-time singularities-local divergences in the amplitude or gradient of a physical observable at a particular time-occur in a diverse range of physical systems. Examples include singularities capable of damaging optical fibres and lasers in nonlinear optical systems(1), and gravitational singularities(2) associated with black holes. In fluid systems, the formation of finite-time singularities cause spray and air-bubble entrainment(3), processes which influence air-sea interaction on a global scale(4,5). Singularities driven by surface tension have been studied in the break-up of pendant drops(6-9) and liquid sheets(10-12). Here we report a theoretical and experimental study of the generation of a singularity by inertial : focusing, in which no break-up of the fluid surface occurs. Inertial forces cause a collapse of the surface that leads to jet formation; our analysis, which includes surface tension effects, predicts that the surface profiles should be describable by a single universal exponent. These theoretical predictions correlate closely with our experimental measurements of a collapsing surface singularity The solution can be generalized to apply to a broad class of singular phenomena.	Univ Maryland, Inst Plasma Res, College Pk, MD 20742 USA; Univ Maryland, Dept Phys, College Pk, MD 20742 USA; Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; Hebrew University of Jerusalem	Lathrop, DP (corresponding author), Univ Maryland, Inst Plasma Res, College Pk, MD 20742 USA.			Fineberg, Jay/0000-0002-8381-6675				Barenblatt GI, 1987, DIMENSIONAL ANAL; BOULTONSTONE JM, 1993, J FLUID MECH, V254, P437, DOI 10.1017/S0022112093002216; Brenner MP, 1997, PHYS FLUIDS, V9, P1573, DOI 10.1063/1.869279; Chen YJ, 1997, J FLUID MECH, V341, P245, DOI 10.1017/S002211209700548X; COOKER MJ, 1992, BREAKING WAVES; Day RF, 1998, PHYS REV LETT, V80, P704, DOI 10.1103/PhysRevLett.80.704; EGGERS J, 1994, J FLUID MECH, V262, P205, DOI 10.1017/S0022112094000480; EGGERS J, 1993, PHYS REV LETT, V71, P3458, DOI 10.1103/PhysRevLett.71.3458; FARADAY M, 1981, PHIL T R SOC LOND, V121, P299; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Hou TY, 1997, PHYS FLUIDS, V9, P1933, DOI 10.1063/1.869313; KELLER JB, 1983, SIAM J APPL MATH, V43, P268, DOI 10.1137/0143018; LONGUETHIGGINS MS, 1995, J FLUID MECH, V290, P183, DOI 10.1017/S0022112095002461; LonguetHiggins MS, 1997, PHILOS T R SOC A, V355, P625, DOI 10.1098/rsta.1997.0029; NEWELL AC, 1992, PHYS REV LETT, V69, P1149, DOI 10.1103/PhysRevLett.69.1149; Sarmiento JL, 1996, SCIENCE, V274, P1346, DOI 10.1126/science.274.5291.1346; Shen Y. R., 1984, PRINCIPLES NONLINEAR; Weinberg S., 1972, GRAVITATION COSMOLOG; ZAKHAROV VE, 1992, BREAKING WAVES	21	186	190	3	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					401	404		10.1038/35000151	http://dx.doi.org/10.1038/35000151			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667786				2022-12-28	WOS:000085121100042
J	Nachman, SA; Stanley, K; Yogev, R; Pelton, S; Wiznia, A; Lee, S; Mofenson, L; Fiscus, S; Rathore, M; Jimenez, E; Borkowsky, W; Pitt, J; Smith, ME; Wells, B; McIntosh, K				Nachman, SA; Stanley, K; Yogev, R; Pelton, S; Wiznia, A; Lee, S; Mofenson, L; Fiscus, S; Rathore, M; Jimenez, E; Borkowsky, W; Pitt, J; Smith, ME; Wells, B; McIntosh, K		Pediat AIDS Clin Trials Grp 338 Study	Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS TYPE-1 RNA; IMMUNODEFICIENCY; ZIDOVUDINE; DIDANOSINE; PROGRAM; PLASMA	Context Although protease inhibitors are used routinely in adults with human immunodeficiency virus (HIV) infection, the role of these drugs in the treatment of clinically stable HIV-infected children is not clear. Objective To evaluate the safety, tolerance, and virologic response produced by a change in antiretroviral therapy in HIV-infected children who were clinically and immunologically stable while receiving previous therapy. Design The Pediatric AIDS Clinical Trials Group 338, a multicenter, phase 2, randomized, open-label controlled trial conducted from February 6 to April 30, 1997 (patient entry period); patients were followed up for 48 weeks. Setting Pediatric HIV research clinics in the United States and Puerto Rico. Patients Two hundred ninety-seven antiretroviral-experienced, protease inhibitor-naive, clinically stable HIV-infected children aged 2 to 17 years. Interventions Children were randomized to receive zidovudine, 160 mg/m(2) 3 times per day, plus lamivudine, 4 mg/kg 2 times per day (n = 100); the same regimen plus ritonavir, 350 mg/m(2) 2 times per day (n = 100); or ritonavir, 350 mg/m(2) 2 times per day, and stavudine, 4 mg/kg 2 times per day (n = 97). Main Outcome Measure Plasma HIV-1 RNA levels at study weeks 12 and 48, compared among the 3 treatment groups. Results At study week 12, 12% of patients in the zidovudine-lamivudine group had undetectable plasma HIV RNA levels (<400 copies/mL) compared with 52% and 54% of patients in the 2- and 3-drug ritonavir-containing groups, respectively (P<.001). Through study week 48, 70% of children continued receiving their ritonavir-containing regimen. At study week 48, 42% of children receiving ritonavir plus 2 nucleosides compared with 27% of those receiving ritonavir and a single nucleoside had undetectable HIV RNA levels (P =.04); however, similar proportions in each group continuing initial therapy had HIV RNA levels of less than 10 000 copies/mL (58% vs 48%, respectively; P=.19). Conclusions In our study, change in antiretroviral therapy to a ritonavir-containing regimen was associated with superior virologic response at study week 12 compared with change to a dual nucleoside analog regimen. More children receiving ritonavir in combination with 2 compared with 1 nucleoside analog had undetectable HIV RNA levels at study week 48.	SUNY Stony Brook, Dept Pediat, Stony Brook, NY 11794 USA; Albert Einstein Coll Med, Jacobi Med Ctr, New York, NY USA; NYU Med Ctr, New York, NY 10016 USA; Columbia Univ Coll Phys & Surg, Dept Pediat Infect Dis, New York, NY USA; Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Cambridge, MA 02138 USA; Boston Med Ctr, Sect Pediat Infect Dis, Boston, MA USA; Childrens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA; Childrens Mem Hosp, Div Infect Dis, Chicago, IL USA; NICHHD, Pediat Adolescent & Maternal AIDS Branch, Bethesda, MD USA; NIAID, Div AIDS, NIH, Bethesda, MD USA; Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ Florida, Hlth Sci Ctr, Dept Pediat, Jacksonville, FL 32209 USA; San Juan City Hosp, Dept Pediat, San Juan, PR USA; Social & Sci Syst, Sect Pediat Infect Dis, Rockville, MD USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Jacobi Medical Center; Yeshiva University; New York University; Columbia University; Harvard University; Harvard T.H. Chan School of Public Health; Boston Medical Center; Harvard University; Boston Children's Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; State University System of Florida; University of Florida; Social & Scientific Systems	Nachman, SA (corresponding author), SUNY Stony Brook, Dept Pediat, HSC T11,080, Stony Brook, NY 11794 USA.	snachman@mail.som.sunysb.edu	Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808; Pelton, Stephen/0000-0003-4862-5344	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041110] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; Brambilla D, 1998, J CLIN MICROBIOL, V36, P311, DOI 10.1128/JCM.36.1.311-314.1998; *DEP HLTH HUM SERV, 1998, MMWR-MORBID MORTAL W, V47, P43; *DEP HLTH HUM SERV, 1998, MMWR-MORBID MORTAL W, V47, P619; Dyer JR, 1999, J CLIN MICROBIOL, V37, P447, DOI 10.1128/JCM.37.2.447-449.1999; Englund JA, 1997, NEW ENGL J MED, V336, P1704, DOI 10.1056/NEJM199706123362403; GELMAN R, 1993, CLIN IMMUNOL IMMUNOP, V66, P150, DOI 10.1006/clin.1993.1019; Hollander M., 2014, NONPARAMETRIC STAT M, V3rd ed.; McKinney RE, 1998, J PEDIATR-US, V133, P500, DOI 10.1016/S0022-3476(98)70057-5; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; Mueller BU, 1998, PEDIATRICS, V101, P335, DOI 10.1542/peds.101.3.335; Notermans DW, 1998, AIDS, V12, P1483, DOI 10.1097/00002030-199812000-00010; PALUMBO PE, 1995, J PEDIATR-US, V126, P592, DOI 10.1016/S0022-3476(95)70357-8; Pocock SJ., 2013, CLIN TRIALS PRACTICA; YenLieberman B, 1996, J CLIN MICROBIOL, V34, P2695, DOI 10.1128/JCM.34.11.2695-2701.1996; YOGEV R, 1997, P 37 INT C ANT AG CH	18	89	93	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					492	498		10.1001/jama.283.4.492	http://dx.doi.org/10.1001/jama.283.4.492			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659875	Bronze			2022-12-28	WOS:000084879800028
J	Kavanagh, AM; Mitchell, H; Giles, GG				Kavanagh, AM; Mitchell, H; Giles, GG			Hormone replacement therapy and accuracy of mammographic screening	LANCET			English	Article							BREAST-CANCER; FAMILY HISTORY; DENSITY; WOMEN; AGE; SENSITIVITY; ESTROGEN; SPECIFICITY; INTERVAL; PROGRAM	Background Hormone replacement therapy (HRT) is commonly used and may affect the accuracy of mammographic screening. Methods We examined the sensitivity, specificity, and small-cancer detection rate according to HRT use in 103 770 women in Victoria, Australia, who attended first-round screening in 1994 and who did not have a personal history of breast cancer or a breast lump or a bloodstained or watery nipple discharge at the time of screening. BreastScreen Victoria provides mammography to women aged 40 years and older every 2 years. Unconditional logistic modelling was used to adjust for age, family history, and symptom status. Findings The sensitivity of screening mammography for a 2-year screening interval was lower in HRT users (64.8% [95% CI 58-72]) than nonusers (77.3% [74-81]). In the target group (50-69 years), the sensitivity was 64.3% (57-72) in HRT users and 79.8% (76-84) in non-users. Among women who were diagnosed with cancer during the 2-year screening interval, HRT users were more likely to have a false negative result than nonusers (odds ratio 1.60 [1.04-2.21]) after adjusting for potential confounding factors. Specificity was 0.6% lower in HRT users compared with nonusers. Among women who did not have cancer diagnosed in the interval, HRT users were more likely to have a false positive result (adjusted odds ratio 1.12 [1.05-1.19]). Interpretation We show that HRT use reduces the sensitivity of mammographic screening. In countries where HRT use is widespread, the reduction in sensitivity with HRT use may undermine the capacity of population-based mammographic-screening programmes to realise their potential mortality benefit.	La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Melbourne, Vic 3000, Australia; Anticanc Council Victoria, Canc Epidemiol Ctr, Carlton South, Vic, Australia; Victoria BreastScreen Registry, Carlton South, Vic, Australia	La Trobe University	Kavanagh, AM (corresponding author), La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, 215 Franklin St, Melbourne, Vic 3000, Australia.		Kavanagh, Anne/U-4826-2019	Kavanagh, Anne/0000-0002-1573-3464; Giles, Graham/0000-0003-4946-9099				Australian Bureau of Statistics, 1999, AUSTR DEM STAT; Beral V, 1997, LANCET, V349, P1103, DOI 10.1016/S0140-6736(05)62328-8; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P503, DOI 10.1093/oxfordjournals.aje.a115364; BERKOWITZ JE, 1990, RADIOLOGY, V174, P199, DOI 10.1148/radiology.174.1.2152982; BRISSON J, 1988, J NATL CANCER I, V80, P1534, DOI 10.1093/jnci/80.19.1534; Cohen MEL, 1997, LANCET, V349, P1624, DOI 10.1016/S0140-6736(05)61662-5; Harding C, 1996, BRIT MED J, V312, P1646, DOI 10.1136/bmj.312.7047.1646; Harvey JA, 1997, J NATL CANCER I, V89, P1623, DOI 10.1093/jnci/89.21.1623; Holli K, 1997, LANCET, V350, P1704, DOI 10.1016/S0140-6736(05)64308-5; HURLEY SF, 1992, EPIDEMIOL REV, V14, P101, DOI 10.1093/oxfordjournals.epirev.a036082; Kavanagh AM, 1999, J MED SCREEN, V6, P139, DOI 10.1136/jms.6.3.139; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; Laya MB, 1996, J NATL CANCER I, V88, P643, DOI 10.1093/jnci/88.10.643; LAYA MB, 1995, RADIOLOGY, V196, P433, DOI 10.1148/radiology.196.2.7617857; Leung W, 1997, SURGERY, V122, P669, DOI 10.1016/S0039-6060(97)90072-6; Litherland JC, 1997, CLIN RADIOL, V52, P276, DOI 10.1016/S0009-9260(97)80053-0; Litherland JC, 1999, CLIN RADIOL, V54, P285, DOI 10.1016/S0009-9260(99)90555-X; Lundstrom E, 1999, AM J OBSTET GYNECOL, V181, P348, DOI 10.1016/S0002-9378(99)70560-0; MA L, 1992, J NATL CANCER I, V84, P781, DOI 10.1093/jnci/84.10.781; MACLENNAN AH, 1995, MED J AUSTRALIA, V162, P420, DOI 10.5694/j.1326-5377.1995.tb139971.x; Magnusson C, 1996, BREAST CANCER RES TR, V38, P325, DOI 10.1007/BF01806152; Marugg RC, 1997, EUR RADIOL, V7, P749, DOI 10.1007/BF02742938; MCNICHOLAS MMJ, 1994, AM J ROENTGENOL, V163, P311, DOI 10.2214/ajr.163.2.8037021; Peer PGM, 1996, BREAST CANCER RES TR, V38, P153, DOI 10.1007/BF01806669; Persson I, 1997, J CLIN ONCOL, V15, P3201, DOI 10.1200/JCO.1997.15.10.3201; Rand T, 1997, ACTA RADIOL, V38, P228; Rosenberg RD, 1998, RADIOLOGY, V209, P511, DOI 10.1148/radiology.209.2.9807581; Roubidoux MA, 1998, RADIOLOGY, V208, P725, DOI 10.1148/radiology.208.3.9722852; Salmon RJ, 1995, LANCET, V346, P1702, DOI 10.1016/S0140-6736(95)92864-2; Schouten LJ, 1997, LANCET, V349, P1104, DOI 10.1016/S0140-6736(05)62329-X; Seradour B, 1999, J MED SCREEN, V6, P99, DOI 10.1136/jms.6.2.99; SHELLEY JM, 1995, AUST J PUBLIC HEALTH, V19, P387; STOMPER PC, 1990, RADIOLOGY, V174, P487, DOI 10.1148/radiology.174.2.2136958; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; Threlfall AG, 1997, LANCET, V349, P472, DOI 10.1016/S0140-6736(05)61182-8; Thurfjell EL, 1997, RADIOLOGY, V203, P339, DOI 10.1148/radiology.203.2.9114085; van Gils CH, 1998, J EPIDEMIOL COMMUN H, V52, P267, DOI 10.1136/jech.52.4.267; WALD NJ, 1995, BRIT MED J, V311, P1189, DOI 10.1136/bmj.311.7014.1189	40	131	136	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					270	274		10.1016/S0140-6736(99)07319-5	http://dx.doi.org/10.1016/S0140-6736(99)07319-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675074				2022-12-28	WOS:000085045600010
J	Barkai, N; Leibler, S				Barkai, N; Leibler, S			Biological rhythms - Circadian clocks limited by noise	NATURE			English	Article									Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University; Princeton University	Barkai, N (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.							Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Edmund L.N., 1988, CELLULAR MOL BASIS B; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Glossop NRJ, 1999, SCIENCE, V286, P766, DOI 10.1126/science.286.5440.766; Goldbeter A., 1995, BIOCH OSCILLATIONS C; KO MSH, 1992, BIOESSAYS, V14, P341, DOI 10.1002/bies.950140510; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; Leloup JC, 1998, J BIOL RHYTHM, V13, P70, DOI 10.1177/074873098128999934; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; Murray J. D., 1994, MATH BIOL; Suri V, 1999, EMBO J, V18, P675, DOI 10.1093/emboj/18.3.675; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	12	394	402	2	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					267	268		10.1038/35002258	http://dx.doi.org/10.1038/35002258			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659837				2022-12-28	WOS:000084899700040
J	Guerinot, ML				Guerinot, ML			Plant biology - The green revolution strikes gold	SCIENCE			English	Editorial Material							BIOSYNTHESIS; EXPRESSION; PHYTOENE		Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Dartmouth College	Guerinot, ML (corresponding author), Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA.							Burkhardt PK, 1997, PLANT J, V11, P1071, DOI 10.1046/j.1365-313X.1997.11051071.x; Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557; DellaPenna D, 1999, SCIENCE, V285, P375, DOI 10.1126/science.285.5426.375; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; FRAY RG, 1995, PLANT J, V8, P693, DOI 10.1046/j.1365-313X.1995.08050693.x; Grusak MA, 1999, ANNU REV PLANT PHYS, V50, P133, DOI 10.1146/annurev.arplant.50.1.133; Hirschberg J, 1999, CURR OPIN BIOTECH, V10, P186, DOI 10.1016/S0958-1669(99)80033-0; Robinson NJ, 1999, NATURE, V397, P694, DOI 10.1038/17800; Shintani D, 1998, SCIENCE, V282, P2098, DOI 10.1126/science.282.5396.2098; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303	11	37	40	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2000	287	5451					241	+		10.1126/science.287.5451.241	http://dx.doi.org/10.1126/science.287.5451.241			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10660423				2022-12-28	WOS:000084769600023
J	Ratsitorahina, M; Chanteau, S; Rahalison, L; Ratsifasoamanana, L; Boisier, P				Ratsitorahina, M; Chanteau, S; Rahalison, L; Ratsifasoamanana, L; Boisier, P			Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar	LANCET			English	Article							ASSAY	Background Plague is a re-emerging disease and pneumonic plague is the most feared clinical form. We describe a well-documented outbreak of pneumonic plague in Madagascar. Methods Field epidemiological data were collected. Biological tests (microscopy, culture of Yersinia pestis, F1 antigen ELISA and dipstick assays, IgG anti-Fl ELISA) were done on sputum, serum, or necropsy samples. The infection rate among 154 contacts was assessed by anti-Fl serological techniques. Findings The index case was a bubonic patient with a secondary lung infection, who contaminated a traditional healer and his family. Funeral ceremonies and attendance on patients contaminated other villagers. In total 18 cases were recorded, and eight died. F1 antigen could be detected in sputum by ELISA and dipstick tests as early as the second day after the onset of the symptoms and also 48 h after treatment. Among the contact population 13 of 154 (8.4%) have been exposed to the plague bacillus (symptomless or latent infections). Interpretation The F1 dipstick assay on sputum is an invaluable diagnostic tool for pneumonic plague. Treatment of patients and chemoprophylaxis of contacts were efficient in stopping the epidemic.	Inst Pasteur Madagascar, Antananarivo, Madagascar; Minist Hlth, Natl Control Plague Programme, Antananarivo, Madagascar	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Madagascar	Chanteau, S (corresponding author), Inst Pasteur Madagascar, POB 1274, Antananarivo, Madagascar.	chanteau@pasteur.mg	BOISIER, PASCAL/A-2922-2009					[Anonymous], 1998, Wkly Epidemiol Rec, V73, P366; BRYGOO E. R., 1958, BULL SOC PATHOL EXOT, V51, P47; Chanteau S, 1998, EMERG INFECT DIS, V4, P101, DOI 10.3201/eid0401.980114; Chanteau S, 1998, T ROY SOC TROP MED H, V92, P572, DOI 10.1016/S0035-9203(98)90923-3; Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004; GIRARD G., 1927, BULL SOC PATH EXOT, V20, P233; POLLITZER R, 1954, WHO MONOGR SER, V22, P533; Rasoamanana B, 1997, CLIN DIAGN LAB IMMUN, V4, P587, DOI 10.1128/CDLI.4.5.587-591.1997; Rasoamanana B, 1996, T ROY SOC TROP MED H, V90, P651, DOI 10.1016/S0035-9203(96)90420-4; THIROUX A, 1920, B SOC PATHOL EXOT, V22, P704; WINTER C C, 1960, Bull World Health Organ, V23, P408; WU LT, 1928, N MANCHURIAN PLAGUE, V6, P55	12	95	100	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	2000	355	9198					111	113		10.1016/S0140-6736(99)05163-6	http://dx.doi.org/10.1016/S0140-6736(99)05163-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288HT	10675169				2022-12-28	WOS:000085557200013
J	Sullivan, AD; Hedberg, K; Fleming, DW				Sullivan, AD; Hedberg, K; Fleming, DW			Legalized physician-assisted suicide in Oregon - The second year.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIEWS	Background and Methods: In 1997, Oregon legalized physician-assisted suicide. We have previously reported data on terminally ill Oregon residents who received prescriptions for lethal medications under the Oregon Death with Dignity Act and who died in 1998. We now report similar data for 1999, obtained from physicians' reports, death certificates, and interviews with physicians. We also report data from interviews with family members. Results: Information on 33 persons who received prescriptions for lethal medications in 1999 was reported to the Oregon Health Division; 26 died after taking the lethal medications, 5 died from their underlying illnesses, and 2 were alive as of January 1, 2000. One additional patient, who received a prescription in 1998, died after taking the medication in 1999. Thus, 27 patients died after ingesting lethal medications in 1999 (9 per 10,000 deaths in Oregon), as compared with 16 patients in 1998 (6 per 10,000). Results: The median age of the 27 patients who died in 1999 after taking lethal medications was 71 years. The most frequent underlying illnesses were cancer (in 17 patients), amyotrophic lateral sclerosis (in 4), and chronic obstructive pulmonary disease (in 4). All 27 patients had health insurance, 21 were receiving hospice care, and 13 were college graduates. According to both physicians and family members, patients requested assistance with suicide for several reasons, including loss of autonomy, loss of control of bodily functions, an inability to participate in activities that make life enjoyable, and a determination to control the manner of death. Conclusions: In the second as compared with the first year of legalized physician-assisted suicide in Oregon, the number of patients who died after ingesting lethal medications increased, but it remained small in relation to the total number of persons in Oregon who died. Patients who request assistance with suicide appear to be motivated by several factors, including loss of autonomy and a determination to control the way in which they die. (N Engl J Med 2000;342:598-604.) (C)2000, Massachusetts Medical Society.	Oregon Hlth Div, Portland, OR 97232 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA	Oregon Health & Science University; Centers for Disease Control & Prevention - USA	Hedberg, K (corresponding author), Oregon Hlth Div, 800 NE Oregon St,Suite 772, Portland, OR 97232 USA.	katrina.hedberg@state.or.us		Sullivan, Amy/0000-0003-3036-6719				Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; Foley K, 1999, HASTINGS CENT REP, V29, P37, DOI 10.2307/3528194; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; GIANELLI D, 1999, AM MED NEWS     0308; HALEY K, 1998, OREGON DEATH DIGNITY; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Mangus RS, 1999, JAMA-J AM MED ASSOC, V282, P2080, DOI 10.1001/jama.282.21.2080; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Quill TE, 1998, ANN INTERN MED, V128, P552, DOI 10.7326/0003-4819-128-7-199804010-00006; *SAS I, 1995, SAS SYST VERS 6 12; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009	13	166	166	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					598	604		10.1056/NEJM200002243420822	http://dx.doi.org/10.1056/NEJM200002243420822			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684921				2022-12-28	WOS:000085422400031
J	DeLano, WL; Ultsch, MH; de Vos, AM; Wells, JA				DeLano, WL; Ultsch, MH; de Vos, AM; Wells, JA			Convergent solutions to binding at a protein-protein interface	SCIENCE			English	Article							CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; DOMAIN; FC; RECEPTOR; COMPLEX; IGG; VARIANTS; FRAGMENT; HORMONE	The hinge region on the Fe fragment of human immunoglobulin G interacts with at least four different natural protein scaffolds that bind at a common site between the C-H2 and C-H3 domains. This "consensus" site was also dominant for binding of random peptides selected in vitro for high affinity (dissociation constant, about 25 nanomolar) by bacteriophage display, Thus, this site appears to be preferred owing to its intrinsic physiochemical properties, and not for biological function alone. A 2.7 angstrom crystal structure of a selected 13-amino acid peptide in complex with Fc demonstrated that the peptide adopts a compact structure radically different from that of the other Fc binding proteins. Nevertheless, the specific Fc binding interactions of the peptide strongly mimic those of the other proteins. Juxtaposition of the available Fc-complex crystal structures showed that the convergent binding surface is highly accessible, adaptive, and hydrophobic and contains relatively few sites for polar interactions. These are all properties that may promote cross-reactive binding, which is common to protein-protein interactions and especially hormone-receptor complexes.	Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Sunesis Pharmaceut, Redwood City, CA 94063 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; Roche Holding; Genentech	Wells, JA (corresponding author), Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA.	jaw@sunesis-pharma.com	Wells, Jim A/O-9854-2016					BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DELANO WL, UNPUB; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB, V1, pCH11; GOUDA H, 1992, BIOCHEMISTRY-US, V31, P9665, DOI 10.1021/bi00155a020; JENDEBERG L, 1995, J MOL RECOGNIT, V8, P270, DOI 10.1002/jmr.300080405; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KARLSSON R, 1995, J IMMUNOL METHODS, V183, P43, DOI 10.1016/0022-1759(95)00030-E; Kay BK, 1998, DRUG DISCOV TODAY, V3, P370, DOI 10.1016/S1359-6446(98)01220-3; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Lowman HB, 1998, BIOCHEMISTRY-US, V37, P8870, DOI 10.1021/bi980426e; Medesan C, 1997, J IMMUNOL, V158, P2211; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; Tsai CJ, 1997, PROTEIN SCI, V6, P53; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YOUNG L, 1994, PROTEIN SCI, V3, P717	26	566	648	6	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2000	287	5456					1279	1283		10.1126/science.287.5456.1279	http://dx.doi.org/10.1126/science.287.5456.1279			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678837				2022-12-28	WOS:000085444700054
J	Rudolph, KL; Chang, S; Millard, M; Schreiber-Agus, N; DePinho, RA				Rudolph, KL; Chang, S; Millard, M; Schreiber-Agus, N; DePinho, RA			Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery	SCIENCE			English	Article							MOUSE CELLS LACKING; LIFE-SPAN; HEPATOCELLULAR-CARCINOMA; PLASMINOGEN-ACTIVATOR; HUMAN FIBROBLASTS; DEATH RATES; LENGTH; DISEASES; PATHOGENESIS; REGENERATION	Accelerated telomere loss has been proposed to be a factor Leading to end-stage organ failure in chronic diseases of high cellular turnover such as liver cirrhosis. To test this hypothesis directly, telomerase-deficient mice, null for the essential telomerase RNA (mTR) gene, were subjected to genetic, surgical, and chemical ablation of the liver. Telomere dysfunction was associated with defects in liver regeneration and accelerated the development of liver cirrhosis in response to chronic liver injury. Adenoviral delivery of mTR into the livers of mTR(-/-) mice with short dysfunctional telomeres restored telomerase activity and telomere function, alleviated cirrhotic pathology, and improved liver function. These studies indicate that telomere dysfunction contributes to chronic diseases of continual cellular loss-replacement and encourage the evaluation of "telomerase therapy" for such diseases.	Dana Farber Canc Inst, Dept Adult Oncol Med & Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Yeshiva University; Albert Einstein College of Medicine	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol Med & Genet, 44 Binney St,M413, Boston, MA 02115 USA.	ron_depinho@dfci.harvard.edu		Rudolph, Karl Lenhard/0000-0002-4839-2862; DePinho, Ronald/0000-0002-5625-577X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034880, R01HD028317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG001019] Funding Source: NIH RePORTER; NIA NIH HHS [K08 AG001019] Funding Source: Medline; NICHD NIH HHS [R01HD28317, R01HD34880] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alcolado R, 1997, CLIN SCI, V92, P103, DOI 10.1042/cs0920103; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; ANTHONY PP, 1977, B WORLD HEALTH ORGAN, V55, P521; Ball SE, 1998, BLOOD, V91, P3582; BEDOSSA P, 1972, HEPATOLOGY, V21, P76095; Blackburn E, 1997, Ciba Found Symp, V211, P2; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Counter CM, 1996, MUTAT RES-REV GENET, V366, P45, DOI 10.1016/S0165-1110(96)90006-8; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; Delhaye M, 1996, HEPATOLOGY, V23, P1003, DOI 10.1002/hep.510230510; Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555; FAUSTO N, 1991, CIBA F SYMP, V157, P165; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; Huang GT, 1998, EUR J CANCER, V34, P1946, DOI 10.1016/S0959-8049(98)00237-8; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; KITADA T, 1995, BIOCHEM BIOPH RES CO, V211, P33, DOI 10.1006/bbrc.1995.1774; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KOJLMA H, 1997, GASTROENTEROLOGY, V112, P493; KORULA J, 1992, LIVER BILIARY DIS, P529; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; McClintock B, 1941, GENETICS, V26, P234; MILANI S, 1991, AM J PATHOL, V139, P1221; Miura N, 1997, CANCER GENET CYTOGEN, V93, P56, DOI 10.1016/S0165-4608(96)00329-9; Mondello C, 1997, EXP CELL RES, V236, P385, DOI 10.1006/excr.1997.3756; NAKISHIO R, 1998, NIPPON RINSHO, V56, P1239; Nichols WS, 1999, SCAND J IMMUNOL, V49, P302, DOI 10.1046/j.1365-3083.1999.00505.x; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Ohyashiki JH, 1999, CLIN CANCER RES, V5, P1155; OHYASHIKI JH, 1994, CANCER RES, V54, P3557; Pan CG, 1997, EXP CELL RES, V231, P346, DOI 10.1006/excr.1997.3475; Park YM, 1998, EXP MOL MED, V30, P35, DOI 10.1038/emm.1998.5; PODOLSKY DK, 1998, HARRISONS PRINCIPLES, P17084; Pommier JP, 1997, VIROLOGY, V231, P148, DOI 10.1006/viro.1997.8512; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Roulot D, 1999, HEPATOLOGY, V29, P1730, DOI 10.1002/hep.510290622; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 1999, HEPATOLOGY, V30, P1159, DOI 10.1002/hep.510300502; RUDOLPH KL, UNPUB; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Smart RG, 1998, J STUD ALCOHOL, V59, P245, DOI 10.15288/jsa.1998.59.245; Smart RG, 1996, ALCOHOL ALCOHOLISM, V31, P487; SMART RG, 1991, J STUD ALCOHOL, V52, P232, DOI 10.15288/jsa.1991.52.232; SMART RG, 1993, MMWR-MORBID MORTAL W, V41, P969; Suda T, 1998, HEPATOLOGY, V27, P402, DOI 10.1002/hep.510270213; TAHARA H, 1995, CANCER RES, V55, P2734; TAMAYO RP, 1983, HEPATOLOGY, V3, P112; Urabe Y, 1996, LIVER, V16, P293; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Williams EJ, 1998, POSTGRAD MED J, V74, P193, DOI 10.1136/pgmj.74.870.193	59	305	324	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2000	287	5456					1253	1258		10.1126/science.287.5456.1253	http://dx.doi.org/10.1126/science.287.5456.1253			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10678830				2022-12-28	WOS:000085444700047
J	Sofair, AN; Kaldjian, LC				Sofair, AN; Kaldjian, LC			Eugenic sterilization and a qualified Nazi analogy: The United States and Germany, 1930-1945	ANNALS OF INTERNAL MEDICINE			English	Review								In the United Slates and Germany before World War II, physicians participated in state-authorized eugenic sterilization programs in an attempt to prevent persons deemed to possess undesirable heritable characteristics from propagating. A comparison of U.S. and German his tories reveals similarities that argue against easy dismissal of a Nazi analogy. On the basis of a review of editorials in New England Journal of Medicine and Journal of the American Medical Association from 1930 to 1945 it is difficult to accept the suggestion that the alliance between the medical profession and the eugenics movement in the United States was short-lived. Comparison of the histories of the eugenic sterilization campaigns in the United States and Nazi Germany reveals important similarities of motivation, intent, and strategy and differences that explain why support for eugenic sterilization in the United States gradually weakened. The eugenics movement in Germany was influenced by economic crisis, radical nationalism, Hitler's totalitarianism, and the medical profession's willing participation and attraction to Nazism for financial and ideological reasons. In the United States, a combination of public unease, Roman Catholic opposition, federal democracy, judicial review, and critical scrutiny by the medical profession reversed the momentum of the eugenics movement and led to the conclusion that eugenic sterilization should be voluntary.	Yale Univ, New Haven, CT USA	Yale University	Sofair, AN (corresponding author), Waterbury Hosp & Hlth Ctr, Dept Med, Yale Primary Care Internal Med Residency Program, 6th Floor,64 Robbins St, Waterbury, CT 06721 USA.			Kaldjian, Lauris/0000-0002-9170-6986				ALEXANDER L, 1949, NEW ENGL J MED, V241, P39, DOI 10.1056/NEJM194907142410201; ALLEN GE, 1989, GENOME, V31, P885, DOI 10.1139/g89-156; [Anonymous], 1861, ORIGIN SPECIES MEANS; Barondess JA, 1998, ANN INTERN MED, V129, P891, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00010; BINDING K, 1992, ISSUES LAW MED, V8, P231; Bloch H, 1973, Bull Hist Med, V47, P297; BLOCH H, 1973, RACIAL HYGIENE MED N, V47, P297; *COMM AM NEUR ASS, 1936, EUG STER, P56; *COMM AM NEUR ASS, 1936, EUG STER, P21; *COMM AM NEUR ASS, 1936, EUR STER, P171; *COMM AM NEUR ASS, 1936, EUG STER, P177; *COMM AM NEUR ASS, 1936, EUG STER, P2; *COMM AM NEUR ASS, 1936, EUG STER, P7; Darwin Charles, 1871, DESCENT MAN SELECTIO, P130; Frick Wilhelm, 1934, EUGEN NEWS, V19, P33; Friedlander H, 1995, ORIGINS NAZI GENOCID, P39; FRIEDLANDER H, 1995, ORIGINS NAZI GENOCID, P21; FRIEDLANDER H, 1995, ORIGINS NAZI GENOCID, P254; FRIEDLANDER H, 1995, ORIGINS NAZI GENOCID, P112; GALLAGHER HG, 1995, TRUST BETRAYED PATIE, P23; GALLAGHER HG, 1995, TRUST BETRAYED PATIE, P94; GALLAGHER HG, 1995, TRUST BETRAYED PATIE, P149; GALTON F, 1965, JAMA-J AM MED ASSOC, V194, P666; HAECKEL E, 1904, WONDERS LIFE, P100; HALLER MH, 1963, EUGENICS HEREDITARIA, P144; HanauskeAbel HM, 1996, BRIT MED J, V313, P1453, DOI 10.1136/bmj.313.7070.1453; Hawkins Mike, 1997, SOCIAL DARWINISM EUR, P3; HOFSTADTER R, 1945, SOCIAL DARWINISM EUR, P68; Horder L, 1936, EUGEN REV, V27, P277; KATER M, 1989, DOCTORS HITLER, P75; KATER M, 1989, DOCTORS HITLER, P131; KATER M, 1989, DOCTORS HITLER, P58; Kater Michael H, 1989, DOCTORS HITLER, p[85, 184, 190]; KEELER C, 1938, J HERED, V29, P71; KEVLES DJ, 1985, NAME EUGENICS GENETI, P168; KEVLES DJ, 1985, NAME EUGENICS AM RAC, P59; KEVLES DJ, 1985, NAME EUGENICS GENETI, P155; KUHL S, 1994, NAZI CONNECTION EUGE, P70; KUHL S, 1994, NAZI CONNECTION EUGE, P50; KUHL S, 1994, NAZI CONNECTION EUGE, V25, P37; LAUGHLIN HH, 1926, EUGENICAL STERILIZAT, P18; Lenz F, 1924, J HERED, V15, P223; LIFTON RJ, 1986, NAZI DOCTORS MED KIL, P90; LIFTON RJ, 1986, NAZI DOCTORS MED KIL, P47; LUDMERER KM, 1972, GENETICS AM SOC HIST, P71; MISCELLANY, 1933, NEW ENGL J MED, V209, P309; Myerson A, 1935, ARCH NEURO PSYCHIATR, V33, P453, DOI 10.1001/archneurpsyc.1935.02250150003001; PAUL DB, 1995, NATURE, V374, P302, DOI 10.1038/374302a0; PAUL DB, 1995, CONTROLLING HUMAN HE, P100; Pickens D. K., 1968, EUGENICS PROGRESSIVE; Popenoe P, 1934, J HERED, V25, P257, DOI 10.1093/oxfordjournals.jhered.a103937; Popenoe P, 1931, J HERED, V22, P277; Popenoe P, 1922, J HERED, V13, P382, DOI 10.1093/oxfordjournals.jhered.a102259; PROCTOR R, 1988, RACIAL HYGIENE MED N, P68; PROCTOR R, 1988, RACIAL HYGIENE MED N, V160, P288; PROCTOR R, 1988, RACIAL HYGIENE MED N, P187; PROCTOR R, 1988, RACIAL HYGIENE MED N, P211; PROCTOR R, 1988, RACIAL HYGIENE MED N, P191; Proctor RN, 1988, RACIAL HYGIENE MED N, P64; REILLY PP, 1991, SURGICAL SOLUTION HI, P118; REILLY PR, 1991, SURG SOLUTION HIST I, P111; ROBITSCHER J, 1973, EUGENIC STERIZATION; ROWE MJ, 1934, MEDICINE, V40, P429; Slater E, 1936, EUGEN REV, V27, P285; STAUB E, 1989, ROOTS EVIL ORIGINS G, P99; TIETZE C, 1926, EUGEN REV, V18, P250; Tietze F, 1939, EUGEN REV, V31, P105; Von Hoffmann G, 1914, J HERED, V5, P435; WEINDING P, 1989, HLTH RACE GERMAN POL, P457; WEINDLING P, 1989, HLTH RACE GERMAN POL, P10; WEINDLING P, 1989, HLTH RACE GERMAN POL, P394; WEINDLING P, 1989, HLTH RACE GERMAN POL, P533; WEINDLING P, 1989, HLTH RACE GERMAN POL, P51; WEINDLING P, 1989, HLTH RACE GERMAN POL, P546; WHITNEY LF, 1934, CASE STERILIZATION, P218; WHITNEY LF, 1934, CASE STERILIZATION, P8; WHITNEY LF, 1934, CASE STERILIZATION, P193; WHITNEY LF, 1934, CASE STERILIZATION, P135; WHITNEY LF, 1934, CASE STERILIZATION, P239; 1934, JAMA, V102, P1502; 1935, JAMA, V104, P2001; 1932, JAMA, V98, P1215; 1935, INT ARZTLICHES B, V2, P17; 1936, N ENGL J MED, V215, P561; 1934, N ENGL J MED, V204, P731; TESTIMONY VICTOR BRA, V1, P7507; 1932, AM J PUBLIC HLTH, V22, P634; 1933, N ENGL J MED, V208, P852; 1926, BUCK V BELL, V274, P207; 1934, N ENGL J MED, V211, P379; 1930, JAMA, V94, P132; 1947, NATL ARCH MICROFILM; 1942, JAMA, V120, P229; 1931, EUGENICAL NEWS, V16, P214; 1945, JAMA, V127, P1131; 1932, JAMA, V99, P774; 1935, N ENGL J MED, V213, P883; 1930, JAMA, V95, P1181; 1934, JAMA, V102, P1610; 1947, TRIALS WAR CRIMINALS, V1, P893	100	36	36	1	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2000	132	4					312	319		10.7326/0003-4819-132-4-200002150-00010	http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285CY	10681287				2022-12-28	WOS:000085372900008
J	Marrie, TJ; Lau, CY; Wheeler, SL; Wong, CJ; Vandervoort, MK; Feagan, BG				Marrie, TJ; Lau, CY; Wheeler, SL; Wong, CJ; Vandervoort, MK; Feagan, BG		CAPITAL Study Investigators	A controlled trial of a critical pathway for treatment of community-acquired pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED TRIAL; CONGESTIVE-HEART-FAILURE; ELDERLY PATIENTS; INTERVENTION TRIALS; OUTCOMES; CARE; COST; READMISSION; STAY	Context Large variations exist among hospitals in the use of treatment resources for community-acquired pneumonia (CAP). Lack of a common approach to the diagnosis and treatment of CAP has been cited as an explanation for these variations. Objective To determine if use of a critical pathway improves the efficiency of treatment for CAP without compromising the well-being of patients. Design Multicenter controlled clinical trial with cluster randomization and up to 6 weeks of follow-up. Setting Nineteen teaching and community hospitals in Canada. Patients A total of 1743 patients with CAP presenting to the emergency departmental 1 of the participating institutions between January 1 and July 31, 1998. Intervention Hospitals were assigned to continue conventional management (n = 10) or implement the critical pathway (n = 9), which consisted of a clinical prediction rule to guide the admission decision, levofloxacin therapy, and practice guidelines. Main Outcome Measures Effectiveness of the critical pathway, as measured by health-related quality of life on the Short-Form 36 Physical Component Summary (SF-36 PCS) scale at 6 weeks; and resource utilization, as measured by the number of bed days per patient managed (BDPM). Results Quality of life and the occurrence of complications, readmission, and mortality were not different for the 2 strategies; the 1-sided 95% confidence limit of the between-group difference in the SF-36 PCS change score was 2.4 points, which was within a predefined 3-point boundary for equivalence. Pathway use was associated with a 1.7-day reduction in BDPM (4.4 vs 6.1 days; P = .04) and an 18% decrease in the admission of low-risk patients (31 % vs 49 %; P = .01). Although inpatients at critical pathway hospitals had more severe disease, they required 1.7 fewer days of intravenous therapy (4.6 vs 6.3 days; P = .01) and were more likely to receive treatment with a single class of antibiotic (64% vs 27%; P < .001). Conclusion In this study, implementation of a critical pathway reduced the use of institutional resources without causing adverse effects on the well-being of patients.	John P Robarts Res Inst, London Clin Trials Res Grp, London, ON N6A 5K8, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Janssen Ortho Inc, Toronto, ON, Canada; St Josephs Hlth Ctr, London, ON, Canada; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Ottawa Civic Hosp, Ottawa, ON K1Y 4E9, Canada; London Hlth Sci Ctr, London, ON, Canada; Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada; Cape Breton Reg Hosp, Sydney, NS, Canada; Colchester Reg Hosp, Truro, NS, Canada; Valley Reg Hosp, Kentville, NS, Canada; Thunder Bay Reg Hosp, Thunder Bay, ON, Canada; Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada; Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada; Ottawa Gen Hosp, Ottawa, ON K1H 8L6, Canada; Hlth Sci Ctr, St Johns, NF, Canada; McMaster Univ, Med Ctr, Hamilton, ON, Canada; Moncton Hosp, Moncton, NB, Canada; Western Reg Hlth Ctr, Yarmouth, NS, Canada; Hlth Serv Assoc S Shore, Bridgewater, NS, Canada; Royal Columbian Hosp, New Westminster, BC, Canada; London Clin Trials Grp, London, ON, Canada	Western University (University of Western Ontario); University of Alberta; Johnson & Johnson; Western University (University of Western Ontario); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Ottawa; Ottawa Hospital Research Institute; London Health Sciences Centre; University of British Columbia; Northern Ontario School of Medicine; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Ottawa; Ottawa Hospital Research Institute; Memorial University Newfoundland; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University	Feagan, BG (corresponding author), John P Robarts Res Inst, London Clin Trials Res Grp, 100 Perth Dr, London, ON N6A 5K8, Canada.		Feagan, Brian G/M-4283-2015; Feagan, Brian/G-3292-2011					BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408; Brown PD, 1998, LANCET, V352, P1295, DOI 10.1016/S0140-6736(98)02239-9; *CDCP, 1997, 1994 NAT HOSP DISCH, V13; DIEHR P, 1995, STAT MED, V14, P1491, DOI 10.1002/sim.4780141309; Donner A, 1996, J CLIN EPIDEMIOL, V49, P435, DOI 10.1016/0895-4356(95)00511-0; DONNER A, 1990, INT J EPIDEMIOL, V19, P795, DOI 10.1093/ije/19.4.795; Ellrodt G, 1997, JAMA-J AM MED ASSOC, V278, P1687, DOI 10.1001/jama.278.20.1687; Falconer J A, 1993, QRB Qual Rev Bull, V19, P8; File TM, 1997, ANTIMICROB AGENTS CH, V41, P1965, DOI 10.1128/AAC.41.9.1965; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; Fine MJ, 1997, ARCH INTERN MED, V157, P47, DOI 10.1001/archinte.157.1.47; FINE MJ, 1993, MED CARE, V31, P371, DOI 10.1097/00005650-199304000-00008; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Gilbert K, 1998, AM J MED, V104, P17, DOI 10.1016/S0002-9343(97)00274-X; Glick HA, 1998, STROKE, V29, P351, DOI 10.1161/01.STR.29.2.351; Grol R, 1998, BRIT MED J, V317, P858, DOI 10.1136/bmj.317.7162.858; Guest JF, 1997, EUR RESPIR J, V10, P1530, DOI 10.1183/09031936.97.10071530; ISAACSON DM, 1996, RECENT RES DEV ANTIM, V1, P391; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; Meehan TP, 1997, JAMA-J AM MED ASSOC, V278, P2080, DOI 10.1001/jama.278.23.2080; Metlay JP, 1997, J GEN INTERN MED, V12, P423, DOI 10.1046/j.1525-1497.1997.00074.x; Niederman MS, 1998, CLIN THER, V20, P820, DOI 10.1016/S0149-2918(98)80144-6; O'Doherty B, 1997, J ANTIMICROB CHEMOTH, V40, P73, DOI 10.1093/jac/40.suppl_1.73; Pearson SD, 1996, AM J MED, V100, P283, DOI 10.1016/S0002-9343(97)89486-7; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; Philbin EF, 1998, AM HEART J, V136, P553, DOI 10.1016/S0002-8703(98)70234-0; RASCHKE RA, 1993, ANN INTERN MED, V119, P874, DOI 10.7326/0003-4819-119-9-199311010-00002; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; TOWNSEND J, 1988, BMJ-BRIT MED J, V297, P544, DOI 10.1136/bmj.297.6647.544; Ware J.E, 1994, PHYS MENTAL HLTH SUM; Ware JH, 1997, NEW ENGL J MED, V337, P1159, DOI 10.1056/NEJM199710163371610; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; WEINGARTEN SR, 1994, CHEST, V105, P1109, DOI 10.1378/chest.105.4.1109; Weingarten SR, 1996, AM J RESP CRIT CARE, V153, P1110, DOI 10.1164/ajrccm.153.3.8630553	35	507	529	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					749	755		10.1001/jama.283.6.749	http://dx.doi.org/10.1001/jama.283.6.749			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280XL	10683053				2022-12-28	WOS:000085129000026
J	Waisbren, SE; Hanley, W; Levy, HL; Shifrin, H; Allred, E; Azen, C; Chang, PN; Cipcic-Schmidt, S; de la Cruz, F; Hall, R; Matalon, R; Nanson, J; Rouse, B; Trefz, F; Koch, R				Waisbren, SE; Hanley, W; Levy, HL; Shifrin, H; Allred, E; Azen, C; Chang, PN; Cipcic-Schmidt, S; de la Cruz, F; Hall, R; Matalon, R; Nanson, J; Rouse, B; Trefz, F; Koch, R			Outcome at age 4 years in offspring of women with maternal phenylketonuria - The maternal PKU collaborative study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERPHENYLALANINEMIA; PREGNANCIES; ALCOHOL; PREVENTION	Context Untreated maternal phenylketonuria (PKU) increases risk for developmental problems in offspring. The extent to which this risk is reduced by maternal dietary therapy at various stages of pregnancy is not known. Objective To determine whether dietary treatment during pregnancy of women with PKU affects developmental outcomes of offspring. Design The Maternal PKU Collaborative Study, an ongoing, longitudinal prospective study begun in 1984. Setting A total of 78 metabolic clinics and obstetrical offices in the United States, Canada, and Germany. Participants A total of 253 children of women with PKU (n = 149), with untreated mild hyperphenylalaninemia (n = 33), or without known metabolic problems (comparison group; n = 71) were followed up to age 4 years. Intervention Women with PKU were offered a low-phenylalanine diet prior to or during pregnancy with the aim of maintaining metabolic control (plasma phenylalanine less than or equal to 10 mg/dL [less than or equal to 605 mu mol/L]). Women with mild hyperphenylalaninemia, who had plasma phenylalanine levels of no more than 10 mg/dL (605 mu mol/L) on a normal diet, were not treated. Main Outcome Measures Children's scores on cognitive and behavioral assessments (McCarthy Scales of Children's Abilities, Test of Language Development, Achenbach Child Behavior Checklist, Vineland Adaptive Behavior Scales, and Home Observation for Measurement of the Environment), compared by maternal metabolic status at 0 to 10 weeks', 10 to 20 weeks', and after 20 weeks' gestation. Results Scores on the McCarthy General Cognitive Index decreased as weeks to metabolic control increased (r = -0.58; P<.001), Offspring of women who had metabolic control prior to pregnancy had a mean (SD) score of 99 (13). Forty-seven percent of offspring whose mothers did not have metabolic control by 20 weeks' gestation had a General Cognitive Index score 2 SDs below the norm. Overall, 30% of children born to mothers with PKU had social and behavioral problems. Conclusions Our data suggest that delayed development in offspring of women with PKU is associated with lack of maternal metabolic control prior to or early in pregnancy. Treatment at any time during pregnancy may reduce the severity of delay.	Childrens Hosp, Genet Serv, Boston, MA 02115 USA; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; NICHHD, Bethesda, MD USA; Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; Childrens Hosp, Minneapolis, MN USA; Univ Tubingen, Tubingen, Germany; Univ Texas, Med Branch, Galveston, TX 77550 USA; Royal Univ Hosp, Saskatoon, SK S7N 0W8, Canada; Childrens Hosp Reutlingen, Reutlingen, Germany	Harvard University; Boston Children's Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Children's Hospital Los Angeles; Children's Hospitals & Clinics of Minnesota; Eberhard Karls University of Tubingen; University of Texas System; University of Texas Medical Branch Galveston; University of Saskatchewan	Waisbren, SE (corresponding author), Childrens Hosp, Genet Serv, 300 Longwood Ave,IC 107, Boston, MA 02115 USA.	waisbren@al.tch.harvard.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD023148] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-2-3148] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACOSTA PB, 1982, J AM DIET ASSOC, V80, P443; [Anonymous], 1991, MANUAL CHILD BEHAV C; Caldwell B., 1984, HOME OBSERVATION MEA; Duran GP, 1999, J AM DIET ASSOC, V99, P1559, DOI 10.1016/S0002-8223(99)00382-X; FRIED PA, 1992, J DEV BEHAV PEDIATR, V13, P383; GHAVAMI M, 1986, CLIN OBSTET GYNECOL, V29, P580, DOI 10.1097/00003081-198609000-00014; Guldberg P, 1998, AM J HUM GENET, V63, P71, DOI 10.1086/301920; Hanley WB, 1996, EUR J PEDIATR, V155, pS169, DOI 10.1007/PL00014240; HANLEY WB, 1987, CLIN BIOCHEM, V20, P149, DOI 10.1016/S0009-9120(87)80112-1; Hollingshead AB, 1965, 2 FACTOR INDEX SOCIA; JANZEN LA, 1995, NEUROTOXICOL TERATOL, V17, P273, DOI 10.1016/0892-0362(94)00063-J; KECSKEMETHY HH, 1993, J INHERIT METAB DIS, V16, P111, DOI 10.1007/BF00711324; Koch R, 1999, MENT RETARD DEV D R, V5, P117; LENKE RR, 1980, NEW ENGL J MED, V303, P1202, DOI 10.1056/NEJM198011203032104; LEVY HL, 1994, ACTA PAEDIATR, V83, P92, DOI 10.1111/j.1651-2227.1994.tb13463.x; Levy HL, 1996, TERATOLOGY, V53, P176; LIPSON A, 1984, J PEDIATR-US, V104, P216, DOI 10.1016/S0022-3476(84)80995-6; LYNCH BC, 1988, EUR J PEDIATR, V148, P72, DOI 10.1007/BF00441820; MATALON R, 1994, J INHERIT METAB DIS, V17, P353, DOI 10.1007/BF00711828; McCarthy D, 1972, MCCARTHY SCALES CHIL; Michals K, 1996, EUR J PEDIATR, V155, pS165, DOI 10.1007/PL00014239; NEWCOMER P, 1991, TEST LANGUAGE DEV PR; PLATT LD, 1992, AM J OBSTET GYNECOL, V166, P1150, DOI 10.1016/S0002-9378(11)90601-2; Rouse B, 1997, AM J MED GENET, V69, P89, DOI 10.1002/(SICI)1096-8628(19970303)69:1<89::AID-AJMG17>3.0.CO;2-K; Sparrow S.S., 2005, VINELAND 2 ADAPTIVE; SPOHR HL, 1993, LANCET, V341, P907, DOI 10.1016/0140-6736(93)91207-3; St James PS, 1999, AM J PUBLIC HEALTH, V89, P762, DOI 10.2105/AJPH.89.5.762; *STATA CORP, 1995, STAT STAT SOFTW REL; Thompson RJ, 1997, J DEV BEHAV PEDIATR, V18, P91; Waisbren SE, 1997, J INHERIT METAB DIS, V20, P21, DOI 10.1023/A:1005349204797; WAISBREN SE, 1994, ACTA PAEDIATR, V83, P98, DOI 10.1111/j.1651-2227.1994.tb13464.x; WAISBREN SE, 1991, AM J PUBLIC HEALTH, V81, P299, DOI 10.2105/AJPH.81.3.299; Waisbren SE, 1998, J INHERIT METAB DIS, V21, P39, DOI 10.1023/A:1005359313883; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Wilkinson L., 1990, SYSTAT SYSTEM STAT	35	37	38	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					756	762		10.1001/jama.283.6.756	http://dx.doi.org/10.1001/jama.283.6.756			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	280XL	10683054				2022-12-28	WOS:000085129000027
J	Williamson, L; Bowness, P; Mowat, A; Ostman-Smith, I				Williamson, L; Bowness, P; Mowat, A; Ostman-Smith, I			Difficulties in diagnosing acute rheumatic fever-arthritis may be short lived and carditis silent	BRITISH MEDICAL JOURNAL			English	Review							POSTSTREPTOCOCCAL REACTIVE ARTHRITIS; HEART-DISEASE; PREVENTION; CRITERIA; CHILDREN		Nuffield Orthopaed Ctr, Dept Rheumatol, Oxford OX3 7LD, England; John Radcliffe Hosp, Dept Paediat Cardiol, Oxford OX3 9DU, England	Nuffield Orthopaedic Centre; University of Oxford	Williamson, L (corresponding author), 17 Coxwell Rd, Faringdon SN7 7EB, England.		Bowness, Paul/AAH-2484-2019	bowness, paul/0000-0003-4597-0484				ALBERT DA, 1995, MEDICINE, V74, P1, DOI 10.1097/00005792-199501000-00001; AYOUB EM, 1962, PEDIATRICS, V29, P527; CREA MA, 1959, PEDIATRICS, V23, P879; DAJANI A, 1995, PEDIATRICS, V96, P758; DAJANI AS, 1992, JAMA-J AM MED ASSOC, V268, P2069, DOI 10.1001/jama.1992.03490150121036; daSilva NA, 1997, RHEUM DIS CLIN N AM, V23, P545, DOI 10.1016/S0889-857X(05)70347-1; DECUNTO CL, 1998, PEDIATR INFECT DIS J, V7, P633; FOGLER G, 1992, BRIT HEART J, V6, P434; HAFFEJEE I, 1992, Q J MED, V84, P641; Jansen TLTA, 1998, BRIT J RHEUMATOL, V37, P335; KUTTNER AG, 1963, NEW ENGL J MED, V268, P1259, DOI 10.1056/NEJM196306062682301; LITTLE PS, 1994, BRIT MED J, V309, P1010, DOI 10.1136/bmj.309.6960.1010; MASON T, 1991, ARCH INTERN MED, V151, P133, DOI 10.1001/archinte.151.1.133; MCLAREN MJ, 1994, ANN INTERN MED, V120, P243, DOI 10.7326/0003-4819-120-3-199402010-00012; MOON RY, 1995, J RHEUMATOL, V22, P529; SCHAFFER FM, 1994, PEDIATRICS, V93, P837; STOLLERMAN GH, 1956, AM J MED, V20, P163, DOI 10.1016/0002-9343(56)90185-1; VEASY LG, 1994, J PEDIATR-US, V124, P9, DOI 10.1016/S0022-3476(94)70247-0; VYSE T, 1991, BRIT MED J, V302, P518, DOI 10.1136/bmj.302.6775.518; WILSON NJ, 1995, INT J CARDIOL, V50, P1, DOI 10.1016/0167-5273(95)02325-Q; ZANGWILL KM, 1991, J PEDIATR-US, V118, P561, DOI 10.1016/S0022-3476(05)83380-3	21	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					362	365		10.1136/bmj.320.7231.362	http://dx.doi.org/10.1136/bmj.320.7231.362			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657336	Green Published			2022-12-28	WOS:000085211400034
J	Capaldi, EA; Smith, AD; Osborne, JL; Fahrbach, SE; Farris, SM; Reynolds, DR; Edwards, AS; Martin, A; Robinson, GE; Poppy, GM; Riley, JR				Capaldi, EA; Smith, AD; Osborne, JL; Fahrbach, SE; Farris, SM; Reynolds, DR; Edwards, AS; Martin, A; Robinson, GE; Poppy, GM; Riley, JR			Ontogeny of orientation flight in the honeybee revealed by harmonic radar	NATURE			English	Article							BEES	Cognitive ethology focuses on the study of animals under natural conditions to reveal ecologically adapted modes of learning. But biologists can more easily study what an animal learns than how it learns. For example, honeybees take repeated 'orientation' flights before becoming foragers at about three weeks of age(1). These flights are a prerequisite for successful homing.(2) Little is known(2,3) about these flights because orienting bees rapidly fly out of the range of human observation. Using harmonic radar, we show for the first time a striking ontogeny to honeybee orientation flights. With increased experience, bees hold trip duration constant but fly faster, so later trips cover a larger area than earlier trips. In addition, each flight is typically restricted to a narrow sector around the hive. Orientation flights provide honeybees with repeated opportunities to view the hive and landscape features from different viewpoints, suggesting that bees learn the local landscape in a progressive fashion. We also show that these changes in orientation flight are related to the number of previous flights taken instead of chronological age, suggesting a learning process adapted to changes in weather conditions, flower availability and the needs of bee colonies.	Univ Illinois, Dept Entomol, Urbana, IL 61801 USA; Univ Greenwich, Nat Resources Inst, Radar Entomol Unit, Malvern WR14 1LL, Worcs, England; IACR Rothamsted, Dept Entomol & Nematol, Harpenden AL5 2JQ, Herts, England	University of Illinois System; University of Illinois Urbana-Champaign; University of Greenwich; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Capaldi, EA (corresponding author), Univ Illinois, Dept Entomol, 320 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA.	ecapaldi@life.uiuc.edu	Poppy, Guy m/D-7513-2012; Osborne, Juliet L/I-6776-2012; Reynolds, Donald R/C-7361-2013	Reynolds, Donald/0000-0001-8749-7491; Farris, Sarah/0000-0003-3307-0550	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004179] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BECKER L, 1958, Z VERGL PHYSIOL, V41, P1; Capaldi EA, 1999, J EXP BIOL, V202, P1655; COLLETT TS, 1992, PHILOS T R SOC B, V337, P295, DOI 10.1098/rstb.1992.0107; DYER FC, 1994, P NATL ACAD SCI USA, V91, P4471, DOI 10.1073/pnas.91.10.4471; LINDAUER M, 1959, Z VERGL PHYSIOL, V42, P43, DOI 10.1007/BF00297689; OBSORNE JL, 1999, J APPL ECOL, V36, P519; Ribbands C.R., 1953, BEHAV SOCIAL LIFE HO; Riley JR, 1996, NATURE, V379, P29, DOI 10.1038/379029b0; *SAS I, 1988, SAS STAT US GUID; VISSCHER PK, 1982, ECOLOGY, V63, P1790, DOI 10.2307/1940121; Vollbehr J., 1975, Zoologische Jb (Allg Zool), V79, P33; Wehner R, 1981, COMP PHYS EVOLUTION, VVII/ 6C, P287, DOI DOI 10.1007/978-3642-67868-4; White G.C., 1990, ANAL WILDLIFE RADIO; Winston M., 1987, The biology of the honey bee.; Zar J. H., 1996, BIOSTATISTICAL ANAL	15	230	234	5	97	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 3	2000	403	6769					537	540		10.1038/35000564	http://dx.doi.org/10.1038/35000564			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282PM	10676960				2022-12-28	WOS:000085227300048
J	Sahni, K				Sahni, K			Death by decree	LANCET			English	Article											Sahni, K (corresponding author), 7990 E Snyder Rd, Tucson, AZ 85750 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					223	224		10.1016/S0140-6736(99)11043-2	http://dx.doi.org/10.1016/S0140-6736(99)11043-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675134				2022-12-28	WOS:000084879700042
J	Yamey, G				Yamey, G			Advertisement breached code of practice	BRITISH MEDICAL JOURNAL			English	News Item																		MEDAWAR C, 1998, BRIT J UROL, V81, P801	1	1	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					335	335		10.1136/bmj.320.7231.335	http://dx.doi.org/10.1136/bmj.320.7231.335			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657321				2022-12-28	WOS:000085211400016
J	Butler, JH				Butler, JH			Atmospheric chemistry - Better budgets for methyl halides?	NATURE			English	Editorial Material							CH3BR; OCEAN		NOAA, Climate Monitoring & Diagnost Lab, Boulder, CO 80303 USA	National Oceanic Atmospheric Admin (NOAA) - USA	Butler, JH (corresponding author), NOAA, Climate Monitoring & Diagnost Lab, 325 Broadway, Boulder, CO 80303 USA.							Butler JH, 1999, NATURE, V399, P749, DOI 10.1038/21586; Gan J, 1998, GEOPHYS RES LETT, V25, P3595, DOI 10.1029/98GL52697; Keppler F, 2000, NATURE, V403, P298, DOI 10.1038/35002055; Khalil MAK, 1999, ATMOS ENVIRON, V33, P1305, DOI 10.1016/S1352-2310(98)00234-9; Kurylo MJ, 1999, SCI ASSESSMENT OZONE, P21; LEETAYLOR JM, IN PRESS J GEOPHYS R; Lobert JM, 1997, GEOPHYS RES LETT, V24, P171, DOI 10.1029/96GL03928; LOBERT JM, 1995, SCIENCE, V267, P1002, DOI 10.1126/science.267.5200.1002; Montzka SA, 1999, NATURE, V398, P690, DOI 10.1038/19499; Moore RM, 1996, J GEOPHYS RES-OCEANS, V101, P28529, DOI 10.1029/96JC02915; Rhew RC, 2000, NATURE, V403, P292, DOI 10.1038/35002043; Yokouchi Y, 2000, NATURE, V403, P295, DOI 10.1038/35002049	12	100	102	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					260	261		10.1038/35002232	http://dx.doi.org/10.1038/35002232			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659833				2022-12-28	WOS:000084899700033
J	Macilwain, C				Macilwain, C			Diversity convention in the balance	NATURE			English	News Item																			0	6	6	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					233	233		10.1038/35002154	http://dx.doi.org/10.1038/35002154			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10681235	Bronze			2022-12-28	WOS:000084899700007
J	Yamey, G				Yamey, G			New advice issued on prevention of sudden infant death	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					335	335		10.1136/bmj.320.7231.335	http://dx.doi.org/10.1136/bmj.320.7231.335			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657321				2022-12-28	WOS:000085211400015
J	Macilwain, C				Macilwain, C			Global-warming sceptics left out in the cold	NATURE			English	News Item																			0	6	6	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					233	233		10.1038/35002154	http://dx.doi.org/10.1038/35002154			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10681235	Bronze			2022-12-28	WOS:000084899700006
J	Ferriman, A				Ferriman, A			Blair promises to raise spending on NHS to European average	BRITISH MEDICAL JOURNAL			English	News Item																			0	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	2000	320	7229					205	205		10.1136/bmj.320.7229.205	http://dx.doi.org/10.1136/bmj.320.7229.205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279DR	10642214	Green Published			2022-12-28	WOS:000085029600010
